
<html lang="en"     class="pb-page"  data-request-id="c0ee3bcd-3510-4f40-aaed-75c244e08ac7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21;article:article:10.1021/acs.jmedchem.0c00830"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight" /></meta><meta name="dc.Creator" content="Terence C. S.  Ho" /></meta><meta name="dc.Creator" content="Alex H. Y.  Chan" /></meta><meta name="dc.Creator" content="A.  Ganesan" /></meta><meta name="dc.Description" content="It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer che..." /></meta><meta name="Description" content="It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer che..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 1, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00830" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00830" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00830" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00830" /></link>
        
    
    

<title>Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00830" /></meta><meta property="og:title" content="Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0024.jpeg" /></meta><meta property="og:description" content="It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00830"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00830">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00830&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00830&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00830&amp;href=/doi/10.1021/acs.jmedchem.0c00830" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12460-12484</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00748" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00887" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Terence C. S. Ho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Terence C. S. Ho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Terence+C.+S.++Ho">Terence C. S. Ho</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alex H. Y. Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alex H. Y. Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alex+H.+Y.++Chan">Alex H. Y. Chan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">A. Ganesan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">A. Ganesan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7918571e18171c0a1817390c1c1857181a570c12"><span class="__cf_email__" data-cfemail="9ffeb1f8fef1faecfef1dfeafafeb1fefcb1eaf4">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=A.++Ganesan">A. Ganesan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4862-7999" title="Orcid link">http://orcid.org/0000-0003-4862-7999</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00830&amp;href=/doi/10.1021%2Facs.jmedchem.0c00830" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12460–12484</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 1, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 May 2020</li><li><span class="item_label"><b>Published</b> online</span>1 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00830" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00830</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12460%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTerence%2BC.%2BS.%2BHo%252C%2BAlex%2BH.%2BY.%2BChan%252C%2BA.%2BGanesan%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c00830%26title%3DThirty%2BYears%2Bof%2BHDAC%2BInhibitors%253A%2B2020%2BInsight%2Band%2BHindsight%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12484%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00830"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4736</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">35</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00830" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Terence&quot;,&quot;last_name&quot;:&quot;C. S. Ho&quot;},{&quot;first_name&quot;:&quot;Alex&quot;,&quot;last_name&quot;:&quot;H. Y. Chan&quot;},{&quot;first_name&quot;:&quot;A.&quot;,&quot;last_name&quot;:&quot;Ganesan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12460-12484&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00830&quot;},&quot;abstract&quot;:&quot;It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00830&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00830" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00830&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00830" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00830&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00830" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00830&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00830&amp;href=/doi/10.1021/acs.jmedchem.0c00830" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00830" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00830" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26pmid%3D32608981%26genre%3Darticle%26aulast%3DHo%26date%3D2020%26atitle%3DThirty%2BYears%2Bof%2BHDAC%2BInhibitors%253A%2B2020%2BInsight%2Band%2BHindsight%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12460%26epage%3D12484%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291399" title="Zinc">Zinc</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291304" title="Organic reactions">Organic reactions</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clinical development for oncology as well as other therapeutic indications. This Perspective reviews the biological and medicinal chemistry advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The human genome contains a modest number of 20 000–25 000 genes coded by only 5% of its DNA sequence. However, it is not the case that “one gene = one protein”, as processes such as mRNA editing lead to a transcriptome that is several-fold higher than the number of genes. A further expansion occurs after protein synthesis through the post-translational modification (PTM) of amino acid side chains. The majority of PTMs are dynamic in nature, enabling a single protein to exist in multiple functional states and to move from one state to another in a reversible manner. The ε-amino side chain of lysine, in particular, is the conduit for a plethora of PTMs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) via alkylation or acylation reactions.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Alkylation increases the size of the lysine side chain while preserving its positively charged nature at physiological pH, whereas acylation results in neutral or even negatively charged side chains ranging from the addition of a single carbon in formylation to the conjugation of proteins such as ubiquitin. Two of these processes, acetylation and methylation, occur in the lysine-rich N-terminal tails of histone proteins where they play a central role in the epigenetic regulation of chromatin structure and the recruitment of its binding partners to modulate gene transcription. Consequently, the enzymes involved in lysine acetylation and methylation and their removal have become important targets for small molecule drug discovery.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> At the present time, five inhibitors of lysine deacetylation and one of lysine methylation have received regulatory approval as anticancer agents. This year marks the 30th anniversary of the disclosure of the natural product trichostatin A as the first potent inhibitor of histone deacetylation. In this Perspective, we summarize the progress since then regarding the biology of lysine deacetylase enzymes, the compounds currently in clinical development against this target, and the discovery of isoform selective inhibitors. Previous reviews in this journal provide a snapshot of the state of the art at earlier time points.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of lysine post-translational modification in proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Lysine acetylation was first observed in the early 1960s in histones due to the abundance of the PTM in these proteins. Soon thereafter, enzymes that catalyze the forward acetylation reaction and the reverse deacetylation reaction were discovered and logically named histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. Unfortunately, this historical nomenclature is well entrenched despite its inaccuracy, as we now know that lysine acetylation is not restricted to histones but a widespread PTM in thousands of human proteins present in diverse cellular compartments.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The PTM is produced via the transfer of an acetyl group from acetyl CoA to a lysine residue, either by a reaction catalyzed by HATs or through an enzyme-free process. Acetylation can dramatically alter the biological properties of a protein (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) as well as being the chemical signal for recognition by bromodomains, a protein–protein interaction subunit found in transcriptional activators.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Meanwhile, a variety of other acyl CoA species undergo a similar reaction with lysine residues in vivo to create distinct PTMs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These include short- and medium-chain saturated carboxylic acids such as formic, propionic, butyric, and myristic; short-chain dicarboxylic acids such as malonic, succinic, and glutaric; and carboxylic acids with additional functionality such as 2-hydroxyisobutyric, crotonic, phosphoglyceric, lipoic, and biotin. Although the precise physiological roles of many of these recently discovered acyllysine PTMs are yet to be deciphered, the inadequacy of the nomenclature’s emphasis on histone proteins and acetylation is apparent.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Examples of the Consequences of Lysine Acetylation in Human Proteins</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">acetylation consequence</th><th class="colsep0 rowsep0" align="center">example</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reduced nucleic acid binding</td><td class="colsep0 rowsep0" align="left">histone-DNA, E2F-DNA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">increased protein binding</td><td class="colsep0 rowsep0" align="left">histone-PCAF, histone-BRD4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reduced protein binding</td><td class="colsep0 rowsep0" align="left">Hsp90-GR, Ku70-p23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">increased stability</td><td class="colsep0 rowsep0" align="left">p53, α-tubulin</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">decreased stability</td><td class="colsep0 rowsep0" align="left">DNMT1, HIF1α</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reduced enzymatic activity</td><td class="colsep0 rowsep0" align="left">Aurora B kinase, RNase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">altered cellular localization</td><td class="colsep0 rowsep0" align="left">STAT3, c-Abl</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">altered aggregation</td><td class="colsep0 rowsep0" align="left">Tau, GRP78</td></tr></tbody></table></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">The 11 Human HDACs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The reversal of lysine acetylation is accomplished by enzymatic cleavage catalyzed by the HDACs. In humans, there are 18 HDACs that fall into two families based on their catalytic mechanism.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Eleven of the HDACs are zinc-dependent metalloenzymes named HDAC1–11 that hydrolyze the amide bond using water as a nucleophile. The remaining seven sirtuins 1–7 employ NAD<sup>+</sup> as a cofactor and transfer the acyl group to the C2 position of the ribose sugar.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Although both enzyme families perform the same chemical reaction of acyllysine cleavage, the term HDAC usually refers to the zinc-dependent enzymes that are the focus of this Perspective.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">X-ray crystal structures are available for the majority of HDAC isoforms with the free protein, protein–inhibitor complexes, and substrates bound to mutated proteins that do not turnover. These extensive studies have provided a detailed understanding of the catalytic mechanism, as exemplified in the model for HDAC8.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The acetyllysine substrate sits in a narrow channel lined with hydrophobic residues, with a tyrosine residue flipping in conformation to enable hydrogen bonding with the carbonyl oxygen (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The hydrophobic nature of the channel and the conformational change by the tyrosine residue serve to provide enzyme specificity for the acyllysine side chain. A zinc cation, coordinated to aspartate and histidine residues, sits at the end of the substrate channel, bound to a water molecule activated by a charge relay mechanism with two adjacent histidine residues. Nucleophilic attack of the carbonyl by the water produces a tetrahedral oxyanion intermediate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), which collapses to give rise to the free lysine and acetate products (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). In some HDAC isoforms, there is an additional hydrophobic internal cavity lateral to the active site also known as the “foot pocket”. This cavity accommodates acyl side chains longer than acetyl in the cases of HDAC8 and HDAC11 (see below) and may aid the entry of water and the release of acetate.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplified illustration of the catalytic mechanism of deacetylation by HDACs: (A) enzyme–substrate complex, with binding interactions between the acetyllysine bearing protein substrate and a tyrosine residue and the zinc cation in the HDAC active site; (B) tetrahedral oxyanion enzyme intermediate arising from nucleophilic attack by water; (C) enzyme–product complex, with the lysine residue and acetate prior to release from the active site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is worth highlighting a few key points regarding the HDAC enzymes:</div><div class="NLM_p">(1) Substrate binding is predominantly through the acetyllysine side chain entering the hydrophobic channel rather than recognition of the protein backbone. In some cases, bonding interactions are observed between HDACs and the amino acid residues that are +1 or −1 with respect to the scissile acetylysine. However, extended contacts such as occur in peptide backbone recognizing proteases are rare in HDACs which are relatively nonspecific in their substrate sequence preferences. The compact nature of substrate binding is an advantage for medicinal chemistry, as small molecule inhibitors need only simulate the acetyllysine residue rather than a longer peptide sequence.</div><div class="NLM_p">(2) Coordination between acetyllysine and the active site zinc cation is critical for substrate binding and catalysis. Indeed, all high affinity HDAC inhibitors barring covalent modifiers achieve their potency by zinc coordination, acting as either monodentate or bidentate ligands to mimic the tetrahedral oxyanion intermediate.</div><div class="NLM_p">(3) In broad terms, the features of the HDAC8 catalytic mechanism hold true for other isoforms. Nevertheless, there are significant variations in the geometry of the active site, the nature of the catalytic residues, the substrate channel, presence or absence of the internal cavity, and positioning of adjacent protein loops. Selective inhibitors that discriminate between HDAC isoforms will need to take advantage of such differences.</div><div class="NLM_p">The human histone deacetylases are further subdivided into four classes according to their sequence homology and cellular localization: class I = HDAC1, HDAC2, HDAC3, and HDAC8; class IIa = HDAC4, HDAC5, HDAC7, and HDAC9; class IIb = HDAC6 and HDAC10; class III = sirtuins 1–7; class IV = HDAC11. However, this classification is somewhat arbitrary and masks the similarities or differences between isoforms in terms of structure and function. In cell-free biochemical assays, HDAC1, HDAC2, HDAC3, and HDAC6 have high enzymatic activity against simple acetyllysine containing peptides and will be discussed first, followed by the other isoforms that are more mysterious in their substrate preferences.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> HDAC1, HDAC2</h3><div class="NLM_p last">These isoforms are core HDACs that are coexpressed and are ubiquitous within and between species.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Although they efficiently hydrolyze acetyllysine peptide substrates on their own in vitro, they predominantly exist in the nucleus as homo- and heterodimer constituents of the NuRD, Sin3A, CoREST, MiDAC, and MIER transcriptional repressor complexes. While there is >80% homology between HDAC1 and HDAC2, they perform independent roles in development and embryonic knockout of either isoform is lethal. On the other hand, in conditional knockouts, there is a level of redundancy with knockout of both isoforms usually needed for a phenotypic effect. HDAC1 and HDAC2 are truly HDACs in the sense that they play a major role in histone deacetylation. In addition, they deacetylate many other nuclear proteins involved in transcriptional regulation including p53, E2F, ATM kinase, and CAF1. There is crosstalk with other epigenetic processes such as methylation, as both DNMT1 and LSD1 are among their substrates.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> HDAC3</h3><div class="NLM_p last">HDAC3 shares ∼50% sequence homology with HDAC1 and HDAC2. The divergence is mainly in the C-terminal region, with HDAC3 containing a domain for binding to the nuclear NCoR/SMRT complexes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In fact, HDAC3 is unstable without the presence of either NCoR or SMRT, and their association is also necessary for the activation of catalysis. Interestingly, the X-ray crystal structure of HDAC3 with the deacetylase-activating domain of SMRT contained a molecule of inositol tetraphosphate at the interface, bringing the two proteins together. Like HDAC1/HDAC2, HDAC3 is ubiquitously expressed and involved in the deacetylation of histones, while other nuclear protein substrates include STAT3 and FOXP3. In addition to distinct roles in embryonic development, HDAC3 is implicated in a number of physiological processes including circadian rhythms, energy metabolism, neuronal function, and bone remodeling.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> HDAC6</h3><div class="NLM_p">If HDAC1–3 are the nuclear workhorses of lysine deacetylation, then HDAC6 is the cytoplasmic equivalent.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> HDAC6 is the largest in size among the HDACs, with a C-terminal ubiquitin-binding zinc finger domain. A nuclear localization sequence (NLS) is opposed by a nuclear export sequence (NES) and Ser-Glu-containing tetrapeptide (SE14) repeats that result in the protein mainly being in the cytoplasm. Through the deacetylation of α-tubulin and cortactin aided by an N-terminal microtubule-binding domain, HDAC6 directly impacts the cytoskeleton and cell mobility. Moreover, HDAC6 is involved in the repair of protein misfolding, as deacetylation of Hsp90 restores its chaperone activity while HDAC6’s ubiquitin-binding domain fosters binding to misfolded proteins and their targeting for destruction by aggresomes. Additional cytoplasmic substrates include Ku70, whose deacetylation leads to a loss in binding to BAX and thereby inhibition of apoptosis, and Tau, in which deacetylation alters the propensity for aggregation. Further to these cytoplasmic roles, HDAC6 can also localize in the nucleus where it functions as a transcriptional repressor similar to HDAC1–3.</div><div class="NLM_p last">Uniquely among the HDACs, HDAC6 contains two catalytic domains CD1 and CD2. While CD2 is a robust lysine deacetylase in vitro, CD1 was considered inactive for a long time. However, recent studies reveal that CD1 is a competent deacetylase with the right substrates, expressing a preference for C-terminal acetyllysine sequences aided by the presence of a lysine residue in CD1 that forms electrostatic interactions with the carboxylate.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Another unusual feature of HDAC6, unlike other isoforms, is that knockout mice are viable and healthy and do not express an obviously defective phenotype.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> HDAC8</h3><div class="NLM_p last">HDAC8 is the only isoform for which the gene lies in the X chromosome. Although it is grouped as a class I nuclear HDAC, it is fundamentally distinct from the HDAC1–3 isoforms in this class.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Unlike the others, HDAC8 is smaller in size and acts independently, as it is bereft of C-terminal protein–protein interaction domains that promote incorporation into multiprotein complexes. In vitro, HDAC8 has a lower <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> value for the hydrolysis of acetyllysine containing peptides compared to HDAC1–3 or HDAC6. Nevertheless, the catalytic activity is significantly higher against tetrameric histone H3/H4 proteins, suggesting that histones are, to some extent, in vivo substrates for HDAC8.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Additional nuclear substrates have been identified such as SMC3, p53, ERRα, and ARID1a. Recently, Lin demonstrated that HDAC8 hydrolyzes acyllysine peptides with acyl chains of 2–16 carbons, and <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> for the longer acyl chains of octanoyl-, dodecanoyl-, and myristoyllysine was higher than for acetyllysine.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These longer chain acyl groups are likely to be accommodated by extending beyond the active site zinc cation to occupy the hydrophobic internal cavity lateral to the substrate channel. It may be that fatty acid deacylation is a more important physiological function of HDAC8 than deacetylation, which would explain the relatively small number of known validated HDAC8 substrates. Physiologically, the incorporation of these longer acyl chains into lysine PTMs could act as a sensor of energy metabolism by reporting on the relative abundance of different acyl CoA species. Alternatively, some fatty acid acylation may occur adventitiously, in which case HDAC8 and HDAC11 (see below) could be operating as proofreading repair enzymes to remove these PTMs.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> HDAC11</h3><div class="NLM_p last">HDAC11 was first reported only in 2002 and is the smallest of the HDAC isoforms, with its catalytic domain accounting for >80% of the protein sequence. Primarily localized in the nucleus, it functions as a transcriptional regulator with an important role in immunomodulation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As an enzyme, HDAC11 has weak activity against acetyllysine substrates. Instead, like HDAC8, it efficiently hydrolyzes acyllysine residues with longer chain lengths such as the C<sub>12</sub> dodecanoyllysine and the C<sub>14</sub> myristoyllysine.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Although an X-ray structure of HDAC11 is unavailable, homology modeling suggests long chain acyl groups are accommodated within an internal cavity in the same manner as HDAC8. Interestingly, HDAC11 is susceptible to product inhibition by free fatty acids such as myristic, palmitic, and stearic acids while palmitoyl-coenzyme A and myristoyl-coenzyme A serve to enhance the fatty acid deacylase activity.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> HDAC4, HDAC5, HDAC7, and HDAC9</h3><div class="NLM_p last">These so-called class IIa isoforms, unlike other HDACs, are expressed in a tissue specific manner. They are relatively large in size, with an N-terminal domain that binds to the MEF2 family of transcriptional repressors.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Both an NLS and NES are present, enabling the class IIa isoforms to move between the nucleus and cytoplasm. The shuttling is regulated by the reversible phosphorylation of multiple serine residues, with the unphosphorylated form being nuclear and acting to influence transcriptional regulation. The C-terminal region contains the active site in which the key tyrosine residue (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) is replaced by a histidine, resulting in weak catalytic activity. By using more electrophilic trifluoroacetyllysine containing peptides, it is possible to carry out in vitro assays and profile HDAC inhibitors against these isoforms. Whether they are truly enzymes in vivo or serve to recognize and bind acetyllysine containing proteins is unclear. The evidence suggests they act as a scaffolding protein, bringing together the acyllysine substrate and HDAC3 containing multiprotein complexes, with the actual hydrolysis carried out by HDAC3. On the other hand, it is worth noting that the archetypal zinc amidohydrolase thermolysin contains a histidine residue in a similar location within the active site that participates in catalysis.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Thus, it is conceivable that the class IIa isoforms are catalytically competent, and their true substrates have yet to be identified. Alternatively, these HDACs may perform dual functions of recognition of an acetyllysine signal followed by slow catalysis as a means of eventual signal termination, in a similar fashion to the binding of GTP to GTPases which then destroy the nucleotide.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> HDAC10</h3><div class="NLM_p last">HDAC10 is found in both the nucleus and cytoplasm and involved in processes such as autophagy, immunoregulation, and DNA repair.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> While it appears to function as a transcriptional repressor, this activity was puzzlingly independent of lysine deacetylation. Recent studies from Christianson have clarified this anomaly and convincingly demonstrated that HDAC10 is an acetylpolyamine hydrolase evolutionarily related to the prokaryotic homologue.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> In HDAC10, a unique 3<sub>10</sub> helix defined by the P(E,A)CE motif serves to narrow the hydrophobic substrate channel, leading to selectivity for acetylpolyamines over more bulky peptides or proteins containing acetyllysine residues. While the HDAC10 active site contains the conserved tyrosine and histidine residues and the zinc activated water typical in HDAC catalysis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), an additional negatively charged glutamate residue unique to this isoform acts as a gatekeeper to favor the binding of cationic acetylpolyamine residues. In fact, the substitution of this glutamate residue by leucine was sufficient to restore acetyllysine hydrolytic activity in the mutant enzyme.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Overview</h3><div class="NLM_p">Our understanding of HDACs is continually evolving with new insights regarding their substrates. Until recently, it seemed the family could be unified under the nomenclature of protein lysine deacylases or KDACs that would encompass both deacetylation and the hydrolysis of other amides. However, the discovery that HDAC10 is a small molecule polyamine deacetylase means that even the KDAC terminology is no longer accurate. Meanwhile, whether HDAC4, HDAC5, HDAC7, and HDAC9 are truly enzymes is debatable. The traditional subdivision of human HDACs according to classes I–IV does not take these recent developments into account, and we prefer to group them according to their in vitro substrate tolerance (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Eleven Human HDAC Isoforms Summarized According to Substrate Preference, Localization, and Key Features</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center">major localization</th><th class="colsep0 rowsep0" align="center">key features</th><th class="colsep0 rowsep0" align="center">substrate examples</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><i>In Vitro Acetyl-Lys Peptide Hydrolases</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC1, HDAC2</td><td class="colsep0 rowsep0" align="left">Nucleus</td><td class="colsep0 rowsep0" align="left">Exist in vivo as NuRD, Sin3A, CoREST, MiDAC, and MIER complexes</td><td class="colsep0 rowsep0" align="left">Histones, transcriptional regulators</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC3</td><td class="colsep0 rowsep0" align="left">Nucleus</td><td class="colsep0 rowsep0" align="left">Complexation with NCoR/SMRT needed for catalysis</td><td class="colsep0 rowsep0" align="left">Histones, transcriptional regulators</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC6</td><td class="colsep0 rowsep0" align="left">Cytoplasm</td><td class="colsep0 rowsep0" align="left">Ubiquitin and microtubule binding domains, two catalytic domains</td><td class="colsep0 rowsep0" align="left">Tubulin, cortactin, Hsp90, Tau</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><i>In Vitro Longer Chain Acyl-Lys Peptide Hydrolases</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC8</td><td class="colsep0 rowsep0" align="left">Nucleus</td><td class="colsep0 rowsep0" align="left">Moderate AcLys hydrolysis with extended sequence recognition, superior for C<sub>8</sub>, C<sub>12</sub>, C<sub>14</sub> acyllysine</td><td class="colsep0 rowsep0" align="left">Histones, p53, SMC3, longer chain acyllysine residues</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC11</td><td class="colsep0 rowsep0" align="left">Nucleus</td><td class="colsep0 rowsep0" align="left">Preference for C<sub>12</sub>, C<sub>14</sub> acyllysine</td><td class="colsep0 rowsep0" align="left">Longer chain acyllysine residues</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><i>In Vitro Ac-polyamine Hydrolase</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC10</td><td class="colsep0 rowsep0" align="left">Cytoplasm</td><td class="colsep0 rowsep0" align="left">Narrow substrate channel with glutamate gatekeeper</td><td class="colsep0 rowsep0" align="left">Acetylpolyamines</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left"><i>In Vitro TrifluoroAc-Lys Peptide Hydrolases</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC4, HDAC5, HDAC7, HDAC9</td><td class="colsep0 rowsep0" align="left">Nucleus and cytoplasm</td><td class="colsep0 rowsep0" align="left">Tissue-specific, MEF2 binding domain</td><td class="colsep0 rowsep0" align="left">None? Recruit substrates for HDAC3</td></tr></tbody></table></div></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A “solar system” of human HDACs. At the core are HDAC1, HDAC2, and HDAC3 which exist in multiprotein complexes in the nucleus. These isoforms deacetylate histones and transcriptional regulators, and homologues are ubiquitous across life forms. Next is HDAC6, responsible for the deacetylation of cytoplasmic proteins, followed by an “asteroid belt” of the pseudoenzymes HDAC4, HDAC5, HDAC7, and HDAC9 with poor catalytic activity. The “outer planets” HDAC8 and HDAC11 preferentially hydrolyze non-acetyl acyllysine substrates, while the distant HDAC10 is a polyamine deacetylase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">While this Perspective is focused on the human HDACs, homologues in other species offer additional opportunities for drug discovery. The selective targeting of fungal HDACs as a means to create novel antifungal agents is one example.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The combination of fluconazole and MethylGene’s MGCD209, an inhibitor of the fungal Hos2 HDAC,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> reached phase 2 clinical trials for the treatment of severe vulvovaginal candidiasis but unfortunately did not show improved efficacy over fluconazole alone. Another major area of research is the HDACs present in parasites responsible for neglected tropical disease. The approved HDAC inhibitors and clinical candidates as well as novel compounds intended to selectively inhibit the parasite enzymes have shown promising results in in vivo models, as summarized in a recent review.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Profiling HDAC Inhibition</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The in vitro profiling of HDAC inhibitors in cell-free enzymatic assays invariably involves the monitoring of product formation using acetyllysine derivatives or peptides based on the N-terminal histone tail sequence that contain an acetyllysine residue.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Assay kits often employ peptides with an AcLys-AMC (aminomethylcoumarin) residue at the C-terminus which undergoes acetyllysine hydrolysis by HDACs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The resulting C-terminal lysine is recognized by the exopeptidase trypsin, which cleaves the backbone amide to release free aminomethylcoumarin that fluoresces at a longer wavelength than the substrate. Although less amenable to high-throughput screening, direct detection of product formation by chromatographic separation or mass spectrometry without the need for trypsin cleavage is among the alternative formats.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In the past, crude cell extracts were used as the source of HDACs, and these mainly contained the nuclear isoforms in an unknown ratio. Nowadays, by use of recombinant HDAC proteins, the detailed profiling of compounds to determine their subtype selectivity against all 11 isoforms can be accomplished.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Fluorescence-based assay for measuring HDAC activity based upon product cleavage by trypsin to release aminomethylcoumarin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Due to differences in protein stability and substrate preference, running HDAC assays against individual isoforms is actually complicated in practice. With regard to the protein, there are options involving full-length enzyme or catalytic domain only or the addition of binding partners to more closely approximate the cellular environment. Purity, with the possibility of residual contamination by other isoforms, and batch to batch variation are further issues. Simple acetyllysine containing substrates undergo efficient hydrolysis by recombinant HDAC1, HDAC2, and HDAC6 in the fluorescent assay, as well as HDAC3 when coexpressed with NCoR.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Although such assays are operationally convenient, it should be kept in mind that the true substrates are proteins (or multimeric complexes thereof) rather than acetyllysine derivatives or peptides. Beyond these isoforms, further tinkering is needed for the other HDACs which have lower catalytic activity for acetyllysine hydrolysis. By switching to more labile (but artificial) trifluoroacetyllysyl substrates in lieu of acetyllysine derivatives or using mutated enzymes with higher turnover, the inhibition can be quantitatively measured. However, these assays may not accurately reflect the in vivo functions of the enzyme. For example, HDAC11 preferentially acts upon non-acetyllysine PTMs, and a recent assay employing a longer acyllysine substrate showed significant differences compared to the traditional trifluoroacetyllysine-based method.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Similarly, the current HDAC10 kits are based on peptides rather than more meaningful acetylpolyamine substrates. As a result of all these complexities, care should be exercised in the interpretation of literature HDAC IC<sub>50</sub> or <i>K</i><sub>i</sub> values taken at different times or from different laboratories, and the experimental procedures consulted for the exact assay method employed and the data obtained for reference standards.</div><div class="NLM_p last">In cell-based studies, HDAC inhibitors are usually profiled by their growth inhibition of human cancer cell lines, with readouts in other cell types used for noncancer therapeutic indications. Evidence of HDAC target engagement is commonly demonstrated by Western blotting of the substrate proteins such as histones for nuclear HDACs, p53 for HDAC1, and tubulin for HDAC6 to show a dose-dependent elevation of acetylation levels. Cellular thermal shift assays (CETSA) are a version that allow for the quantification of ligand binding in intact cells.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The NanoBRET technology based on competitive binding between inhibitor and a fluorescent tracer is an alternative approach that enables the measurement of target engagement and drug reisdence time in cells.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, downstream effects as a result of HDAC inhibition can be measured, ranging from phenotypic changes such as cell differentiation to altered protein expression levels such as induction of the p21 (CIP1/WAF1) cyclin-dependent kinase inhibitor.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Natural Product HDAC Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To inhibit a HDAC, the logical starting point is to mimic the tetrahedral oxyanion enzyme intermediate (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) and design a molecule that coordinates to the active site zinc cation with a slender hydrophobic linker to fit the substrate binding channel. In addition, it is helpful to anchor the molecule at the other end with a cap that can potentially engage in additional binding interactions with the rim of the enzyme. In fact, this simple model for a HDAC pharmacophore composed of three elements (zinc binding group, linker, and cap) is sufficiently powerful to account for the vast majority of HDAC inhibitors and is widely used since it was proposed by Jung in 1997.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">As the medicinal chemist par excellence, nature has successfully used the three-point model for the design of nanomolar HDAC inhibitors with a variety of zinc binding groups, linkers, and caps. As mentioned in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, the <i>Streptomyces</i> metabolite trichostatin A (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was the first potent HDAC inhibitor to be identified, by Yoshida 30 years ago.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Trichostatin A perfectly illustrates the HDAC pharmacophore: the hydroxamic acid functions as a bidentate zinc chelator, as later confirmed through X-ray crystallography of trichostatin A-HDAC complexes, while the diene is a rigid linker that sits in the substrate channel and terminates with a substituted phenyl ring as the cap. The cap’s tertiary amine substituent, protruding out of the enzyme surface, presumably aids in drug solvation by the aqueous environment. Psammaplin A (<b>2</b>) isolated from a marine sponge is a symmetrical prodrug, undergoing disulfide reduction to the active molecule which conforms to the three-point pharmacophore with the thiol as a monodentate zinc binding group.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Since thiols have poor bioavailability, the disulfide protection ensures higher stability and cell permeability prior to metabolic activation. A masked thiol prodrug features once again in the depsipeptide family of HDAC inhibitors, either as a reducible disulfide in the bacterial natural products romidepsin (FK228, <b>3</b>) and spiruchostatin A (<b>4</b>) or as a hydrolytically labile thioester in largazole (<b>5</b>) of cyanobacterial origin.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Upon metabolism, the free thiol common to all three natural products becomes the zinc binding group, as observed in the X-ray structure of largazole with HDAC8.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Examples of potent natural product HDAC inhibitors, with zinc binding atoms indicated in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While trichostatin A with its simple aromatic cap is a nonselective HDAC inhibitor, both romidepsin and largazole contain larger macrocyclic caps that contribute to their enzyme affinity as well as enable isoform discrimination.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The importance of augmenting zinc and substrate channel binding with additional interactions is illustrated by the marine sponge natural product azumamide E (<b>6</b>). Synthetic carboxylic acids have fared poorly as HDAC inhibitors despite their successful use as zinc binding groups against other metalloenzymes. Although the short chain butyric, phenylbutyric, and valproic acids have been explored as HDAC inhibitors in the clinic, their sole redeeming factor is the existence of prior human safety and pharmacokinetic data. The actual inhibition of HDACs by these carboxylic acids is weak, verging upon the high micromolar level, and they will not be discussed further. Azumamide E, on the other hand, achieves submicromolar potency with selectivity for HDAC1 over HDAC6, and the macrocyclic scaffold presumably makes a significant contribution to these properties. Interestingly, a synthetic analogue with the carboxylic acid replaced by a bidentate hydroxamic acid is even more active as a HDAC inhibitor.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Trapoxin A (<b>7</b>), one of a family of fungal cyclic tetrapeptide HDAC inhibitors, is another interesting example as ketones are normally inefficient ligands for zinc. The X-ray structure of <b>7</b> with HDAC8 indicates the ketone is a substrate mimic, reacting with the active site water to form a tetrahedral <i>gem</i>-diolate which then functions as a bidentate zinc binding group.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p last">Although medicinal chemists work on many epigenetic targets for drug discovery, HDACs are apparently the only one that nature has taken seriously and the only one against which highly active secondary metabolites have been discovered. This emphasis probably reflects the producing microbial or marine organism’s need for chemical defense against competing species or predators. In this regard, the rapid toxicity arising from HDAC inhibition is evolutionarily more helpful compared to the slower consequences of the disruption of DNA or histone methylation. A further question is which HDAC should be inhibited, with the core HDAC1/HDAC2 isoforms being prime candidates due to their direct impact upon gene transcription and the existence of homologues in virtually all species. Indeed, it is unlikely to be a coincidence that all the natural products in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> strongly inhibit HDAC1/HDAC2 with nanomolar IC<sub>50</sub> values and, except for the nonselective trichostatin A, are less active against the cytoplasmic HDAC6. Turner has suggested that evolutionary exposure to natural product and environmental HDAC inhibitors may have forced organisms to develop resistance mechanisms, and these same pathways are now subverted by tumor cells to their advantage upon chemotherapy with such agents.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Clinical Candidate and Approved HDAC Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In a tour de force of chemical biology, Breslow started with DMSO as a lead for cell differentiation and eventually progressed to a more active series of hydroxamic acids culminating in suberoylanilide hydroxamic acid (SAHA).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Later acquired by Merck, SAHA now known as vorinostat (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) became the first HDAC inhibitor to receive FDA approval in 2006 for the treatment of cutaneous T-cell lymphoma. In parallel, the depsipeptide natural product romidepsin (<b>3</b>) was also discovered on the basis of phenotypic activity before its molecular target was identified. Romidepsin advanced to clinical development by Gloucester Pharmaceuticals before receiving FDA approval in 2009 for cutaneous T-cell lymphoma as well. Another natural depsipeptide, spiruchostatin A (OBP-801, <b>4</b>), is under investigation in phase 1 clinical trials for the treatment of solid tumors.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Meanwhile, the elucidation of the mechanism of action of trichostatin A led to tremendous medicinal chemistry interest in hydroxamic acids as HDAC inhibitors, and they remain the most popular choice of zinc binding group against this target. Subsequent to vorinostat, six other clinical candidates tefinostat (<b>9</b>),<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> CG200745 (<b>10</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> ricolinostat (<b>11</b>),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> citarinostat (<b>12</b>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> CUDC-101 (<b>13</b>),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and tinostamustine (<b>14</b>)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> have appeared that feature similar aliphatic hydroxamic acids with linear methylene chains. The X-ray structure of the vorinostat-HDAC8 complex (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) illustrates the typical bidentate coordination observed with hydroxamic acids within the HDAC active site.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Clinical candidate HDAC inhibitors with aliphatic hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding interactions in the vorinostat-HDAC8 X-ray structure. The zinc cation is displayed as a centroid with the coordinating Asp and His residues in pink. The His and Tyr residues involved in water activation and substrate binding respectively are indicated in blue. Reproduced with permission from   <cite><i>European Journal of Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Bertrand, P.</span></contrib-group>, Inside HDAC with HDAC Inhibitors, Vol. <em>45</em>, pp 2095–2116, Copyright <span class="NLM_year">2010,</span> Elsevier.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A second family of HDAC inhibitors, inspired by trichostatin A, contain a more rigid alkenyl hydroxamic acid. In 2014, belinostat (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), originating from Prolifix and now marketed by Onxeo/Spectrum, became the third HDAC inhibitor to be approved for T-cell lymphoma after vorinostat and romidepsin.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> A year later, Novartis’s panobinostat (<b>16</b>) was approved for the treatment of relapsed or refractory multiple myeloma by both the FDA and the EMA.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Two other alkenyl hydroxamic acids resminostat (<b>17</b>)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and pracinostat (<b>18</b>)<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> are in clinical trials. A newer series of compounds contains an even more rigid phenylhydroxamic acid: givinostat (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>),<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> abexinostat (<b>20</b>),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> AR-42 (<b>21</b>),<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and bisthianostat (<b>22</b>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> A more polar pyrimidinyl heteroaromatic hydroxamic acid was employed in quisinostat (<b>23</b>),<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> nanatinostat (<b>24</b>),<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and fimepinostat (<b>25</b>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Clinical candidate HDAC inhibitors with alkenyl hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Clinical candidate HDAC inhibitors with aromatic hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacodynamic data against individual HDAC isoforms are available for the approved drugs and the majority of clinical candidates (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Romidepsin has the typical profile of natural product HDAC inhibitors, with a high activity against the nuclear isoforms HDAC1–3.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> There is selectivity, as the natural product is sparing against HDAC8 and HDAC6 although the non-acetyllysine hydrolyzing HDAC10 and HDAC11 are also strongly inhibited. Compared to romidepsin, the forerunner of the hydroxamic acids, vorinostat, has a saturated aliphatic linker and a phenyl cap. With its relatively simple and unconstrained structure, vorinostat would not be predicted to be selective (nor was it intended to be, since the subtleties of isoform function were unknown at the time), and in biochemical enzyme assays it inhibits both the nuclear and cytoplasmic HDACs indiscriminately at submicromolar levels. Although the later hydroxamic acids show an extensive diversity in the architecture of their linker and cap regions, they share a common pharmacological profile insofar that all potently inhibit HDAC1–3 just like vorinostat or romidepsin.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values of Clinical Candidate and Approved Thiol and Hydroxamic Acid HDAC Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="11" align="center">HDAC isoform, IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center">8</th><th class="colsep0 rowsep0" align="center">4</th><th class="colsep0 rowsep0" align="center">5</th><th class="colsep0 rowsep0" align="center">7</th><th class="colsep0 rowsep0" align="center">9</th><th class="colsep0 rowsep0" align="center">6</th><th class="colsep0 rowsep0" align="center">10</th><th class="colsep0 rowsep0" align="center">11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">romidepsin (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">647</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">226</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat (<b>8</b>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">173</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">129</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ricolinostat (<b>11</b>)</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">citarinostat (<b>12</b>)</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">137</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">belinostat (<b>15</b>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">panobinostat (<b>16</b>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pracinostat (<b>18</b>)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">104</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">247</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">givinostat (<b>19</b>)</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">293</td><td class="colsep0 rowsep0" align="left">136</td><td class="colsep0 rowsep0" align="left">837</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">532</td><td class="colsep0 rowsep0" align="left">524</td><td class="colsep0 rowsep0" align="left">512</td><td class="colsep0 rowsep0" align="left">312</td><td class="colsep0 rowsep0" align="left">331</td><td class="colsep0 rowsep0" align="left">287</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">abexinostat (<b>20</b>)</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">148</td><td class="colsep0 rowsep0" align="left">370</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">350</td><td class="colsep0 rowsep0" align="left">168</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bisthianostat (<b>22</b>)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">quisinostat (<b>23</b>)</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">119</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fimepinostat (<b>25</b>)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">191</td><td class="colsep0 rowsep0" align="left">409</td><td class="colsep0 rowsep0" align="left">674</td><td class="colsep0 rowsep0" align="left">426</td><td class="colsep0 rowsep0" align="left">554</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">For these compounds, <i>K</i><sub>i</sub> values are given, from a side-by-side comparison in ref <a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a>. Data for other compounds compiled from refs <a onclick="showRef(event, 'ref51 ref52 ref60 ref61 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref60 ref61 ref63 ref64">(51,52,60,61,63,64)</a>, <a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a>, and <a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a>.</p></div></div></div><div class="NLM_p">Besides the hydroxamic acids, <i>ortho</i>-aminoanilides (or benzamides) are a second class of synthetic HDAC inhibitors that have yielded clinical candidates. X-ray crystallography of enzyme–inhibitor complexes shows bidentate coordination of the carbonyl oxygen and aniline nitrogen with the active site zinc cation. Nevertheless, <i>ortho</i>-aminoanilides would be expected to be weaker metal binders than hydroxamic acids, and this is reflected in their typical micromolar IC<sub>50</sub> values in standard assay conditions compared to the nanomolar potency of the latter. However, the <i>ortho</i>-aminoanilides exhibit unusual kinetics, being tight-binding inhibitors with slow-on/slow-off rates that benefit from preincubation and equilibration compared to the fast-on/fast-off behavior observed with hydroxamic acids. For example, with preincubation, an <i>ortho</i>-aminoanilide had <i>K</i><sub>i</sub> values of 148 and 5 nM respectively against HDAC1 and HDAC3, compared to 5 and 8 nM respectively for vorinostat (whose activity was unchanged upon preincubation).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Pfizer’s tacedinaline (<b>26</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>)<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> was an early <i>ortho</i>-aminoanilide clinical candidate  with a simpler cap compared to entinostat (<b>27</b>)<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and mocetinostat (<b>28</b>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Tucidinostat (<b>29</b>) from Shenzen Chipscreen Biosciences received approval from the CFDA in 2015 for the treatment of peripheral T-cell lymphoma and marks the first example of a “Made in China” drug where the entire drug discovery process was carried out there.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Domatinostat (<b>30</b>)<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and CXD101 (<b>31</b>)<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> are additional <i>ortho</i>-aminoanilides in clinical trials.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Clinical candidate <i>ortho</i>-aminoanilide HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The available literature data on <i>ortho</i>-aminoanilides (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) indicate they are similar as a class, inhibiting HDAC1–3 while poorly active against HDAC6 and HDAC8. The larger dimensions of the <i>ortho</i>-aminoanilide compared to a thiol or hydroxamic acid zinc binding group can be accommodated by the lateral cavity present in HDAC1–3 but absent in HDAC6. Although HDAC8 contains the lateral cavity, the substitution of a tryptophan residue for a leucine present in HDAC1–3 leads to a shallower channel that does not bind to the <i>ortho</i>-aminoanilide. To some extent, the <i>ortho</i>-aminoanilides are similar in their activity profile to romidepsin and related depsipeptide natural products in that they predominantly inhibit HDAC1–3.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. IC<sub>50</sub> Values of Clinical Candidate and Approved <i>ortho</i>-Aminoanilide HDAC Inhibitors Compiled from Refs <a onclick="showRef(event, 'ref69 ref70 ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71 ref72 ref73 ref74">(69−74)</a><a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="11" align="center">HDAC isoform, IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">1</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">3</th><th class="colsep0 rowsep0" align="center">8</th><th class="colsep0 rowsep0" align="center">4</th><th class="colsep0 rowsep0" align="center">5</th><th class="colsep0 rowsep0" align="center">7</th><th class="colsep0 rowsep0" align="center">9</th><th class="colsep0 rowsep0" align="center">6</th><th class="colsep0 rowsep0" align="center">10</th><th class="colsep0 rowsep0" align="center">11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tacedinaline (<b>26</b>)</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">entinostat (<b>27</b>)</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mocetinostat (<b>28</b>)</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tucidinostat (<b>29</b>)</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">domatinostat (<b>30</b>)</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">9.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXD101 (<b>31</b>)</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">Note that values are in μM, unlike the nM in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, and assay conditions may not have involved enzyme preincubation.</p></div></div></div><div class="NLM_p last">In addition to the compounds discussed above, there are HDAC inhibitors in phase 1 clinical trials with undisclosed structures: CKD-504 and CKD-506 (Chong Kung Dan Pharmaceutical Corp.), CS3003 (CStone Pharmaceuticals), HG146 (HitGen), KA2507 (Karus Therapeutics), and OKI-179 (OnKure). The majority are reported to be HDAC6 selective inhibitors, while OKI-179 is a synthetic analogue of largazole (<b>5</b>).</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">HDAC Inhibitors as Cytotoxic Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">After the DNMTs, HDACs were the next epigenetic target to receive scrutiny for drug discovery, and this rapidly accelerated with the early discovery of compounds that displayed potent antiproliferative activity in human cancer cell lines that was recapitulated in tumor xenograft animal models. At the same time, the simplicity and flexibility of the HDAC pharmacophore provided medicinal chemists with the freedom to operate and design and optimize independent lead series. Since the first-in-human experiments with vorinostat in 2000, HDAC inhibitors have been investigated in nearly a thousand clinical trials, primarily in oncology but numerous other indications as well. It is fair to say the accumulated clinical experience from the past 2 decades is disappointing as it did not fulfill the promise of the earlier data from in vitro and in vivo models. Efficacy with an acceptable margin of safety and tolerability has mainly been observed in certain hematological cancers.<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> To date, we have four approvals for T-cell lymphoma, one for multiple myeloma and one for combination therapy against breast cancer, and the HDAC inhibitors are not first-line therapy against any of these indications.</div><div class="NLM_p">What HDAC inhibitors actually do in cells is an extremely complicated question. Microarray experiments indicate that <10% of the genome undergoes significantly altered expression upon treatment with a HDAC inhibitor.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In a cancer cell, these perturbations appear to disrupt their metastable state and drive the cell toward nonproliferative fates involving a combination of differentiation, immunomodulation, chromatin instability, reduced DNA damage repair, reactive oxygen species production, cell cycle arrest, apoptosis, autophagy, and the reduction of angiogenesis and cell migration.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> These effects are most strongly felt in hematological cancers, perhaps due to the fact that the tumor is derived in a complex process of hematopoiesis from stem cells. Epigenetic programming plays a heavy role in this transformation, and the blood cell lineages appear to be more plastic and susceptible to reprogramming compared to more terminally differentiated cancer types. The particular success in the treatment of T-cell lymphoma is strongly linked to immunomodulation, as HDAC inhibitors cause a reduction in the “cytokine storm” characteristic of this disorder.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Meanwhile, it has proven challenging to find a therapeutic window that allows the higher dosing needed against more aggressive cancers without compromising patient tolerability.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Resistance to HDAC inhibitors is a further issue,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> mainly arising via compensating changes in HAT/HDAC expression levels, the induction of p21 (CIP1/WAF1) and thioredoxin, and drug efflux by ABC transporters.</div><div class="NLM_p">The first clinical candidates vorinostat and romidepsin have limited oral bioavailability, and their trials required intravenous administration. Romidepsin, with its complex structure, was considered intractable for analogue generation, although this would eventually change through the design of efficient total synthesis routes by academic groups.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> While vorinostat is a much simpler molecule and an oral formulation was later developed, it suffers from extensive metabolism through hydroxamic acid glucuronidation and oxidative cleavage of the aliphatic methylene chain. For fast followers, the main challenge was to improve target affinity and the pharmacokinetic liabilities, and both aspects were successfully addressed in second generation HDAC inhibitors. However, the primary focus was cancer, in which the cytotoxic activity is largely driven by the inhibition of HDAC1–3. Thus, medicinal chemistry lead optimization consciously or subconsciously selected for compounds with high activity against these nuclear isoforms. In the clinic, both the older and the newer compounds exhibit a similar pattern of dose limiting toxicities and adverse events dominated by fatigue, diarrhea, bone marrow toxicity, thrombocytopenia, and in some cases cardiac abnormalities. Since these are observed regardless of the nature of the inhibitor, they are likely to be on-target effects due to systemic HDAC inhibition rather than compound specific idiosyncrasies. The pleiotropic nature of the cellular response to HDAC inhibition is indicative of a global disruption of gene expression, which leads to the following conclusions:</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">1.  The Clinical Effects Are Driven by HDAC1, HDAC2, and HDAC3 Inhibition</h3><div class="NLM_p last">The inhibition of these isoforms increases the acetylation of histones and other nuclear proteins, leading to gene activation through increased accessibility of DNA by RNA pol II and the promotion of protein–protein interactions between bromodomain containing proteins and acetyllysine residues. Our current portfolio of clinical candidates (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) is unanimously identical in its high activity against HDAC1–3, and we believe this is the reason why compounds are not particularly differentiated from one another in their biological effects.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">2.  The Inhibition of Isoforms in Addition to HDAC1–3 by Current Candidates Is Likely To Be Undesirable</h3><div class="NLM_p last">The clinical compounds primarily vary in their selectivity between the nuclear isoforms HDAC1–3 and the cytoplasmic HDAC6. Some inhibit both the nuclear and cytoplasmic enzymes strongly (e.g., vorinostat and fast followers), while others are either selective for HDAC1–3 (e.g., romidepsin, <i>ortho</i>-aminoanilides) or HDAC6 (e.g., ricolinostat). However, these differences have not translated into major shifts in therapeutic application or dramatic clinical benefit for one compound over another. Meanwhile, a lack of activity observed in enzyme assays against HDAC4, HDAC5, HDAC7, and HDAC9 is a misleading measure of selectivity, as a compound may still be capable of binding to the active sites and thereby abrogate their nonenzymatic role in protein scaffolding. As for HDAC8, HDAC10, and HDAC11, the traditional assays indicate differing levels of inhibition that may again be of questionable relevance given their preference for non-acetyllysine substrates. Although there are fine distinctions in biochemical in vitro selectivity between the clinical inhibitors in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, this may conceal a broader in vivo spectrum of activity against the majority of isoforms. While the inhibition of isoforms other than HDAC1–3 may be beneficial, in nonselective compounds any advantage that accrues is likely to be swamped out by the side effects arising from HDAC1–3 inhibition. The history of medicinal chemistry suggests that improved target selectivity usually leads to a superior safety profile, and this is likely to hold true for HDACs as well.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">3.  The Clinical Compounds Are Cytotoxic Agents</h3><div class="NLM_p last">Although HDAC inhibitors are a modern chapter in drug discovery, their phenotypic effects are widespread and not restricted to a particular cellular pathway or compartment. Their activity profile as drugs, at least in its present manifestation, is reminiscent of classical cytotoxic agents rather than a targeted therapy. In their account of the discovery of vorinostat (SAHA),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Breslow and Marks made these prescient comments: “Even if some increase or decrease in transcription of particular genes is helpful in the anticancer effects of SAHA, as has been proven to be the case, a continuing long-term modulation induced by a drug that is slowly released from the receptor pocket (and indeed might bind reasonably strongly to other sites) could cause undesirable effects. SAHA has hit the happy medium. It is potent enough to be useful and tolerated in patients. If the dosing is intermittent, such as not to maintain a continuous “therapeutic” level of SAHA, it can be released from the binding site periodically so as to allow the deacetylation activities in cells. This is a general consideration, which could well be true of many other medicinal compounds. Thus, it is probably a mistake for medicinal chemists to set out first to find the most potent compound they can achieve in a series and then to look at any question of toxicity, as is often done. As with SAHA, in other series there will be examples in which the medium potency compound has enough efficacy to be a useful drug but not so much as to cause unacceptable side effects.”</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Clinical Performance of HDAC Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Monotherapy</h3><div class="NLM_p">Aside from the approvals in hematological cancers, HDAC inhibitors are under exploration in single agent phase 2/3 clinical trials for other oncology applications as well as noncancer indications (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Among these examples, tefinostat is designed to have selective toxicity in liver cancer. Hepatocytes express carboxylesterase-1 that hydrolyzes the tefinostat ester to a pharmacologically active carboxylic acid which is retained due to its ionized nature, whereas in other cells efflux of the neutral drug limits exposure. Panobinostat, aside from its approval in multiple myeloma, is under investigation as an immunomodulator for graft-versus-host diseases following allogeneic hematopoietic stem cell transplantation.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Outside oncology, vorinostat is in early studies for the treatment of epilepsy<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> and Cushing’s disease.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Meanwhile, Italfarmaco is pursuing the development of givinostat for Duchenne and Becker muscular dystrophy,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> while Regenacy is targeting ricolinostat for diabetic neuropathic pain.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Early indications from multiple myeloma clinical trials are encouraging regarding the tolerability of ricolinostat, 10-fold selective for HDAC6 over HDAC1–3, compared to inhibitors with lower selectivity.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Drug Approvals and Examples of Phase 2/3 Trials Conducted with HDAC Inhibitors<a class="ref internalNav" href="#tbl5-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">organization</th><th class="colsep0 rowsep0" align="center">indication</th><th class="colsep0 rowsep0" align="center">status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">romidepsin</td><td class="colsep0 rowsep0" rowspan="3" align="left">Bristol Myers Squibb</td><td class="colsep0 rowsep0" align="left">cutaneous T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">FDA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">peripheral T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">FDA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HIV, +3BNC117</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03041012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">vorinostat</td><td class="colsep0 rowsep0" rowspan="4" align="left">Merck</td><td class="colsep0 rowsep0" align="left">cutaneous T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">FDA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">epilepsy</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03894826</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cushing’s disease</td><td class="colsep0 rowsep0" align="left">phase 2, no. 04339751</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer, +pembrolizumab, tamoxifen</td><td class="colsep0 rowsep0" align="left">phase 2, no. 04190056</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tefinostat</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline</td><td class="colsep0 rowsep0" align="left">hepatocellular carcinoma</td><td class="colsep0 rowsep0" align="left">phase 1/2, no. 02759601</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ricolinostat</td><td class="colsep0 rowsep0" align="left">Regenacy</td><td class="colsep0 rowsep0" align="left">diabetic neuropathic pain</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03176472</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">belinostat</td><td class="colsep0 rowsep0" align="left">Onxeo, Spectrum</td><td class="colsep0 rowsep0" align="left">peripheral T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">FDA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">panobinostat</td><td class="colsep0 rowsep0" rowspan="3" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">multiple myeloma</td><td class="colsep0 rowsep0" align="left">FDA, EMA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">graft-versus-host disease</td><td class="colsep0 rowsep0" align="left">phase 3, no. 04326764</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">myelodysplastic syndrome, +azacitidine</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03151304</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">pracinostat</td><td class="colsep0 rowsep0" rowspan="2" align="left">Helsinn, Menarini</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia, +azacitidine</td><td class="colsep0 rowsep0" align="left">phase 3, no. 03151408</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">myelodysplastic syndrome, +azacitidine</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03151304</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">givinostat</td><td class="colsep0 rowsep0" rowspan="2" align="left">Italfarmaco</td><td class="colsep0 rowsep0" align="left">Duchenne muscular dystrophy</td><td class="colsep0 rowsep0" align="left">phase 2/3, no. 03373968</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">polycythemia vera, +hydroxyurea</td><td class="colsep0 rowsep0" align="left">phase 2, no. 00928707</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">abexinostat</td><td class="colsep0 rowsep0" rowspan="2" align="left">Xynomics</td><td class="colsep0 rowsep0" align="left">follicular lymphoma</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03934567</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">renal carcinoma, +pazopanib</td><td class="colsep0 rowsep0" align="left">phase 3, no. 03592472</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">entinostat</td><td class="colsep0 rowsep0" rowspan="2" align="left">Syndax</td><td class="colsep0 rowsep0" align="left">breast cancer, +exemestane</td><td class="colsep0 rowsep0" align="left">phase 3, no. 02115282 and no. 03538171</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">renal carcinoma, +IL-2</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03501381</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="4" align="left">tucidinostat</td><td class="colsep0 rowsep0" rowspan="4" align="left">Chipscreen</td><td class="colsep0 rowsep0" align="left">peripheral T-cell lymphoma</td><td class="colsep0 rowsep0" align="left">CFDA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B-cell lymphoma</td><td class="colsep0 rowsep0" align="left">phase 3, no. 04231448</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer, +exemestane</td><td class="colsep0 rowsep0" align="left">NMPA approved</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">soft-tissue sarcoma, +toripalimab</td><td class="colsep0 rowsep0" align="left">phase 2, no. 04025931</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">domatinostat</td><td class="colsep0 rowsep0" align="left">4SC</td><td class="colsep0 rowsep0" align="left">GI cancers, +avelumab</td><td class="colsep0 rowsep0" align="left">phase 2, no. 03812796</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl5-fn1"><div class="footnote" id="tbl5-fn1"><sup><sup>a</sup></sup><p class="last">For combination trials, the other drugs involved are indicated with “+”. The clinical trial is identified by the ClinicalTrials.gov NCT number.</p></div></div></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Combination Therapy</h3><div class="NLM_p">The development of resistance is a major obstacle to cancer chemotherapy, and one of the contributing factors is the stem cell-like tumor phenotype that fosters epigenetic reprogramming in response to the drug. This suggests that combination with a HDAC inhibitor could be valuable in sensitizing cancer cells to the treatment, and many clinical trials have investigated this hypothesis.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> Combination therapy of HDAC inhibitors with cytotoxic agents has not shown significant promise, and this further supports our conclusion that nonselective HDAC inhibitors themselves behave as cytotoxic agents. Meanwhile, the approval of panobinostat for multiple myeloma has led to multiple trials with first-line therapies against this indication such as bortezomib and lenalidomide.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Numerous studies have focused on the potential synergy between kinase and HDAC inhibitors, and a phase 3 trial is investigating the combination of abexinostat and pazopanib.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><div class="NLM_p">Promising results were observed in the treatment of postmenopausal breast cancer using the combination of the aromatase inhibitor exemestane and the <i>ortho</i>-aminoanilide HDAC inhibitor entinostat.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> A larger phase 3 trial in China with a similar combination of exemestane and tucidinostat reported positive results that led to the 2019 NMPA approval of this combination for the treatment of breast cancer.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> This landmark event represents the first approval of a HDAC inhibitor for an indication outside hematological cancers.</div><div class="NLM_p last">Since both HDACs and DNMTs are transcriptional repressors, combined epigenetic therapy against these two targets is an attractive proposition. Pracinostat is in late stage trials in combination with the DNMT inhibitor azacitidine for the treatment of myelodysplastic syndrome and newly diagnosed acute myeloid leukemia.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> At an earlier stage, biologic antibodies, including immunotherapy agents,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> are being explored in combination trials with various HDAC inhibitors. Among the nononcologic indications, the ability of HDAC inhibitors to reactivate latent reservoirs of the HIV virus to undergo replication appears to be the most promising for combination therapy. The potency of romidepsin in inhibiting the nuclear HDAC1–3 isoforms suggests it is a good candidate for viral transcriptional activation, and phase 2 trials with the neutralizing antibody 3BNC117 are underway.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Dual Mechanism Agents</h3><div class="NLM_p last">An interesting approach to leveraging HDAC inhibitors is to take advantage of their simple three-point binding model. Since the cap region is not involved in critical contacts with the active site, it is possible to introduce an independent second pharmacophore here to give dual mechanism of action agents that achieve the equivalent of combination therapy within a single entity.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> The U.S. company Curis has pioneered this strategy, and their first clinical candidate CUDC-101 is a hybrid of vorinostat and erlotinib with a nanomolar activity profile against both HDACs and receptor tyrosine kinases.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> A second Curis candidate fimepinostat is a hybrid of pyrimidinyl HDAC inhibitors and the PI3K inhibitor pictilisib, with nanomolar IC<sub>50</sub> values against all four PI3K isoforms in addition to its HDAC inhibition. Fimepinostat has received FDA Fast Track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> It was shown to be similarly potent as romidepsin in the reversal of HIV-1 latency, without a negative effect on T cell proliferation.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Mundipharma’s tinostamustine is a more recent dual mechanism of action agent related to the DNA alkylating agent bendamustine and combines this activity with HDAC inhibition. Serendipitously, the HDAC inhibitor domatinostat was recently found to have a second target as it potently inhibits tubulin polymerization.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Larger late stage trials are needed before the efficacy and tolerability of these four multitargeting drugs can be evaluated in a clinical setting.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Atypical HDAC Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Not all HDAC inhibitors fully adhere to the classical zinc binding group–linker–cap model, and some outliers illustrate the possibilities for such nonconformist compounds. Intriguingly, Olsen’s romidepsin analogue <b>32</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) has the thiol zinc binding group removed.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> While the compound is 2 orders of magnitude weaker in HDAC inhibition than romidepsin, it still possesses a respectable level of activity. Since zinc binding groups generally come with associated pharmacokinetic issues, this example suggests that it is possible to avoid them altogether if sufficient binding by other means is possible. Meanwhile, in the HDAC8 bound X-ray structure of Novartis’s phenylalanine derivative <b>33</b>, the two aromatic rings sit within the hydrophobic substrate channel and the internal cavity (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), meaning that this inhibitor has no cap.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The X-ray structure shows coordination between the zinc cation and the α-aminoamide, a rare motif for a zinc binding group. As the internal cavity is absent in HDAC6, <b>33</b> is inactive against this isoform and moreover shows selectively for HDAC8 over HDAC1 and HDAC2. The cyclopentenyl hydroxamic acid <b>34</b> is an even more minimal “capless” HDAC inhibitor with some selectivity for HDAC6.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Some examples of unusual HDAC inhibitors. In this and subsequent figures, IC<sub>50</sub> values (or in some instances <i>K</i><sub>i</sub>) against individual isoforms are given, with values below 1 μM highlighted in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray structure of the <b>33</b>-HDAC8 complex showing active site interactions. Reproduced with permission from   <cite><i>Bioorganic & Medicinal
Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Whitehead, L.</span>; <span class="NLM_string-name">Dobler, M. R.</span>; <span class="NLM_string-name">Radetich, B.</span>; <span class="NLM_string-name">Zhu, Y.</span>; <span class="NLM_string-name">Atadja, P. W.</span>; <span class="NLM_string-name">Claiborne, T.</span>; <span class="NLM_string-name">Grob, J. E.</span>; <span class="NLM_string-name">McRiner, A.</span>; <span class="NLM_string-name">Pancost, M. R.</span>; <span class="NLM_string-name">Patnaik, A.</span>; <span class="NLM_string-name">Shao, W.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Tichkule, R.</span>; <span class="NLM_string-name">Tommasi, R. A.</span>; <span class="NLM_string-name">Vash, B.</span>; <span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Stams, T.</span></contrib-group>, Human HDAC Isoform Selectivity Achieved via Exploitation of the Acetate Release Channel with Structurally Unique Small Molecule Inhibitors, Vol. <em>19</em>, pp 4626–4634, Copyright <span class="NLM_year">2011</span>, Elsevier.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two other unusual HDAC inhibitors are <b>35</b> and <b>36</b>. The benzoylhydrazide <b>35</b> is a typical example of this class with reported selectivity for the nuclear isoforms HDAC1–3.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Although X-ray crystallographic evidence of the binding mode is unavailable, docking studies suggest zinc coordination is not involved and the compound has unusual fast-on/slow-off kinetics. On the other hand, the vorinostat analogue <b>36</b> highlights that the linker is not just a space filling moiety. By switching from the suberoyl linker to its perfluorinated variant, the activity of the approved drug is virtually lost against human HDACs. However, <b>36</b> gains in potency against two bacterial HDAC-like enzymes PA3774 and PA0321 from the pathogen <i>Pseudomonas aeruginosa</i>.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div class="NLM_p">The heterocycle <b>37</b>, despite its compact nature and apparent lack of a linker or zinc binding group, was reported to selectively inhibit HDAC8. Further investigation revealed that <b>37</b> is an electrophilic thiol-reactive species that leads to covalent modification of the Cys28, Cys153, Cys244, Cys314, and Cys352 residues within HDAC8.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Both mixed disulfide and thiocyanate adducts were identified, and enzyme inhibition was predicted to be predominantly due to reaction with the Cys153 residue within the substrate binding channel of this isoform. Perhaps the romidepsin analogue <b>32</b> has a similar mechanism of action involving allosteric modification of Cys residues by conjugate addition to the dehydroalanine residue, as this would explain why a similar largazole analogue lacking the unsaturated alkene was devoid of activity.</div><div class="NLM_p last">Naturally, allosteric modulators need not adhere to the standard model for HDAC active site binding. However, there are few examples of small molecules reported to bind with high affinity to HDACs outside the active site. Tasquinimod (<b>38</b>) is an antagonist of the calcium-binding protein S100A9 in phase 3 clinical trials for castration-resistant prostate cancer. It was also shown to bind HDAC4 with a <i>K</i><sub>d</sub> of 10–30 nM, and homology modeling suggests allosteric binding that locks HDAC4 in an inactive conformation that is unable to interact with HDAC3.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> In endothelial cells, the administration of tasquinimod induced the same phenotype of reduced vascular inflammation as HDAC4 silencing, suggesting that the interaction between HDAC4 and tasquinimod does have a functional consequence.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">Isoform Selectivity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">At the preclinical stage, the most exciting development in HDAC inhibitor discovery is the identification of compounds with an enhanced isoform selectivity profile compared to those in clinical development. At the same time, it is worth asking what selectivity actually means. The enzymatic activity of HDAC1, HDAC2, HDAC3, and HDAC6 can be reliably tracked with acetyllysine containing peptides and provides meaningful data on inhibitor selectivity between these isoforms, keeping in mind that in vivo kinetics while bound to other proteins and acting upon protein substrates will be different. For all other HDAC isoforms, in vitro selectivity as measured by commercial assays is of varying physiological relevance and needs to be backed up by independent demonstration of cellular target engagement through orthogonal detection methods. Despite these caveats, highly selective compounds are now available that are valuable tools for understanding the optimum specificity for cancer and neurodegenerative disorders, two of the most important targets for HDAC inhibitors.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a> In addition, selective inhibitors are likely to be crucial for extending HDAC inhibition therapy to chronic diseases that require wider safety profiles such as inflammation,<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> T-cell regulation,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> obesity,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> fibrosis,<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> and alcohol use disorder.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">There are several patterns of isoform selectivity that appear particularly promising. First, targeting transcriptional regulation would benefit from the selective inhibition of the nuclear enzymes HDAC1, HDAC2, and HDAC3 (or a subset of these three) with minimal activity against other isoforms. Conversely, selective cytoplasmic HDAC6 inhibition will have its own therapeutic applications if unaccompanied by interference with nuclear isoforms. Next, there is the opportunity to focus on the turnover of non-acetyllysine PTMs or polyamine acetylation through the selective inhibition of HDAC8, HDAC11, or HDAC10. Finally, the active site occupancy of HDAC4, HDAC5, HDAC7, or HDAC9 (without necessarily affecting catalysis) might be sufficient for pharmacological activity and eliminate their ability to bind acetyllysine containing proteins. Moreover, more complex composite patterns of selectivity can be envisioned that combine one or more of the above options without reaching the unwanted inhibition of all 11 enzymes to a substantial degree.</div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> HDAC1 and HDAC2</h3><div class="NLM_p">Selective inhibitors of these nuclear isoforms would be particularly useful against indications such as cancer and viral replication in which the deacetylation of histone and transcriptional regulators plays a vital role. Although the clinical compounds adequately inhibit HDAC1 and HDAC2, they are also active against some or all of the other isoforms at physiologically relevant concentrations (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) and a cleaner profile could be advantageous. Merck discovered that the addition of a 5-phenyl or 5-thienyl substituent to <i>ortho</i>-aminoanilide HDAC inhibitors, as exemplified by <b>39</b> and <b>40</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>)<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> or by Acetylon’s ACY-957 (<b>41</b>), conferred high HDAC1/HDAC2 selectivity. The aryl group of the biphenyl moiety occupies the internal cavity, and in these two isoforms there is a Ser107 residue while HDAC3 contains a bulkier Tyr residue that limits access. Compound <b>39</b> outperformed nonselective HDAC inhibitors in vitro and in vivo against B-cell acute lymphoblastic leukemia but not other B-cell-derived malignancies, suggesting the selective inhibition of HDAC1/HDAC2 is sufficient for this condition.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> As a single agent and in combination with the DNMT inhibitor azacitidine, <b>41</b> had promising results against acute myeloid leukemia, including activity against primary patient derived cells and in vivo xenograft models.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The PROTAC approach of recruiting an E3 ubiquitin ligase to foster degradation of a protein of interest has recently been applied to epigenetic targets.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The <i>ortho</i>-aminoanilide <b>42</b> incorporates a ligand for the von Hippel–Lindau E3 ligase.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Treatment of HCT116 cells with 10 μM <b>42</b> for 24 h led to nearly complete degradation of HDAC1 and HDAC2.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of biaryl <i>ortho</i>-aminoanilide selective HDAC1/HDAC2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">HDAC2 is implicated in the negative regulation of memory formation and synaptic plasticity in the brain, with long-term potentiation impaired in HDAC2 overexpressing mice.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Treatment with vorinostat ameliorated contextual fear conditioning but had no effect in HDAC2-deficient mice, suggesting nonredundancy between HDAC2 and HDAC1. While the high sequence homology between these two isoforms is an obstacle to the development of inhibitors that discriminate between the two, there are examples of <i>ortho</i>-aminoanilides that achieve a level of kinetic selectivity. Although the Broad Institute’s BRD4884 (<b>43</b>) inhibits HDAC1 more strongly, it has a residence time half-life of 20 min with HDAC1 compared to 143 min with HDAC2.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In the BRD4884-HDAC2 X-ray structure (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), there is a bridging water molecule between the pyran oxygen and the enzyme that provides additional stabilization to the complex.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. The X-ray structure of <b>43</b>-HDAC2 is typical of <i>ortho</i>-aminoanilides. Bidentate coordination is observed with the zinc cation, while the addition of a 5-aryl substituent enables occupancy of the lateral internal 14 Å cavity. Reproduced with permission from   <cite><i>Bioorganic & Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Wagner, F. F.</span>; <span class="NLM_string-name">Weïwer, M.</span>; <span class="NLM_string-name">Steinbacher, S.</span>; <span class="NLM_string-name">Schomburg, A.</span>; <span class="NLM_string-name">Reinemer, P.</span>; <span class="NLM_string-name">Gale, J. P.</span>; <span class="NLM_string-name">Campbell, A. J.</span>; <span class="NLM_string-name">Fisher, S. L.</span>; <span class="NLM_string-name">Zhao, W.-N.</span>; <span class="NLM_string-name">Reis, S. A.</span>; <span class="NLM_string-name">Hennig, K. M.</span>; <span class="NLM_string-name">Thomas, M.</span>; <span class="NLM_string-name">Müller, P.</span>; <span class="NLM_string-name">Jefson, M. R.</span>; <span class="NLM_string-name">Fass, D. M.</span>; <span class="NLM_string-name">Haggarty, S. J.</span>; <span class="NLM_string-name">Zhang, Y.-L.</span>; <span class="NLM_string-name">Holson, E. B.</span></contrib-group>, Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors, Vol. <em>24</em>, pp 4008–4015, Copyright <span class="NLM_year">2016</span>, Elsevier.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> HDAC3</h3><div class="NLM_p">HDAC3 exists in multiprotein complexes that contain NCoR/SMRT which are distinct from the repressor complexes occupied by HDAC1/HDAC2. Furthermore, the selective inhibition of HDAC3 offers the ability to indirectly modulate the tissue-specific HDAC4/HDAC5/HDAC7/HDAC9, since they recruit acetyllysine containing substrates for hydrolysis by HDAC3. The design of selective HDAC3 inhibitors has recently been comprehensively reviewed.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The 4-fluoro derivative (<b>44</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) of the clinical candidate tacedinaline has a markedly HDAC3 selective profile compared to the latter attributed to both steric and electronic effects.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The more extended cap in RGFP996 (<b>45</b>) from Repligen results in even higher selectivity for HDAC3 over other isoforms. More recently, the amide bearing HDAC3 selective inhibitor <b>46</b> has been reported,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> which will be useful in teasing out any compound class specific properties of the <i>ortho</i>-aminoanilides <b>44</b> and <b>45</b>.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of selective HDAC3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The availability of HDAC3 selective probes has proven to be illuminating in a number of in vivo disease models. In CNS applications, <b>45</b> has promoted the extinction of drug-seeking behavior,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> induced memory enhancement,<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> reduced cognitive decline in Huntington’s and Alzheimer’s disease,<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a> and was protective in a stroke model.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Furthermore, <b>45</b> activated brown and beige fat, suggesting potential cardiovascular applications arising through the involvement of HDAC3 with the transcriptional coactivator PRDM16.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Meanwhile, <b>44</b> was shown to reactivate HIV-1 replication from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> and to suppress pancreatic islet inflammation and β-cell apoptosis in nonobese diabetic mice.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> HDAC6</h3><div class="NLM_p">The inhibition of HDAC1–3 is critical for achieving a truly epigenetic effect involving transcriptional regulation in the nucleus. On the other hand, orthogonal inhibition of the major cytoplasmic isoform HDAC6 is potentially valuable against a host of human diseases. HDAC6 knockout mice are viable and fertile, and although abnormalities were reported in dopaminergic signaling,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> this is in stark contrast with the lethality or clearly defective phenotypes observed with other isoforms. This suggests that a highly selective HDAC6 inhibitor would be well tolerated and avoids the on-target side effects of more promiscuous compounds. The substrate channel in HDAC6’s second catalytic domain (CD2) is wider and shallower compared to HDAC1–3, favoring compounds with shorter linkers and larger, extended caps. However, because of similarities in the active sites between HDAC6 and HDAC8, discriminating between these two isoforms is more challenging. Kozikowski has pioneered the development of HDAC6-selective arylhydroxamic acid inhibitors such as tubastatin A (<b>47</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) which is widely employed as a tool compound.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Kozikowski’s SW-100 (<b>48</b>) and Liou’s MPT0G211 (<b>49</b>) are examples of more recent brain-penetrant inhibitors with a superior HDAC6/HDAC8 selectivity profile compared to tubastatin A.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> Instead of a phenyl linker, Acetylon’s ACY-1083 (<b>50</b>) contains a pyrimidinyl ring and is reported to be >250-fold selective for HDAC6 over other isoforms.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Examples of selective HDAC6 inhibitors. See also the HDAC10 discussion on tubastatin (<b>47</b>) and analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A PROTAC example with a nonselective hydroxamic acid HDAC iunhibitor linked to a cereblon ligand nevertheless led to the selective degradation of HDAC6.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Subsequently, the group reported <b>51</b> in which the HDAC6 selective scaffold of nexturastat A was affixed to the cereblon ligand pomalidomide.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> In MM1S cells, <b>51</b> had a DC<sub>50</sub> of 1.6 nM for the selective degradation of HDAC6.</div><div class="NLM_p">X-ray crystallographic studies with HDAC6 selective arylhydroxamic acids indicate monocoordination within the shallower active site compared to the more common bidentate zinc coordination observed against other isoforms.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Meanwhile, the aryl group engages in π–π interactions with the substrate channel while the cap extends into the solvent exposed enzyme rim, as illustrated by the binding of <b>50</b> to HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Recent studies (see below) suggest that tubastatin and related compounds with a basic amine in the linker or cap region are also capable of inhibiting the acetylspermidine hydrolysis activity of HDAC10.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) Simulated annealing omit map of the <b>50-</b>HDAC6 (catalytic domain 2) binding. The hydroxamic acid engages in monocoordinate interactions with the zinc cation, while the carbonyl group hydrogen-bonds the active site water involved in amide hydrolysis. The linker makes an additional hydrogen bond with Ser531. (b) Cutaway view of the active site surface highlighting the zinc coordination polyhedron and the aromatic interactions between the inhibitor and the substrate binding channel. Reproduced with permission from   <cite><i>Bioorganic & Medicinal Chemistry Letters</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry-letters" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry-letters</a>); <contrib-group><span class="NLM_string-name">Osko, J. D.</span>; <span class="NLM_string-name">Christianson, D. W.</span></contrib-group>, Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6, Vol. <em>30</em>, 127023, Copyright <span class="NLM_year">2020</span>, Elsevier.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The inhibition of HDAC6 has been extensively studied in cell-based and in vivo disease models, although some examples involved compounds with lower selectivity profiles than <b>47</b>–<b>51</b> and phenotypic effects may be due to residual effects against other HDAC isoforms. Robust data have been obtained in animal models for cancer and neurodegenerative disorders, with early stage clinical trials ongoing for the treatment of hematological malignancies, solid tumors, and Huntington’s disease, as well as Regenacy’s planned phase 2 trial with ricolinostat for diabetic neuropathic pain.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147,148)</a> In addition, earlier preclinical studies are promising against a number of other indications.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div></div><div id="sec9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> HDAC8</h3><div class="NLM_p">The challenge with HDAC8 inhibition is to avoid hitting the other nuclear isoforms HDAC1–3 as well as the cytoplasmic HDAC6.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> With regard to the latter, <i>ortho</i>- or <i>meta</i>-substituted aromatic linkers are helpful, compared to the <i>para</i>-substitution typical in HDAC6 selective inhibitors. Pharmacyclic’s PCI-34051 (<b>52</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) was the first to exhibit high selectivity for HDAC8 and is the most widely used tool compound for this isoform.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Newer examples include Huang’s cinnamoyl terphenylhydroxamic acid WK2-16 (<b>53</b>) and Beeler’s phenylalanine derived hydroxamic acid <b>54</b>.<a onclick="showRef(event, 'ref152 ref153'); return false;" href="javascript:void(0);" class="ref ref152 ref153">(152,153)</a> In animal models, selective HDAC8 inhibitors have shown promise in neuroblastoma<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> as well as different inflammatory settings such as hypertensive inflammation,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> neuroinflammation,<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> and airway inflammation.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Recently, <b>52</b> was shown to resensitize melanoma tumor xenograft cells to inhibition by the tyrosine kinase inhibitor erlotinib.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Examples of selective HDAC8 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> HDAC11</h3><div class="NLM_p">The first selective HDAC11 inhibitor FT895 (<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) was recently reported by FORMA, and modeling suggests that the pyrazine ring extends into the internal cavity adjacent to the zinc cation.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> While fluorescent acetyllysine peptide substrates were used in FORMA’s enzymatic assays, Lin employed a potentially more relevant myristoyllysine peptide with HPLC monitoring to discover acylhydrazide inhibitor <b>56</b>.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> In this assay, <b>55</b> and <b>56</b> were of similar potency in inhibiting demyristoylation. Presumably, <b>56</b> binds to HDAC11 with the alkyl chain occupying the internal cavity. With the availability of such probes, in vivo investigations will become possible to validate the importance of HDAC11 as a therapeutic target.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Examples of selective HDAC11 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> HDAC10</h3><div class="NLM_p">The profiling of approved and clinical candidate HDAC inhibitors indicates that many strongly inhibit HDAC10 in assay kits employing trifluoroacetyllysine substrates. Although we now know that HDAC10 is a small molecule polyamine deacetylase, the assay results indicate that many HDAC inhibitors are capable of entering and occupying the substrate channel. Recently, instead of the conventional monitoring of product formation, Miller employed a FRET ligand displacement assay. In this assay, the HDAC6 selective inhibitor tubastatin A (<b>47</b>) actually bound more strongly to HDAC10 than HDAC6.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Since tubastatin A was much more effective than other HDAC inhibitors tested, it is likely that the molecule’s amine forms a favorable electrostatic interaction with the glutamate gatekeeper residue unique to HDAC10. From a library of tubastatin A analogues, compounds <b>57</b> and <b>58</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) were slightly more potent in HDAC10 binding, perhaps due to a greater rotational flexibility to accommodate interaction with the glutamate. Furher improvements will be needed to ensure HDAC6/HDAC10 selectivity with these tubastatin A based compounds.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Tubastatin A (<b>47</b>), analogues <b>57</b> and <b>58</b>, and the spermidine hydroxamic acid <b>59</b>. Note that IC<sub>50</sub> values for <b>47</b>, <b>57</b>, and <b>58</b> correspond to a FRET displacement assay for HDAC10 and enzymatic assays for other isoforms. The value for <b>59</b> comes from an assay monitoring <i>N</i>-acetylputrescine hydrolysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Christianson examined a number of spermidine derivatives as potential inhibitors, using an enzymatic assay based on <i>N</i>-acetylputrescine hydrolysis. The hydroxamic acid <b>59</b> is a submicromolar HDAC10 inhibitor, and the X-ray structure (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) of <b>59</b> complexed to <i>Danio rerio</i> (zebrafish) HDAC10 has provided useful information on the binding interactions. The hydroxamic acid engages in bidentate coordination with the zinc cation, while the methylene chain features a bifurcated hydrogen bond between the secondary amine NH proton and the gatekeeper glutamate residue.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Polder omit map of <b>59</b> bound to the active site of HDAC10. The hydroxamic acid is coordinated as a bidentate ligand to the zinc cation, while the NH proton engages in hydrogen bonding with the Glu274 gatekeeper residue. Reproduced with permission from <i>Biochemistry</i>,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> HDAC4, HDAC5, HDAC7, HDAC9</h3><div class="NLM_p">Since these isoforms have low catalytic activity, assays have employed mutant enzymes or reactive trifluoroacetyllysine substrates. While the physiological relevance of such data is questionable, it does give an idea of active site occupancy. The highly selective inhibitor TMP269 (<b>60</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) was reported by Tempero and contains an unusual oxadiazole zinc binding group.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The X-ray structure of <b>60</b> bound to HDAC7 revealed a U-shaped conformation with interactions between a fluorine and the oxadiazole oxygen with the zinc, at relatively long distances of 2.7 and 3.0 Å, respectively, compared to the ∼2 Å observed with hydroxamic acids. Thus, the binding involves weak electrostatic interactions with zinc rather than direct coordination. Because these HDACs have an active site tyrosine (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) replaced by the smaller histidine, the more roomy substrate binding channel is able to accommodate the bulky trifluoromethyloxadiazole unlike the other isoforms, leading to high selectivity. In mouse models, <b>60</b> demonstrated protective activity against pulmonary arterial hypertension and cerebral ischemia/reperfusion injury.<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164,165)</a> The structurally related analogue TMP195 reduced mycobacterial infection in a zebrafish embryo model for tuberculosis.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0022.jpeg" id="GRAPHIC-d7e2946-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Examples of selective HDAC4, HDAC5, HDAC7, HDAC9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The CHDI Foundation reported a more conventional hydroxamic acid inhibitor <b>61</b> but with an unusual chiral cyclopropane scaffold.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The first generation compound lacking the cyclopropyl fluorine substituent had poorer pharmacokinetic properties due to glucuronidation. An X-ray structure of <i>des</i>-fluoro-<b>61</b> with HDAC4 (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) indicates bidentate coordination of the hydroxamic acid with the phenyl ring in a lower pocket engaged in π-stacking interactions. More recently, CHDI has disclosed the aromatic hydroxamic acid CHDI-390576 (<b>62</b>) with good plasma, muscle, and brain exposure in vivo upon oral administration in mice.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0023.jpeg" id="GRAPHIC-d7e2985-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Binding interactions of <i>des</i>-fluoro-<b>61</b> (with H instead of F at C1) within the HDAC4 active site, showing the occupancy of the selectivity pocket by the phenyl ring. Reproduced with permission from <i>ACS Medicinal Chemistry Letters</i>, Copyright 2016, American Chemical Society.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The timeline from bench to bedside was remarkably speedy for HDACs. The clinical trials of a HDAC inhibitor began in 2000, only 4 years after the first mammalian HDAC was characterized. In the past 20 years, over 30 HDAC inhibitors have entered clinical development with five regulatory approvals. Nevertheless, these medicinal chemistry successes have occurred despite the biological complexity of the target. Although there are only 11 human HDACs, this small number carries out a set of at least five cellular functions: nuclear lysine deacetylation (HDAC1/2/3), cytoplasmic lysine deacetylation (HDAC6), fatty acid deacylation (HDAC8/11), polyamine deacylation (HDAC10), and acetyllysine recognition (HDAC4/5/7/9). We believe that selectivity will be the key to unlocking the full therapeutic value of HDAC inhibitors, and a toolkit of compounds is now available (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) that will fuel future discoveries in HDAC biology and drug discovery.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of the Major Isoform Selective HDAC Inhibitors and the Selectivity Issues Faced within Each Class</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">isoform</th><th class="colsep0 rowsep0" align="center">compound class</th><th class="colsep0 rowsep0" align="center">examples</th><th class="colsep0 rowsep0" align="center">selectivity challenge</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC1/2</td><td class="colsep0 rowsep0" align="left">5-aryl-<i>ortho</i>-aminoanilides</td><td class="colsep0 rowsep0" align="left"><b>39</b>–<b>43</b></td><td class="colsep0 rowsep0" align="left">HDAC1 vs 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC3</td><td class="colsep0 rowsep0" align="left">4-fluoro-<i>ortho</i>-aminoanilides</td><td class="colsep0 rowsep0" align="left"><b>44</b>, <b>45</b></td><td class="colsep0 rowsep0" align="left">HDAC1/2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC6</td><td class="colsep0 rowsep0" align="left"><i>para</i>-arylhydroxamic acids</td><td class="colsep0 rowsep0" align="left"><b>47</b>–<b>51</b></td><td class="colsep0 rowsep0" align="left">HDAC8/10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC8</td><td class="colsep0 rowsep0" align="left"><i>ortho</i>/<i>meta</i>-arylhydroxamic acids</td><td class="colsep0 rowsep0" align="left"><b>52</b>–<b>54</b></td><td class="colsep0 rowsep0" align="left">HDAC6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC11</td><td class="colsep0 rowsep0" align="left"><i>ortho</i>/<i>meta</i>-arylhydroxamic acids</td><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">HDAC8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC10</td><td class="colsep0 rowsep0" align="left">basic hydroxamic acids</td><td class="colsep0 rowsep0" align="left"><b>47</b>, <b>57</b>–<b>59</b></td><td class="colsep0 rowsep0" align="left">HDAC6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HDAC4/5/7/9</td><td class="colsep0 rowsep0" align="left">oxadiazoles, α-branched hydroxamic acids</td><td class="colsep0 rowsep0" align="left"><b>60</b>–<b>62</b></td><td class="colsep0 rowsep0" align="left">HDAC4 vs -5 vs -7 vs -9</td></tr></tbody></table></div></div><div class="NLM_p last">While the next 30 years are too distant for accurate predictions, we anticipate that major advances will already occur within the next decade along many fronts including the following:<ul class="NLM_list-list_type-bullet"><li><p class="inline">Target validation to identify the ideal HDAC inhibitor profile for specific therapeutic indications;</p></li><li><p class="inline">Unconventional approaches to HDAC drug discovery, e.g., dual mechanism agents, PROTACs, covalent inhibitors, nonactive site modulators;</p></li><li><p class="inline">Personalized medicine and patient stratification strategies, which are rare at the present time for HDAC inhibitor therapy;</p></li><li><p class="inline">Clinical optimization of HDAC dosing regimens, particularly the timing of administration for combination therapies.</p></li></ul></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00830" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">A. Ganesan</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4862-7999" title="Orcid link">http://orcid.org/0000-0003-4862-7999</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b2a652c2a252e382a250b3e2e2a652a28653e20"><span class="__cf_email__" data-cfemail="1d7c337a7c73786e7c735d68787c337c7e336876">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terence C. S. Ho</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</span>; 
    <span>Present Address:
                        T.C.S.H.: Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alex H. Y. Chan</span> - <span class="hlFld-Affiliation affiliation">School of Pharmacy, University of East Anglia, Norwich NR4 7TJ, United Kingdom</span>; 
    <span>Present Address:
                        A.H.Y.C.: Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): A. Ganesan is a shareholder in Karus Therapeutics.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Terence C. S. Ho</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=BIO-d7e3148-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Terence C. S. Ho</b> obtained his Master’s degree in Pharmacy (MPharm) from the University of East Anglia (U.K.) in 2017. During the course, he undertook a final year project under Professor Mark Searcey on peptide stapling of peptide chains to inhibit the p53-MDM2 protein–protein interaction for applications in oncology. In 2018, he started studying Medicine (MBBS) at the University of East Anglia and is currently in his second year.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Alex H. Y. Chan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=BIO-d7e3153-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Alex H. Y. Chan</b> received his first class Master’s degree in Pharmacy (MPharm) from the University of East Anglia (U.K.) in 2017. He won the Andrew Thompson Prize for the best medicinal chemistry research project on the design and synthesis of triazole-based HDAC inhibitors for <i>Schistosomiasis</i> therapy under the supervision of Professor Ganesan. Currently he is a second year doctoral student in Chemistry at the University of Cambridge (U.K.) under the supervision of Dr. Finian Leeper working on the design, synthesis, and biological evaluation of thiamine pyrophosphate dependent enzyme inhibitors for malarial treatment. His research interests lie in discovering small molecules as selective drugs to combat infectious diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="26" class="article__inlineFigure"><h2 class="fig-label">A. Ganesan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=BIO-d7e3161-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>A. Ganesan</b> obtained his undergraduate degree in Chemistry from National University of Singapore. After graduate studies at the University of California—Berkeley and postdoctoral research at Harvard University, he returned to Singapore to work at the Centre for Natural Product Research. Subsequently, he was Principal Investigator at Singapore’s Institute of Molecular and Cell Biology and Reader at the University of Southampton’s Department of Chemistry before taking up his present position. Ganesan’s interests are in drug discovery, natural products, and epigenetics. He was a Chair of the European COST Networks TD0905 Epigenetics: From Bench to Bedside and CM1406 Epigenetic Chemical Biology. He is a cofounder of Karus Therapeutics and sits on the IUPAC Drug Discovery and Development and the RSC Bioorganic and Medicinal Chemistry Sector committees.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">Abl</td><td class="NLM_def"><p class="first last">Abelson murine leukemia viral oncogene homolog</p></td></tr><tr><td class="NLM_term">ARID</td><td class="NLM_def"><p class="first last">AT-rich interactive domain-containing protein</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia-telangiectasia mutated</p></td></tr><tr><td class="NLM_term">BAX</td><td class="NLM_def"><p class="first last">BCL2 associated X protein</p></td></tr><tr><td class="NLM_term">BRD</td><td class="NLM_def"><p class="first last">bromodomain</p></td></tr><tr><td class="NLM_term">CAF</td><td class="NLM_def"><p class="first last">chromatin assembly factor</p></td></tr><tr><td class="NLM_term">CFDA</td><td class="NLM_def"><p class="first last">China Food and Drug Administration</p></td></tr><tr><td class="NLM_term">CIP</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase inhibitory protein</p></td></tr><tr><td class="NLM_term">CoREST</td><td class="NLM_def"><p class="first last">co-repressor for element-1-silencing transcription factor</p></td></tr><tr><td class="NLM_term">DC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal concentration of protein degradation</p></td></tr><tr><td class="NLM_term">DNMT</td><td class="NLM_def"><p class="first last">DNA methyltransferase</p></td></tr><tr><td class="NLM_term">E2F</td><td class="NLM_def"><p class="first last">E2 promoter binding factor</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">ERR</td><td class="NLM_def"><p class="first last">estrogen-related receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FOXP</td><td class="NLM_def"><p class="first last">forkhead box P</p></td></tr><tr><td class="NLM_term">FRET</td><td class="NLM_def"><p class="first last">fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">GR</td><td class="NLM_def"><p class="first last">glucocorticoid receptor</p></td></tr><tr><td class="NLM_term">GRP</td><td class="NLM_def"><p class="first last">glucose-regulated protein</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HIF</td><td class="NLM_def"><p class="first last">hypoxia-inducing factor</p></td></tr><tr><td class="NLM_term">Hos</td><td class="NLM_def"><p class="first last">histone deacetylase-A one similar</p></td></tr><tr><td class="NLM_term">Hsp</td><td class="NLM_def"><p class="first last">heat shock protein</p></td></tr><tr><td class="NLM_term">Ku</td><td class="NLM_def"><p class="first last">lupus Ku autoantigen protein</p></td></tr><tr><td class="NLM_term">LSD</td><td class="NLM_def"><p class="first last">lysine-specific demethylase</p></td></tr><tr><td class="NLM_term">MEF</td><td class="NLM_def"><p class="first last">myocyte enhancer factor</p></td></tr><tr><td class="NLM_term">MiDAC</td><td class="NLM_def"><p class="first last">mitotic deacetylase complex</p></td></tr><tr><td class="NLM_term">MIER</td><td class="NLM_def"><p class="first last">mesoderm induction early response</p></td></tr><tr><td class="NLM_term">NCoR</td><td class="NLM_def"><p class="first last">nuclear receptor co-repressor</p></td></tr><tr><td class="NLM_term">NCT</td><td class="NLM_def"><p class="first last">national clinical trial</p></td></tr><tr><td class="NLM_term">NES</td><td class="NLM_def"><p class="first last">nuclear export sequence</p></td></tr><tr><td class="NLM_term">NLS</td><td class="NLM_def"><p class="first last">nuclear localization sequence</p></td></tr><tr><td class="NLM_term">NMPA</td><td class="NLM_def"><p class="first last">National Medical Products Administration</p></td></tr><tr><td class="NLM_term">NuRD</td><td class="NLM_def"><p class="first last">nucleosome remodeling and deacetylation</p></td></tr><tr><td class="NLM_term">PCAF</td><td class="NLM_def"><p class="first last">P300/CBP-associated factor (KAT2B)</p></td></tr><tr><td class="NLM_term">PRDM</td><td class="NLM_def"><p class="first last">PR domain containing</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">PTM</td><td class="NLM_def"><p class="first last">post-translational modification</p></td></tr><tr><td class="NLM_term">SMC</td><td class="NLM_def"><p class="first last">structural maintenance of chromosome</p></td></tr><tr><td class="NLM_term">SMRT</td><td class="NLM_def"><p class="first last">silencing mediator of retinoic and thyroid receptors</p></td></tr><tr><td class="NLM_term">Sin</td><td class="NLM_def"><p class="first last">SWI-independent</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">WAF</td><td class="NLM_def"><p class="first last">wild-type activating fragment</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34146" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34146" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 168 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiardi, A.</span></span> <span> </span><span class="NLM_article-title">Why Always Lysine? The Ongoing Tale of One of the Most Modified Amino Acids</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2015.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.jbior.2015.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26482291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=144-150&author=C.+Azevedoauthor=A.+Saiardi&title=Why+Always+Lysine%3F+The+Ongoing+Tale+of+One+of+the+Most+Modified+Amino+Acids&doi=10.1016%2Fj.jbior.2015.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Why always lysine? The ongoing tale of one of the most modified amino acids</span></div><div class="casAuthors">Azevedo, Cristina; Saiardi, Adolfo</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The complex physiol. of living organisms must be finely-tuned to permit the flexibility required to respond to the changing environment.  Evolution has provided an interconnected and intricate array of regulatory mechanisms to facilitate this fine-tuning.  The no. of genes cannot alone explain the complexity of these mechanisms.  Rather, signalling is regulated at multiple levels, from genomic to transcriptional, translational and post-translational.  Post-translational modification (PTM) of proteins offers an addnl. level of regulation after protein synthesis that allows a rapid, controlled and reversible response to environmental cues.  Many amino acid side chains are post-translationally modified.  These modifications can either be enzymic, such as the phosphorylation of serine, threonine and tyrosine residues, or non-enzymic, such as the nitrosylation of cysteine residues.  Strikingly, lysine residues are targeted by a particularly high no. of PTMs including acetylation, methylation, ubiquitination and sumoylation.  Addnl., lysines have recently been identified as the target of the non-enzymic PTM polyphosphorylation.  This novel PTM sees linear chains of inorg. polyphosphates (polyP) covalently attached to lysine residues.  Interestingly, polyphosphorylation is indirectly dependent on inositol pyrophosphates, a class of cellular messengers.  The attachment of polyP to lysine occurs through the phosphoramidate bond, which, unlike the phosphester bond, is unstable under the conditions used in common mass spectroscopy.  This characteristic, together with the diversity of lysine PTMs, suggests that many other lysine modifications may still remain unidentified, raising the intriguing possibility that lysine PTMs may be the major means by which signalling pathways modify protein behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0XJSfdwX8MLVg90H21EOLACvtfcHk0lgnw_hNEBH0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLbE&md5=88ac71aaf09c2e91a1b3d6715f00c5ef</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2015.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2015.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DAzevedo%26aufirst%3DC.%26aulast%3DSaiardi%26aufirst%3DA.%26atitle%3DWhy%2520Always%2520Lysine%253F%2520The%2520Ongoing%2520Tale%2520of%2520One%2520of%2520the%2520Most%2520Modified%2520Amino%2520Acids%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2016%26volume%3D60%26spage%3D144%26epage%3D150%26doi%3D10.1016%2Fj.jbior.2015.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span> <span> </span><span class="NLM_article-title">PLMD: An Updated Data Resource of Protein Lysine Modifications</span>. <i>J. Genet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.jgg.2017.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.jgg.2017.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28529077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1crpslGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=243-250&author=H.+Xuauthor=J.+Zhouauthor=S.+Linauthor=W.+Dengauthor=Y.+Zhangauthor=Y.+Xue&title=PLMD%3A+An+Updated+Data+Resource+of+Protein+Lysine+Modifications&doi=10.1016%2Fj.jgg.2017.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PLMD: An updated data resource of protein lysine modifications</span></div><div class="casAuthors">Xu Haodong; Zhou Jiaqi; Lin Shaofeng; Deng Wankun; Zhang Ying; Xue Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of genetics and genomics = Yi chuan xue bao</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">243-250</span>
        ISSN:<span class="NLM_cas:issn">1673-8527</span>.
    </div><div class="casAbstract">Post-translational modifications (PTMs) occurring at protein lysine residues, or protein lysine modifications (PLMs), play critical roles in regulating biological processes.  Due to the explosive expansion of the amount of PLM substrates and the discovery of novel PLM types, here we greatly updated our previous studies, and presented a much more integrative resource of protein lysine modification database (PLMD).  In PLMD, we totally collected and integrated 284,780 modification events in 53,501 proteins across 176 eukaryotes and prokaryotes for up to 20 types of PLMs, including ubiquitination, acetylation, sumoylation, methylation, succinylation, malonylation, glutarylation, glycation, formylation, hydroxylation, butyrylation, propionylation, crotonylation, pupylation, neddylation, 2-hydroxyisobutyrylation, phosphoglycerylation, carboxylation, lipoylation and biotinylation.  Using the data set, a motif-based analysis was performed for each PLM type, and the results demonstrated that different PLM types preferentially recognize distinct sequence motifs for the modifications.  Moreover, various PLMs synergistically orchestrate specific cellular biological processes by mutual crosstalks with each other, and we totally found 65,297 PLM events involved in 90 types of PLM co-occurrences on the same lysine residues.  Finally, various options were provided for accessing the data, while original references and other annotations were also present for each PLM substrate.  Taken together, we anticipated the PLMD database can serve as a useful resource for further researches of PLMs.  PLMD 3.0 was implemented in PHP + MySQL and freely available at http://plmd.biocuckoo.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0gNGqbz_zRyO2kE7krGOBfW6udTcc2eZmOWbz6V_qorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crpslGnug%253D%253D&md5=4283785555a1adc9ed4928e8c40b2c07</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jgg.2017.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jgg.2017.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DPLMD%253A%2520An%2520Updated%2520Data%2520Resource%2520of%2520Protein%2520Lysine%2520Modifications%26jtitle%3DJ.%2520Genet.%2520Genomics%26date%3D2017%26volume%3D44%26spage%3D243%26epage%3D250%26doi%3D10.1016%2Fj.jgg.2017.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Drug Discovery: A Success Story for Cofactor Interference</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">20170069</span>, <span class="refDoi"> DOI: 10.1098/rstb.2017.0069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1098%2Frstb.2017.0069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29685973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Cmsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170069&author=A.+Ganesan&title=Epigenetic+Drug+Discovery%3A+A+Success+Story+for+Cofactor+Interference&doi=10.1098%2Frstb.2017.0069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic drug discovery: a success story for cofactor interference</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1748</span>),
    <span class="NLM_cas:pages">20170069/1-20170069/15</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Within the past two decades, seven epigenetic drugs have received regulatory approval and numerous other candidates are currently in clin. trials.  Among the epigenetic targets are the writer and eraser enzymes that are, resp., responsible for the reversible introduction and removal of structural modifications in the nucleosome.  This reviewdiscusses the progress achieved in the design and development of inhibitors against the key writer and eraser pairs: DNA methyltransferases and Tet demethylases; lysine/arginine methyltransferases and lysine demethylases; and histone acetyltransferases and histone deacetylases.  A common theme for the successful inhibition of these enzymes in a potent and selective manner is the targeting of the cofactors present in the active site, namely zinc and iron cations, S-adenosylmethione, NAD, FAD and acetyl CoA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohR1yq_2gzbVg90H21EOLACvtfcHk0lgnw_hNEBH0iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Cmsb7M&md5=9c9e20f8b16a73a1835320e82698e68a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0069%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520Drug%2520Discovery%253A%2520A%2520Success%2520Story%2520for%2520Cofactor%2520Interference%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26spage%3D20170069%26doi%3D10.1098%2Frstb.2017.0069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvedere, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5116</span>, <span class="refDoi"> DOI: 10.1021/jm0303094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0303094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0ljReKZ7f7o94Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116%26doi%3D10.1021%2Fjm0303094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelloni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattori, D.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: From Bench to Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+Deacetylase+Inhibitors%3A+From+Bench+to+Clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0ljReKZ7f7o94Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span> <span> </span><span class="NLM_article-title">Functions and Mechanisms of Non-Histone Protein Acetylation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/s41580-018-0081-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41580-018-0081-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30467427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Gmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=156-174&author=T.+Naritaauthor=B.+T.+Weinertauthor=C.+Choudhary&title=Functions+and+Mechanisms+of+Non-Histone+Protein+Acetylation&doi=10.1038%2Fs41580-018-0081-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Functions and mechanisms of non-histone protein acetylation</span></div><div class="casAuthors">Narita, Takeo; Weinert, Brian T.; Choudhary, Chunaram</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-174</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Nε-lysine acetylation was discovered more than half a century ago as a post-translational modification of histones and has been extensively studied in the context of transcription regulation.  In the past decade, proteomic analyses have revealed that non-histone proteins are frequently acetylated and constitute a major portion of the acetylome in mammalian cells.  Indeed, non-histone protein acetylation is involved in key cellular processes relevant to physiol. and disease, such as gene transcription, DNA damage repair, cell division, signal transduction, protein folding, autophagy and metab.  Acetylation affects protein functions through diverse mechanisms, including by regulating protein stability, enzymic activity, subcellular localization and crosstalk with other post-translational modifications and by controlling protein-protein and protein-DNA interactions.  In this Review, we discuss recent progress in our understanding of the scope, functional diversity and mechanisms of non-histone protein acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH-USxtMkV_LVg90H21EOLACvtfcHk0ljReKZ7f7o94Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Gmt7s%253D&md5=bb798999d02e0c5345cd8f6055e5b53a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0081-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0081-3%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DWeinert%26aufirst%3DB.%2BT.%26aulast%3DChoudhary%26aufirst%3DC.%26atitle%3DFunctions%2520and%2520Mechanisms%2520of%2520Non-Histone%2520Protein%2520Acetylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D156%26epage%3D174%26doi%3D10.1038%2Fs41580-018-0081-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Bromodomains: A New Target Class for Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0030-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41573-019-0030-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31273347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=609-628&author=A.+G.+Cochranauthor=A.+R.+Coneryauthor=R.+J.+Sims&title=Bromodomains%3A+A+New+Target+Class+for+Drug+Development&doi=10.1038%2Fs41573-019-0030-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bromodomains: a new target class for drug development</span></div><div class="casAuthors">Cochran, Andrea G.; Conery, Andrew R.; Sims, III, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-mol. targets.  This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chem. probe discovery to understand the biol. potential of new agents that targeted bromodomains.  The original examples, inhibitors of the bromodomain and extra-terminal (BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compds. have since advanced to human clin. trials.  Here, we review the current state of BET inhibitor biol. in relation to clin. development, and we discuss the next wave of bromodomain inhibitors with clin. potential in oncol. and non-oncol. indications.  The lessons learned from BET inhibitor programs should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6QwxqowW9NbVg90H21EOLACvtfcHk0ljReKZ7f7o94Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL&md5=88e56eec8edeb7c325d28156ec131ed8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomains%253A%2520A%2520New%2520Target%2520Class%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D609%26epage%3D628%26doi%3D10.1038%2Fs41573-019-0030-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span> <span> </span><span class="NLM_article-title">Acetylation & Co: An Expanding Repertoire of Histone Acylations Regulates Chromatin and Transcription</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1042/EBC20180061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FEBC20180061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30940741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGnt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=97-107&author=C.+E.+Barnesauthor=D.+M.+Englishauthor=S.+M.+Cowley&title=Acetylation+%26+Co%3A+An+Expanding+Repertoire+of+Histone+Acylations+Regulates+Chromatin+and+Transcription&doi=10.1042%2FEBC20180061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation & Co: an expanding repertoire of histone acylations regulates chromatin and transcription</span></div><div class="casAuthors">Barnes, Claire E.; English, David M.; Cowley, Shaun M.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-107</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">1744-1358</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Packaging the long and fragile genomes of eukaryotic species into nucleosomes is all well and good, but how do cells gain access to the DNA again after it has been bundled away.  The soln., in every species from yeast to man, is to post-translationally modify histones, altering their chem. properties to either relax the chromatin, label it for remodelling or make it more compact still.  Histones are subject to a myriad of modifications: acetylation, methylation, phosphorylation, ubiquitination etc.  This review focuses on histone acylations, a diverse group of modifications which occur on the ε-amino group of Lysine residues and includes the well-characterised Lysine acetylation.  Over the last 50 years, histone acetylation has been extensively characterised, with the discovery of histone acetyltransferases (HATs) and histone deacetylases (HDACs), and global mapping expts., revealing an assocn. of hyperacetylated histones with accessible, transcriptionally active chromatin.  More recently, there has been an explosion in the no. of unique short chain 'acylations' identified by MS, including: propionylation, butyrylation, crotonylation, succinylation, malonylation and 2-hydroxyisobutyrylation.  These novel modifications add a range of chem. environments to histones, and similar to acetylation, appear to accumulate at transcriptional start sites and correlate with gene activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwJxjetItuZLVg90H21EOLACvtfcHk0liDMATCMOUNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGnt7nK&md5=09d86e16c33ae8b5a720eb720553383e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FEBC20180061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20180061%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DC.%2BE.%26aulast%3DEnglish%26aufirst%3DD.%2BM.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26atitle%3DAcetylation%2520%2526%2520Co%253A%2520An%2520Expanding%2520Repertoire%2520of%2520Histone%2520Acylations%2520Regulates%2520Chromatin%2520and%2520Transcription%26jtitle%3DEssays%2520Biochem.%26date%3D2019%26volume%3D63%26spage%3D97%26epage%3D107%26doi%3D10.1042%2FEBC20180061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span> <span> </span><span class="NLM_article-title">Chemical and Structural Biology of Protein Lysine Deacetylases</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.2183/pjab.93.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2183%2Fpjab.93.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2017&pages=297-321&author=M.+Yoshidaauthor=N.+Kudoauthor=S.+Kosonoauthor=A.+Ito&title=Chemical+and+Structural+Biology+of+Protein+Lysine+Deacetylases&doi=10.2183%2Fpjab.93.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and structural biology of protein lysine deacetylases</span></div><div class="casAuthors">Yoshida, Minoru; Kudo, Norio; Kosono, Saori; Ito, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">297-321</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Histone acetylation is a reversible posttranslational modification that plays a fundamental role in regulating eukaryotic gene expression and chromatin structure/function.  Key enzymes for removing acetyl groups from histones are metal (zinc)-dependent and NAD+-dependent histone deacetylases (HDACs).  The mol. function of HDACs have been extensively characterized by various approaches including chem., mol., and structural biol., which demonstrated that HDACs regulate cell proliferation, differentiation, and metabolic homeostasis, and that their alterations are deeply involved in various human disorders including cancer.  Notably, drug discovery efforts have achieved success in developing HDAC-targeting therapeutics for treatment of several cancers.  However, recent advancements in proteomics technol. have revealed much broader aspects of HDACs beyond gene expression control.  Not only histones but also a large no. of cellular proteins are subject to acetylation by histone acetyltransferases (HATs) and deacetylation by HDACs.  Furthermore, some of their structures can flexibly accept and hydrolyze other acyl groups on protein lysine residues.  This review mainly focuses on structural aspects of HDAC enzymic activity regulated by interaction with substrates, co-factors, small mol. inhibitors, and activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooNCxxHhMcPrVg90H21EOLACvtfcHk0liDMATCMOUNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWmt7k%253D&md5=427a1d6f1ea3a8815499e9cad809d377</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2183%2Fpjab.93.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.93.019%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKudo%26aufirst%3DN.%26aulast%3DKosono%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DA.%26atitle%3DChemical%2520and%2520Structural%2520Biology%2520of%2520Protein%2520Lysine%2520Deacetylases%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2017%26volume%3D93%26spage%3D297%26epage%3D321%26doi%3D10.2183%2Fpjab.93.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span> <span> </span><span class="NLM_article-title">Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.tips.2017.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28389129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFShsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=459-472&author=Y.+Jiangauthor=J.+Liuauthor=D.+Chenauthor=L.+Yanauthor=W.+Zheng&title=Sirtuin+Inhibition%3A+Strategies%2C+Inhibitors%2C+and+Therapeutic+Potential&doi=10.1016%2Fj.tips.2017.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential</span></div><div class="casAuthors">Jiang, Yanhong; Liu, Jiajia; Chen, Di; Yan, Lingling; Zheng, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The β-NAD+-dependent Nε-acyl-lysine deacylation reaction catalyzed by sirtuin family members has been increasingly demonstrated to be important in regulating multiple crucial cellular processes and has also been proposed to be a therapeutic target for multiple human diseases.  Accordingly, its inhibitors have been actively pursued over the past few years.  In addn., we have also seen the pharmacol. assessment of sirtuin inhibitory compds., although to a lesser extent.  In this review, we first discuss how sirtuin inhibitors were discovered with the use of various approaches.  We then follow with a discussion of pharmacol. studies using sirtuin inhibitors.  Our aim here is to set a stage for developing future superior sirtuin inhibitors and for an expanded effort in exploiting inhibitors to explore and/or validate the therapeutic potential stemming from the inhibition of the sirtuin-catalyzed deacylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdIcVkqx8urVg90H21EOLACvtfcHk0liDMATCMOUNVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFShsro%253D&md5=57bafc78f57e063488d37b2a6793d0d2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DSirtuin%2520Inhibition%253A%2520Strategies%252C%2520Inhibitors%252C%2520and%2520Therapeutic%2520Potential%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.tips.2017.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery</span>. In  <i>Topics in Medicinal Chemistry 33. Epigenetic Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-28&author=A.+Ganesanauthor=A.+Mai&title=Topics+in+Medicinal+Chemistry+33.+Epigenetic+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520for%2520Drug%2520Discovery%26btitle%3DTopics%2520in%2520Medicinal%2520Chemistry%252033.%2520Epigenetic%2520Chemistry%26aulast%3DMai%26aufirst%3DA.%26pub%3DSpringer%26date%3D2020%26spage%3D1%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of the Zinc-Dependent Histone Deacetylases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2019.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.sbi.2019.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30743180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=9-18&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+the+Zinc-Dependent+Histone+Deacetylases&doi=10.1016%2Fj.sbi.2019.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Zinc-dependent histone deacetylases (HDACs) regulate the biol. function of histone and non-histone proteins through the hydrolysis of acetyllysine side chains to yield free lysine and acetate.  Certain HDAC isoenzymes exhibit alternative catalytic activities, such as polyamine deacetylase or lysine fatty acid deacylase activity.  To date, crystal structures have been reported for class I HDACs (1-3, and 8), class IIa HDACs (4 and 7), and class IIb HDACs (6 and 10).  Conserved active site residues mediate the chem. of substrate activation and hydrolysis in these isoenzymes through a metal-activated water mol. assisted by general base-general acid catalysis.  Upregulated HDAC activity is obsd. in cancer and neurodegenerative disease, and four HDAC inhibitors are currently approved for use in cancer chemotherapy.  Crystal structures of HDAC-inhibitor complexes guide the design of new inhibitors with high affinity and selectivity for specific HDAC isoenzymes implicated in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Vx86t86y6rVg90H21EOLACvtfcHk0lhEUNVx020ybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D&md5=1dd392837f88a1f079861d44a3f529f5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2019.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2019.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2019%26volume%3D59%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.sbi.2019.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span> <span> </span><span class="NLM_article-title">The Physiological Roles of Histone Deacetylase (HDAC) 1 and 2: Complex Co-Stars with Multiple Leading Parts</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/BST20130010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FBST20130010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23697933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=741-749&author=R.+D.+W.+Kellyauthor=S.+M.+Cowley&title=The+Physiological+Roles+of+Histone+Deacetylase+%28HDAC%29+1+and+2%3A+Complex+Co-Stars+with+Multiple+Leading+Parts&doi=10.1042%2FBST20130010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts</span></div><div class="casAuthors">Kelly, Richard D. W.; Cowley, Shaun M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">741-749</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  HDACs (histone deacetylases) 1 and 2 are ubiquitous long-lived proteins, which are often found together in three major multiprotein co-repressor complexes: Sin3, NuRD (nucleosome remodeling and deacetylation) and CoREST (co-repressor for element-1-silencing transcription factor).  Although there is a burgeoning no. of non-histone proteins within the acetylome, these complexes contain multiple DNA/chromatin-recognition motifs, which, in combination with transcription factors, target HDAC1/2 to chromatin.  Their physiol. roles should therefore be viewed within the framework of chromatin manipulation.  Classically, HDACs were thought to be recruited predominantly by transcriptional repressors to facilitate local histone deacetylation and transcriptional repression.  More recently, genome-wide assays have mapped HDAC1/2 and their assocd. proteins to transcriptionally active loci and have provided alternative context-specific functions, whereby their repressive functions are subtly exerted to balance transcriptional activation and repression.  With a few significant exceptions (early embryogenesis, brain development), HDAC1 and HDAC2 are functionally redundant.  In most mouse knockout studies, deletion of both enzymes is required in order to produce a substantial phenotype.  HDAC1/2 activity has been implicated in the development of numerous tissue and cell types, including heart, skin, brain, B-cells and T-cells.  A common feature in all HDAC1/2-knockout, -knockdown and small-mol. inhibitor studies is a redn. in cell proliferation.  A generic role in cell cycle progression could be exploited in cancer cells, by blocking HDAC1/2 activity with small-mol. inhibitors, making them potentially useful drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphMiAYD8az_rVg90H21EOLACvtfcHk0lhEUNVx020ybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2qsLw%253D&md5=47aa120c4321fedd4011fbfea6ca2243</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2FBST20130010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130010%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BD.%2BW.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26atitle%3DThe%2520Physiological%2520Roles%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%25201%2520and%25202%253A%2520Complex%2520Co-Stars%2520with%2520Multiple%2520Leading%2520Parts%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26spage%3D741%26epage%3D749%26doi%3D10.1042%2FBST20130010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, M. A.</span></span> <span> </span><span class="NLM_article-title">Integrative Regulation of Physiology by Histone Deacetylase 3</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1038/s41580-018-0076-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41580-018-0076-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30390028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=102-115&author=M.+J.+Emmettauthor=M.+A.+Lazar&title=Integrative+Regulation+of+Physiology+by+Histone+Deacetylase+3&doi=10.1038%2Fs41580-018-0076-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative regulation of physiology by histone deacetylase 3</span></div><div class="casAuthors">Emmett, Matthew J.; Lazar, Mitchell A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">102-115</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cell-type-specific gene expression is physiol. modulated by the binding of transcription factors to genomic enhancer sequences, to which chromatin modifiers such as histone deacetylases (HDACs) are recruited.  Drugs that inhibit HDACs are in clin. use but lack specificity.  HDAC3 is a stoichiometric component of nuclear receptor co-repressor complexes whose enzymic activity depends on this interaction.  HDAC3 is required for many aspects of mammalian development and physiol., for example, for controlling metab. and circadian rhythms.  In this Review, we discuss the mechanisms by which HDAC3 regulates cell type-specific enhancers, the structure of HDAC3 and its function as part of nuclear receptor co-repressors, its enzymic activity and its post-translational modifications.  We then discuss the plethora of tissue-specific physiol. functions of HDAC3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwR_7xsbnjLVg90H21EOLACvtfcHk0lhEUNVx020ybw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7zL&md5=ab5a2912fc482c16b42e8e7d49a08750</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0076-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0076-0%26sid%3Dliteratum%253Aachs%26aulast%3DEmmett%26aufirst%3DM.%2BJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26atitle%3DIntegrative%2520Regulation%2520of%2520Physiology%2520by%2520Histone%2520Deacetylase%25203%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D102%26epage%3D115%26doi%3D10.1038%2Fs41580-018-0076-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 in Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+Deacetylase+6+in+Cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0li47SPhZDyGWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%25206%2520in%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultetyova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snajdr, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadzima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlinova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">The Unraveling of Substrate Specificity of Histone Deacetylase 6 Domains Using Acetylome Peptide Microarrays and Peptide Libraries</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">4035</span>– <span class="NLM_lpage">4045</span>, <span class="refDoi"> DOI: 10.1096/fj.201801680R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1096%2Ffj.201801680R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30496698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptl2itbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=4035-4045&author=Z.+Kutilauthor=L.+Skultetyovaauthor=D.+Rauhauthor=M.+Meleshinauthor=I.+Snajdrauthor=Z.+Novakovaauthor=J.+Mikesovaauthor=J.+Pavlicekauthor=M.+Hadzimaauthor=P.+Baranovaauthor=B.+Havlinovaauthor=P.+Majerauthor=M.+Schutkowskiauthor=C.+Barinka&title=The+Unraveling+of+Substrate+Specificity+of+Histone+Deacetylase+6+Domains+Using+Acetylome+Peptide+Microarrays+and+Peptide+Libraries&doi=10.1096%2Ffj.201801680R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries</span></div><div class="casAuthors">Kutil, Zsofia; Skultetyova, Lubica; Rauh, David; Meleshin, Marat; Snajdr, Ivan; Novakova, Zora; Mikesova, Jana; Pavlicek, Jiri; Hadzima, Martin; Baranova, Petra; Havlinova, Barbora; Majer, Pavel; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">4035-4045</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is amultidomain cytosolic hydrolase actingmostly on nonhistone protein substrates.  Investigations of the substrate specificity of HDAC6 are confounded by the presence of 2 catalytically active deacetylase domains (DD1 and DD2).  In this study, acetylome peptide microarrays and peptide libraries were used to map the substrate specificity of DD1 and DD2 of human HDAC6.  The results show that DD1 is solely responsible for the deacetylation of substrates harboring the acetyllysine at their C terminus, whereas DD2 exclusively deacetylates peptides with an internal acetyllysine residue.  Also, statistical anal. of the deacetylation data revealed amino acid preferences at individual positions flanking the acetyllysine, where glycine and arginine residues are favored at positions N-terminal to the central acetyllysine; neg. charged glutamate is strongly disfavored throughout the sequence.  Finally, the deacylation activity of HDAC6 was profiled by using a panel of acyl derivs. of the optimized peptide substrate and showed that HDAC6 acts as a proficient deformylase.  Our data thus offer a detailed insight into the substrate preferences of the individual HDAC6 domains at the peptide level, and these findings can in turn help in elucidating the biol. roles of the enzyme and facilitate the development of new domain-specific inhibitors as research tools or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjEuwCTtndhrVg90H21EOLACvtfcHk0li47SPhZDyGWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptl2itbg%253D&md5=c94c8d4d8ba9993f2357854616d4abc9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801680R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801680R%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DSkultetyova%26aufirst%3DL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DSnajdr%26aufirst%3DI.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DHadzima%26aufirst%3DM.%26aulast%3DBaranova%26aufirst%3DP.%26aulast%3DHavlinova%26aufirst%3DB.%26aulast%3DMajer%26aufirst%3DP.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DThe%2520Unraveling%2520of%2520Substrate%2520Specificity%2520of%2520Histone%2520Deacetylase%25206%2520Domains%2520Using%2520Acetylome%2520Peptide%2520Microarrays%2520and%2520Peptide%2520Libraries%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D4035%26epage%3D4045%26doi%3D10.1096%2Ffj.201801680R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0li47SPhZDyGWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">HDAC8: A Multifaceted Target for Therapeutic Interventions</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.tips.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=481-492&author=A.+Chakrabartiauthor=I.+Oehmeauthor=O.+Wittauthor=G.+Oliveiraauthor=W.+Sipplauthor=C.+Romierauthor=R.+J.+Pierceauthor=M.+Jung&title=HDAC8%3A+A+Multifaceted+Target+for+Therapeutic+Interventions&doi=10.1016%2Fj.tips.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8: a multifaceted target for therapeutic interventions</span></div><div class="casAuthors">Chakrabarti, Alokta; Oehme, Ina; Witt, Olaf; Oliveira, Guilherme; Sippl, Wolfgang; Romier, Christophe; Pierce, Raymond J.; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections.  It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins.  In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors crit. to tumorigenesis.  In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection.  The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors.  Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPwG01nKtWHLVg90H21EOLACvtfcHk0lgzgUOMkGbsFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D&md5=c99b5c390930dc17398d15f20127758b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOliveira%26aufirst%3DG.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DPierce%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHDAC8%253A%2520A%2520Multifaceted%2520Target%2520for%2520Therapeutic%2520Interventions%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D481%26epage%3D492%26doi%3D10.1016%2Fj.tips.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castañeda, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Substrate Selectivity Is Determined by Long- and Short-Range Interactions Leading to Enhanced Reactivity for Full-Length Histone Substrates Compared with Peptides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">21568</span>– <span class="NLM_lpage">21577</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.811026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M117.811026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29109148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=21568-21577&author=C.+A.+Casta%C3%B1edaauthor=N.+A.+Wolfsonauthor=K.+R.+Lengauthor=Y.-M.+Kuoauthor=A.+J.+Andrewsauthor=C.+A.+Fierke&title=HDAC8+Substrate+Selectivity+Is+Determined+by+Long-+and+Short-Range+Interactions+Leading+to+Enhanced+Reactivity+for+Full-Length+Histone+Substrates+Compared+with+Peptides&doi=10.1074%2Fjbc.M117.811026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides</span></div><div class="casAuthors">Castaneda, Carol Ann; Wolfson, Noah A.; Leng, Katherine R.; Kuo, Yin-Ming; Andrews, Andrew J.; Fierke, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21568-21577</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) catalyze deacetylation of acetyl-lysine residues within proteins.  To date, HDAC substrate specificity and selectivity have been largely estd. using peptide substrates.  However, it is unclear whether peptide substrates accurately reflect the substrate selectivity of HDAC8 toward full-length proteins.  Here, we compare HDAC8 substrate selectivity in the context of peptides, full-length proteins, and protein-nucleic acid complexes.  We demonstrate that HDAC8 catalyzes deacetylation of tetrameric histone (H3/H4) substrates with catalytic efficiencies that are 40-300-fold higher than those for corresponding peptide substrates.  Thus, we conclude that addnl. contacts with protein substrates enhance catalytic efficiency.  However, the catalytic efficiency decreases for larger multiprotein complexes.  These differences in HDAC8 substrate selectivity for peptides and full-length proteins suggest that HDAC8 substrate preference is based on a combination of short- and long-range interactions.  In summary, this work presents detailed kinetics for HDAC8-catalyzed deacetylation of singly-acetylated, full-length protein substrates, revealing that HDAC8 substrate selectivity is detd. by multiple factors.  These insights provide a foundation for understanding recognition of full-length proteins by HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiSrdVpHIIfbVg90H21EOLACvtfcHk0lgzgUOMkGbsFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yjsA%253D%253D&md5=7f39302747468f75a431cfeaa5e4ed96</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.811026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.811026%26sid%3Dliteratum%253Aachs%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DC.%2BA.%26aulast%3DWolfson%26aufirst%3DN.%2BA.%26aulast%3DLeng%26aufirst%3DK.%2BR.%26aulast%3DKuo%26aufirst%3DY.-M.%26aulast%3DAndrews%26aufirst%3DA.%2BJ.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26atitle%3DHDAC8%2520Substrate%2520Selectivity%2520Is%2520Determined%2520by%2520Long-%2520and%2520Short-Range%2520Interactions%2520Leading%2520to%2520Enhanced%2520Reactivity%2520for%2520Full-Length%2520Histone%2520Substrates%2520Compared%2520with%2520Peptides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D21568%26epage%3D21577%26doi%3D10.1074%2Fjbc.M117.811026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aramsangtienchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2685-2692&author=P.+Aramsangtienchaiauthor=N.+A.+Spiegelmanauthor=B.+Heauthor=S.+P.+Millerauthor=L.+Daiauthor=Y.+Zhaoauthor=H.+Lin&title=HDAC8+Catalyzes+the+Hydrolysis+of+Long+Chain+Fatty+Acyl+Lysine&doi=10.1021%2Facschembio.6b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine</span></div><div class="casAuthors">Aramsangtienchai, Pornpun; Spiegelman, Nicole A.; He, Bin; Miller, Seth P.; Dai, Lunzhi; Zhao, Yingming; Lin, Hening</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2685-2692</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The histone deacetylase (HDAC) family regulates many biol. pathways through the deacetylation of lysine residues on histone and nonhistone proteins.  Mammals have 18 HDACs that are classified into four classes.  Class I, II, and IV are zinc-dependent, while class III is NAD (NAD+)-dependent lysine deacetylase or sirtuins.  HDAC8, a class I HDAC family member, has been shown to have low deacetylation activity compared to other HDACs in vitro.  Recent studies showed that several sirtuins, with low deacetylase activities, can actually hydrolyze other acyl lysine modifications more efficiently.  Inspired by this, we tested the activity of HDAC8 using a variety of different acyl lysine peptides.  Screening a panel of peptides with different acyl lysine modifications, we found that HDAC8 can catalyze the removal of acyl groups with 2-16 carbons from lysine 9 of the histone H3 peptide (H3K9).  Interestingly, the catalytic efficiencies (kcat/Km) of HDAC8 on octanoyl, dodecanoyl, and myristoyl lysine are several-fold better than that on acetyl lysine.  The increased catalytic efficiencies of HDAC8 on larger fatty acyl groups are due to the much lower Km values.  T-cell leukemia Jurkat cells treated with a HDAC8 specific inhibitor, PCI-34051, exhibited an increase in global fatty acylation compared to control treatment.  Thus, the de-fatty-acylation activity of HDAC8 is likely physiol. relevant.  This is the first report of a zinc-dependent HDAC with de-fatty-acylation activity, and identification of HDAC8 de-fatty-acylation targets will help to further understand the function of HDAC8 and protein lysine fatty acylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDqpFjVQQljLVg90H21EOLACvtfcHk0lgzgUOMkGbsFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtrbL&md5=bdfdd0bb0199e094719008da1b0d1520</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00396%26sid%3Dliteratum%253Aachs%26aulast%3DAramsangtienchai%26aufirst%3DP.%26aulast%3DSpiegelman%26aufirst%3DN.%2BA.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26atitle%3DHDAC8%2520Catalyzes%2520the%2520Hydrolysis%2520of%2520Long%2520Chain%2520Fatty%2520Acyl%2520Lysine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2685%26epage%3D2692%26doi%3D10.1021%2Facschembio.6b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanginlar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC11 Is a Regulator of Diverse Immune Functions</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1861</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bbagrm.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29222071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWns7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1861&publication_year=2018&pages=54-59&author=C.+Yanginlarauthor=C.+Logie&title=HDAC11+Is+a+Regulator+of+Diverse+Immune+Functions&doi=10.1016%2Fj.bbagrm.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC11 is a regulator of diverse immune functions</span></div><div class="casAuthors">Yanginlar, Cansu; Logie, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1861</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-59</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases deacetylate histone and non-histone protein targets.  Aberrant HDAC expression and function have been obsd. in several diseases, which make these enzymes attractive treatment targets.  Here, we summarize recent literature that addresses the roles of HDAC11 on the regulation of different immune cells including neutrophils, myeloid derived suppressor cells and T-cells.  HDAC11 was initially identified as a neg. regulator of the well-known anti-inflammatory cytokine IL-10.  Hence, antagonizing HDAC11 activity may have anti-tumor potential, whereas activating HDAC11 may be useful to treat chronic inflammation or autoimmunity.  However, to anticipate biol. side-effects of HDAC11 modulators, more mol. insights will be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZ7apoQdA2bVg90H21EOLACvtfcHk0li89i3XNLsfUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWns7vE&md5=a818f8f833ef4bdb1eff570043861923</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DYanginlar%26aufirst%3DC.%26aulast%3DLogie%26aufirst%3DC.%26atitle%3DHDAC11%2520Is%2520a%2520Regulator%2520of%2520Diverse%2520Immune%2520Functions%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2018%26volume%3D1861%26spage%3D54%26epage%3D59%26doi%3D10.1016%2Fj.bbagrm.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=685-693&author=Z.+Kutilauthor=Z.+Novakovaauthor=M.+Meleshinauthor=J.+Mikesovaauthor=M.+Schutkowskiauthor=C.+Barinka&title=Histone+Deacetylase+11+Is+a+Fatty-Acid+Deacylase&doi=10.1021%2Facschembio.7b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span></div><div class="casAuthors">Kutil, Zsofia; Novakova, Zora; Meleshin, Marat; Mikesova, Jana; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) is a sole member of the class IV HDAC subfamily with negligible intrinsic deacetylation activity.  Here, we report in vitro profiling of HDAC11 deacylase activities, and our data unequivocally show that the enzyme efficiently removes acyl moieties spanning 8-18 carbons from the side chain nitrogen of the lysine residue of a peptidic substrate.  Addnl., N-linked lipoic acid and biotin are removed by the enzyme, although with lower efficacy.  Catalytic efficiencies toward dodecanoylated and myristoylated peptides were 77 700 and 149 000 M-1 s-1, resp., making HDAC11 the most proficient fatty-acid deacylase of the HDAC family.  Interestingly, HDAC11 is strongly inhibited by free myristic, palmitic, and stearic acids with inhibition consts. of 6.5, 0.9, and 1.6 μM, resp.  At the same time, its deacylase activity is stimulated more than 2.5-fold by both palmitoyl-CoA and myristoyl-CoA, pointing toward metabolic control of the enzymic activity by fatty-acid metabolites.  Our data reveal novel enzymic activity of HDAC11 that can, in turn, facilitate the uncovering of addnl. biol. functions of the enzyme as well as the design of isoform-specific HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNsptw7rk7bVg90H21EOLACvtfcHk0li89i3XNLsfUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D&md5=07233a3bfed4f158c6d5752fc18a8c1f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00942%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%252011%2520Is%2520a%2520Fatty-Acid%2520Deacylase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D685%26epage%3D693%26doi%3D10.1021%2Facschembio.7b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Yruela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galleano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 11 Is an ε-<i>N</i>-Myristoyllysine Hydrolase</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.chembiol.2018.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29731425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVyju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=849-856&author=C.+Moreno-Yruelaauthor=I.+Galleanoauthor=A.+S.+Madsenauthor=C.+A.+Olsen&title=Histone+Deacetylase+11+Is+an+%CE%B5-N-Myristoyllysine+Hydrolase&doi=10.1016%2Fj.chembiol.2018.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase</span></div><div class="casAuthors">Moreno-Yruela, Carlos; Galleano, Iacopo; Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">849-856.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymes regulate diverse biol. function, including gene expression, rendering them potential targets for intervention in a no. of diseases, with a handful of compds. approved for treatment of certain hematol. cancers.  Among the human zinc-dependent HDACs, the most recently discovered member, HDAC11, is the only member assigned to subclass IV.  It is the smallest protein and has the least well understood biol. function.  Here, we show that HDAC11 cleaves long-chain acyl modifications on lysine side chains with remarkable efficiency.  We further show that several common types of HDAC inhibitors, including the approved drugs romidepsin and vorinostat, do not inhibit this enzymic activity.  Macrocyclic hydroxamic acid-contg. peptides, on the other hand, potently inhibit HDAC11 demyristoylation activity.  These findings should be taken carefully into consideration in future investigations of the biol. function of HDAC11 and will serve as a foundation for the development of selective chem. probes targeting HDAC11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5H2-YHI3qbVg90H21EOLACvtfcHk0li89i3XNLsfUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVyju7c%253D&md5=9c805196d1b26c2c31459940e0e949f7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Yruela%26aufirst%3DC.%26aulast%3DGalleano%26aufirst%3DI.%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DHistone%2520Deacetylase%252011%2520Is%2520an%2520%25CE%25B5-N-Myristoyllysine%2520Hydrolase%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D849%26epage%3D856%26doi%3D10.1016%2Fj.chembiol.2018.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asfaha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves Avelar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Class IIa Histone Deacetylases Research</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">115087</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2019.115087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31561937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=115087&author=Y.+Asfahaauthor=C.+Schrenkauthor=L.+A.+Alves+Avelarauthor=A.+Hamacherauthor=M.+Pfliegerauthor=M.+U.+Kassackauthor=T.+Kurz&title=Recent+Advances+in+Class+IIa+Histone+Deacetylases+Research&doi=10.1016%2Fj.bmc.2019.115087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in class IIa histone deacetylases research</span></div><div class="casAuthors">Asfaha, Yodita; Schrenk, Christian; Alves Avelar, Leandro A.; Hamacher, Alexandra; Pflieger, Marc; Kassack, Matthias U.; Kurz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">115087</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Epigenetic control plays an important role in gene regulation through chem. modifications of DNA and post-translational modifications of histones.  An essential post-translational modification is the histone acetylation/deacetylation-process which is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  The mammalian zinc dependent HDAC family is subdivided into three classes: class I (HDACs 1-3, 8), class II (IIa: HDACs 4, 5, 7, 9; IIb: HDACs 6, 10) and class IV (HDAC 11).  In this review, recent studies on the biol. role and regulation of class IIa HDACs as well as their contribution in neurodegenerative diseases, immune disorders and cancer will be presented.  Furthermore, the development, synthesis, and future perspectives of selective class IIa inhibitors will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2A6En_QF4WbVg90H21EOLACvtfcHk0lhh7bY0FDz_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksr7M&md5=d03cc974f3c66539242026af7ac00856</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115087%26sid%3Dliteratum%253Aachs%26aulast%3DAsfaha%26aufirst%3DY.%26aulast%3DSchrenk%26aufirst%3DC.%26aulast%3DAlves%2BAvelar%26aufirst%3DL.%2BA.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DPflieger%26aufirst%3DM.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKurz%26aufirst%3DT.%26atitle%3DRecent%2520Advances%2520in%2520Class%2520IIa%2520Histone%2520Deacetylases%2520Research%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D115087%26doi%3D10.1016%2Fj.bmc.2019.115087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. M.</span></span> <span> </span><span class="NLM_article-title">Structural basis of the action of thermolysin and related zinc peptidases</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1021/ar00153a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00153a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaL1cXltVKrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1988&pages=333-340&author=B.+M.+Matthews&title=Structural+basis+of+the+action+of+thermolysin+and+related+zinc+peptidases&doi=10.1021%2Far00153a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of the action of thermolysin and related zinc peptidases</span></div><div class="casAuthors">Matthews, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">333-40</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with refs., of the structure and reaction mechanism of thermolysin and other Zn-contg. proteolytic enzymes, such as carboxypeptidase A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovcGWEFEzE5rVg90H21EOLACvtfcHk0lhh7bY0FDz_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVKrsLo%253D&md5=25cc216c6b4ee3d888132acb4f7dd23e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Far00153a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00153a003%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DB.%2BM.%26atitle%3DStructural%2520basis%2520of%2520the%2520action%2520of%2520thermolysin%2520and%2520related%2520zinc%2520peptidases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1988%26volume%3D21%26spage%3D333%26epage%3D340%26doi%3D10.1021%2Far00153a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeneke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.3390/cells4020135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fcells4020135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25915736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVKitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=135-168&author=E.+Koenekeauthor=O.+Wittauthor=I.+Oehme&title=HDAC+Family+Members+Intertwined+in+the+Regulation+of+Autophagy%3A+A+Druggable+Vulnerability+in+Aggressive+Tumor+Entities&doi=10.3390%2Fcells4020135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities</span></div><div class="casAuthors">Koeneke, Emily; Witt, Olaf; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-168</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The exploitation of autophagy by some cancer entities to support survival and dodge death has been well-described.  Though its role as a constitutive process is important in normal, healthy cells, in the milieu of malignantly transformed and highly proliferative cells, autophagy is crit. for escaping metabolic and genetic stressors.  In recent years, the importance of histone deacetylases (HDACs) in cancer biol. has been heavily investigated, and the enzyme family has been shown to play a role in autophagy, too.  HDAC inhibitors (HDACi) are being integrated into cancer therapy and clin. trials are ongoing.  The effect of HDACi on autophagy and, conversely, the effect of autophagy on HDACi efficacy are currently under investigation.  With the development of HDACi that are able to selectively target individual HDAC isoenzymes, there is great potential for specific therapy that has more well-defined effects on cancer biol. and also minimizes toxicity.  Here, the role of autophagy in the context of cancer and the interplay of this process with HDACs will be summarized.  Identification of key HDAC isoenzymes involved in autophagy and the ability to target specific isoenzymes yields the potential to cripple and ultimately eliminate malignant cells depending on autophagy as a survival mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8tgPx9Co3mLVg90H21EOLACvtfcHk0lhh7bY0FDz_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVKitbY%253D&md5=562219b08ca8c4a9c93e15e92687a1b0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fcells4020135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells4020135%26sid%3Dliteratum%253Aachs%26aulast%3DKoeneke%26aufirst%3DE.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520Family%2520Members%2520Intertwined%2520in%2520the%2520Regulation%2520of%2520Autophagy%253A%2520A%2520Druggable%2520Vulnerability%2520in%2520Aggressive%2520Tumor%2520Entities%26jtitle%3DCells%26date%3D2015%26volume%3D4%26spage%3D135%26epage%3D168%26doi%3D10.3390%2Fcells4020135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 10 Structure and Molecular Function as a Polyamine Deacetylase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15368</span>, <span class="refDoi"> DOI: 10.1038/ncomms15368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fncomms15368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28516954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFyisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15368&author=Y.+Haiauthor=S.+A.+Shinskyauthor=N.+J.+Porterauthor=D.+W.+Christianson&title=Histone+Deacetylase+10+Structure+and+Molecular+Function+as+a+Polyamine+Deacetylase&doi=10.1038%2Fncomms15368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 10 structure and molecular function as a polyamine deacetylase</span></div><div class="casAuthors">Hai, Yang; Shinsky, Stephen A.; Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15368</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cationic polyamines such as spermidine and spermine are crit. in all forms of life, as they regulate the function of biol. macromols.  Intracellular polyamine metab. is regulated by reversible acetylation and dysregulated polyamine metab. is assocd. with neoplastic diseases such as colon cancer, prostate cancer and neuroblastoma.  Here we report that histone deacetylase 10 (HDAC10) is a robust polyamine deacetylase, using recombinant enzymes from Homo sapiens (human) and Danio rerio (zebrafish).  The 2.85 Å-resoln. crystal structure of zebrafish HDAC10 complexed with a transition-state analog inhibitor reveals that a glutamate gatekeeper and a sterically constricted active site confer specificity for N8-acetylspermidine hydrolysis and disfavor acetyllysine hydrolysis.  Both HDAC10 and spermidine are known to promote cellular survival through autophagy.  Accordingly, this work sets a foundation for studying the chem. biol. of autophagy through the structure-based design of inhibitors that may also serve as new leads for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa9laHMWjizLVg90H21EOLACvtfcHk0lhh7bY0FDz_Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFyisrY%253D&md5=e192e4b219dcb0b46b05ece566f8a59d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncomms15368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15368%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DShinsky%26aufirst%3DS.%2BA.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%252010%2520Structure%2520and%2520Molecular%2520Function%2520as%2520a%2520Polyamine%2520Deacetylase%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15368%26doi%3D10.1038%2Fncomms15368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3105-3114&author=S.+A.+Shinskyauthor=D.+W.+Christianson&title=Polyamine+Deacetylase+Structure+and+Catalysis%3A+Prokaryotic+Acetylpolyamine+Amidohydrolase+and+Eukaryotic+HDAC10&doi=10.1021%2Facs.biochem.8b00079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10</span></div><div class="casAuthors">Shinsky, Stephen A.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3105-3114</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polyamines such as putrescine, spermidine, and spermine are small aliph. cations that serve myriad biol. functions in all forms of life.  While polyamine biosynthesis and cellular trafficking pathways are generally well-defined, only recently has the mol. basis of reversible polyamine acetylation been established.  In particular, enzymes that catalyze polyamine deacetylation reactions have been identified and structurally characterized: histone deacetylase 10 (HDAC10) from Homo sapiens and Danio rerio (zebrafish) is a highly specific N8-acetylspermidine deacetylase, and its prokaryotic counterpart, acetylpolyamine amidohydrolase (APAH) from Mycoplana ramosa, is a broad-specificity polyamine deacetylase.  Similar to the greater family of HDACs, which mainly serve as lysine deacetylases, both enzymes adopt the characteristic arginase-deacetylase fold and employ a Zn2+-activated water mol. for catalysis.  In contrast with HDACs, however, the active sites of HDAC10 and APAH are sterically constricted to enforce specificity for long, slender polyamine substrates and exclude bulky peptides and proteins contg. acetyl-L-lysine.  Crystal structures of APAH and D. rerio HDAC10 reveal that quaternary structure, i.e., dimer assembly, provides the steric constriction that directs the polyamine substrate specificity of APAH, whereas tertiary structure, a unique 310 helix defined by the P(E,A)CE motif, provides the steric constriction that directs the polyamine substrate specificity of HDAC10.  Given the recent identification of HDAC10 and spermidine as mediators of autophagy, HDAC10 is rapidly emerging as a biomarker and target for the design of isoenzyme-selective inhibitors that will suppress autophagic responses to cancer chemotherapy, thereby rendering cancer cells more susceptible to cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRp3v9v7ryrLVg90H21EOLACvtfcHk0lhKCbWMFC1Pxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgsrw%253D&md5=f909b6b4f46bd1a7eb5f12b800295fc5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00079%26sid%3Dliteratum%253Aachs%26aulast%3DShinsky%26aufirst%3DS.%2BA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DPolyamine%2520Deacetylase%2520Structure%2520and%2520Catalysis%253A%2520Prokaryotic%2520Acetylpolyamine%2520Amidohydrolase%2520and%2520Eukaryotic%2520HDAC10%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3105%26epage%3D3114%26doi%3D10.1021%2Facs.biochem.8b00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuchler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenull, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivarathri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span> <span> </span><span class="NLM_article-title">Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e1005938</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.ppat.1005938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27832212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2mtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005938&author=K.+Kuchlerauthor=S.+Jenullauthor=R.+Shivarathriauthor=N.+Chauhan&title=Fungal+KATs%2FKDACs%3A+A+New+Highway+to+Better+Antifungal+Drugs%3F&doi=10.1371%2Fjournal.ppat.1005938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Fungal KATs/KDACs: a new highway to better antifungal drugs?</span></div><div class="casAuthors">Kuchler, Karl; Jenull, Sabrina; Shivarathri, Raju; Chauhan, Neeraj</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1005938/1-e1005938/15</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  We provide a comprehensive overview of chromatin modification in human fungal pathogens, particularly those altering virulence.  The focus is on lysine deacetylases (KDACs) and lysine acetyltransferases (KATs) in Candida spp.  We discuss how the modulation of KATs/KDACs in Candida spp. could pave the way for novel therapeutic strategies to combat fungal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod-Z1p6GfHcrVg90H21EOLACvtfcHk0lhKCbWMFC1Pxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2mtL4%253D&md5=de23517424eb6138f6e98fd6ae4f1e8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005938%26sid%3Dliteratum%253Aachs%26aulast%3DKuchler%26aufirst%3DK.%26aulast%3DJenull%26aufirst%3DS.%26aulast%3DShivarathri%26aufirst%3DR.%26aulast%3DChauhan%26aufirst%3DN.%26atitle%3DFungal%2520KATs%252FKDACs%253A%2520A%2520New%2520Highway%2520to%2520Better%2520Antifungal%2520Drugs%253F%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3De1005938%26doi%3D10.1371%2Fjournal.ppat.1005938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhomberg, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, M.</span></span> <span> </span><span class="NLM_article-title"><i>In Vitro</i> Activity of a Hos2 Deacetylase Inhibitor, MGCD290, in Combination with Echinocandins against Echinocandin-Resistant <i>Candida</i> Species</span>. <i>Diagn. Microbiol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1016/j.diagmicrobio.2014.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.diagmicrobio.2014.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25600842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSnsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2015&pages=259-263&author=M.+A.+Pfallerauthor=P.+R.+Rhombergauthor=S.+A.+Messerauthor=M.+Castanheira&title=In+Vitro+Activity+of+a+Hos2+Deacetylase+Inhibitor%2C+MGCD290%2C+in+Combination+with+Echinocandins+against+Echinocandin-Resistant+Candida+Species&doi=10.1016%2Fj.diagmicrobio.2014.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species</span></div><div class="casAuthors">Pfaller, M. A.; Rhomberg, P. R.; Messer, S. A.; Castanheira, M.</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Microbiology and Infectious Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-263</span>CODEN:
                <span class="NLM_cas:coden">DMIDDZ</span>;
        ISSN:<span class="NLM_cas:issn">0732-8893</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MGCD290, a Hos2 fungal histone deacetylase inhibitor, showed modest activity when tested alone (MIC range, 0.12-4 μg/mL; MIC50/90, 0.5/4 μg/mL) against Candida glabrata (n = 15; 14 fks mutants; 5 also fluconazole resistant), Candida albicans (8 fks mutants; 2 also fluconazole resistant), Candida tropicalis (4 fks mutants), and Candida krusei (3 fks mutants).  However, MGCD290 showed synergy or partial synergy for 33.3%, 30.1%, 36.7%, and 80.0% of the isolates when tested with anidulafungin, caspofungin, micafungin, and fluconazole, resp.  Favorable interactions were achieved with low concns. of MGCD290 (0.015-0.25 μg/mL), and categorical shifts were obsd. in 2 of 8 (25.0%) isolates of C. albicans and 2 of 3 (66.7%) isolates of C. krusei and in 4 of the 5 (80.0%) fluconazole-resistant isolates of C. glabrata.  MGCD290 exerts a distinctly favorable influence on the MICs of fluconazole and the echinocandins, resulting in conversion from resistance to susceptibility regardless of fks mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIr_O0BjzX4rVg90H21EOLACvtfcHk0lhKCbWMFC1Pxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSnsbjL&md5=3a7550a215a89b52495ec6ebf5297bb1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.diagmicrobio.2014.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diagmicrobio.2014.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DRhomberg%26aufirst%3DP.%2BR.%26aulast%3DMesser%26aufirst%3DS.%2BA.%26aulast%3DCastanheira%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520a%2520Hos2%2520Deacetylase%2520Inhibitor%252C%2520MGCD290%252C%2520in%2520Combination%2520with%2520Echinocandins%2520against%2520Echinocandin-Resistant%2520Candida%2520Species%26jtitle%3DDiagn.%2520Microbiol.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D81%26spage%3D259%26epage%3D263%26doi%3D10.1016%2Fj.diagmicrobio.2014.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Acetylation/Deacetylation in Parasites: An Update (2017–2020)</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32615359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShs7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=65-74&author=R.+Fioravantiauthor=N.+Mautoneauthor=A.+Rovereauthor=D.+Rotiliauthor=A.+Mai&title=Targeting+Histone+Acetylation%2FDeacetylation+in+Parasites%3A+An+Update+%282017%E2%80%932020%29&doi=10.1016%2Fj.cbpa.2020.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone acetylation/deacetylation in parasites: an update (2017-2020)</span></div><div class="casAuthors">Fioravanti, Rossella; Mautone, Nicola; Rovere, Annarita; Rotili, Dante; Mai, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone modifying enzymes have vital roles in the growth and survival of both parasites and humans.  Targeting the epigenome can be a new strategy for the treatment of parasitic diseases.  Compds. modulating histone acetylation/deacetylation have recently been reported hampering Plasmodium, Schistosoma, Leishmania, and Trypanosoma infections.  Beside new histone deacetylase inhibitors, PfGCN5 and bromodomain inhibitors have been recently described to inhibit Plasmodium proliferation.  Sm histone deacetylase 8 and SmSIRT2, as well as Leishmania and Trypanosoma sirtuins (SIR2rps), seem to be the most reliable targets to effectively fight the related protozoan infections.  The selectivity toward parasite over mammalian cells is still an open question, and significant optimization efforts of epidrugs are still required to improve potency/selectivity and decrease toxicity.  Recent reports on the alteration of cellular signaling pathways provoked by parasite infection through changes in the host acetylation/deacetylation status at gene promoters may suggest novel therapeutic strategies to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDelX-elfRebVg90H21EOLACvtfcHk0linRE1UbtbUKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShs7zI&md5=e6aeb0f2d6d55dd1f1d408c8be7a0de4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DMautone%26aufirst%3DN.%26aulast%3DRovere%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DTargeting%2520Histone%2520Acetylation%252FDeacetylation%2520in%2520Parasites%253A%2520An%2520Update%2520%25282017%25E2%2580%25932020%2529%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D65%26epage%3D74%26doi%3D10.1016%2Fj.cbpa.2020.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heltweg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Assays for the Determination of Histone Deacetylase Activity</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2005.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ymeth.2005.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=16087348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1ahs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2005&pages=332-337&author=B.+Heltwegauthor=J.+Trappauthor=M.+Jung&title=In+Vitro+Assays+for+the+Determination+of+Histone+Deacetylase+Activity&doi=10.1016%2Fj.ymeth.2005.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assays for the determination of histone deacetylase activity</span></div><div class="casAuthors">Heltweg, Birgit; Trapp, Johannes; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases are important regulators of transcription and an emerging target for anticancer drugs.  We present an overview over various assay formats that include radiolabeled histones, oligopeptides, and small mols. as substrates.  The advantages and disadvantages of the various formats in terms of, e.g., substrate availability, throughput or subtype selectivity are discussed.  Detailed procedures for various assay types that can be used for different problems, such as library screening or fluorescent inhibitor testing, are given.  We present a new protocol for a simple high-throughput assay for NAD+-dependent (class III) histone deacetylases, also termed sirtuins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEetxUXugzbbVg90H21EOLACvtfcHk0linRE1UbtbUKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1ahs74%253D&md5=acdab3410a71c11ba6a2835d1e7378c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2005.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2005.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHeltweg%26aufirst%3DB.%26aulast%3DTrapp%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Assays%2520for%2520the%2520Determination%2520of%2520Histone%2520Deacetylase%2520Activity%26jtitle%3DMethods%26date%3D2005%26volume%3D36%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.ymeth.2005.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span> <span> </span><span class="NLM_article-title">Profiling Technologies for the Identification and Characterization of Small-Molecule Histone Deacetylase Inhibitors</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ddtec.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26723889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC28rms1Witg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=24-28&author=D.+Liao&title=Profiling+Technologies+for+the+Identification+and+Characterization+of+Small-Molecule+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.ddtec.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors</span></div><div class="casAuthors">Liao Daiqing</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are promising drug targets for treating cancer, neurologic, inflammatory and metabolic diseases.  Four small molecule inhibitors of HDACs have gained regulatory approval for treating lymphomas and multiple myelomas.  Highly sensitive in vitro and cell-based profiling technologies have been developed to discover HDAC inhibitors (HDACi) and characterize their inhibitory potency, target-binding specificity and kinetics.  In particular, proteomic profiling can define the specificity of an inhibitor at a single residue resolution.  Chemoproteomic profiling can determine the potency, specificity and binding kinetics of an inhibitor on a specific HDAC complex in cell extracts.  As inhibitors with new chemical scaffolds are of particular interest to improve HDAC isoform-specificity and pharmaceutical properties, effective profiling technologies will continue to have important utility.  Here we briefly review recent developments of HDAC inhibitor profiling technologies and discuss distinct features of various technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2PU1XOycdfCA3UY9EwTNrfW6udTcc2eY0l0s_nV3Jvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rms1Witg%253D%253D&md5=2d1efd9c5e1ca2cb2b4a6aa77dca5b21</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DD.%26atitle%3DProfiling%2520Technologies%2520for%2520the%2520Identification%2520and%2520Characterization%2520of%2520Small-Molecule%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2015%26volume%3D18%26spage%3D24%26epage%3D28%26doi%3D10.1016%2Fj.ddtec.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span> <span> </span><span class="NLM_article-title">Chemical Phylogenetics of Histone Deacetylases</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nchembio.313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnchembio.313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20139990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1OmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=238-243&author=J.+E.+Bradnerauthor=N.+Westauthor=M.+L.+Grachanauthor=E.+F.+Greenbergauthor=S.+J.+Haggartyauthor=T.+Warnowauthor=R.+Mazitschek&title=Chemical+Phylogenetics+of+Histone+Deacetylases&doi=10.1038%2Fnchembio.313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical phylogenetics of histone deacetylases</span></div><div class="casAuthors">Bradner, James E.; West, Nathan; Grachan, Melissa L.; Greenberg, Edward F.; Haggarty, Stephen J.; Warnow, Tandy; Mazitschek, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-243</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The broad study of histone deacetylases in chem., biol. and medicine relies on tool compds. to derive mechanistic insights.  A phylogenetic anal. of class I and II histone deacetylases (HDACs) as targets of a comprehensive, structurally diverse panel of inhibitors revealed unexpected isoform selectivity even among compds. widely perceived as nonselective.  The synthesis and study of a focused library of cinnamic hydroxamates allowed the identification of, to our knowledge, the first nonselective HDAC inhibitor.  These data will guide a more informed use of HDAC inhibitors as chem. probes and therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVyndO9wa6LVg90H21EOLACvtfcHk0linRE1UbtbUKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1OmsLY%253D&md5=4f23cb8a5e3fb4090ead9eaa8b992c4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.313%26sid%3Dliteratum%253Aachs%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DGrachan%26aufirst%3DM.%2BL.%26aulast%3DGreenberg%26aufirst%3DE.%2BF.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWarnow%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26atitle%3DChemical%2520Phylogenetics%2520of%2520Histone%2520Deacetylases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D238%26epage%3D243%26doi%3D10.1038%2Fnchembio.313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Profiling of Substrates for Zinc-Dependent Lysine Deacylase Enzymes: HDAC3 Exhibits Decrotonylase Activity in Vitro</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9083</span>– <span class="NLM_lpage">9087</span>, <span class="refDoi"> DOI: 10.1002/anie.201203754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fanie.201203754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=9083-9087&author=A.+S.+Madsenauthor=C.+A.+Olsen&title=Profiling+of+Substrates+for+Zinc-Dependent+Lysine+Deacylase+Enzymes%3A+HDAC3+Exhibits+Decrotonylase+Activity+in+Vitro&doi=10.1002%2Fanie.201203754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of Substrates for Zinc-dependent Lysine Deacylase Enzymes: HDAC3 Exhibits Decrotonylase Activity In Vitro</span></div><div class="casAuthors">Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9083-9087, S9083/1-S9083/6</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The present investigation, rooted in a systematic screening of the activities of the eleven human zinc-dependent lysine deacylase (KDAC) enzymes against a series of fluorogenic substrates, has led to several discoveries as outlined above.  Most importantly, we found that HDAC3-NCoR1 exhibited decrotonylase activity with a catalytic efficiency that is comparable to the deacetylase activity of other KDAC isoforms.  Moreover, inhibition of the decrotonylase activity by well-known histone deacetylase inhibitors was demonstrated.  Elucidation of the possible implications of this discovery in cellular environments will be an important future objective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEp650IMzvcLVg90H21EOLACvtfcHk0ljkkWD7Ag4gmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzM&md5=ad86825a5f6dc6d0458e222ee3d01db3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201203754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201203754%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DProfiling%2520of%2520Substrates%2520for%2520Zinc-Dependent%2520Lysine%2520Deacylase%2520Enzymes%253A%2520HDAC3%2520Exhibits%2520Decrotonylase%2520Activity%2520in%2520Vitro%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D9083%26epage%3D9087%26doi%3D10.1002%2Fanie.201203754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikešová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zessin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nováková, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alquicer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span> <span> </span><span class="NLM_article-title">Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19895</span>– <span class="NLM_lpage">19904</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b02808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b02808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGhs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=19895-19904&author=Z.+Kutilauthor=J.+Mike%C5%A1ov%C3%A1author=M.+Zessinauthor=M.+Meleshinauthor=Z.+Nov%C3%A1kov%C3%A1author=G.+Alquicerauthor=A.+Kozikowskiauthor=W.+Sipplauthor=C.+Ba%C5%99inkaauthor=M.+Schutkowski&title=Continuous+Activity+Assay+for+HDAC11+Enabling+Reevaluation+of+HDAC+Inhibitors&doi=10.1021%2Facsomega.9b02808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors</span></div><div class="casAuthors">Kutil, Zsofia; Mikesova, Jana; Zessin, Matthes; Meleshin, Marat; Novakova, Zora; Alquicer, Glenda; Kozikowski, Alan; Sippl, Wolfgang; Barinka, Cyril; Schutkowski, Mike</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19895-19904</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment.  Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide deriv. as a substrate.  The threonine residue in the +1 position was replaced by the quencher amino acid 3'-nitro-L-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid.  The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats.  The Z'-factor is higher than 0.85 for the 15μM substrate concn., and the signal-to-noise ratio exceeds 150 for 384-well plates.  In the absence of NAD+, this substrate is specific for HDAC11.  Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvGIYSDcYp47Vg90H21EOLACvtfcHk0ljkkWD7Ag4gmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGhs73L&md5=65cbcf4d3f259c6942f22e5ec0f79cbc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b02808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b02808%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DMike%25C5%25A1ov%25C3%25A1%26aufirst%3DJ.%26aulast%3DZessin%26aufirst%3DM.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DNov%25C3%25A1kov%25C3%25A1%26aufirst%3DZ.%26aulast%3DAlquicer%26aufirst%3DG.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DSchutkowski%26aufirst%3DM.%26atitle%3DContinuous%2520Activity%2520Assay%2520for%2520HDAC11%2520Enabling%2520Reevaluation%2520of%2520HDAC%2520Inhibitors%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D19895%26epage%3D19904%26doi%3D10.1021%2Facsomega.9b02808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iovino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Cellular Analysis of the Action of Epigenetic Drugs and Probes</span>. <i>Epigenetics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1080/15592294.2016.1274472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F15592294.2016.1274472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28071961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ktF2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=308-322&author=M.+Hauauthor=F.+Zenkauthor=A.+Ganesanauthor=N.+Iovinoauthor=M.+Jung&title=Cellular+Analysis+of+the+Action+of+Epigenetic+Drugs+and+Probes&doi=10.1080%2F15592294.2016.1274472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular analysis of the action of epigenetic drugs and probes</span></div><div class="casAuthors">Hau Mirjam; Jung Manfred; Zenk Fides; Iovino Nicola; Ganesan A; Ganesan A; Jung Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Epigenetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">308-322</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small molecule drugs and probes are important tools in drug discovery, pharmacology, and cell biology.  This is of course also true for epigenetic inhibitors.  Important examples for the use of established epigenetic inhibitors are the study of the mechanistic role of a certain target in a cellular setting or the modulation of a certain phenotype in an approach that aims toward therapeutic application.  Alternatively, cellular testing may aim at the validation of a new epigenetic inhibitor in drug discovery approaches.  Cellular and eventually animal models provide powerful tools for these different approaches but certain caveats have to be recognized and taken into account.  This involves both the selectivity of the pharmacological tool as well as the specificity and the robustness of the cellular system.  In this article, we present an overview of different methods that are used to profile and screen for epigenetic agents and comment on their limitations.  We describe not only diverse successful case studies of screening approaches using different assay formats, but also some problematic cases, critically discussing selected applications of these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_hWgAwu_M1WGmni0r9GoKfW6udTcc2eZPxcPy-JdKpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ktF2ksg%253D%253D&md5=3be4f0536ae926010fcff504a43a4199</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F15592294.2016.1274472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15592294.2016.1274472%26sid%3Dliteratum%253Aachs%26aulast%3DHau%26aufirst%3DM.%26aulast%3DZenk%26aufirst%3DF.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DIovino%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DCellular%2520Analysis%2520of%2520the%2520Action%2520of%2520Epigenetic%2520Drugs%2520and%2520Probes%26jtitle%3DEpigenetics%26date%3D2017%26volume%3D12%26spage%3D308%26epage%3D322%26doi%3D10.1080%2F15592294.2016.1274472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcho, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Target Engagement and Drug Residence Time Can Be Observed in Living Cells with BRET</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10091</span>, <span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+Engagement+and+Drug+Residence+Time+Can+Be+Observed+in+Living+Cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0lg_hIIiyeAPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520Engagement%2520and%2520Drug%2520Residence%2520Time%2520Can%2520Be%2520Observed%2520in%2520Living%2520Cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loidl, P.</span></span> <span> </span><span class="NLM_article-title">Analogues of Trichostatin A and Trapoxin B as Histone Deacetylase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(97)00284-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS0960-894X%2897%2900284-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaK2sXks1yqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=1655-1658&author=M.+Jungauthor=K.+Hoffmannauthor=G.+Broschauthor=P.+Loidl&title=Analogues+of+Trichostatin+A+and+Trapoxin+B+as+Histone+Deacetylase+Inhibitors&doi=10.1016%2FS0960-894X%2897%2900284-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of trichostatin A and trapoxin B as histone deacetylase inhibitors</span></div><div class="casAuthors">Jung, Manfred; Hoffmann, Katharina; Brosch, Gerald; Loidl, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1655-1658</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylase are potent inducers of differentiation and bear considerable potential as drugs for chemoprevention and treatment of cancer.  So far only complex natural products and a few synthetic congeners have been identified as specific inhibitors.  A set of simple analogs was prepd. in as little as four synthetic steps that have inhibitory potencies in the range of known cyclotetrapeptide inhibitors.  These compds. are interesting leads for the design of potent inhibitors of histone deacetylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosg5Tlr5gMJbVg90H21EOLACvtfcHk0lg_hIIiyeAPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1yqtbk%253D&md5=d25d0e726ea341ab3e6630625ca389cf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2900284-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252900284-9%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DBrosch%26aufirst%3DG.%26aulast%3DLoidl%26aufirst%3DP.%26atitle%3DAnalogues%2520of%2520Trichostatin%2520A%2520and%2520Trapoxin%2520B%2520as%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D1655%26epage%3D1658%26doi%3D10.1016%2FS0960-894X%2897%2900284-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beppu, T.</span></span> <span> </span><span class="NLM_article-title">Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">17174</span>– <span class="NLM_lpage">17179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=2211619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVyqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=17174-17179&author=M.+Yoshidaauthor=M.+Kijimaauthor=M.+Akitaauthor=T.+Beppu&title=Potent+and+Specific+Inhibition+of+Mammalian+Histone+Deacetylase+Both+in+Vivo+and+in+Vitro+by+Trichostatin+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A</span></div><div class="casAuthors">Yoshida, Minoru; Kijima, Masako; Akita, Mitsuru; Beppu, Teruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17174-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">(R)-Trichostatin A (TSA) is a Streptomyces product which causes the induction of Friend cell differentiation and specific inhibition of the cell cycle of normal rat fibroblasts in the G1 and G2 phases at very low concns.  TSA caused an accumulation of acetylated histone species in a variety of mammalian cell lines.  Pulse-labeling expts. indicated that TSA markedly prolonged the in vivo half-life of the labile acetyl groups on histones in mouse mammary gland tumor cells, FM3A.  The partially purified histone deacetylase from wild-type FM3A cells was effectively inhibited by TSA in a noncompetitive manner with Ki = 3.4 nM.  A newly isolated mutant cell line of FM3A resistant to TSA did not show the accumulation of the acetylated histones in the presence of a higher concn. of TSA.  The histone deacetylase prepn. from the mutant showed decreased sensitivity to TSA (Ki = 31 nM, noncompetitive).  These results clearly indicate that TSA is a potent and specific inhibitor of histone deacetylase and that the in vivo effect of TSA on cell proliferation and differentiation can be attributed to the inhibition of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_EbVVcRXYbVg90H21EOLACvtfcHk0lg_hIIiyeAPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVyqsrY%253D&md5=f2bed4f3b2d1502fd3610dfdf376b2dc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKijima%26aufirst%3DM.%26aulast%3DAkita%26aufirst%3DM.%26aulast%3DBeppu%26aufirst%3DT.%26atitle%3DPotent%2520and%2520Specific%2520Inhibition%2520of%2520Mammalian%2520Histone%2520Deacetylase%2520Both%2520in%2520Vivo%2520and%2520in%2520Vitro%2520by%2520Trichostatin%2520A%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D17174%26epage%3D17179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">384</span>, <span class="refDoi"> DOI: 10.3390/md17070384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fmd17070384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Sm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=384&author=Q.+Jingauthor=X.+Huauthor=Y.+Maauthor=J.+Muauthor=W.+Liuauthor=F.+Xuauthor=Z.+Liauthor=J.+Baiauthor=H.+Huaauthor=D.+Li&title=Marine-Derived+Natural+Lead+Compound+Disulfide-Linked+Dimer+Psammaplin+A%3A+Biological+Activity+and+Structural+Modification&doi=10.3390%2Fmd17070384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Marine-derived natural lead compound disulfide-linked dimer psammaplin a: biological activity and structural modification</span></div><div class="casAuthors">Jing, Qinxue; Hu, Xu; Ma, Yanzi; Mu, Jiahui; Liu, Weiwei; Xu, Fanxing; Li, Zhanlin; Bai, Jiao; Hua, Huiming; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">384</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Marine natural products are considered to be valuable resources that are furnished with diverse chem. structures and various bioactivities.  To date, there are seven compds. derived from marine natural products which have been approved as therapeutic drugs by the U.S.  Food and Drug Administration.  Numerous bromotyrosine derivs. have been isolated as a type of marine natural products.  Among them, psammaplin A, including the oxime groups and carbon-sulfur bonds, was the first identified sym. bromotyrosine-derived disulfide dimer.  It has been found to have a broad bioactive spectrum, esp. in terms of antimicrobial and antiproliferative activities.  The highest potential indole-derived psammaplin A deriv., UVI5008, is used as an epigenetic modulator with multiple enzyme inhibitory activities.  Inspired by these reasons, psammaplin A has gradually become a research focus for pharmacologists and chemists.  To the best of our knowledge, there is no systematic review about the biol. activity and structural modification of psammaplin A.  In this review, the pharmacol. effects, total synthesis, and synthesized derivs. of psammaplin A are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqckO9X_vSey7Vg90H21EOLACvtfcHk0lh6QG2TOEKvvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Sm&md5=106ef508d2187b5a672430f92dcacab7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fmd17070384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd17070384%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DMarine-Derived%2520Natural%2520Lead%2520Compound%2520Disulfide-Linked%2520Dimer%2520Psammaplin%2520A%253A%2520Biological%2520Activity%2520and%2520Structural%2520Modification%26jtitle%3DMar.%2520Drugs%26date%3D2019%26volume%3D17%26spage%3D384%26doi%3D10.3390%2Fmd17070384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Romidepsin and the Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=13-20&author=A.+Ganesanauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch2%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DRomidepsin%2520and%2520the%2520Zinc-Binding%2520Thiol%2520Family%2520of%2520Natural%2520Product%2520HDAC%2520Inhibitors%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D13%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of Zinc-Dependent Histone Deacetylases (HDACs)</span>. In  <i>Macrocycles in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, J.</span></span>, Ed.; <span class="NLM_publisher-name">RSC</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">140</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=109-140&author=A.+Ganesanauthor=J.+Levin&title=Macrocycles+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%26btitle%3DMacrocycles%2520in%2520Drug%2520Discovery%26aulast%3DLevin%26aufirst%3DJ.%26pub%3DRSC%26date%3D2015%26spage%3D109%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusetani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packham, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors, and Design of a More Potent Analogue</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1021/ol070046y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol070046y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1105-1108&author=S.+Wenauthor=K.+L.+Careyauthor=Y.+Nakaoauthor=N.+Fusetaniauthor=G.+Packhamauthor=A.+Ganesan&title=Total+Synthesis+of+Azumamide+A+and+Azumamide+E%2C+Evaluation+as+Histone+Deacetylase+Inhibitors%2C+and+Design+of+a+More+Potent+Analogue&doi=10.1021%2Fol070046y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors, and Design of a More Potent Analog</span></div><div class="casAuthors">Wen, Shijun; Carey, Krystle L.; Nakao, Yoichi; Fusetani, Nobuhiro; Packham, Graham; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1105-1108</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unprecedented diastereoselective Mannich reaction of a Z-allylsulfoximine was a key step in the total synthesis of the marine natural products azumamide A and E, and an unnatural analog.  Their relative potency as histone deacetylase inhibitors was evaluated and found to correlate with predicted zinc-binding affinity.  The stereoselective Mannich reaction of an unusual β,γ-unsatd. sulfinylimine is likely the most challenging transformation accomplished to date with the Ellman auxiliary, and enabled a concise route with only 15 steps in the longest linear sequence.  Within the azumamide series, histone deacetylase (HDAC) inhibitory activity is in the order carboxamide < carboxylic acid < hydroxamic acid, as predicted by the relative zinc binding of these compds.  The biol. activity of the azumamides is significantly weaker than FK228 (IC50 of 15 ± 9 nM in the same assay).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf820ZWbDDobVg90H21EOLACvtfcHk0lh6QG2TOEKvvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKru7Y%253D&md5=ff577d9a068da7ee5a3d16f1c7299525</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fol070046y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070046y%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DS.%26aulast%3DCarey%26aufirst%3DK.%2BL.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DFusetani%26aufirst%3DN.%26aulast%3DPackham%26aufirst%3DG.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTotal%2520Synthesis%2520of%2520Azumamide%2520A%2520and%2520Azumamide%2520E%252C%2520Evaluation%2520as%2520Histone%2520Deacetylase%2520Inhibitors%252C%2520and%2520Design%2520of%2520a%2520More%2520Potent%2520Analogue%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D1105%26epage%3D1108%26doi%3D10.1021%2Fol070046y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2281</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2281-2286&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Binding+of+the+Microbial+Cyclic+Tetrapeptide+Trapoxin+A+to+the+Class+I+Histone+Deacetylase+HDAC8&doi=10.1021%2Facschembio.7b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2281-2286</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trapoxin A is a microbial cyclic tetrapeptide that is an essentially irreversible inhibitor of class I histone deacetylases (HDACs).  The inhibitory warhead is the α,β-epoxyketone side-chain of (2S,9S)-2-amino-8-oxo-9,10-epoxydecanoic acid (L-Aoe), which mimics the side-chain of the HDAC substrate, acetyl-L-lysine.  Here, we report the crystal structure of the HDAC8-trapoxin A complex at 1.24 Å resoln., revealing that the ketone moiety of L-Aoe undergoes nucleophilic attack to form a Zn-bound tetrahedral gem-diolate that mimics the tetrahedral intermediate and its flanking transition states in catalysis.  Mass spectrometry, activity measurements, and isothermal titrn. calorimetry confirmed that trapoxin A binds tightly (Kd = 3 ± 1 nM) and did not covalently modify the enzyme, so that the epoxide moiety of L-Aoe remained intact.  Comparison of the HDAC8-trapoxin A complex with the HDAC6-HC toxin complex provided new insight regarding the inhibitory potency of L-Aoe-contg. natural products against class I and class II HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQnr9n3hdyWbVg90H21EOLACvtfcHk0lh6QG2TOEKvvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2gsrjE&md5=18fbcd74c854bf9183e3d67074338aae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00330%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBinding%2520of%2520the%2520Microbial%2520Cyclic%2520Tetrapeptide%2520Trapoxin%2520A%2520to%2520the%2520Class%2520I%2520Histone%2520Deacetylase%2520HDAC8%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2281%26epage%3D2286%26doi%3D10.1021%2Facschembio.7b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors for Cancer Therapy: An Evolutionarily Ancient Resistance Response May Explain Their Limited Success</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1002/bies.201600070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fbies.201600070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27717012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=1102-1110&author=J.+A.+Halsallauthor=B.+M.+Turner&title=Histone+Deacetylase+Inhibitors+for+Cancer+Therapy%3A+An+Evolutionarily+Ancient+Resistance+Response+May+Explain+Their+Limited+Success&doi=10.1002%2Fbies.201600070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success</span></div><div class="casAuthors">Halsall, John A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) are in clin. trials against a variety of cancers.  Despite early successes, results against the more common solid tumors have been mixed.  How is it that so many cancers, and most normal cells, tolerate the disruption caused by HDACi-induced protein hyperacetylation.  And why are a few cancers so sensitive.  Here we discuss recent results showing that human cells mount a coordinated transcriptional response to HDACi that mitigates their toxic effects.  We present a hypothetical signaling system that could trigger and mediate this response.  To account for the existence of such a response, we note that HDACi of various chem. types are made by a variety of organisms to kill or suppress competitors.  We suggest that the resistance response in human cells is a necessary evolutionary consequence of exposure to environmental HDACi.  We speculate that cancers sensitive to HDACi are those in which the resistance response has been compromised by mutation.  Identifying such mutations will allow targeting of HDACi therapy to potentially susceptible cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7U6IHqXkgWbVg90H21EOLACvtfcHk0ljRyqsWQaW75w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGgsrjF&md5=14fa316e9184e46a79486cd7daf7185d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbies.201600070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.201600070%26sid%3Dliteratum%253Aachs%26aulast%3DHalsall%26aufirst%3DJ.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520for%2520Cancer%2520Therapy%253A%2520An%2520Evolutionarily%2520Ancient%2520Resistance%2520Response%2520May%2520Explain%2520Their%2520Limited%2520Success%26jtitle%3DBioEssays%26date%3D2016%26volume%3D38%26spage%3D1102%26epage%3D1110%26doi%3D10.1002%2Fbies.201600070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl Sulfoxide to Vorinostat: Development of This Histone Deacetylase Inhibitor as an Anticancer Drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+Sulfoxide+to+Vorinostat%3A+Development+of+This+Histone+Deacetylase+Inhibitor+as+an+Anticancer+Drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0ljRyqsWQaW75w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520Sulfoxide%2520to%2520Vorinostat%253A%2520Development%2520of%2520This%2520Histone%2520Deacetylase%2520Inhibitor%2520as%2520an%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor OBP-801 and Eribulin Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells with the Suppression of Survivin, Bcl-XL, and the MAPK Pathway</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4815-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2Fs10549-018-4815-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29752686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVWkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=43-52&author=H.+Onoauthor=Y.+Sowaauthor=M.+Horinakaauthor=Y.+Iizumiauthor=M.+Watanabeauthor=M.+Moritaauthor=E.+Nishimotoauthor=T.+Taguchiauthor=T.+Sakai&title=The+Histone+Deacetylase+Inhibitor+OBP-801+and+Eribulin+Synergistically+Inhibit+the+Growth+of+Triple-Negative+Breast+Cancer+Cells+with+the+Suppression+of+Survivin%2C+Bcl-XL%2C+and+the+MAPK+Pathway&doi=10.1007%2Fs10549-018-4815-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway</span></div><div class="casAuthors">Ono, Hisako; Sowa, Yoshihiro; Horinaka, Mano; Iizumi, Yosuke; Watanabe, Motoki; Morita, Mie; Nishimoto, Emi; Taguchi, Tetsuya; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-52</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) is the most aggressive subtype of breast cancer.  Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup anal. in this clin. trial indicated the efficacy of eribulin in patients with TNBC.  However, the prognosis of patients with TNBC is still poor due to various mol. characteristics.  Therefore, there is an urgent need for a more effective treatment for the management of TNBC.  Methods: We investigated the synergistic effect of a novel histone deacetylase (HDAC) inhibitor, OBP-801, and eribulin in TNBC cell lines because OBP-801 has been known to enhance the anti-tumor activities of other chemotherapeutic agents.  The cell growth was analyzed, and the flow cytometry anal. was conducted to evaluate the effects on cell cycle and the induction of apoptosis.  The mechanism underlying the enhancement of inhibition of TNBC cell growth was investigated through Western blot analyses.  Results: The combination treatment of OBP-801 with eribulin showed the synergistic inhibition of the growth in TNBC cells, involved with the enhancement of apoptosis.  We, for the first time, found that eribulin upregulated survivin and also that OBP-801 could remarkably suppress the upregulation of survivin by eribulin.  Moreover, this combination potently suppressed Bcl-xL and the MAPK pathway compared with either agent alone.  Conclusion: We found that the combination of OBP-801 and eribulin synergistically inhibited the growth with apoptosis in TNBC cells, suggesting that this combination might be a promising novel strategy for treating TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBSLC3wSoh8bVg90H21EOLACvtfcHk0ljRyqsWQaW75w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVWkt7Y%253D&md5=e7e7d0a0a5abdfe1df1df55d0c5d92c2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4815-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4815-x%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DH.%26aulast%3DSowa%26aufirst%3DY.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DIizumi%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DNishimoto%26aufirst%3DE.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520OBP-801%2520and%2520Eribulin%2520Synergistically%2520Inhibit%2520the%2520Growth%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520Cells%2520with%2520the%2520Suppression%2520of%2520Survivin%252C%2520Bcl-XL%252C%2520and%2520the%2520MAPK%2520Pathway%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26spage%3D43%26epage%3D52%26doi%3D10.1007%2Fs10549-018-4815-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breems, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Loosdrecht, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooftman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnam, P. M.</span></span> <span> </span><span class="NLM_article-title">A Phase I First-in-Human Study with Tefinostat – a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor – in Patients with Advanced Haematological Malignancies</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1111/bjh.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1111%2Fbjh.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23647373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=191-201&author=G.+J.+Ossenkoppeleauthor=B.+Lowenbergauthor=P.+Zacheeauthor=N.+Veyauthor=D.+Breemsauthor=A.+A.+Van+de+Loosdrechtauthor=A.+H.+Davidsonauthor=G.+Wellsauthor=L.+Needhamauthor=L.+Bawdenauthor=M.+Toalauthor=L.+Hooftmanauthor=P.+M.+Debnam&title=A+Phase+I+First-in-Human+Study+with+Tefinostat+%E2%80%93+a+Monocyte%2FMacrophage+Targeted+Histone+Deacetylase+Inhibitor+%E2%80%93+in+Patients+with+Advanced+Haematological+Malignancies&doi=10.1111%2Fbjh.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies</span></div><div class="casAuthors">Ossenkoppele, Gert J.; Lowenberg, Bob; Zachee, Pierre; Vey, Norbert; Breems, Dimitri; Van de Loosdrecht, Arjan A.; Davidson, Alan H.; Wells, Graham; Needham, Lindsey; Bawden, Lindsay; Toal, Martin; Hooftman, Leon; Debnam, Phillip M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi).  This first-in-human, std. 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to det. the safety, tolerability, pharmacokinetic and pharmacodynamic profile of tefinostat in relapsed/refractory haematol. diseases.  Eighteen patients were enrolled at doses of 20-640 mg.  Plasma concns. of tefinostat exceeded those demonstrated to give in vitro anti-proliferative activity.  Flow cytometric pharmacodynamic assays demonstrated monocyte-targeted increases in protein acetylation, without corresponding changes in lymphocytes.  Dose-limiting toxicities (DLTs) were not obsd. and dose escalation was halted at 640 mg without identification of the max. tolerated dose.  Drug-related toxicities were largely Common Toxicity Criteria for Adverse Events grade 1/2 and included nausea, anorexia, fatigue, constipation, rash and increased blood creatinine.  A patient with chronic monomyelocytic leukemia achieved a bone marrow response, with no change in peripheral monocytes.  An acute myeloid leukemia type M2 patient showed a >50% decrease in bone marrow blasts and clearance of peripheral blasts.  In conclusion, tefinostat produces monocyte-targeted HDACi activity and is well tolerated, without the DLTs, e.g. fatigue, diarrhea, thrombocytopenia, commonly seen with non-targeted HDACi.  The early signs of efficacy and absence of significant toxicity warrant further evaluation of tefinostat in larger studies. (clinicaltrials.gov identifier: NCT00820508).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPAYWIEsUwrVg90H21EOLACvtfcHk0lg0Bzh0lXt9tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsLvP&md5=7919124df9886fccba41990d05f2e110</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12359%26sid%3Dliteratum%253Aachs%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DBreems%26aufirst%3DD.%26aulast%3DVan%2Bde%2BLoosdrecht%26aufirst%3DA.%2BA.%26aulast%3DDavidson%26aufirst%3DA.%2BH.%26aulast%3DWells%26aufirst%3DG.%26aulast%3DNeedham%26aufirst%3DL.%26aulast%3DBawden%26aufirst%3DL.%26aulast%3DToal%26aufirst%3DM.%26aulast%3DHooftman%26aufirst%3DL.%26aulast%3DDebnam%26aufirst%3DP.%2BM.%26atitle%3DA%2520Phase%2520I%2520First-in-Human%2520Study%2520with%2520Tefinostat%2520%25E2%2580%2593%2520a%2520Monocyte%252FMacrophage%2520Targeted%2520Histone%2520Deacetylase%2520Inhibitor%2520%25E2%2580%2593%2520in%2520Patients%2520with%2520Advanced%2520Haematological%2520Malignancies%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D191%26epage%3D201%26doi%3D10.1111%2Fbjh.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. Y.</span></span> <span> </span><span class="NLM_article-title">CG200745, an HDAC Inhibitor, Induces Anti-Tumour Effects in Cholangiocarcinoma Cell Lines via miRNAs Targeting the Hippo Pathway</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10921</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41598-017-11094-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28883618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1cblvVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=10921&author=D.+E.+Jungauthor=S.+B.+Parkauthor=K.+Kimauthor=C.+Kimauthor=S.+Y.+Song&title=CG200745%2C+an+HDAC+Inhibitor%2C+Induces+Anti-Tumour+Effects+in+Cholangiocarcinoma+Cell+Lines+via+miRNAs+Targeting+the+Hippo+Pathway&doi=10.1038%2Fs41598-017-11094-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway</span></div><div class="casAuthors">Jung Dawoon E; Song Si Young; Park Soo Been; Song Si Young; Kim Kahee; Kim Chanyang; Song Si Young</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10921</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholangiocarcinoma is a devastating malignancy with fatal complications that exhibits low response and resistance to chemotherapy.  Here, we evaluated the anticancer effects of CG200745, a novel histone deacetylase inhibitor, either alone or in combination with standard chemotherapy drugs in cholangiocarcinoma cells.  CG200745 dose-dependently reduced the viability of cholangiocarcinoma cells in vitro and decreased tumour volume and weight in a xenograft model.  Administering CG200745 along with other chemotherapeutic agents including gemcitabine, 5-fluorouracil (5-FU), cisplatin, oxaliplatin, or gemcitabine plus cisplatin further decreased cholangiocarcinoma cell viability, with a combination index < 1 that indicated synergistic action.  CG200745 also enhanced the sensitivity of gemcitabine-resistant cells to gemcitabine and 5-FU, thereby decreasing cell viability and inducing apoptosis.  This was accompanied by downregulation of YAP, TEAD4, TGF-β2, SMAD3, NOTCH3, HES5, Axl, and Gas6 and upregulation of the miRNAs miR-22-3p, miR-22-5p, miR-194-5p, miR-194-3p, miR-194-5p, miR-210-3p, and miR-509-3p.  The Ingenuity Pathway Analysis revealed that CG200745 mainly targets the Hippo signalling pathway by inducing miR-509-3p expression.  Thus, CG200745 inhibits cholangiocarcinoma growth in vitro and in vivo, and acts synergistically when administered in combination with standard chemotherapeutic agents, enabling dose reduction.  CG200745 is therefore expected to improve the outcome of cholangiocarcinoma patients who exhibit resistance to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeWlASM7-ZiYkFb3mqPUYDfW6udTcc2eYklBLllkkoPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cblvVOmtw%253D%253D&md5=5dc34d45ee88005a0c365d1278c9526a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11094-3%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DD.%2BE.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DS.%2BY.%26atitle%3DCG200745%252C%2520an%2520HDAC%2520Inhibitor%252C%2520Induces%2520Anti-Tumour%2520Effects%2520in%2520Cholangiocarcinoma%2520Cell%2520Lines%2520via%2520miRNAs%2520Targeting%2520the%2520Hippo%2520Pathway%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D10921%26doi%3D10.1038%2Fs41598-017-11094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+Activity%2C+Pharmacodynamic%2C+and+Pharmacokinetic+Properties+of+a+Selective+HDAC6+Inhibitor%2C+ACY-1215%2C+in+Combination+with+Bortezomib+in+Multiple+Myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lg0Bzh0lXt9tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520Activity%252C%2520Pharmacodynamic%252C%2520and%2520Pharmacokinetic%2520Properties%2520of%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520ACY-1215%252C%2520in%2520Combination%2520with%2520Bortezomib%2520in%2520Multiple%2520Myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC Inhibition by ACY-241 Enhances the Activity of Paclitaxel in Solid Tumor Models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+Inhibition+by+ACY-241+Enhances+the+Activity+of+Paclitaxel+in+Solid+Tumor+Models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2eZjooP5sT-WZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520Inhibition%2520by%2520ACY-241%2520Enhances%2520the%2520Activity%2520of%2520Paclitaxel%2520in%2520Solid%2520Tumor%2520Models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.-X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.-J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-Ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+Potent+Multi-Acting+HDAC%2C+EGFR%2C+and+HER2+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lgkIla7nKb7OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-Ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520Potent%2520Multi-Acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehrling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150518092027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2174%2F1871520615666150518092027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=20-28&author=T.+Mehrlingauthor=Y.+Chen&title=The+Alkylating-HDAC+Inhibition+Fusion+Principle%3A+Taking+Chemotherapy+to+the+Next+Level+with+the+First+in+Class+Molecule+EDO-S101&doi=10.2174%2F1871520615666150518092027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150518092027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150518092027%26sid%3Dliteratum%253Aachs%26aulast%3DMehrling%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520Alkylating-HDAC%2520Inhibition%2520Fusion%2520Principle%253A%2520Taking%2520Chemotherapy%2520to%2520the%2520Next%2520Level%2520with%2520the%2520First%2520in%2520Class%2520Molecule%2520EDO-S101%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D16%26spage%3D20%26epage%3D28%26doi%3D10.2174%2F1871520615666150518092027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDAC with HDAC Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2095</span>– <span class="NLM_lpage">2116</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2010.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20223566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFeju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=2095-2116&author=P.+Bertrand&title=Inside+HDAC+with+HDAC+Inhibitors&doi=10.1016%2Fj.ejmech.2010.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDAC with HDAC inhibitors</span></div><div class="casAuthors">Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2095-2116</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors are a large group of diverse mols. intrinsically able to inhibit cell proliferation in various cancer cell lines.  Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin remodelling.  As the initial histone deacetylase activity of HDAC has been extended to other proteins, the possible other biol. mechanisms modified by HDAC inhibitor treatments are still to be clarified.  The need for HDAC isoform selective inhibitors is an important issue to serve this goal.  This review discusses the approaches proposed by several research groups working on the synthesis of HDAC inhibitors, based on modeling studies and the way these findings were used to obtain new HDAC inhibitors with possible isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SWr-oCMKcLVg90H21EOLACvtfcHk0lgoc9s3SwvRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFeju7k%253D&md5=14baba1e0371420b05d7e7b82d3187e6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDAC%2520with%2520HDAC%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D2095%26epage%3D2116%26doi%3D10.1016%2Fj.ejmech.2010.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P. W.</span>; <span class="NLM_string-name">Loza, E.</span>; <span class="NLM_string-name">Carstensen, E.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Belinostat</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">58</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=31-58&author=P.+W.+Finn&author=E.+Loza&author=E.+Carstensenauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DP.%2BW.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Belinostat%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D31%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span>; <span class="NLM_string-name">Perez, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">88</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=59-88&author=P.+Atadja&author=L.+Perezauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch4%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Farydak%2520%2528NVP-LBH589%252C%2520Panobinostat%2529%2520as%2520an%2520Anticancer%2520Drug%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D59%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandl-Weber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinel, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oduncu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidmaier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Inhibitor of Histone Deacetylase Resminostat (RAS2410) Inhibits Proliferation and Induces Apoptosis in Multiple Myeloma (MM) Cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08124.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1111%2Fj.1365-2141.2010.08124.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20201941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1eqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2010&pages=518-528&author=S.+Mandl-Weberauthor=F.+G.+Meinelauthor=R.+Jankowskyauthor=F.+Oduncuauthor=R.+Schmidmaierauthor=P.+Baumann&title=The+Novel+Inhibitor+of+Histone+Deacetylase+Resminostat+%28RAS2410%29+Inhibits+Proliferation+and+Induces+Apoptosis+in+Multiple+Myeloma+%28MM%29+Cells&doi=10.1111%2Fj.1365-2141.2010.08124.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells</span></div><div class="casAuthors">Mandl-Weber, Sonja; Meinel, Felix G.; Jankowsky, Ruediger; Oduncu, Fuat; Schmidmaier, Ralf; Baumann, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-528</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) is a promising mechanism for novel, anti-myeloma agents.  We investigated the effects of the novel HDAC inhibitor resminostat on multiple myeloma (MM) cells in vitro.  Resminostat is a potent inhibitor of HDACs 1, 3 and 6 [50% inhibitory concn. (IC50) = 43-72 nmol/l] representing HDAC classes I and II and induces hyperacetylation of histone H4 in MM cells.  Low micromolar concns. of resminostat abrogated cell growth and strongly induced apoptosis (IC50 = 2·5-3 μmol/l in 3 out of 4 MM cell lines) in MM cell lines as well as primary MM cells.  At 1 μmol/l, resminostat inhibited proliferation and induced G0/G1 cell cycle arrest in 3 out of 4 MM cell lines accompanied with decreased levels of cyclin D1, cdc25a, Cdk4 and pRb as well as upregulation of p21.  Resminostat decreased phosphorylation of 4E-BP1 and p70S6k indicating an interference with Akt pathway signalling.  Treatment with resminostat resulted in increased protein levels of Bim and Bax and decreased levels of Bcl-xL.  Caspases 3, 8 and 9 were activated by resminostat.  Furthermore, synergistic effects were obsd. for combinations of resminostat with melphalan and the proteasome inhibitors bortezomib and S-2209.  In conclusion, we have identified potent anti-myeloma activity for this novel HDAC inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQdfMVUdhHk7Vg90H21EOLACvtfcHk0lgoc9s3SwvRVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1eqt70%253D&md5=16b57835f5e5d19d8cd587b299820d98</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08124.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08124.x%26sid%3Dliteratum%253Aachs%26aulast%3DMandl-Weber%26aufirst%3DS.%26aulast%3DMeinel%26aufirst%3DF.%2BG.%26aulast%3DJankowsky%26aufirst%3DR.%26aulast%3DOduncu%26aufirst%3DF.%26aulast%3DSchmidmaier%26aufirst%3DR.%26aulast%3DBaumann%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Inhibitor%2520of%2520Histone%2520Deacetylase%2520Resminostat%2520%2528RAS2410%2529%2520Inhibits%2520Proliferation%2520and%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520%2528MM%2529%2520Cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D149%26spage%3D518%26epage%3D528%26doi%3D10.1111%2Fj.1365-2141.2010.08124.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khng, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantharaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2<i>E</i>)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1<i>H</i>-benzimidazol-5-yl}-<i>N</i>-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4694</span>– <span class="NLM_lpage">4720</span>, <span class="refDoi"> DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282E%29-3-%7B2-Butyl-1-%5B2-%28diethylamino%29ethyl%5D-1H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+Orally+Active+Histone+Deacetylase+Inhibitor+with+a+Superior+Preclinical+Profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span></div><div class="casAuthors">Wang, Haishan; Yu, Niefang; Chen, Dizhong; Lee, Ken Chi Lik; Lye, Pek Ling; Chang, Joyce Wei Wei; Deng, Weiping; Ng, Melvin Chi Yeh; Lu, Ting; Khoo, Mui Ling; Poulsen, Anders; Sangthongpitag, Kanda; Wu, Xiaofeng; Hu, Changyong; Goh, Kee Chuan; Wang, Xukun; Fang, Lijuan; Goh, Kay Lin; Khng, Hwee Hoon; Goh, Siok Kun; Yeo, Pauline; Liu, Xin; Bonday, Zahid; Wood, Jeanette M.; Dymock, Brian W.; Kantharaj, Ethirajulu; Sun, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4694-4720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(1,2-disubstituted-1H-benzimidazol-5-yl)-N-hydroxyacrylamides was designed and synthesized as HDAC inhibitors.  Extensive SARs have been established for in vitro potency (HDAC1 enzyme and COLO 205 cellular IC50), liver microsomal stability (t1/2), cytochrome P 450 inhibition (3A4 IC50), and clogP, among others.  These parameters were fine-tuned by carefully adjusting the substituents at positions 1 and 2 of the benzimidazole ring.  After comprehensive in vitro and in vivo profiling of the selected compds., SB939 (I) was identified as a preclin. development candidate.  I is a potent pan-HDAC inhibitor with excellent druglike properties, is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties.  When orally dosed to tumor-bearing mice, I is enriched in tumor tissue which may contribute to its potent antitumor activity and prolonged duration of action.  I is currently being tested in phase I and phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9r-fRIzdS7Vg90H21EOLACvtfcHk0lh_fOQykxsnfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D&md5=a69bf922fb86c47ddee9c9fc112cc9a2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282E%2529-3-%257B2-Butyl-1-%255B2-%2528diethylamino%2529ethyl%255D-1H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520Orally%2520Active%2520Histone%2520Deacetylase%2520Inhibitor%2520with%2520a%2520Superior%2520Preclinical%2520Profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nold, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascagni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4(+) T-Cells and Monocytes and Is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e3181d3dca3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1097%2FQAI.0b013e3181d3dca3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20300007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1-9&author=S.+Matalonauthor=B.+E.+Palmerauthor=M.+F.+Noldauthor=A.+Furlanauthor=A.+Kassuauthor=G.+Fossatiauthor=P.+Mascagniauthor=C.+A.+Dinarello&title=The+Histone+Deacetylase+Inhibitor+ITF2357+Decreases+Surface+CXCR4+and+CCR5+Expression+on+CD4%28%2B%29+T-Cells+and+Monocytes+and+Is+Superior+to+Valproic+Acid+for+Latent+HIV-1+Expression+in+Vitro&doi=10.1097%2FQAI.0b013e3181d3dca3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro</span></div><div class="casAuthors">Matalon, Shay; Palmer, Brent E.; Nold, Marcel F.; Furlan, Antonio; Kassu, Afework; Fossati, Gianluca; Mascagni, Paolo; Dinarello, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chromatin-assocd. repression is one mechanism that maintains HIV-1 latency.  Inhibition of histone deacetylases (HDAC) reverses this repression resulting in viral expression from quiescently infected cells.  Clin. studies with the HDAC inhibitor valproic acid (VPA) failed to substantially decrease the latent pool within resting CD4 cells.  Here we compared the efficacy of ITF2357, an orally active and safe HDAC inhibitor, with VPA for HIV-1 expression from latently infected cells in vitro.  We also evaluated the effect of ITF2357 on the surface expression of CXCR4 and CCR5.  Latently infected cell lines were incubated with either ITF2357 or VPA and p24 levels were measured.  Peripheral blood mononuclear cells of uninfected donors were treated with ITF2357 and HIV-1 coreceptors expression was assessed by flow cytometry.  At clin. relevant concns., ITF2357 increased p24 by 15-fold in ACH2 cells and by 9-fold in U1 cells, whereas VPA increased expression less than 2-fold.  Analogs of ITF2357 primarily targeting HDAC-1 increased p24 up to 30-fold.  In CD4 T cells treated with ITF2357, CXCR4 expression decreased by 54% (P < 0.001).  ITF2357 is superior to VPA in inducing HIV-1 from latently infected cells.  Safely used in humans, ITF2357 is an attractive candidate for HIV-1 clin. purging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPgJCLYVZvFrVg90H21EOLACvtfcHk0lh_fOQykxsnfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFCmtr8%253D&md5=00472fbb9d15158fb97d3f20d8bd230c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e3181d3dca3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e3181d3dca3%26sid%3Dliteratum%253Aachs%26aulast%3DMatalon%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DB.%2BE.%26aulast%3DNold%26aufirst%3DM.%2BF.%26aulast%3DFurlan%26aufirst%3DA.%26aulast%3DKassu%26aufirst%3DA.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DMascagni%26aufirst%3DP.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520ITF2357%2520Decreases%2520Surface%2520CXCR4%2520and%2520CCR5%2520Expression%2520on%2520CD4%2528%252B%2529%2520T-Cells%2520and%2520Monocytes%2520and%2520Is%2520Superior%2520to%2520Valproic%2520Acid%2520for%2520Latent%2520HIV-1%2520Expression%2520in%2520Vitro%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2010%26volume%3D54%26spage%3D1%26epage%3D9%26doi%3D10.1097%2FQAI.0b013e3181d3dca3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span> <span> </span><span class="NLM_article-title">CRA-024781: A Novel Synthetic Inhibitor of Histone Deacetylase Enzymes with Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1309</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1535-7163.MCT-05-0442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=16731764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1309-1317&author=J.+J.+Buggyauthor=Z.+A.+Caoauthor=K.+E.+Bassauthor=E.+Vernerauthor=S.+Balasubramanianauthor=L.+Liuauthor=B.+E.+Schultzauthor=P.+R.+Youngauthor=S.+A.+Dalrymple&title=CRA-024781%3A+A+Novel+Synthetic+Inhibitor+of+Histone+Deacetylase+Enzymes+with+Antitumor+Activity+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-05-0442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo</span></div><div class="casAuthors">Buggy, Joseph J.; Cao, Z. Alexander; Bass, Kathryn E.; Verner, Erik; Balasubramanian, Sriram; Liu, Liang; Schultz, Brian E.; Young, Peter R.; Dalrymple, Stacie A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1309-1317</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clin. trials for cancer.  CRA-024781 inhibited pure recombinant HDAC1 with a Ki of 0.007 μmol/L, and also inhibited the other HDAC isoenzymes HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range.  Treatment of cultured tumor cell lines grown in vitro with CRA-024781 resulted in the accumulation of acetylated histone and acetylated tubulin, resulting in an inhibition of tumor cell growth and the induction of apoptosis.  CRA-024781 parenterally administered to mice harboring HCT116 or DLD-1 colon tumor xenografts resulted in a statistically significant redn. in tumor growth at doses that were well tolerated as measured by body wt.  Inhibition of tumor growth was accompanied by an increase in the acetylation of α-tubulin in peripheral blood mononuclear cells, and an alteration in the expression of many genes in the tumors, including several involved in apoptosis and cell growth.  These results reveal CRA-024781 to be a novel HDAC inhibitor with potent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8uJX28obQWrVg90H21EOLACvtfcHk0lh_fOQykxsnfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVWms7Y%253D&md5=fa761c94dd4f3a031493476dd75af602</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0442%26sid%3Dliteratum%253Aachs%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DCao%26aufirst%3DZ.%2BA.%26aulast%3DBass%26aufirst%3DK.%2BE.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26atitle%3DCRA-024781%253A%2520A%2520Novel%2520Synthetic%2520Inhibitor%2520of%2520Histone%2520Deacetylase%2520Enzymes%2520with%2520Antitumor%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1309%26epage%3D1317%26doi%3D10.1158%2F1535-7163.MCT-05-0442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5530</span>– <span class="NLM_lpage">5535</span>, <span class="refDoi"> DOI: 10.1021/jm0503749</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503749" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVChuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5530-5535&author=Q.+Luauthor=D.-S.+Wangauthor=C.-S.+Chenauthor=Y.-D.+Huauthor=C.-S.+Chen&title=Structure-Based+Optimization+of+Phenylbutyrate-Derived+Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0503749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors</span></div><div class="casAuthors">Lu, Qiang; Wang, Da-Sheng; Chen, Chang-Shi; Hu, Yuan-Dong; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5535</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn2+-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), a hydroxamate-tethered phenylbutyrate deriv. with sub-micromolar potency in inhibiting HDAC activity and cancer cell proliferation.  In this study, the authors carried out structure-based optimization of HTPB by using the framework generated by the structure of histone deacetylase-like protein (HDLP)-trichostatin A (TSA) complexes.  Docking of HTPB into the HDLP binding domain suggested that the hydrophobic microenvironment encompassed by Phe-198 and Phe-200 could be exploited for structural optimization.  This premise was corroborated by the greater potency of (S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide [(S)-11] (IC50 in HDAC inhibition, 16 nM), of which the iso-Pr moiety was favorable in interacting with this hydrophobic motif.  (S)-11 at concns. as low as 0.1 μM was effective in causing histone hyperacetylation and p21WAF/CIP1 overexpression and suppressing proliferation in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4OaBQW0Sp7LVg90H21EOLACvtfcHk0ljy8XinKY_VXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVChuro%253D&md5=59248d348fc589b9f29a4fc742adf8b7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm0503749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503749%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DD.-S.%26aulast%3DChen%26aufirst%3DC.-S.%26aulast%3DHu%26aufirst%3DY.-D.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DStructure-Based%2520Optimization%2520of%2520Phenylbutyrate-Derived%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5530%26epage%3D5535%26doi%3D10.1021%2Fjm0503749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F.-J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01792</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01792" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGjsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=804-815&author=S.-W.+Zhangauthor=C.-J.+Gongauthor=M.-B.+Suauthor=F.+Chenauthor=T.+Heauthor=Y.-M.+Zhangauthor=Q.-Q.+Shenauthor=Y.+Suauthor=J.+Dingauthor=J.+Liauthor=Y.+Chenauthor=F.-J.+Nan&title=Synthesis+and+in+Vitro+and+in+Vivo+Biological+Evaluation+of+Tissue-Specific+Bisthiazole+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Zhang, Shu-Wei; Gong, Chao-Jun; Su, Ming-Bo; Chen, Fei; He, Ting; Zhang, Yang-Ming; Shen, Qian-Qian; Su, Yi; Ding, Jian; Li, Jia; Chen, Yi; Nan, Fa-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">804-815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bisthiazole-based hydroxamic acids as novel potent HDAC inhibitors was developed during our previous work.  In the present work, a new series of highly potent bisthiazole-based compds. were designed and synthesized.  Among the prepd. compds., compd. I, which contains an α-(S)-methyl-substituted benzyl group, displays potent inhibitory activity toward human HDACs and several cancer cells lines.  Compd. I has a favorable PK profile and high tissue distribution specificity in the colon, as well as good efficacy in the AOM-DSS mouse model for colitis-assocd. colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBs6U7tbjKrVg90H21EOLACvtfcHk0ljy8XinKY_VXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGjsrbL&md5=06179fbf0b3ed71f7bf27284cd5f9668</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01792%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.-W.%26aulast%3DGong%26aufirst%3DC.-J.%26aulast%3DSu%26aufirst%3DM.-B.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DShen%26aufirst%3DQ.-Q.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DNan%26aufirst%3DF.-J.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Biological%2520Evaluation%2520of%2520Tissue-Specific%2520Bisthiazole%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D804%26epage%3D815%26doi%3D10.1021%2Facs.jmedchem.9b01792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliën, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilatte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decrane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vreys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talloen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Jardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Emelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span> <span> </span><span class="NLM_article-title">JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6841</span>– <span class="NLM_lpage">6851</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+Novel+%E2%80%9CSecond-Generation%E2%80%9D+Oral+Histone+Deacetylase+Inhibitor%2C+Shows+Broad-Spectrum+Preclinical+Antitumoral+Activity&doi=10.1158%2F1078-0432.CCR-09-0547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0ljy8XinKY_VXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520Novel%2520%25E2%2580%259CSecond-Generation%25E2%2580%259D%2520Oral%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Shows%2520Broad-Spectrum%2520Preclinical%2520Antitumoral%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851%26doi%3D10.1158%2F1078-0432.CCR-09-0547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meurs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8663</span>– <span class="NLM_lpage">8678</span>, <span class="refDoi"> DOI: 10.1021/jm101177s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101177s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8663-8678&author=D.+Moffatauthor=S.+Patelauthor=F.+Dayauthor=A.+Belfieldauthor=A.+Donaldauthor=M.+Rowlandsauthor=J.+Wibawaauthor=D.+Brothertonauthor=L.+Stimsonauthor=V.+Clarkauthor=J.+Owenauthor=L.+Bawdenauthor=G.+Boxauthor=E.+Boneauthor=P.+Mortensonauthor=A.+Hardcastleauthor=S.+van+Meursauthor=S.+Ecclesauthor=F.+Raynaudauthor=W.+Aherne&title=Discovery+of+2-%286-%7B%5B%286-Fluoroquinolin-2-yl%29methyl%5Damino%7Dbicyclo%5B3.1.0%5Dhex-3-yl%29-N-hydroxypyrimidine-5-carboxamide+%28CHR-3996%29%2C+a+Class+I+Selective+Orally+Active+Histone+Deacetylase+Inhibitor&doi=10.1021%2Fjm101177s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</span></div><div class="casAuthors">Moffat, David; Patel, Sanjay; Day, Francesca; Belfield, Andrew; Donald, Alastair; Rowlands, Martin; Wibawa, Judata; Brotherton, Deborah; Stimson, Lindsay; Clark, Vanessa; Owen, Jo; Bawden, Lindsay; Box, Gary; Bone, Elisabeth; Mortenson, Paul; Hardcastle, Anthea; van Meurs, Sandra; Eccles, Suzanne; Raynaud, Florence; Aherne, Wynne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8663-8678</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described.  The compds. are potent enzyme inhibitors (IC50 values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups.  Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compds. that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor.  One compd., 21r (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft.  In addn. 21r showed good activity in combination with other anticancer agents in in vitro studies.  On the basis of these results, 21r was nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB5TcEwdw2cbVg90H21EOLACvtfcHk0lg4knzTC7hXAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FO&md5=9a434b2ed87fe4cfb37c68bb92734be2</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm101177s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101177s%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DF.%26aulast%3DBelfield%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DRowlands%26aufirst%3DM.%26aulast%3DWibawa%26aufirst%3DJ.%26aulast%3DBrotherton%26aufirst%3DD.%26aulast%3DStimson%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DBawden%26aufirst%3DL.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBone%26aufirst%3DE.%26aulast%3DMortenson%26aufirst%3DP.%26aulast%3DHardcastle%26aufirst%3DA.%26aulast%3Dvan%2BMeurs%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DAherne%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25202-%25286-%257B%255B%25286-Fluoroquinolin-2-yl%2529methyl%255Damino%257Dbicyclo%255B3.1.0%255Dhex-3-yl%2529-N-hydroxypyrimidine-5-carboxamide%2520%2528CHR-3996%2529%252C%2520a%2520Class%2520I%2520Selective%2520Orally%2520Active%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8663%26epage%3D8678%26doi%3D10.1021%2Fjm101177s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+Network+Disruption+by+a+Single+Molecule+Inhibitor+Targeting+Both+Histone+Deacetylase+Activity+and+Phosphatidylinositol+3-Kinase+Signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lg4knzTC7hXAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520Network%2520Disruption%2520by%2520a%2520Single%2520Molecule%2520Inhibitor%2520Targeting%2520Both%2520Histone%2520Deacetylase%2520Activity%2520and%2520Phosphatidylinositol%25203-Kinase%2520Signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luesch, H.</span></span> <span> </span><span class="NLM_article-title">Largazole: From Discovery to Broad-Spectrum Therapy</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1039/c2np00066k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1039%2Fc2np00066k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22334030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=449-456&author=J.+Hongauthor=H.+Luesch&title=Largazole%3A+From+Discovery+to+Broad-Spectrum+Therapy&doi=10.1039%2Fc2np00066k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Largazole: From discovery to broad-spectrum therapy</span></div><div class="casAuthors">Hong, Jiyong; Luesch, Hendrik</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-456</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering up to 2011The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chem. scaffold and potently inhibits class I histone deacetylases (HDACs).  Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells.  The intriguing structure and biol. activity of largazole have attracted strong interest from the synthetic chem. community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic.  This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biol. studies, including in vivo anticancer and osteogenic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolf01UpCv74LVg90H21EOLACvtfcHk0ljSRe2qpmRPMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wkur0%253D&md5=4cc376f2d79f2e9c7cb79cdfdd415e38</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1039%2Fc2np00066k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2np00066k%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DLuesch%26aufirst%3DH.%26atitle%3DLargazole%253A%2520From%2520Discovery%2520to%2520Broad-Spectrum%2520Therapy%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2012%26volume%3D29%26spage%3D449%26epage%3D456%26doi%3D10.1039%2Fc2np00066k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesfeld, J. M.</span></span> <span> </span><span class="NLM_article-title">Pimelic Diphenylamide 106 is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">35402</span>– <span class="NLM_lpage">35409</span>, <span class="refDoi"> DOI: 10.1074/jbc.M807045200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M807045200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18953021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVylsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35402-35409&author=C.+J.+Chouauthor=D.+Hermanauthor=J.+M.+Gottesfeld&title=Pimelic+Diphenylamide+106+is+a+Slow%2C+Tight-binding+Inhibitor+of+Class+I+Histone+Deacetylases&doi=10.1074%2Fjbc.M807045200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases</span></div><div class="casAuthors">Chou, C. James; Herman, David; Gottesfeld, Joel M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35402-35409</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors, including various benzamides and hydroxamates, are currently in clin. development for a broad range of human diseases, including cancer and neurodegenerative diseases.  We recently reported the identification of a family of benzamide-type HDAC inhibitors that are relatively non-toxic compared with the hydroxamates.  Members of this class of compds. have shown efficacy in cell-based and mouse models for the neurodegenerative diseases Friedreich ataxia and Huntington disease.  Considerable differences in IC50 values for the various HDAC enzymes have been reported for many of the HDAC inhibitors, leading to confusion as to the HDAC isotype specificities of these compds.  Here we show that a benzamide HDAC inhibitor, a pimelic diphenylamide (106), is a class I HDAC inhibitor, demonstrating no activity against class II HDACs.  106 Is a slow, tight-binding inhibitor of HDACs 1, 2, and 3, although inhibition for these enzymes occurs through different mechanisms.  Inhibitor 106 also has preference toward HDAC3 with Ki of ∼14 nM, 15 times lower than the Ki for HDAC1.  In comparison, the hydroxamate suberoylanilide hydroxamic acid does not discriminate between these enzymes and exhibits a fast-on/fast-off inhibitory mechanism.  These observations may explain a paradox involving the relative activities of pimelic diphenylamides vs. hydroxamates as gene activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJtDFGy6MbVg90H21EOLACvtfcHk0ljSRe2qpmRPMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVylsr3L&md5=ffcdd2b6a6884d7fa48076c9bf228011</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M807045200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M807045200%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DHerman%26aufirst%3DD.%26aulast%3DGottesfeld%26aufirst%3DJ.%2BM.%26atitle%3DPimelic%2520Diphenylamide%2520106%2520is%2520a%2520Slow%252C%2520Tight-binding%2520Inhibitor%2520of%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D35402%26epage%3D35409%26doi%3D10.1074%2Fjbc.M807045200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallais, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaisburg, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span> <span> </span><span class="NLM_article-title">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5543</span>– <span class="NLM_lpage">5546</span>, <span class="refDoi"> DOI: 10.1021/jm701079h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701079h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5543-5546&author=O.+M.+Moradeiauthor=T.+C.+Mallaisauthor=S.+Frechetteauthor=I.+Paquinauthor=P.+E.+Tessierauthor=S.+M.+Leitauthor=M.+Fournelauthor=C.+Bonfilsauthor=M.-C.+Trachy-Bourgetauthor=J.+Liuauthor=T.+P.+Yanauthor=A.-H.+Luauthor=J.+Rahilauthor=J.+Wangauthor=S.+Lefebvreauthor=Z.+Liauthor=A.+F.+Vaisburgauthor=J.+M.+Besterman&title=Novel+Aminophenyl+Benzamide-Type+Histone+Deacetylase+Inhibitors+with+Enhanced+Potency+and+Selectivity&doi=10.1021%2Fjm701079h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span></div><div class="casAuthors">Moradei, Oscar M.; Mallais, Tammy C.; Frechette, Sylvie; Paquin, Isabelle; Tessier, Pierre E.; Leit, Silvana M.; Fournel, Marielle; Bonfils, Claire; Trachy-Bourget, Marie-Claude; Liu, Jianhong; Yan, Theresa P.; Lu, Ai-Hua; Rahil, Jubrail; Wang, James; Lefebvre, Sylvain; Li, Zuomei; Vaisburg, Arkadii F.; Besterman, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5543-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows.  A part of this endeavor was the exploration of the 14 Å internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compd. 4 (I) with the unusual bis(aryl)-type pharmacophore.  SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlM848KF3mo7Vg90H21EOLACvtfcHk0ljjbFqaDVs9wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL&md5=17012416f4be84479762acac0cff5e6f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm701079h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701079h%26sid%3Dliteratum%253Aachs%26aulast%3DMoradei%26aufirst%3DO.%2BM.%26aulast%3DMallais%26aufirst%3DT.%2BC.%26aulast%3DFrechette%26aufirst%3DS.%26aulast%3DPaquin%26aufirst%3DI.%26aulast%3DTessier%26aufirst%3DP.%2BE.%26aulast%3DLeit%26aufirst%3DS.%2BM.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DTrachy-Bourget%26aufirst%3DM.-C.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DA.-H.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVaisburg%26aufirst%3DA.%2BF.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26atitle%3DNovel%2520Aminophenyl%2520Benzamide-Type%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Enhanced%2520Potency%2520and%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5543%26epage%3D5546%26doi%3D10.1021%2Fjm701079h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldog, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khramtsov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghs, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span> <span> </span><span class="NLM_article-title">Determination of the Class and Isoform Selectivity of Small-Molecule Histone Deacetylase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1042/BJ20070779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FBJ20070779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=17868033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2008&pages=581-589&author=N.+Khanauthor=M.+Jeffersauthor=S.+Kumarauthor=C.+Hackettauthor=F.+Boldogauthor=N.+Khramtsovauthor=X.+Qianauthor=E.+Millsauthor=S.+C.+Berghsauthor=N.+Careyauthor=P.+W.+Finnauthor=L.+S.+Collinsauthor=A.+Tumberauthor=J.+W.+Ritchieauthor=P.+B.+Jensenauthor=H.+S.+Lichensteinauthor=M.+Sehested&title=Determination+of+the+Class+and+Isoform+Selectivity+of+Small-Molecule+Histone+Deacetylase+Inhibitors&doi=10.1042%2FBJ20070779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors</span></div><div class="casAuthors">Khan, Nagma; Jeffers, Michael; Kumar, Sampath; Hackett, Craig; Boldog, Ferenc; Khramtsov, Nicholai; Qian, Xiaozhong; Mills, Evan; Berghs, Stanny C.; Carey, Nessa; Finn, Paul W.; Collins, Laura S.; Tumber, Anthony; Ritchie, James W.; Jensen, Peter Buhl; Lichenstein, Henri S.; Sehested, Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">581-589</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription.  While HDACs can be subdivided into three main classes, the class I, class II and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms that show aberrant levels in tumors, will prove more effective as an anticancer strategy in the clinic.  To address the above issues, we have tested a no. of clin. relevant HDACis (HDAC inhibitors) against a panel of rhHDAC (recombinant human HDAC) isoforms.  Eight rhHDACs were expressed using a baculoviral system, and a Fluor de Lys (Biomol International) HDAC assay was optimized for each purified isoform.  The potency and selectivity of ten HDACs on class I isoforms (rhHDAC1, rhHDAC2, rhHDAC3 and rhHDAC8) and class II HDAC isoforms (rhHDAC4, rhHDAC6, rhHDAC7 and rhHDAC9) was detd.  MS-275 was HDAC1-selective, MGCD0103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs.  The hydroxamic acid-derived compds. (trichostatin A, NVP-LAQ824, panobinostat, ITF2357, vorinostat and belinostat) were potent pan-HDAC inhibitors.  The growth-inhibitory effect of the HDACis on HeLa cells showed that both pan-HDAC and class-I-specific inhibitors inhibited cell growth.  The results also showed that both pan-HDAC and class-I-specific inhibitor treatment resulted in increased acetylation of histones, but only pan-HDAC inhibitor treatment resulted in increased tubulin acetylation, which is in agreement with their activity towards the HDAC6 isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb1RAVCAf77Vg90H21EOLACvtfcHk0ljjbFqaDVs9wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSru7o%253D&md5=6d268ef4776d3165c6b0a61179642969</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1042%2FBJ20070779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070779%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHackett%26aufirst%3DC.%26aulast%3DBoldog%26aufirst%3DF.%26aulast%3DKhramtsov%26aufirst%3DN.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DMills%26aufirst%3DE.%26aulast%3DBerghs%26aufirst%3DS.%2BC.%26aulast%3DCarey%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DP.%2BW.%26aulast%3DCollins%26aufirst%3DL.%2BS.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DRitchie%26aufirst%3DJ.%2BW.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DLichenstein%26aufirst%3DH.%2BS.%26aulast%3DSehested%26aufirst%3DM.%26atitle%3DDetermination%2520of%2520the%2520Class%2520and%2520Isoform%2520Selectivity%2520of%2520Small-Molecule%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D409%26spage%3D581%26epage%3D589%26doi%3D10.1042%2FBJ20070779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ste-Croix, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, Has Broad Spectrum Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1535-7163.MCT-07-2026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18413790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=759-768&author=M.+Fournelauthor=C.+Bonfilsauthor=Y.+Houauthor=P.+T.+Yanauthor=M.-C.+Trachy-Bourgetauthor=A.+Kalitaauthor=J.+Liuauthor=A.-H.+Luauthor=N.+Z.+Zhouauthor=M.-F.+Robertauthor=J.+Gillespieauthor=J.+J.+Wangauthor=H.+Ste-Croixauthor=J.+Rahilauthor=S.+Lefebvreauthor=O.+Moradeiauthor=D.+Delormeauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=Z.+Li&title=MGCD0103%2C+a+Novel+Isotype-Selective+Histone+Deacetylase+Inhibitor%2C+Has+Broad+Spectrum+Antitumor+Activity+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-07-2026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo</span></div><div class="casAuthors">Fournel, Marielle; Bonfils, Claire; Hou, Yu; Yan, Pu Theresa; Trachy-Bourget, Marie-Claude; Kalita, Ann; Liu, Jianhong; Lu, Ai-Hua; Zhou, Nancy Z.; Robert, Marie-France; Gillespie, Jeffrey; Wang, James J.; Ste-Croix, Helene; Rahil, Jubrail; Lefebvre, Sylvain; Moradei, Oscar; Delorme, Daniel; MacLeod, A. Robert; Besterman, Jeffrey M.; Li, Zuomei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">759-768</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clin. investigation.  The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma.  Questions remain concerning which HDAC isotype(s) are the best to target for anticancer activity and whether increased efficacy and safety will result with an isotype-selective HDAC inhibitor.  We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.  In intact cells, MGCD0103 inhibited only a fraction of the total HDAC activity and showed long-lasting inhibitory activity even upon drug removal.  MGCD0103 induced hyperacetylation of histones, selectively induced apoptosis, and caused cell cycle blockade in various human cancer cell lines in a dose-dependent manner.  MGCD0103 exhibited potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro, and HDAC inhibitory activity was required for these effects.  In vivo, MGCD0103 significantly inhibited growth of human tumor xenografts in nude mice in a dose-dependent manner and the antitumor activity correlated with induction of histone acetylation in tumors.  Our findings suggest that the isotype-selective HDAC inhibition by MGCD0103 is sufficient for antitumor activity in vivo and that further clin. investigation is warranted. [Mol Cancer Ther 2008;7(4):759-68].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokegpWTxBJyrVg90H21EOLACvtfcHk0ljjbFqaDVs9wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gms70%253D&md5=48604f141d969585efaa71c4005496cf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2026%26sid%3Dliteratum%253Aachs%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DP.%2BT.%26aulast%3DTrachy-Bourget%26aufirst%3DM.-C.%26aulast%3DKalita%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DA.-H.%26aulast%3DZhou%26aufirst%3DN.%2BZ.%26aulast%3DRobert%26aufirst%3DM.-F.%26aulast%3DGillespie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DMoradei%26aufirst%3DO.%26aulast%3DDelorme%26aufirst%3DD.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DMGCD0103%252C%2520a%2520Novel%2520Isotype-Selective%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Has%2520Broad%2520Spectrum%2520Antitumor%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D759%26epage%3D768%26doi%3D10.1158%2F1535-7163.MCT-07-2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Development of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China</span>. <i>Intractable Rare Dis. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5582/irdr.2016.01024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.5582%2Firdr.2016.01024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27672541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=185-191&author=X.+Luauthor=Z.+Ningauthor=Z.+Liauthor=H.+Caoauthor=X.+Wang&title=Development+of+Chidamide+for+Peripheral+T-Cell+Lymphoma%2C+the+First+Orphan+Drug+Approved+in+China&doi=10.5582%2Firdr.2016.01024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span></div><div class="casAuthors">Lu Xianping; Ning Zhiqiang; Li Zhibin; Cao Haixiang; Wang Xinhao</div><div class="citationInfo"><span class="NLM_cas:title">Intractable & rare diseases research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">2186-3644</span>.
    </div><div class="casAbstract">Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies.  The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000.  Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment.  Functioning as a genuine epigenetic modulator, chidamide induces growth arrest and apoptosis in tumor cells and enhances cellular antitumor immunity.  Based on the overall results from preclinical and phase I clinical studies, exploratory and pivotal phase II trials of chidamide for relapsed or refractory PTCL were conducted from March 2009 to May 2012, and the results led to CFDA approval of chidamide for the indication in December 2014, being the first approved orphan drug according to the research & development approach of orphan drugs in China, as well as the first orally active drug for PTCL in China and worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsI-YolguuyLP3FVUi_gf8fW6udTcc2eaeEdBKnfDT4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D&md5=5c1f310ea15bb4a706f54d5fdc55c7d5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.5582%2Firdr.2016.01024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Firdr.2016.01024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520Chidamide%2520for%2520Peripheral%2520T-Cell%2520Lymphoma%252C%2520the%2520First%2520Orphan%2520Drug%2520Approved%2520in%2520China%26jtitle%3DIntractable%2520Rare%2520Dis.%2520Res.%26date%3D2016%26volume%3D5%26spage%3D185%26epage%3D191%26doi%3D10.5582%2Firdr.2016.01024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bretz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnitzke, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronthaler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, S.</span></span> <span> </span><span class="NLM_article-title">Domatinostat Favors the Immunotherapy Response by Modulating the Tumor Immune Microenvironment (TIME)</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi"> DOI: 10.1186/s40425-019-0745-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs40425-019-0745-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31703604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmvVeqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=294&author=A.+C.+Bretzauthor=U.+Parnitzkeauthor=K.+Kronthalerauthor=T.+Drekerauthor=R.+Bartzauthor=F.+Hermannauthor=A.+Ammendolaauthor=T.+Wulffauthor=S.+Hamm&title=Domatinostat+Favors+the+Immunotherapy+Response+by+Modulating+the+Tumor+Immune+Microenvironment+%28TIME%29&doi=10.1186%2Fs40425-019-0745-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)</span></div><div class="casAuthors">Bretz Anne Catherine; Parnitzke Ulrike; Kronthaler Kerstin; Dreker Tobias; Bartz Rene; Hermann Frank; Ammendola Astrid; Wulff Tanja; Hamm Svetlana</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL numbers.  Nonetheless, a significant proportion of patients with pre-existing immunity fail to respond, indicating a therapeutic potential for combining PD-(L)1 blockade with additional immunomodulatory agents in both CTL-high and -low immune phenotypes.  Here, we evaluated domatinostat (4SC-202), a class I-selective histone deacetylase (HDAC) inhibitor, for its effect on the TIME and its antitumoral efficacy using syngeneic mouse models with CTL-high or CTL-low tumors.  METHODS:  Domatinostat was evaluated in PD-1 blockade-insensitive CTL-low (CT26) and CTL-high (C38) syngeneic models alone and in combination with different immune-inhibitory and -stimulatory approaches.  Effects on the immunophenotype were assessed via flow cytometry and RNA-seq analyses.  The changes in RNA-seq-based immune signatures determined in a murine setting were investigated in patient samples from the first-dose cohort of the SENSITIZE trial (NCT03278665) evaluating domatinostat combined with pembrolizumab in advanced-stage melanoma patients refractory/nonresponding to PD-1 blockade.  RESULTS:  Domatinostat increased the expression of antigen-presenting machinery (APM) genes and MHC class I and II molecules, along with CTL infiltration, in tumors of both immune phenotypes.  In combination with PD-(L)1 blockade, domatinostat augmented antitumor effects substantially above the effects of single-agent therapies, displaying greater benefit in tumors with pre-existing CTLs.  In this setting, the combination of domatinostat with agonistic anti-4-1BB or both PD-1 and LAG3 blockade further increased the antitumor efficacy.  In CTL-low tumors, domatinostat enhanced the expression of genes known to reinforce immune responses against tumors.  Specifically, domatinostat increased the expression of Ifng and genes associated with responses to pembrolizumab and nivolumab.  Clinically, these findings were confirmed in patients with advanced melanoma treated with domatinostat for 14 days, who demonstrated elevated expression of APM and MHC genes, the IFNG gene, and the IFN-γ and pembrolizumab response signatures in individual tumor samples.  CONCLUSION:  In summary, these data suggest a promising potential of domatinostat in combination with immunotherapy to improve the outcome of refractory cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkBIQjojbRPqx48Rj5GnGofW6udTcc2eaeEdBKnfDT4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmvVeqsw%253D%253D&md5=e93f15f76651efe45da4b87d95dcf3bf</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0745-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0745-3%26sid%3Dliteratum%253Aachs%26aulast%3DBretz%26aufirst%3DA.%2BC.%26aulast%3DParnitzke%26aufirst%3DU.%26aulast%3DKronthaler%26aufirst%3DK.%26aulast%3DDreker%26aufirst%3DT.%26aulast%3DBartz%26aufirst%3DR.%26aulast%3DHermann%26aufirst%3DF.%26aulast%3DAmmendola%26aufirst%3DA.%26aulast%3DWulff%26aufirst%3DT.%26aulast%3DHamm%26aufirst%3DS.%26atitle%3DDomatinostat%2520Favors%2520the%2520Immunotherapy%2520Response%2520by%2520Modulating%2520the%2520Tumor%2520Immune%2520Microenvironment%2520%2528TIME%2529%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D294%26doi%3D10.1186%2Fs40425-019-0745-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soilleux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tysoe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, M. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1002/cncr.31791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcncr.31791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30332497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Sru7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2019&pages=99-108&author=T.+A.+Eyreauthor=G.+P.+Collinsauthor=A.+Guptaauthor=N.+Coupeauthor=S.+Sheikhauthor=J.+Whittakerauthor=L.+M.+Wangauthor=L.+Campoauthor=E.+Soilleuxauthor=F.+Tysoeauthor=R.+Cousinsauthor=N.+La+Thangueauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=D.+Kerrauthor=M.+R.+Middleton&title=A+Phase+1+Study+to+Assess+the+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+CXD101+in+Patients+with+Advanced+Cancer&doi=10.1002%2Fcncr.31791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer</span></div><div class="casAuthors">Eyre, Toby A.; Collins, Graham P.; Gupta, Avinash; Coupe, Nicholas; Sheikh, Semira; Whittaker, John; Wang, Lai Mun; Campo, Leticia; Soilleux, Elizabeth; Tysoe, Finn; Cousins, Richard; La Thangue, Nick; Folkes, Lisa K.; Stratford, Michael R. L.; Kerr, David; Middleton, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-108</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : In the current study, the authors sought to det. the max. tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.  Methods : The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21-day cycle (3+3 design).  Results : A total of 39 patients were enrolled, 36 of whom received CXD101.  Of the 30 patients in the escalation cohort, 29 were evaluable for detn. of the dose-limiting toxicity (DLT).  DLTs were noted at doses of 16 mg twice daily (1 of 6 patients), 20 mg twice daily (1 of 6 patients), and 24/25 mg twice daily (2 of 5 patients, both of whom developed neutropenic fever).  The MTD was 20 mg twice daily, which achieved maximal plasma concns. (±std. deviation) of 231±76 nM to 342±126 nM, which was within the biol. active range.  Six patients received 20 mg twice daily in an expansion cohort.  The most frequent adverse events were fatigue, nausea, and reversible cytopenia.  Key grade 3 to 4 adverse events (according to Common Terminol. Criteria for Adverse Events criteria [version 4.03]) included thrombocytopenia (11%), neutropenia (17%), and neutropenic fever (2%) across the 133 CXD101 cycles given.  The toxicity profile was similar to that of licensing studies with other histone deacetylase inhibitors.  In 22 evaluable patients receiving a dose of ≥16 mg twice daily (17 of whom had lymphoma and 5 of whom had solid tumors), 3 partial responses (2 in patients with classic Hodgkin lymphoma after allogenic stem cell transplantation and 1 in a patient with angioimmunoblastic T-cell lymphoma) and 1 complete response (in a patient with follicular lymphoma) were noted (overall response rate of 18%) in addn. to 9 patients who achieved durable stable disease.  Responses were noted predominantly among patients with lymphoma (tumor redn. noted in 63% of patients on std. computed tomog.).  Conclusions : The MTD in the current study was found to be 20 mg twice daily.  Encouraging and durable activity was obsd. in patients with Hodgkin lymphoma, T-cell lymphoma, and follicular lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhG58M9eTdLLVg90H21EOLACvtfcHk0lhuIGVSfiAFBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Sru7%252FE&md5=47f6b7cf4c4a7a67eb8622f7256f7315</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31791%26sid%3Dliteratum%253Aachs%26aulast%3DEyre%26aufirst%3DT.%2BA.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DCoupe%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DS.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DL.%26aulast%3DSoilleux%26aufirst%3DE.%26aulast%3DTysoe%26aufirst%3DF.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DKerr%26aufirst%3DD.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DA%2520Phase%25201%2520Study%2520to%2520Assess%2520the%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520CXD101%2520in%2520Patients%2520with%2520Advanced%2520Cancer%26jtitle%3DCancer%26date%3D2019%26volume%3D125%26spage%3D99%26epage%3D108%26doi%3D10.1002%2Fcncr.31791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cengiz
Seval, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span> <span> </span><span class="NLM_article-title">A Comparative Safety Review of Histone Deacetylase Inhibitors for the Treatment of Myeloma</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1080/14740338.2019.1615051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F14740338.2019.1615051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31070945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1CjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=563-571&author=G.+Cengiz%0ASevalauthor=M.+Beksac&title=A+Comparative+Safety+Review+of+Histone+Deacetylase+Inhibitors+for+the+Treatment+of+Myeloma&doi=10.1080%2F14740338.2019.1615051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma</span></div><div class="casAuthors">Cengiz Seval, Guldane; Beksac, Meral</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">563-571</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Dysregulation of histone deacetylase (HDAC) activity is an epigenetic hallmark of multiple myeloma (MM), leading to aberrant gene expression and cellular signaling in myeloma cell growth, survival and resistance to therapy.  Hyper-methylation at diagnosis is a frequent observation, which eventually may convert to hypo-methylation during advanced phases.: A literature search on 'HDAC inhibitors' and 'multiple myeloma' was carried out using PubMed and Google Scholar in the prepn. of this overview on clin. efficacy and safety data.: First-generation non-selective HDAC inhibitors have demonstrated minimal single-agent activity in refractory MM.  Subsequently, combination therapy has proven an improvement in progression-free survival (PFS) but not response rates.  The main concerns are assocd. with toxicities.  Ongoing studies on new and more selective agents, i.e.  Romidepsin or Ricolinostat, are promising in terms of better efficacy and less toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5tYPY2lf0OrVg90H21EOLACvtfcHk0ljwdcOaiBt2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1CjsLs%253D&md5=3618b598fda7cac6afaf19708516a5be</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F14740338.2019.1615051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2019.1615051%26sid%3Dliteratum%253Aachs%26aulast%3DCengiz%2BSeval%26aufirst%3DG.%26aulast%3DBeksac%26aufirst%3DM.%26atitle%3DA%2520Comparative%2520Safety%2520Review%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Myeloma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2019%26volume%3D18%26spage%3D563%26epage%3D571%26doi%3D10.1080%2F14740338.2019.1615051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M.</span></span> <span> </span><span class="NLM_article-title">The Safety Profile of Vorinostat (Suberoylanilide Hydroxamic Acid) in Hematologic Malignancies: A Review of Clinical Studies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2015.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ctrv.2015.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26827693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVeqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=58-66&author=M.+Duvicauthor=M.+Dimopoulos&title=The+Safety+Profile+of+Vorinostat+%28Suberoylanilide+Hydroxamic+Acid%29+in+Hematologic+Malignancies%3A+A+Review+of+Clinical+Studies&doi=10.1016%2Fj.ctrv.2015.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies</span></div><div class="casAuthors">Duvic, Madeleine; Dimopoulos, Meletios</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone acetyltransferases and histone deacetylases (HDACs) are multifunctional enzymes that posttranslationally modify both histone and nonhistone acetylation sites, affecting a broad range of cellular processes (e.g., cell cycle, apoptosis, and protein folding) often dysregulated in cancer.  HDAC inhibitors are small mols. that directly interact with HDAC catalytic sites preventing the removal of acetyl groups, thereby counteracting the effects of HDACs.  Since the first HDAC inhibitor, valproic acid, was investigated as a potential antitumor agent, there have been a no. of other HDAC inhibitors developed to improve efficacy and safety.  Despite significant progress in the management of patients with hematol. malignancies, overall survival is still poor.  The discovery that HDACs may play a role in hematol. malignancies and preclin. studies showing promising activity with HDAC inhibitors in various tumor types, led to clin. evaluation of HDAC inhibitors as potential treatment options for patients with advanced hematol. malignancies.  The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma.  This review highlights the safety of HDAC inhibitors currently approved or being investigated for the treatment of hematol. malignancies, with a specific focus on the safety experience with vorinostat in cutaneous T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9eEu3gdyDrVg90H21EOLACvtfcHk0ljwdcOaiBt2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVeqtrs%253D&md5=30a9e3f94e222ebbac6ded7469341e9d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2015.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2015.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26aulast%3DDimopoulos%26aufirst%3DM.%26atitle%3DThe%2520Safety%2520Profile%2520of%2520Vorinostat%2520%2528Suberoylanilide%2520Hydroxamic%2520Acid%2529%2520in%2520Hematologic%2520Malignancies%253A%2520A%2520Review%2520of%2520Clinical%2520Studies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D43%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.ctrv.2015.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1616</span>, <span class="refDoi"> DOI: 10.3390/ijms20071616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20071616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1616&author=W.+Liauthor=Z.+Sun&title=Mechanism+of+Action+for+HDAC+Inhibitors-Insights+from+Omics+Approaches&doi=10.3390%2Fijms20071616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action for HDAC inhibitors-insights from omics approaches</span></div><div class="casAuthors">Li, Wenbo; Sun, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1616</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDIs) are a class of prominent epigenetic drugs that are currently being tested in hundreds of clin. trials against a variety of diseases.  A few compds. have already been approved for treating lymphoma or myeloma.  HDIs bind to the zinc-contg. catalytic domain of the histone deacetylase (HDACs) and they repress the deacetylase enzymic activity.  The broad therapeutic effect of HDIs with seemingly low toxicity is somewhat puzzling when considering that most HDIs lack strict specificity toward any individual HDAC and, even if they do, each individual HDAC has diverse functions under different physiol. scenarios.  Here, we review recent mechanistic studies using omics approaches, including epigenomics, transcriptomics, proteomics, metabolomics, and chemoproteomics, methods.  These omics studies provide non-biased insights into the mechanism of action for HDIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa1rV-6hFcLbVg90H21EOLACvtfcHk0ljwdcOaiBt2mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVyqsg%253D%253D&md5=7fc9546a3abafb1ebf0a80a96bd18402</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3390%2Fijms20071616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071616%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DZ.%26atitle%3DMechanism%2520of%2520Action%2520for%2520HDAC%2520Inhibitors-Insights%2520from%2520Omics%2520Approaches%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1616%26doi%3D10.3390%2Fijms20071616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0li9RSpzSbbXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma</span>. <i>Dermatol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1016/j.det.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.det.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26433847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=757-764&author=M.+Duvic&title=Histone+Deacetylase+Inhibitors+for+Cutaneous+T-Cell+Lymphoma&doi=10.1016%2Fj.det.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma</span></div><div class="casAuthors">Duvic, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic Clinics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">757-764</span>CODEN:
                <span class="NLM_cas:coden">DRMCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0733-8635</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review describes Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU84YKmfugI7Vg90H21EOLACvtfcHk0li9RSpzSbbXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajtr3L&md5=4a2da2fbcfb52afe60cbf95c105c6cbd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.det.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.det.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520for%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DDermatol.%2520Clin.%26date%3D2015%26volume%3D33%26spage%3D757%26epage%3D764%26doi%3D10.1016%2Fj.det.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span> <span> </span><span class="NLM_article-title">Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s40264-018-0773-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2Fs40264-018-0773-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30649740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=235-245&author=R.+R.+Shah&title=Safety+and+Tolerability+of+Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Oncology&doi=10.1007%2Fs40264-018-0773-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology</span></div><div class="casAuthors">Shah, Rashmi R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematol. malignancies (T-cell lymphomas and multiple myeloma).  However, they are not as effective in solid tumors.  Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat.  These agents are assocd. with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects.  Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the ECG, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias.  In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large no. of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesized and are currently under clin. development.  Preliminary evidence from early studies suggests that they may be effective in non-haematol. cancers as well when used in combination with other therapeutic modalities, but that they too appear to be assocd. with the above class-related adverse effects.  As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications will become clearer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_FzvurFGlNLVg90H21EOLACvtfcHk0li9RSpzSbbXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtrY%253D&md5=db23e29ac410c716393aae079abf18cd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs40264-018-0773-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-018-0773-9%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26atitle%3DSafety%2520and%2520Tolerability%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Oncology%26jtitle%3DDrug%2520Saf.%26date%3D2019%26volume%3D42%26spage%3D235%26epage%3D245%26doi%3D10.1007%2Fs40264-018-0773-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flower, A.</span>; <span class="NLM_string-name">Abla, O.</span></span> <span> </span><span class="NLM_article-title">Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma</span>. In  <i>Resistance to Targeted Therapies in Lymphomas</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, A. C.</span>, <span class="NLM_string-name">Cairo, M. S.</span></span>, Eds.; Resistance to Targeted Anti-Cancer Therapeutics; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">110</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2F978-3-030-24424-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=87-110&author=A.+Flower&author=O.+Ablaauthor=A.+C.+Xavier&author=M.+S.+Cairo&title=Resistance+to+Targeted+Therapies+in+Lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-24424-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-030-24424-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DFlower%26aufirst%3DA.%26atitle%3DResistance%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Lymphoma%26btitle%3DResistance%2520to%2520Targeted%2520Therapies%2520in%2520Lymphomas%26aulast%3DXavier%26aufirst%3DA.%2BC.%26pub%3DSpringer%26date%3D2019%26spage%3D87%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yurek-George, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecil, A. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, A. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packham, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5720</span>– <span class="NLM_lpage">5726</span>, <span class="refDoi"> DOI: 10.1021/jm0703800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0703800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WmtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5720-5726&author=A.+Yurek-Georgeauthor=A.+R.+L.+Cecilauthor=A.+H.+K.+Moauthor=S.+Wenauthor=H.+Rogersauthor=F.+Habensauthor=S.+Maedaauthor=M.+Yoshidaauthor=G.+Packhamauthor=A.+Ganesan&title=The+First+Biologically+Active+Synthetic+Analogues+of+FK228%2C+the+Depsipeptide+Histone+Deacetylase+Inhibitor&doi=10.1021%2Fjm0703800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor</span></div><div class="casAuthors">Yurek-George, Alexander; Cecil, Alexander Richard Liam; Mo, Alex Hon Kit; Wen, Shijun; Rogers, Helen; Habens, Fay; Maeda, Satoko; Yoshida, Minoru; Packham, Graham; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5720-5726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclic peptide lactone analogs of the histone deacetylase (HDAC) inhibitor FK228 such as I (R = Me, Me2CH) are prepd.; their inhibition of human breast cancer cell line and of HDAC 1 and 6 is detd.  The dehydrobutyrine residue in FK228 is not essential and can be replaced by other residues such as D-valine without loss of HDAC inhibition.  Conformational restriction by the macrocyclic scaffold is important for HDAC inhibition; a linear peptide analog inhibits neither HDAC1 or HDAC6 and does not inhibit breast cancer cells.  The bridging disulfide of FK228 can be removed and one of its component cysteines replaced with an alanine residue with little or no loss in HDAC inhibition if the resultant thiol is protected (for example with an acetyl group).  The FK228 analogs are less effective at inhibiting HDAC6 (a class II HDAC) than HDAC1 (a class I HDAC).  The structure of I (R = Me) is detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLSbpJiC7igbVg90H21EOLACvtfcHk0ljcFQhPxPsD4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WmtL7M&md5=7c44919259524c0d825e373c8466e536</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm0703800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0703800%26sid%3Dliteratum%253Aachs%26aulast%3DYurek-George%26aufirst%3DA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DMo%26aufirst%3DA.%2BH.%2BK.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DH.%26aulast%3DHabens%26aufirst%3DF.%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DPackham%26aufirst%3DG.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThe%2520First%2520Biologically%2520Active%2520Synthetic%2520Analogues%2520of%2520FK228%252C%2520the%2520Depsipeptide%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5720%26epage%3D5726%26doi%3D10.1021%2Fjm0703800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, L.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1002/slct.201702295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fslct.201702295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1KgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=176-187&author=Q.+Zhangauthor=Y.+Daiauthor=Z.+Caiauthor=L.+Mou&title=HDAC+Inhibitors%3A+Novel+Immunosuppressants+for+Allo-+and+Xeno-+Transplantation&doi=10.1002%2Fslct.201702295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation</span></div><div class="casAuthors">Zhang, Qing; Dai, Yifan; Cai, Zhiming; Mou, Lisha</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-187</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Immune rejection is the major obstacle to graft survival and quality of life of recipients after organ transplantation.  The immunosuppressants applied in clin. face severe safety and efficacy issues.  Histone deacetylases (HDACs) are emerging novel drug targets in the treatment of malignancies and immune disorders.  HDAC inhibitors show potential as valuable immune regulators after allo- or xeno-organ transplantation.  However, studies that evaluate HDAC inhibitors and mechanisms are still limited.  In this review, we focused on the immunomodulatory effects of HDAC inhibitors in transplantation.  Finally, we discussed the implications and challenges of applying HDAC inhibitors in allo- and xeno-transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYyN829xfyirVg90H21EOLACvtfcHk0ljcFQhPxPsD4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1KgsQ%253D%253D&md5=c6369c4cc8947c9357dbc266e66b5e9e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fslct.201702295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201702295%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DMou%26aufirst%3DL.%26atitle%3DHDAC%2520Inhibitors%253A%2520Novel%2520Immunosuppressants%2520for%2520Allo-%2520and%2520Xeno-%2520Transplantation%26jtitle%3DChemistrySelect%26date%3D2018%26volume%3D3%26spage%3D176%26epage%3D187%26doi%3D10.1002%2Fslct.201702295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citraro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’agostino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, E.</span></span> <span> </span><span class="NLM_article-title">Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5546</span>– <span class="NLM_lpage">5562</span>, <span class="refDoi"> DOI: 10.2174/1381612823666171024130001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2174%2F1381612823666171024130001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=5546-5562&author=R.+Citraroauthor=A.+Leoauthor=M.+Santoroauthor=G.+D%E2%80%99agostinoauthor=A.+Constantiauthor=E.+Russo&title=Role+of+Histone+Deacetylases+%28HDACs%29+in+Epilepsy+and+Epileptogenesis&doi=10.2174%2F1381612823666171024130001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F1381612823666171024130001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666171024130001%26sid%3Dliteratum%253Aachs%26aulast%3DCitraro%26aufirst%3DR.%26aulast%3DLeo%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599agostino%26aufirst%3DG.%26aulast%3DConstanti%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DE.%26atitle%3DRole%2520of%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520in%2520Epilepsy%2520and%2520Epileptogenesis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2018%26volume%3D23%26spage%3D5546%26epage%3D5562%26doi%3D10.2174%2F1381612823666171024130001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatain, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walbridge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboina, P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1210/jc.2017-00464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1210%2Fjc.2017-00464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28505327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1crntl2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=2825-2835&author=J.+Luauthor=G.+P.+Chatainauthor=A.+Bugariniauthor=X.+Wangauthor=D.+Maricauthor=S.+Walbridgeauthor=Z.+Zhuangauthor=P.+Chittiboina&title=Histone+Deacetylase+Inhibitor+SAHA+Is+a+Promising+Treatment+of+Cushing+Disease&doi=10.1210%2Fjc.2017-00464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease</span></div><div class="casAuthors">Lu Jie; Chatain Gregoire P; Chittiboina Prashant; Bugarini Alejandro; Wang Xiang; Walbridge Stuart; Zhuang Zhengping; Chittiboina Prashant; Maric Dragan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2825-2835</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Context:  Remission failure following transsphenoidal surgery in Cushing disease (CD) from pituitary corticotroph tumors (CtTs) remains clinically challenging.  Histone deacetylase inhibitors (HDACis) are antitumor drugs approved for clinical use, with the potential to affect adrenocorticotropin hormone (ACTH) hypersecretion by inhibiting pro-opiomelanocortin (POMC) transcription.  Objective:  Testing the efficacy of suberoylanilide hydroxamic acid (SAHA) on human and murine ACTH-secreting tumor (AtT-20) cells.  Design:  Cell viability, ACTH secretion (enzyme-linked immunosorbent assay), apoptosis, and gene expression profile were investigated on AtT-20 cells.  In vivo efficacy was examined in an athymic nude mouse AtT-20 xenograft model.  SAHA efficacy against human-derived corticotroph tumor (hCtT) (n = 8) was tested in vitro.  Setting:  National Institutes of Health.  Intervention:  SAHA (0.5 to 8 μM).  Main Outcome Measures:  AtT-20 and hCtT cell survival, in vitro/invivo ACTH measurements.  Results:  SAHA (1 μM) reduced AtT-20 viability to 75% at 24 hours, 43% at 48 hours (analysis of variance; P = 0.002).  Apoptosis was confirmed with elevated BAX/Bcl2 ratio and FACS.  Intriguingly, early (3-hour) significant decline (70%; P < 0.0001) of secreted ACTH and diminished POMC transcription was observed with SAHA (1 μM).  Microarray analysis revealed a direct association between liver X receptor alpha (LXRα) and POMC expression.  Accordingly, SAHA reduced LXRα in AtT-20 cells but not in normal murine corticotrophs.  Xenografted nude-mice tumor involution (126 ± 33/160 ± 35 vs 337 ± 49 mm3; P = 0.0005) was observed with 5-day intraperitoneal SAHA, with reversal of elevated ACTH (P < 0.0001).  SAHA did not affect serum ACTH in nontumor mice.  Lastly, we confirmed that SAHA (1 μM/24 h) decreased hCtT survival (78.92%; P = 0.0007) and ACTH secretion (83.64%; P = 0.03).  Conclusion:  Our findings demonstrate SAHA's efficacy in reducing survival and ACTH secretion in AtT-20 and hCtT cells, providing a potential intervention for recurrent/unremitting CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwKtl5uJA9kK_dlEzl_fBafW6udTcc2eYs-oO93hsK1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crntl2isg%253D%253D&md5=5076c79a890e45c6368833c69acf7992</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1210%2Fjc.2017-00464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2017-00464%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChatain%26aufirst%3DG.%2BP.%26aulast%3DBugarini%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMaric%26aufirst%3DD.%26aulast%3DWalbridge%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DChittiboina%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520SAHA%2520Is%2520a%2520Promising%2520Treatment%2520of%2520Cushing%2520Disease%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2017%26volume%3D102%26spage%3D2825%26epage%3D2835%26doi%3D10.1210%2Fjc.2017-00464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandoná, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucciarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccone, V.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors for Muscular Dystrophies: Progress and Prospects</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1517/21678707.2016.1130617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1517%2F21678707.2016.1130617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=125-127&author=M.+Sandon%C3%A1author=S.+Consalviauthor=L.+Tucciaroneauthor=P.+L.+Puriauthor=V.+Saccone&title=HDAC+Inhibitors+for+Muscular+Dystrophies%3A+Progress+and+Prospects&doi=10.1517%2F21678707.2016.1130617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F21678707.2016.1130617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F21678707.2016.1130617%26sid%3Dliteratum%253Aachs%26aulast%3DSandon%25C3%25A1%26aufirst%3DM.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DTucciarone%26aufirst%3DL.%26aulast%3DPuri%26aufirst%3DP.%2BL.%26aulast%3DSaccone%26aufirst%3DV.%26atitle%3DHDAC%2520Inhibitors%2520for%2520Muscular%2520Dystrophies%253A%2520Progress%2520and%2520Prospects%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2016%26volume%3D4%26spage%3D125%26epage%3D127%26doi%3D10.1517%2F21678707.2016.1130617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">The Etiological Changes of Acetylation in Peripheral Nerve Injury-Induced Neuropathic Hypersensitivity</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1744806918798408</span>, <span class="refDoi"> DOI: 10.1177/1744806918798408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1177%2F1744806918798408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1744806918798408&author=X.+Wangauthor=X.+Shenauthor=Y.+Xuauthor=S.+Xuauthor=F.+Xiaauthor=B.+Zhuauthor=Y.+Liuauthor=W.+Wangauthor=H.+Wuauthor=F.+Wang&title=The+Etiological+Changes+of+Acetylation+in+Peripheral+Nerve+Injury-Induced+Neuropathic+Hypersensitivity&doi=10.1177%2F1744806918798408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1177%2F1744806918798408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1744806918798408%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26atitle%3DThe%2520Etiological%2520Changes%2520of%2520Acetylation%2520in%2520Peripheral%2520Nerve%2520Injury-Induced%2520Neuropathic%2520Hypersensitivity%26jtitle%3DMol.%2520Pain%26date%3D2018%26volume%3D14%26spage%3D1744806918798408%26doi%3D10.1177%2F1744806918798408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelewicz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3315</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-16-2526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28053023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3307-3315&author=D.+T.+Voglauthor=N.+Rajeauthor=S.+Jagannathauthor=P.+Richardsonauthor=P.+Hariauthor=R.+Orlowskiauthor=J.+G.+Supkoauthor=D.+Tamangauthor=M.+Yangauthor=S.+S.+Jonesauthor=C.+Wheelerauthor=R.+J.+Markelewiczauthor=S.+Lonial&title=Ricolinostat%2C+the+First+Selective+Histone+Deacetylase+6+Inhibitor%2C+in+Combination+with+Bortezomib+and+Dexamethasone+for+Relapsed+or+Refractory+Multiple+Myeloma&doi=10.1158%2F1078-0432.CCR-16-2526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma</span></div><div class="casAuthors">Vogl, Dan T.; Raje, Noopur; Jagannath, Sundar; Richardson, Paul; Hari, Parameswaran; Orlowski, Robert; Supko, Jeffrey G.; Tamang, David; Yang, Min; Jones, Simon S.; Wheeler, Catherine; Markelewicz, Robert J.; Lonial, Sagar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3307-3315</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity.  Preclin. models suggest that the obsd. synergy is due to the role of HDAC6 in mediating resistance to proteasome inhibition via the aggresome/autophagy pathway of protein degrdn.  Exptl. Design: We conducted a phase I/II trial of the HDAC6-selective inhibitor ricolinostat to define the safety, preliminary efficacy, and recommended phase II dose in combination with std. proteasome inhibitor therapy.  Patients with relapsed or refractory multiple myeloma received oral ricolinostat on days 1-5 and 8-12 of each 21-day cycle.  Results: Single-agent ricolinostat therapy resulted in neither significant toxicity nor clin. responses.  Combination therapy with bortezomib and dexamethasone was well-tolerated during dose escalation but led to dose-limiting diarrhea in an expansion cohort at a ricolinostat dose of 160 mg twice daily.  Combination therapy at a ricolinostat dose of 160 mg daily in a second expansion cohort was well tolerated, with less severe hematol., gastrointestinal, and constitutional toxicities compared with published data on nonselective HDAC inhibitors.  The overall response rate in combination with daily ricolinostat at ≥160 mg was 37%.  The response rate to combination therapy among bortezomib-refractory patients was 14%.  Samples taken during therapy showed dose-dependent increases of acetylated tubulin in peripheral blood lymphocytes.  Conclusions: At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy.  Clin Cancer Res; 23(13); 3307-15. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFQogphgLWbLVg90H21EOLACvtfcHk0lg9GMnSAVIfjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurbL&md5=2dd174501d2f331aeb0eff42072001d1</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2526%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DMarkelewicz%26aufirst%3DR.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DRicolinostat%252C%2520the%2520First%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Bortezomib%2520and%2520Dexamethasone%2520for%2520Relapsed%2520or%2520Refractory%2520Multiple%2520Myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3307%26epage%3D3315%26doi%3D10.1158%2F1078-0432.CCR-16-2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suraweera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">92</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffonc.2018.00092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29651407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=92&author=A.+Suraweeraauthor=K.+J.+O%E2%80%99Byrneauthor=D.+J.+Richard&title=Combination+Therapy+With+Histone+Deacetylase+Inhibitors+%28HDACi%29+for+the+Treatment+of+Cancer%3A+Achieving+the+Full+Therapeutic+Potential+of+HDACi&doi=10.3389%2Ffonc.2018.00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span></div><div class="casAuthors">Suraweera Amila; O'Byrne Kenneth J; Richard Derek J; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">92</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression.  Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones.  HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer.  Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents.  While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors.  The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies.  In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies.  We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTprF0Hdrz8rZZoeNcnHOQ9fW6udTcc2eZMImCKUwV4Cbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D&md5=2f0ace7215bc7519c23cad264f73693d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00092%26sid%3Dliteratum%253Aachs%26aulast%3DSuraweera%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520Therapy%2520With%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACi%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%253A%2520Achieving%2520the%2520Full%2520Therapeutic%2520Potential%2520of%2520HDACi%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D92%26doi%3D10.3389%2Ffonc.2018.00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspeslagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almouzni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span> <span> </span><span class="NLM_article-title">Combining Epigenetic Drugs with Other Therapies for Solid Tumours - Past Lessons and Future Promise</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/s41571-019-0267-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41571-019-0267-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31570827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=91-107&author=D.+Morelauthor=D.+Jefferyauthor=S.+Aspeslaghauthor=G.+Almouzniauthor=S.+Postel-Vinay&title=Combining+Epigenetic+Drugs+with+Other+Therapies+for+Solid+Tumours+-+Past+Lessons+and+Future+Promise&doi=10.1038%2Fs41571-019-0267-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise</span></div><div class="casAuthors">Morel, Daphne; Jeffery, Daniel; Aspeslagh, Sandrine; Almouzni, Genevieve; Postel-Vinay, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-107</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Epigenetic dysregulation has long been recognized as a key factor contributing to tumorigenesis and tumor maintenance that can influence all of the recognized hallmarks of cancer.  Despite regulatory approvals for the treatment of certain haematol. malignancies, the efficacy of the first generation of epigenetic drugs (epi-drugs) in patients with solid tumors has been disappointing; however, successes have now been achieved in selected solid tumor subtypes, thanks to the development of novel compds. and a better understanding of cancer biol. that have enabled precision medicine approaches.  Several lines of evidence support that, beyond their potential as monotherapies, epigenetic drugs could have important roles in synergy with other anticancer therapies or in reversing acquired therapy resistance.  Herein, it review the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other forms of anticancer therapy, including chemotherapy, radiation therapy, hormone therapy, molecularly targeted therapy and immunotherapy.  It provide a crit. appraisal of the preclin. rationale, completed clin. studies and ongoing clin. trials relating to combination therapies incorporating epi-drugs.  Finally, it propose and discuss rational clin. trial designs and drug development strategies, considering key factors including patient selection, tumor biomarker evaluation, drug scheduling and response assessment and study end points, with the aim of optimizing the development of such combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4bPhevWFgGrVg90H21EOLACvtfcHk0lhIjgfMfHWhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOltbbK&md5=17a9efc27b0eec2b869b9f830a41294e</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41571-019-0267-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-019-0267-4%26sid%3Dliteratum%253Aachs%26aulast%3DMorel%26aufirst%3DD.%26aulast%3DJeffery%26aufirst%3DD.%26aulast%3DAspeslagh%26aufirst%3DS.%26aulast%3DAlmouzni%26aufirst%3DG.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26atitle%3DCombining%2520Epigenetic%2520Drugs%2520with%2520Other%2520Therapies%2520for%2520Solid%2520Tumours%2520-%2520Past%2520Lessons%2520and%2520Future%2520Promise%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D17%26spage%3D91%26epage%3D107%26doi%3D10.1038%2Fs41571-019-0267-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, H. N.</span></span> <span> </span><span class="NLM_article-title">The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2018.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.clml.2018.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30001985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=611-627&author=H.+N.+Abramson&title=The+Multiple+Myeloma+Drug+Pipeline%E2%80%942018%3A+A+Review+of+Small+Molecules+and+Their+Therapeutic+Targets&doi=10.1016%2Fj.clml.2018.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets</span></div><div class="casAuthors">Abramson Hanley N</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">611-627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease.  Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM.  Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s.  Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common.  The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets.  In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio.  Included are agents that affect myeloma epigenetics and the ubiquitination-proteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS29pXs7jYk7MSzjBFCN0BJfW6udTcc2eakWOzxp5p3oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D&md5=3ead649460f6be413b2f7e82b659a8bf</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DH.%2BN.%26atitle%3DThe%2520Multiple%2520Myeloma%2520Drug%2520Pipeline%25E2%2580%25942018%253A%2520A%2520Review%2520of%2520Small%2520Molecules%2520and%2520Their%2520Therapeutic%2520Targets%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2018%26volume%3D18%26spage%3D611%26epage%3D627%26doi%3D10.1016%2Fj.clml.2018.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelink, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripps, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroserio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1239</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.70.5350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1200%2FJCO.2016.70.5350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28221861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=1231-1239&author=R.+Aggarwalauthor=S.+Thomasauthor=N.+Pawlowskaauthor=I.+Bartelinkauthor=J.+Grabowskyauthor=T.+Jahanauthor=A.+Crippsauthor=A.+Harbauthor=J.+Lengauthor=A.+Reinertauthor=I.+Mastroserioauthor=T.-G.+Truongauthor=C.+J.+Ryanauthor=P.+N.+Munster&title=Inhibiting+Histone+Deacetylase+as+a+Means+to+Reverse+Resistance+to+Angiogenesis+Inhibitors%3A+Phase+I+Study+of+Abexinostat+Plus+Pazopanib+in+Advanced+Solid+Tumor+Malignancies&doi=10.1200%2FJCO.2016.70.5350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies</span></div><div class="casAuthors">Aggarwal, Rahul; Thomas, Scott; Pawlowska, Nela; Bartelink, Imke; Grabowsky, Jennifer; Jahan, Thierry; Cripps, Amy; Harb, Armand; Leng, Jim; Reinert, Anne; Mastroserio, Ilaria; Truong, Thach-Giao; Ryan, Charles J.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1231-1239,S1-S2</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance.  Patients and Methods: Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12, and 15 to 19 (schedule A) or on days 1 to 4, 8 to 11, and 15 to 18 (schedule B).  Dose escalation (3 + 3 design) in all solid tumors was followed by dose expansion in renal cell carcinoma (RCC).  Results: Fifty-one patients with RCC (N = 22) were enrolled, including 30 (59%) with one or more lines of prior VEGF-targeting therapy.  Five dose-limiting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were obsd. with schedule A; one dose-limiting toxicity was obsd. (elevated AST/ALT) was obsd. with schedule B.  Grade ≥ 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).  The recommended phase II dose was established as abexinostat 45 mg/m2 twice a day administered per schedule B plus pazopanib 800 mg/d.  Objective response rate was 21% overall and 27% in the RCC subset.  Median duration of response was 9.1 mo (1.2 to > 49 mo).  Eight patients (16%) had durable control of disease for > 12 mo.  Durable tumor regressions were obsd. in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with ongoing response > 3.5 years.  Peripheral blood histone acetylation and HDAC2 gene expression were assocd. with durable response to treatment.  Conclusion: Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzop0Tif1NLVg90H21EOLACvtfcHk0lhIjgfMfHWhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D&md5=31cf19bad52faca73593d583c71e4a6f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.70.5350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.70.5350%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DBartelink%26aufirst%3DI.%26aulast%3DGrabowsky%26aufirst%3DJ.%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DCripps%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DJ.%26aulast%3DReinert%26aufirst%3DA.%26aulast%3DMastroserio%26aufirst%3DI.%26aulast%3DTruong%26aufirst%3DT.-G.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DInhibiting%2520Histone%2520Deacetylase%2520as%2520a%2520Means%2520to%2520Reverse%2520Resistance%2520to%2520Angiogenesis%2520Inhibitors%253A%2520Phase%2520I%2520Study%2520of%2520Abexinostat%2520Plus%2520Pazopanib%2520in%2520Advanced%2520Solid%2520Tumor%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D1231%26epage%3D1239%26doi%3D10.1200%2FJCO.2016.70.5350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yardley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melichar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane with or without Entinostat in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment with a Nonsteroidal Aromatase Inhibitor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.43.7251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1200%2FJCO.2012.43.7251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23650416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2128-2135&author=D.+A.+Yardleyauthor=R.+R.+Ismail-Khanauthor=B.+Melicharauthor=M.+Lichinitserauthor=P.+N.+Munsterauthor=P.+M.+Kleinauthor=S.+Cruickshankauthor=K.+D.+Millerauthor=M.+J.+Leeauthor=J.+B.+Trepel&title=Randomized+Phase+II%2C+Double-Blind%2C+Placebo-Controlled+Study+of+Exemestane+with+or+without+Entinostat+in+Postmenopausal+Women+with+Locally+Recurrent+or+Metastatic+Estrogen+Receptor-Positive+Breast+Cancer+Progressing+on+Treatment+with+a+Nonsteroidal+Aromatase+Inhibitor&doi=10.1200%2FJCO.2012.43.7251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</span></div><div class="casAuthors">Yardley, Denise A.; Ismail-Khan, Roohi R.; Melichar, Bohuslav; Lichinitser, Mikhail; Munster, Pamela N.; Klein, Pamela M.; Cruickshank, Scott; Miller, Kathy D.; Lee, Min J.; Trepel, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2135</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-pos. (ER+) breast cancer.  This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane vs. exemestane alone.  Patients and Methods: Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor were randomly assigned to exemestane 25 mg daily plus entinostat 5 mg once per wk (EE) or exemestane plus placebo (EP).  The primary end point was progression-free survival (PFS).  Blood was collected in a subset of patients for evaluation of protein lysine acetylation as a biomarker of entinostat activity.  Results: One hundred thirty patients were randomly assigned (EE group, n = 64; EP group, n = 66).  Based on intent-to-treat anal., treatment with EE improved median PFS to 4.3 mo vs. 2.3 mo with EP (hazard ratio [HR], 0.73; 95% CI, 0.50 to 1.07; one-sided P = .055; two-sided P = .11 [predefined significance level of .10, one-sided]).  Median overall survival was an exploratory end point and improved to 28.1 mo with EE vs. 19.8 mo with EP (HR, 0.59; 95% CI, 0.36 to 0.97; P = .036).  Fatigue and neutropenia were the most frequent grade 3/4 toxicities.  Treatment discontinuation because of adverse events was higher in the EE group vs. the EP group (11% v 2%).  Protein lysine hyperacetylation in the EE biomarker subset was assocd. with prolonged PFS.  Conclusion: Entinostat added to exemestane is generally well tolerated and demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II study.  Acetylation changes may provide an opportunity to maximize clin. benefit with entinostat.  Plans for a confirmatory study are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopc-999rEFo7Vg90H21EOLACvtfcHk0lgYyamP9ZVLTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF&md5=d11f73761ef87fe34fab169ae22e8390</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.7251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.7251%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DIsmail-Khan%26aufirst%3DR.%2BR.%26aulast%3DMelichar%26aufirst%3DB.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DKlein%26aufirst%3DP.%2BM.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26atitle%3DRandomized%2520Phase%2520II%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Study%2520of%2520Exemestane%2520with%2520or%2520without%2520Entinostat%2520in%2520Postmenopausal%2520Women%2520with%2520Locally%2520Recurrent%2520or%2520Metastatic%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancer%2520Progressing%2520on%2520Treatment%2520with%2520a%2520Nonsteroidal%2520Aromatase%2520Inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2128%26epage%3D2135%26doi%3D10.1200%2FJCO.2012.43.7251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">Tucidinostat plus Exemestane for Postmenopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30164-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS1470-2045%2819%2930164-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31036468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFSnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=806-815&author=Z.+Jiangauthor=W.+Liauthor=X.+Huauthor=Q.+Zhangauthor=T.+Sunauthor=S.+Cuiauthor=S.+Wangauthor=Q.+Ouyangauthor=Y.+Yinauthor=C.+Gengauthor=Z.+Tongauthor=Y.+Chengauthor=Y.+Panauthor=Y.+Sunauthor=H.+Wangauthor=T.+Ouyangauthor=K.+Guauthor=J.+Fengauthor=X.+Wangauthor=S.+Wangauthor=T.+Liuauthor=J.+Gaoauthor=M.+Cristofanilliauthor=Z.+Ningauthor=X.+Lu&title=Tucidinostat+plus+Exemestane+for+Postmenopausal+Patients+with+Advanced%2C+Hormone+Receptor-Positive+Breast+Cancer+%28ACE%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2819%2930164-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Jiang, Zefei; Li, Wei; Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Cui, Shude; Wang, Shusen; Ouyang, Quchang; Yin, Yongmei; Geng, Cuizhi; Tong, Zhongsheng; Cheng, Ying; Pan, Yueyin; Sun, Yuping; Wang, Hong; Ouyang, Tao; Gu, Kangsheng; Feng, Jifeng; Wang, Xiaojia; Wang, Shubin; Liu, Tianshu; Gao, Jinghua; Cristofanilli, Massimo; Ning, Zhiqiang; Lu, Xianping</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">806-815</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Assess the efficacy and safety of combination in a randomised trial in a larger population of postmenopausal patients with advanced, hormone receptor-pos. breast cancer.  Eligible patients were postmenopausal women with hormone receptor-pos., HER2-neg. breast cancer and who had at least one measurable lesion, adequate organ function.  All patients in both groups also received 25 mg oral exemestane daily.  The primary endpoint was investigator-assessed progression-free survival.  Efficacy analyses were done in the full anal. set population, comprising all patients who received at least one dose of any study treatment, and safety analyses were done in all patients who received at least one dose of any study treatment and for whom at least one safety case report form was available.  The median duration of follow-up was 13·9 mo.  Investigator-assessed median progression-free survival was 7·4 mo in the tucidinostat group and 3·8 mo in the placebo group.  The most common grade 3 or 4 adverse events were neutropenia, thrombocytopenia and leucopenia.  Tucidinostat plus exemestane improved progression-free survival.  Grade 3-4 haematol. adverse events were more common in the tucidinostat plus exemestane group than in the placebo plus exemestane group.  Tucidinostat plus exemestane could represent a new treatment option for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLXAjqoJCxwbVg90H21EOLACvtfcHk0lgYyamP9ZVLTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFSnsb0%253D&md5=4b411211c8d4765c2f2908e2e09371ad</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930164-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930164-0%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DOuyang%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DTucidinostat%2520plus%2520Exemestane%2520for%2520Postmenopausal%2520Patients%2520with%2520Advanced%252C%2520Hormone%2520Receptor-Positive%2520Breast%2520Cancer%2520%2528ACE%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D806%26epage%3D815%26doi%3D10.1016%2FS1470-2045%2819%2930164-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abaza, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, L.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkes, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foudray, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Dose Escalation Multicenter Trial of Pracinostat Alone and in Combination with Azacitidine in Patients with Advanced Hematologic Malignancies</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">4851</span>– <span class="NLM_lpage">4859</span>, <span class="refDoi"> DOI: 10.1002/cncr.30949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcncr.30949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28841236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=4851-4859&author=Y.+M.+Abazaauthor=T.+M.+Kadiaauthor=E.+J.+Jabbourauthor=M.+Y.+Konoplevaauthor=G.+Borthakurauthor=A.+Ferrajoliauthor=Z.+Estrovauthor=W.+G.+Wierdaauthor=A.+Alfonsoauthor=T.+H.+Chongauthor=C.+Chuahauthor=L.-P.+Kohauthor=B.-C.+Gohauthor=J.+E.+Changauthor=D.+E.+Durkesauthor=M.+C.+Foudrayauthor=H.+M.+Kantarjianauthor=X.+Q.+Dongauthor=G.+Garcia-Manero&title=Phase+1+Dose+Escalation+Multicenter+Trial+of+Pracinostat+Alone+and+in+Combination+with+Azacitidine+in+Patients+with+Advanced+Hematologic+Malignancies&doi=10.1002%2Fcncr.30949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies</span></div><div class="casAuthors">Abaza, Yasmin M.; Kadia, Tapan M.; Jabbour, Elias J.; Konopleva, Marina Y.; Borthakur, Gautam; Ferrajoli, Alessandra; Estrov, Zeev; Wierda, William G.; Alfonso, Ana; Chong, Toh Han; Chuah, Charles; Koh, Liang-Piu; Goh, Boon-Cher; Chang, Julie E.; Durkes, Daniel E.; Foudray, Maria Cielo; Kantarjian, Hagop M.; Dong, Xiao Qin; Garcia-Manero, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4851-4859</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines.  Pracinostat is reported to have modest clin. activity in patients with advanced solid tumors.  Given the higher preclin. sensitivity of hematol. malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, max. tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematol. malignancies.  METHODS : Pracinostat was administered orally 3 times a week for 3 wk on a 28-day cycle.  Patients were assigned to 7 dose levels using a 3 + 3 dose escalation design.  RESULTS : A total of 44 patients were enrolled, 25 of whom had AML and 14 of whom had myelodysplastic syndrome.  The max. tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg.  Two patients with AML achieved a response: 1 complete remission (CR) and 1 complete cytogenetic response.  Despite a dose-dependent increase in the plasma concn. of pracinostat, a similar increase in histone acetylation was not obsd.  As an extension, 10 addnl. patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine.  Six patients achieved a CR and 3 achieved a CR without platelet recovery with no added toxicity.  CONCLUSIONS : The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematol. malignancies.  Cancer 2017;123:4851-9. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xSYY-7MfErVg90H21EOLACvtfcHk0lgYyamP9ZVLTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsb%252FI&md5=30a7a705e4982a5ec1bc25ade2fd1ca4</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcncr.30949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.30949%26sid%3Dliteratum%253Aachs%26aulast%3DAbaza%26aufirst%3DY.%2BM.%26aulast%3DKadia%26aufirst%3DT.%2BM.%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DKonopleva%26aufirst%3DM.%2BY.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAlfonso%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DT.%2BH.%26aulast%3DChuah%26aufirst%3DC.%26aulast%3DKoh%26aufirst%3DL.-P.%26aulast%3DGoh%26aufirst%3DB.-C.%26aulast%3DChang%26aufirst%3DJ.%2BE.%26aulast%3DDurkes%26aufirst%3DD.%2BE.%26aulast%3DFoudray%26aufirst%3DM.%2BC.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDong%26aufirst%3DX.%2BQ.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26atitle%3DPhase%25201%2520Dose%2520Escalation%2520Multicenter%2520Trial%2520of%2520Pracinostat%2520Alone%2520and%2520in%2520Combination%2520with%2520Azacitidine%2520in%2520Patients%2520with%2520Advanced%2520Hematologic%2520Malignancies%26jtitle%3DCancer%26date%3D2017%26volume%3D123%26spage%3D4851%26epage%3D4859%26doi%3D10.1002%2Fcncr.30949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abaza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness-Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamlou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, E.</span></span> <span> </span><span class="NLM_article-title">Pracinostat plus Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 2 Study</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018027409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1182%2Fbloodadvances.2018027409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30760466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyht7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=508-518&author=G.+Garcia-Maneroauthor=Y.+Abazaauthor=K.+Takahashiauthor=B.+C.+Medeirosauthor=M.+Arellanoauthor=S.+K.+Khaledauthor=M.+Patnaikauthor=O.+Odenikeauthor=H.+Sayarauthor=M.+Tummalaauthor=P.+Patelauthor=L.+Maness-Harrisauthor=R.+Stuartauthor=E.+Traerauthor=K.+Karamlouauthor=A.+Yacoubauthor=R.+Ghalieauthor=R.+Giorginoauthor=E.+Atallah&title=Pracinostat+plus+Azacitidine+in+Older+Patients+with+Newly+Diagnosed+Acute+Myeloid+Leukemia%3A+Results+of+a+Phase+2+Study&doi=10.1182%2Fbloodadvances.2018027409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study</span></div><div class="casAuthors">Garcia-Manero, Guillermo; Abaza, Yasmin; Takahashi, Koichi; Medeiros, Bruno C.; Arellano, Martha; Khaled, Samer K.; Patnaik, Mrinal; Odenike, Olatoyosi; Sayar, Hamid; Tummala, Mohan; Patel, Prapti; Maness-Harris, Lori; Stuart, Robert; Traer, Elie; Karamlou, Kasra; Yacoub, Abdulraheem; Ghalie, Richard; Giorgino, Ruben; Atallah, Ehab</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine.  This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for std. induction chemotherapy.  Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle.  Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphol. leukemia-free state (MLFS) rates of the combination.  Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen.  Fifty patients (33 de novo, 12 secondary, and 5 therapyrelated AML) were enrolled.  Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%).  Median OS and PFS were 19.1 mo (95% confidence interval [CI], 10-26.5 mo) and 12.6 mo (95% CI, 10-17.7 mo), resp., with a 1-yr OS rate of 62%.  Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities.  The 30- and 60-day all-cause mortality rates were 2% and 10%, resp.  DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment.  Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy.  A larger controlled trial is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHJhiSa1cirVg90H21EOLACvtfcHk0lhWFNmBTP0U1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyht7%252FL&md5=4a1a8b98ee7ef7f39ea5e445feb7aa75</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018027409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018027409%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DAbaza%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DArellano%26aufirst%3DM.%26aulast%3DKhaled%26aufirst%3DS.%2BK.%26aulast%3DPatnaik%26aufirst%3DM.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DSayar%26aufirst%3DH.%26aulast%3DTummala%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DManess-Harris%26aufirst%3DL.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DKaramlou%26aufirst%3DK.%26aulast%3DYacoub%26aufirst%3DA.%26aulast%3DGhalie%26aufirst%3DR.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DAtallah%26aufirst%3DE.%26atitle%3DPracinostat%2520plus%2520Azacitidine%2520in%2520Older%2520Patients%2520with%2520Newly%2520Diagnosed%2520Acute%2520Myeloid%2520Leukemia%253A%2520Results%2520of%2520a%2520Phase%25202%2520Study%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26spage%3D508%26epage%3D518%26doi%3D10.1182%2Fbloodadvances.2018027409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moufarrij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2241</span>, <span class="refDoi"> DOI: 10.3390/ijms20092241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20092241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFKisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=2241&author=D.+Banikauthor=S.+Moufarrijauthor=A.+Villagra&title=Immunoepigenetics+Combination+Therapies%3A+An+Overview+of+the+Role+of+HDACs+in+Cancer+Immunotherapy&doi=10.3390%2Fijms20092241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy</span></div><div class="casAuthors">Banik, Debarati; Moufarrij, Sara; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2241</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combating cancer, autoimmune, neurodegenerative, and infectious diseases.  The same has also encouraged the evaluation of multiple HDACi candidates in preclin. studies in cancer and other diseases as well as the FDA-approval towards clin. use for specific agents.  In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis.  We have also included a brief overview of the classification of HDACis as well as their various roles in physiol. and pathophysiol. scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer.  Given the crit. role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME.  We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clin. trials or show promising preclin. effects for future consideration.  Finally, we have included examples of ongoing trials for each of the above categories of HDACis as standalone agents or in combination with immunotherapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GmQhr5gjNLVg90H21EOLACvtfcHk0lhWFNmBTP0U1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFKisLY%253D&md5=c1f66bb1baecc85c323cd085de31c52e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3390%2Fijms20092241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20092241%26sid%3Dliteratum%253Aachs%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DMoufarrij%26aufirst%3DS.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DImmunoepigenetics%2520Combination%2520Therapies%253A%2520An%2520Overview%2520of%2520the%2520Role%2520of%2520HDACs%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D2241%26doi%3D10.3390%2Fijms20092241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosás-Umbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Riol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedeño, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moltó, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group">BCN02 Study Group</span> <span> </span><span class="NLM_article-title"><i>In Vivo</i> Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">418</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffimmu.2020.00418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32265913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=418&author=M.+Ros%C3%A1s-Umbertauthor=M.+Ruiz-Riolauthor=M.+A.+Fern%C3%A1ndezauthor=M.+Marszalekauthor=P.+Collauthor=C.+Manzardoauthor=S.+Cede%C3%B1oauthor=J.+M.+Mir%C3%B3author=B.+Clotetauthor=T.+Hankeauthor=J.+Molt%C3%B3author=B.+Motheauthor=C.+Branderauthor=BCN02+Study+Group&title=In+Vivo+Effects+of+Romidepsin+on+T-Cell+Activation%2C+Apoptosis+and+Function+in+the+BCN02+HIV-1+Kick%26Kill+Clinical+Trial&doi=10.3389%2Ffimmu.2020.00418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial</span></div><div class="casAuthors">Rosas-Umbert, Miriam; Ruiz-Riol, Marta; Fernandez, Marco A.; Marszalek, Marta; Coll, Pep; Manzardo, Christian; Cedeno, Samandhy; Miro, Jose M.; Clotet, Bonaventura; Hanke, Tomas; Molto, Jose; Mothe, Beatriz; Brander, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">418</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy.  However, in vitro expts. suggested that RMD could also impair T-cell functionality, particularly of activated T cells.  Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited.  In order to address whether the in vitro observations are replicated in vivo, we detd. the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clin. trial (NCT02616874).  BCN02 was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent.  Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells.  Although RMD reduced the no. of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8+ T cells was preserved over the RMD treatment.  These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRjmovg4g0LVg90H21EOLACvtfcHk0lhWFNmBTP0U1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7bJ&md5=38312233ee1075cefbb25afb71e0b1d7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00418%26sid%3Dliteratum%253Aachs%26aulast%3DRos%25C3%25A1s-Umbert%26aufirst%3DM.%26aulast%3DRuiz-Riol%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%2BA.%26aulast%3DMarszalek%26aufirst%3DM.%26aulast%3DColl%26aufirst%3DP.%26aulast%3DManzardo%26aufirst%3DC.%26aulast%3DCede%25C3%25B1o%26aufirst%3DS.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMolt%25C3%25B3%26aufirst%3DJ.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3D%26atitle%3DIn%2520Vivo%2520Effects%2520of%2520Romidepsin%2520on%2520T-Cell%2520Activation%252C%2520Apoptosis%2520and%2520Function%2520in%2520the%2520BCN02%2520HIV-1%2520Kick%2526Kill%2520Clinical%2520Trial%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D418%26doi%3D10.3389%2Ffimmu.2020.00418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: An Epigenetic Epiphany</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcmdc.201500394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1227-1241&author=A.+Ganesan&title=Multitarget+Drugs%3A+An+Epigenetic+Epiphany&doi=10.1002%2Fcmdc.201500394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drugs: an Epigenetic Epiphany</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1241</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epigenetics refers to changes in a biol. phenotype that are not due to an underlying change in genotype.  In eukaryotes, epigenetics involves a set of chem. modifications of the DNA and the histone proteins in nucleosomes.  These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to det. whether specific genes are expressed or silenced.  Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer.  This review summarizes the progress of epigenetic targets that have reached a clin. stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwdZM3u9Wbc7Vg90H21EOLACvtfcHk0lhNRpvCHqt95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D&md5=736284dc3f05db0032c9a304884f980d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500394%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMultitarget%2520Drugs%253A%2520An%2520Epigenetic%2520Epiphany%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1227%26epage%3D1241%26doi%3D10.1002%2Fcmdc.201500394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Two-Hit Wonders: The Expanding Universe of Multitargeting Epigenetic Agents</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32784072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKnsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=135-154&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Two-Hit+Wonders%3A+The+Expanding+Universe+of+Multitargeting+Epigenetic+Agents&doi=10.1016%2Fj.cbpa.2020.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Two-hit wonders: The expanding universe of multitargeting epigenetic agents</span></div><div class="casAuthors">de Lera, Angel R.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-154</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Multitargeting involves the application of mols. that are deliberately intended to bind to two or more unrelated cellular targets with high affinity.  In epigenetic chem. biol. and drug discovery, the rational design of multitargeting agents has evolved to a sophisticated level, and there are now five examples that have reached clin. trials.  This review covers recent developments in the field and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwQn-GXR3grVg90H21EOLACvtfcHk0lhNRpvCHqt95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKnsbvO&md5=b5383c9c221fbcb6dcf7483d98aa7b78</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTwo-Hit%2520Wonders%253A%2520The%2520Expanding%2520Universe%2520of%2520Multitargeting%2520Epigenetic%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154%26doi%3D10.1016%2Fj.cbpa.2020.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+Phase+I+Study+of+CUDC-101%2C+a+Multitarget+Inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+Combination+with+Chemoradiation+in+Patients+with+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0lhNRpvCHqt95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520CUDC-101%252C%2520a%2520Multitarget%2520Inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520Combination%2520with%2520Chemoradiation%2520in%2520Patients%2520with%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharavi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafeez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">CUDC-907 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC-Alterations: Results from an Expanded Phase I Trial</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1923</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.172882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3324%2Fhaematol.2017.172882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28860342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1923-1930&author=Y.+Okiauthor=K.+R.+Kellyauthor=I.+Flinnauthor=M.+R.+Patelauthor=R.+Gharaviauthor=A.+Maauthor=J.+Parkerauthor=A.+Hafeezauthor=D.+Tuckauthor=A.+Younes&title=CUDC-907+in+Relapsed%2FRefractory+Diffuse+Large+B-Cell+Lymphoma%2C+Including+Patients+with+MYC-Alterations%3A+Results+from+an+Expanded+Phase+I+Trial&doi=10.3324%2Fhaematol.2017.172882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial</span></div><div class="casAuthors">Oki, Yasuhiro; Kelly, Kevin R.; Flinn, Ian; Patel, Manish R.; Gharavi, Robert; Ma, Anna; Parker, Jefferson; Hafeez, Amir; Tuck, David; Younes, Anas</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1923-1930</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">CUDC-907 is a first-in-class, oral small mol. inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and γ) enzymes, with demonstrated anti-tumor activity in multiple pre-clin. models, including MYC-driven ones.  In this report, we present the safety and preliminary activity results of CUDC-907, with and without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with a particular focus on those with MYC-altered disease.  Thirty-seven DLBCL patients were enrolled, 14 with confirmed MYCaltered disease.  Twenty-five patients received monotherapy treatment, and 12 received the combination of CUDC-907 with rituximab.  CUDC- 907 monotherapy and combination demonstrated similar safety profiles consisting primarily of Grade 1/2 hematol. and gastrointestinal events.  The most frequently reported Grade ≥3 treatment-related events were thrombocytopenia, neutropenia, diarrhea, fatigue, and anemia.  Eleven responses (5 complete responses and 6 partial responses) were reported, for a response rate of 37% (11 out of 30) in evaluable patients [30% (11 out of 37) including all patients].  The objective response rate in evaluable MYC-altered DLBCL patients was 64% (7 out of 11; 4 complete responses and 3 partial responses), while it was 29% (2 out of 7) in MYC unaltered, and 17% (2 out of 12) in those with unknown MYC status.  Median duration of response was 11.2 mo overall; 13.6 mo in MYC-altered patients, 6.0 mo in MYC unaltered, and 7.8 mo in those with MYC status unknown.  The tolerable safety profile and encouraging evidence of durable anti-tumor activity, particularly in MYC-altered patients, support the continued development of CUDC- 907 in these populations of high unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypZUdcHYATLVg90H21EOLACvtfcHk0lh-d3kvl4YQqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrvF&md5=d171b5741d884db0e52b611b5de12e67</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.172882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.172882%26sid%3Dliteratum%253Aachs%26aulast%3DOki%26aufirst%3DY.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DGharavi%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DHafeez%26aufirst%3DA.%26aulast%3DTuck%26aufirst%3DD.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DCUDC-907%2520in%2520Relapsed%252FRefractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%252C%2520Including%2520Patients%2520with%2520MYC-Alterations%253A%2520Results%2520from%2520an%2520Expanded%2520Phase%2520I%2520Trial%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D1923%26epage%3D1930%26doi%3D10.3324%2Fhaematol.2017.172882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunst, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjær, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span> <span> </span><span class="NLM_article-title">Fimepinostat, a Novel Dual Inhibitor of HDAC and PI3K, Effectively Reverses HIV-1 Latency Ex Vivo without T Cell Activation</span>. <i>J. Virus Eradication</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S2055-6640(20)30042-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS2055-6640%2820%2930042-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31700655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsFCntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=133-137&author=J.+D.+Gunstauthor=K.+Kj%C3%A6rauthor=R.+Olesenauthor=T.+A.+Rasmussenauthor=L.+%C3%98stergaardauthor=P.+W.+Dentonauthor=O.+S.+S%C3%B8gaardauthor=M.+Tolstrup&title=Fimepinostat%2C+a+Novel+Dual+Inhibitor+of+HDAC+and+PI3K%2C+Effectively+Reverses+HIV-1+Latency+Ex+Vivo+without+T+Cell+Activation&doi=10.1016%2FS2055-6640%2820%2930042-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation</span></div><div class="casAuthors">Gunst Jesper D; Kjaer Kathrine; Olesen Rikke; Rasmussen Thomas A; Ostergaard Lars; Denton Paul W; Sogaard Ole S; Tolstrup Martin; Gunst Jesper D; Kjaer Kathrine; Olesen Rikke; Rasmussen Thomas A; Ostergaard Lars; Denton Paul W; Sogaard Ole S; Tolstrup Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virus eradication</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-137</span>
        ISSN:<span class="NLM_cas:issn">2055-6640</span>.
    </div><div class="casAbstract">Objectives:  To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term combination antiretroviral therapy (cART).  Methods:  Latently HIV-1-infected J-lat Tat-GFP and ACH-2 cell lines were stimulated with clinically relevant concentrations of fimepinostat using the HDAC inhibitors (HDACi) panobinostat and romidepsin for comparison.  Next, CD4+ T cells from donors living with HIV-1 on long-term cART were stimulated ex vivo and cell-associated unspliced HIV-1 RNA was measured to quantify changes in HIV-1 transcription.  Finally, the impact of fimepinostat on T cell activation (CD69 expression) and proliferation (Ki67 expression) was determined using peripheral blood mononuclear cells from uninfected donors.  Results:  We found fimepinostat to be a potent latency-reversing agent.  This was true in two latently infected cell lines as well as ex vivo in CD4+ T cells isolated from donors living with HIV-1.  Relative to therapeutic dosing levels, fimepinostat showed latency-reversing potential comparable to romidepsin, which is the most potent HDACi tested in HIV-1 cure-related trials.  Interestingly, in contrast to romidepsin, fimepinostat stimulation resulted in decreased T cell activation and had no negative impact on T cell proliferation.  Conclusions:  At therapeutic concentration, the dual HDAC and PI3K inhibitor fimepinostat was a potent HIV-1 latency-reversing agent and it did not induce T cell activation and proliferation.  The potential of fimepinostat as a latency-reversing agent warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrn5zMD5IQFOb6AVA-44PTfW6udTcc2eYbsM5nVa7qfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsFCntg%253D%253D&md5=f6975baff3acbff2625d591b285f933d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS2055-6640%2820%2930042-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2055-6640%252820%252930042-X%26sid%3Dliteratum%253Aachs%26aulast%3DGunst%26aufirst%3DJ.%2BD.%26aulast%3DKj%25C3%25A6r%26aufirst%3DK.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3D%25C3%2598stergaard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DS%25C3%25B8gaard%26aufirst%3DO.%2BS.%26aulast%3DTolstrup%26aufirst%3DM.%26atitle%3DFimepinostat%252C%2520a%2520Novel%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520Effectively%2520Reverses%2520HIV-1%2520Latency%2520Ex%2520Vivo%2520without%2520T%2520Cell%2520Activation%26jtitle%3DJ.%2520Virus%2520Eradication%26date%3D2019%26volume%3D5%26spage%3D133%26epage%3D137%26doi%3D10.1016%2FS2055-6640%2820%2930042-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wobser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glunz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butelmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebeler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houben, R.</span></span> <span> </span><span class="NLM_article-title">Elucidating the Mechanism of Action of Domatinostat (4SC-202) in Cutaneous T Cell Lymphoma Cells</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/s13045-019-0719-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-019-0719-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30885250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3cblsFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=30&author=M.+Wobserauthor=A.+Weberauthor=A.+Glunzauthor=S.+Tauchauthor=K.+Seitzauthor=T.+Butelmannauthor=S.+Hesbacherauthor=M.+Goebelerauthor=R.+Bartzauthor=H.+Kohlhofauthor=D.+Schramaauthor=R.+Houben&title=Elucidating+the+Mechanism+of+Action+of+Domatinostat+%284SC-202%29+in+Cutaneous+T+Cell+Lymphoma+Cells&doi=10.1186%2Fs13045-019-0719-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells</span></div><div class="casAuthors">Wobser Marion; Weber Alexandra; Glunz Amelie; Tauch Saskia; Seitz Kristina; Butelmann Tobias; Hesbacher Sonja; Goebeler Matthias; Schrama David; Houben Roland; Bartz Rene; Kohlhof Hella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL).  However, there is a need for further improvement of this therapeutic approach.  Here, we compared the mode of action of romidepsin (FK228), an established class I histone deacetylase inhibitor, and domatinostat (4SC-202), a novel inhibitor of class I HDACs, which has been reported to also target the lysine-specific histone demethylase 1A (LSD1).  METHODS:  We performed MTS assays and flow cytometric analyses of propidium iodide or annexin V-stained cells to assess drug impact on cellular proliferation, cell cycle distribution, and survival.  Histone acetylation and methylation as well as caspase activation was analyzed by immunoblot.  Gene expression analysis was performed using NanosString technology.  Knockdown and knockout of LSD1 was achieved with shRNA and CRISPR/Cas9, respectively, while the CRISPR/Cas9 synergistic activation mediator system was used to induce expression of endogenous HDACs and LSD1.  Furthermore, time-lapse fluorescence microscopy and an in vitro tubulin polymerization assay were applied.  RESULTS:  While FK228 as well as 4SC-202 potently induced cell death in six different CTCL cell lines, only in the case of 4SC-202 death was preceded by an accumulation of cells in the G2/M phase of the cell cycle.  Surprisingly, apoptosis and accumulation of cells with double DNA content occurred already at 4SC-202 concentrations hardly affecting histone acetylation and methylation, and provoking significantly less changes in gene expression compared to biologically equivalent doses of FK228.  Indeed, we provide evidence that the 4SC-202-induced G2/M arrest in CTCL cells is independent of de novo transcription.  Furthermore, neither enforced expression of HDAC1 nor knockdown or knockout of LSD1 affected the 4SC-202-induced effects.  Since time-lapse microscopy revealed that 4SC-202 could affect mitotic spindle formation, we performed an in vitro tubulin polymerization assay revealing that 4SC-202 can directly inhibit microtubule formation.  CONCLUSIONS:  We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells.  The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression.  Indeed, the compound is also a potent microtubule-destabilizing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOPg7NgwlRXz0O18WR3iAofW6udTcc2eYbsM5nVa7qfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cblsFWgtA%253D%253D&md5=a62322dcc37b502aabda2a832a0d08a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0719-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0719-4%26sid%3Dliteratum%253Aachs%26aulast%3DWobser%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DGlunz%26aufirst%3DA.%26aulast%3DTauch%26aufirst%3DS.%26aulast%3DSeitz%26aufirst%3DK.%26aulast%3DButelmann%26aufirst%3DT.%26aulast%3DHesbacher%26aufirst%3DS.%26aulast%3DGoebeler%26aufirst%3DM.%26aulast%3DBartz%26aufirst%3DR.%26aulast%3DKohlhof%26aufirst%3DH.%26aulast%3DSchrama%26aufirst%3DD.%26aulast%3DHouben%26aufirst%3DR.%26atitle%3DElucidating%2520the%2520Mechanism%2520of%2520Action%2520of%2520Domatinostat%2520%25284SC-202%2529%2520in%2520Cutaneous%2520T%2520Cell%2520Lymphoma%2520Cells%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D30%26doi%3D10.1186%2Fs13045-019-0719-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitir, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maolanon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaço, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fristrup, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Chemical Editing of Macrocyclic Natural Products and Kinetic Profiling Reveal Slow, Tight-Binding Histone Deacetylase Inhibitors with Picomolar Affinities</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5134</span>– <span class="NLM_lpage">5146</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWhtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5134-5146&author=B.+Kitirauthor=A.+R.+Maolanonauthor=R.+G.+Ohmauthor=A.+R.+Cola%C3%A7oauthor=P.+Fristrupauthor=A.+S.+Madsenauthor=C.+A.+Olsen&title=Chemical+Editing+of+Macrocyclic+Natural+Products+and+Kinetic+Profiling+Reveal+Slow%2C+Tight-Binding+Histone+Deacetylase+Inhibitors+with+Picomolar+Affinities&doi=10.1021%2Facs.biochem.7b00725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities</span></div><div class="casAuthors">Kitir, Betul; Maolanon, Alex R.; Ohm, Ragnhild G.; Colaco, Ana R.; Fristrup, Peter; Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5134-5146</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are validated targets for treatment of certain cancer types and play numerous regulatory roles in biol., ranging from epigenetics to metab.  Small mols. are highly important as tool compds. for probing these mechanisms as well as for the development of new medicines.  Therefore, detailed mechanistic information and precise characterization of the chem. probes used to investigate the effects of HDAC enzymes are vital.  We interrogated Nature's arsenal of macrocyclic nonribosomal peptide HDAC inhibitors by chem. synthesis and evaluation of more than 30 natural products and analogs.  This furnished surprising trends in binding affinities for the various macrocycles, which were then exploited for the design of highly potent class I and IIb HDAC inhibitors.  Furthermore, thorough kinetic investigation revealed unexpected inhibitory mechanisms of important tool compds. as well as the approved drug Istodax (romidepsin).  This work provides novel inhibitors with varying potencies, selectivity profiles, and mechanisms of inhibition and, importantly, affords insight into known tool compds. that will improve the interpretation of their effects in biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0CeWzCSTmbVg90H21EOLACvtfcHk0li6IIdd-S__Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWhtrvO&md5=614f5678846c7ad31987012cc83a7f4b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00725%26sid%3Dliteratum%253Aachs%26aulast%3DKitir%26aufirst%3DB.%26aulast%3DMaolanon%26aufirst%3DA.%2BR.%26aulast%3DOhm%26aufirst%3DR.%2BG.%26aulast%3DCola%25C3%25A7o%26aufirst%3DA.%2BR.%26aulast%3DFristrup%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DChemical%2520Editing%2520of%2520Macrocyclic%2520Natural%2520Products%2520and%2520Kinetic%2520Profiling%2520Reveal%2520Slow%252C%2520Tight-Binding%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Picomolar%2520Affinities%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D5134%26epage%3D5146%26doi%3D10.1021%2Facs.biochem.7b00725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRiner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancost, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span> <span> </span><span class="NLM_article-title">Human HDAC Isoform Selectivity Achieved via Exploitation of the Acetate Release Channel with Structurally Unique Small Molecule Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4626</span>– <span class="NLM_lpage">4634</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2011.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=21723733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2ju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4626-4634&author=L.+Whiteheadauthor=M.+R.+Doblerauthor=B.+Radetichauthor=Y.+Zhuauthor=P.+W.+Atadjaauthor=T.+Claiborneauthor=J.+E.+Grobauthor=A.+McRinerauthor=M.+R.+Pancostauthor=A.+Patnaikauthor=W.+Shaoauthor=M.+Shultzauthor=R.+Tichkuleauthor=R.+A.+Tommasiauthor=B.+Vashauthor=P.+Wangauthor=T.+Stams&title=Human+HDAC+Isoform+Selectivity+Achieved+via+Exploitation+of+the+Acetate+Release+Channel+with+Structurally+Unique+Small+Molecule+Inhibitors&doi=10.1016%2Fj.bmc.2011.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors</span></div><div class="casAuthors">Whitehead, Lewis; Dobler, Markus R.; Radetich, Branko; Zhu, Yanyi; Atadja, Peter W.; Claiborne, Tavina; Grob, Jonathan E.; McRiner, Andrew; Pancost, Margaret R.; Patnaik, Anup; Shao, Wenlin; Shultz, Michael; Tichkule, Ritesh; Tommasi, Ruben A.; Vash, Brian; Wang, Ping; Stams, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4626-4634</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report the discovery of a family of novel yet simple, amino-acid derived class I HDAC inhibitors that demonstrate isoform selectivity via access to the internal acetate release channel.  Isoform selectivity criteria is discussed on the basis of X-ray crystallog. and mol. modeling of these novel inhibitors bound to HDAC8, potentially revealing insights into the mechanism of enzymic function through novel structural features revealed at the at. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgV7MIGevIxrVg90H21EOLACvtfcHk0li6IIdd-S__Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2ju7w%253D&md5=c252ec223e909e92ec165f60a1a33b16</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DWhitehead%26aufirst%3DL.%26aulast%3DDobler%26aufirst%3DM.%2BR.%26aulast%3DRadetich%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DAtadja%26aufirst%3DP.%2BW.%26aulast%3DClaiborne%26aufirst%3DT.%26aulast%3DGrob%26aufirst%3DJ.%2BE.%26aulast%3DMcRiner%26aufirst%3DA.%26aulast%3DPancost%26aufirst%3DM.%2BR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DShultz%26aufirst%3DM.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTommasi%26aufirst%3DR.%2BA.%26aulast%3DVash%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStams%26aufirst%3DT.%26atitle%3DHuman%2520HDAC%2520Isoform%2520Selectivity%2520Achieved%2520via%2520Exploitation%2520of%2520the%2520Acetate%2520Release%2520Channel%2520with%2520Structurally%2520Unique%2520Small%2520Molecule%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4626%26epage%3D4634%26doi%3D10.1016%2Fj.bmc.2011.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidoud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoine, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemercier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1772</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1021/jm301355j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301355j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1772-1776&author=F.+F.+Wagnerauthor=D.+E.+Olsonauthor=J.+P.+Galeauthor=T.+Kayaauthor=M.+We%C3%AFwerauthor=N.+Aidoudauthor=M.+Thomasauthor=E.+L.+Davoineauthor=B.+C.+Lemercierauthor=Y.-L.+Zhangauthor=E.+B.+Holson&title=Potent+and+Selective+Inhibition+of+Histone+Deacetylase+6+%28HDAC6%29+Does+Not+Require+a+Surface-Binding+Motif&doi=10.1021%2Fjm301355j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span></div><div class="casAuthors">Wagner, Florence F.; Olson, David E.; Gale, Jennifer P.; Kaya, Taner; Weiwer, Michel; Aidoud, Nadia; Thomas, Meryl; Davoine, Emeline L.; Lemercier, Berenice C.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).  Several inhibitors, including compd. 14 (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif.  The binding of these highly efficient ligands for HDAC6 is rationalized via structure-activity relationships.  These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp84k2hCSqrAbVg90H21EOLACvtfcHk0li6IIdd-S__Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D&md5=eee6262f17350f3f7c411ab37840e3fe</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm301355j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301355j%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DAidoud%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDavoine%26aufirst%3DE.%2BL.%26aulast%3DLemercier%26aufirst%3DB.%2BC.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Does%2520Not%2520Require%2520a%2520Surface-Binding%2520Motif%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1772%26epage%3D1776%26doi%3D10.1021%2Fjm301355j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span> <span> </span><span class="NLM_article-title">Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold That Selectively Inhibit Class I Histone Deacetylases</span>. <i>Chem. Biol. (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.chembiol.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25699604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=273-284&author=Y.+Wangauthor=R.+L.+Stoweauthor=C.+E.+Pinelloauthor=G.+Tianauthor=F.+Madouxauthor=D.+Liauthor=L.+Y.+Zhaoauthor=J.-L.+Liauthor=Y.+Wangauthor=Y.+Wangauthor=H.+Maauthor=P.+Hodderauthor=W.+R.+Roushauthor=D.+Liao&title=Identification+of+Histone+Deacetylase+Inhibitors+with+Benzoylhydrazide+Scaffold+That+Selectively+Inhibit+Class+I+Histone+Deacetylases&doi=10.1016%2Fj.chembiol.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Yunfei; Stowe, Ryan L.; Pinello, Christie E.; Tian, Guimei; Madoux, Franck; Li, Dawei; Zhao, Lisa Y.; Li, Jian-Liang; Wang, Yuren; Wang, Yuan; Ma, Haiching; Hodder, Peter; Roush, William R.; Liao, Daiqing</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-284</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases (HDACi) hold considerable therapeutic promise as clin. anticancer therapies.  However, currently known HDACi exhibit limited isoform specificity, off-target activity, and undesirable pharmaceutical properties.  Thus, HDACi with new chemotypes are needed to overcome these limitations.  Here, we identify a class of HDACi with a previously undescribed benzoylhydrazide scaffold that is selective for the class I HDACs.  These compds. are competitive inhibitors with a fast-on/slow-off HDAC-binding mechanism.  We show that the lead compd., UF010, inhibits cancer cell proliferation via class I HDAC inhibition.  This causes global changes in protein acetylation and gene expression, resulting in activation of tumor suppressor pathways and concurrent inhibition of several oncogenic pathways.  The isotype selectivity coupled with interesting biol. activities in suppressing tumor cell proliferation support further preclin. development of the UF010 class of compds. for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3GHZ2LiwvbVg90H21EOLACvtfcHk0lgsyv75K9Yl2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlWjsrg%253D&md5=b4e40e24ebe7e1ee7f6f1dacefaa5a39</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DStowe%26aufirst%3DR.%2BL.%26aulast%3DPinello%26aufirst%3DC.%2BE.%26aulast%3DTian%26aufirst%3DG.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DL.%2BY.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DLiao%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Benzoylhydrazide%2520Scaffold%2520That%2520Selectively%2520Inhibit%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DChem.%2520Biol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D22%26spage%3D273%26epage%3D284%26doi%3D10.1016%2Fj.chembiol.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Almes, F.-J.</span></span> <span> </span><span class="NLM_article-title">Perfluorinated Hydroxamic Acids Are Potent and Selective Inhibitors of HDAC-like Enzymes from <i>Pseudomonas aeruginosa</i></span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2017.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28259626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1OrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1508-1512&author=C.+Meynersauthor=B.+Wolffauthor=A.+Kleinschekauthor=A.+Kr%C3%A4merauthor=F.-J.+Meyer-Almes&title=Perfluorinated+Hydroxamic+Acids+Are+Potent+and+Selective+Inhibitors+of+HDAC-like+Enzymes+from+Pseudomonas+aeruginosa&doi=10.1016%2Fj.bmcl.2017.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa</span></div><div class="casAuthors">Meyners, Christian; Wolff, Benjamin; Kleinschek, Alexander; Kraemer, Andreas; Meyer-Almes, Franz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1508-1512</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of perfluorinated suberoylanilide hydroxamic acid (PFSAHA) derivs. was prepd. and profiled against a panel of human and bacterial members of the Histone deacetylase (HDAC) family.  Some of the active substances show nanomolar inhibitory activity and several hundred fold selectivity for the HDAC like enzyme PA3774 from P. aeruginosa.  The extraordinary selectivity against human HDACs results from the distinct oligomeric state of PA3774 which consists of two head-to-head dimers.  The binding pocket is defined by the surface of both opposite monomers confining the access of ligands to the active site.  In addn., the arom. cap group of PFSAHA undergoes an edge-to-face arom. interaction with phenylalanine from the opposite monomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyU5sZhX7jcLVg90H21EOLACvtfcHk0lgsyv75K9Yl2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1OrsLo%253D&md5=514752697eda40f813ce46a14ac5f4ed</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DMeyners%26aufirst%3DC.%26aulast%3DWolff%26aufirst%3DB.%26aulast%3DKleinschek%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DMeyer-Almes%26aufirst%3DF.-J.%26atitle%3DPerfluorinated%2520Hydroxamic%2520Acids%2520Are%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC-like%2520Enzymes%2520from%2520Pseudomonas%2520aeruginosa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1508%26epage%3D1512%26doi%3D10.1016%2Fj.bmcl.2017.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänsch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopranovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wössner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschhöfer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner-Weiß, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Almes, F.-J.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibition of Histone Deacetylase 8 by 3,4-Dihydro-2H-Pyrimido[1,2-c][1,3]Benzothiazin-6-Imine</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2019.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bbagen.2019.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30611847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1OktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2019&pages=577-585&author=M.+Muthauthor=N.+J%C3%A4nschauthor=A.+Kopranovicauthor=A.+Kr%C3%A4merauthor=N.+W%C3%B6ssnerauthor=M.+Jungauthor=F.+Kirschh%C3%B6ferauthor=G.+Brenner-Wei%C3%9Fauthor=F.-J.+Meyer-Almes&title=Covalent+Inhibition+of+Histone+Deacetylase+8+by+3%2C4-Dihydro-2H-Pyrimido%5B1%2C2-c%5D%5B1%2C3%5DBenzothiazin-6-Imine&doi=10.1016%2Fj.bbagen.2019.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine</span></div><div class="casAuthors">Muth, Marius; Jaensch, Niklas; Kopranovic, Aleksandra; Kraemer, Andreas; Woessner, Nathalie; Jung, Manfred; Kirschhoefer, Frank; Brenner-Weiss, Gerald; Meyer-Almes, Franz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC8 is an established target for T-cell lymphoma and childhood neuroblastoma.  Benzothiazine-imines are promising HDAC8 inhibitors with unknown binding mechanism lacking a usual zinc binding group.  In this study high-resoln. and quant. HPLC-coupled ESI-MS/MS techniques are combined with crystal structure detn. and a variety of biochem. and computational methods to elucidate the reaction mechanism between benzothiazine-imine 1 and HDAC8.  (1) 1 Is a covalent inhibitor of HDAC8; (2) inhibition is reversible in the presence of reducing agents; (3) C153 in the active site and C102 are involved in the inhibition mechanism; (4) 1 modifies various cysteines in HDAC8 forming either thiocyanates or mixed disulfides with 3; (5) 1 and 5 dock in close proximity to C153 within the active site.  This is supposed to accelerate covalent inactivation particularly in HDAC8 and suggested as major determinant for the obsd. nanomolar potency and selectivity of 1.1 and its analogs are interesting model compds. but unsuitable for therapeutic treatment due to their high unselective reactivity towards thiol groups.  However, the postulated preceding non-covalent binding mode of 1 opens a door to optimized next generation compds. that combine potent and selective non-covalent recognition with low reactivity towards C153 at the active site of HDAC8.1 represents a completely new class of inhibitors for HDAC8.  Initial non-covalent interaction at the bottom of the active site is suggested to be the key for its selectivity.  Further optimization of non-covalent interaction and thiol-reactivity provides opportunities to develop therapeutic useful covalent HDAC8 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVvW1gAYv4RrVg90H21EOLACvtfcHk0lgsyv75K9Yl2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1OktA%253D%253D&md5=5ee3a572b054b4c461828c04c52671d6</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2019.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2019.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nsch%26aufirst%3DN.%26aulast%3DKopranovic%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DW%25C3%25B6ssner%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DKirschh%25C3%25B6fer%26aufirst%3DF.%26aulast%3DBrenner-Wei%25C3%259F%26aufirst%3DG.%26aulast%3DMeyer-Almes%26aufirst%3DF.-J.%26atitle%3DCovalent%2520Inhibition%2520of%2520Histone%2520Deacetylase%25208%2520by%25203%252C4-Dihydro-2H-Pyrimido%255B1%252C2-c%255D%255B1%252C3%255DBenzothiazin-6-Imine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2019%26volume%3D1863%26spage%3D577%26epage%3D585%26doi%3D10.1016%2Fj.bbagen.2019.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachhap, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leanderson, T.</span></span> <span> </span><span class="NLM_article-title">Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F0008-5472.CAN-12-2730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23149916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1386-1399&author=J.+T.+Isaacsauthor=L.+Antonyauthor=S.+L.+Dalrympleauthor=W.+N.+Brennenauthor=S.+Gerberauthor=H.+Hammersauthor=M.+Wissingauthor=S.+Kachhapauthor=J.+Luoauthor=L.+Xingauthor=P.+Bj%C3%B6rkauthor=A.+Olssonauthor=A.+Bj%C3%B6rkauthor=T.+Leanderson&title=Tasquinimod+Is+an+Allosteric+Modulator+of+HDAC4+Survival+Signaling+within+the+Compromised+Cancer+Microenvironment&doi=10.1158%2F0008-5472.CAN-12-2730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment</span></div><div class="casAuthors">Isaacs, John T.; Antony, Lizamma; Dalrymple, Susan L.; Brennen, W. Nathaniel; Gerber, Stephanie; Hammers, Hans; Wissing, Michel; Kachhap, Sushant; Luo, Jun; Xing, Li; Bjoerk, Per; Olsson, Anders; Bjoerk, Anders; Leanderson, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1386-1399</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings define the mechanism of action of an antiangiogenic drug currently in phase III trials and suggest how to leverage its efficacy in combination with other drugs that target the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzLRrQMEPB-bVg90H21EOLACvtfcHk0lhHBTty6TpMjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wks7o%253D&md5=8757c850001639d461b163e4852b802f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2730%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DAntony%26aufirst%3DL.%26aulast%3DDalrymple%26aufirst%3DS.%2BL.%26aulast%3DBrennen%26aufirst%3DW.%2BN.%26aulast%3DGerber%26aufirst%3DS.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DWissing%26aufirst%3DM.%26aulast%3DKachhap%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DP.%26aulast%3DOlsson%26aufirst%3DA.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DA.%26aulast%3DLeanderson%26aufirst%3DT.%26atitle%3DTasquinimod%2520Is%2520an%2520Allosteric%2520Modulator%2520of%2520HDAC4%2520Survival%2520Signaling%2520within%2520the%2520Compromised%2520Cancer%2520Microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D1386%26epage%3D1399%26doi%3D10.1158%2F0008-5472.CAN-12-2730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suguro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC4 Regulates Vascular Inflammation via Activation of Autophagy</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvy051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1093%2Fcvr%2Fcvy051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29529137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslSjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2018&pages=1016-1028&author=D.+Yangauthor=C.+Xiaoauthor=F.+Longauthor=Z.+Suauthor=W.+Jiaauthor=M.+Qinauthor=M.+Huangauthor=W.+Wuauthor=R.+Suguroauthor=X.+Liuauthor=Y.+Zhu&title=HDAC4+Regulates+Vascular+Inflammation+via+Activation+of+Autophagy&doi=10.1093%2Fcvr%2Fcvy051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC4 regulates vascular inflammation via activation of autophagy</span></div><div class="casAuthors">Yang, Di; Xiao, ChenXi; Long, Fen; Su, ZhengHua; Jia, WanWan; Qin, Ming; Huang, MengWei; Wu, WeiJun; Suguro, Rinkiko; Liu, XinHua; Zhu, YiZhun</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1016-1028</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">1755-3245</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Angiotensin II (Ang II) causes vascular inflammation, leading to vascular endothelial cell dysfunction, and is assocd. with the development of cardiovascular diseases.  Therefore, interventions in inflammation may contribute to the redn. of cardiovascular diseases.  Here, we aim to demonstrate that HDAC4, one of class IIa family histone de-acetylases (HDACs) members, promotes autophagy-dependent vascular inflammation.  Methods and results: By loss-of-function approaches, our study provides the first evidence that HDAC4 mediates Ang II-induced vascular inflammation in vitro and in vivo.  In response to the Ang II, HDAC4 expression is up-regulated rapidly, with increased autophagic flux and inflammatory mediators in vascular endothelial cells (VECs).  In turn, HDAC4 deficiency suppresses activation of autophagy, leading to reduced inflammation in Ang II-induced VECs.  Consistently, using autophagy inhibitor or silencing LC3-II also alleviates vascular inflammation.  Furthermore, HDAC4 regulates autophagy via facilitating transcription factor forkhead box O3a (FoxO3a) de-acetylation, thereby to increase its transcriptional activity.  Loss of HDAC4 in VECs results in inhibition of FoxO3a de-acetylation to block its transcriptional activity, leading to downregulation of the downstream FoxO3a target, and hence reduces autophagy and vascular inflammation.  FoxO3a silencing using siRNA approach significantly inhibits activation of autophagy.  Finally, knockdown of HDAC4 in Ang II-infused mouse models ameliorates vascular inflammation, suggesting that inhibitor of HDAC4 may be potential therapeutics for vascular diseases assocd. with inflammation.  Conclusions: These results suggest that HDAC4-mediated FoxO3a acetylation regulates Ang II-induced autophagy activation, which in turn plays an essential role in causing vascular inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJamMJuSWVDLVg90H21EOLACvtfcHk0lhHBTty6TpMjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslSjtr8%253D&md5=40497be6174507e76e7dc47669f2c322</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvy051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvy051%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DC.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DSuguro%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DHDAC4%2520Regulates%2520Vascular%2520Inflammation%2520via%2520Activation%2520of%2520Autophagy%26jtitle%3DCardiovasc.%2520Res.%26date%3D2018%26volume%3D114%26spage%3D1016%26epage%3D1028%26doi%3D10.1093%2Fcvr%2Fcvy051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1725470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F13543776.2020.1725470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32008402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=263-274&author=C.+Zhaoauthor=H.+Dongauthor=Q.+Xuauthor=Y.+Zhang&title=Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Cancer%3A+A+Patent+Review+%282017-Present%29&doi=10.1080%2F13543776.2020.1725470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)</span></div><div class="casAuthors">Zhao, Chunlong; Dong, Hang; Xu, Qifu; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.  This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019.  HDACs are important epigenetic targets and HDAC inhibitors have become important biol. active compds. for the treatment of cancers.  Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors.  Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid.  Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alc. use disorder (AUD), neurol. disorders, age-related diseases, and so forth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdA-S5sLkahbVg90H21EOLACvtfcHk0lhHBTty6TpMjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D&md5=8c3d1f76892b3d33fb6b41d22d561e96</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Cancer%253A%2520A%2520Patent%2520Review%2520%25282017-Present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D263%26epage%3D274%26doi%3D10.1080%2F13543776.2020.1725470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">537</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffphar.2020.00537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32390854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKkurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=537&author=S.+Shuklaauthor=B.+L.+Tekwani&title=Histone+Deacetylases+Inhibitors+in+Neurodegenerative+Diseases%2C+Neuroprotection+and+Neuronal+Differentiation&doi=10.3389%2Ffphar.2020.00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitors in neurodegenerative diseases,neuroprotection and neuronal differentiation</span></div><div class="casAuthors">Shukla, Surabhi; Tekwani, Babu L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">537</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Histone deacetylases (HADC) are the enzymes that remove acetyl group from lysine residue of histones and non-histone proteins and regulate the process of transcription by binding to transcription factors and regulating fundamental cellular process such as cellular proliferation, differentiation and development.  In neurodegenerative diseases, the histone acetylation homeostasis is greatly impaired, shifting towards a state of hypoacetylation.  The histone hyperacetylation produced by direct inhibition of HDACs leads to neuroprotective actions.  This review attempts to elaborate on role of small mol. inhibitors of HDACs on neuronal differentiation and throws light on the potential of HDAC inhibitors as therapeutic agents for treatment of neurodegenerative diseases.  The role of HDACs in neuronal cellular and disease models and their modulation with HDAC inhibitors are also discussed.  Significance of these HDAC inhibitors has been reviewed on the process of neuronal differentiation, neurite outgrowth and neuroprotection regarding their potential therapeutic application for treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSm-R2zDO-HLVg90H21EOLACvtfcHk0li9WAW16wW0ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKkurnI&md5=c5b86039e4458e70c2e481b9133d46d2</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00537%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26atitle%3DHistone%2520Deacetylases%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%252C%2520Neuroprotection%2520and%2520Neuronal%2520Differentiation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D537%26doi%3D10.3389%2Ffphar.2020.00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwinderman, M. R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Weerd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">Targeting HDAC Complexes in Asthma and COPD</span>. <i>Epigenomes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.3390/epigenomes3030019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fepigenomes3030019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=19&author=M.+R.+H.+Zwindermanauthor=S.+de+Weerdauthor=F.+J.+Dekker&title=Targeting+HDAC+Complexes+in+Asthma+and+COPD&doi=10.3390%2Fepigenomes3030019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HDAC complexes in asthma and COPD</span></div><div class="casAuthors">Zwinderman, Martijn R. H.; de Weerd, Sander; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">EPIGD8</span>;
        ISSN:<span class="NLM_cas:issn">2075-4655</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Around three million patients die due to airway inflammatory diseases each year.  The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD).  Therefore, new therapies are urgently needed.  Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation.  Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD.  The diverse set of selective and non-selective HDAC inhibitors used in pre-clin. models of airway inflammation show promising results, but several challenges still need to be overcome.  One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes.  Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjwu9X9DD_LVg90H21EOLACvtfcHk0li9WAW16wW0ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFyr&md5=797188345106298228cf9cd061721ff3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3390%2Fepigenomes3030019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fepigenomes3030019%26sid%3Dliteratum%253Aachs%26aulast%3DZwinderman%26aufirst%3DM.%2BR.%2BH.%26aulast%3Dde%2BWeerd%26aufirst%3DS.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DTargeting%2520HDAC%2520Complexes%2520in%2520Asthma%2520and%2520COPD%26jtitle%3DEpigenomes%26date%3D2019%26volume%3D3%26spage%3D19%26doi%3D10.3390%2Fepigenomes3030019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiser, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Function in CD4+ T Cells</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1038/s41577-018-0037-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41577-018-0037-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30022149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlClsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=617-634&author=W.+Ellmeierauthor=C.+Seiser&title=Histone+Deacetylase+Function+in+CD4%2B+T+Cells&doi=10.1038%2Fs41577-018-0037-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase function in CD4+ T cells</span></div><div class="casAuthors">Ellmeier, Wilfried; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-634</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The differentiation of T helper cell subsets and their acquisition of effector functions are accompanied by changes in gene expression programs, which in part are regulated and maintained by epigenetic processes.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are key epigenetic regulators that function by mediating dynamic changes in the acetylation of histones at lysine residues.  In addn., many non-histone proteins are also acetylated, and reversible acetylation affects their functional properties, demonstrating that HDACs mediate effects beyond the epigenetic regulation of gene expression.  In this review, we discuss studies revealing that HDACs are key regulators of CD4+ T cell-mediated immunity in mice and humans and that HDACs are promising targets in T cell-mediated immune diseases.  Finally, we discuss unanswered questions and future research directions to promote the concept that isoform-selective HDAC inhibitors might broaden the clin. application of HDAC inhibitors beyond their current use in certain types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg8hA-jOikkLVg90H21EOLACvtfcHk0li9WAW16wW0ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlClsLvI&md5=bf25f2055c9eebefb78a63b1d8b6f382</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41577-018-0037-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-018-0037-z%26sid%3Dliteratum%253Aachs%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DSeiser%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%2520Function%2520in%2520CD4%252B%2520T%2520Cells%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D617%26epage%3D634%26doi%3D10.1038%2Fs41577-018-0037-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khullar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandhwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, A.</span></span> <span> </span><span class="NLM_article-title">HDAC in Obesity: A Critical Insight</span>. <i>Obesity Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">100212</span>, <span class="refDoi"> DOI: 10.1016/j.obmed.2020.100212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.obmed.2020.100212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=100212&author=P.+Nijhawanauthor=T.+Behlauthor=G.+Khullarauthor=G.+Palauthor=M.+Kandhwalauthor=A.+Goyal&title=HDAC+in+Obesity%3A+A+Critical+Insight&doi=10.1016%2Fj.obmed.2020.100212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.obmed.2020.100212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.obmed.2020.100212%26sid%3Dliteratum%253Aachs%26aulast%3DNijhawan%26aufirst%3DP.%26aulast%3DBehl%26aufirst%3DT.%26aulast%3DKhullar%26aufirst%3DG.%26aulast%3DPal%26aufirst%3DG.%26aulast%3DKandhwal%26aufirst%3DM.%26aulast%3DGoyal%26aufirst%3DA.%26atitle%3DHDAC%2520in%2520Obesity%253A%2520A%2520Critical%2520Insight%26jtitle%3DObesity%2520Med.%26date%3D2020%26volume%3D18%26spage%3D100212%26doi%3D10.1016%2Fj.obmed.2020.100212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, Y. Y.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors as Antifibrotic Drugs in Cardiac and Pulmonary Fibrosis</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2040622319862697</span>, <span class="refDoi"> DOI: 10.1177/2040622319862697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1177%2F2040622319862697" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2040622319862697&author=X.+Lyuauthor=M.+Huauthor=J.+Pengauthor=X.+Zhangauthor=Y.+Y.+Sanders&title=HDAC+Inhibitors+as+Antifibrotic+Drugs+in+Cardiac+and+Pulmonary+Fibrosis&doi=10.1177%2F2040622319862697"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1177%2F2040622319862697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622319862697%26sid%3Dliteratum%253Aachs%26aulast%3DLyu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DY.%2BY.%26atitle%3DHDAC%2520Inhibitors%2520as%2520Antifibrotic%2520Drugs%2520in%2520Cardiac%2520and%2520Pulmonary%2520Fibrosis%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2019%26volume%3D10%26spage%3D2040622319862697%26doi%3D10.1177%2F2040622319862697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozdarska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanblanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naassila, M.</span></span> <span> </span><span class="NLM_article-title">Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00115</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00115" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OmsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1745-1766&author=E.+Bourguetauthor=K.+Ozdarskaauthor=G.+Moroyauthor=J.+Jeanblancauthor=M.+Naassila&title=Class+I+HDAC+Inhibitors%3A+Potential+New+Epigenetic+Therapeutics+for+Alcohol+Use+Disorder+%28AUD%29&doi=10.1021%2Facs.jmedchem.7b00115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)</span></div><div class="casAuthors">Bourguet, Erika; Ozdarska, Katarzyna; Moroy, Gautier; Jeanblanc, Jerome; Naassila, Mickael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1745-1766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alc. use disorder (AUD) represents a serious public health issue, and discovery of new therapies is a pressing necessity.  Alc. exposure has been widely demonstrated to modulate epigenetic mechanisms, such as histone acetylation/deacetylation balance, in part via histone deacetylase (HDAC) inhibition.  Epigenetic factors have been suggested to play a key role in AUD.  To date, 18 different mammalian HDAC isoforms have been identified, and these have been divided into four classes.  Since recent studies have suggested that both epigenetic mechanisms underlying AUD and the efficacy of HDAC inhibitors (HDACIs) in different animal models of AUD may involve class I HDACs, the authors herein report the development of class I HDACIs, including information regarding their structure, potency, and selectivity.  More effort is required to improve the selectivity, pharmacokinetics, and toxicity profiles of HDACIs to achieve a better understanding of their efficacy in reducing addictive behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SpmCx2VAE7Vg90H21EOLACvtfcHk0lgUz7ho_jAE8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OmsbzE&md5=3d92f98a349cbdfcd4fa148e586a3044</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00115%26sid%3Dliteratum%253Aachs%26aulast%3DBourguet%26aufirst%3DE.%26aulast%3DOzdarska%26aufirst%3DK.%26aulast%3DMoroy%26aufirst%3DG.%26aulast%3DJeanblanc%26aufirst%3DJ.%26aulast%3DNaassila%26aufirst%3DM.%26atitle%3DClass%2520I%2520HDAC%2520Inhibitors%253A%2520Potential%2520New%2520Epigenetic%2520Therapeutics%2520for%2520Alcohol%2520Use%2520Disorder%2520%2528AUD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1745%26epage%3D1766%26doi%3D10.1021%2Facs.jmedchem.7b00115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Close, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenific, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span> <span> </span><span class="NLM_article-title">Exploration of the Internal Cavity of Histone Deacetylase (HDAC) with Selective HDAC1/HDAC2 Inhibitors (SHI-1:2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2007.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18182289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=973-978&author=J.+L.+Methotauthor=P.+K.+Chakravartyauthor=M.+Chenardauthor=J.+Closeauthor=J.+C.+Cruzauthor=W.+K.+Dahlbergauthor=J.+Flemingauthor=C.+L.+Hamblettauthor=J.+E.+Hamillauthor=P.+Harringtonauthor=A.+Harschauthor=R.+Heidebrechtauthor=B.+Hughesauthor=J.+Jungauthor=C.+M.+Kenificauthor=A.+M.+Kralauthor=P.+T.+Meinkeauthor=R.+E.+Middletonauthor=N.+Ozerovaauthor=D.+L.+Slomanauthor=M.+G.+Stantonauthor=A.+A.+Szewczakauthor=S.+Tyagarajanauthor=D.+J.+Witterauthor=J.+P.+Secristauthor=T.+A.+Miller&title=Exploration+of+the+Internal+Cavity+of+Histone+Deacetylase+%28HDAC%29+with+Selective+HDAC1%2FHDAC2+Inhibitors+%28SHI-1%3A2%29&doi=10.1016%2Fj.bmcl.2007.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)</span></div><div class="casAuthors">Methot, Joey L.; Chakravarty, Prasun K.; Chenard, Melissa; Close, Joshua; Cruz, Jonathan C.; Dahlberg, William K.; Fleming, Judith; Hamblett, Christopher L.; Hamill, Julie E.; Harrington, Paul; Harsch, Andreas; Heidebrecht, Richard; Hughes, Bethany; Jung, Joon; Kenific, Candia M.; Kral, Astrid M.; Meinke, Peter T.; Middleton, Richard E.; Ozerova, Nicole; Sloman, David L.; Stanton, Matthew G.; Szewczak, Alexander A.; Tyagarajan, Sriram; Witter, David J.; Secrist, J. Paul; Miller, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">973-978</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors report herein the initial exploration of novel selective HDAC1/HDAC2 inhibitors (SHI-1:2).  Optimized SHI-1:2 structures exhibit enhanced intrinsic activity against HDAC1 and HDAC2, and are greater than 100-fold selective vs. other HDACs, including HDAC3.  Based on the SAR of these agents and the current understanding of the HDAC active site, the authors postulate that the SHI-1:2 extend the existing HDAC inhibitor pharmacophore to include an internal binding domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOxv4RIybcrVg90H21EOLACvtfcHk0lgUz7ho_jAE8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbw%253D&md5=7796d5e1f54e3f5106bedea1f0e47f5a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DChakravarty%26aufirst%3DP.%2BK.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DClose%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DFleming%26aufirst%3DJ.%26aulast%3DHamblett%26aufirst%3DC.%2BL.%26aulast%3DHamill%26aufirst%3DJ.%2BE.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DHeidebrecht%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKenific%26aufirst%3DC.%2BM.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DOzerova%26aufirst%3DN.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26atitle%3DExploration%2520of%2520the%2520Internal%2520Cavity%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520with%2520Selective%2520HDAC1%252FHDAC2%2520Inhibitors%2520%2528SHI-1%253A2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D973%26epage%3D978%26doi%3D10.1016%2Fj.bmcl.2007.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenific, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span> <span> </span><span class="NLM_article-title">Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/ml4004233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4004233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=340-345&author=J.+L.+Methotauthor=D.+M.+Hoffmanauthor=D.+J.+Witterauthor=M.+G.+Stantonauthor=P.+Harringtonauthor=C.+Hamblettauthor=P.+Siliphaivanhauthor=K.+Wilsonauthor=J.+Hubbsauthor=R.+Heidebrechtauthor=A.+M.+Kralauthor=N.+Ozerovaauthor=J.+C.+Flemingauthor=H.+Wangauthor=A.+A.+Szewczakauthor=R.+E.+Middletonauthor=B.+Hughesauthor=J.+C.+Cruzauthor=B.+B.+Hainesauthor=M.+Chenardauthor=C.+M.+Kenificauthor=A.+Harschauthor=J.+P.+Secristauthor=T.+A.+Miller&title=Delayed+and+Prolonged+Histone+Hyperacetylation+with+a+Selective+HDAC1%2FHDAC2+Inhibitor&doi=10.1021%2Fml4004233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor</span></div><div class="casAuthors">Methot, Joey L.; Hoffman, Dawn Mampreian; Witter, David J.; Stanton, Matthew G.; Harrington, Paul; Hamblett, Christopher; Siliphaivanh, Phieng; Wilson, Kevin; Hubbs, Jed; Heidebrecht, Richard; Kral, Astrid M.; Ozerova, Nicole; Fleming, Judith C.; Wang, Hongmei; Szewczak, Alexander A.; Middleton, Richard E.; Hughes, Bethany; Cruz, Jonathan C.; Haines, Brian B.; Chenard, Melissa; Kenific, Candia M.; Harsch, Andreas; Secrist, J. Paul; Miller, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described.  Kinetic anal. indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 prepns.  Delayed histone hyperacetylation and gene expression changes were also obsd. in cell culture, and histone acetylation was obsd. in vivo beyond disappearance of drug from plasma.  In vivo studies further demonstrated that continuous target inhibition was well tolerated and efficacious in tumor-bearing mice, leading to tumor growth inhibition with either once-daily or intermittent administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9WsDyqz8g8rVg90H21EOLACvtfcHk0lgUz7ho_jAE8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKntw%253D%253D&md5=6cc13071d384ad39cfe3aa7ed4327b0e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fml4004233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4004233%26sid%3Dliteratum%253Aachs%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%2BM.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHamblett%26aufirst%3DC.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DHubbs%26aufirst%3DJ.%26aulast%3DHeidebrecht%26aufirst%3DR.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DOzerova%26aufirst%3DN.%26aulast%3DFleming%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DHaines%26aufirst%3DB.%2BB.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DKenific%26aufirst%3DC.%2BM.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26atitle%3DDelayed%2520and%2520Prolonged%2520Histone%2520Hyperacetylation%2520with%2520a%2520Selective%2520HDAC1%252FHDAC2%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Fml4004233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bariteau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vempati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minehart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivtsov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2348</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-14-1290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25688158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2348-2358&author=M.+C.+Stubbsauthor=W.+Kimauthor=M.+Bariteauauthor=T.+Davisauthor=S.+Vempatiauthor=J.+Minehartauthor=M.+Witkinauthor=J.+Qiauthor=A.+V.+Krivtsovauthor=J.+E.+Bradnerauthor=A.+L.+Kungauthor=S.+A.+Armstrong&title=Selective+Inhibition+of+HDAC1+and+HDAC2+as+a+Potential+Therapeutic+Option+for+B-ALL&doi=10.1158%2F1078-0432.CCR-14-1290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL</span></div><div class="casAuthors">Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Minehart, Janna; Witkin, Matthew; Qi, Jun; Krivtsov, Andrei V.; Bradner, James E.; Kung, Andrew L.; Armstrong, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2348-2358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematol. malignancies.  One such hematol. malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-mol. inhibitors that target epigenetic mechanisms.  Exptl. Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity.  Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL.  Mouse xenografts of B-cell malignancy-derived cell lines and a pediatric B-ALL were used to demonstrate pharmacol. efficacy.  Results: Nonselective HDAC inhibitors were cytotoxic to a panel of B-ALL cell lines as well as to xenografted human leukemia patient samples.  Assessment of isoform-specific HDACi indicated that targeting HDAC1-3 with class I HDAC-specific inhibitors was sufficient to inhibit growth of B-ALL cell lines.  Furthermore, shRNA-mediated knockdown of HDAC1 or HDAC2 resulted in growth inhibition in these cells.  We then assessed a compd. that specifically inhibits only HDAC1 and HDAC2.  This compd. suppressed growth and induced apoptosis in B-ALL cell lines in vitro and in vivo, whereas it was far less effective against other B-cell-derived malignancies.  Conclusions: Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL.  Clin Cancer Res; 21(10); 2348-58. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod1Nglu1KSXbVg90H21EOLACvtfcHk0ljobcsR-qclQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOkuro%253D&md5=0f75e4cd1aa5e23856aa4fadbe6342e6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1290%26sid%3Dliteratum%253Aachs%26aulast%3DStubbs%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DBariteau%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DT.%26aulast%3DVempati%26aufirst%3DS.%26aulast%3DMinehart%26aufirst%3DJ.%26aulast%3DWitkin%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DKrivtsov%26aufirst%3DA.%2BV.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520Inhibition%2520of%2520HDAC1%2520and%2520HDAC2%2520as%2520a%2520Potential%2520Therapeutic%2520Option%2520for%2520B-ALL%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2348%26epage%3D2358%26doi%3D10.1158%2F1078-0432.CCR-14-1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearstone, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0169128</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0169128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.pone.0169128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28060870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvVegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0169128&author=C.+Minauthor=N.+Mooreauthor=J.+R.+Shearstoneauthor=S.+N.+Quayleauthor=P.+Huangauthor=J.+H.+van+Duzerauthor=M.+B.+Jarpeauthor=S.+S.+Jonesauthor=M.+Yang&title=Selective+Inhibitors+of+Histone+Deacetylases+1+and+2+Synergize+with+Azacitidine+in+Acute+Myeloid+Leukemia&doi=10.1371%2Fjournal.pone.0169128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia</span></div><div class="casAuthors">Min, Chengyin; Moore, Nathan; Shearstone, Jeffrey R.; Quayle, Steven N.; Huang, Pengyu; van Duzer, John H.; Jarpe, Matthew B.; Jones, Simon S.; Yang, Min</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0169128/1-e0169128/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells.  Outcomes for patients with AML remain poor, highlighting the need for novel treatment options.  Aberrant epigenetic regulation plays an important role in the pathogenesis of AML, and inhibitors of DNA methyltransferase or histone deacetylase (HDAC) enzymes have exhibited activity in preclin. AML models.  Combination studies with HDAC inhibitors plus DNA methyltransferase inhibitors have potential beneficial clin. activity in AML, however the toxicity profiles of non-selective HDAC inhibitors in the combination setting limit their clin. utility.  In this work, we describe the preclin. development of selective inhibitors of HDAC1 and HDAC2, which are hypothesized to have improved safety profiles, for combination therapy in AML.  We demonstrate that selective inhibition of HDAC1 and HDAC2 is sufficient to achieve efficacy both as a single agent and in combination with azacitidine in preclin. models of AML, including established AML cell lines, primary leukemia cells from AML patient bone marrow samples and in vivo xenograft models of human AML.  Gene expression profiling of AML cells treated with either an HDAC1/2 inhibitor, azacitidine, or the combination of both have identified a list of genes involved in transcription and cell cycle regulation as potential mediators of the combinatorial effects of HDAC1/2 inhibition with azacitidine.  Together, these findings support the clin. evaluation of selective HDAC1/2 inhibitors in combination with azacitidine in AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkinwKH8HeabVg90H21EOLACvtfcHk0ljobcsR-qclQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvVegsbw%253D&md5=1f549b8d377869735e758ba914749eab</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0169128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0169128%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DN.%26aulast%3DShearstone%26aufirst%3DJ.%2BR.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJarpe%26aufirst%3DM.%2BB.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DM.%26atitle%3DSelective%2520Inhibitors%2520of%2520Histone%2520Deacetylases%25201%2520and%25202%2520Synergize%2520with%2520Azacitidine%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0169128%26doi%3D10.1371%2Fjournal.pone.0169128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) for Epigenetics Research</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32146413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=8-16&author=A.+Vogelmannauthor=D.+Robaaauthor=W.+Sipplauthor=M.+Jung&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+for+Epigenetics+Research&doi=10.1016%2Fj.cbpa.2020.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span></div><div class="casAuthors">Vogelmann, Anja; Robaa, Dina; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-16</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. and allow selective protein degrdn. by addressing the natural ubiquitin proteasome system.  As this new strategy of chem. induced protein degrdn. can serve as a biol. tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins.  A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these mols.  In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2o_9L2Y8GbVg90H21EOLACvtfcHk0ljobcsR-qclQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D&md5=6a4f3b70d6c6a446c744b9788b7582cf</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmann%26aufirst%3DA.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520for%2520Epigenetics%2520Research%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D8%26epage%3D16%26doi%3D10.1016%2Fj.cbpa.2020.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgkinson, J. T.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Mediated Degradation of Class I Histone Deacetylase Enzymes in Corepressor Complexes</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4479</span>, <span class="refDoi"> DOI: 10.1039/D0CC01485K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1039%2FD0CC01485K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32201871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1Ojtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=4476-4479&author=J.+P.+Smalleyauthor=G.+E.+Adamsauthor=C.+J.+Millardauthor=Y.+Songauthor=J.+K.+S.+Norrisauthor=J.+W.+R.+Schwabeauthor=S.+M.+Cowleyauthor=J.+T.+Hodgkinson&title=PROTAC-Mediated+Degradation+of+Class+I+Histone+Deacetylase+Enzymes+in+Corepressor+Complexes&doi=10.1039%2FD0CC01485K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes</span></div><div class="casAuthors">Smalley, Joshua P.; Adams, Grace E.; Millard, Christopher J.; Song, Yun; Norris, James K. S.; Schwabe, John W. R.; Cowley, Shaun Michael; Hodgkinson, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3.  The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand.  Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degrdn. strategy as an alternative to class I HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGPSST5ixb4LVg90H21EOLACvtfcHk0lgGhOC5jgQzAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1Ojtbs%253D&md5=0da062ae0370678dcf46c882dedbc8d5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FD0CC01485K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0CC01485K%26sid%3Dliteratum%253Aachs%26aulast%3DSmalley%26aufirst%3DJ.%2BP.%26aulast%3DAdams%26aufirst%3DG.%2BE.%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BK.%2BS.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%2BR.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DHodgkinson%26aufirst%3DJ.%2BT.%26atitle%3DPROTAC-Mediated%2520Degradation%2520of%2520Class%2520I%2520Histone%2520Deacetylase%2520Enzymes%2520in%2520Corepressor%2520Complexes%26jtitle%3DChem.%2520Commun.%26date%3D2020%26volume%3D56%26spage%3D4476%26epage%3D4479%26doi%3D10.1039%2FD0CC01485K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.-H.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases in Memory and Cognition</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">re12</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aaa0069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1126%2Fscisignal.aaa0069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25492968" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=re12&author=J.+Penneyauthor=L.-H.+Tsai&title=Histone+Deacetylases+in+Memory+and+Cognition&doi=10.1126%2Fscisignal.aaa0069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaa0069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaa0069%26sid%3Dliteratum%253Aachs%26aulast%3DPenney%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DHistone%2520Deacetylases%2520in%2520Memory%2520and%2520Cognition%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dre12%26doi%3D10.1126%2Fscisignal.aaa0069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2016.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27377864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4008-4015&author=F.+F.+Wagnerauthor=M.+We%C3%AFwerauthor=S.+Steinbacherauthor=A.+Schomburgauthor=P.+Reinemerauthor=J.+P.+Galeauthor=A.+J.+Campbellauthor=S.+L.+Fisherauthor=W.-N.+Zhaoauthor=S.+A.+Reisauthor=K.+M.+Hennigauthor=M.+Thomasauthor=P.+M%C3%BCllerauthor=M.+R.+Jefsonauthor=D.+M.+Fassauthor=S.+J.+Haggartyauthor=Y.-L.+Zhangauthor=E.+B.+Holson&title=Kinetic+and+Structural+Insights+into+the+Binding+of+Histone+Deacetylase+1+and+2+%28HDAC1%2C+2%29+Inhibitors&doi=10.1016%2Fj.bmc.2016.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors</span></div><div class="casAuthors">Wagner, Florence F.; Weiwer, Michel; Steinbacher, Stefan; Schomburg, Adrian; Reinemer, Peter; Gale, Jennifer P.; Campbell, Arthur J.; Fisher, Stewart L.; Zhao, Wen-Ning; Reis, Surya A.; Hennig, Krista M.; Thomas, Meryl; Muller, Peter; Jefson, Martin R.; Fass, Daniel M.; Haggarty, Stephen J.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4008-4015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described.  Different kinetic and thermodn. selectivity profiles were obtained by varying the moiety occupying an 11 Å channel leading to the Zn2+ catalytic pocket of HDACs 1 and 2, two paralogs with a high degree of structural similarity.  The design of these novel inhibitors was informed by two ligand-bound crystal structures of truncated hHDAC2.  BRD4884 and BRD7232 possess kinetic selectivity for HDAC1 vs. HDAC2.  We demonstrate that the binding kinetics of HDAC inhibitors can be tuned for individual isoforms in order to modulate target residence time while retaining functional activity and increased histone H4K12 and H3K9 acetylation in primary mouse neuronal cell culture assays.  These chromatin modifiers, with tuned binding kinetic profiles, can be used to define the relation between target engagement requirements and the pharmacodynamic response of HDACs in different disease applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQpWplRRVod7Vg90H21EOLACvtfcHk0lgGhOC5jgQzAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E&md5=bcbe1addb5d30073f345fd77d529dcd4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSchomburg%26aufirst%3DA.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DReis%26aufirst%3DS.%2BA.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DJefson%26aufirst%3DM.%2BR.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DKinetic%2520and%2520Structural%2520Insights%2520into%2520the%2520Binding%2520of%2520Histone%2520Deacetylase%25201%2520and%25202%2520%2528HDAC1%252C%25202%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4008%26epage%3D4015%26doi%3D10.1016%2Fj.bmc.2016.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 3 (HDAC3) Inhibitors as Anticancer Agents: A Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2020.112171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32163814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVeisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112171&author=R.+Sarkarauthor=S.+Banerjeeauthor=S.+A.+Aminauthor=N.+Adhikariauthor=T.+Jha&title=Histone+Deacetylase+3+%28HDAC3%29+Inhibitors+as+Anticancer+Agents%3A+A+Review&doi=10.1016%2Fj.ejmech.2020.112171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review</span></div><div class="casAuthors">Sarkar, Rajat; Banerjee, Suvankar; Amin, Sk Abdul; Adhikari, Nilanjan; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers.  HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory diseases, rheumatoid arthritis (RA), etc.  Inhibition of HDAC3 metalloenzyme is a dynamic approach for drug design and discovery.  This approach has gained considerable interest in recent years.  The development of an effective therapeutic agent against HDAC3 is still challenging.  A lot of work is still in demand.  This current communication is a part of our extended work on HDAC3 inhibitors to achieve deep insight of knowledge about the structural information of HDAC3 inhibitors.  This article is unique in terms of detailed structure-activity relationships (SARs) anal.  This may help to find out some important clues to design better active HDAC3 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo0GLJbEUe9LVg90H21EOLACvtfcHk0lgGhOC5jgQzAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVeisr0%253D&md5=d9911556755793d92c3e073b89b9b00e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112171%26sid%3Dliteratum%253Aachs%26aulast%3DSarkar%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DHistone%2520Deacetylase%25203%2520%2528HDAC3%2529%2520Inhibitors%2520as%2520Anticancer%2520Agents%253A%2520A%2520Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112171%26doi%3D10.1016%2Fj.ejmech.2020.112171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chattopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrup-Poulsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=363-374&author=F.+F.+Wagnerauthor=M.+Lundhauthor=T.+Kayaauthor=P.+McCarrenauthor=Y.-L.+Zhangauthor=S.+Chattopadhyayauthor=J.+P.+Galeauthor=T.+Galboauthor=S.+L.+Fisherauthor=B.+C.+Meierauthor=A.+Vetereauthor=S.+Richardsonauthor=N.+G.+Morganauthor=D.+P.+Christensenauthor=T.+J.+Gilbertauthor=J.+M.+Hookerauthor=M.+Leroyauthor=D.+Walpitaauthor=T.+Mandrup-Poulsenauthor=B.+K.+Wagnerauthor=E.+B.+Holson&title=An+Isochemogenic+Set+of+Inhibitors+To+Define+the+Therapeutic+Potential+of+Histone+Deacetylases+in+%CE%B2-Cell+Protection&doi=10.1021%2Facschembio.5b00640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection</span></div><div class="casAuthors">Wagner, Florence F.; Lundh, Morten; Kaya, Taner; McCarren, Patrick; Zhang, Yan-Ling; Chattopadhyay, Shrikanta; Gale, Jennifer P.; Galbo, Thomas; Fisher, Stewart L.; Meier, Bennett C.; Vetere, Amedeo; Richardson, Sarah; Morgan, Noel G.; Christensen, Dan Ploug; Gilbert, Tamara J.; Hooker, Jacob M.; Leroy, Melanie; Walpita, Deepika; Mandrup-Poulsen, Thomas; Wagner, Bridget K.; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">363-374</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modulation of histone deacetylase (HDAC) activity has been implicated as a potential therapeutic strategy for multiple diseases.  However, it has been difficult to dissect the role of individual HDACs due to a lack of selective small-mol. inhibitors.  Here, we report the synthesis of a series of highly potent and isoform-selective class I HDAC inhibitors, rationally designed by exploiting minimal structural changes to the clin. experienced HDAC inhibitor CI-994.  We used this toolkit of isochemogenic or chem. matched inhibitors to probe the role of class I HDACs in β-cell pathobiol. and demonstrate for the first time that selective inhibition of an individual HDAC isoform retains beneficial biol. activity and mitigates mechanism-based toxicities.  The highly selective HDAC3 inhibitor BRD3308 suppressed pancreatic β-cell apoptosis induced by inflammatory cytokines, as expected, or now glucolipotoxic stress, and increased functional insulin release.  In addn., BRD3308 had no effect on human megakaryocyte differentiation, while inhibitors of HDAC1 and 2 were toxic.  Our findings demonstrate that the selective inhibition of HDAC3 represents a potential path forward as a therapy to protect pancreatic β-cells from inflammatory cytokines and nutrient overload in diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_12m-jRoObVg90H21EOLACvtfcHk0li9nYzZ65wm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCnsL4%253D&md5=0d57ffcfc229ec4efe3857882ff9113e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00640%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DLundh%26aufirst%3DM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DMcCarren%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DChattopadhyay%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DGalbo%26aufirst%3DT.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26aulast%3DChristensen%26aufirst%3DD.%2BP.%26aulast%3DGilbert%26aufirst%3DT.%2BJ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DLeroy%26aufirst%3DM.%26aulast%3DWalpita%26aufirst%3DD.%26aulast%3DMandrup-Poulsen%26aufirst%3DT.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DAn%2520Isochemogenic%2520Set%2520of%2520Inhibitors%2520To%2520Define%2520the%2520Therapeutic%2520Potential%2520of%2520Histone%2520Deacetylases%2520in%2520%25CE%25B2-Cell%2520Protection%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D363%26epage%3D374%26doi%3D10.1021%2Facschembio.5b00640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresciani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ontoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancofiore, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciammaichella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malancona, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veneziano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span> <span> </span><span class="NLM_article-title">Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlals7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=481-486&author=A.+Brescianiauthor=J.+M.+Ontoriaauthor=I.+Biancofioreauthor=A.+Cellucciauthor=A.+Ciammaichellaauthor=A.+Di+Marcoauthor=F.+Ferrignoauthor=A.+Franconeauthor=S.+Malanconaauthor=E.+Monteagudoauthor=E.+Niziauthor=P.+Paceauthor=S.+Ponziauthor=I.+Rossettiauthor=M.+Venezianoauthor=V.+Summaauthor=S.+Harper&title=Improved+Selective+Class+I+HDAC+and+Novel+Selective+HDAC3+Inhibitors%3A+Beyond+Hydroxamic+Acids+and+Benzamides&doi=10.1021%2Facsmedchemlett.8b00517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Improved selective class I HDAC and novel selective HDAC3 inhibitors: Beyond hydroxamic acids and benzamides</span></div><div class="casAuthors">Bresciani, Alberto; Ontoria, Jesus M.; Biancofiore, Ilaria; Cellucci, Antonella; Ciammaichella, Alina; Di Marco, Annalise; Ferrigno, Federica; Francone, Alessandra; Malancona, Savina; Monteagudo, Edith; Nizi, Emanuela; Pace, Paola; Ponzi, Simona; Rossetti, Ilaria; Veneziano, Maria; Summa, Vincenzo; Harper, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">481-486</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The application of class I HDAC inhibitors as cancer therapies is well established, but more recently their development for nononcol. indications has increased.  We report here on the generation of improved class I selective human HDAC inhibitors based on an ethylketone zinc binding group (ZBG) in place of the hydroxamic acid that features the majority of HDAC inhibitors.  We also describe a novel set of HDAC3 isoform selective inhibitors that show stronger potency and selectivity than the most commonly used HDAC3 selective tool compd. RGFP966.  These compds. are again based on an alternative ZBG with respect to the ortho-anilide that is featured in HDAC3 selective compds. reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzwbKCL5A6bVg90H21EOLACvtfcHk0li9nYzZ65wm2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlals7jO&md5=2882346cee38482adab18732afde3470</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00517%26sid%3Dliteratum%253Aachs%26aulast%3DBresciani%26aufirst%3DA.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DBiancofiore%26aufirst%3DI.%26aulast%3DCellucci%26aufirst%3DA.%26aulast%3DCiammaichella%26aufirst%3DA.%26aulast%3DDi%2BMarco%26aufirst%3DA.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFrancone%26aufirst%3DA.%26aulast%3DMalancona%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DP.%26aulast%3DPonzi%26aufirst%3DS.%26aulast%3DRossetti%26aufirst%3DI.%26aulast%3DVeneziano%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DHarper%26aufirst%3DS.%26atitle%3DImproved%2520Selective%2520Class%2520I%2520HDAC%2520and%2520Novel%2520Selective%2520HDAC3%2520Inhibitors%253A%2520Beyond%2520Hydroxamic%2520Acids%2520and%2520Benzamides%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D481%26epage%3D486%26doi%3D10.1021%2Facsmedchemlett.8b00517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malvaez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuown, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogge, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarabadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">HDAC3-Selective Inhibitor Enhances Extinction of Cocaine-Seeking Behavior in a Persistent Manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2652</span>, <span class="refDoi"> DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-Selective+Inhibitor+Enhances+Extinction+of+Cocaine-Seeking+Behavior+in+a+Persistent+Manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0lhSn78l_kyEkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-Selective%2520Inhibitor%2520Enhances%2520Extinction%2520of%2520Cocaine-Seeking%2520Behavior%2520in%2520a%2520Persistent%2520Manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieszczad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudugunti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaugh, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13124</span>– <span class="NLM_lpage">13132</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0914-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1523%2FJNEUROSCI.0914-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26400942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=13124-13132&author=K.+M.+Bieszczadauthor=K.+Bechayauthor=J.+R.+Ruscheauthor=V.+Jacquesauthor=S.+Kuduguntiauthor=W.+Miaoauthor=N.+M.+Weinbergerauthor=J.+L.+McGaughauthor=M.+A.+Wood&title=Histone+Deacetylase+Inhibition+via+RGFP966+Releases+the+Brakes+on+Sensory+Cortical+Plasticity+and+the+Specificity+of+Memory+Formation&doi=10.1523%2FJNEUROSCI.0914-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition via RGFP966 releases the brakes on sensory cortical plasticity and the specificity of memory formation</span></div><div class="casAuthors">Bieszczad, Kasia M.; Bechay, Kiro; Rusche, James R.; Jacques, Vincent; Kudugunti, Shashi; Miao, Wenyan; Weinberger, Norman M.; McGaugh, James L.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13124-13132</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Research over the past decade indicates a novel role for epigenetic mechanisms in memory formation.  Of particular interest is chromatin modification by histone deacetylases (HDACs), which, in general, neg. regulate transcription.  HDAC deletion or inhibition facilitates transcription during memory consolidation and enhances long-lasting forms of synaptic plasticity and long-term memory.  A key open question remains: How does blocking HDAC activity lead to memory enhancements.  To address this question, we tested whether a normal function of HDACs is to gate information processing during memory formation.  We used a class I HDAC inhibitor, RGFP966 (C21H19FN4O), to test the role of HDAC inhibition for information processing in an auditory memory model of learning-induced cortical plasticity.  HDAC inhibition may act beyond memory enhancement per se to instead regulate information in ways that lead to encoding more vivid sensory details into memory.  Indeed, we found that RGFP966 controls memory induction for acoustic details of sound-to-reward learning.  Rats treated with RGFP966 while learning to assoc. sound with reward had stronger memory and addnl. information encoded into memory for highly specific features of sounds assocd. with reward.  Moreover, behavioral effects occurred with unusually specific plasticity in primary auditory cortex (A1).  Class I HDAC inhibition appears to engage A1 plasticity that enables addnl. acoustic features to become encoded in memory.  Thus, epigenetic mechanisms act to regulate sensory cortical plasticity, which offers an information processing mechanism for gating what and how much is encoded to produce exceptionally persistent and vivid memories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriop2-XG6WvLVg90H21EOLACvtfcHk0lhSn78l_kyEkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSqsbw%253D&md5=0e62a727995215ab22a3dd29003baffe</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0914-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0914-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DBieszczad%26aufirst%3DK.%2BM.%26aulast%3DBechay%26aufirst%3DK.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DKudugunti%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DWeinberger%26aufirst%3DN.%2BM.%26aulast%3DMcGaugh%26aufirst%3DJ.%2BL.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibition%2520via%2520RGFP966%2520Releases%2520the%2520Brakes%2520on%2520Sensory%2520Cortical%2520Plasticity%2520and%2520the%2520Specificity%2520of%2520Memory%2520Formation%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D13124%26epage%3D13132%26doi%3D10.1523%2FJNEUROSCI.0914-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suelves, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkham-McCarthy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahue, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginés, S.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of Histone Deacetylase 3 Prevents Cognitive Deficits and Suppresses Striatal CAG Repeat Expansions in Huntington’s Disease Mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6082</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-05125-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41598-017-05125-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28729730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1cjpslCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=6082&author=N.+Suelvesauthor=L.+Kirkham-McCarthyauthor=R.+S.+Lahueauthor=S.+Gin%C3%A9s&title=A+Selective+Inhibitor+of+Histone+Deacetylase+3+Prevents+Cognitive+Deficits+and+Suppresses+Striatal+CAG+Repeat+Expansions+in+Huntington%E2%80%99s+Disease+Mice&doi=10.1038%2Fs41598-017-05125-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice</span></div><div class="casAuthors">Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Kirkham-McCarthy Lucy; Lahue Robert S; Lahue Robert S</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6082</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Huntington's disease (HD) is a neurodegenerative disorder whose major symptoms include progressive motor and cognitive dysfunction.  Cognitive decline is a critical quality of life concern for HD patients and families.  The enzyme histone deacetylase 3 (HDAC3) appears to be important in HD pathology by negatively regulating genes involved in cognitive functions.  Furthermore, HDAC3 has been implicated in the aberrant transcriptional patterns that help cause disease symptoms in HD mice.  HDAC3 also helps fuel CAG repeat expansions in human cells, suggesting that HDAC3 may power striatal expansions in the HTT gene thought to drive disease progression.  This multifaceted role suggests that early HDAC3 inhibition offers an attractive mechanism to prevent HD cognitive decline and to suppress striatal expansions.  This hypothesis was investigated by treating Hdh(Q111) knock-in mice with the HDAC3-selective inhibitor RGFP966.  Chronic early treatment prevented long-term memory impairments and normalized specific memory-related gene expression in hippocampus.  Additionally, RGFP966 prevented corticostriatal-dependent motor learning deficits, significantly suppressed striatal CAG repeat expansions, partially rescued striatal protein marker expression and reduced accumulation of mutant huntingtin oligomeric forms.  These novel results highlight RGFP966 as an appealing multiple-benefit therapy in HD that concurrently prevents cognitive decline and suppresses striatal CAG repeat expansions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRtWXDYtrkV4JKJbLTgsvCfW6udTcc2eZgjXUWRiTiMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjpslCmsQ%253D%253D&md5=0c384551190fd157825f8a29f675a79f</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-05125-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-05125-2%26sid%3Dliteratum%253Aachs%26aulast%3DSuelves%26aufirst%3DN.%26aulast%3DKirkham-McCarthy%26aufirst%3DL.%26aulast%3DLahue%26aufirst%3DR.%2BS.%26aulast%3DGin%25C3%25A9s%26aufirst%3DS.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25203%2520Prevents%2520Cognitive%2520Deficits%2520and%2520Suppresses%2520Striatal%2520CAG%2520Repeat%2520Expansions%2520in%2520Huntington%25E2%2580%2599s%2520Disease%2520Mice%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D6082%26doi%3D10.1038%2Fs41598-017-05125-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janczura, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volmar, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlestedt, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC3 Reverses Alzheimer’s Disease-Related Pathologies in Vitro and in the 3xTg-AD Mouse Model</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E11148</span>– <span class="NLM_lpage">E11157</span>, <span class="refDoi"> DOI: 10.1073/pnas.1805436115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1073%2Fpnas.1805436115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30397132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1CrtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E11148-E11157&author=K.+J.+Janczuraauthor=C.-H.+Volmarauthor=G.+C.+Sartorauthor=S.+J.+Raoauthor=N.+R.+Ricciardiauthor=G.+Lambertauthor=S.+P.+Brothersauthor=C.+Wahlestedt&title=Inhibition+of+HDAC3+Reverses+Alzheimer%E2%80%99s+Disease-Related+Pathologies+in+Vitro+and+in+the+3xTg-AD+Mouse+Model&doi=10.1073%2Fpnas.1805436115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model</span></div><div class="casAuthors">Janczura, Karolina J.; Volmar, Claude-Henry; Sartor, Gregory C.; Rao, Sunil J.; Ricciardi, Natalie R.; Lambert, Guerline; Brothers, Shaun P.; Wahlestedt, Claes</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">E11148-E11157</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) the leading cause of age-related dementia.  Neuropathol. hallmarks of AD include brain deposition of β-amyloid plaques and accumulation of both hyperphosphorylated and acetylated tau.  RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-assocd. sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1-42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw).  In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathol. tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1-42 protein levels in the brain and periphery, and improves spatial learning and memory.  Finally, we show that RGFP-966 decreases Aβ1-42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients.  These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins assocd. with AD pathophysiol., supporting the notion that HDAC3 may be a disease-modifying therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx2OY5AvswdLVg90H21EOLACvtfcHk0lgy958DPeXntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1CrtrrP&md5=f36c313cbc1bb2c7dc7cc1590351cb18</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1805436115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1805436115%26sid%3Dliteratum%253Aachs%26aulast%3DJanczura%26aufirst%3DK.%2BJ.%26aulast%3DVolmar%26aufirst%3DC.-H.%26aulast%3DSartor%26aufirst%3DG.%2BC.%26aulast%3DRao%26aufirst%3DS.%2BJ.%26aulast%3DRicciardi%26aufirst%3DN.%2BR.%26aulast%3DLambert%26aufirst%3DG.%26aulast%3DBrothers%26aufirst%3DS.%2BP.%26aulast%3DWahlestedt%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520HDAC3%2520Reverses%2520Alzheimer%25E2%2580%2599s%2520Disease-Related%2520Pathologies%2520in%2520Vitro%2520and%2520in%2520the%25203xTg-AD%2520Mouse%2520Model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE11148%26epage%3DE11157%26doi%3D10.1073%2Fpnas.1805436115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">The HDAC3 Inhibitor RGFP966 Ameliorated Ischemic Brain Damage by Downregulating the AIM2 Inflammasome</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1096/fj.201900394RRR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1096%2Ffj.201900394RRR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31914678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=648-662&author=M.-J.+Zhangauthor=Q.-C.+Zhaoauthor=M.-X.+Xiaauthor=J.+Chenauthor=Y.-T.+Chenauthor=X.+Caoauthor=Y.+Liuauthor=Z.-Q.+Yuanauthor=X.-Y.+Wangauthor=Y.+Xu&title=The+HDAC3+Inhibitor+RGFP966+Ameliorated+Ischemic+Brain+Damage+by+Downregulating+the+AIM2+Inflammasome&doi=10.1096%2Ffj.201900394RRR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome</span></div><div class="casAuthors">Zhang, Mei-Juan; Zhao, Qiu-Chen; Xia, Ming-Xu; Chen, Jian; Chen, Yan-Ting; Cao, Xiang; Liu, Yi; Yuan, Zeng-Qiang; Wang, Xiao-Ying; Xu, Yun</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">648-662</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">1530-6860</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Here, we investigated the potential contributions of HDAC3 to inflammasome activation in primary cultured microglia and exptl. stroke models.  In this study, we documented that HDAC3 expression was increased in microglia of mouse exptl. stroke model.  I.p. injection of RGFP966 (a selective inhibitor of HDAC3) decreased infarct size and alleviated neurol. deficits after the onset of middle cerebral artery occlusion (MCAO).  In vitro data indicated that LPS stimulation evoked a time-dependent increase of HDAC3 and absent in melanoma 2 (AIM2) inflammasome in primary cultured microglia.  Interestingly, AIM2 was subjected to spatiotemporal regulation by RGFP966.  The ability of RGFP966 to inhibit the AIM2 inflammasome was confirmed in an exptl. mouse model of stroke.  As expected, AIM2 knockout mice also demonstrated significant resistance to ischemia injury compared with their wild-type littermates.  RGFP966 failed to exhibit extra protective effects in AIM2-/- stroke mice.  Furthermore, we found that RGFP966 enhanced STAT1 acetylation and subsequently attenuated STAT1 phosphorylation, which may at least partially contributed to the neg. regulation of AIM2 by RGFP966.  Together, we initially found that RGFP966 alleviated the inflammatory response and protected against ischemic stroke by regulating the AIM2 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQ01mRJhlBLVg90H21EOLACvtfcHk0lgy958DPeXntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFeisrk%253D&md5=f5e57cc9d86792fdbbcc4c0e1f346b70</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1096%2Ffj.201900394RRR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201900394RRR%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.-J.%26aulast%3DZhao%26aufirst%3DQ.-C.%26aulast%3DXia%26aufirst%3DM.-X.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3DWang%26aufirst%3DX.-Y.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DThe%2520HDAC3%2520Inhibitor%2520RGFP966%2520Ameliorated%2520Ischemic%2520Brain%2520Damage%2520by%2520Downregulating%2520the%2520AIM2%2520Inflammasome%26jtitle%3DFASEB%2520J.%26date%3D2020%26volume%3D34%26spage%3D648%26epage%3D662%26doi%3D10.1096%2Ffj.201900394RRR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emont, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">HDAC3-Selective Inhibition Activates Brown and Beige Fat Through PRDM16</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2527</span>, <span class="refDoi"> DOI: 10.1210/en.2018-00257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1210%2Fen.2018-00257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29757434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=2520-2527&author=J.+Liaoauthor=J.+Jiangauthor=H.+Junauthor=X.+Qiaoauthor=M.+P.+Emontauthor=D.-I.+Kimauthor=J.+Wu&title=HDAC3-Selective+Inhibition+Activates+Brown+and+Beige+Fat+Through+PRDM16&doi=10.1210%2Fen.2018-00257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibition activates brown and beige fat through PRDM16</span></div><div class="casAuthors">Liao, Jiling; Jiang, Juan; Jun, Heejin; Qiao, Xiaona; Emont, Margo P.; Kim, Dong-il; Wu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2520-2527</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">It has been reported that class I histone deacetylase (HDAC) inhibition increases thermogenesis in fat, but adipocyte-specific Hdac3 deletions have presented inconsistent results.  In this study, we obsd. that HDAC3 protein levels were lower in brown fat compared with inguinal s.c. adipose tissue, and they decreased in both fat depots upon cold exposure.  PR domain-contg. 16 (PRDM16) phys. interacted with HDAC3, and treatment with HDAC3-selective inhibitor RGFP966 induced thermogenic gene expression in murine and human fat cultures.  This induction was blunted in the absence of PRDM16.  Our results provide evidence that HDAC3 is involved in thermogenesis, suggesting selective inhibition of HDAC3 in brown and beige fat might hold therapeutic potential for counteracting human obesity and metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqb21XRjyTPLVg90H21EOLACvtfcHk0lgy958DPeXntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksrzE&md5=d5fdb74f3a6bf631936b87b570763e6e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1210%2Fen.2018-00257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2018-00257%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DEmont%26aufirst%3DM.%2BP.%26aulast%3DKim%26aufirst%3DD.-I.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DHDAC3-Selective%2520Inhibition%2520Activates%2520Brown%2520and%2520Beige%2520Fat%2520Through%2520PRDM16%26jtitle%3DEndocrinology%26date%3D2018%26volume%3D159%26spage%3D2520%26epage%3D2527%26doi%3D10.1210%2Fen.2018-00257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e102684</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0102684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.pone.0102684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25136952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1CisrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e102684&author=K.+M.+Bartonauthor=N.+M.+Archinauthor=K.+S.+Keedyauthor=A.+S.+Espesethauthor=Y.+Zhangauthor=J.+Galeauthor=F.+F.+Wagnerauthor=E.+B.+Holsonauthor=D.+M.+Margolis&title=Selective+HDAC+Inhibition+for+the+Disruption+of+Latent+HIV-1+Infection&doi=10.1371%2Fjournal.pone.0102684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition for the disruption of latent HIV-1 infection</span></div><div class="casAuthors">Barton, Kirston M.; Archin, Nancie M.; Keedy, Kara S.; Espeseth, Amy S.; Zhang, Yan-Ling; Gale, Jennifer; Wagner, Florence F.; Holson, Edward B.; Margolis, David M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e102684/1-e102684/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Selective histone deacetylase (HDAC) inhibitors have emerged as a potential anti-latency therapy for persistent human immunodeficiency virus type 1 (HIV-1) infection.  We utilized a combination of small mol. inhibitors and short hairpin (sh)RNA-mediated gene knockdown strategies to delineate the key HDAC(s) to be targeted for selective induction of latent HIV-1 expression.  Individual depletion of HDAC3 significantly induced expression from the HIV-1 promoter in the 2D10 latency cell line model.  However, depletion of HDAC1 or -2 alone or in combination did not significantly induce HIV-1 expression.  Co-depletion of HDAC2 and -3 resulted in a significant increase in expression from the HIV-1 promoter.  Furthermore, concurrent knockdown of HDAC1, -2, and -3 resulted in a significant increase in expression from the HIV-1 promoter.  Using small mol. HDAC inhibitors of differing selectivity to ablate the residual HDAC activity that remained after (sh)RNA depletion, the effect of depletion of HDAC3 was further enhanced.  Enzymic inhibition of HDAC3 with the selective small-mol. inhibitor BRD3308 activated HIV-1 transcription in the 2D10 cell line.  Furthermore, ex vivo exposure to BRD3308 induced outgrowth of HIV-1 from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients.  Taken together these findings suggest that HDAC3 is an essential target to disrupt HIV-1 latency, and inhibition of HDAC2 may also contribute to the effort to purge and eradicate latent HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTcoQnQy8hCrVg90H21EOLACvtfcHk0lgy958DPeXntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1CisrbM&md5=d967dbe2a9b6004029ded4b8cad2f657</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0102684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0102684%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%2BM.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DKeedy%26aufirst%3DK.%2BS.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGale%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DSelective%2520HDAC%2520Inhibition%2520for%2520the%2520Disruption%2520of%2520Latent%2520HIV-1%2520Infection%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De102684%26doi%3D10.1371%2Fjournal.pone.0102684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, R. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">Isoform-Selective Inhibitor of Histone Deacetylase 3 (HDAC3) Limits Pancreatic Islet Infiltration and Protects Female Nonobese Diabetic Mice from Diabetes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">17598</span>– <span class="NLM_lpage">17608</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.804328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M117.804328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28860191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslehsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=17598-17608&author=E.+Diriceauthor=R.+W.+S.+Ngauthor=R.+Martinezauthor=J.+Huauthor=F.+F.+Wagnerauthor=E.+B.+Holsonauthor=B.+K.+Wagnerauthor=R.+N.+Kulkarni&title=Isoform-Selective+Inhibitor+of+Histone+Deacetylase+3+%28HDAC3%29+Limits+Pancreatic+Islet+Infiltration+and+Protects+Female+Nonobese+Diabetic+Mice+from+Diabetes&doi=10.1074%2Fjbc.M117.804328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes</span></div><div class="casAuthors">Dirice, Ercument; Ng, Raymond W. S.; Martinez, Rachael; Hu, Jiang; Wagner, Florence F.; Holson, Edward B.; Wagner, Bridget K.; Kulkarni, Rohit N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">17598-17608</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Preservation of insulin-secreting β-cells is an important goal for therapies aimed at restoring normoglycemia in patients with diabetes.  One approach, the inhibition of histone deacetylases (HDACs), has been reported to suppress pancreatic islet inflammation and β-cell apoptosis in vitro.  In this report, we demonstrate the efficacy of HDAC inhibitors (HDACi) in vivo.  We show that daily administration of BRD3308, an isoform-selective HDAC3 inhibitor, for 2 wk to female nonobese diabetic (NOD) mice, beginning at 3 wk of age, followed by twice-weekly injections until age 25 wk, protects the animals from diabetes.  The preservation of β-cells was because of a significant decrease in islet infiltration of mononuclear cells.  Moreover, the BRD3308 treatment increased basal insulin secretion from islets cultured in vitro.  All metabolic tissues tested in vehicle- or BRD3308-treated groups showed virtually no sign of immune cell infiltration, except minimal infiltration in white adipose tissue in animals treated with the highest BRD3308 dose (10 mg/kg), providing addnl. evidence of protection from immune attack in the treated groups.  Furthermore, pancreata from animals treated with 10 mg/kg BRD3308 exhibited significantly decreased nos. of apoptotic β-cells compared with those treated with vehicle or low-dose BRD3308.  Finally, animals treated with 1 or 10 mg/kg BRD3308 had enhanced β-cell proliferation.  These in vivo results point to the potential use of selective HDAC3 inhibitors as a therapeutic approach to suppress pancreatic islet infiltration and prevent β-cell death with the long-term goal of limiting the progression of type 1 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89zBZOQ7dFrVg90H21EOLACvtfcHk0lh_NZbczVy0-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslehsrfI&md5=b05649e9b132289bd49ad76398f6615c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.804328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.804328%26sid%3Dliteratum%253Aachs%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DNg%26aufirst%3DR.%2BW.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DIsoform-Selective%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25203%2520%2528HDAC3%2529%2520Limits%2520Pancreatic%2520Islet%2520Infiltration%2520and%2520Protects%2520Female%2520Nonobese%2520Diabetic%2520Mice%2520from%2520Diabetes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D17598%26epage%3D17608%26doi%3D10.1074%2Fjbc.M117.804328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic Abnormalities in Hdac6-Deficient Mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.neuropharm.2016.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27544826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWms7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2016&pages=470-479&author=M.+Fukadaauthor=A.+Nakayamaauthor=T.+Mamiyaauthor=T.-P.+Yaoauthor=Y.+Kawaguchi&title=Dopaminergic+Abnormalities+in+Hdac6-Deficient+Mice&doi=10.1016%2Fj.neuropharm.2016.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic abnormalities in Hdac6-deficient mice</span></div><div class="casAuthors">Fukada, Masahide; Nakayama, Atsuo; Mamiya, Takayoshi; Yao, Tso-Pang; Kawaguchi, Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (Hdac6), a multifunctional cytoplasmic deacetylase, is abundant in brain.  We previously demonstrated that global Hdac6 depletion causes aberrant emotional behaviors in mice.  Identification of affected brain systems and its mol. basis will lead to new insights into relations between protein acetylation events and psychiatric disorders.  Here we report the dopaminergic abnormalities in Hdac6 KO mice.  The dopamine transmission mediated by D1-like and D2-like G protein-coupled dopamine receptors is known to play roles in controlling movement, cognition, and motivational processes, and its dysfunction causes psychiatric disorders.  We found that Hdac6 KO mice showed significantly increased locomotor response to novel, but not to habituated environment.  In addn., Hdac6 KO mice showed a long-lasting sensitivity to psychostimulants, increased locomotor response to D2-like, but not D1 dopamine receptor agonists, and rapid locomotor response to apomorphine, a direct dopamine agonist, in dopamine-depleted condition.  Hdac6 protein was expressed in dopaminergic neurons and their terminals in adult mice brain, and Hdac6-depletion augmented acetylation levels of dopamine-enriched synaptosomal proteins.  In Hdac6 KO mice, the striatal content of dopamine and its metabolites was normal in basal condition, but mRNA level of D2 dopamine receptor in the striatum was decreased by 30%.  Taken together, our results provide evidence that Hdac6 deficiency leads to aberrant dopamine-dependent behaviors by enhancing postsynaptic dopamine D2 receptor response.  This study points out the possibility that Hdac6 and reversible-acetylation events play a regulatory role in D2 dopamine receptor signaling, and thus participate in the pathol. of the dopamine-related psychiatric disorders such as schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8PJJhzaicLbVg90H21EOLACvtfcHk0lh_NZbczVy0-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWms7nI&md5=f4521641c7a0e965b5ca3679818923d3</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DFukada%26aufirst%3DM.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMamiya%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DT.-P.%26aulast%3DKawaguchi%26aufirst%3DY.%26atitle%3DDopaminergic%2520Abnormalities%2520in%2520Hdac6-Deficient%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D110%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.neuropharm.2016.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lh_NZbczVy0-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Ba%C5%99inkaauthor=M.+B.+Robersauthor=L.+Van+Den%0ABoschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+Penetrable+Histone+Deacetylase+6+Inhibitor+SW-100+Ameliorates+Memory+and+Learning+Impairments+in+a+Mouse+Model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span></div><div class="casAuthors">Kozikowski, Alan P.; Shen, Sida; Pardo, Marta; Tavares, Mauricio T.; Szarics, Dora; Benoy, Veronick; Zimprich, Chad A.; Kutil, Zsofia; Zhang, Guiping; Barinka, Cyril; Robers, Matthew B.; Van Den Bosch, Ludo; Eubanks, James H.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1679-1695</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures.  Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacol. and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-/- mice.  This small mol. demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms.  Moreover, through its inhibition of the α-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates α-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated α-tubulin levels in the hippocampus of Fmr1-/- mice.  Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1-/- mice, thus modeling the intellectual deficiencies assocd. with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphc-8bfGiZh7Vg90H21EOLACvtfcHk0lhfM55Xk4ZzzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E&md5=b1e70a1a45522720d481985b3a4339f3</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520Penetrable%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SW-100%2520Ameliorates%2520Memory%2520and%2520Learning%2520Impairments%2520in%2520a%2520Mouse%2520Model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">(<i>N</i>-Hydroxycarbonylbenylamino)Quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma <i>in Vitro</i> and <i>in Vivo</i></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.-Y.+Leeauthor=K.+Nepaliauthor=F.-I.+Huangauthor=C.-Y.+Changauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29Quinolines+as+Selective+Histone+Deacetylase+6+Inhibitors+Suppress+Growth+of+Multiple+Myeloma+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0lhfM55Xk4ZzzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529Quinolines%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520Suppress%2520Growth%2520of%2520Multiple%2520Myeloma%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krukowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golonzhka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumet, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Inhibition Effectively Reverses Chemotherapy-Induced Peripheral Neuropathy</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1097%2Fj.pain.0000000000000893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28267067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslyrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2017&pages=1126-1137&author=K.+Krukowskiauthor=J.+Maauthor=O.+Golonzhkaauthor=G.+O.+Laumetauthor=T.+Guttiauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+B.+Jarpeauthor=C.+J.+Heijnenauthor=A.+Kavelaars&title=HDAC6+Inhibition+Effectively+Reverses+Chemotherapy-Induced+Peripheral+Neuropathy&doi=10.1097%2Fj.pain.0000000000000893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy</span></div><div class="casAuthors">Krukowski, Karen; Ma, Jiacheng; Golonzhka, Olga; Laumet, Geoffroy O.; Gutti, Tanuja; van Duzer, John H.; Mazitschek, Ralph; Jarpe, Matthew B.; Heijnen, Cobi J.; Kavelaars, Annemieke</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1126-1137</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment.  Currently, there is no Food and Drug Administration-approved treatment available.  Histone deacetylase 6 (HDAC6) is a microtubule-assocd. deacetylase whose function includes regulation of α-tubulin-dependent intracellular mitochondrial transport.  Here, we examd. the effect of HDAC6 inhibition on established cisplatin-induced peripheral neuropathy.  We used a novel HDAC6 inhibitor ACY-1083, which shows 260-fold selectivity towards HDAC6 vs other HDACs.  Our results show that HDAC6 inhibition prevented cisplatin-induced mech. allodynia, and also completely reversed already existing cisplatin-induced mech. allodynia, spontaneous pain, and numbness.  These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clin. trials for cancer treatment.  Mechanistically, treatment with the HDAC6 inhibitor increased α-tubulin acetylation in the peripheral nerve.  In addn., HDAC6 inhibition restored the cisplatin-induced redn. in mitochondrial bioenergetics and mitochondrial content in the tibial nerve, indicating increased mitochondrial transport.  At a later time point, dorsal root ganglion mitochondrial bioenergetics also improved.  HDAC6 inhibition restored the loss of intraepidermal nerve fiber d. in cisplatin-treated mice.  Our results demonstrate that pharmacol. inhibition of HDAC6 completely reverses all the hallmarks of established cisplatin-induced peripheral neuropathy by normalization of mitochondrial function in dorsal root ganglia and nerve, and restoration of intraepidermal innervation.  These results are esp. promising because one of the HDAC6 inhibitors tested here is currently in clin. trials as an add-on cancer therapy, highlighting the potential for a fast clin. translation of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PdcGHNGMjrVg90H21EOLACvtfcHk0lhfM55Xk4ZzzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslyrsLY%253D&md5=a9adb6661143e5735bea8c8481a8c5d5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000893%26sid%3Dliteratum%253Aachs%26aulast%3DKrukowski%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DGolonzhka%26aufirst%3DO.%26aulast%3DLaumet%26aufirst%3DG.%2BO.%26aulast%3DGutti%26aufirst%3DT.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DJarpe%26aufirst%3DM.%2BB.%26aulast%3DHeijnen%26aufirst%3DC.%2BJ.%26aulast%3DKavelaars%26aufirst%3DA.%26atitle%3DHDAC6%2520Inhibition%2520Effectively%2520Reverses%2520Chemotherapy-Induced%2520Peripheral%2520Neuropathy%26jtitle%3DPain%26date%3D2017%26volume%3D158%26spage%3D1126%26epage%3D1137%26doi%3D10.1097%2Fj.pain.0000000000000893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of the First Small Molecule Histone Deacetylase 6 (HDAC6) Degraders</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2493</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29871848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2493-2497&author=K.+Yangauthor=Y.+Songauthor=H.+Xieauthor=H.+Wuauthor=Y.-T.+Wuauthor=E.+D.+Leistenauthor=W.+Tang&title=Development+of+the+First+Small+Molecule+Histone+Deacetylase+6+%28HDAC6%29+Degraders&doi=10.1016%2Fj.bmcl.2018.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span></div><div class="casAuthors">Yang, Ka; Song, Yanling; Xie, Haibo; Wu, Hao; Wu, Yi-Ting; Leisten, Eric D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2493-2497</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins.  Over expression of HDACs have been obsd. in cancers and other diseases.  Targeted protein degrdn. by "hijacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technol. to "knock-out" endogenous disease-causing proteins.  The authors applied this strategy to the development of the first small mol. degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands.  Through cell-based assays, the authors discovered novel bifunctional mols. (dHDAC6) that could selectively degrade HDAC6.  Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9t1stJ7Qkf7Vg90H21EOLACvtfcHk0lj7zaOsxk2o0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF&md5=20be52b05a327184f824ccf9cf88333f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.-T.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520the%2520First%2520Small%2520Molecule%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Degraders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2493%26epage%3D2497%26doi%3D10.1016%2Fj.bmcl.2018.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+Multifunctional+Histone+Deacetylase+6+Degraders+with+Potent+Antimyeloma+Activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0lj7zaOsxk2o0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520Multifunctional%2520Histone%2520Deacetylase%25206%2520Degraders%2520with%2520Potent%2520Antimyeloma%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Determinants+of+Affinity+and+Selectivity+in+the+Binding+of+Inhibitors+to+Histone+Deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0lj7zaOsxk2o0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Determinants%2520of%2520Affinity%2520and%2520Selectivity%2520in%2520the%2520Binding%2520of%2520Inhibitors%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 in Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+Deacetylase+6+in+Cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0liZKZRQoRySEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%25206%2520in%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A Patent Review of Histone Deacetylase 6 Inhibitors in Neurodegenerative Diseases (2014–2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+Patent+Review+of+Histone+Deacetylase+6+Inhibitors+in+Neurodegenerative+Diseases+%282014%E2%80%932019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0liZKZRQoRySEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520Patent%2520Review%2520of%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%2520%25282014%25E2%2580%25932019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=23-39&author=M.+Brindisiauthor=A.+P.+Saraswatiauthor=S.+Brogiauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Old+but+Gold%3A+Tracking+the+New+Guise+of+Histone+Deacetylase+6+%28HDAC6%29+Enzyme+as+a+Biomarker+and+Therapeutic+Target+in+Rare+Diseases&doi=10.1021%2Facs.jmedchem.9b00924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span></div><div class="casAuthors">Brindisi, Margherita; Saraswati, A. Prasanth; Brogi, Simone; Gemma, Sandra; Butini, Stefania; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-39</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation orchestrates many cellular processes and greatly influences key disease mechanisms.  Histone deacetylase (HDAC) enzymes play a crucial role either as biomarkers or therapeutic targets owing to their involvement in specific pathophysiol. pathways.  Beyond their well-characterized role as histone modifiers, HDACs also interact with several non-histone substrates and their increased expression has been highlighted in specific diseases.  HDAC6 isoform, due to its unique cytoplasmic localization, modulates the acetylation status of tubulin, HSP90, TGF-β and peroxiredoxins.  HDAC6 also exerts non-catalytic activities, through its interaction with ubiquitin.  Both catalytic and non-catalytic functions of HDACs are being actively studied in the field of specific rare disorders, beyond the well-established role in carcinogenesis.  This perspective outlines the application of HDAC(6) inhibitors in rare diseases, such as Rett syndrome, inherited retinal disorders, idiopathic pulmonary fibrosis and Charcot-Marie-Tooth disease, highlighting their therapeutic potential as innovative and targeted disease-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kzJmRToypbVg90H21EOLACvtfcHk0liZKZRQoRySEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK&md5=688368246471313ed025f0c230167052</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00924%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DOld%2520but%2520Gold%253A%2520Tracking%2520the%2520New%2520Guise%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Enzyme%2520as%2520a%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Rare%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D23%26epage%3D39%26doi%3D10.1021%2Facs.jmedchem.9b00924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 8 (HDAC8) and Its Inhibitors with Selectivity to Other Isoforms: An Overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2018.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30594678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=214-240&author=S.+Banerjeeauthor=N.+Adhikariauthor=S.+A.+Aminauthor=T.+Jha&title=Histone+Deacetylase+8+%28HDAC8%29+and+Its+Inhibitors+with+Selectivity+to+Other+Isoforms%3A+An+Overview&doi=10.1016%2Fj.ejmech.2018.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview</span></div><div class="casAuthors">Banerjee, Suvankar; Adhikari, Nilanjan; Amin, Sk Abdul; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-240</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The histone deacetylases (HDACs) enzymes provided crucial role in transcriptional regulation of cells through deacetylation of nuclear histone proteins.  The pan-HDAC inhibitors can confront these conditions but have chances to affect epigenetic functions of other HDAC isoforms.  Designing of selective HDAC8 inhibitors is a key feature to combat the pathophysiol. and diseased conditions involving the HDAC8 activity.  This review is concerned about the structural and positional aspects of HDAC8 in the HDAC family.  It also covers the contributions of HDAC8 in the pathophysiol. conditions, a preliminary discussion about the recent scenario of HDAC8 inhibitors.  This review might help to deliver the structural, functional and computational information in order to identify and design potent and selective HDAC8 inhibitors for target specific treatment of diseases involving HDAC8 enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KrWyCwpPdrVg90H21EOLACvtfcHk0ljjHQt01CuLXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltF2q&md5=cf4ca3ae21d10662da0ce32f0c336b72</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DHistone%2520Deacetylase%25208%2520%2528HDAC8%2529%2520and%2520Its%2520Inhibitors%2520with%2520Selectivity%2520to%2520Other%2520Isoforms%253A%2520An%2520Overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D214%26epage%3D240%26doi%3D10.1016%2Fj.ejmech.2018.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1026</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fleu.2008.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18256683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVSrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1026-1034&author=S.+Balasubramanianauthor=J.+Ramosauthor=W.+Luoauthor=M.+Sirisawadauthor=E.+Vernerauthor=J.+J.+Buggy&title=A+Novel+Histone+Deacetylase+8+%28HDAC8%29-Specific+Inhibitor+PCI-34051+Induces+Apoptosis+in+T-Cell+Lymphomas&doi=10.1038%2Fleu.2008.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas</span></div><div class="casAuthors">Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1026-1034</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have developed a potent, histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 with >200-fold selectivity over the other HDAC isoforms.  PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines.  Unlike broad-spectrum HDAC inhibitors, PCI-34051 does not cause detectable histone or tubulin acetylation.  Cells defective in T-cell receptor signaling were still sensitive to PCI-34051-induced apoptosis, whereas a phospholipase C-γ1 (PLCγ1)-defective line was resistant.  Jurkat cells showed a dose-dependent decrease in PCI-34051-induced apoptosis upon treatment with a PLC inhibitor U73122, but not with an inactive analog.  We found that rapid intracellular calcium mobilization from endoplasmic reticulum (ER) and later cytochrome c release from mitochondria are essential for the apoptotic mechanism.  The rapid Ca2+ flux was dependent on PCI-34051 concn., and was blocked by the PLC inhibitor U73122.  Further, apoptosis was blocked by Ca2+ chelators (BAPTA) and enhanced by Ca2+ effectors (thapsigargin), supporting this model.  These studies show that HDAC8-selective inhibitors have a unique mechanism of action involving PLCγ1 activation and calcium-induced apoptosis, and could offer benefits including a greater therapeutic index for treating T-cell malignancies.  Leukemia (2008) 22, 1026-1034; doi:10.1038/leu.2008.9; published online 7 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-VB4Wb3h1bVg90H21EOLACvtfcHk0ljjHQt01CuLXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVSrtr0%253D&md5=03446a05b396ea9497e4f6f9254cae03</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.9%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DRamos%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Novel%2520Histone%2520Deacetylase%25208%2520%2528HDAC8%2529-Specific%2520Inhibitor%2520PCI-34051%2520Induces%2520Apoptosis%2520in%2520T-Cell%2520Lymphomas%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1026%26epage%3D1034%26doi%3D10.1038%2Fleu.2008.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of <i>ortho</i>-Aryl <i>N</i>-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcmdc.201200300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22907916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1815-1824&author=W.-J.+Huangauthor=Y.-C.+Wangauthor=S.-W.+Chaoauthor=C.-Y.+Yangauthor=L.-C.+Chenauthor=M.-H.+Linauthor=W.-C.+Houauthor=M.-Y.+Chenauthor=T.-L.+Leeauthor=P.+Yangauthor=C.-I.+Chang&title=Synthesis+and+Biological+Evaluation+of+ortho-Aryl+N-Hydroxycinnamides+as+Potent+Histone+Deacetylase+%28HDAC%29+8+Isoform-Selective+Inhibitors&doi=10.1002%2Fcmdc.201200300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Huang, Wei-Jan; Wang, Yi-Ching; Chao, Shi-Wei; Yang, Chen-Yui; Chen, Liang-Chieh; Lin, Mei-Hsiang; Hou, Wen-Chi; Chen, Mei-Yu; Lee, Tai-Lin; Yang, Ping; Chang, Chung-I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1815-1824, S1815/1-S1815/41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes that play a crucial role in biol. process and diseases.  In contrast to other isoenzymes, HDAC8 is uniquely incapable of histone acetylation.  To delineate its physiol. function, we developed HDAC8-selective inhibitors using knowledge-based design combined with structural modeling techniques.  Enzyme inhibitory anal. demonstrated that some of the resulting compds. exhibited anti-HDAC8 activity superior to PCI34051, a known HDAC8-specific inhibitor, with IC50 values in the range of 5-50 nM.  Among them, compd. (I) showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); it exhibited cytotoxicity against human lung CL1-5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR-90 cells.  Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1-5 is higher than that in H1299 and CL1-1 cells, a result consistent with the differential cytotoxicity of compd. I.  These results suggest the effectiveness of our design concept, which may lead to a tool compd. for studying the specific role of HDAC8 in cellular biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4xm7qu7wc7Vg90H21EOLACvtfcHk0ljjHQt01CuLXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL&md5=05279fdc5e9bc353f12fa3b1b0f3e365</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200300%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DWang%26aufirst%3DY.-C.%26aulast%3DChao%26aufirst%3DS.-W.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DLin%26aufirst%3DM.-H.%26aulast%3DHou%26aufirst%3DW.-C.%26aulast%3DChen%26aufirst%3DM.-Y.%26aulast%3DLee%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.-I.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520ortho-Aryl%2520N-Hydroxycinnamides%2520as%2520Potent%2520Histone%2520Deacetylase%2520%2528HDAC%2529%25208%2520Isoform-Selective%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1815%26epage%3D1824%26doi%3D10.1002%2Fcmdc.201200300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingham, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">Development of a Potent and Selective HDAC8 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=929-932&author=O.+J.+Inghamauthor=R.+M.+Paranalauthor=W.+B.+Smithauthor=R.+A.+Escobarauthor=H.+Yuehauthor=T.+Snyderauthor=J.+A.+Porcoauthor=J.+E.+Bradnerauthor=A.+B.+Beeler&title=Development+of+a+Potent+and+Selective+HDAC8+Inhibitor&doi=10.1021%2Facsmedchemlett.6b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent and Selective HDAC8 Inhibitor</span></div><div class="casAuthors">Ingham, Oscar J.; Paranal, Ronald M.; Smith, William B.; Escobar, Randolph A.; Yueh, Han; Snyder, Tracy; Porco, John A.; Bradner, James E.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-932</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel, isoform-selective inhibitor of histone deacetylase 8 (HDAC8) has been discovered by the repurposing of a diverse compd. collection.  Medicinal chem. optimization led to the identification of a highly potent (0.8 nM) and selective inhibitor I of HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF0r_7S2dWLVg90H21EOLACvtfcHk0lgKcgFmVbI4yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP&md5=69ab76f942dfc6a6b7801b90f48aa619</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00239%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DO.%2BJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DEscobar%26aufirst%3DR.%2BA.%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DT.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520Potent%2520and%2520Selective%2520HDAC8%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Facsmedchemlett.6b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeneke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trippel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burhenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp-Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernekorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of HDAC8 Decreases Neuroblastoma Growth in Vitro and in Vivo and Enhances Retinoic Acid-Mediated Differentiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1657</span>, <span class="refDoi"> DOI: 10.1038/cddis.2015.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fcddis.2015.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25695609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e1657&author=I.+Rettigauthor=E.+Koenekeauthor=F.+Trippelauthor=W.+C.+Muellerauthor=J.+Burhenneauthor=A.+Kopp-Schneiderauthor=J.+Fabianauthor=A.+Schoberauthor=U.+Fernekornauthor=A.+von+Deimlingauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=O.+Wittauthor=I.+Oehme&title=Selective+Inhibition+of+HDAC8+Decreases+Neuroblastoma+Growth+in+Vitro+and+in+Vivo+and+Enhances+Retinoic+Acid-Mediated+Differentiation&doi=10.1038%2Fcddis.2015.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation</span></div><div class="casAuthors">Rettig, I.; Koeneke, E.; Trippel, F.; Mueller, W. C.; Burhenne, J.; Kopp-Schneider, A.; Fabian, J.; Schober, A.; Fernekorn, U.; von Deimling, A.; Deubzer, H. E.; Milde, T.; Witt, O.; Oehme, I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1657</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">For differentiation-defective malignancies, compds. that modulate transcription, such as retinoic acid and histone deacetylase (HDAC) inhibitors, are of particular interest.  HDAC inhibitors are currently under investigation for the treatment of a broad spectrum of cancer diseases.  However, one clin. drawback is class-specific toxicity of unselective inhibitors, limiting their full anticancer potential.  Selective targeting of individual HDAC isoenzymes in defined tumor entities may therefore be an attractive alternative treatment approach.  We have previously identified HDAC family member 8 (HDAC8) as a novel target in childhood neuroblastoma.  Using small-mol. inhibitors, we now demonstrate that selective inhibition of HDAC8 exhibits antineuroblastoma activity without toxicity in two xenograft mouse models of MYCN oncogene-amplified neuroblastoma.  In contrast, the unselective HDAC inhibitor vorinostat was more toxic in the same models.  HDAC8-selective inhibition induced cell cycle arrest and differentiation in vitro and in vivo.  Upon combination with retinoic acid, differentiation was significantly enhanced, as demonstrated by elongated neurofilament-pos. neurites and upregulation of NTRK1.  Addnl., MYCN oncogene expression was downregulated in vitro and tumor cell growth was markedly reduced in vivo.  Mechanistic studies suggest that cAMP-response element-binding protein (CREB) links HDAC8- and retinoic acid-mediated gene transcription.  In conclusion, HDAC-selective targeting can be effective in tumors exhibiting HDAC isoenzyme-dependent tumor growth in vivo and can be combined with differentiation-inducing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ55O9b9Q78LVg90H21EOLACvtfcHk0lgKcgFmVbI4yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSis7s%253D&md5=41a5cfe6aaa685304b3bef0eae03a8ff</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2015.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2015.24%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DI.%26aulast%3DKoeneke%26aufirst%3DE.%26aulast%3DTrippel%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DW.%2BC.%26aulast%3DBurhenne%26aufirst%3DJ.%26aulast%3DKopp-Schneider%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DJ.%26aulast%3DSchober%26aufirst%3DA.%26aulast%3DFernekorn%26aufirst%3DU.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DSelective%2520Inhibition%2520of%2520HDAC8%2520Decreases%2520Neuroblastoma%2520Growth%2520in%2520Vitro%2520and%2520in%2520Vivo%2520and%2520Enhances%2520Retinoic%2520Acid-Mediated%2520Differentiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2015%26volume%3D6%26spage%3De1657%26doi%3D10.1038%2Fcddis.2015.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seok, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, M. H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 8 Improves Vascular Hypertrophy, Relaxation, and Inflammation in Angiotensin II Hypertensive Mice</span>. <i>Clin. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/s40885-019-0118-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs40885-019-0118-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31223486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ptFKqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=13&author=H.+J.+Keeauthor=Y.+Ryuauthor=Y.+M.+Seokauthor=S.+Y.+Choiauthor=S.+Sunauthor=G.+R.+Kimauthor=M.+H.+Jeong&title=Selective+Inhibition+of+Histone+Deacetylase+8+Improves+Vascular+Hypertrophy%2C+Relaxation%2C+and+Inflammation+in+Angiotensin+II+Hypertensive+Mice&doi=10.1186%2Fs40885-019-0118-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice</span></div><div class="casAuthors">Kee Hae Jin; Ryu Yuhee; Choi Sin Young; Sun Simei; Kim Gwi Ran; Jeong Myung Ho; Kee Hae Jin; Ryu Yuhee; Choi Sin Young; Sun Simei; Kim Gwi Ran; Jeong Myung Ho; Seok Young Mi; Choi Sin Young; Sun Simei</div><div class="citationInfo"><span class="NLM_cas:title">Clinical hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn">2056-5909</span>.
    </div><div class="casAbstract">Background:  The dysregulation of histone deacetylase (HDAC) protein expression or its enzyme activity is implicated in a variety of diseases.  Cardiac HDAC6 and HDAC8 enzyme activity induced by deoxycorticosterone acetate (DOCA) hypertension was attenuated by sodium valproate, a pan-HDAC inhibitor.  However, the HDAC6-selective inhibitor, tubastatin A, did not attenuate angiotensin II-induced hypertension.  The purpose of this study was to investigate whether PCI34051, an HDAC8-selective inhibitor, can modulate angiotensin II-induced hypertension and its regulatory mechanism.  Methods:  An angiotensin II-regulated mouse model was used in this study.  Animals received vehicle or PCI34051 (3 mg·kg - (1)·day- (1)) via intraperitoneal injection.  Systolic blood pressure was measured by the tail-cuff method.  Blood vessel thickness was measured following hematoxylin and eosin staining, VCAM-1 immunohistochemistry was performed in the aortas, and mRNA expression of renin-angiotensin system components, inflammation markers, and NADPH oxidase (Nox) was determined by RT-PCR.  The effect of PCI34051 on vasorelaxation was studied in rat aortic rings, and its effect on nitric oxide (NO) production was determined using DAF-FM DA, a fluorescent dye, in human umbilical vascular endothelial cells (HUVECs).  Results:  PCI34051 administration reduced systolic blood pressure via downregulation of angiotensin II receptor type 1 (AT1) mRNA expression.  PCI34051 treatment attenuated vascular hypertrophy by decreasing E2F3 and GATA6 mRNA expression.  Vascular relaxation after PCI34051 treatment was more dependent on vascular endothelial cells and it was blocked by an NO synthase (NOS) inhibitor.  In addition, NO production increased in HUVECs after PCI34051 treatment; this was decreased by the NOS inhibitor.  The expression of inflammatory molecules and adhesion molecules VCAM-1 and ICAM-1 decreased in the aortas of angiotensin II-infused mice after PCI34051 administration.  However, PCI34051 did not affect Nox or its regulatory subunits.  Conclusions:  PCI34051 lowered high blood pressure through modulation of arterial remodeling, vasoconstriction, and inflammation in an angiotensin II-induced hypertension model.  We suggest that HDAC8 could be a potential therapeutic target for hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTT5hClw2T1CDAEfvC7EH1LfW6udTcc2ebHQBkceYArKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ptFKqug%253D%253D&md5=0453cd6f56a952926a8a293adb1636d5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs40885-019-0118-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40885-019-0118-8%26sid%3Dliteratum%253Aachs%26aulast%3DKee%26aufirst%3DH.%2BJ.%26aulast%3DRyu%26aufirst%3DY.%26aulast%3DSeok%26aufirst%3DY.%2BM.%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DG.%2BR.%26aulast%3DJeong%26aufirst%3DM.%2BH.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25208%2520Improves%2520Vascular%2520Hypertrophy%252C%2520Relaxation%252C%2520and%2520Inflammation%2520in%2520Angiotensin%2520II%2520Hypertensive%2520Mice%26jtitle%3DClin.%2520Hypertens.%26date%3D2019%26volume%3D25%26spage%3D13%26doi%3D10.1186%2Fs40885-019-0118-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, G.</span></span> <span> </span><span class="NLM_article-title">HADC8 Inhibitor WK2-16 Therapeutically Targets Lipopolysaccharide-Induced Mouse Model of Neuroinflammation and Microglial Activation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">410</span>, <span class="refDoi"> DOI: 10.3390/ijms20020410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20020410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=410&author=F.-L.+Linauthor=J.-L.+Yenauthor=Y.-C.+Kuoauthor=J.-J.+Kangauthor=Y.-W.+Chengauthor=W.-J.+Huangauthor=G.+Hsiao&title=HADC8+Inhibitor+WK2-16+Therapeutically+Targets+Lipopolysaccharide-Induced+Mouse+Model+of+Neuroinflammation+and+Microglial+Activation&doi=10.3390%2Fijms20020410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 inhibitor WK2-16 therapeutically targets lipopolysaccharide-induced mouse model of neuroinflammation and microglial activation</span></div><div class="casAuthors">Lin, Fan-Li; Yen, Jing-Lun; Kuo, Yu-Cheng; Kang, Jaw-Jou; Cheng, Yu-Wen; Huang, Wei-Jan; Hsiao, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">410/1-410/20</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glial activation and neuroinflammatory processes play important roles in the pathogenesis of brain abscess and neurodegenerative diseases.  Activated glial cells can secrete various proinflammatory cytokines and neurotoxic mediators, which contribute to the exacerbation of neuronal cell death.  The inhibition of glial activation has been shown to alleviate neurodegenerative conditions.  The present study was to investigate the specific HDAC8 inhibitor WK2-16, esp. its effects on the neuroinflammatory responses through glial inactivation.  WK2-16 significantly reduced the gelatinolytic activity of MMP-9, and expression of COX-2/iNOS proteins in striatal lipopolysaccharide (LPS)-induced neuroinflammation in C57BL/6 mice.  The treatment of WK2-16 markedly improved neurobehavioral deficits.  Immunofluorescent staining revealed that WK2-16 reduced LPS-stimulated astrogliosis and microglial activation in situ.  Consistently, cellular studies revealed that WK2-16 significantly suppressed LPS-induced mouse microglia BV-2 cell proliferation.  WK2-16 was proven to concn.-dependently induce the levels of acetylated SMC3 in microglial BV-2 cells.  It also reduced the expression of COX-2/iNOS proteins and TNF-α prodn. in LPS-activated microglial BV-2 cells.  The signaling studies demonstrated that WK2-16 markedly inhibited LPS-activated STAT-1/-3 and Akt activation, but not NF-κB or MAPK signaling.  In summary, the HDAC8 inhibitor WK2-16 exhibited neuroprotective effects through its anti-neuroinflammation and glial inactivation properties, esp. in microglia in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdGFyq2_YsLVg90H21EOLACvtfcHk0liG-x1cbilCBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs73I&md5=517707261c6f79a54a5c3266507d7d70</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.3390%2Fijms20020410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020410%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DF.-L.%26aulast%3DYen%26aufirst%3DJ.-L.%26aulast%3DKuo%26aufirst%3DY.-C.%26aulast%3DKang%26aufirst%3DJ.-J.%26aulast%3DCheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DHsiao%26aufirst%3DG.%26atitle%3DHADC8%2520Inhibitor%2520WK2-16%2520Therapeutically%2520Targets%2520Lipopolysaccharide-Induced%2520Mouse%2520Model%2520of%2520Neuroinflammation%2520and%2520Microglial%2520Activation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D410%26doi%3D10.3390%2Fijms20020410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Inhibitor Attenuates Airway Responses to Antigen Stimulus through Synchronously Suppressing Galectin-3 Expression and Reducing Macrophage-2 Polarization</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi"> DOI: 10.1186/s12931-020-1322-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs12931-020-1322-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32111211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvValtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=62&author=M.-L.+Liauthor=X.-M.+Suauthor=Y.+Renauthor=X.+Zhaoauthor=L.-F.+Kongauthor=J.+Kang&title=HDAC8+Inhibitor+Attenuates+Airway+Responses+to+Antigen+Stimulus+through+Synchronously+Suppressing+Galectin-3+Expression+and+Reducing+Macrophage-2+Polarization&doi=10.1186%2Fs12931-020-1322-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization</span></div><div class="casAuthors">Li, Meng-lu; Su, Xin-ming; Ren, Yuan; Zhao, Xuan; Kong, Ling-fei; Kang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">This study was to investigate of the mechanism by which histone deacetylase (HDAC) 8 inhibitor ameliorated airway hyperresponsiveness (AHR) and allergic airway inflammation.  Repetitive measurements of enhanced pause (Penh) were executed by increasing concns. of acetyl-β-methacholine chloride (0 - 50 mg/mL).  Cells in bronchoalveolar lavage fluid (BALF) and pathol. changes of lungs were examd., resp.  The expression levels of HDAC8, Galecitn (Gal)-3, CD68, CD86, CD163, Arg1 and NOS2 in lungs were measured.  Significant increases in Penh and IL-4 level were detected with a large inflammatory infiltrate, comprised predominantly of macrophages and eosinophils, into the BALF in OVA-exposed lungs.  HDAC8, Gal-3, CD68, CD86, CD163, Arg1 and NOS2 proteins were over-expressed with the significant changes in the Arg1 and NOS2 mRNA levels in the lungs and the IL-4-treated cells.  PCI intervention obviously reduced the counts of CD163+ cells.  Furthermore, Gal-3 knockdown suppressed Arg1 expression in the cells.  Immunofluorescence staining displayed simultaneous changes in HDAC8 and Gal-3 expression in the investigated samples.  Treatment with PCI resulted in synchronous redn. of HDAC8 and Gal-3 expression in the Co-IP complexes.  The HDAC8 inhibitor ameliorates AHR and airway inflammation in animal model of allergic asthma through reducing HDAC8-Gal-3 interaction and M2 macrophage polarization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcIbmDMC1Nm7Vg90H21EOLACvtfcHk0liG-x1cbilCBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvValtLs%253D&md5=287694ded95d2e09f47503b8df9db36f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1186%2Fs12931-020-1322-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-020-1322-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.-L.%26aulast%3DSu%26aufirst%3DX.-M.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DL.-F.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DHDAC8%2520Inhibitor%2520Attenuates%2520Airway%2520Responses%2520to%2520Antigen%2520Stimulus%2520through%2520Synchronously%2520Suppressing%2520Galectin-3%2520Expression%2520and%2520Reducing%2520Macrophage-2%2520Polarization%26jtitle%3DRespir.%2520Res.%26date%3D2020%26volume%3D21%26spage%3D62%26doi%3D10.1186%2Fs12931-020-1322-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faião-Flores, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messina, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondak, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F0008-5472.CAN-19-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30987999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCrsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=2947-2961&author=M.+F.+Emmonsauthor=F.+Fai%C3%A3o-Floresauthor=R.+Sharmaauthor=R.+Thapaauthor=J.+L.+Messinaauthor=J.+C.+Beckerauthor=D.+Schadendorfauthor=E.+Setoauthor=V.+K.+Sondakauthor=J.+M.+Koomenauthor=Y.+A.+Chenauthor=E.+K.+Lauauthor=L.+Wanauthor=J.+D.+Lichtauthor=K.+S.+M.+Smalley&title=HDAC8+Regulates+a+Stress+Response+Pathway+in+Melanoma+to+Mediate+Escape+from+BRAF+Inhibitor+Therapy&doi=10.1158%2F0008-5472.CAN-19-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF Inhibitor therapy</span></div><div class="casAuthors">Emmons, Michael F.; Faiao-Flores, Fernanda; Sharma, Ritin; Thapa, Ram; Messina, Jane L.; Becker, Jurgen C.; Schadendorf, Dirk; Seto, Edward; Sondak, Vernon K.; Koomen, John M.; Chen, Yian A.; Lau, Eric K.; Wan, Lixin; Licht, Jonathan D.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2947-2961</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Melanoma cells have the ability to switch to a dedifferentiated, invasive phenotype in response to multiple stimuli.  Here, we show that exposure of melanomas to multiple stresses including BRAF-MEK inhibitor therapy, hypoxia, and UV irradn. leads to an increase in histone deacetylase 8 (HDAC8) activity and the adoption of a drug-resistant phenotype.  Mass spectrometry-based phosphoproteomics implicated HDAC8 in the regulation of MAPK and AP-1 signaling.  Introduction of HDAC8 into drug-na.ovrddot.ive melanoma cells conveyed resistance both in vitro and in vivo.  HDAC8-mediated BRAF inhibitor resistance was mediated via receptor tyrosine kinase activation, leading to MAPK signaling.  Although HDACs function at the histone level, they also regulate nonhistone substrates, and introduction of HDAC8 decreased the acetylation of c-Jun, increasing its transcriptional activity and enriching for an AP-1 gene signature.  Mutation of the putative c-Jun acetylation site at lysine 273 increased transcriptional activation of c-Jun in melanoma cells and conveyed resistance to BRAF inhibition.  In vivo xenograft studies confirmed the key role of HDAC8 in therapeutic adaptation, with both nonselective and HDAC8-specific inhibitors enhancing the durability of BRAF inhibitor therapy.  Our studies demonstrate that HDAC8-specific inhibitors limit the adaptation of melanoma cells to multiple stresses including BRAF-MEK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2INUuzvGwQLVg90H21EOLACvtfcHk0liG-x1cbilCBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCrsL%252FF&md5=4958b2d9dfeae190f0ddef2e077a1536</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0040%26sid%3Dliteratum%253Aachs%26aulast%3DEmmons%26aufirst%3DM.%2BF.%26aulast%3DFai%25C3%25A3o-Flores%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DR.%26aulast%3DMessina%26aufirst%3DJ.%2BL.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BA.%26aulast%3DLau%26aufirst%3DE.%2BK.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26atitle%3DHDAC8%2520Regulates%2520a%2520Stress%2520Response%2520Pathway%2520in%2520Melanoma%2520to%2520Mediate%2520Escape%2520from%2520BRAF%2520Inhibitor%2520Therapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D2947%26epage%3D2961%26doi%3D10.1158%2F0008-5472.CAN-19-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudnitskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel <i>N</i>-Hydroxy-2-Arylisoindoline-4-Carboxamides as Potent and Selective Inhibitors of HDAC11</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2143</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29776742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslShtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2143-2147&author=M.+W.+Martinauthor=J.+Y.+Leeauthor=D.+R.+Lanciaauthor=P.+Y.+Ngauthor=B.+Hanauthor=J.+R.+Thomasonauthor=M.+S.+Lynesauthor=C.+G.+Marshallauthor=C.+Contiauthor=A.+Collisauthor=M.+A.+Moralesauthor=K.+Doshiauthor=A.+Rudnitskayaauthor=L.+Yaoauthor=X.+Zheng&title=Discovery+of+Novel+N-Hydroxy-2-Arylisoindoline-4-Carboxamides+as+Potent+and+Selective+Inhibitors+of+HDAC11&doi=10.1016%2Fj.bmcl.2018.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11</span></div><div class="casAuthors">Martin, Matthew W.; Lee, Jennifer Y.; Lancia, David R., Jr.; Ng, Pui Yee; Han, Bingsong; Thomason, Jennifer R.; Lynes, Maureen S.; Marshall, C. Gary; Conti, Chiara; Collis, Alan; Morales, Monica Alvarez; Doshi, Kshama; Rudnitskaya, Aleksandra; Yao, Lili; Zheng, Xiaozhang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2143-2147</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11.  The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported.  An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biol. of HDAC11 and its potential use as a therapeutic target for oncol. and inflammation indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1a4YGLwigwrVg90H21EOLACvtfcHk0lg_jAUJn1z9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslShtb0%253D&md5=c5eec0204b7c318059e83838181aff4c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLancia%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DP.%2BY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DLynes%26aufirst%3DM.%2BS.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DConti%26aufirst%3DC.%26aulast%3DCollis%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DM.%2BA.%26aulast%3DDoshi%26aufirst%3DK.%26aulast%3DRudnitskaya%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Novel%2520N-Hydroxy-2-Arylisoindoline-4-Carboxamides%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC11%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2143%26epage%3D2147%26doi%3D10.1016%2Fj.bmcl.2018.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span> <span> </span><span class="NLM_article-title">Activity-Guided Design of HDAC11-Specific Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00292</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00292" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yjs7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1393-1397&author=S.+I.+Sonauthor=J.+Caoauthor=C.-L.+Zhuauthor=S.+P.+Millerauthor=H.+Lin&title=Activity-Guided+Design+of+HDAC11-Specific+Inhibitors&doi=10.1021%2Facschembio.9b00292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-guided design of HDAC11-specific inhibitors</span></div><div class="casAuthors">Son, Se In; Cao, Ji; Zhu, Cheng-Liang; Miller, Seth P.; Lin, Hening</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1397</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mammalian histone deacetylases (HDACs) are a class of enzymes that play important roles in biol. pathways.  Existing HDAC inhibitors target multiple HDACs without much selectivity.  Inhibitors that target one particular HDAC will be useful for investigating the biol. functions of HDACs and for developing better therapeutics.  Here, we report the development of HDAC11-specific inhibitors using an activity-guided rational design approach.  The enzymic activity and biol. function of HDAC11 have been little known, but recent reports suggest that it has efficient defatty-acylation activity and that inhibiting it could be useful for treating a variety of human diseases, including viral infection, multiple sclerosis, and metabolic diseases.  Our best inhibitor, SIS17(I), is active in cells and inhibited the demyristoylation of a known HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.  The activity-guided design may also be useful for the development of isoform-specific inhibitors for other classes of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYlAO5SOhnvLVg90H21EOLACvtfcHk0lg_jAUJn1z9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yjs7%252FP&md5=c98f2b6413cea1f0fbf337b368818581</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00292%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%2BI.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DC.-L.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DLin%26aufirst%3DH.%26atitle%3DActivity-Guided%2520Design%2520of%2520HDAC11-Specific%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1393%26epage%3D1397%26doi%3D10.1021%2Facschembio.9b00292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Géraldy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue Is Implicated</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4426-4443&author=M.+G%C3%A9raldyauthor=M.+Morgenauthor=P.+Sehrauthor=R.+R.+Steimbachauthor=D.+Moiauthor=J.+Ridingerauthor=I.+Oehmeauthor=O.+Wittauthor=M.+Malzauthor=M.+S.+Nogueiraauthor=O.+Kochauthor=N.+Gunkelauthor=A.+K.+Miller&title=Selective+Inhibition+of+Histone+Deacetylase+10%3A+Hydrogen+Bonding+to+the+Gatekeeper+Residue+Is+Implicated&doi=10.1021%2Facs.jmedchem.8b01936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span></div><div class="casAuthors">Geraldy, Magalie; Morgen, Michael; Sehr, Peter; Steimbach, Raphael R.; Moi, Davide; Ridinger, Johannes; Oehme, Ina; Witt, Olaf; Malz, Mona; Nogueira, Mauro S.; Koch, Oliver; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4426-4443</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of isoenzyme-selective histone deacetylase (HDAC) inhibitors is crit. for understanding the biol. functions of individual HDACs and for validating HDACs as drug targets.  The isoenzyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published.  Using two complementary assays, the authors found tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10.  The authors synthesized tubastatin A derivs. and found that a basic amine in the cap group was required for strong HDAC10 binding.  HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line.  Furthermore, docking into human HDAC10 homol. models indicated that a hydrogen-bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding.  Taken together, the authors' data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the tubastatin A scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl1kc8D1boarVg90H21EOLACvtfcHk0lg_jAUJn1z9Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D&md5=9c8fbb8ac46ca0db29df3848cb5e9b50</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01936%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25A9raldy%26aufirst%3DM.%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DSehr%26aufirst%3DP.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DMoi%26aufirst%3DD.%26aulast%3DRidinger%26aufirst%3DJ.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DNogueira%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%252010%253A%2520Hydrogen%2520Bonding%2520to%2520the%2520Gatekeeper%2520Residue%2520Is%2520Implicated%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4426%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b01936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst-Gervasoni, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Binding of <i>N</i><sup>8</sup>-Acetylspermidine Analogues to Histone Deacetylase 10 Reveals Molecular Strategies for Blocking Polyamine Deacetylation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4957</span>– <span class="NLM_lpage">4969</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFynu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4957-4969&author=C.+J.+Herbst-Gervasoniauthor=D.+W.+Christianson&title=Binding+of+N8-Acetylspermidine+Analogues+to+Histone+Deacetylase+10+Reveals+Molecular+Strategies+for+Blocking+Polyamine+Deacetylation&doi=10.1021%2Facs.biochem.9b00906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of N8-Acetylspermidine Analogues to Histone Deacetylase 10 Reveals Molecular Strategies for Blocking Polyamine Deacetylation</span></div><div class="casAuthors">Herbst-Gervasoni, Corey J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4957-4969</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic histone deacetylase 10 (HDAC10) is a Zn2+-dependent hydrolase that exhibits catalytic specificity for the hydrolysis of the polyamine N8-acetylspermidine.  The recently detd. crystal structure of HDAC10 from Danio rerio (zebrafish) reveals a narrow active site cleft and a neg. charged "gatekeeper" (E274) that favors the binding of the slender cationic substrate.  Since HDAC10 expression is upregulated in advanced-stage neuroblastoma and induces autophagy, the selective inhibition of HDAC10 suppresses the autophagic response and renders cancer cells more susceptible to cytotoxic chemotherapeutic drugs.  Here, we describe X-ray crystal structures of zebrafish HDAC10 complexed with eight different analogs of N8-acetylspermidine.  These analogs contain different Zn2+-binding groups, such as hydroxamate, thiolate, and the tetrahedral gem-diolate resulting from the addn. of a Zn2+-bound water mol. to a ketone carbonyl group.  Notably, the chem. that accompanies the binding of ketonic substrate analogs is identical to the chem. involved in the first step of catalysis, i.e., nucleophilic attack of a Zn2+-bound water mol. at the scissile carbonyl group of N8-acetylspermidine.  The most potent inhibitor studied contains a thiolate Zn2+-binding group.  These structures reveal interesting geometric changes in the metal coordination polyhedron that accommodate inhibitor binding.  Addnl. interactions in the active site highlight features contributing to substrate specificity.  These interactions are likely to contribute to inhibitor binding selectivity and will inform the future design of compds. selective for HDAC10 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2JBdeKMN-dLVg90H21EOLACvtfcHk0li7fSBpCT9qfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFynu77E&md5=e3a349c0f8dda9f061325dfd415c7a93</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00906%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst-Gervasoni%26aufirst%3DC.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBinding%2520of%2520N8-Acetylspermidine%2520Analogues%2520to%2520Histone%2520Deacetylase%252010%2520Reveals%2520Molecular%2520Strategies%2520for%2520Blocking%2520Polyamine%2520Deacetylation%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4957%26epage%3D4969%26doi%3D10.1021%2Facs.biochem.9b00906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective Class IIa Histone Deacetylase Inhibition via a Nonchelating Zinc-Binding Group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+Class+IIa+Histone+Deacetylase+Inhibition+via+a+Nonchelating+Zinc-Binding+Group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0li7fSBpCT9qfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibition%2520via%2520a%2520Nonchelating%2520Zinc-Binding%2520Group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papangeli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwangbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, H. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1164/rccm.201805-0817LE</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1164%2Frccm.201805-0817LE" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30106596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nvFyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=1345-1348&author=A.+Soferauthor=S.+Leeauthor=I.+Papangeliauthor=T.+Adachiauthor=C.+Hwangboauthor=S.+Comhairauthor=P.+DaSilva-Jardineauthor=J.+Kimauthor=J.+J.+Schwarzauthor=S.+C.+Erzurumauthor=H.+J.+Chun&title=Therapeutic+Engagement+of+the+Histone+Deacetylase+IIA-Myocyte+Enhancer+Factor+2+Axis+Improves+Experimental+Pulmonary+Hypertension&doi=10.1164%2Frccm.201805-0817LE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension</span></div><div class="casAuthors">Sofer Avraham; Lee Seyoung; Papangeli Irinna; Adachi Takaomi; Hwangbo Cheol; Chun Hyung J; Comhair Suzy; Erzurum Serpil C; DaSilva-Jardine Paul; Kim Jongmin; Schwarz John J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1345-1348</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq_6kKTeex5MERNNga7KD-fW6udTcc2eYzfq25DCUKvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nvFyksQ%253D%253D&md5=a40b798e2dfe4c3796e430b7f4cf4bb1</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1164%2Frccm.201805-0817LE&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201805-0817LE%26sid%3Dliteratum%253Aachs%26aulast%3DSofer%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPapangeli%26aufirst%3DI.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DHwangbo%26aufirst%3DC.%26aulast%3DComhair%26aufirst%3DS.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BJ.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DH.%2BJ.%26atitle%3DTherapeutic%2520Engagement%2520of%2520the%2520Histone%2520Deacetylase%2520IIA-Myocyte%2520Enhancer%2520Factor%25202%2520Axis%2520Improves%2520Experimental%2520Pulmonary%2520Hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D198%26spage%3D1345%26epage%3D1348%26doi%3D10.1164%2Frccm.201805-0817LE" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Mechanism of TMP269, a Selective Class IIA Histone Deacetylase Inhibitor, after Cerebral Ischemia/Reperfusion Injury</span>. <i>Neural Regener. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.4103/1673-5374.265562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.4103%2F1673-5374.265562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31552900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=277-284&author=L.+Suauthor=D.+Liangauthor=S.-Y.+Kuangauthor=Q.+Dongauthor=X.+Hanauthor=Z.+Wang&title=Neuroprotective+Mechanism+of+TMP269%2C+a+Selective+Class+IIA+Histone+Deacetylase+Inhibitor%2C+after+Cerebral+Ischemia%2FReperfusion+Injury&doi=10.4103%2F1673-5374.265562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective mechanism of TMP269, a selective class IIA histone deacetylase inhibitor, after cerebral ischemia/reperfusion injury</span></div><div class="casAuthors">Su Lu; Kuang Shen-Yi; Dong Qiang; Han Xiang; Wang Zheng; Liang Dan</div><div class="citationInfo"><span class="NLM_cas:title">Neural regeneration research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-284</span>
        ISSN:<span class="NLM_cas:issn">1673-5374</span>.
    </div><div class="casAbstract">TMP269 is a selective class IIA histone deacetylase inhibitor that has a protective effect on the central nervous system, whose specific mechanism of action is unclear.  We aimed to reveal the optimal concentration of TMP269 for protecting against cerebral ischemia/reperfusion injury and its neuroprotective mechanism.  Male Sprague-Dawley rats were randomly divided into sham, ischemia/reperfusion, and 1, 4, 10 and 16 mg/kg TMP269 groups.  Cerebral ischemia/reperfusion injury was induced by middle cerebral artery occlusion.  TMP269 was intraperitoneally administered at different doses 0.5 hours before ischemia induction.  Western blot assay and immunohistochemistry were used to detect effects of TMP269 on histone 2 acetylation.  The results showed that the level of histone 2 acetylation was increased 24 hours after TMP269 injection. 2,3,5-Triphenyltetrazolium chloride staining was utilized to examine effect of TMP269 on infarct volume.  The results found that different doses of TMP269 could reduce the infarct volume.  Western blot assay, immunohistochemistry and Evans blue staining were employed to measure the effect of TMP269 on blood-brain barrier.  The results showed that TMP269 counteracted the abnormal endothelial cell permeability changes caused by cerebral ischemia/reperfusion.  Western blot assay and immunohistochemistry were used to determine the effect of TMP269 on tissue kallikrein.  The results found that TMP269 up-regulated the expression of tissue kallikrein.  Western blot assay further determined the optimal concentration to be 4 mg/kg.  In conclusion, TMP269 plays a neuroprotective role by up-regulating the level of histone 2 acetylation, alleviating endothelial cell injury after cerebral ischemia/reperfusion, and up-regulating the expression of tissue kallikrein.  The experimental protocol was approved in 2014 by the Department of Laboratory Animal Science, Fudan University, China (approval No. 20140143C001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrdKz2tBsAwwaK-_ZudimnfW6udTcc2eYzfq25DCUKvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvFehuw%253D%253D&md5=b8bf2ed761e77bc8d43d52334c69efb1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4103%2F1673-5374.265562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F1673-5374.265562%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DS.-Y.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DNeuroprotective%2520Mechanism%2520of%2520TMP269%252C%2520a%2520Selective%2520Class%2520IIA%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520after%2520Cerebral%2520Ischemia%252FReperfusion%2520Injury%26jtitle%3DNeural%2520Regener.%2520Res.%26date%3D2020%26volume%3D15%26spage%3D277%26epage%3D284%26doi%3D10.4103%2F1673-5374.265562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, B. E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walburg, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrieling, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mara Pinto Dabés Guimarães, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaink, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenhoff, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haks, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, M. T.</span></span> <span> </span><span class="NLM_article-title">Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances <i>in Vitro</i> and <i>in Vivo</i> Anti-Mycobacterial Activity in Human Macrophages and in Zebrafish</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffimmu.2020.00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32117228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGiurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=36&author=J.+D.+Moreiraauthor=B.+E.+V.+Kochauthor=S.+van+Veenauthor=K.+V.+Walburgauthor=F.+Vrielingauthor=T.+Mara+Pinto+Dab%C3%A9s+Guimar%C3%A3esauthor=A.+H.+Meijerauthor=H.+P.+Spainkauthor=T.+H.+M.+Ottenhoffauthor=M.+C.+Haksauthor=M.+T.+Heemskerk&title=Functional+Inhibition+of+Host+Histone+Deacetylases+%28HDACs%29+Enhances+in+Vitro+and+in+Vivo+Anti-Mycobacterial+Activity+in+Human+Macrophages+and+in+Zebrafish&doi=10.3389%2Ffimmu.2020.00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish</span></div><div class="casAuthors">Moreira, Josimar D.; Koch, Bjorn E. V.; Van Veen, Suzanne; Walburg, Kimberley V.; Vrieling, Frank; Guimaraes, Tania Mara Pinto Dabes; Meijer, Annemarie H.; Spaink, Herman P.; Ottenhoff, Tom H. M.; Haks, Marieelle C.; Heemskerk, Matthias T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rapid and persistent increase of drug-resistant Mycobacterium tuberculosis (Mtb) infections poses increasing global problems in combating tuberculosis (TB), prompting for the development of alternative strategies including host-directed therapy (HDT).  Since Mtb is an intracellular pathogen with a remarkable ability to manipulate host intracellular signaling pathways to escape from host defense, pharmacol. reprogramming of the immune system represents a novel, potentially powerful therapeutic strategy that should be effective also against drug-resistant Mtb.  Here, we found that host-pathogen interactions in Mtb-infected primary human macrophages affected host epigenetic features by modifying histone deacetylase (HDAC) transcriptomic levels.  In addn., broad spectrum inhibition of HDACs enhanced the antimicrobial response of both pro-inflammatory macrophages (Mφ1) and anti-inflammatory macrophages (Mφ2), while selective inhibition of class IIa HDACs mainly decreased bacterial outgrowth in Mφ2.  Moreover, chem. inhibition of HDAC activity during differentiation polarized macrophages into a more bactericidal phenotype with a concomitant decrease in the secretion levels of inflammatory cytokines.  Importantly, in vivo chem. inhibition of HDAC activity in Mycobacterium marinum-infected zebrafish embryos, a well-characterized animal model for tuberculosis, significantly reduced mycobacterial burden, validating our in vitro findings in primary human macrophages.  Collectively, these data identify HDACs as druggable host targets for HDT against intracellular Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHZm0Rg24ymrVg90H21EOLACvtfcHk0lgmvfkTs9xzAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGiurnK&md5=8b2b570eda24d14ea00274ca39311809</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00036%26sid%3Dliteratum%253Aachs%26aulast%3DMoreira%26aufirst%3DJ.%2BD.%26aulast%3DKoch%26aufirst%3DB.%2BE.%2BV.%26aulast%3Dvan%2BVeen%26aufirst%3DS.%26aulast%3DWalburg%26aufirst%3DK.%2BV.%26aulast%3DVrieling%26aufirst%3DF.%26aulast%3DMara%2BPinto%2BDab%25C3%25A9s%2BGuimar%25C3%25A3es%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DA.%2BH.%26aulast%3DSpaink%26aufirst%3DH.%2BP.%26aulast%3DOttenhoff%26aufirst%3DT.%2BH.%2BM.%26aulast%3DHaks%26aufirst%3DM.%2BC.%26aulast%3DHeemskerk%26aufirst%3DM.%2BT.%26atitle%3DFunctional%2520Inhibition%2520of%2520Host%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520Enhances%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Anti-Mycobacterial%2520Activity%2520in%2520Human%2520Macrophages%2520and%2520in%2520Zebrafish%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D36%26doi%3D10.3389%2Ffimmu.2020.00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville-Stones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34-39&author=C.+A.+Luckhurstauthor=P.+Brecciaauthor=A.+J.+Stottauthor=O.+Azizauthor=H.+L.+Birchauthor=R.+W.+B%C3%BCrliauthor=S.+J.+Hughesauthor=R.+E.+Jarvisauthor=M.+Lamersauthor=P.+M.+Leonardauthor=K.+L.+Matthewsauthor=G.+McAllisterauthor=S.+Pollackauthor=E.+Saville-Stonesauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Potent%2C+Selective%2C+and+CNS-Penetrant+Tetrasubstituted+Cyclopropane+Class+IIa+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Luckhurst, Christopher A.; Breccia, Perla; Stott, Andrew J.; Aziz, Omar; Birch, Helen L.; Burli, Roland W.; Hughes, Samantha J.; Jarvis, Rebecca E.; Lamers, Marieke; Leonard, Philip M.; Matthews, Kim L.; McAllister, George; Pollack, Scott; Saville-Stones, Elizabeth; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective class IIa HDAC tetrasubstituted cyclopropane hydroxamic acid inhibitors were identified with high oral bioavailability that exhibited good brain and muscle exposure.  Compd. (I) displayed suitable properties for assessment of the impact of class IIa HDAC catalytic site inhibition in preclin. disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01yllqODDNLVg90H21EOLACvtfcHk0lg_aDn7moch1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE&md5=dfc4f299bc59bdb7bcf92f7e0bccda0d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00302%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBirch%26aufirst%3DH.%2BL.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DJarvis%26aufirst%3DR.%2BE.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%2BM.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DSaville-Stones%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DPotent%252C%2520Selective%252C%2520and%2520CNS-Penetrant%2520Tetrasubstituted%2520Cyclopropane%2520Class%2520IIa%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D34%26epage%3D39%26doi%3D10.1021%2Facsmedchemlett.5b00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maillard, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Development and Characterization of a CNS-Penetrant Benzhydryl Hydroxamic Acid Class IIa Histone Deacetylase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30463802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=83-88&author=C.+A.+Luckhurstauthor=O.+Azizauthor=V.+Beaumontauthor=R.+W.+B%C3%BCrliauthor=P.+Brecciaauthor=M.+C.+Maillardauthor=A.+F.+Haughanauthor=M.+Lamersauthor=P.+Leonardauthor=K.+L.+Matthewsauthor=G.+Raphyauthor=A.+J.+Stottauthor=I.+Munoz-Sanjuanauthor=B.+Thomasauthor=M.+Wallauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Development+and+Characterization+of+a+CNS-Penetrant+Benzhydryl+Hydroxamic+Acid+Class+IIa+Histone+Deacetylase+Inhibitor&doi=10.1016%2Fj.bmcl.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor</span></div><div class="casAuthors">Luckhurst, Christopher A.; Aziz, Omar; Beaumont, Vahri; Burli, Roland W.; Breccia, Perla; Maillard, Michel C.; Haughan, Alan F.; Lamers, Marieke; Leonard, Phil; Matthews, Kim L.; Raphy, Gilles; Stott, Andrew J.; Munoz-Sanjuan, Ignacio; Thomas, Beth; Wall, Michael; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor 22(I), with >500-fold selectivity over class I HDACs (1,2,3) and ∼150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.  Dose escalation pharmacokinetic anal. demonstrated that upon oral administration, compd. 22 can reach exposure levels in mouse plasma, muscle and brain in excess of cellular class IIa HDAC IC50 levels for ∼8 h.  Given the interest in aberrant class IIa HDAC function for a no. of neurodegenerative, neuromuscular, cardiac and oncol. indications, compd. 22 (also known as CHDI-390576) provides a selective and potent compd. to query the role of class IIa HDAC biol., and the impact of class IIa catalytic site occupancy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgNfS2AXrN7Vg90H21EOLACvtfcHk0lg_aDn7moch1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM&md5=8348010d11e3fe0114ca1a2e596206d4</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DMaillard%26aufirst%3DM.%2BC.%26aulast%3DHaughan%26aufirst%3DA.%2BF.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DRaphy%26aufirst%3DG.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DDevelopment%2520and%2520Characterization%2520of%2520a%2520CNS-Penetrant%2520Benzhydryl%2520Hydroxamic%2520Acid%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D83%26epage%3D88%26doi%3D10.1016%2Fj.bmcl.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 35 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Nilanjan Adhikari, Tarun Jha, <span class="NLM_string-name hlFld-ContribAuthor">Balaram Ghosh</span>. </span><span class="cited-content_cbyCitation_article-title">Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8827-8869. <a href="https://doi.org/10.1021/acs.jmedchem.0c01676" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01676%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDissecting%252BHistone%252BDeacetylase%252B3%252Bin%252BMultiple%252BDisease%252BConditions%25253A%252BSelective%252BInhibition%252Bas%252Ba%252BPromising%252BTherapeutic%252BStrategy%26aulast%3DAdhikari%26aufirst%3DNilanjan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D24092020%26date%3D23062021%26volume%3D64%26issue%3D13%26spage%3D8827%26epage%3D8869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaopeng Peng, Jingxuan Chen, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8447-8473. <a href="https://doi.org/10.1021/acs.jmedchem.1c00413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEfficient%252BSynthesis%252Band%252BBioevaluation%252Bof%252BNovel%252BDual%252BTubulin%25252FHistone%252BDeacetylase%252B3%252BInhibitors%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DPeng%26aufirst%3DXiaopeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D07062021%26volume%3D64%26issue%3D12%26spage%3D8447%26epage%3D8473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng He, C. James Chou, Matthias Scheiner, Eleonora Poeta, Natalia Yuan Chen, Sandra Gunesch, Matthias Hoffmann, Christoph Sotriffer, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3794-3812. <a href="https://doi.org/10.1021/acs.jmedchem.0c01940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelatonin-%252Band%252BFerulic%252BAcid-Based%252BHDAC6%252BSelective%252BInhibitors%252BExhibit%252BPronounced%252BImmunomodulatory%252BEffects%252BIn%252BVitro%252Band%252BNeuroprotective%252BEffects%252Bin%252Ba%252BPharmacological%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DHe%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D26032021%26volume%3D64%26issue%3D7%26spage%3D3794%26epage%3D3812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olasunkanmi O. Olaoye, Paris R. Watson, Nabanita Nawar, Mulu Geletu, Abootaleb Sedighi, Shazreh Bukhari, Yasir S. Raouf, Pimyupa Manaswiyoungkul, Fettah Erdogan, Ayah Abdeldayem, Aaron D. Cabral, Muhammad Murtaza Hassan, Krimo Toutah, Andrew E. Shouksmith, Justyna M. Gawel, Johan Israelian, Tudor B. Radu, Niyati Kachhiyapatel, Elvin D. de Araujo, David W. Christianson, <span class="NLM_string-name hlFld-ContribAuthor">Patrick T. Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2691-2704. <a href="https://doi.org/10.1021/acs.jmedchem.0c01922" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01922%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUnique%252BMolecular%252BInteraction%252Bwith%252Bthe%252BHistone%252BDeacetylase%252B6%252BCatalytic%252BTunnel%25253A%252BCrystallographic%252Band%252BBiological%252BCharacterization%252Bof%252Ba%252BModel%252BChemotype%26aulast%3DOlaoye%26aufirst%3DOlasunkanmi%2BO.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D06112020%26date%3D12022021%26volume%3D64%26issue%3D5%26spage%3D2691%26epage%3D2704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mario Prejanò, Pietro Vidossich, Nino Russo, Marco De Vivo, <span class="NLM_string-name hlFld-ContribAuthor">Tiziana Marino</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into the Catalytic Mechanism of Domains CD1 and CD2 in Histone Deacetylase 6 from Quantum Calculations. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (5)
                                     , 3084-3093. <a href="https://doi.org/10.1021/acscatal.0c04729" title="DOI URL">https://doi.org/10.1021/acscatal.0c04729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c04729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c04729%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DInsights%252Binto%252Bthe%252BCatalytic%252BMechanism%252Bof%252BDomains%252BCD1%252Band%252BCD2%252Bin%252BHistone%252BDeacetylase%252B6%252Bfrom%252BQuantum%252BCalculations%26aulast%3DPrejan%25C3%25B2%26aufirst%3DMario%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D30102020%26date%3D12022021%26date%3D23022021%26volume%3D11%26issue%3D5%26spage%3D3084%26epage%3D3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jeffrey Y. W. Mak, Kai-Chen Wu, Praveer K. Gupta, Sheila Barbero, Maddison G. McLaughlin, Andrew J. Lucke, Jiahui Tng, Junxian Lim, Zhixuan Loh, Matthew J. Sweet, Robert C. Reid, Ligong Liu, <span class="NLM_string-name hlFld-ContribAuthor">David P. Fairlie</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 2186-2204. <a href="https://doi.org/10.1021/acs.jmedchem.0c01967" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01967</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01967%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHDAC7%252BInhibition%252Bby%252BPhenacetyl%252Band%252BPhenylbenzoyl%252BHydroxamates%26aulast%3DMak%26aufirst%3DJeffrey%2BY.%2BW.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13112020%26date%3D11022021%26volume%3D64%26issue%3D4%26spage%3D2186%26epage%3D2204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, Mussa Yussuf Khamis, Yi-Han Li, Li-Ying Ma, <span class="NLM_string-name hlFld-ContribAuthor">Hong-Min Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1362-1391. <a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BReview%252Bof%252BProgress%252Bin%252BHistone%252BDeacetylase%252B6%252BInhibitors%252BResearch%25253A%252BStructural%252BSpecificity%252Band%252BFunctional%252BDiversity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D01022021%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lei Chen, Shiyi Jin, Jian Gao, Tongtong Liu, Yuebo Shao, Jie Feng, Kangyi Wang, Tao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ding Du</span>. </span><span class="cited-content_cbyCitation_article-title">N-Heterocyclic Carbene/Magnesium Cocatalyzed Radical Relay Assembly of Aliphatic Keto Nitriles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (2)
                                     , 394-399. <a href="https://doi.org/10.1021/acs.orglett.0c03883" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03883%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DN-Heterocyclic%252BCarbene%25252FMagnesium%252BCocatalyzed%252BRadical%252BRelay%252BAssembly%252Bof%252BAliphatic%252BKeto%252BNitriles%26aulast%3DChen%26aufirst%3DLei%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24112020%26date%3D29122020%26volume%3D23%26issue%3D2%26spage%3D394%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shabir Ahmad  Ganai</span>. </span><span class="cited-content_cbyCitation_article-title">Characterizing binding intensity and energetic features of histone deacetylase inhibitor pracinostat towards class I HDAC isozymes through futuristic drug designing strategy. </span><span class="cited-content_cbyCitation_journal-name">In Silico Pharmacology</span><span> <strong>2021,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1007/s40203-021-00077-y" title="DOI URL">https://doi.org/10.1007/s40203-021-00077-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40203-021-00077-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40203-021-00077-y%26sid%3Dliteratum%253Aachs%26jtitle%3DIn%2520Silico%2520Pharmacology%26atitle%3DCharacterizing%252Bbinding%252Bintensity%252Band%252Benergetic%252Bfeatures%252Bof%252Bhistone%252Bdeacetylase%252Binhibitor%252Bpracinostat%252Btowards%252Bclass%252BI%252BHDAC%252Bisozymes%252Bthrough%252Bfuturistic%252Bdrug%252Bdesigning%252Bstrategy%26aulast%3DGanai%26aufirst%3DShabir%2BAhmad%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Shi</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Tong  Yu</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113588. <a href="https://doi.org/10.1016/j.ejmech.2021.113588" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113588%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DResearch%252Bprogress%252Bof%252Bdual%252Binhibitors%252Btargeting%252Bcrosstalk%252Bbetween%252Bhistone%252Bepigenetic%252Bmodulators%252Bfor%252Bcancer%252Btherapy%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D222%26spage%3D113588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Liang</span>, <span class="hlFld-ContribAuthor ">Junxin  Xue</span>, <span class="hlFld-ContribAuthor ">Zefu  Yao</span>, <span class="hlFld-ContribAuthor ">Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113526. <a href="https://doi.org/10.1016/j.ejmech.2021.113526" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113526%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C%252B4-disubstituted-imidazolidine-2%25252C%252B5-dione%252Bderivatives%252Bas%252BHDAC6%252Bselective%252Binhibitors%26aulast%3DLiang%26aufirst%3DTao%26date%3D2021%26volume%3D221%26spage%3D113526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Jishun  Quan</span>, <span class="hlFld-ContribAuthor ">Haoxuan  Song</span>, <span class="hlFld-ContribAuthor ">Dongzhu  Li</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>, <span class="hlFld-ContribAuthor ">Yanjuan  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105081. <a href="https://doi.org/10.1016/j.bioorg.2021.105081" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105081%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DNovel%252Bpyrrolo%25255B2%25252C1-c%25255D%25255B1%25252C4%25255Dbenzodiazepine-3%25252C11-dione%252B%252528PBD%252529%252Bderivatives%252Bas%252Bselective%252BHDAC6%252Binhibitors%252Bto%252Bsuppress%252Btumor%252Bmetastasis%252Band%252Binvasion%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DLi%26aufirst%3DYanchun%26date%3D2021%26volume%3D114%26spage%3D105081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Chao  Duan</span>, <span class="hlFld-ContribAuthor ">Lin-Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Hong-Mei  Ren</span>, <span class="hlFld-ContribAuthor ">Shao-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Yue-Jiao  Liu</span>, <span class="hlFld-ContribAuthor ">Yong-Tao  Xu</span>, <span class="hlFld-ContribAuthor ">Zi-Hao  He</span>, <span class="hlFld-ContribAuthor ">Yu  Song</span>, <span class="hlFld-ContribAuthor ">Hang  Yuan</span>, <span class="hlFld-ContribAuthor ">Shu-Hui  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Guan</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113453. <a href="https://doi.org/10.1016/j.ejmech.2021.113453" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113453%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bdual%252Binhibitors%252Btargeting%252Blysine%252Bspecific%252Bdemethylase%252B1%252B%252528LSD1%252529%252Band%252Bhistone%252Bdeacetylases%252B%252528HDAC%252529%252Bfor%252Btreatment%252Bof%252Bgastric%252Bcancer%26aulast%3DDuan%26aufirst%3DYing-Chao%26date%3D2021%26volume%3D220%26spage%3D113453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Kurohara</span>, <span class="hlFld-ContribAuthor ">Keita  Tanaka</span>, <span class="hlFld-ContribAuthor ">Daisuke  Takahashi</span>, <span class="hlFld-ContribAuthor ">Satoshi  Ueda</span>, <span class="hlFld-ContribAuthor ">Yasunobu  Yamashita</span>, <span class="hlFld-ContribAuthor ">Yuri  Takada</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Takeshima</span>, <span class="hlFld-ContribAuthor ">Shengwang  Yu</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Itoh</span>, <span class="hlFld-ContribAuthor ">Koji  Hase</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Suzuki</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Histone Deacetylase 6‐Selective Inhibitors Bearing 3,3,3‐Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>118 </em><a href="https://doi.org/10.1002/cbic.202100255" title="DOI URL">https://doi.org/10.1002/cbic.202100255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202100255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202100255%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DIdentification%252Bof%252BNovel%252BHistone%252BDeacetylase%252B6%2525E2%252580%252590Selective%252BInhibitors%252BBearing%252B3%25252C3%25252C3%2525E2%252580%252590Trifluorolactic%252BAmide%252B%252528TFLAM%252529%252BMotif%252Bas%252Ba%252BZinc%252BBinding%252BGroup%26aulast%3DKurohara%26aufirst%3DTakashi%26date%3D2021%26date%3D2021%26volume%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabian  Fischer</span>, <span class="hlFld-ContribAuthor ">Leandro A  Alves Avelar</span>. </span><span class="cited-content_cbyCitation_article-title">A short overview of resistance to approved histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 1153-1155. <a href="https://doi.org/10.4155/fmc-2021-0102" title="DOI URL">https://doi.org/10.4155/fmc-2021-0102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2021-0102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2021-0102%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bshort%252Boverview%252Bof%252Bresistance%252Bto%252Bapproved%252Bhistone%252Bdeacetylase%2525C2%2525A0inhibitors%26aulast%3DFischer%26aufirst%3DFabian%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D1153%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haitang  Yang</span>, <span class="hlFld-ContribAuthor ">Beibei  Sun</span>, <span class="hlFld-ContribAuthor ">Ke  Xu</span>, <span class="hlFld-ContribAuthor ">Yunfei  He</span>, <span class="hlFld-ContribAuthor ">Tuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Sean R R  Hall</span>, <span class="hlFld-ContribAuthor ">Swee T.  Tan</span>, <span class="hlFld-ContribAuthor ">Ralph A.  Schmid</span>, <span class="hlFld-ContribAuthor ">Ren-Wang  Peng</span>, <span class="hlFld-ContribAuthor ">Guohong  Hu</span>, <span class="hlFld-ContribAuthor ">Feng  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">EBioMedicine</span><span> <strong>2021,</strong> <em>69 </em>, 103457. <a href="https://doi.org/10.1016/j.ebiom.2021.103457" title="DOI URL">https://doi.org/10.1016/j.ebiom.2021.103457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ebiom.2021.103457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ebiom.2021.103457%26sid%3Dliteratum%253Aachs%26jtitle%3DEBioMedicine%26atitle%3DPharmaco-transcriptomic%252Bcorrelation%252Banalysis%252Breveals%252Bnovel%252Bresponsive%252Bsignatures%252Bto%252BHDAC%252Binhibitors%252Band%252Bidentifies%252BDasatinib%252Bas%252Ba%252Bsynergistic%252Binteractor%252Bin%252Bsmall-cell%252Blung%252Bcancer%26aulast%3DYang%26aufirst%3DHaitang%26date%3D2021%26volume%3D69%26spage%3D103457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elodie  Renaude</span>, <span class="hlFld-ContribAuthor ">Marie  Kroemer</span>, <span class="hlFld-ContribAuthor ">Christophe  Borg</span>, <span class="hlFld-ContribAuthor ">Paul  Peixoto</span>, <span class="hlFld-ContribAuthor ">Eric  Hervouet</span>, <span class="hlFld-ContribAuthor ">Romain  Loyon</span>, <span class="hlFld-ContribAuthor ">Olivier  Adotévi</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fimmu.2021.669992" title="DOI URL">https://doi.org/10.3389/fimmu.2021.669992</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2021.669992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2021.669992%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DEpigenetic%252BReprogramming%252Bof%252BCD4%25252B%252BHelper%252BT%252BCells%252Bas%252Ba%252BStrategy%252Bto%252BImprove%252BAnticancer%252BImmunotherapy%26aulast%3DRenaude%26aufirst%3DElodie%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marton  Siklos</span>, <span class="hlFld-ContribAuthor ">Stefan  Kubicek</span>. </span><span class="cited-content_cbyCitation_article-title">T
              herapeutic targeting of chromatin: status and opportunities. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1111/febs.15966" title="DOI URL">https://doi.org/10.1111/febs.15966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15966%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DT%252Bherapeutic%252Btargeting%252Bof%252Bchromatin%25253A%252Bstatus%252Band%252Bopportunities%26aulast%3DSiklos%26aufirst%3DMarton%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jefferson A.  Leite</span>, <span class="hlFld-ContribAuthor ">Bruno  Ghirotto</span>, <span class="hlFld-ContribAuthor ">Vitor P.  Targhetta</span>, <span class="hlFld-ContribAuthor ">Jean  Lima</span>, <span class="hlFld-ContribAuthor ">Niels O. S.  Câmara</span>. </span><span class="cited-content_cbyCitation_article-title">Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>10 </em><a href="https://doi.org/10.1111/bph.15570" title="DOI URL">https://doi.org/10.1111/bph.15570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15570%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DSirtuins%252Bas%252Bpharmacological%252Btargets%252Bin%252Bneurodegenerative%252Band%252Bneuropsychiatric%252Bdisorders%26aulast%3DLeite%26aufirst%3DJefferson%2BA.%26date%3D2021%26date%3D2021%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sachin B.  Wagh</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Maslivetc</span>, <span class="hlFld-ContribAuthor ">James J.  La Clair</span>, <span class="hlFld-ContribAuthor ">Alexander  Kornienko</span>. </span><span class="cited-content_cbyCitation_article-title">Lessons in Organic Fluorescent Probe Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.1002/cbic.202100171" title="DOI URL">https://doi.org/10.1002/cbic.202100171</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202100171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202100171%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DLessons%252Bin%252BOrganic%252BFluorescent%252BProbe%252BDiscovery%26aulast%3DWagh%26aufirst%3DSachin%2BB.%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui-Qin  Kang</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Tao</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Li</span>, <span class="hlFld-ContribAuthor ">Jun-Ru  Zhao</span>, <span class="hlFld-ContribAuthor ">Ya-Gao</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113392. <a href="https://doi.org/10.1016/j.ejmech.2021.113392" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113392%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnovel%252B1%25252C3-diaryl-1%25252C2%25252C4-triazole-capped%252Bhistone%252Bdeacetylase%252B6%252Binhibitors%252Bwith%252Bpotential%252Banti-gastric%252Bcancer%252Bactivity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26volume%3D218%26spage%3D113392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunhong  Nong</span>, <span class="hlFld-ContribAuthor ">Yanyan  Hou</span>, <span class="hlFld-ContribAuthor ">Yuting  Pu</span>, <span class="hlFld-ContribAuthor ">Si  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Lan</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 628-641. <a href="https://doi.org/10.1177/24725552211002463" title="DOI URL">https://doi.org/10.1177/24725552211002463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/24725552211002463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F24725552211002463%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DDevelopment%252Band%252BValidation%252Bof%252BHigh-Content%252BAnalysis%252Bfor%252BScreening%252BHDAC6-Selective%252BInhibitors%26aulast%3DNong%26aufirst%3DYunhong%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D628%26epage%3D641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ammar D.  Elmezayen</span>, <span class="hlFld-ContribAuthor ">Yelekçi  Kemal</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based virtual screening for novel potential selective inhibitors of class IIa histone deacetylases for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2021,</strong> <em>92 </em>, 107491. <a href="https://doi.org/10.1016/j.compbiolchem.2021.107491" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2021.107491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2021.107491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2021.107491%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DStructure-based%252Bvirtual%252Bscreening%252Bfor%252Bnovel%252Bpotential%252Bselective%252Binhibitors%252Bof%252Bclass%252BIIa%252Bhistone%252Bdeacetylases%252Bfor%252Bcancer%252Btreatment%26aulast%3DElmezayen%26aufirst%3DAmmar%2BD.%26date%3D2021%26volume%3D92%26spage%3D107491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas G.  Gillette</span>. </span><span class="cited-content_cbyCitation_article-title">HDAC Inhibition in the Heart. </span><span class="cited-content_cbyCitation_journal-name">Circulation</span><span> <strong>2021,</strong> <em>143 </em>
                                    (19)
                                     , 1891-1893. <a href="https://doi.org/10.1161/CIRCULATIONAHA.121.054262" title="DOI URL">https://doi.org/10.1161/CIRCULATIONAHA.121.054262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1161/CIRCULATIONAHA.121.054262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1161%2FCIRCULATIONAHA.121.054262%26sid%3Dliteratum%253Aachs%26jtitle%3DCirculation%26atitle%3DHDAC%252BInhibition%252Bin%252Bthe%252BHeart%26aulast%3DGillette%26aufirst%3DThomas%2BG.%26date%3D2021%26volume%3D143%26issue%3D19%26spage%3D1891%26epage%3D1893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey D.  Bondarev</span>, <span class="hlFld-ContribAuthor ">Misty M.  Attwood</span>, <span class="hlFld-ContribAuthor ">Jörgen  Jonsson</span>, <span class="hlFld-ContribAuthor ">Vladimir N.  Chubarev</span>, <span class="hlFld-ContribAuthor ">Vadim V.  Tarasov</span>, <span class="hlFld-ContribAuthor ">Helgi B.  Schiöth</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of HDAC inhibitors: Emerging indications and novel molecules. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1111/bcp.14889" title="DOI URL">https://doi.org/10.1111/bcp.14889</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14889%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DRecent%252Bdevelopments%252Bof%252BHDAC%252Binhibitors%25253A%252BEmerging%252Bindications%252Band%252Bnovel%252Bmolecules%26aulast%3DBondarev%26aufirst%3DAndrey%2BD.%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minh Thanh  La</span>, <span class="hlFld-ContribAuthor ">Byung‐Hoon  Jeong</span>, <span class="hlFld-ContribAuthor ">Hee‐Kwon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel
              N
              ‐(2‐aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2021,</strong> <em>42 </em>
                                    (5)
                                     , 740-743. <a href="https://doi.org/10.1002/bkcs.12254" title="DOI URL">https://doi.org/10.1002/bkcs.12254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.12254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.12254%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BN%252B%2525E2%252580%252590%2525282%2525E2%252580%252590aminophenyl%252529benzamide%252BDerivatives%252Bas%252BHistone%252BDeacetylase%252BInhibitors%252Band%252BTheir%252BAntitumor%252BActivity%252BStudy%26aulast%3DLa%26aufirst%3DMinh%2BThanh%26date%3D2021%26date%3D2021%26volume%3D42%26issue%3D5%26spage%3D740%26epage%3D743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mussa  Yussuf Khamis</span>, <span class="hlFld-ContribAuthor ">Hui-Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qin  Ma</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Li</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104754. <a href="https://doi.org/10.1016/j.bioorg.2021.104754" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104754%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DOvercome%252Bthe%252Btumor%252Bimmunotherapy%252Bresistance%252Bby%252Bcombination%252Bof%252Bthe%252BHDAC6%252Binhibitors%252Bwith%252Bantitumor%252Bimmunomodulatory%252Bagents%26aulast%3DYussuf%2BKhamis%26aufirst%3DMussa%26date%3D2021%26volume%3D109%26spage%3D104754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clemens  Zwergel</span>, <span class="hlFld-ContribAuthor ">Elisabetta  Di Bello</span>, <span class="hlFld-ContribAuthor ">Rossella  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Conte</span>, <span class="hlFld-ContribAuthor ">Angela  Nebbioso</span>, <span class="hlFld-ContribAuthor ">Roberta  Mazzone</span>, <span class="hlFld-ContribAuthor ">Gerald  Brosch</span>, <span class="hlFld-ContribAuthor ">Ciro  Mercurio</span>, <span class="hlFld-ContribAuthor ">Mario  Varasi</span>, <span class="hlFld-ContribAuthor ">Lucia  Altucci</span>, <span class="hlFld-ContribAuthor ">Sergio  Valente</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyridine‐Based Hydroxamates and 2′‐Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (6)
                                     , 989-999. <a href="https://doi.org/10.1002/cmdc.202000854" title="DOI URL">https://doi.org/10.1002/cmdc.202000854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000854%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNovel%252BPyridine%2525E2%252580%252590Based%252BHydroxamates%252Band%252B2%2525E2%252580%2525B2%2525E2%252580%252590Aminoanilides%252Bas%252BHistone%252BDeacetylase%252BInhibitors%25253A%252BBiochemical%252BProfile%252Band%252BAnticancer%252BActivity%26aulast%3DZwergel%26aufirst%3DClemens%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D6%26spage%3D989%26epage%3D999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Jenke</span>, <span class="hlFld-ContribAuthor ">Nina  Reßing</span>, <span class="hlFld-ContribAuthor ">Finn K.  Hansen</span>, <span class="hlFld-ContribAuthor ">Achim  Aigner</span>, <span class="hlFld-ContribAuthor ">Thomas  Büch</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 634. <a href="https://doi.org/10.3390/cancers13040634" title="DOI URL">https://doi.org/10.3390/cancers13040634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040634%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DAnticancer%252BTherapy%252Bwith%252BHDAC%252BInhibitors%25253A%252BMechanism-Based%252BCombination%252BStrategies%252Band%252BFuture%252BPerspectives%26aulast%3DJenke%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gargi Nikhil  Vaidya</span>, <span class="hlFld-ContribAuthor ">Pooja  Rana</span>, <span class="hlFld-ContribAuthor ">Ashwini  Venkatesh</span>, <span class="hlFld-ContribAuthor ">Deep Rohan  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Darshan  Contractor</span>, <span class="hlFld-ContribAuthor ">Dinesh Parshuram  Satpute</span>, <span class="hlFld-ContribAuthor ">Mithilesh  Nagpure</span>, <span class="hlFld-ContribAuthor ">Alok  Jain</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Paradigm shift of “classical” HDAC inhibitors to “hybrid” HDAC inhibitors in therapeutic interventions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112844. <a href="https://doi.org/10.1016/j.ejmech.2020.112844" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112844%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DParadigm%252Bshift%252Bof%252B%2525E2%252580%25259Cclassical%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bto%252B%2525E2%252580%25259Chybrid%2525E2%252580%25259D%252BHDAC%252Binhibitors%252Bin%252Btherapeutic%252Binterventions%26aulast%3DVaidya%26aufirst%3DGargi%2BNikhil%26date%3D2021%26volume%3D209%26spage%3D112844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert S.  Lahue</span>. </span><span class="cited-content_cbyCitation_article-title">New developments in Huntington’s disease and other triplet repeat diseases: DNA repair turns to the dark side. </span><span class="cited-content_cbyCitation_journal-name">Neuronal Signaling</span><span> <strong>2020,</strong> <em>4 </em>
                                    (4)
                                     <a href="https://doi.org/10.1042/NS20200010" title="DOI URL">https://doi.org/10.1042/NS20200010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/NS20200010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FNS20200010%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuronal%2520Signaling%26atitle%3DNew%252Bdevelopments%252Bin%252BHuntington%2525E2%252580%252599s%252Bdisease%252Band%252Bother%252Btriplet%252Brepeat%252Bdiseases%25253A%252BDNA%252Brepair%252Bturns%252Bto%252Bthe%252Bdark%252Bside%26aulast%3DLahue%26aufirst%3DRobert%25C2%25A0S.%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priya  Mondal</span>, <span class="hlFld-ContribAuthor ">Jagadish  Natesh</span>, <span class="hlFld-ContribAuthor ">Dhanamjai  Penta</span>, <span class="hlFld-ContribAuthor ">Syed Musthapa  Meeran</span>. </span><span class="cited-content_cbyCitation_article-title">Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.1016/j.semcancer.2020.12.006" title="DOI URL">https://doi.org/10.1016/j.semcancer.2020.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2020.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2020.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DProgress%252Band%252Bpromises%252Bof%252Bepigenetic%252Bdrugs%252Band%252Bepigenetic%252Bdiets%252Bin%252Bcancer%252Bprevention%252Band%252Btherapy%25253A%252BA%252Bclinical%252Bupdate%26aulast%3DMondal%26aufirst%3DPriya%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhua  Liu</span>, <span class="hlFld-ContribAuthor ">Yuchen  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Si</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic acid hybrids as the potential anticancer agents: An Overview. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112679. <a href="https://doi.org/10.1016/j.ejmech.2020.112679" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112679%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxamic%252Bacid%252Bhybrids%252Bas%252Bthe%252Bpotential%252Banticancer%252Bagents%25253A%252BAn%252BOverview%26aulast%3DLiu%26aufirst%3DWenhua%26date%3D2020%26volume%3D205%26spage%3D112679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua P.  Smalley</span>, <span class="hlFld-ContribAuthor ">Shaun M.  Cowley</span>, <span class="hlFld-ContribAuthor ">James T.  Hodgkinson</span>. </span><span class="cited-content_cbyCitation_article-title">Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (19)
                                     , 4394. <a href="https://doi.org/10.3390/molecules25194394" title="DOI URL">https://doi.org/10.3390/molecules25194394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25194394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25194394%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBifunctional%252BHDAC%252BTherapeutics%25253A%252BOne%252BDrug%252Bto%252BRule%252BThem%252BAll%25253F%26aulast%3DSmalley%26aufirst%3DJoshua%2BP.%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D19%26spage%3D4394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of lysine post-translational modification in proteins.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Simplified illustration of the catalytic mechanism of deacetylation by HDACs: (A) enzyme–substrate complex, with binding interactions between the acetyllysine bearing protein substrate and a tyrosine residue and the zinc cation in the HDAC active site; (B) tetrahedral oxyanion enzyme intermediate arising from nucleophilic attack by water; (C) enzyme–product complex, with the lysine residue and acetate prior to release from the active site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. A “solar system” of human HDACs. At the core are HDAC1, HDAC2, and HDAC3 which exist in multiprotein complexes in the nucleus. These isoforms deacetylate histones and transcriptional regulators, and homologues are ubiquitous across life forms. Next is HDAC6, responsible for the deacetylation of cytoplasmic proteins, followed by an “asteroid belt” of the pseudoenzymes HDAC4, HDAC5, HDAC7, and HDAC9 with poor catalytic activity. The “outer planets” HDAC8 and HDAC11 preferentially hydrolyze non-acetyl acyllysine substrates, while the distant HDAC10 is a polyamine deacetylase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Fluorescence-based assay for measuring HDAC activity based upon product cleavage by trypsin to release aminomethylcoumarin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Examples of potent natural product HDAC inhibitors, with zinc binding atoms indicated in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Clinical candidate HDAC inhibitors with aliphatic hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding interactions in the vorinostat-HDAC8 X-ray structure. The zinc cation is displayed as a centroid with the coordinating Asp and His residues in pink. The His and Tyr residues involved in water activation and substrate binding respectively are indicated in blue. Reproduced with permission from   <cite><i>European Journal of Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/european-journal-of-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Bertrand, P.</span></contrib-group>, Inside HDAC with HDAC Inhibitors, Vol. <em>45</em>, pp 2095–2116, Copyright <span class="NLM_year">2010,</span> Elsevier.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Clinical candidate HDAC inhibitors with alkenyl hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Clinical candidate HDAC inhibitors with aromatic hydroxamic acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Clinical candidate <i>ortho</i>-aminoanilide HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Some examples of unusual HDAC inhibitors. In this and subsequent figures, IC<sub>50</sub> values (or in some instances <i>K</i><sub>i</sub>) against individual isoforms are given, with values below 1 μM highlighted in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. X-ray structure of the <b>33</b>-HDAC8 complex showing active site interactions. Reproduced with permission from   <cite><i>Bioorganic & Medicinal
Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Whitehead, L.</span>; <span class="NLM_string-name">Dobler, M. R.</span>; <span class="NLM_string-name">Radetich, B.</span>; <span class="NLM_string-name">Zhu, Y.</span>; <span class="NLM_string-name">Atadja, P. W.</span>; <span class="NLM_string-name">Claiborne, T.</span>; <span class="NLM_string-name">Grob, J. E.</span>; <span class="NLM_string-name">McRiner, A.</span>; <span class="NLM_string-name">Pancost, M. R.</span>; <span class="NLM_string-name">Patnaik, A.</span>; <span class="NLM_string-name">Shao, W.</span>; <span class="NLM_string-name">Shultz, M.</span>; <span class="NLM_string-name">Tichkule, R.</span>; <span class="NLM_string-name">Tommasi, R. A.</span>; <span class="NLM_string-name">Vash, B.</span>; <span class="NLM_string-name">Wang, P.</span>; <span class="NLM_string-name">Stams, T.</span></contrib-group>, Human HDAC Isoform Selectivity Achieved via Exploitation of the Acetate Release Channel with Structurally Unique Small Molecule Inhibitors, Vol. <em>19</em>, pp 4626–4634, Copyright <span class="NLM_year">2011</span>, Elsevier.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of biaryl <i>ortho</i>-aminoanilide selective HDAC1/HDAC2 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. The X-ray structure of <b>43</b>-HDAC2 is typical of <i>ortho</i>-aminoanilides. Bidentate coordination is observed with the zinc cation, while the addition of a 5-aryl substituent enables occupancy of the lateral internal 14 Å cavity. Reproduced with permission from   <cite><i>Bioorganic & Medicinal Chemistry</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry</a>); <contrib-group><span class="NLM_string-name">Wagner, F. F.</span>; <span class="NLM_string-name">Weïwer, M.</span>; <span class="NLM_string-name">Steinbacher, S.</span>; <span class="NLM_string-name">Schomburg, A.</span>; <span class="NLM_string-name">Reinemer, P.</span>; <span class="NLM_string-name">Gale, J. P.</span>; <span class="NLM_string-name">Campbell, A. J.</span>; <span class="NLM_string-name">Fisher, S. L.</span>; <span class="NLM_string-name">Zhao, W.-N.</span>; <span class="NLM_string-name">Reis, S. A.</span>; <span class="NLM_string-name">Hennig, K. M.</span>; <span class="NLM_string-name">Thomas, M.</span>; <span class="NLM_string-name">Müller, P.</span>; <span class="NLM_string-name">Jefson, M. R.</span>; <span class="NLM_string-name">Fass, D. M.</span>; <span class="NLM_string-name">Haggarty, S. J.</span>; <span class="NLM_string-name">Zhang, Y.-L.</span>; <span class="NLM_string-name">Holson, E. B.</span></contrib-group>, Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors, Vol. <em>24</em>, pp 4008–4015, Copyright <span class="NLM_year">2016</span>, Elsevier.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Examples of selective HDAC3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Examples of selective HDAC6 inhibitors. See also the HDAC10 discussion on tubastatin (<b>47</b>) and analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (a) Simulated annealing omit map of the <b>50-</b>HDAC6 (catalytic domain 2) binding. The hydroxamic acid engages in monocoordinate interactions with the zinc cation, while the carbonyl group hydrogen-bonds the active site water involved in amide hydrolysis. The linker makes an additional hydrogen bond with Ser531. (b) Cutaway view of the active site surface highlighting the zinc coordination polyhedron and the aromatic interactions between the inhibitor and the substrate binding channel. Reproduced with permission from   <cite><i>Bioorganic & Medicinal Chemistry Letters</i></cite> (<a href="https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry-letters" class="extLink">https://www.sciencedirect.com/journal/bioorganic-and-medicinal-chemistry-letters</a>); <contrib-group><span class="NLM_string-name">Osko, J. D.</span>; <span class="NLM_string-name">Christianson, D. W.</span></contrib-group>, Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6, Vol. <em>30</em>, 127023, Copyright <span class="NLM_year">2020</span>, Elsevier.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Examples of selective HDAC8 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Examples of selective HDAC11 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Tubastatin A (<b>47</b>), analogues <b>57</b> and <b>58</b>, and the spermidine hydroxamic acid <b>59</b>. Note that IC<sub>50</sub> values for <b>47</b>, <b>57</b>, and <b>58</b> correspond to a FRET displacement assay for HDAC10 and enzymatic assays for other isoforms. The value for <b>59</b> comes from an assay monitoring <i>N</i>-acetylputrescine hydrolysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Polder omit map of <b>59</b> bound to the active site of HDAC10. The hydroxamic acid is coordinated as a bidentate ligand to the zinc cation, while the NH proton engages in hydrogen bonding with the Glu274 gatekeeper residue. Reproduced with permission from <i>Biochemistry</i>,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0022.jpeg" id="rightTab-GRAPHIC-d7e2946-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Examples of selective HDAC4, HDAC5, HDAC7, HDAC9 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/medium/jm0c00830_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0023.jpeg" id="rightTab-GRAPHIC-d7e2985-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Binding interactions of <i>des</i>-fluoro-<b>61</b> (with H instead of F at C1) within the HDAC4 active site, showing the occupancy of the selectivity pocket by the phenyl ring. Reproduced with permission from <i>ACS Medicinal Chemistry Letters</i>, Copyright 2016, American Chemical Society.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00830/20201105/images/large/jm0c00830_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00830&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 168 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiardi, A.</span></span> <span> </span><span class="NLM_article-title">Why Always Lysine? The Ongoing Tale of One of the Most Modified Amino Acids</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">150</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2015.09.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.jbior.2015.09.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26482291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=144-150&author=C.+Azevedoauthor=A.+Saiardi&title=Why+Always+Lysine%3F+The+Ongoing+Tale+of+One+of+the+Most+Modified+Amino+Acids&doi=10.1016%2Fj.jbior.2015.09.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Why always lysine? The ongoing tale of one of the most modified amino acids</span></div><div class="casAuthors">Azevedo, Cristina; Saiardi, Adolfo</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The complex physiol. of living organisms must be finely-tuned to permit the flexibility required to respond to the changing environment.  Evolution has provided an interconnected and intricate array of regulatory mechanisms to facilitate this fine-tuning.  The no. of genes cannot alone explain the complexity of these mechanisms.  Rather, signalling is regulated at multiple levels, from genomic to transcriptional, translational and post-translational.  Post-translational modification (PTM) of proteins offers an addnl. level of regulation after protein synthesis that allows a rapid, controlled and reversible response to environmental cues.  Many amino acid side chains are post-translationally modified.  These modifications can either be enzymic, such as the phosphorylation of serine, threonine and tyrosine residues, or non-enzymic, such as the nitrosylation of cysteine residues.  Strikingly, lysine residues are targeted by a particularly high no. of PTMs including acetylation, methylation, ubiquitination and sumoylation.  Addnl., lysines have recently been identified as the target of the non-enzymic PTM polyphosphorylation.  This novel PTM sees linear chains of inorg. polyphosphates (polyP) covalently attached to lysine residues.  Interestingly, polyphosphorylation is indirectly dependent on inositol pyrophosphates, a class of cellular messengers.  The attachment of polyP to lysine occurs through the phosphoramidate bond, which, unlike the phosphester bond, is unstable under the conditions used in common mass spectroscopy.  This characteristic, together with the diversity of lysine PTMs, suggests that many other lysine modifications may still remain unidentified, raising the intriguing possibility that lysine PTMs may be the major means by which signalling pathways modify protein behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0XJSfdwX8MLVg90H21EOLACvtfcHk0lh8neolwPfj_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ertLbE&md5=88ac71aaf09c2e91a1b3d6715f00c5ef</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2015.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2015.09.008%26sid%3Dliteratum%253Aachs%26aulast%3DAzevedo%26aufirst%3DC.%26aulast%3DSaiardi%26aufirst%3DA.%26atitle%3DWhy%2520Always%2520Lysine%253F%2520The%2520Ongoing%2520Tale%2520of%2520One%2520of%2520the%2520Most%2520Modified%2520Amino%2520Acids%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2016%26volume%3D60%26spage%3D144%26epage%3D150%26doi%3D10.1016%2Fj.jbior.2015.09.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Y.</span></span> <span> </span><span class="NLM_article-title">PLMD: An Updated Data Resource of Protein Lysine Modifications</span>. <i>J. Genet. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/j.jgg.2017.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.jgg.2017.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28529077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1crpslGnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=243-250&author=H.+Xuauthor=J.+Zhouauthor=S.+Linauthor=W.+Dengauthor=Y.+Zhangauthor=Y.+Xue&title=PLMD%3A+An+Updated+Data+Resource+of+Protein+Lysine+Modifications&doi=10.1016%2Fj.jgg.2017.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">PLMD: An updated data resource of protein lysine modifications</span></div><div class="casAuthors">Xu Haodong; Zhou Jiaqi; Lin Shaofeng; Deng Wankun; Zhang Ying; Xue Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of genetics and genomics = Yi chuan xue bao</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">243-250</span>
        ISSN:<span class="NLM_cas:issn">1673-8527</span>.
    </div><div class="casAbstract">Post-translational modifications (PTMs) occurring at protein lysine residues, or protein lysine modifications (PLMs), play critical roles in regulating biological processes.  Due to the explosive expansion of the amount of PLM substrates and the discovery of novel PLM types, here we greatly updated our previous studies, and presented a much more integrative resource of protein lysine modification database (PLMD).  In PLMD, we totally collected and integrated 284,780 modification events in 53,501 proteins across 176 eukaryotes and prokaryotes for up to 20 types of PLMs, including ubiquitination, acetylation, sumoylation, methylation, succinylation, malonylation, glutarylation, glycation, formylation, hydroxylation, butyrylation, propionylation, crotonylation, pupylation, neddylation, 2-hydroxyisobutyrylation, phosphoglycerylation, carboxylation, lipoylation and biotinylation.  Using the data set, a motif-based analysis was performed for each PLM type, and the results demonstrated that different PLM types preferentially recognize distinct sequence motifs for the modifications.  Moreover, various PLMs synergistically orchestrate specific cellular biological processes by mutual crosstalks with each other, and we totally found 65,297 PLM events involved in 90 types of PLM co-occurrences on the same lysine residues.  Finally, various options were provided for accessing the data, while original references and other annotations were also present for each PLM substrate.  Taken together, we anticipated the PLMD database can serve as a useful resource for further researches of PLMs.  PLMD 3.0 was implemented in PHP + MySQL and freely available at http://plmd.biocuckoo.org.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0gNGqbz_zRyO2kE7krGOBfW6udTcc2eaQKCYmgblKv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crpslGnug%253D%253D&md5=4283785555a1adc9ed4928e8c40b2c07</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jgg.2017.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jgg.2017.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DY.%26atitle%3DPLMD%253A%2520An%2520Updated%2520Data%2520Resource%2520of%2520Protein%2520Lysine%2520Modifications%26jtitle%3DJ.%2520Genet.%2520Genomics%26date%3D2017%26volume%3D44%26spage%3D243%26epage%3D250%26doi%3D10.1016%2Fj.jgg.2017.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Epigenetic Drug Discovery: A Success Story for Cofactor Interference</span>. <i>Philos. Trans. R. Soc., B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">20170069</span>, <span class="refDoi"> DOI: 10.1098/rstb.2017.0069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1098%2Frstb.2017.0069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29685973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Cmsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2018&pages=20170069&author=A.+Ganesan&title=Epigenetic+Drug+Discovery%3A+A+Success+Story+for+Cofactor+Interference&doi=10.1098%2Frstb.2017.0069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic drug discovery: a success story for cofactor interference</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Philosophical Transactions of the Royal Society, B: Biological Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1748</span>),
    <span class="NLM_cas:pages">20170069/1-20170069/15</span>CODEN:
                <span class="NLM_cas:coden">PTRBAE</span>;
        ISSN:<span class="NLM_cas:issn">0962-8436</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">Within the past two decades, seven epigenetic drugs have received regulatory approval and numerous other candidates are currently in clin. trials.  Among the epigenetic targets are the writer and eraser enzymes that are, resp., responsible for the reversible introduction and removal of structural modifications in the nucleosome.  This reviewdiscusses the progress achieved in the design and development of inhibitors against the key writer and eraser pairs: DNA methyltransferases and Tet demethylases; lysine/arginine methyltransferases and lysine demethylases; and histone acetyltransferases and histone deacetylases.  A common theme for the successful inhibition of these enzymes in a potent and selective manner is the targeting of the cofactors present in the active site, namely zinc and iron cations, S-adenosylmethione, NAD, FAD and acetyl CoA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrohR1yq_2gzbVg90H21EOLACvtfcHk0lge8_5AIVGsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Cmsb7M&md5=9c9e20f8b16a73a1835320e82698e68a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1098%2Frstb.2017.0069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frstb.2017.0069%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DEpigenetic%2520Drug%2520Discovery%253A%2520A%2520Success%2520Story%2520for%2520Cofactor%2520Interference%26jtitle%3DPhilos.%2520Trans.%2520R.%2520Soc.%252C%2520B%26date%3D2018%26volume%3D373%26spage%3D20170069%26doi%3D10.1098%2Frstb.2017.0069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvedere, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5116</span>, <span class="refDoi"> DOI: 10.1021/jm0303094</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0303094" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5097-5116&author=T.+A.+Millerauthor=D.+J.+Witterauthor=S.+Belvedere&title=Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0303094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors</span></div><div class="casAuthors">Miller, Thomas A.; Witter, David J.; Belvedere, Sandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5097-5116</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the medicinal chem. and structure-activity relationships underlying advances in histone deacetylase (HDAC) class I/II inhibitor discovery, design, and optimization.  HDAC structural studies and HDAC inhibitory activity of small-mol. hydroxamic acids, carboxylates, benzamides, electrophilic ketones, and cyclic peptides are described.  Miscellaneousness and selectivity of the class I/II HDACs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU5UlOsBUF7rVg90H21EOLACvtfcHk0lge8_5AIVGsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosVCktbg%253D&md5=d2d0a95d87d699334c1630df5deda38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm0303094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0303094%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DT.%2BA.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DBelvedere%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5097%26epage%3D5116%26doi%3D10.1021%2Fjm0303094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelloni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binaschi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fattori, D.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: From Bench to Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+Deacetylase+Inhibitors%3A+From+Bench+to+Clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lge8_5AIVGsSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinert, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, C.</span></span> <span> </span><span class="NLM_article-title">Functions and Mechanisms of Non-Histone Protein Acetylation</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/s41580-018-0081-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41580-018-0081-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30467427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Gmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=156-174&author=T.+Naritaauthor=B.+T.+Weinertauthor=C.+Choudhary&title=Functions+and+Mechanisms+of+Non-Histone+Protein+Acetylation&doi=10.1038%2Fs41580-018-0081-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Functions and mechanisms of non-histone protein acetylation</span></div><div class="casAuthors">Narita, Takeo; Weinert, Brian T.; Choudhary, Chunaram</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">156-174</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Nε-lysine acetylation was discovered more than half a century ago as a post-translational modification of histones and has been extensively studied in the context of transcription regulation.  In the past decade, proteomic analyses have revealed that non-histone proteins are frequently acetylated and constitute a major portion of the acetylome in mammalian cells.  Indeed, non-histone protein acetylation is involved in key cellular processes relevant to physiol. and disease, such as gene transcription, DNA damage repair, cell division, signal transduction, protein folding, autophagy and metab.  Acetylation affects protein functions through diverse mechanisms, including by regulating protein stability, enzymic activity, subcellular localization and crosstalk with other post-translational modifications and by controlling protein-protein and protein-DNA interactions.  In this Review, we discuss recent progress in our understanding of the scope, functional diversity and mechanisms of non-histone protein acetylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH-USxtMkV_LVg90H21EOLACvtfcHk0lgk4RT3TKavoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Gmt7s%253D&md5=bb798999d02e0c5345cd8f6055e5b53a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0081-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0081-3%26sid%3Dliteratum%253Aachs%26aulast%3DNarita%26aufirst%3DT.%26aulast%3DWeinert%26aufirst%3DB.%2BT.%26aulast%3DChoudhary%26aufirst%3DC.%26atitle%3DFunctions%2520and%2520Mechanisms%2520of%2520Non-Histone%2520Protein%2520Acetylation%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D156%26epage%3D174%26doi%3D10.1038%2Fs41580-018-0081-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conery, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, R. J.</span></span> <span> </span><span class="NLM_article-title">Bromodomains: A New Target Class for Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">628</span>, <span class="refDoi"> DOI: 10.1038/s41573-019-0030-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41573-019-0030-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31273347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=609-628&author=A.+G.+Cochranauthor=A.+R.+Coneryauthor=R.+J.+Sims&title=Bromodomains%3A+A+New+Target+Class+for+Drug+Development&doi=10.1038%2Fs41573-019-0030-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Bromodomains: a new target class for drug development</span></div><div class="casAuthors">Cochran, Andrea G.; Conery, Andrew R.; Sims, III, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">609-628</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader' modules found in proteins with varied functions, were highly tractable small-mol. targets.  This is an unusual property for protein-protein or protein-peptide interaction domains, and it prompted a wave of chem. probe discovery to understand the biol. potential of new agents that targeted bromodomains.  The original examples, inhibitors of the bromodomain and extra-terminal (BET) class of bromodomains, showed enticing anti-inflammatory and anticancer activities, and several compds. have since advanced to human clin. trials.  Here, we review the current state of BET inhibitor biol. in relation to clin. development, and we discuss the next wave of bromodomain inhibitors with clin. potential in oncol. and non-oncol. indications.  The lessons learned from BET inhibitor programs should affect efforts to develop drugs that target non-BET bromodomains and other epigenetic readers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6QwxqowW9NbVg90H21EOLACvtfcHk0lgk4RT3TKavoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWitbnL&md5=88e56eec8edeb7c325d28156ec131ed8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fs41573-019-0030-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-019-0030-7%26sid%3Dliteratum%253Aachs%26aulast%3DCochran%26aufirst%3DA.%2BG.%26aulast%3DConery%26aufirst%3DA.%2BR.%26aulast%3DSims%26aufirst%3DR.%2BJ.%26atitle%3DBromodomains%253A%2520A%2520New%2520Target%2520Class%2520for%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D609%26epage%3D628%26doi%3D10.1038%2Fs41573-019-0030-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span> <span> </span><span class="NLM_article-title">Acetylation & Co: An Expanding Repertoire of Histone Acylations Regulates Chromatin and Transcription</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1042/EBC20180061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FEBC20180061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30940741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslGnt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=97-107&author=C.+E.+Barnesauthor=D.+M.+Englishauthor=S.+M.+Cowley&title=Acetylation+%26+Co%3A+An+Expanding+Repertoire+of+Histone+Acylations+Regulates+Chromatin+and+Transcription&doi=10.1042%2FEBC20180061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation & Co: an expanding repertoire of histone acylations regulates chromatin and transcription</span></div><div class="casAuthors">Barnes, Claire E.; English, David M.; Cowley, Shaun M.</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-107</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">1744-1358</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Packaging the long and fragile genomes of eukaryotic species into nucleosomes is all well and good, but how do cells gain access to the DNA again after it has been bundled away.  The soln., in every species from yeast to man, is to post-translationally modify histones, altering their chem. properties to either relax the chromatin, label it for remodelling or make it more compact still.  Histones are subject to a myriad of modifications: acetylation, methylation, phosphorylation, ubiquitination etc.  This review focuses on histone acylations, a diverse group of modifications which occur on the ε-amino group of Lysine residues and includes the well-characterised Lysine acetylation.  Over the last 50 years, histone acetylation has been extensively characterised, with the discovery of histone acetyltransferases (HATs) and histone deacetylases (HDACs), and global mapping expts., revealing an assocn. of hyperacetylated histones with accessible, transcriptionally active chromatin.  More recently, there has been an explosion in the no. of unique short chain 'acylations' identified by MS, including: propionylation, butyrylation, crotonylation, succinylation, malonylation and 2-hydroxyisobutyrylation.  These novel modifications add a range of chem. environments to histones, and similar to acetylation, appear to accumulate at transcriptional start sites and correlate with gene activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwJxjetItuZLVg90H21EOLACvtfcHk0lgk4RT3TKavoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslGnt7nK&md5=09d86e16c33ae8b5a720eb720553383e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FEBC20180061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FEBC20180061%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DC.%2BE.%26aulast%3DEnglish%26aufirst%3DD.%2BM.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26atitle%3DAcetylation%2520%2526%2520Co%253A%2520An%2520Expanding%2520Repertoire%2520of%2520Histone%2520Acylations%2520Regulates%2520Chromatin%2520and%2520Transcription%26jtitle%3DEssays%2520Biochem.%26date%3D2019%26volume%3D63%26spage%3D97%26epage%3D107%26doi%3D10.1042%2FEBC20180061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span> <span> </span><span class="NLM_article-title">Chemical and Structural Biology of Protein Lysine Deacetylases</span>. <i>Proc. Jpn. Acad., Ser. B</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.2183/pjab.93.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2183%2Fpjab.93.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2017&pages=297-321&author=M.+Yoshidaauthor=N.+Kudoauthor=S.+Kosonoauthor=A.+Ito&title=Chemical+and+Structural+Biology+of+Protein+Lysine+Deacetylases&doi=10.2183%2Fpjab.93.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and structural biology of protein lysine deacetylases</span></div><div class="casAuthors">Yoshida, Minoru; Kudo, Norio; Kosono, Saori; Ito, Akihiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Japan Academy, Series B: Physical and Biological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">297-321</span>CODEN:
                <span class="NLM_cas:coden">PJABDW</span>;
        ISSN:<span class="NLM_cas:issn">0386-2208</span>.
    
            (<span class="NLM_cas:orgname">Nippon Gakushiin</span>)
        </div><div class="casAbstract">A review.  Histone acetylation is a reversible posttranslational modification that plays a fundamental role in regulating eukaryotic gene expression and chromatin structure/function.  Key enzymes for removing acetyl groups from histones are metal (zinc)-dependent and NAD+-dependent histone deacetylases (HDACs).  The mol. function of HDACs have been extensively characterized by various approaches including chem., mol., and structural biol., which demonstrated that HDACs regulate cell proliferation, differentiation, and metabolic homeostasis, and that their alterations are deeply involved in various human disorders including cancer.  Notably, drug discovery efforts have achieved success in developing HDAC-targeting therapeutics for treatment of several cancers.  However, recent advancements in proteomics technol. have revealed much broader aspects of HDACs beyond gene expression control.  Not only histones but also a large no. of cellular proteins are subject to acetylation by histone acetyltransferases (HATs) and deacetylation by HDACs.  Furthermore, some of their structures can flexibly accept and hydrolyze other acyl groups on protein lysine residues.  This review mainly focuses on structural aspects of HDAC enzymic activity regulated by interaction with substrates, co-factors, small mol. inhibitors, and activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooNCxxHhMcPrVg90H21EOLACvtfcHk0lhSqm7lt4WSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWmt7k%253D&md5=427a1d6f1ea3a8815499e9cad809d377</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2183%2Fpjab.93.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2183%252Fpjab.93.019%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKudo%26aufirst%3DN.%26aulast%3DKosono%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DA.%26atitle%3DChemical%2520and%2520Structural%2520Biology%2520of%2520Protein%2520Lysine%2520Deacetylases%26jtitle%3DProc.%2520Jpn.%2520Acad.%252C%2520Ser.%2520B%26date%3D2017%26volume%3D93%26spage%3D297%26epage%3D321%26doi%3D10.2183%2Fpjab.93.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span> <span> </span><span class="NLM_article-title">Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2017.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.tips.2017.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28389129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFShsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=459-472&author=Y.+Jiangauthor=J.+Liuauthor=D.+Chenauthor=L.+Yanauthor=W.+Zheng&title=Sirtuin+Inhibition%3A+Strategies%2C+Inhibitors%2C+and+Therapeutic+Potential&doi=10.1016%2Fj.tips.2017.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential</span></div><div class="casAuthors">Jiang, Yanhong; Liu, Jiajia; Chen, Di; Yan, Lingling; Zheng, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-472</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The β-NAD+-dependent Nε-acyl-lysine deacylation reaction catalyzed by sirtuin family members has been increasingly demonstrated to be important in regulating multiple crucial cellular processes and has also been proposed to be a therapeutic target for multiple human diseases.  Accordingly, its inhibitors have been actively pursued over the past few years.  In addn., we have also seen the pharmacol. assessment of sirtuin inhibitory compds., although to a lesser extent.  In this review, we first discuss how sirtuin inhibitors were discovered with the use of various approaches.  We then follow with a discussion of pharmacol. studies using sirtuin inhibitors.  Our aim here is to set a stage for developing future superior sirtuin inhibitors and for an expanded effort in exploiting inhibitors to explore and/or validate the therapeutic potential stemming from the inhibition of the sirtuin-catalyzed deacylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAdIcVkqx8urVg90H21EOLACvtfcHk0lhSqm7lt4WSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFShsro%253D&md5=57bafc78f57e063488d37b2a6793d0d2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2017.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2017.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DSirtuin%2520Inhibition%253A%2520Strategies%252C%2520Inhibitors%252C%2520and%2520Therapeutic%2520Potential%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26spage%3D459%26epage%3D472%26doi%3D10.1016%2Fj.tips.2017.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery</span>. In  <i>Topics in Medicinal Chemistry 33. Epigenetic Chemistry</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-28&author=A.+Ganesanauthor=A.+Mai&title=Topics+in+Medicinal+Chemistry+33.+Epigenetic+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520for%2520Drug%2520Discovery%26btitle%3DTopics%2520in%2520Medicinal%2520Chemistry%252033.%2520Epigenetic%2520Chemistry%26aulast%3DMai%26aufirst%3DA.%26pub%3DSpringer%26date%3D2020%26spage%3D1%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure, Mechanism, and Inhibition of the Zinc-Dependent Histone Deacetylases</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2019.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.sbi.2019.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30743180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=9-18&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Structure%2C+Mechanism%2C+and+Inhibition+of+the+Zinc-Dependent+Histone+Deacetylases&doi=10.1016%2Fj.sbi.2019.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Zinc-dependent histone deacetylases (HDACs) regulate the biol. function of histone and non-histone proteins through the hydrolysis of acetyllysine side chains to yield free lysine and acetate.  Certain HDAC isoenzymes exhibit alternative catalytic activities, such as polyamine deacetylase or lysine fatty acid deacylase activity.  To date, crystal structures have been reported for class I HDACs (1-3, and 8), class IIa HDACs (4 and 7), and class IIb HDACs (6 and 10).  Conserved active site residues mediate the chem. of substrate activation and hydrolysis in these isoenzymes through a metal-activated water mol. assisted by general base-general acid catalysis.  Upregulated HDAC activity is obsd. in cancer and neurodegenerative disease, and four HDAC inhibitors are currently approved for use in cancer chemotherapy.  Crystal structures of HDAC-inhibitor complexes guide the design of new inhibitors with high affinity and selectivity for specific HDAC isoenzymes implicated in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Vx86t86y6rVg90H21EOLACvtfcHk0lhSqm7lt4WSww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGit7o%253D&md5=1dd392837f88a1f079861d44a3f529f5</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2019.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2019.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%252C%2520Mechanism%252C%2520and%2520Inhibition%2520of%2520the%2520Zinc-Dependent%2520Histone%2520Deacetylases%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2019%26volume%3D59%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.sbi.2019.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span> <span> </span><span class="NLM_article-title">The Physiological Roles of Histone Deacetylase (HDAC) 1 and 2: Complex Co-Stars with Multiple Leading Parts</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1042/BST20130010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FBST20130010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23697933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotV2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=741-749&author=R.+D.+W.+Kellyauthor=S.+M.+Cowley&title=The+Physiological+Roles+of+Histone+Deacetylase+%28HDAC%29+1+and+2%3A+Complex+Co-Stars+with+Multiple+Leading+Parts&doi=10.1042%2FBST20130010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts</span></div><div class="casAuthors">Kelly, Richard D. W.; Cowley, Shaun M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">741-749</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  HDACs (histone deacetylases) 1 and 2 are ubiquitous long-lived proteins, which are often found together in three major multiprotein co-repressor complexes: Sin3, NuRD (nucleosome remodeling and deacetylation) and CoREST (co-repressor for element-1-silencing transcription factor).  Although there is a burgeoning no. of non-histone proteins within the acetylome, these complexes contain multiple DNA/chromatin-recognition motifs, which, in combination with transcription factors, target HDAC1/2 to chromatin.  Their physiol. roles should therefore be viewed within the framework of chromatin manipulation.  Classically, HDACs were thought to be recruited predominantly by transcriptional repressors to facilitate local histone deacetylation and transcriptional repression.  More recently, genome-wide assays have mapped HDAC1/2 and their assocd. proteins to transcriptionally active loci and have provided alternative context-specific functions, whereby their repressive functions are subtly exerted to balance transcriptional activation and repression.  With a few significant exceptions (early embryogenesis, brain development), HDAC1 and HDAC2 are functionally redundant.  In most mouse knockout studies, deletion of both enzymes is required in order to produce a substantial phenotype.  HDAC1/2 activity has been implicated in the development of numerous tissue and cell types, including heart, skin, brain, B-cells and T-cells.  A common feature in all HDAC1/2-knockout, -knockdown and small-mol. inhibitor studies is a redn. in cell proliferation.  A generic role in cell cycle progression could be exploited in cancer cells, by blocking HDAC1/2 activity with small-mol. inhibitors, making them potentially useful drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphMiAYD8az_rVg90H21EOLACvtfcHk0ligKrPbBUiydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotV2qsLw%253D&md5=47aa120c4321fedd4011fbfea6ca2243</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1042%2FBST20130010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20130010%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DR.%2BD.%2BW.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26atitle%3DThe%2520Physiological%2520Roles%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%25201%2520and%25202%253A%2520Complex%2520Co-Stars%2520with%2520Multiple%2520Leading%2520Parts%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2013%26volume%3D41%26spage%3D741%26epage%3D749%26doi%3D10.1042%2FBST20130010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, M. A.</span></span> <span> </span><span class="NLM_article-title">Integrative Regulation of Physiology by Histone Deacetylase 3</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1038/s41580-018-0076-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41580-018-0076-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30390028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=102-115&author=M.+J.+Emmettauthor=M.+A.+Lazar&title=Integrative+Regulation+of+Physiology+by+Histone+Deacetylase+3&doi=10.1038%2Fs41580-018-0076-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Integrative regulation of physiology by histone deacetylase 3</span></div><div class="casAuthors">Emmett, Matthew J.; Lazar, Mitchell A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">102-115</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Cell-type-specific gene expression is physiol. modulated by the binding of transcription factors to genomic enhancer sequences, to which chromatin modifiers such as histone deacetylases (HDACs) are recruited.  Drugs that inhibit HDACs are in clin. use but lack specificity.  HDAC3 is a stoichiometric component of nuclear receptor co-repressor complexes whose enzymic activity depends on this interaction.  HDAC3 is required for many aspects of mammalian development and physiol., for example, for controlling metab. and circadian rhythms.  In this Review, we discuss the mechanisms by which HDAC3 regulates cell type-specific enhancers, the structure of HDAC3 and its function as part of nuclear receptor co-repressors, its enzymic activity and its post-translational modifications.  We then discuss the plethora of tissue-specific physiol. functions of HDAC3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAwR_7xsbnjLVg90H21EOLACvtfcHk0ligKrPbBUiydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7zL&md5=ab5a2912fc482c16b42e8e7d49a08750</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41580-018-0076-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41580-018-0076-0%26sid%3Dliteratum%253Aachs%26aulast%3DEmmett%26aufirst%3DM.%2BJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26atitle%3DIntegrative%2520Regulation%2520of%2520Physiology%2520by%2520Histone%2520Deacetylase%25203%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2019%26volume%3D20%26spage%3D102%26epage%3D115%26doi%3D10.1038%2Fs41580-018-0076-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 in Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+Deacetylase+6+in+Cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0ligKrPbBUiydA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%25206%2520in%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skultetyova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snajdr, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadzima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranova, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Havlinova, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">The Unraveling of Substrate Specificity of Histone Deacetylase 6 Domains Using Acetylome Peptide Microarrays and Peptide Libraries</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">4035</span>– <span class="NLM_lpage">4045</span>, <span class="refDoi"> DOI: 10.1096/fj.201801680R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1096%2Ffj.201801680R" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30496698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptl2itbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=4035-4045&author=Z.+Kutilauthor=L.+Skultetyovaauthor=D.+Rauhauthor=M.+Meleshinauthor=I.+Snajdrauthor=Z.+Novakovaauthor=J.+Mikesovaauthor=J.+Pavlicekauthor=M.+Hadzimaauthor=P.+Baranovaauthor=B.+Havlinovaauthor=P.+Majerauthor=M.+Schutkowskiauthor=C.+Barinka&title=The+Unraveling+of+Substrate+Specificity+of+Histone+Deacetylase+6+Domains+Using+Acetylome+Peptide+Microarrays+and+Peptide+Libraries&doi=10.1096%2Ffj.201801680R"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries</span></div><div class="casAuthors">Kutil, Zsofia; Skultetyova, Lubica; Rauh, David; Meleshin, Marat; Snajdr, Ivan; Novakova, Zora; Mikesova, Jana; Pavlicek, Jiri; Hadzima, Martin; Baranova, Petra; Havlinova, Barbora; Majer, Pavel; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">4035-4045</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is amultidomain cytosolic hydrolase actingmostly on nonhistone protein substrates.  Investigations of the substrate specificity of HDAC6 are confounded by the presence of 2 catalytically active deacetylase domains (DD1 and DD2).  In this study, acetylome peptide microarrays and peptide libraries were used to map the substrate specificity of DD1 and DD2 of human HDAC6.  The results show that DD1 is solely responsible for the deacetylation of substrates harboring the acetyllysine at their C terminus, whereas DD2 exclusively deacetylates peptides with an internal acetyllysine residue.  Also, statistical anal. of the deacetylation data revealed amino acid preferences at individual positions flanking the acetyllysine, where glycine and arginine residues are favored at positions N-terminal to the central acetyllysine; neg. charged glutamate is strongly disfavored throughout the sequence.  Finally, the deacylation activity of HDAC6 was profiled by using a panel of acyl derivs. of the optimized peptide substrate and showed that HDAC6 acts as a proficient deformylase.  Our data thus offer a detailed insight into the substrate preferences of the individual HDAC6 domains at the peptide level, and these findings can in turn help in elucidating the biol. roles of the enzyme and facilitate the development of new domain-specific inhibitors as research tools or therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjEuwCTtndhrVg90H21EOLACvtfcHk0lgeduLjdn2fnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptl2itbg%253D&md5=c94c8d4d8ba9993f2357854616d4abc9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1096%2Ffj.201801680R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201801680R%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DSkultetyova%26aufirst%3DL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DSnajdr%26aufirst%3DI.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DHadzima%26aufirst%3DM.%26aulast%3DBaranova%26aufirst%3DP.%26aulast%3DHavlinova%26aufirst%3DB.%26aulast%3DMajer%26aufirst%3DP.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DThe%2520Unraveling%2520of%2520Substrate%2520Specificity%2520of%2520Histone%2520Deacetylase%25206%2520Domains%2520Using%2520Acetylome%2520Peptide%2520Microarrays%2520and%2520Peptide%2520Libraries%26jtitle%3DFASEB%2520J.%26date%3D2019%26volume%3D33%26spage%3D4035%26epage%3D4045%26doi%3D10.1096%2Ffj.201801680R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0lgeduLjdn2fnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakrabarti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">HDAC8: A Multifaceted Target for Therapeutic Interventions</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.04.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.tips.2015.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26013035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=481-492&author=A.+Chakrabartiauthor=I.+Oehmeauthor=O.+Wittauthor=G.+Oliveiraauthor=W.+Sipplauthor=C.+Romierauthor=R.+J.+Pierceauthor=M.+Jung&title=HDAC8%3A+A+Multifaceted+Target+for+Therapeutic+Interventions&doi=10.1016%2Fj.tips.2015.04.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8: a multifaceted target for therapeutic interventions</span></div><div class="casAuthors">Chakrabarti, Alokta; Oehme, Ina; Witt, Olaf; Oliveira, Guilherme; Sippl, Wolfgang; Romier, Christophe; Pierce, Raymond J.; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-492</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections.  It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins.  In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors crit. to tumorigenesis.  In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection.  The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors.  Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPwG01nKtWHLVg90H21EOLACvtfcHk0lgeduLjdn2fnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlGqsL4%253D&md5=c99b5c390930dc17398d15f20127758b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DChakrabarti%26aufirst%3DA.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOliveira%26aufirst%3DG.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DPierce%26aufirst%3DR.%2BJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DHDAC8%253A%2520A%2520Multifaceted%2520Target%2520for%2520Therapeutic%2520Interventions%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D481%26epage%3D492%26doi%3D10.1016%2Fj.tips.2015.04.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castañeda, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfson, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fierke, C. A.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Substrate Selectivity Is Determined by Long- and Short-Range Interactions Leading to Enhanced Reactivity for Full-Length Histone Substrates Compared with Peptides</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">21568</span>– <span class="NLM_lpage">21577</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.811026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M117.811026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29109148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1yjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=21568-21577&author=C.+A.+Casta%C3%B1edaauthor=N.+A.+Wolfsonauthor=K.+R.+Lengauthor=Y.-M.+Kuoauthor=A.+J.+Andrewsauthor=C.+A.+Fierke&title=HDAC8+Substrate+Selectivity+Is+Determined+by+Long-+and+Short-Range+Interactions+Leading+to+Enhanced+Reactivity+for+Full-Length+Histone+Substrates+Compared+with+Peptides&doi=10.1074%2Fjbc.M117.811026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides</span></div><div class="casAuthors">Castaneda, Carol Ann; Wolfson, Noah A.; Leng, Katherine R.; Kuo, Yin-Ming; Andrews, Andrew J.; Fierke, Carol A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">21568-21577</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) catalyze deacetylation of acetyl-lysine residues within proteins.  To date, HDAC substrate specificity and selectivity have been largely estd. using peptide substrates.  However, it is unclear whether peptide substrates accurately reflect the substrate selectivity of HDAC8 toward full-length proteins.  Here, we compare HDAC8 substrate selectivity in the context of peptides, full-length proteins, and protein-nucleic acid complexes.  We demonstrate that HDAC8 catalyzes deacetylation of tetrameric histone (H3/H4) substrates with catalytic efficiencies that are 40-300-fold higher than those for corresponding peptide substrates.  Thus, we conclude that addnl. contacts with protein substrates enhance catalytic efficiency.  However, the catalytic efficiency decreases for larger multiprotein complexes.  These differences in HDAC8 substrate selectivity for peptides and full-length proteins suggest that HDAC8 substrate preference is based on a combination of short- and long-range interactions.  In summary, this work presents detailed kinetics for HDAC8-catalyzed deacetylation of singly-acetylated, full-length protein substrates, revealing that HDAC8 substrate selectivity is detd. by multiple factors.  These insights provide a foundation for understanding recognition of full-length proteins by HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiSrdVpHIIfbVg90H21EOLACvtfcHk0lgeduLjdn2fnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1yjsA%253D%253D&md5=7f39302747468f75a431cfeaa5e4ed96</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.811026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.811026%26sid%3Dliteratum%253Aachs%26aulast%3DCasta%25C3%25B1eda%26aufirst%3DC.%2BA.%26aulast%3DWolfson%26aufirst%3DN.%2BA.%26aulast%3DLeng%26aufirst%3DK.%2BR.%26aulast%3DKuo%26aufirst%3DY.-M.%26aulast%3DAndrews%26aufirst%3DA.%2BJ.%26aulast%3DFierke%26aufirst%3DC.%2BA.%26atitle%3DHDAC8%2520Substrate%2520Selectivity%2520Is%2520Determined%2520by%2520Long-%2520and%2520Short-Range%2520Interactions%2520Leading%2520to%2520Enhanced%2520Reactivity%2520for%2520Full-Length%2520Histone%2520Substrates%2520Compared%2520with%2520Peptides%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D21568%26epage%3D21577%26doi%3D10.1074%2Fjbc.M117.811026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aramsangtienchai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2685</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2685-2692&author=P.+Aramsangtienchaiauthor=N.+A.+Spiegelmanauthor=B.+Heauthor=S.+P.+Millerauthor=L.+Daiauthor=Y.+Zhaoauthor=H.+Lin&title=HDAC8+Catalyzes+the+Hydrolysis+of+Long+Chain+Fatty+Acyl+Lysine&doi=10.1021%2Facschembio.6b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine</span></div><div class="casAuthors">Aramsangtienchai, Pornpun; Spiegelman, Nicole A.; He, Bin; Miller, Seth P.; Dai, Lunzhi; Zhao, Yingming; Lin, Hening</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2685-2692</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The histone deacetylase (HDAC) family regulates many biol. pathways through the deacetylation of lysine residues on histone and nonhistone proteins.  Mammals have 18 HDACs that are classified into four classes.  Class I, II, and IV are zinc-dependent, while class III is NAD (NAD+)-dependent lysine deacetylase or sirtuins.  HDAC8, a class I HDAC family member, has been shown to have low deacetylation activity compared to other HDACs in vitro.  Recent studies showed that several sirtuins, with low deacetylase activities, can actually hydrolyze other acyl lysine modifications more efficiently.  Inspired by this, we tested the activity of HDAC8 using a variety of different acyl lysine peptides.  Screening a panel of peptides with different acyl lysine modifications, we found that HDAC8 can catalyze the removal of acyl groups with 2-16 carbons from lysine 9 of the histone H3 peptide (H3K9).  Interestingly, the catalytic efficiencies (kcat/Km) of HDAC8 on octanoyl, dodecanoyl, and myristoyl lysine are several-fold better than that on acetyl lysine.  The increased catalytic efficiencies of HDAC8 on larger fatty acyl groups are due to the much lower Km values.  T-cell leukemia Jurkat cells treated with a HDAC8 specific inhibitor, PCI-34051, exhibited an increase in global fatty acylation compared to control treatment.  Thus, the de-fatty-acylation activity of HDAC8 is likely physiol. relevant.  This is the first report of a zinc-dependent HDAC with de-fatty-acylation activity, and identification of HDAC8 de-fatty-acylation targets will help to further understand the function of HDAC8 and protein lysine fatty acylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDqpFjVQQljLVg90H21EOLACvtfcHk0ljBsZFpWpcIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtrbL&md5=bdfdd0bb0199e094719008da1b0d1520</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00396%26sid%3Dliteratum%253Aachs%26aulast%3DAramsangtienchai%26aufirst%3DP.%26aulast%3DSpiegelman%26aufirst%3DN.%2BA.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DH.%26atitle%3DHDAC8%2520Catalyzes%2520the%2520Hydrolysis%2520of%2520Long%2520Chain%2520Fatty%2520Acyl%2520Lysine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2685%26epage%3D2692%26doi%3D10.1021%2Facschembio.6b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanginlar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC11 Is a Regulator of Diverse Immune Functions</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1861</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bbagrm.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29222071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWns7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1861&publication_year=2018&pages=54-59&author=C.+Yanginlarauthor=C.+Logie&title=HDAC11+Is+a+Regulator+of+Diverse+Immune+Functions&doi=10.1016%2Fj.bbagrm.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC11 is a regulator of diverse immune functions</span></div><div class="casAuthors">Yanginlar, Cansu; Logie, Colin</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1861</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-59</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases deacetylate histone and non-histone protein targets.  Aberrant HDAC expression and function have been obsd. in several diseases, which make these enzymes attractive treatment targets.  Here, we summarize recent literature that addresses the roles of HDAC11 on the regulation of different immune cells including neutrophils, myeloid derived suppressor cells and T-cells.  HDAC11 was initially identified as a neg. regulator of the well-known anti-inflammatory cytokine IL-10.  Hence, antagonizing HDAC11 activity may have anti-tumor potential, whereas activating HDAC11 may be useful to treat chronic inflammation or autoimmunity.  However, to anticipate biol. side-effects of HDAC11 modulators, more mol. insights will be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZ7apoQdA2bVg90H21EOLACvtfcHk0ljBsZFpWpcIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWns7vE&md5=a818f8f833ef4bdb1eff570043861923</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DYanginlar%26aufirst%3DC.%26aulast%3DLogie%26aufirst%3DC.%26atitle%3DHDAC11%2520Is%2520a%2520Regulator%2520of%2520Diverse%2520Immune%2520Functions%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2018%26volume%3D1861%26spage%3D54%26epage%3D59%26doi%3D10.1016%2Fj.bbagrm.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikesova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00942</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00942" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=685-693&author=Z.+Kutilauthor=Z.+Novakovaauthor=M.+Meleshinauthor=J.+Mikesovaauthor=M.+Schutkowskiauthor=C.+Barinka&title=Histone+Deacetylase+11+Is+a+Fatty-Acid+Deacylase&doi=10.1021%2Facschembio.7b00942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is a Fatty-Acid Deacylase</span></div><div class="casAuthors">Kutil, Zsofia; Novakova, Zora; Meleshin, Marat; Mikesova, Jana; Schutkowski, Mike; Barinka, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-693</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) is a sole member of the class IV HDAC subfamily with negligible intrinsic deacetylation activity.  Here, we report in vitro profiling of HDAC11 deacylase activities, and our data unequivocally show that the enzyme efficiently removes acyl moieties spanning 8-18 carbons from the side chain nitrogen of the lysine residue of a peptidic substrate.  Addnl., N-linked lipoic acid and biotin are removed by the enzyme, although with lower efficacy.  Catalytic efficiencies toward dodecanoylated and myristoylated peptides were 77 700 and 149 000 M-1 s-1, resp., making HDAC11 the most proficient fatty-acid deacylase of the HDAC family.  Interestingly, HDAC11 is strongly inhibited by free myristic, palmitic, and stearic acids with inhibition consts. of 6.5, 0.9, and 1.6 μM, resp.  At the same time, its deacylase activity is stimulated more than 2.5-fold by both palmitoyl-CoA and myristoyl-CoA, pointing toward metabolic control of the enzymic activity by fatty-acid metabolites.  Our data reveal novel enzymic activity of HDAC11 that can, in turn, facilitate the uncovering of addnl. biol. functions of the enzyme as well as the design of isoform-specific HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozNsptw7rk7bVg90H21EOLACvtfcHk0ljBsZFpWpcIYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCjug%253D%253D&md5=07233a3bfed4f158c6d5752fc18a8c1f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00942%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DMikesova%26aufirst%3DJ.%26aulast%3DSchutkowski%26aufirst%3DM.%26aulast%3DBarinka%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%252011%2520Is%2520a%2520Fatty-Acid%2520Deacylase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D685%26epage%3D693%26doi%3D10.1021%2Facschembio.7b00942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Yruela, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galleano, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 11 Is an ε-<i>N</i>-Myristoyllysine Hydrolase</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">849</span>– <span class="NLM_lpage">856</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2018.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.chembiol.2018.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29731425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVyju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=849-856&author=C.+Moreno-Yruelaauthor=I.+Galleanoauthor=A.+S.+Madsenauthor=C.+A.+Olsen&title=Histone+Deacetylase+11+Is+an+%CE%B5-N-Myristoyllysine+Hydrolase&doi=10.1016%2Fj.chembiol.2018.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase</span></div><div class="casAuthors">Moreno-Yruela, Carlos; Galleano, Iacopo; Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">849-856.e8</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymes regulate diverse biol. function, including gene expression, rendering them potential targets for intervention in a no. of diseases, with a handful of compds. approved for treatment of certain hematol. cancers.  Among the human zinc-dependent HDACs, the most recently discovered member, HDAC11, is the only member assigned to subclass IV.  It is the smallest protein and has the least well understood biol. function.  Here, we show that HDAC11 cleaves long-chain acyl modifications on lysine side chains with remarkable efficiency.  We further show that several common types of HDAC inhibitors, including the approved drugs romidepsin and vorinostat, do not inhibit this enzymic activity.  Macrocyclic hydroxamic acid-contg. peptides, on the other hand, potently inhibit HDAC11 demyristoylation activity.  These findings should be taken carefully into consideration in future investigations of the biol. function of HDAC11 and will serve as a foundation for the development of selective chem. probes targeting HDAC11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5H2-YHI3qbVg90H21EOLACvtfcHk0ljalkL7a0RX1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVyju7c%253D&md5=9c805196d1b26c2c31459940e0e949f7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno-Yruela%26aufirst%3DC.%26aulast%3DGalleano%26aufirst%3DI.%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DHistone%2520Deacetylase%252011%2520Is%2520an%2520%25CE%25B5-N-Myristoyllysine%2520Hydrolase%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D849%26epage%3D856%26doi%3D10.1016%2Fj.chembiol.2018.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asfaha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves Avelar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in Class IIa Histone Deacetylases Research</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">115087</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2019.115087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31561937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVKksr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=115087&author=Y.+Asfahaauthor=C.+Schrenkauthor=L.+A.+Alves+Avelarauthor=A.+Hamacherauthor=M.+Pfliegerauthor=M.+U.+Kassackauthor=T.+Kurz&title=Recent+Advances+in+Class+IIa+Histone+Deacetylases+Research&doi=10.1016%2Fj.bmc.2019.115087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in class IIa histone deacetylases research</span></div><div class="casAuthors">Asfaha, Yodita; Schrenk, Christian; Alves Avelar, Leandro A.; Hamacher, Alexandra; Pflieger, Marc; Kassack, Matthias U.; Kurz, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">115087</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Epigenetic control plays an important role in gene regulation through chem. modifications of DNA and post-translational modifications of histones.  An essential post-translational modification is the histone acetylation/deacetylation-process which is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  The mammalian zinc dependent HDAC family is subdivided into three classes: class I (HDACs 1-3, 8), class II (IIa: HDACs 4, 5, 7, 9; IIb: HDACs 6, 10) and class IV (HDAC 11).  In this review, recent studies on the biol. role and regulation of class IIa HDACs as well as their contribution in neurodegenerative diseases, immune disorders and cancer will be presented.  Furthermore, the development, synthesis, and future perspectives of selective class IIa inhibitors will be highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2A6En_QF4WbVg90H21EOLACvtfcHk0ljalkL7a0RX1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVKksr7M&md5=d03cc974f3c66539242026af7ac00856</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115087%26sid%3Dliteratum%253Aachs%26aulast%3DAsfaha%26aufirst%3DY.%26aulast%3DSchrenk%26aufirst%3DC.%26aulast%3DAlves%2BAvelar%26aufirst%3DL.%2BA.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DPflieger%26aufirst%3DM.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKurz%26aufirst%3DT.%26atitle%3DRecent%2520Advances%2520in%2520Class%2520IIa%2520Histone%2520Deacetylases%2520Research%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D115087%26doi%3D10.1016%2Fj.bmc.2019.115087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, B. M.</span></span> <span> </span><span class="NLM_article-title">Structural basis of the action of thermolysin and related zinc peptidases</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1021/ar00153a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar00153a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaL1cXltVKrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1988&pages=333-340&author=B.+M.+Matthews&title=Structural+basis+of+the+action+of+thermolysin+and+related+zinc+peptidases&doi=10.1021%2Far00153a003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of the action of thermolysin and related zinc peptidases</span></div><div class="casAuthors">Matthews, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">333-40</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with refs., of the structure and reaction mechanism of thermolysin and other Zn-contg. proteolytic enzymes, such as carboxypeptidase A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovcGWEFEzE5rVg90H21EOLACvtfcHk0ljalkL7a0RX1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXltVKrsLo%253D&md5=25cc216c6b4ee3d888132acb4f7dd23e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Far00153a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far00153a003%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DB.%2BM.%26atitle%3DStructural%2520basis%2520of%2520the%2520action%2520of%2520thermolysin%2520and%2520related%2520zinc%2520peptidases%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1988%26volume%3D21%26spage%3D333%26epage%3D340%26doi%3D10.1021%2Far00153a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koeneke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.3390/cells4020135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fcells4020135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25915736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVKitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=135-168&author=E.+Koenekeauthor=O.+Wittauthor=I.+Oehme&title=HDAC+Family+Members+Intertwined+in+the+Regulation+of+Autophagy%3A+A+Druggable+Vulnerability+in+Aggressive+Tumor+Entities&doi=10.3390%2Fcells4020135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities</span></div><div class="casAuthors">Koeneke, Emily; Witt, Olaf; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-168</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The exploitation of autophagy by some cancer entities to support survival and dodge death has been well-described.  Though its role as a constitutive process is important in normal, healthy cells, in the milieu of malignantly transformed and highly proliferative cells, autophagy is crit. for escaping metabolic and genetic stressors.  In recent years, the importance of histone deacetylases (HDACs) in cancer biol. has been heavily investigated, and the enzyme family has been shown to play a role in autophagy, too.  HDAC inhibitors (HDACi) are being integrated into cancer therapy and clin. trials are ongoing.  The effect of HDACi on autophagy and, conversely, the effect of autophagy on HDACi efficacy are currently under investigation.  With the development of HDACi that are able to selectively target individual HDAC isoenzymes, there is great potential for specific therapy that has more well-defined effects on cancer biol. and also minimizes toxicity.  Here, the role of autophagy in the context of cancer and the interplay of this process with HDACs will be summarized.  Identification of key HDAC isoenzymes involved in autophagy and the ability to target specific isoenzymes yields the potential to cripple and ultimately eliminate malignant cells depending on autophagy as a survival mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8tgPx9Co3mLVg90H21EOLACvtfcHk0ljalkL7a0RX1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVKitbY%253D&md5=562219b08ca8c4a9c93e15e92687a1b0</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fcells4020135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells4020135%26sid%3Dliteratum%253Aachs%26aulast%3DKoeneke%26aufirst%3DE.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520Family%2520Members%2520Intertwined%2520in%2520the%2520Regulation%2520of%2520Autophagy%253A%2520A%2520Druggable%2520Vulnerability%2520in%2520Aggressive%2520Tumor%2520Entities%26jtitle%3DCells%26date%3D2015%26volume%3D4%26spage%3D135%26epage%3D168%26doi%3D10.3390%2Fcells4020135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 10 Structure and Molecular Function as a Polyamine Deacetylase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15368</span>, <span class="refDoi"> DOI: 10.1038/ncomms15368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fncomms15368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28516954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotFyisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15368&author=Y.+Haiauthor=S.+A.+Shinskyauthor=N.+J.+Porterauthor=D.+W.+Christianson&title=Histone+Deacetylase+10+Structure+and+Molecular+Function+as+a+Polyamine+Deacetylase&doi=10.1038%2Fncomms15368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 10 structure and molecular function as a polyamine deacetylase</span></div><div class="casAuthors">Hai, Yang; Shinsky, Stephen A.; Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15368</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cationic polyamines such as spermidine and spermine are crit. in all forms of life, as they regulate the function of biol. macromols.  Intracellular polyamine metab. is regulated by reversible acetylation and dysregulated polyamine metab. is assocd. with neoplastic diseases such as colon cancer, prostate cancer and neuroblastoma.  Here we report that histone deacetylase 10 (HDAC10) is a robust polyamine deacetylase, using recombinant enzymes from Homo sapiens (human) and Danio rerio (zebrafish).  The 2.85 Å-resoln. crystal structure of zebrafish HDAC10 complexed with a transition-state analog inhibitor reveals that a glutamate gatekeeper and a sterically constricted active site confer specificity for N8-acetylspermidine hydrolysis and disfavor acetyllysine hydrolysis.  Both HDAC10 and spermidine are known to promote cellular survival through autophagy.  Accordingly, this work sets a foundation for studying the chem. biol. of autophagy through the structure-based design of inhibitors that may also serve as new leads for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa9laHMWjizLVg90H21EOLACvtfcHk0lgwF6xZvj28gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotFyisrY%253D&md5=e192e4b219dcb0b46b05ece566f8a59d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncomms15368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15368%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DShinsky%26aufirst%3DS.%2BA.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520Deacetylase%252010%2520Structure%2520and%2520Molecular%2520Function%2520as%2520a%2520Polyamine%2520Deacetylase%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15368%26doi%3D10.1038%2Fncomms15368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinsky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.8b00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.8b00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3105-3114&author=S.+A.+Shinskyauthor=D.+W.+Christianson&title=Polyamine+Deacetylase+Structure+and+Catalysis%3A+Prokaryotic+Acetylpolyamine+Amidohydrolase+and+Eukaryotic+HDAC10&doi=10.1021%2Facs.biochem.8b00079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10</span></div><div class="casAuthors">Shinsky, Stephen A.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3105-3114</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polyamines such as putrescine, spermidine, and spermine are small aliph. cations that serve myriad biol. functions in all forms of life.  While polyamine biosynthesis and cellular trafficking pathways are generally well-defined, only recently has the mol. basis of reversible polyamine acetylation been established.  In particular, enzymes that catalyze polyamine deacetylation reactions have been identified and structurally characterized: histone deacetylase 10 (HDAC10) from Homo sapiens and Danio rerio (zebrafish) is a highly specific N8-acetylspermidine deacetylase, and its prokaryotic counterpart, acetylpolyamine amidohydrolase (APAH) from Mycoplana ramosa, is a broad-specificity polyamine deacetylase.  Similar to the greater family of HDACs, which mainly serve as lysine deacetylases, both enzymes adopt the characteristic arginase-deacetylase fold and employ a Zn2+-activated water mol. for catalysis.  In contrast with HDACs, however, the active sites of HDAC10 and APAH are sterically constricted to enforce specificity for long, slender polyamine substrates and exclude bulky peptides and proteins contg. acetyl-L-lysine.  Crystal structures of APAH and D. rerio HDAC10 reveal that quaternary structure, i.e., dimer assembly, provides the steric constriction that directs the polyamine substrate specificity of APAH, whereas tertiary structure, a unique 310 helix defined by the P(E,A)CE motif, provides the steric constriction that directs the polyamine substrate specificity of HDAC10.  Given the recent identification of HDAC10 and spermidine as mediators of autophagy, HDAC10 is rapidly emerging as a biomarker and target for the design of isoenzyme-selective inhibitors that will suppress autophagic responses to cancer chemotherapy, thereby rendering cancer cells more susceptible to cytotoxic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRp3v9v7ryrLVg90H21EOLACvtfcHk0lgwF6xZvj28gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgsrw%253D&md5=f909b6b4f46bd1a7eb5f12b800295fc5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.8b00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.8b00079%26sid%3Dliteratum%253Aachs%26aulast%3DShinsky%26aufirst%3DS.%2BA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DPolyamine%2520Deacetylase%2520Structure%2520and%2520Catalysis%253A%2520Prokaryotic%2520Acetylpolyamine%2520Amidohydrolase%2520and%2520Eukaryotic%2520HDAC10%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26spage%3D3105%26epage%3D3114%26doi%3D10.1021%2Facs.biochem.8b00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuchler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenull, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivarathri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N.</span></span> <span> </span><span class="NLM_article-title">Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e1005938</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.ppat.1005938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27832212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitV2mtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=e1005938&author=K.+Kuchlerauthor=S.+Jenullauthor=R.+Shivarathriauthor=N.+Chauhan&title=Fungal+KATs%2FKDACs%3A+A+New+Highway+to+Better+Antifungal+Drugs%3F&doi=10.1371%2Fjournal.ppat.1005938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Fungal KATs/KDACs: a new highway to better antifungal drugs?</span></div><div class="casAuthors">Kuchler, Karl; Jenull, Sabrina; Shivarathri, Raju; Chauhan, Neeraj</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1005938/1-e1005938/15</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">A review.  We provide a comprehensive overview of chromatin modification in human fungal pathogens, particularly those altering virulence.  The focus is on lysine deacetylases (KDACs) and lysine acetyltransferases (KATs) in Candida spp.  We discuss how the modulation of KATs/KDACs in Candida spp. could pave the way for novel therapeutic strategies to combat fungal infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod-Z1p6GfHcrVg90H21EOLACvtfcHk0lgwF6xZvj28gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitV2mtL4%253D&md5=de23517424eb6138f6e98fd6ae4f1e8f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005938%26sid%3Dliteratum%253Aachs%26aulast%3DKuchler%26aufirst%3DK.%26aulast%3DJenull%26aufirst%3DS.%26aulast%3DShivarathri%26aufirst%3DR.%26aulast%3DChauhan%26aufirst%3DN.%26atitle%3DFungal%2520KATs%252FKDACs%253A%2520A%2520New%2520Highway%2520to%2520Better%2520Antifungal%2520Drugs%253F%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3De1005938%26doi%3D10.1371%2Fjournal.ppat.1005938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhomberg, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, M.</span></span> <span> </span><span class="NLM_article-title"><i>In Vitro</i> Activity of a Hos2 Deacetylase Inhibitor, MGCD290, in Combination with Echinocandins against Echinocandin-Resistant <i>Candida</i> Species</span>. <i>Diagn. Microbiol. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1016/j.diagmicrobio.2014.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.diagmicrobio.2014.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25600842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVSnsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2015&pages=259-263&author=M.+A.+Pfallerauthor=P.+R.+Rhombergauthor=S.+A.+Messerauthor=M.+Castanheira&title=In+Vitro+Activity+of+a+Hos2+Deacetylase+Inhibitor%2C+MGCD290%2C+in+Combination+with+Echinocandins+against+Echinocandin-Resistant+Candida+Species&doi=10.1016%2Fj.diagmicrobio.2014.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species</span></div><div class="casAuthors">Pfaller, M. A.; Rhomberg, P. R.; Messer, S. A.; Castanheira, M.</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Microbiology and Infectious Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-263</span>CODEN:
                <span class="NLM_cas:coden">DMIDDZ</span>;
        ISSN:<span class="NLM_cas:issn">0732-8893</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">MGCD290, a Hos2 fungal histone deacetylase inhibitor, showed modest activity when tested alone (MIC range, 0.12-4 μg/mL; MIC50/90, 0.5/4 μg/mL) against Candida glabrata (n = 15; 14 fks mutants; 5 also fluconazole resistant), Candida albicans (8 fks mutants; 2 also fluconazole resistant), Candida tropicalis (4 fks mutants), and Candida krusei (3 fks mutants).  However, MGCD290 showed synergy or partial synergy for 33.3%, 30.1%, 36.7%, and 80.0% of the isolates when tested with anidulafungin, caspofungin, micafungin, and fluconazole, resp.  Favorable interactions were achieved with low concns. of MGCD290 (0.015-0.25 μg/mL), and categorical shifts were obsd. in 2 of 8 (25.0%) isolates of C. albicans and 2 of 3 (66.7%) isolates of C. krusei and in 4 of the 5 (80.0%) fluconazole-resistant isolates of C. glabrata.  MGCD290 exerts a distinctly favorable influence on the MICs of fluconazole and the echinocandins, resulting in conversion from resistance to susceptibility regardless of fks mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIr_O0BjzX4rVg90H21EOLACvtfcHk0lhKGqRSLsSkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVSnsbjL&md5=3a7550a215a89b52495ec6ebf5297bb1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.diagmicrobio.2014.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.diagmicrobio.2014.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DRhomberg%26aufirst%3DP.%2BR.%26aulast%3DMesser%26aufirst%3DS.%2BA.%26aulast%3DCastanheira%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Activity%2520of%2520a%2520Hos2%2520Deacetylase%2520Inhibitor%252C%2520MGCD290%252C%2520in%2520Combination%2520with%2520Echinocandins%2520against%2520Echinocandin-Resistant%2520Candida%2520Species%26jtitle%3DDiagn.%2520Microbiol.%2520Infect.%2520Dis.%26date%3D2015%26volume%3D81%26spage%3D259%26epage%3D263%26doi%3D10.1016%2Fj.diagmicrobio.2014.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mautone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Acetylation/Deacetylation in Parasites: An Update (2017–2020)</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32615359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlShs7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=65-74&author=R.+Fioravantiauthor=N.+Mautoneauthor=A.+Rovereauthor=D.+Rotiliauthor=A.+Mai&title=Targeting+Histone+Acetylation%2FDeacetylation+in+Parasites%3A+An+Update+%282017%E2%80%932020%29&doi=10.1016%2Fj.cbpa.2020.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone acetylation/deacetylation in parasites: an update (2017-2020)</span></div><div class="casAuthors">Fioravanti, Rossella; Mautone, Nicola; Rovere, Annarita; Rotili, Dante; Mai, Antonello</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone modifying enzymes have vital roles in the growth and survival of both parasites and humans.  Targeting the epigenome can be a new strategy for the treatment of parasitic diseases.  Compds. modulating histone acetylation/deacetylation have recently been reported hampering Plasmodium, Schistosoma, Leishmania, and Trypanosoma infections.  Beside new histone deacetylase inhibitors, PfGCN5 and bromodomain inhibitors have been recently described to inhibit Plasmodium proliferation.  Sm histone deacetylase 8 and SmSIRT2, as well as Leishmania and Trypanosoma sirtuins (SIR2rps), seem to be the most reliable targets to effectively fight the related protozoan infections.  The selectivity toward parasite over mammalian cells is still an open question, and significant optimization efforts of epidrugs are still required to improve potency/selectivity and decrease toxicity.  Recent reports on the alteration of cellular signaling pathways provoked by parasite infection through changes in the host acetylation/deacetylation status at gene promoters may suggest novel therapeutic strategies to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDelX-elfRebVg90H21EOLACvtfcHk0lhKGqRSLsSkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlShs7zI&md5=e6aeb0f2d6d55dd1f1d408c8be7a0de4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DMautone%26aufirst%3DN.%26aulast%3DRovere%26aufirst%3DA.%26aulast%3DRotili%26aufirst%3DD.%26aulast%3DMai%26aufirst%3DA.%26atitle%3DTargeting%2520Histone%2520Acetylation%252FDeacetylation%2520in%2520Parasites%253A%2520An%2520Update%2520%25282017%25E2%2580%25932020%2529%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D65%26epage%3D74%26doi%3D10.1016%2Fj.cbpa.2020.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heltweg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Assays for the Determination of Histone Deacetylase Activity</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.ymeth.2005.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ymeth.2005.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=16087348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1ahs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2005&pages=332-337&author=B.+Heltwegauthor=J.+Trappauthor=M.+Jung&title=In+Vitro+Assays+for+the+Determination+of+Histone+Deacetylase+Activity&doi=10.1016%2Fj.ymeth.2005.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assays for the determination of histone deacetylase activity</span></div><div class="casAuthors">Heltweg, Birgit; Trapp, Johannes; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Histone deacetylases are important regulators of transcription and an emerging target for anticancer drugs.  We present an overview over various assay formats that include radiolabeled histones, oligopeptides, and small mols. as substrates.  The advantages and disadvantages of the various formats in terms of, e.g., substrate availability, throughput or subtype selectivity are discussed.  Detailed procedures for various assay types that can be used for different problems, such as library screening or fluorescent inhibitor testing, are given.  We present a new protocol for a simple high-throughput assay for NAD+-dependent (class III) histone deacetylases, also termed sirtuins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEetxUXugzbbVg90H21EOLACvtfcHk0lhKGqRSLsSkEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1ahs74%253D&md5=acdab3410a71c11ba6a2835d1e7378c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ymeth.2005.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymeth.2005.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHeltweg%26aufirst%3DB.%26aulast%3DTrapp%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Assays%2520for%2520the%2520Determination%2520of%2520Histone%2520Deacetylase%2520Activity%26jtitle%3DMethods%26date%3D2005%26volume%3D36%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.ymeth.2005.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span> <span> </span><span class="NLM_article-title">Profiling Technologies for the Identification and Characterization of Small-Molecule Histone Deacetylase Inhibitors</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2015.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ddtec.2015.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26723889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC28rms1Witg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=24-28&author=D.+Liao&title=Profiling+Technologies+for+the+Identification+and+Characterization+of+Small-Molecule+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.ddtec.2015.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitors</span></div><div class="casAuthors">Liao Daiqing</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today. Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">24-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are promising drug targets for treating cancer, neurologic, inflammatory and metabolic diseases.  Four small molecule inhibitors of HDACs have gained regulatory approval for treating lymphomas and multiple myelomas.  Highly sensitive in vitro and cell-based profiling technologies have been developed to discover HDAC inhibitors (HDACi) and characterize their inhibitory potency, target-binding specificity and kinetics.  In particular, proteomic profiling can define the specificity of an inhibitor at a single residue resolution.  Chemoproteomic profiling can determine the potency, specificity and binding kinetics of an inhibitor on a specific HDAC complex in cell extracts.  As inhibitors with new chemical scaffolds are of particular interest to improve HDAC isoform-specificity and pharmaceutical properties, effective profiling technologies will continue to have important utility.  Here we briefly review recent developments of HDAC inhibitor profiling technologies and discuss distinct features of various technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2PU1XOycdfCA3UY9EwTNrfW6udTcc2eYlfut2BB6Vq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rms1Witg%253D%253D&md5=2d1efd9c5e1ca2cb2b4a6aa77dca5b21</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2015.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2015.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DD.%26atitle%3DProfiling%2520Technologies%2520for%2520the%2520Identification%2520and%2520Characterization%2520of%2520Small-Molecule%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2015%26volume%3D18%26spage%3D24%26epage%3D28%26doi%3D10.1016%2Fj.ddtec.2015.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grachan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warnow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span> <span> </span><span class="NLM_article-title">Chemical Phylogenetics of Histone Deacetylases</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nchembio.313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnchembio.313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20139990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1OmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=238-243&author=J.+E.+Bradnerauthor=N.+Westauthor=M.+L.+Grachanauthor=E.+F.+Greenbergauthor=S.+J.+Haggartyauthor=T.+Warnowauthor=R.+Mazitschek&title=Chemical+Phylogenetics+of+Histone+Deacetylases&doi=10.1038%2Fnchembio.313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical phylogenetics of histone deacetylases</span></div><div class="casAuthors">Bradner, James E.; West, Nathan; Grachan, Melissa L.; Greenberg, Edward F.; Haggarty, Stephen J.; Warnow, Tandy; Mazitschek, Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-243</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The broad study of histone deacetylases in chem., biol. and medicine relies on tool compds. to derive mechanistic insights.  A phylogenetic anal. of class I and II histone deacetylases (HDACs) as targets of a comprehensive, structurally diverse panel of inhibitors revealed unexpected isoform selectivity even among compds. widely perceived as nonselective.  The synthesis and study of a focused library of cinnamic hydroxamates allowed the identification of, to our knowledge, the first nonselective HDAC inhibitor.  These data will guide a more informed use of HDAC inhibitors as chem. probes and therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXVyndO9wa6LVg90H21EOLACvtfcHk0liCClwF4Ti1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1OmsLY%253D&md5=4f23cb8a5e3fb4090ead9eaa8b992c4a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.313%26sid%3Dliteratum%253Aachs%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DGrachan%26aufirst%3DM.%2BL.%26aulast%3DGreenberg%26aufirst%3DE.%2BF.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DWarnow%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26atitle%3DChemical%2520Phylogenetics%2520of%2520Histone%2520Deacetylases%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D238%26epage%3D243%26doi%3D10.1038%2Fnchembio.313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Profiling of Substrates for Zinc-Dependent Lysine Deacylase Enzymes: HDAC3 Exhibits Decrotonylase Activity in Vitro</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">9083</span>– <span class="NLM_lpage">9087</span>, <span class="refDoi"> DOI: 10.1002/anie.201203754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fanie.201203754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=9083-9087&author=A.+S.+Madsenauthor=C.+A.+Olsen&title=Profiling+of+Substrates+for+Zinc-Dependent+Lysine+Deacylase+Enzymes%3A+HDAC3+Exhibits+Decrotonylase+Activity+in+Vitro&doi=10.1002%2Fanie.201203754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of Substrates for Zinc-dependent Lysine Deacylase Enzymes: HDAC3 Exhibits Decrotonylase Activity In Vitro</span></div><div class="casAuthors">Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9083-9087, S9083/1-S9083/6</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The present investigation, rooted in a systematic screening of the activities of the eleven human zinc-dependent lysine deacylase (KDAC) enzymes against a series of fluorogenic substrates, has led to several discoveries as outlined above.  Most importantly, we found that HDAC3-NCoR1 exhibited decrotonylase activity with a catalytic efficiency that is comparable to the deacetylase activity of other KDAC isoforms.  Moreover, inhibition of the decrotonylase activity by well-known histone deacetylase inhibitors was demonstrated.  Elucidation of the possible implications of this discovery in cellular environments will be an important future objective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEp650IMzvcLVg90H21EOLACvtfcHk0liCClwF4Ti1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOmtbzM&md5=ad86825a5f6dc6d0458e222ee3d01db3</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201203754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201203754%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DProfiling%2520of%2520Substrates%2520for%2520Zinc-Dependent%2520Lysine%2520Deacylase%2520Enzymes%253A%2520HDAC3%2520Exhibits%2520Decrotonylase%2520Activity%2520in%2520Vitro%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2012%26volume%3D51%26spage%3D9083%26epage%3D9087%26doi%3D10.1002%2Fanie.201203754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikešová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zessin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meleshin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nováková, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alquicer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutkowski, M.</span></span> <span> </span><span class="NLM_article-title">Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">19895</span>– <span class="NLM_lpage">19904</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b02808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b02808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFGhs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2019&pages=19895-19904&author=Z.+Kutilauthor=J.+Mike%C5%A1ov%C3%A1author=M.+Zessinauthor=M.+Meleshinauthor=Z.+Nov%C3%A1kov%C3%A1author=G.+Alquicerauthor=A.+Kozikowskiauthor=W.+Sipplauthor=C.+Ba%C5%99inkaauthor=M.+Schutkowski&title=Continuous+Activity+Assay+for+HDAC11+Enabling+Reevaluation+of+HDAC+Inhibitors&doi=10.1021%2Facsomega.9b02808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors</span></div><div class="casAuthors">Kutil, Zsofia; Mikesova, Jana; Zessin, Matthes; Meleshin, Marat; Novakova, Zora; Alquicer, Glenda; Kozikowski, Alan; Sippl, Wolfgang; Barinka, Cyril; Schutkowski, Mike</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">19895-19904</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 11 (HDAC11) preferentially removes fatty acid residues from lysine side chains in a peptide or protein environment.  Here, we report the development and validation of a continuous fluorescence-based activity assay using an internally quenched TNFα-derived peptide deriv. as a substrate.  The threonine residue in the +1 position was replaced by the quencher amino acid 3'-nitro-L-tyrosine and the fatty acyl moiety substituted by 2-aminobenzoylated 11-aminoundecanoic acid.  The resulting peptide substrate enables fluorescence-based direct and continuous readout of HDAC11-mediated amide bond cleavage fully compatible with high-throughput screening formats.  The Z'-factor is higher than 0.85 for the 15μM substrate concn., and the signal-to-noise ratio exceeds 150 for 384-well plates.  In the absence of NAD+, this substrate is specific for HDAC11.  Reevaluation of inhibitory data using our novel assay revealed limited potency and selectivity of known HDAC inhibitors, including Elevenostat, a putative HDAC11-specific inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvGIYSDcYp47Vg90H21EOLACvtfcHk0liCClwF4Ti1cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFGhs73L&md5=65cbcf4d3f259c6942f22e5ec0f79cbc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b02808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b02808%26sid%3Dliteratum%253Aachs%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DMike%25C5%25A1ov%25C3%25A1%26aufirst%3DJ.%26aulast%3DZessin%26aufirst%3DM.%26aulast%3DMeleshin%26aufirst%3DM.%26aulast%3DNov%25C3%25A1kov%25C3%25A1%26aufirst%3DZ.%26aulast%3DAlquicer%26aufirst%3DG.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DSchutkowski%26aufirst%3DM.%26atitle%3DContinuous%2520Activity%2520Assay%2520for%2520HDAC11%2520Enabling%2520Reevaluation%2520of%2520HDAC%2520Inhibitors%26jtitle%3DACS%2520Omega%26date%3D2019%26volume%3D4%26spage%3D19895%26epage%3D19904%26doi%3D10.1021%2Facsomega.9b02808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iovino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Cellular Analysis of the Action of Epigenetic Drugs and Probes</span>. <i>Epigenetics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1080/15592294.2016.1274472</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F15592294.2016.1274472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28071961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ktF2ksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=308-322&author=M.+Hauauthor=F.+Zenkauthor=A.+Ganesanauthor=N.+Iovinoauthor=M.+Jung&title=Cellular+Analysis+of+the+Action+of+Epigenetic+Drugs+and+Probes&doi=10.1080%2F15592294.2016.1274472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular analysis of the action of epigenetic drugs and probes</span></div><div class="casAuthors">Hau Mirjam; Jung Manfred; Zenk Fides; Iovino Nicola; Ganesan A; Ganesan A; Jung Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Epigenetics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">308-322</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Small molecule drugs and probes are important tools in drug discovery, pharmacology, and cell biology.  This is of course also true for epigenetic inhibitors.  Important examples for the use of established epigenetic inhibitors are the study of the mechanistic role of a certain target in a cellular setting or the modulation of a certain phenotype in an approach that aims toward therapeutic application.  Alternatively, cellular testing may aim at the validation of a new epigenetic inhibitor in drug discovery approaches.  Cellular and eventually animal models provide powerful tools for these different approaches but certain caveats have to be recognized and taken into account.  This involves both the selectivity of the pharmacological tool as well as the specificity and the robustness of the cellular system.  In this article, we present an overview of different methods that are used to profile and screen for epigenetic agents and comment on their limitations.  We describe not only diverse successful case studies of screening approaches using different assay formats, but also some problematic cases, critically discussing selected applications of these systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_hWgAwu_M1WGmni0r9GoKfW6udTcc2eZp5BCZeKky_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ktF2ksg%253D%253D&md5=3be4f0536ae926010fcff504a43a4199</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F15592294.2016.1274472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15592294.2016.1274472%26sid%3Dliteratum%253Aachs%26aulast%3DHau%26aufirst%3DM.%26aulast%3DZenk%26aufirst%3DF.%26aulast%3DGanesan%26aufirst%3DA.%26aulast%3DIovino%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DCellular%2520Analysis%2520of%2520the%2520Action%2520of%2520Epigenetic%2520Drugs%2520and%2520Probes%26jtitle%3DEpigenetics%26date%3D2017%26volume%3D12%26spage%3D308%26epage%3D322%26doi%3D10.1080%2F15592294.2016.1274472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodroofe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupcho, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niles, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span> <span> </span><span class="NLM_article-title">Target Engagement and Drug Residence Time Can Be Observed in Living Cells with BRET</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">10091</span>, <span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+Engagement+and+Drug+Residence+Time+Can+Be+Observed+in+Living+Cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0lg8daJPYRAA6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520Engagement%2520and%2520Drug%2520Residence%2520Time%2520Can%2520Be%2520Observed%2520in%2520Living%2520Cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brosch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loidl, P.</span></span> <span> </span><span class="NLM_article-title">Analogues of Trichostatin A and Trapoxin B as Histone Deacetylase Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1658</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(97)00284-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS0960-894X%2897%2900284-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaK2sXks1yqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=1655-1658&author=M.+Jungauthor=K.+Hoffmannauthor=G.+Broschauthor=P.+Loidl&title=Analogues+of+Trichostatin+A+and+Trapoxin+B+as+Histone+Deacetylase+Inhibitors&doi=10.1016%2FS0960-894X%2897%2900284-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Analogs of trichostatin A and trapoxin B as histone deacetylase inhibitors</span></div><div class="casAuthors">Jung, Manfred; Hoffmann, Katharina; Brosch, Gerald; Loidl, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1655-1658</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylase are potent inducers of differentiation and bear considerable potential as drugs for chemoprevention and treatment of cancer.  So far only complex natural products and a few synthetic congeners have been identified as specific inhibitors.  A set of simple analogs was prepd. in as little as four synthetic steps that have inhibitory potencies in the range of known cyclotetrapeptide inhibitors.  These compds. are interesting leads for the design of potent inhibitors of histone deacetylase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosg5Tlr5gMJbVg90H21EOLACvtfcHk0lg8daJPYRAA6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks1yqtbk%253D&md5=d25d0e726ea341ab3e6630625ca389cf</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2897%2900284-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252897%252900284-9%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DBrosch%26aufirst%3DG.%26aulast%3DLoidl%26aufirst%3DP.%26atitle%3DAnalogues%2520of%2520Trichostatin%2520A%2520and%2520Trapoxin%2520B%2520as%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D1655%26epage%3D1658%26doi%3D10.1016%2FS0960-894X%2897%2900284-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beppu, T.</span></span> <span> </span><span class="NLM_article-title">Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">17174</span>– <span class="NLM_lpage">17179</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=2211619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADyaK3cXlvVyqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=1990&pages=17174-17179&author=M.+Yoshidaauthor=M.+Kijimaauthor=M.+Akitaauthor=T.+Beppu&title=Potent+and+Specific+Inhibition+of+Mammalian+Histone+Deacetylase+Both+in+Vivo+and+in+Vitro+by+Trichostatin+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A</span></div><div class="casAuthors">Yoshida, Minoru; Kijima, Masako; Akita, Mitsuru; Beppu, Teruhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">17174-9</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">(R)-Trichostatin A (TSA) is a Streptomyces product which causes the induction of Friend cell differentiation and specific inhibition of the cell cycle of normal rat fibroblasts in the G1 and G2 phases at very low concns.  TSA caused an accumulation of acetylated histone species in a variety of mammalian cell lines.  Pulse-labeling expts. indicated that TSA markedly prolonged the in vivo half-life of the labile acetyl groups on histones in mouse mammary gland tumor cells, FM3A.  The partially purified histone deacetylase from wild-type FM3A cells was effectively inhibited by TSA in a noncompetitive manner with Ki = 3.4 nM.  A newly isolated mutant cell line of FM3A resistant to TSA did not show the accumulation of the acetylated histones in the presence of a higher concn. of TSA.  The histone deacetylase prepn. from the mutant showed decreased sensitivity to TSA (Ki = 31 nM, noncompetitive).  These results clearly indicate that TSA is a potent and specific inhibitor of histone deacetylase and that the in vivo effect of TSA on cell proliferation and differentiation can be attributed to the inhibition of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM_EbVVcRXYbVg90H21EOLACvtfcHk0liUfkP5DBu7wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlvVyqsrY%253D&md5=f2bed4f3b2d1502fd3610dfdf376b2dc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKijima%26aufirst%3DM.%26aulast%3DAkita%26aufirst%3DM.%26aulast%3DBeppu%26aufirst%3DT.%26atitle%3DPotent%2520and%2520Specific%2520Inhibition%2520of%2520Mammalian%2520Histone%2520Deacetylase%2520Both%2520in%2520Vivo%2520and%2520in%2520Vitro%2520by%2520Trichostatin%2520A%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1990%26volume%3D265%26spage%3D17174%26epage%3D17179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span> <span> </span><span class="NLM_article-title">Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">384</span>, <span class="refDoi"> DOI: 10.3390/md17070384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fmd17070384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Sm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=384&author=Q.+Jingauthor=X.+Huauthor=Y.+Maauthor=J.+Muauthor=W.+Liuauthor=F.+Xuauthor=Z.+Liauthor=J.+Baiauthor=H.+Huaauthor=D.+Li&title=Marine-Derived+Natural+Lead+Compound+Disulfide-Linked+Dimer+Psammaplin+A%3A+Biological+Activity+and+Structural+Modification&doi=10.3390%2Fmd17070384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Marine-derived natural lead compound disulfide-linked dimer psammaplin a: biological activity and structural modification</span></div><div class="casAuthors">Jing, Qinxue; Hu, Xu; Ma, Yanzi; Mu, Jiahui; Liu, Weiwei; Xu, Fanxing; Li, Zhanlin; Bai, Jiao; Hua, Huiming; Li, Dahong</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">384</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Marine natural products are considered to be valuable resources that are furnished with diverse chem. structures and various bioactivities.  To date, there are seven compds. derived from marine natural products which have been approved as therapeutic drugs by the U.S.  Food and Drug Administration.  Numerous bromotyrosine derivs. have been isolated as a type of marine natural products.  Among them, psammaplin A, including the oxime groups and carbon-sulfur bonds, was the first identified sym. bromotyrosine-derived disulfide dimer.  It has been found to have a broad bioactive spectrum, esp. in terms of antimicrobial and antiproliferative activities.  The highest potential indole-derived psammaplin A deriv., UVI5008, is used as an epigenetic modulator with multiple enzyme inhibitory activities.  Inspired by these reasons, psammaplin A has gradually become a research focus for pharmacologists and chemists.  To the best of our knowledge, there is no systematic review about the biol. activity and structural modification of psammaplin A.  In this review, the pharmacol. effects, total synthesis, and synthesized derivs. of psammaplin A are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqckO9X_vSey7Vg90H21EOLACvtfcHk0liUfkP5DBu7wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Sm&md5=106ef508d2187b5a672430f92dcacab7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fmd17070384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd17070384%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DMu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHua%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26atitle%3DMarine-Derived%2520Natural%2520Lead%2520Compound%2520Disulfide-Linked%2520Dimer%2520Psammaplin%2520A%253A%2520Biological%2520Activity%2520and%2520Structural%2520Modification%26jtitle%3DMar.%2520Drugs%26date%3D2019%26volume%3D17%26spage%3D384%26doi%3D10.3390%2Fmd17070384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Romidepsin and the Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=13-20&author=A.+Ganesanauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch2%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DRomidepsin%2520and%2520the%2520Zinc-Binding%2520Thiol%2520Family%2520of%2520Natural%2520Product%2520HDAC%2520Inhibitors%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D13%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of Zinc-Dependent Histone Deacetylases (HDACs)</span>. In  <i>Macrocycles in Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, J.</span></span>, Ed.; <span class="NLM_publisher-name">RSC</span>: <span class="NLM_publisher-loc">Cambridge, U.K.</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">140</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=109-140&author=A.+Ganesanauthor=J.+Levin&title=Macrocycles+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520Zinc-Dependent%2520Histone%2520Deacetylases%2520%2528HDACs%2529%26btitle%3DMacrocycles%2520in%2520Drug%2520Discovery%26aulast%3DLevin%26aufirst%3DJ.%26pub%3DRSC%26date%3D2015%26spage%3D109%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusetani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packham, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors, and Design of a More Potent Analogue</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.1021/ol070046y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol070046y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFKru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2007&pages=1105-1108&author=S.+Wenauthor=K.+L.+Careyauthor=Y.+Nakaoauthor=N.+Fusetaniauthor=G.+Packhamauthor=A.+Ganesan&title=Total+Synthesis+of+Azumamide+A+and+Azumamide+E%2C+Evaluation+as+Histone+Deacetylase+Inhibitors%2C+and+Design+of+a+More+Potent+Analogue&doi=10.1021%2Fol070046y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors, and Design of a More Potent Analog</span></div><div class="casAuthors">Wen, Shijun; Carey, Krystle L.; Nakao, Yoichi; Fusetani, Nobuhiro; Packham, Graham; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1105-1108</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unprecedented diastereoselective Mannich reaction of a Z-allylsulfoximine was a key step in the total synthesis of the marine natural products azumamide A and E, and an unnatural analog.  Their relative potency as histone deacetylase inhibitors was evaluated and found to correlate with predicted zinc-binding affinity.  The stereoselective Mannich reaction of an unusual β,γ-unsatd. sulfinylimine is likely the most challenging transformation accomplished to date with the Ellman auxiliary, and enabled a concise route with only 15 steps in the longest linear sequence.  Within the azumamide series, histone deacetylase (HDAC) inhibitory activity is in the order carboxamide < carboxylic acid < hydroxamic acid, as predicted by the relative zinc binding of these compds.  The biol. activity of the azumamides is significantly weaker than FK228 (IC50 of 15 ± 9 nM in the same assay).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf820ZWbDDobVg90H21EOLACvtfcHk0liUfkP5DBu7wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFKru7Y%253D&md5=ff577d9a068da7ee5a3d16f1c7299525</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fol070046y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol070046y%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DS.%26aulast%3DCarey%26aufirst%3DK.%2BL.%26aulast%3DNakao%26aufirst%3DY.%26aulast%3DFusetani%26aufirst%3DN.%26aulast%3DPackham%26aufirst%3DG.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTotal%2520Synthesis%2520of%2520Azumamide%2520A%2520and%2520Azumamide%2520E%252C%2520Evaluation%2520as%2520Histone%2520Deacetylase%2520Inhibitors%252C%2520and%2520Design%2520of%2520a%2520More%2520Potent%2520Analogue%26jtitle%3DOrg.%2520Lett.%26date%3D2007%26volume%3D9%26spage%3D1105%26epage%3D1108%26doi%3D10.1021%2Fol070046y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2281</span>– <span class="NLM_lpage">2286</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2281-2286&author=N.+J.+Porterauthor=D.+W.+Christianson&title=Binding+of+the+Microbial+Cyclic+Tetrapeptide+Trapoxin+A+to+the+Class+I+Histone+Deacetylase+HDAC8&doi=10.1021%2Facschembio.7b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8</span></div><div class="casAuthors">Porter, Nicholas J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2281-2286</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trapoxin A is a microbial cyclic tetrapeptide that is an essentially irreversible inhibitor of class I histone deacetylases (HDACs).  The inhibitory warhead is the α,β-epoxyketone side-chain of (2S,9S)-2-amino-8-oxo-9,10-epoxydecanoic acid (L-Aoe), which mimics the side-chain of the HDAC substrate, acetyl-L-lysine.  Here, we report the crystal structure of the HDAC8-trapoxin A complex at 1.24 Å resoln., revealing that the ketone moiety of L-Aoe undergoes nucleophilic attack to form a Zn-bound tetrahedral gem-diolate that mimics the tetrahedral intermediate and its flanking transition states in catalysis.  Mass spectrometry, activity measurements, and isothermal titrn. calorimetry confirmed that trapoxin A binds tightly (Kd = 3 ± 1 nM) and did not covalently modify the enzyme, so that the epoxide moiety of L-Aoe remained intact.  Comparison of the HDAC8-trapoxin A complex with the HDAC6-HC toxin complex provided new insight regarding the inhibitory potency of L-Aoe-contg. natural products against class I and class II HDACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQnr9n3hdyWbVg90H21EOLACvtfcHk0lgsFq57xib5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2gsrjE&md5=18fbcd74c854bf9183e3d67074338aae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00330%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBinding%2520of%2520the%2520Microbial%2520Cyclic%2520Tetrapeptide%2520Trapoxin%2520A%2520to%2520the%2520Class%2520I%2520Histone%2520Deacetylase%2520HDAC8%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D2281%26epage%3D2286%26doi%3D10.1021%2Facschembio.7b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halsall, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, B. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors for Cancer Therapy: An Evolutionarily Ancient Resistance Response May Explain Their Limited Success</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1002/bies.201600070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fbies.201600070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27717012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGgsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2016&pages=1102-1110&author=J.+A.+Halsallauthor=B.+M.+Turner&title=Histone+Deacetylase+Inhibitors+for+Cancer+Therapy%3A+An+Evolutionarily+Ancient+Resistance+Response+May+Explain+Their+Limited+Success&doi=10.1002%2Fbies.201600070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success</span></div><div class="casAuthors">Halsall, John A.; Turner, Bryan M.</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1102-1110</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) are in clin. trials against a variety of cancers.  Despite early successes, results against the more common solid tumors have been mixed.  How is it that so many cancers, and most normal cells, tolerate the disruption caused by HDACi-induced protein hyperacetylation.  And why are a few cancers so sensitive.  Here we discuss recent results showing that human cells mount a coordinated transcriptional response to HDACi that mitigates their toxic effects.  We present a hypothetical signaling system that could trigger and mediate this response.  To account for the existence of such a response, we note that HDACi of various chem. types are made by a variety of organisms to kill or suppress competitors.  We suggest that the resistance response in human cells is a necessary evolutionary consequence of exposure to environmental HDACi.  We speculate that cancers sensitive to HDACi are those in which the resistance response has been compromised by mutation.  Identifying such mutations will allow targeting of HDACi therapy to potentially susceptible cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7U6IHqXkgWbVg90H21EOLACvtfcHk0lgsFq57xib5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGgsrjF&md5=14fa316e9184e46a79486cd7daf7185d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fbies.201600070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.201600070%26sid%3Dliteratum%253Aachs%26aulast%3DHalsall%26aufirst%3DJ.%2BA.%26aulast%3DTurner%26aufirst%3DB.%2BM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520for%2520Cancer%2520Therapy%253A%2520An%2520Evolutionarily%2520Ancient%2520Resistance%2520Response%2520May%2520Explain%2520Their%2520Limited%2520Success%26jtitle%3DBioEssays%26date%3D2016%26volume%3D38%26spage%3D1102%26epage%3D1110%26doi%3D10.1002%2Fbies.201600070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span> <span> </span><span class="NLM_article-title">Dimethyl Sulfoxide to Vorinostat: Development of This Histone Deacetylase Inhibitor as an Anticancer Drug</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1038/nbt1272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+Sulfoxide+to+Vorinostat%3A+Development+of+This+Histone+Deacetylase+Inhibitor+as+an+Anticancer+Drug&doi=10.1038%2Fnbt1272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lgsFq57xib5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520Sulfoxide%2520to%2520Vorinostat%253A%2520Development%2520of%2520This%2520Histone%2520Deacetylase%2520Inhibitor%2520as%2520an%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90%26doi%3D10.1038%2Fnbt1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, T.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor OBP-801 and Eribulin Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells with the Suppression of Survivin, Bcl-XL, and the MAPK Pathway</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1007/s10549-018-4815-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2Fs10549-018-4815-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29752686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVWkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2018&pages=43-52&author=H.+Onoauthor=Y.+Sowaauthor=M.+Horinakaauthor=Y.+Iizumiauthor=M.+Watanabeauthor=M.+Moritaauthor=E.+Nishimotoauthor=T.+Taguchiauthor=T.+Sakai&title=The+Histone+Deacetylase+Inhibitor+OBP-801+and+Eribulin+Synergistically+Inhibit+the+Growth+of+Triple-Negative+Breast+Cancer+Cells+with+the+Suppression+of+Survivin%2C+Bcl-XL%2C+and+the+MAPK+Pathway&doi=10.1007%2Fs10549-018-4815-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway</span></div><div class="casAuthors">Ono, Hisako; Sowa, Yoshihiro; Horinaka, Mano; Iizumi, Yosuke; Watanabe, Motoki; Morita, Mie; Nishimoto, Emi; Taguchi, Tetsuya; Sakai, Toshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-52</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Triple-neg. breast cancer (TNBC) is the most aggressive subtype of breast cancer.  Eribulin was approved for the treatment of metastatic breast cancer through the EMBRACE trial, and a subgroup anal. in this clin. trial indicated the efficacy of eribulin in patients with TNBC.  However, the prognosis of patients with TNBC is still poor due to various mol. characteristics.  Therefore, there is an urgent need for a more effective treatment for the management of TNBC.  Methods: We investigated the synergistic effect of a novel histone deacetylase (HDAC) inhibitor, OBP-801, and eribulin in TNBC cell lines because OBP-801 has been known to enhance the anti-tumor activities of other chemotherapeutic agents.  The cell growth was analyzed, and the flow cytometry anal. was conducted to evaluate the effects on cell cycle and the induction of apoptosis.  The mechanism underlying the enhancement of inhibition of TNBC cell growth was investigated through Western blot analyses.  Results: The combination treatment of OBP-801 with eribulin showed the synergistic inhibition of the growth in TNBC cells, involved with the enhancement of apoptosis.  We, for the first time, found that eribulin upregulated survivin and also that OBP-801 could remarkably suppress the upregulation of survivin by eribulin.  Moreover, this combination potently suppressed Bcl-xL and the MAPK pathway compared with either agent alone.  Conclusion: We found that the combination of OBP-801 and eribulin synergistically inhibited the growth with apoptosis in TNBC cells, suggesting that this combination might be a promising novel strategy for treating TNBC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBSLC3wSoh8bVg90H21EOLACvtfcHk0lgsFq57xib5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVWkt7Y%253D&md5=e7e7d0a0a5abdfe1df1df55d0c5d92c2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs10549-018-4815-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-018-4815-x%26sid%3Dliteratum%253Aachs%26aulast%3DOno%26aufirst%3DH.%26aulast%3DSowa%26aufirst%3DY.%26aulast%3DHorinaka%26aufirst%3DM.%26aulast%3DIizumi%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DNishimoto%26aufirst%3DE.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSakai%26aufirst%3DT.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520OBP-801%2520and%2520Eribulin%2520Synergistically%2520Inhibit%2520the%2520Growth%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520Cells%2520with%2520the%2520Suppression%2520of%2520Survivin%252C%2520Bcl-XL%252C%2520and%2520the%2520MAPK%2520Pathway%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2018%26volume%3D171%26spage%3D43%26epage%3D52%26doi%3D10.1007%2Fs10549-018-4815-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breems, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Loosdrecht, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Needham, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooftman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnam, P. M.</span></span> <span> </span><span class="NLM_article-title">A Phase I First-in-Human Study with Tefinostat – a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor – in Patients with Advanced Haematological Malignancies</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1111/bjh.12359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1111%2Fbjh.12359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23647373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=191-201&author=G.+J.+Ossenkoppeleauthor=B.+Lowenbergauthor=P.+Zacheeauthor=N.+Veyauthor=D.+Breemsauthor=A.+A.+Van+de+Loosdrechtauthor=A.+H.+Davidsonauthor=G.+Wellsauthor=L.+Needhamauthor=L.+Bawdenauthor=M.+Toalauthor=L.+Hooftmanauthor=P.+M.+Debnam&title=A+Phase+I+First-in-Human+Study+with+Tefinostat+%E2%80%93+a+Monocyte%2FMacrophage+Targeted+Histone+Deacetylase+Inhibitor+%E2%80%93+in+Patients+with+Advanced+Haematological+Malignancies&doi=10.1111%2Fbjh.12359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies</span></div><div class="casAuthors">Ossenkoppele, Gert J.; Lowenberg, Bob; Zachee, Pierre; Vey, Norbert; Breems, Dimitri; Van de Loosdrecht, Arjan A.; Davidson, Alan H.; Wells, Graham; Needham, Lindsey; Bawden, Lindsay; Toal, Martin; Hooftman, Leon; Debnam, Phillip M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-201</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Tefinostat (CHR-2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi).  This first-in-human, std. 3 + 3 dose escalating trial of oral, once daily tefinostat was conducted to det. the safety, tolerability, pharmacokinetic and pharmacodynamic profile of tefinostat in relapsed/refractory haematol. diseases.  Eighteen patients were enrolled at doses of 20-640 mg.  Plasma concns. of tefinostat exceeded those demonstrated to give in vitro anti-proliferative activity.  Flow cytometric pharmacodynamic assays demonstrated monocyte-targeted increases in protein acetylation, without corresponding changes in lymphocytes.  Dose-limiting toxicities (DLTs) were not obsd. and dose escalation was halted at 640 mg without identification of the max. tolerated dose.  Drug-related toxicities were largely Common Toxicity Criteria for Adverse Events grade 1/2 and included nausea, anorexia, fatigue, constipation, rash and increased blood creatinine.  A patient with chronic monomyelocytic leukemia achieved a bone marrow response, with no change in peripheral monocytes.  An acute myeloid leukemia type M2 patient showed a >50% decrease in bone marrow blasts and clearance of peripheral blasts.  In conclusion, tefinostat produces monocyte-targeted HDACi activity and is well tolerated, without the DLTs, e.g. fatigue, diarrhea, thrombocytopenia, commonly seen with non-targeted HDACi.  The early signs of efficacy and absence of significant toxicity warrant further evaluation of tefinostat in larger studies. (clinicaltrials.gov identifier: NCT00820508).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUPAYWIEsUwrVg90H21EOLACvtfcHk0lj0VFVg_2mgcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVKhsLvP&md5=7919124df9886fccba41990d05f2e110</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12359%26sid%3Dliteratum%253Aachs%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DZachee%26aufirst%3DP.%26aulast%3DVey%26aufirst%3DN.%26aulast%3DBreems%26aufirst%3DD.%26aulast%3DVan%2Bde%2BLoosdrecht%26aufirst%3DA.%2BA.%26aulast%3DDavidson%26aufirst%3DA.%2BH.%26aulast%3DWells%26aufirst%3DG.%26aulast%3DNeedham%26aufirst%3DL.%26aulast%3DBawden%26aufirst%3DL.%26aulast%3DToal%26aufirst%3DM.%26aulast%3DHooftman%26aufirst%3DL.%26aulast%3DDebnam%26aufirst%3DP.%2BM.%26atitle%3DA%2520Phase%2520I%2520First-in-Human%2520Study%2520with%2520Tefinostat%2520%25E2%2580%2593%2520a%2520Monocyte%252FMacrophage%2520Targeted%2520Histone%2520Deacetylase%2520Inhibitor%2520%25E2%2580%2593%2520in%2520Patients%2520with%2520Advanced%2520Haematological%2520Malignancies%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D191%26epage%3D201%26doi%3D10.1111%2Fbjh.12359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S. Y.</span></span> <span> </span><span class="NLM_article-title">CG200745, an HDAC Inhibitor, Induces Anti-Tumour Effects in Cholangiocarcinoma Cell Lines via miRNAs Targeting the Hippo Pathway</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">10921</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41598-017-11094-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28883618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1cblvVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=10921&author=D.+E.+Jungauthor=S.+B.+Parkauthor=K.+Kimauthor=C.+Kimauthor=S.+Y.+Song&title=CG200745%2C+an+HDAC+Inhibitor%2C+Induces+Anti-Tumour+Effects+in+Cholangiocarcinoma+Cell+Lines+via+miRNAs+Targeting+the+Hippo+Pathway&doi=10.1038%2Fs41598-017-11094-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway</span></div><div class="casAuthors">Jung Dawoon E; Song Si Young; Park Soo Been; Song Si Young; Kim Kahee; Kim Chanyang; Song Si Young</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10921</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholangiocarcinoma is a devastating malignancy with fatal complications that exhibits low response and resistance to chemotherapy.  Here, we evaluated the anticancer effects of CG200745, a novel histone deacetylase inhibitor, either alone or in combination with standard chemotherapy drugs in cholangiocarcinoma cells.  CG200745 dose-dependently reduced the viability of cholangiocarcinoma cells in vitro and decreased tumour volume and weight in a xenograft model.  Administering CG200745 along with other chemotherapeutic agents including gemcitabine, 5-fluorouracil (5-FU), cisplatin, oxaliplatin, or gemcitabine plus cisplatin further decreased cholangiocarcinoma cell viability, with a combination index < 1 that indicated synergistic action.  CG200745 also enhanced the sensitivity of gemcitabine-resistant cells to gemcitabine and 5-FU, thereby decreasing cell viability and inducing apoptosis.  This was accompanied by downregulation of YAP, TEAD4, TGF-β2, SMAD3, NOTCH3, HES5, Axl, and Gas6 and upregulation of the miRNAs miR-22-3p, miR-22-5p, miR-194-5p, miR-194-3p, miR-194-5p, miR-210-3p, and miR-509-3p.  The Ingenuity Pathway Analysis revealed that CG200745 mainly targets the Hippo signalling pathway by inducing miR-509-3p expression.  Thus, CG200745 inhibits cholangiocarcinoma growth in vitro and in vivo, and acts synergistically when administered in combination with standard chemotherapeutic agents, enabling dose reduction.  CG200745 is therefore expected to improve the outcome of cholangiocarcinoma patients who exhibit resistance to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeWlASM7-ZiYkFb3mqPUYDfW6udTcc2ea5-kcdEEdZ9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cblvVOmtw%253D%253D&md5=5dc34d45ee88005a0c365d1278c9526a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11094-3%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DD.%2BE.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DS.%2BY.%26atitle%3DCG200745%252C%2520an%2520HDAC%2520Inhibitor%252C%2520Induces%2520Anti-Tumour%2520Effects%2520in%2520Cholangiocarcinoma%2520Cell%2520Lines%2520via%2520miRNAs%2520Targeting%2520the%2520Hippo%2520Pathway%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D10921%26doi%3D10.1038%2Fs41598-017-11094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+Activity%2C+Pharmacodynamic%2C+and+Pharmacokinetic+Properties+of+a+Selective+HDAC6+Inhibitor%2C+ACY-1215%2C+in+Combination+with+Bortezomib+in+Multiple+Myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lj0VFVg_2mgcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520Activity%252C%2520Pharmacodynamic%252C%2520and%2520Pharmacokinetic%2520Properties%2520of%2520a%2520Selective%2520HDAC6%2520Inhibitor%252C%2520ACY-1215%252C%2520in%2520Combination%2520with%2520Bortezomib%2520in%2520Multiple%2520Myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC Inhibition by ACY-241 Enhances the Activity of Paclitaxel in Solid Tumor Models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+Inhibition+by+ACY-241+Enhances+the+Activity+of+Paclitaxel+in+Solid+Tumor+Models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2eYwCvofEbuXPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520Inhibition%2520by%2520ACY-241%2520Enhances%2520the%2520Activity%2520of%2520Paclitaxel%2520in%2520Solid%2520Tumor%2520Models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-<i>N</i>-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2000</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1021/jm901453q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901453q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2000-2009&author=X.+Caiauthor=H.-X.+Zhaiauthor=J.+Wangauthor=J.+Forresterauthor=H.+Quauthor=L.+Yinauthor=C.-J.+Laiauthor=R.+Baoauthor=C.+Qian&title=Discovery+of+7-%284-%283-Ethynylphenylamino%29-7-methoxyquinazolin-6-yloxy%29-N-hydroxyheptanamide+%28CUDC-101%29+as+a+Potent+Multi-Acting+HDAC%2C+EGFR%2C+and+HER2+Inhibitor+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm901453q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Cai, Xiong; Zhai, Hai-Xiao; Wang, Jing; Forrester, Jeffrey; Qu, Hui; Yin, Ling; Lai, Cheng-Jung; Bao, Rudi; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2000-2009</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compds. with potent, multiacting HDAC, EGFR, and HER2 inhibition and identified 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide 8 (CUDC-101) as a drug candidate, which is now in clin. development. 8 displays potent in vitro inhibitory activity against HDAC, EGFR, and HER2 with an IC50 of 4.4, 2.4, and 15.7 nM, resp.  In most tumor cell lines tested, 8 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib.  In vivo, 8 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers.  These results suggest that a single compd. that simultaneously inhibits HDAC, EGFR, and HER2 may offer greater therapeutic benefits in cancer over single-acting agents through the interference with multiple pathways and potential synergy among HDAC and EGFR/HER2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBQl1iMXW3rVg90H21EOLACvtfcHk0lgJhOghyMZmNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslSgsb0%253D&md5=d4dc339f2fd750d52e511abf3dbf18bd</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm901453q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901453q%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25207-%25284-%25283-Ethynylphenylamino%2529-7-methoxyquinazolin-6-yloxy%2529-N-hydroxyheptanamide%2520%2528CUDC-101%2529%2520as%2520a%2520Potent%2520Multi-Acting%2520HDAC%252C%2520EGFR%252C%2520and%2520HER2%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2000%26epage%3D2009%26doi%3D10.1021%2Fjm901453q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehrling, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2174/1871520615666150518092027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2174%2F1871520615666150518092027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=20-28&author=T.+Mehrlingauthor=Y.+Chen&title=The+Alkylating-HDAC+Inhibition+Fusion+Principle%3A+Taking+Chemotherapy+to+the+Next+Level+with+the+First+in+Class+Molecule+EDO-S101&doi=10.2174%2F1871520615666150518092027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.2174%2F1871520615666150518092027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520615666150518092027%26sid%3Dliteratum%253Aachs%26aulast%3DMehrling%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DY.%26atitle%3DThe%2520Alkylating-HDAC%2520Inhibition%2520Fusion%2520Principle%253A%2520Taking%2520Chemotherapy%2520to%2520the%2520Next%2520Level%2520with%2520the%2520First%2520in%2520Class%2520Molecule%2520EDO-S101%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2015%26volume%3D16%26spage%3D20%26epage%3D28%26doi%3D10.2174%2F1871520615666150518092027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDAC with HDAC Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2095</span>– <span class="NLM_lpage">2116</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2010.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2010.02.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20223566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFeju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=2095-2116&author=P.+Bertrand&title=Inside+HDAC+with+HDAC+Inhibitors&doi=10.1016%2Fj.ejmech.2010.02.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDAC with HDAC inhibitors</span></div><div class="casAuthors">Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2095-2116</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors are a large group of diverse mols. intrinsically able to inhibit cell proliferation in various cancer cell lines.  Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin remodelling.  As the initial histone deacetylase activity of HDAC has been extended to other proteins, the possible other biol. mechanisms modified by HDAC inhibitor treatments are still to be clarified.  The need for HDAC isoform selective inhibitors is an important issue to serve this goal.  This review discusses the approaches proposed by several research groups working on the synthesis of HDAC inhibitors, based on modeling studies and the way these findings were used to obtain new HDAC inhibitors with possible isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SWr-oCMKcLVg90H21EOLACvtfcHk0lgpKt-6jybO1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFeju7k%253D&md5=14baba1e0371420b05d7e7b82d3187e6</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDAC%2520with%2520HDAC%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D2095%26epage%3D2116%26doi%3D10.1016%2Fj.ejmech.2010.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P. W.</span>; <span class="NLM_string-name">Loza, E.</span>; <span class="NLM_string-name">Carstensen, E.</span></span> <span> </span><span class="NLM_article-title">The Discovery and Development of Belinostat</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">58</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=31-58&author=P.+W.+Finn&author=E.+Loza&author=E.+Carstensenauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch3%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DP.%2BW.%26atitle%3DThe%2520Discovery%2520and%2520Development%2520of%2520Belinostat%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D31%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P.</span>; <span class="NLM_string-name">Perez, L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug</span>. In  <i>Successful Drug Discovery</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J.</span>, <span class="NLM_string-name">Childers, W. E.</span></span>, Eds.; <span class="NLM_publisher-name">Wiley-VCH</span>: <span class="NLM_publisher-loc">Weinheim, Germany</span>, <span class="NLM_year">2016</span>; Vol  <span class="NLM_volume">2</span>, pp  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">88</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2F9783527800315.ch4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=59-88&author=P.+Atadja&author=L.+Perezauthor=J.+Fischer&author=W.+E.+Childers&title=Successful+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2F9783527800315.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9783527800315.ch4%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Farydak%2520%2528NVP-LBH589%252C%2520Panobinostat%2529%2520as%2520an%2520Anticancer%2520Drug%26btitle%3DSuccessful%2520Drug%2520Discovery%26aulast%3DFischer%26aufirst%3DJ.%26pub%3DWiley-VCH%26date%3D2016%26volume%3D2%26spage%3D59%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandl-Weber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinel, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jankowsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oduncu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidmaier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, P.</span></span> <span> </span><span class="NLM_article-title">The Novel Inhibitor of Histone Deacetylase Resminostat (RAS2410) Inhibits Proliferation and Induces Apoptosis in Multiple Myeloma (MM) Cells</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2141.2010.08124.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1111%2Fj.1365-2141.2010.08124.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20201941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXns1eqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2010&pages=518-528&author=S.+Mandl-Weberauthor=F.+G.+Meinelauthor=R.+Jankowskyauthor=F.+Oduncuauthor=R.+Schmidmaierauthor=P.+Baumann&title=The+Novel+Inhibitor+of+Histone+Deacetylase+Resminostat+%28RAS2410%29+Inhibits+Proliferation+and+Induces+Apoptosis+in+Multiple+Myeloma+%28MM%29+Cells&doi=10.1111%2Fj.1365-2141.2010.08124.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells</span></div><div class="casAuthors">Mandl-Weber, Sonja; Meinel, Felix G.; Jankowsky, Ruediger; Oduncu, Fuat; Schmidmaier, Ralf; Baumann, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">518-528</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) is a promising mechanism for novel, anti-myeloma agents.  We investigated the effects of the novel HDAC inhibitor resminostat on multiple myeloma (MM) cells in vitro.  Resminostat is a potent inhibitor of HDACs 1, 3 and 6 [50% inhibitory concn. (IC50) = 43-72 nmol/l] representing HDAC classes I and II and induces hyperacetylation of histone H4 in MM cells.  Low micromolar concns. of resminostat abrogated cell growth and strongly induced apoptosis (IC50 = 2·5-3 μmol/l in 3 out of 4 MM cell lines) in MM cell lines as well as primary MM cells.  At 1 μmol/l, resminostat inhibited proliferation and induced G0/G1 cell cycle arrest in 3 out of 4 MM cell lines accompanied with decreased levels of cyclin D1, cdc25a, Cdk4 and pRb as well as upregulation of p21.  Resminostat decreased phosphorylation of 4E-BP1 and p70S6k indicating an interference with Akt pathway signalling.  Treatment with resminostat resulted in increased protein levels of Bim and Bax and decreased levels of Bcl-xL.  Caspases 3, 8 and 9 were activated by resminostat.  Furthermore, synergistic effects were obsd. for combinations of resminostat with melphalan and the proteasome inhibitors bortezomib and S-2209.  In conclusion, we have identified potent anti-myeloma activity for this novel HDAC inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQdfMVUdhHk7Vg90H21EOLACvtfcHk0lgpKt-6jybO1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXns1eqt70%253D&md5=16b57835f5e5d19d8cd587b299820d98</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2010.08124.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2010.08124.x%26sid%3Dliteratum%253Aachs%26aulast%3DMandl-Weber%26aufirst%3DS.%26aulast%3DMeinel%26aufirst%3DF.%2BG.%26aulast%3DJankowsky%26aufirst%3DR.%26aulast%3DOduncu%26aufirst%3DF.%26aulast%3DSchmidmaier%26aufirst%3DR.%26aulast%3DBaumann%26aufirst%3DP.%26atitle%3DThe%2520Novel%2520Inhibitor%2520of%2520Histone%2520Deacetylase%2520Resminostat%2520%2528RAS2410%2529%2520Inhibits%2520Proliferation%2520and%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520%2528MM%2529%2520Cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2010%26volume%3D149%26spage%3D518%26epage%3D528%26doi%3D10.1111%2Fj.1365-2141.2010.08124.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangthongpitag, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khng, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantharaj, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2<i>E</i>)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1<i>H</i>-benzimidazol-5-yl}-<i>N</i>-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4694</span>– <span class="NLM_lpage">4720</span>, <span class="refDoi"> DOI: 10.1021/jm2003552</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2003552" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4694-4720&author=H.+Wangauthor=N.+Yuauthor=D.+Chenauthor=K.+C.+L.+Leeauthor=P.+L.+Lyeauthor=J.+W.+W.+Changauthor=W.+Dengauthor=M.+C.+Y.+Ngauthor=T.+Luauthor=M.+L.+Khooauthor=A.+Poulsenauthor=K.+Sangthongpitagauthor=X.+Wuauthor=C.+Huauthor=K.+C.+Gohauthor=X.+Wangauthor=L.+Fangauthor=K.+L.+Gohauthor=H.+H.+Khngauthor=S.+K.+Gohauthor=P.+Yeoauthor=X.+Liuauthor=Z.+Bondayauthor=J.+M.+Woodauthor=B.+W.+Dymockauthor=E.+Kantharajauthor=E.+T.+Sun&title=Discovery+of+%282E%29-3-%7B2-Butyl-1-%5B2-%28diethylamino%29ethyl%5D-1H-benzimidazol-5-yl%7D-N-hydroxyacrylamide+%28SB939%29%2C+an+Orally+Active+Histone+Deacetylase+Inhibitor+with+a+Superior+Preclinical+Profile&doi=10.1021%2Fjm2003552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile</span></div><div class="casAuthors">Wang, Haishan; Yu, Niefang; Chen, Dizhong; Lee, Ken Chi Lik; Lye, Pek Ling; Chang, Joyce Wei Wei; Deng, Weiping; Ng, Melvin Chi Yeh; Lu, Ting; Khoo, Mui Ling; Poulsen, Anders; Sangthongpitag, Kanda; Wu, Xiaofeng; Hu, Changyong; Goh, Kee Chuan; Wang, Xukun; Fang, Lijuan; Goh, Kay Lin; Khng, Hwee Hoon; Goh, Siok Kun; Yeo, Pauline; Liu, Xin; Bonday, Zahid; Wood, Jeanette M.; Dymock, Brian W.; Kantharaj, Ethirajulu; Sun, Eric T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4694-4720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 3-(1,2-disubstituted-1H-benzimidazol-5-yl)-N-hydroxyacrylamides was designed and synthesized as HDAC inhibitors.  Extensive SARs have been established for in vitro potency (HDAC1 enzyme and COLO 205 cellular IC50), liver microsomal stability (t1/2), cytochrome P 450 inhibition (3A4 IC50), and clogP, among others.  These parameters were fine-tuned by carefully adjusting the substituents at positions 1 and 2 of the benzimidazole ring.  After comprehensive in vitro and in vivo profiling of the selected compds., SB939 (I) was identified as a preclin. development candidate.  I is a potent pan-HDAC inhibitor with excellent druglike properties, is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties.  When orally dosed to tumor-bearing mice, I is enriched in tumor tissue which may contribute to its potent antitumor activity and prolonged duration of action.  I is currently being tested in phase I and phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd9r-fRIzdS7Vg90H21EOLACvtfcHk0lgpKt-6jybO1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1emsr8%253D&md5=a69bf922fb86c47ddee9c9fc112cc9a2</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm2003552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2003552%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DK.%2BC.%2BL.%26aulast%3DLye%26aufirst%3DP.%2BL.%26aulast%3DChang%26aufirst%3DJ.%2BW.%2BW.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DNg%26aufirst%3DM.%2BC.%2BY.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DKhoo%26aufirst%3DM.%2BL.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DSangthongpitag%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DGoh%26aufirst%3DK.%2BL.%26aulast%3DKhng%26aufirst%3DH.%2BH.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DYeo%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DKantharaj%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DE.%2BT.%26atitle%3DDiscovery%2520of%2520%25282E%2529-3-%257B2-Butyl-1-%255B2-%2528diethylamino%2529ethyl%255D-1H-benzimidazol-5-yl%257D-N-hydroxyacrylamide%2520%2528SB939%2529%252C%2520an%2520Orally%2520Active%2520Histone%2520Deacetylase%2520Inhibitor%2520with%2520a%2520Superior%2520Preclinical%2520Profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4694%26epage%3D4720%26doi%3D10.1021%2Fjm2003552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matalon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nold, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascagni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinarello, C. A.</span></span> <span> </span><span class="NLM_article-title">The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4(+) T-Cells and Monocytes and Is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro</span>. <i>JAIDS, J. Acquired Immune Defic. Syndr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1097/QAI.0b013e3181d3dca3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1097%2FQAI.0b013e3181d3dca3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=20300007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFCmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=1-9&author=S.+Matalonauthor=B.+E.+Palmerauthor=M.+F.+Noldauthor=A.+Furlanauthor=A.+Kassuauthor=G.+Fossatiauthor=P.+Mascagniauthor=C.+A.+Dinarello&title=The+Histone+Deacetylase+Inhibitor+ITF2357+Decreases+Surface+CXCR4+and+CCR5+Expression+on+CD4%28%2B%29+T-Cells+and+Monocytes+and+Is+Superior+to+Valproic+Acid+for+Latent+HIV-1+Expression+in+Vitro&doi=10.1097%2FQAI.0b013e3181d3dca3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro</span></div><div class="casAuthors">Matalon, Shay; Palmer, Brent E.; Nold, Marcel F.; Furlan, Antonio; Kassu, Afework; Fossati, Gianluca; Mascagni, Paolo; Dinarello, Charles A.</div><div class="citationInfo"><span class="NLM_cas:title">JAIDS, Journal of Acquired Immune Deficiency Syndromes</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">JJASFJ</span>;
        ISSN:<span class="NLM_cas:issn">1525-4135</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chromatin-assocd. repression is one mechanism that maintains HIV-1 latency.  Inhibition of histone deacetylases (HDAC) reverses this repression resulting in viral expression from quiescently infected cells.  Clin. studies with the HDAC inhibitor valproic acid (VPA) failed to substantially decrease the latent pool within resting CD4 cells.  Here we compared the efficacy of ITF2357, an orally active and safe HDAC inhibitor, with VPA for HIV-1 expression from latently infected cells in vitro.  We also evaluated the effect of ITF2357 on the surface expression of CXCR4 and CCR5.  Latently infected cell lines were incubated with either ITF2357 or VPA and p24 levels were measured.  Peripheral blood mononuclear cells of uninfected donors were treated with ITF2357 and HIV-1 coreceptors expression was assessed by flow cytometry.  At clin. relevant concns., ITF2357 increased p24 by 15-fold in ACH2 cells and by 9-fold in U1 cells, whereas VPA increased expression less than 2-fold.  Analogs of ITF2357 primarily targeting HDAC-1 increased p24 up to 30-fold.  In CD4 T cells treated with ITF2357, CXCR4 expression decreased by 54% (P < 0.001).  ITF2357 is superior to VPA in inducing HIV-1 from latently infected cells.  Safely used in humans, ITF2357 is an attractive candidate for HIV-1 clin. purging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPgJCLYVZvFrVg90H21EOLACvtfcHk0lgGTeBBb1tQJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFCmtr8%253D&md5=00472fbb9d15158fb97d3f20d8bd230c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1097%2FQAI.0b013e3181d3dca3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAI.0b013e3181d3dca3%26sid%3Dliteratum%253Aachs%26aulast%3DMatalon%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DB.%2BE.%26aulast%3DNold%26aufirst%3DM.%2BF.%26aulast%3DFurlan%26aufirst%3DA.%26aulast%3DKassu%26aufirst%3DA.%26aulast%3DFossati%26aufirst%3DG.%26aulast%3DMascagni%26aufirst%3DP.%26aulast%3DDinarello%26aufirst%3DC.%2BA.%26atitle%3DThe%2520Histone%2520Deacetylase%2520Inhibitor%2520ITF2357%2520Decreases%2520Surface%2520CXCR4%2520and%2520CCR5%2520Expression%2520on%2520CD4%2528%252B%2529%2520T-Cells%2520and%2520Monocytes%2520and%2520Is%2520Superior%2520to%2520Valproic%2520Acid%2520for%2520Latent%2520HIV-1%2520Expression%2520in%2520Vitro%26jtitle%3DJAIDS%252C%2520J.%2520Acquired%2520Immune%2520Defic.%2520Syndr.%26date%3D2010%26volume%3D54%26spage%3D1%26epage%3D9%26doi%3D10.1097%2FQAI.0b013e3181d3dca3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span> <span> </span><span class="NLM_article-title">CRA-024781: A Novel Synthetic Inhibitor of Histone Deacetylase Enzymes with Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1309</span>– <span class="NLM_lpage">1317</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1535-7163.MCT-05-0442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=16731764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVWms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1309-1317&author=J.+J.+Buggyauthor=Z.+A.+Caoauthor=K.+E.+Bassauthor=E.+Vernerauthor=S.+Balasubramanianauthor=L.+Liuauthor=B.+E.+Schultzauthor=P.+R.+Youngauthor=S.+A.+Dalrymple&title=CRA-024781%3A+A+Novel+Synthetic+Inhibitor+of+Histone+Deacetylase+Enzymes+with+Antitumor+Activity+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-05-0442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo</span></div><div class="casAuthors">Buggy, Joseph J.; Cao, Z. Alexander; Bass, Kathryn E.; Verner, Erik; Balasubramanian, Sriram; Liu, Liang; Schultz, Brian E.; Young, Peter R.; Dalrymple, Stacie A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1309-1317</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clin. trials for cancer.  CRA-024781 inhibited pure recombinant HDAC1 with a Ki of 0.007 μmol/L, and also inhibited the other HDAC isoenzymes HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range.  Treatment of cultured tumor cell lines grown in vitro with CRA-024781 resulted in the accumulation of acetylated histone and acetylated tubulin, resulting in an inhibition of tumor cell growth and the induction of apoptosis.  CRA-024781 parenterally administered to mice harboring HCT116 or DLD-1 colon tumor xenografts resulted in a statistically significant redn. in tumor growth at doses that were well tolerated as measured by body wt.  Inhibition of tumor growth was accompanied by an increase in the acetylation of α-tubulin in peripheral blood mononuclear cells, and an alteration in the expression of many genes in the tumors, including several involved in apoptosis and cell growth.  These results reveal CRA-024781 to be a novel HDAC inhibitor with potent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8uJX28obQWrVg90H21EOLACvtfcHk0lgGTeBBb1tQJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVWms7Y%253D&md5=fa761c94dd4f3a031493476dd75af602</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0442%26sid%3Dliteratum%253Aachs%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DCao%26aufirst%3DZ.%2BA.%26aulast%3DBass%26aufirst%3DK.%2BE.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26atitle%3DCRA-024781%253A%2520A%2520Novel%2520Synthetic%2520Inhibitor%2520of%2520Histone%2520Deacetylase%2520Enzymes%2520with%2520Antitumor%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1309%26epage%3D1317%26doi%3D10.1158%2F1535-7163.MCT-05-0442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5530</span>– <span class="NLM_lpage">5535</span>, <span class="refDoi"> DOI: 10.1021/jm0503749</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503749" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVChuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5530-5535&author=Q.+Luauthor=D.-S.+Wangauthor=C.-S.+Chenauthor=Y.-D.+Huauthor=C.-S.+Chen&title=Structure-Based+Optimization+of+Phenylbutyrate-Derived+Histone+Deacetylase+Inhibitors&doi=10.1021%2Fjm0503749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors</span></div><div class="casAuthors">Lu, Qiang; Wang, Da-Sheng; Chen, Chang-Shi; Hu, Yuan-Dong; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5530-5535</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previously, the authors developed a strategy to develop a novel class of histone deacetylase (HDAC) inhibitors by tethering short-chain fatty acids with Zn2+-chelating motifs, which led to N-hydroxy-4-(4-phenylbutyryl-amino)benzamide (HTPB), a hydroxamate-tethered phenylbutyrate deriv. with sub-micromolar potency in inhibiting HDAC activity and cancer cell proliferation.  In this study, the authors carried out structure-based optimization of HTPB by using the framework generated by the structure of histone deacetylase-like protein (HDLP)-trichostatin A (TSA) complexes.  Docking of HTPB into the HDLP binding domain suggested that the hydrophobic microenvironment encompassed by Phe-198 and Phe-200 could be exploited for structural optimization.  This premise was corroborated by the greater potency of (S)-(+)-N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)-benzamide [(S)-11] (IC50 in HDAC inhibition, 16 nM), of which the iso-Pr moiety was favorable in interacting with this hydrophobic motif.  (S)-11 at concns. as low as 0.1 μM was effective in causing histone hyperacetylation and p21WAF/CIP1 overexpression and suppressing proliferation in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4OaBQW0Sp7LVg90H21EOLACvtfcHk0lgXxhM9v86Bqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVChuro%253D&md5=59248d348fc589b9f29a4fc742adf8b7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm0503749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503749%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DD.-S.%26aulast%3DChen%26aufirst%3DC.-S.%26aulast%3DHu%26aufirst%3DY.-D.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DStructure-Based%2520Optimization%2520of%2520Phenylbutyrate-Derived%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5530%26epage%3D5535%26doi%3D10.1021%2Fjm0503749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F.-J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01792</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01792" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGjsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=804-815&author=S.-W.+Zhangauthor=C.-J.+Gongauthor=M.-B.+Suauthor=F.+Chenauthor=T.+Heauthor=Y.-M.+Zhangauthor=Q.-Q.+Shenauthor=Y.+Suauthor=J.+Dingauthor=J.+Liauthor=Y.+Chenauthor=F.-J.+Nan&title=Synthesis+and+in+Vitro+and+in+Vivo+Biological+Evaluation+of+Tissue-Specific+Bisthiazole+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facs.jmedchem.9b01792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Zhang, Shu-Wei; Gong, Chao-Jun; Su, Ming-Bo; Chen, Fei; He, Ting; Zhang, Yang-Ming; Shen, Qian-Qian; Su, Yi; Ding, Jian; Li, Jia; Chen, Yi; Nan, Fa-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">804-815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bisthiazole-based hydroxamic acids as novel potent HDAC inhibitors was developed during our previous work.  In the present work, a new series of highly potent bisthiazole-based compds. were designed and synthesized.  Among the prepd. compds., compd. I, which contains an α-(S)-methyl-substituted benzyl group, displays potent inhibitory activity toward human HDACs and several cancer cells lines.  Compd. I has a favorable PK profile and high tissue distribution specificity in the colon, as well as good efficacy in the AOM-DSS mouse model for colitis-assocd. colonic tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxBs6U7tbjKrVg90H21EOLACvtfcHk0lgXxhM9v86Bqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGjsrbL&md5=06179fbf0b3ed71f7bf27284cd5f9668</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01792%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.-W.%26aulast%3DGong%26aufirst%3DC.-J.%26aulast%3DSu%26aufirst%3DM.-B.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DShen%26aufirst%3DQ.-Q.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DNan%26aufirst%3DF.-J.%26atitle%3DSynthesis%2520and%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Biological%2520Evaluation%2520of%2520Tissue-Specific%2520Bisthiazole%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D804%26epage%3D815%26doi%3D10.1021%2Facs.jmedchem.9b01792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mariën, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beliën, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilatte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decrane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vreys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bol, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talloen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goris, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Jardin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janicot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Emelen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span> <span> </span><span class="NLM_article-title">JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6841</span>– <span class="NLM_lpage">6851</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+Novel+%E2%80%9CSecond-Generation%E2%80%9D+Oral+Histone+Deacetylase+Inhibitor%2C+Shows+Broad-Spectrum+Preclinical+Antitumoral+Activity&doi=10.1158%2F1078-0432.CCR-09-0547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0lgXxhM9v86Bqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520Novel%2520%25E2%2580%259CSecond-Generation%25E2%2580%259D%2520Oral%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Shows%2520Broad-Spectrum%2520Preclinical%2520Antitumoral%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851%26doi%3D10.1158%2F1078-0432.CCR-09-0547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfield, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlands, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brotherton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bawden, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardcastle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meurs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-<i>N</i>-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8663</span>– <span class="NLM_lpage">8678</span>, <span class="refDoi"> DOI: 10.1021/jm101177s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101177s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8663-8678&author=D.+Moffatauthor=S.+Patelauthor=F.+Dayauthor=A.+Belfieldauthor=A.+Donaldauthor=M.+Rowlandsauthor=J.+Wibawaauthor=D.+Brothertonauthor=L.+Stimsonauthor=V.+Clarkauthor=J.+Owenauthor=L.+Bawdenauthor=G.+Boxauthor=E.+Boneauthor=P.+Mortensonauthor=A.+Hardcastleauthor=S.+van+Meursauthor=S.+Ecclesauthor=F.+Raynaudauthor=W.+Aherne&title=Discovery+of+2-%286-%7B%5B%286-Fluoroquinolin-2-yl%29methyl%5Damino%7Dbicyclo%5B3.1.0%5Dhex-3-yl%29-N-hydroxypyrimidine-5-carboxamide+%28CHR-3996%29%2C+a+Class+I+Selective+Orally+Active+Histone+Deacetylase+Inhibitor&doi=10.1021%2Fjm101177s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor</span></div><div class="casAuthors">Moffat, David; Patel, Sanjay; Day, Francesca; Belfield, Andrew; Donald, Alastair; Rowlands, Martin; Wibawa, Judata; Brotherton, Deborah; Stimson, Lindsay; Clark, Vanessa; Owen, Jo; Bawden, Lindsay; Box, Gary; Bone, Elisabeth; Mortenson, Paul; Hardcastle, Anthea; van Meurs, Sandra; Eccles, Suzanne; Raynaud, Florence; Aherne, Wynne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8663-8678</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of HDAC inhibitors demonstrating class I subtype selectivity and good oral bioavailability is described.  The compds. are potent enzyme inhibitors (IC50 values less than 100 nM), and improved activity in cell proliferation assays was achieved by modulation of polar surface area (PSA) through the introduction of novel linking groups.  Employing oral pharmacokinetic studies in mice, comparing drug levels in spleen to plasma, we selected compds. that were tested for efficacy in human tumor xenograft studies based on their potential to distribute into tumor.  One compd., 21r (CHR-3996), showed good oral activity in these models, including dose-related activity in a LoVo xenograft.  In addn. 21r showed good activity in combination with other anticancer agents in in vitro studies.  On the basis of these results, 21r was nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB5TcEwdw2cbVg90H21EOLACvtfcHk0lhJrDLa-Mq7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FO&md5=9a434b2ed87fe4cfb37c68bb92734be2</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm101177s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101177s%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DDay%26aufirst%3DF.%26aulast%3DBelfield%26aufirst%3DA.%26aulast%3DDonald%26aufirst%3DA.%26aulast%3DRowlands%26aufirst%3DM.%26aulast%3DWibawa%26aufirst%3DJ.%26aulast%3DBrotherton%26aufirst%3DD.%26aulast%3DStimson%26aufirst%3DL.%26aulast%3DClark%26aufirst%3DV.%26aulast%3DOwen%26aufirst%3DJ.%26aulast%3DBawden%26aufirst%3DL.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBone%26aufirst%3DE.%26aulast%3DMortenson%26aufirst%3DP.%26aulast%3DHardcastle%26aufirst%3DA.%26aulast%3Dvan%2BMeurs%26aufirst%3DS.%26aulast%3DEccles%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DAherne%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25202-%25286-%257B%255B%25286-Fluoroquinolin-2-yl%2529methyl%255Damino%257Dbicyclo%255B3.1.0%255Dhex-3-yl%2529-N-hydroxypyrimidine-5-carboxamide%2520%2528CHR-3996%2529%252C%2520a%2520Class%2520I%2520Selective%2520Orally%2520Active%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8663%26epage%3D8678%26doi%3D10.1021%2Fjm101177s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifcak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DellaRocca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span> <span> </span><span class="NLM_article-title">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4104</span>– <span class="NLM_lpage">4113</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-12-0055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22693356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4104-4113&author=C.+Qianauthor=C.-J.+Laiauthor=R.+Baoauthor=D.-G.+Wangauthor=J.+Wangauthor=G.-X.+Xuauthor=R.+Atoyanauthor=H.+Quauthor=L.+Yinauthor=M.+Samsonauthor=B.+Zifcakauthor=A.+W.+S.+Maauthor=S.+DellaRoccaauthor=M.+Borekauthor=H.-X.+Zhaiauthor=X.+Caiauthor=M.+Voi&title=Cancer+Network+Disruption+by+a+Single+Molecule+Inhibitor+Targeting+Both+Histone+Deacetylase+Activity+and+Phosphatidylinositol+3-Kinase+Signaling&doi=10.1158%2F1078-0432.CCR-12-0055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling</span></div><div class="casAuthors">Qian, Changgeng; Lai, Cheng-Jung; Bao, Rudi; Wang, Da-Gong; Wang, Jing; Xu, Guang-Xin; Atoyan, Ruzanna; Qu, Hui; Yin, Ling; Samson, Maria; Zifcak, Brian; Ma, Anna Wai See; Della Rocca, Steven; Borek, Mylissa; Zhai, Hai-Xiao; Cai, Xiong; Voi, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4104-4113</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting signaling networks and act synergistically with phosphatidylinositol 3-kinase (PI3K) inhibitors, we developed a strategy to simultaneously inhibit HDACs and PI3K in cancer cells.  Exptl. Design: We constructed dual-acting inhibitors by incorporating HDAC inhibitory functionality into a PI3K inhibitor pharmacophore.  CUDC-907, a development candidate selected from these dual inhibitors, was evaluated in vitro and in vivo to det. its pharmacol. properties, anticancer activity, and mechanism of action.  Results: CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes.  Through its integrated HDAC inhibitory activity, CUDC-907 durably inhibits the PI3K-AKT-mTOR pathway and compensatory signaling mols. such as RAF, MEK, MAPK, and STAT-3, as well as upstream receptor tyrosine kinases.  CUDC-907 shows greater growth inhibition and proapoptotic activity than single-target PI3K or HDAC inhibitors in both cultured and implanted cancer cells.  Conclusions: CUDC-907 may offer improved therapeutic benefits through simultaneous, sustained disruption of multiple oncogenic signaling networks.  Clin Cancer Res; 18(15); 4104-13. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvXaG5-2QzbVg90H21EOLACvtfcHk0lhJrDLa-Mq7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCktbbL&md5=be0d379f13fded2bed326cece99af8d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0055%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DC.-J.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DD.-G.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DG.-X.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DMa%26aufirst%3DA.%2BW.%2BS.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DBorek%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DVoi%26aufirst%3DM.%26atitle%3DCancer%2520Network%2520Disruption%2520by%2520a%2520Single%2520Molecule%2520Inhibitor%2520Targeting%2520Both%2520Histone%2520Deacetylase%2520Activity%2520and%2520Phosphatidylinositol%25203-Kinase%2520Signaling%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4104%26epage%3D4113%26doi%3D10.1158%2F1078-0432.CCR-12-0055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luesch, H.</span></span> <span> </span><span class="NLM_article-title">Largazole: From Discovery to Broad-Spectrum Therapy</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1039/c2np00066k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1039%2Fc2np00066k" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22334030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Wkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=449-456&author=J.+Hongauthor=H.+Luesch&title=Largazole%3A+From+Discovery+to+Broad-Spectrum+Therapy&doi=10.1039%2Fc2np00066k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Largazole: From discovery to broad-spectrum therapy</span></div><div class="casAuthors">Hong, Jiyong; Luesch, Hendrik</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-456</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering up to 2011The cyclic depsipeptide largazole from a cyanobacterium of the genus Symploca is a marine natural product with a novel chem. scaffold and potently inhibits class I histone deacetylases (HDACs).  Largazole possesses highly differential growth-inhibitory activity, preferentially targeting transformed over non-transformed cells.  The intriguing structure and biol. activity of largazole have attracted strong interest from the synthetic chem. community to establish synthetic routes to largazole and to investigate its potential as a cancer therapeutic.  This Highlight surveys recent advances in this area with a focus on the discovery, synthesis, target identification, structure-activity relationships, HDAC8-largazole thiol crystal structure, and biol. studies, including in vivo anticancer and osteogenic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolf01UpCv74LVg90H21EOLACvtfcHk0lhJrDLa-Mq7ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Wkur0%253D&md5=4cc376f2d79f2e9c7cb79cdfdd415e38</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1039%2Fc2np00066k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2np00066k%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DLuesch%26aufirst%3DH.%26atitle%3DLargazole%253A%2520From%2520Discovery%2520to%2520Broad-Spectrum%2520Therapy%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2012%26volume%3D29%26spage%3D449%26epage%3D456%26doi%3D10.1039%2Fc2np00066k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesfeld, J. M.</span></span> <span> </span><span class="NLM_article-title">Pimelic Diphenylamide 106 is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">35402</span>– <span class="NLM_lpage">35409</span>, <span class="refDoi"> DOI: 10.1074/jbc.M807045200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M807045200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18953021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVylsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=35402-35409&author=C.+J.+Chouauthor=D.+Hermanauthor=J.+M.+Gottesfeld&title=Pimelic+Diphenylamide+106+is+a+Slow%2C+Tight-binding+Inhibitor+of+Class+I+Histone+Deacetylases&doi=10.1074%2Fjbc.M807045200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases</span></div><div class="casAuthors">Chou, C. James; Herman, David; Gottesfeld, Joel M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35402-35409</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors, including various benzamides and hydroxamates, are currently in clin. development for a broad range of human diseases, including cancer and neurodegenerative diseases.  We recently reported the identification of a family of benzamide-type HDAC inhibitors that are relatively non-toxic compared with the hydroxamates.  Members of this class of compds. have shown efficacy in cell-based and mouse models for the neurodegenerative diseases Friedreich ataxia and Huntington disease.  Considerable differences in IC50 values for the various HDAC enzymes have been reported for many of the HDAC inhibitors, leading to confusion as to the HDAC isotype specificities of these compds.  Here we show that a benzamide HDAC inhibitor, a pimelic diphenylamide (106), is a class I HDAC inhibitor, demonstrating no activity against class II HDACs.  106 Is a slow, tight-binding inhibitor of HDACs 1, 2, and 3, although inhibition for these enzymes occurs through different mechanisms.  Inhibitor 106 also has preference toward HDAC3 with Ki of ∼14 nM, 15 times lower than the Ki for HDAC1.  In comparison, the hydroxamate suberoylanilide hydroxamic acid does not discriminate between these enzymes and exhibits a fast-on/fast-off inhibitory mechanism.  These observations may explain a paradox involving the relative activities of pimelic diphenylamides vs. hydroxamates as gene activators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJtDFGy6MbVg90H21EOLACvtfcHk0liAD6Cyrh4vrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVylsr3L&md5=ffcdd2b6a6884d7fa48076c9bf228011</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M807045200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M807045200%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DHerman%26aufirst%3DD.%26aulast%3DGottesfeld%26aufirst%3DJ.%2BM.%26atitle%3DPimelic%2520Diphenylamide%2520106%2520is%2520a%2520Slow%252C%2520Tight-binding%2520Inhibitor%2520of%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D35402%26epage%3D35409%26doi%3D10.1074%2Fjbc.M807045200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallais, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frechette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessier, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leit, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaisburg, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span> <span> </span><span class="NLM_article-title">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5543</span>– <span class="NLM_lpage">5546</span>, <span class="refDoi"> DOI: 10.1021/jm701079h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701079h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5543-5546&author=O.+M.+Moradeiauthor=T.+C.+Mallaisauthor=S.+Frechetteauthor=I.+Paquinauthor=P.+E.+Tessierauthor=S.+M.+Leitauthor=M.+Fournelauthor=C.+Bonfilsauthor=M.-C.+Trachy-Bourgetauthor=J.+Liuauthor=T.+P.+Yanauthor=A.-H.+Luauthor=J.+Rahilauthor=J.+Wangauthor=S.+Lefebvreauthor=Z.+Liauthor=A.+F.+Vaisburgauthor=J.+M.+Besterman&title=Novel+Aminophenyl+Benzamide-Type+Histone+Deacetylase+Inhibitors+with+Enhanced+Potency+and+Selectivity&doi=10.1021%2Fjm701079h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity</span></div><div class="casAuthors">Moradei, Oscar M.; Mallais, Tammy C.; Frechette, Sylvie; Paquin, Isabelle; Tessier, Pierre E.; Leit, Silvana M.; Fournel, Marielle; Bonfils, Claire; Trachy-Bourget, Marie-Claude; Liu, Jianhong; Yan, Theresa P.; Lu, Ai-Hua; Rahil, Jubrail; Wang, James; Lefebvre, Sylvain; Li, Zuomei; Vaisburg, Arkadii F.; Besterman, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5543-5546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows.  A part of this endeavor was the exploration of the 14 Å internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compd. 4 (I) with the unusual bis(aryl)-type pharmacophore.  SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlM848KF3mo7Vg90H21EOLACvtfcHk0liAD6Cyrh4vrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKksLrL&md5=17012416f4be84479762acac0cff5e6f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm701079h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701079h%26sid%3Dliteratum%253Aachs%26aulast%3DMoradei%26aufirst%3DO.%2BM.%26aulast%3DMallais%26aufirst%3DT.%2BC.%26aulast%3DFrechette%26aufirst%3DS.%26aulast%3DPaquin%26aufirst%3DI.%26aulast%3DTessier%26aufirst%3DP.%2BE.%26aulast%3DLeit%26aufirst%3DS.%2BM.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DTrachy-Bourget%26aufirst%3DM.-C.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DA.-H.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVaisburg%26aufirst%3DA.%2BF.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26atitle%3DNovel%2520Aminophenyl%2520Benzamide-Type%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Enhanced%2520Potency%2520and%2520Selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5543%26epage%3D5546%26doi%3D10.1021%2Fjm701079h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldog, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khramtsov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghs, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehested, M.</span></span> <span> </span><span class="NLM_article-title">Determination of the Class and Isoform Selectivity of Small-Molecule Histone Deacetylase Inhibitors</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1042/BJ20070779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1042%2FBJ20070779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=17868033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2008&pages=581-589&author=N.+Khanauthor=M.+Jeffersauthor=S.+Kumarauthor=C.+Hackettauthor=F.+Boldogauthor=N.+Khramtsovauthor=X.+Qianauthor=E.+Millsauthor=S.+C.+Berghsauthor=N.+Careyauthor=P.+W.+Finnauthor=L.+S.+Collinsauthor=A.+Tumberauthor=J.+W.+Ritchieauthor=P.+B.+Jensenauthor=H.+S.+Lichensteinauthor=M.+Sehested&title=Determination+of+the+Class+and+Isoform+Selectivity+of+Small-Molecule+Histone+Deacetylase+Inhibitors&doi=10.1042%2FBJ20070779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors</span></div><div class="casAuthors">Khan, Nagma; Jeffers, Michael; Kumar, Sampath; Hackett, Craig; Boldog, Ferenc; Khramtsov, Nicholai; Qian, Xiaozhong; Mills, Evan; Berghs, Stanny C.; Carey, Nessa; Finn, Paul W.; Collins, Laura S.; Tumber, Anthony; Ritchie, James W.; Jensen, Peter Buhl; Lichenstein, Henri S.; Sehested, Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">581-589</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The human HDAC (histone deacetylase) family, a well-validated anticancer target, plays a key role in the control of gene expression through regulation of transcription.  While HDACs can be subdivided into three main classes, the class I, class II and class III HDACs (sirtuins), it is presently unclear whether inhibiting multiple HDACs using pan-HDAC inhibitors, or targeting specific isoforms that show aberrant levels in tumors, will prove more effective as an anticancer strategy in the clinic.  To address the above issues, we have tested a no. of clin. relevant HDACis (HDAC inhibitors) against a panel of rhHDAC (recombinant human HDAC) isoforms.  Eight rhHDACs were expressed using a baculoviral system, and a Fluor de Lys (Biomol International) HDAC assay was optimized for each purified isoform.  The potency and selectivity of ten HDACs on class I isoforms (rhHDAC1, rhHDAC2, rhHDAC3 and rhHDAC8) and class II HDAC isoforms (rhHDAC4, rhHDAC6, rhHDAC7 and rhHDAC9) was detd.  MS-275 was HDAC1-selective, MGCD0103 was HDAC1- and HDAC2-selective, apicidin was HDAC2- and HDAC3-selective and valproic acid was a specific inhibitor of class I HDACs.  The hydroxamic acid-derived compds. (trichostatin A, NVP-LAQ824, panobinostat, ITF2357, vorinostat and belinostat) were potent pan-HDAC inhibitors.  The growth-inhibitory effect of the HDACis on HeLa cells showed that both pan-HDAC and class-I-specific inhibitors inhibited cell growth.  The results also showed that both pan-HDAC and class-I-specific inhibitor treatment resulted in increased acetylation of histones, but only pan-HDAC inhibitor treatment resulted in increased tubulin acetylation, which is in agreement with their activity towards the HDAC6 isoform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHb1RAVCAf77Vg90H21EOLACvtfcHk0liAD6Cyrh4vrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSru7o%253D&md5=6d268ef4776d3165c6b0a61179642969</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1042%2FBJ20070779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070779%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DJeffers%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHackett%26aufirst%3DC.%26aulast%3DBoldog%26aufirst%3DF.%26aulast%3DKhramtsov%26aufirst%3DN.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DMills%26aufirst%3DE.%26aulast%3DBerghs%26aufirst%3DS.%2BC.%26aulast%3DCarey%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DP.%2BW.%26aulast%3DCollins%26aufirst%3DL.%2BS.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DRitchie%26aufirst%3DJ.%2BW.%26aulast%3DJensen%26aufirst%3DP.%2BB.%26aulast%3DLichenstein%26aufirst%3DH.%2BS.%26aulast%3DSehested%26aufirst%3DM.%26atitle%3DDetermination%2520of%2520the%2520Class%2520and%2520Isoform%2520Selectivity%2520of%2520Small-Molecule%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D409%26spage%3D581%26epage%3D589%26doi%3D10.1042%2FBJ20070779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonfils, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachy-Bourget, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ste-Croix, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahil, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moradei, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macleod, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besterman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, Has Broad Spectrum Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i></span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">768</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1535-7163.MCT-07-2026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18413790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gms70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=759-768&author=M.+Fournelauthor=C.+Bonfilsauthor=Y.+Houauthor=P.+T.+Yanauthor=M.-C.+Trachy-Bourgetauthor=A.+Kalitaauthor=J.+Liuauthor=A.-H.+Luauthor=N.+Z.+Zhouauthor=M.-F.+Robertauthor=J.+Gillespieauthor=J.+J.+Wangauthor=H.+Ste-Croixauthor=J.+Rahilauthor=S.+Lefebvreauthor=O.+Moradeiauthor=D.+Delormeauthor=A.+R.+Macleodauthor=J.+M.+Bestermanauthor=Z.+Li&title=MGCD0103%2C+a+Novel+Isotype-Selective+Histone+Deacetylase+Inhibitor%2C+Has+Broad+Spectrum+Antitumor+Activity+in+Vitro+and+in+Vivo&doi=10.1158%2F1535-7163.MCT-07-2026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo</span></div><div class="casAuthors">Fournel, Marielle; Bonfils, Claire; Hou, Yu; Yan, Pu Theresa; Trachy-Bourget, Marie-Claude; Kalita, Ann; Liu, Jianhong; Lu, Ai-Hua; Zhou, Nancy Z.; Robert, Marie-France; Gillespie, Jeffrey; Wang, James J.; Ste-Croix, Helene; Rahil, Jubrail; Lefebvre, Sylvain; Moradei, Oscar; Delorme, Daniel; MacLeod, A. Robert; Besterman, Jeffrey M.; Li, Zuomei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">759-768</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clin. investigation.  The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma.  Questions remain concerning which HDAC isotype(s) are the best to target for anticancer activity and whether increased efficacy and safety will result with an isotype-selective HDAC inhibitor.  We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro.  In intact cells, MGCD0103 inhibited only a fraction of the total HDAC activity and showed long-lasting inhibitory activity even upon drug removal.  MGCD0103 induced hyperacetylation of histones, selectively induced apoptosis, and caused cell cycle blockade in various human cancer cell lines in a dose-dependent manner.  MGCD0103 exhibited potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro, and HDAC inhibitory activity was required for these effects.  In vivo, MGCD0103 significantly inhibited growth of human tumor xenografts in nude mice in a dose-dependent manner and the antitumor activity correlated with induction of histone acetylation in tumors.  Our findings suggest that the isotype-selective HDAC inhibition by MGCD0103 is sufficient for antitumor activity in vivo and that further clin. investigation is warranted. [Mol Cancer Ther 2008;7(4):759-68].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokegpWTxBJyrVg90H21EOLACvtfcHk0lhgOsfAMCEI-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gms70%253D&md5=48604f141d969585efaa71c4005496cf</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2026%26sid%3Dliteratum%253Aachs%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DP.%2BT.%26aulast%3DTrachy-Bourget%26aufirst%3DM.-C.%26aulast%3DKalita%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DA.-H.%26aulast%3DZhou%26aufirst%3DN.%2BZ.%26aulast%3DRobert%26aufirst%3DM.-F.%26aulast%3DGillespie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DRahil%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DMoradei%26aufirst%3DO.%26aulast%3DDelorme%26aufirst%3DD.%26aulast%3DMacleod%26aufirst%3DA.%2BR.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DMGCD0103%252C%2520a%2520Novel%2520Isotype-Selective%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Has%2520Broad%2520Spectrum%2520Antitumor%2520Activity%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D759%26epage%3D768%26doi%3D10.1158%2F1535-7163.MCT-07-2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Development of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China</span>. <i>Intractable Rare Dis. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5582/irdr.2016.01024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.5582%2Firdr.2016.01024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27672541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=185-191&author=X.+Luauthor=Z.+Ningauthor=Z.+Liauthor=H.+Caoauthor=X.+Wang&title=Development+of+Chidamide+for+Peripheral+T-Cell+Lymphoma%2C+the+First+Orphan+Drug+Approved+in+China&doi=10.5582%2Firdr.2016.01024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span></div><div class="casAuthors">Lu Xianping; Ning Zhiqiang; Li Zhibin; Cao Haixiang; Wang Xinhao</div><div class="citationInfo"><span class="NLM_cas:title">Intractable & rare diseases research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">2186-3644</span>.
    </div><div class="casAbstract">Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies.  The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000.  Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment.  Functioning as a genuine epigenetic modulator, chidamide induces growth arrest and apoptosis in tumor cells and enhances cellular antitumor immunity.  Based on the overall results from preclinical and phase I clinical studies, exploratory and pivotal phase II trials of chidamide for relapsed or refractory PTCL were conducted from March 2009 to May 2012, and the results led to CFDA approval of chidamide for the indication in December 2014, being the first approved orphan drug according to the research & development approach of orphan drugs in China, as well as the first orally active drug for PTCL in China and worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsI-YolguuyLP3FVUi_gf8fW6udTcc2eYy1pvoDwUvRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D&md5=5c1f310ea15bb4a706f54d5fdc55c7d5</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.5582%2Firdr.2016.01024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Firdr.2016.01024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520Chidamide%2520for%2520Peripheral%2520T-Cell%2520Lymphoma%252C%2520the%2520First%2520Orphan%2520Drug%2520Approved%2520in%2520China%26jtitle%3DIntractable%2520Rare%2520Dis.%2520Res.%26date%3D2016%26volume%3D5%26spage%3D185%26epage%3D191%26doi%3D10.5582%2Firdr.2016.01024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bretz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parnitzke, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronthaler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamm, S.</span></span> <span> </span><span class="NLM_article-title">Domatinostat Favors the Immunotherapy Response by Modulating the Tumor Immune Microenvironment (TIME)</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi"> DOI: 10.1186/s40425-019-0745-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs40425-019-0745-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31703604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmvVeqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=294&author=A.+C.+Bretzauthor=U.+Parnitzkeauthor=K.+Kronthalerauthor=T.+Drekerauthor=R.+Bartzauthor=F.+Hermannauthor=A.+Ammendolaauthor=T.+Wulffauthor=S.+Hamm&title=Domatinostat+Favors+the+Immunotherapy+Response+by+Modulating+the+Tumor+Immune+Microenvironment+%28TIME%29&doi=10.1186%2Fs40425-019-0745-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)</span></div><div class="casAuthors">Bretz Anne Catherine; Parnitzke Ulrike; Kronthaler Kerstin; Dreker Tobias; Bartz Rene; Hermann Frank; Ammendola Astrid; Wulff Tanja; Hamm Svetlana</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The efficacy of PD-(L)1 blockade depends on the composition of the tumor immune microenvironment (TIME) and is generally higher in tumors with pre-existing cytotoxic T cells (CTL) than in those with low CTL numbers.  Nonetheless, a significant proportion of patients with pre-existing immunity fail to respond, indicating a therapeutic potential for combining PD-(L)1 blockade with additional immunomodulatory agents in both CTL-high and -low immune phenotypes.  Here, we evaluated domatinostat (4SC-202), a class I-selective histone deacetylase (HDAC) inhibitor, for its effect on the TIME and its antitumoral efficacy using syngeneic mouse models with CTL-high or CTL-low tumors.  METHODS:  Domatinostat was evaluated in PD-1 blockade-insensitive CTL-low (CT26) and CTL-high (C38) syngeneic models alone and in combination with different immune-inhibitory and -stimulatory approaches.  Effects on the immunophenotype were assessed via flow cytometry and RNA-seq analyses.  The changes in RNA-seq-based immune signatures determined in a murine setting were investigated in patient samples from the first-dose cohort of the SENSITIZE trial (NCT03278665) evaluating domatinostat combined with pembrolizumab in advanced-stage melanoma patients refractory/nonresponding to PD-1 blockade.  RESULTS:  Domatinostat increased the expression of antigen-presenting machinery (APM) genes and MHC class I and II molecules, along with CTL infiltration, in tumors of both immune phenotypes.  In combination with PD-(L)1 blockade, domatinostat augmented antitumor effects substantially above the effects of single-agent therapies, displaying greater benefit in tumors with pre-existing CTLs.  In this setting, the combination of domatinostat with agonistic anti-4-1BB or both PD-1 and LAG3 blockade further increased the antitumor efficacy.  In CTL-low tumors, domatinostat enhanced the expression of genes known to reinforce immune responses against tumors.  Specifically, domatinostat increased the expression of Ifng and genes associated with responses to pembrolizumab and nivolumab.  Clinically, these findings were confirmed in patients with advanced melanoma treated with domatinostat for 14 days, who demonstrated elevated expression of APM and MHC genes, the IFNG gene, and the IFN-γ and pembrolizumab response signatures in individual tumor samples.  CONCLUSION:  In summary, these data suggest a promising potential of domatinostat in combination with immunotherapy to improve the outcome of refractory cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkBIQjojbRPqx48Rj5GnGofW6udTcc2eYy1pvoDwUvRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmvVeqsw%253D%253D&md5=e93f15f76651efe45da4b87d95dcf3bf</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0745-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0745-3%26sid%3Dliteratum%253Aachs%26aulast%3DBretz%26aufirst%3DA.%2BC.%26aulast%3DParnitzke%26aufirst%3DU.%26aulast%3DKronthaler%26aufirst%3DK.%26aulast%3DDreker%26aufirst%3DT.%26aulast%3DBartz%26aufirst%3DR.%26aulast%3DHermann%26aufirst%3DF.%26aulast%3DAmmendola%26aufirst%3DA.%26aulast%3DWulff%26aufirst%3DT.%26aulast%3DHamm%26aufirst%3DS.%26atitle%3DDomatinostat%2520Favors%2520the%2520Immunotherapy%2520Response%2520by%2520Modulating%2520the%2520Tumor%2520Immune%2520Microenvironment%2520%2528TIME%2529%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D294%26doi%3D10.1186%2Fs40425-019-0745-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soilleux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tysoe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Thangue, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkes, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, M. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1002/cncr.31791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcncr.31791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30332497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Sru7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2019&pages=99-108&author=T.+A.+Eyreauthor=G.+P.+Collinsauthor=A.+Guptaauthor=N.+Coupeauthor=S.+Sheikhauthor=J.+Whittakerauthor=L.+M.+Wangauthor=L.+Campoauthor=E.+Soilleuxauthor=F.+Tysoeauthor=R.+Cousinsauthor=N.+La+Thangueauthor=L.+K.+Folkesauthor=M.+R.+L.+Stratfordauthor=D.+Kerrauthor=M.+R.+Middleton&title=A+Phase+1+Study+to+Assess+the+Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+CXD101+in+Patients+with+Advanced+Cancer&doi=10.1002%2Fcncr.31791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer</span></div><div class="casAuthors">Eyre, Toby A.; Collins, Graham P.; Gupta, Avinash; Coupe, Nicholas; Sheikh, Semira; Whittaker, John; Wang, Lai Mun; Campo, Leticia; Soilleux, Elizabeth; Tysoe, Finn; Cousins, Richard; La Thangue, Nick; Folkes, Lisa K.; Stratford, Michael R. L.; Kerr, David; Middleton, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-108</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : In the current study, the authors sought to det. the max. tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.  Methods : The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21-day cycle (3+3 design).  Results : A total of 39 patients were enrolled, 36 of whom received CXD101.  Of the 30 patients in the escalation cohort, 29 were evaluable for detn. of the dose-limiting toxicity (DLT).  DLTs were noted at doses of 16 mg twice daily (1 of 6 patients), 20 mg twice daily (1 of 6 patients), and 24/25 mg twice daily (2 of 5 patients, both of whom developed neutropenic fever).  The MTD was 20 mg twice daily, which achieved maximal plasma concns. (±std. deviation) of 231±76 nM to 342±126 nM, which was within the biol. active range.  Six patients received 20 mg twice daily in an expansion cohort.  The most frequent adverse events were fatigue, nausea, and reversible cytopenia.  Key grade 3 to 4 adverse events (according to Common Terminol. Criteria for Adverse Events criteria [version 4.03]) included thrombocytopenia (11%), neutropenia (17%), and neutropenic fever (2%) across the 133 CXD101 cycles given.  The toxicity profile was similar to that of licensing studies with other histone deacetylase inhibitors.  In 22 evaluable patients receiving a dose of ≥16 mg twice daily (17 of whom had lymphoma and 5 of whom had solid tumors), 3 partial responses (2 in patients with classic Hodgkin lymphoma after allogenic stem cell transplantation and 1 in a patient with angioimmunoblastic T-cell lymphoma) and 1 complete response (in a patient with follicular lymphoma) were noted (overall response rate of 18%) in addn. to 9 patients who achieved durable stable disease.  Responses were noted predominantly among patients with lymphoma (tumor redn. noted in 63% of patients on std. computed tomog.).  Conclusions : The MTD in the current study was found to be 20 mg twice daily.  Encouraging and durable activity was obsd. in patients with Hodgkin lymphoma, T-cell lymphoma, and follicular lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhG58M9eTdLLVg90H21EOLACvtfcHk0lgUUvcIW5Sjsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Sru7%252FE&md5=47f6b7cf4c4a7a67eb8622f7256f7315</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31791%26sid%3Dliteratum%253Aachs%26aulast%3DEyre%26aufirst%3DT.%2BA.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DCoupe%26aufirst%3DN.%26aulast%3DSheikh%26aufirst%3DS.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DL.%26aulast%3DSoilleux%26aufirst%3DE.%26aulast%3DTysoe%26aufirst%3DF.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DLa%2BThangue%26aufirst%3DN.%26aulast%3DFolkes%26aufirst%3DL.%2BK.%26aulast%3DStratford%26aufirst%3DM.%2BR.%2BL.%26aulast%3DKerr%26aufirst%3DD.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26atitle%3DA%2520Phase%25201%2520Study%2520to%2520Assess%2520the%2520Safety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520CXD101%2520in%2520Patients%2520with%2520Advanced%2520Cancer%26jtitle%3DCancer%26date%3D2019%26volume%3D125%26spage%3D99%26epage%3D108%26doi%3D10.1002%2Fcncr.31791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cengiz
Seval, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span> <span> </span><span class="NLM_article-title">A Comparative Safety Review of Histone Deacetylase Inhibitors for the Treatment of Myeloma</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1080/14740338.2019.1615051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F14740338.2019.1615051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31070945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXps1CjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=563-571&author=G.+Cengiz%0ASevalauthor=M.+Beksac&title=A+Comparative+Safety+Review+of+Histone+Deacetylase+Inhibitors+for+the+Treatment+of+Myeloma&doi=10.1080%2F14740338.2019.1615051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma</span></div><div class="casAuthors">Cengiz Seval, Guldane; Beksac, Meral</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">563-571</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Dysregulation of histone deacetylase (HDAC) activity is an epigenetic hallmark of multiple myeloma (MM), leading to aberrant gene expression and cellular signaling in myeloma cell growth, survival and resistance to therapy.  Hyper-methylation at diagnosis is a frequent observation, which eventually may convert to hypo-methylation during advanced phases.: A literature search on 'HDAC inhibitors' and 'multiple myeloma' was carried out using PubMed and Google Scholar in the prepn. of this overview on clin. efficacy and safety data.: First-generation non-selective HDAC inhibitors have demonstrated minimal single-agent activity in refractory MM.  Subsequently, combination therapy has proven an improvement in progression-free survival (PFS) but not response rates.  The main concerns are assocd. with toxicities.  Ongoing studies on new and more selective agents, i.e.  Romidepsin or Ricolinostat, are promising in terms of better efficacy and less toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5tYPY2lf0OrVg90H21EOLACvtfcHk0lgUUvcIW5Sjsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXps1CjsLs%253D&md5=3618b598fda7cac6afaf19708516a5be</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F14740338.2019.1615051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2019.1615051%26sid%3Dliteratum%253Aachs%26aulast%3DCengiz%2BSeval%26aufirst%3DG.%26aulast%3DBeksac%26aufirst%3DM.%26atitle%3DA%2520Comparative%2520Safety%2520Review%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Myeloma%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2019%26volume%3D18%26spage%3D563%26epage%3D571%26doi%3D10.1080%2F14740338.2019.1615051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M.</span></span> <span> </span><span class="NLM_article-title">The Safety Profile of Vorinostat (Suberoylanilide Hydroxamic Acid) in Hematologic Malignancies: A Review of Clinical Studies</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2015.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ctrv.2015.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26827693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVeqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=58-66&author=M.+Duvicauthor=M.+Dimopoulos&title=The+Safety+Profile+of+Vorinostat+%28Suberoylanilide+Hydroxamic+Acid%29+in+Hematologic+Malignancies%3A+A+Review+of+Clinical+Studies&doi=10.1016%2Fj.ctrv.2015.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies</span></div><div class="casAuthors">Duvic, Madeleine; Dimopoulos, Meletios</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Histone acetyltransferases and histone deacetylases (HDACs) are multifunctional enzymes that posttranslationally modify both histone and nonhistone acetylation sites, affecting a broad range of cellular processes (e.g., cell cycle, apoptosis, and protein folding) often dysregulated in cancer.  HDAC inhibitors are small mols. that directly interact with HDAC catalytic sites preventing the removal of acetyl groups, thereby counteracting the effects of HDACs.  Since the first HDAC inhibitor, valproic acid, was investigated as a potential antitumor agent, there have been a no. of other HDAC inhibitors developed to improve efficacy and safety.  Despite significant progress in the management of patients with hematol. malignancies, overall survival is still poor.  The discovery that HDACs may play a role in hematol. malignancies and preclin. studies showing promising activity with HDAC inhibitors in various tumor types, led to clin. evaluation of HDAC inhibitors as potential treatment options for patients with advanced hematol. malignancies.  The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma.  This review highlights the safety of HDAC inhibitors currently approved or being investigated for the treatment of hematol. malignancies, with a specific focus on the safety experience with vorinostat in cutaneous T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor9eEu3gdyDrVg90H21EOLACvtfcHk0lgUUvcIW5Sjsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVeqtrs%253D&md5=30a9e3f94e222ebbac6ded7469341e9d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2015.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2015.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26aulast%3DDimopoulos%26aufirst%3DM.%26atitle%3DThe%2520Safety%2520Profile%2520of%2520Vorinostat%2520%2528Suberoylanilide%2520Hydroxamic%2520Acid%2529%2520in%2520Hematologic%2520Malignancies%253A%2520A%2520Review%2520of%2520Clinical%2520Studies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2016%26volume%3D43%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.ctrv.2015.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1616</span>, <span class="refDoi"> DOI: 10.3390/ijms20071616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20071616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVyqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1616&author=W.+Liauthor=Z.+Sun&title=Mechanism+of+Action+for+HDAC+Inhibitors-Insights+from+Omics+Approaches&doi=10.3390%2Fijms20071616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action for HDAC inhibitors-insights from omics approaches</span></div><div class="casAuthors">Li, Wenbo; Sun, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1616</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDIs) are a class of prominent epigenetic drugs that are currently being tested in hundreds of clin. trials against a variety of diseases.  A few compds. have already been approved for treating lymphoma or myeloma.  HDIs bind to the zinc-contg. catalytic domain of the histone deacetylase (HDACs) and they repress the deacetylase enzymic activity.  The broad therapeutic effect of HDIs with seemingly low toxicity is somewhat puzzling when considering that most HDIs lack strict specificity toward any individual HDAC and, even if they do, each individual HDAC has diverse functions under different physiol. scenarios.  Here, we review recent mechanistic studies using omics approaches, including epigenomics, transcriptomics, proteomics, metabolomics, and chemoproteomics, methods.  These omics studies provide non-biased insights into the mechanism of action for HDIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa1rV-6hFcLbVg90H21EOLACvtfcHk0lhWZR4NQvd0Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVyqsg%253D%253D&md5=7fc9546a3abafb1ebf0a80a96bd18402</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3390%2Fijms20071616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071616%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DZ.%26atitle%3DMechanism%2520of%2520Action%2520for%2520HDAC%2520Inhibitors-Insights%2520from%2520Omics%2520Approaches%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1616%26doi%3D10.3390%2Fijms20071616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lhWZR4NQvd0Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma</span>. <i>Dermatol. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1016/j.det.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.det.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26433847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=757-764&author=M.+Duvic&title=Histone+Deacetylase+Inhibitors+for+Cutaneous+T-Cell+Lymphoma&doi=10.1016%2Fj.det.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma</span></div><div class="casAuthors">Duvic, Madeleine</div><div class="citationInfo"><span class="NLM_cas:title">Dermatologic Clinics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">757-764</span>CODEN:
                <span class="NLM_cas:coden">DRMCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0733-8635</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review describes Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU84YKmfugI7Vg90H21EOLACvtfcHk0lhWZR4NQvd0Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajtr3L&md5=4a2da2fbcfb52afe60cbf95c105c6cbd</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.det.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.det.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520for%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DDermatol.%2520Clin.%26date%3D2015%26volume%3D33%26spage%3D757%26epage%3D764%26doi%3D10.1016%2Fj.det.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R. R.</span></span> <span> </span><span class="NLM_article-title">Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/s40264-018-0773-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2Fs40264-018-0773-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30649740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=235-245&author=R.+R.+Shah&title=Safety+and+Tolerability+of+Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Oncology&doi=10.1007%2Fs40264-018-0773-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology</span></div><div class="casAuthors">Shah, Rashmi R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematol. malignancies (T-cell lymphomas and multiple myeloma).  However, they are not as effective in solid tumors.  Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat.  These agents are assocd. with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects.  Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the ECG, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias.  In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large no. of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesized and are currently under clin. development.  Preliminary evidence from early studies suggests that they may be effective in non-haematol. cancers as well when used in combination with other therapeutic modalities, but that they too appear to be assocd. with the above class-related adverse effects.  As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications will become clearer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_FzvurFGlNLVg90H21EOLACvtfcHk0lhWZR4NQvd0Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFOqtrY%253D&md5=db23e29ac410c716393aae079abf18cd</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1007%2Fs40264-018-0773-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-018-0773-9%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DR.%2BR.%26atitle%3DSafety%2520and%2520Tolerability%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Oncology%26jtitle%3DDrug%2520Saf.%26date%3D2019%26volume%3D42%26spage%3D235%26epage%3D245%26doi%3D10.1007%2Fs40264-018-0773-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flower, A.</span>; <span class="NLM_string-name">Abla, O.</span></span> <span> </span><span class="NLM_article-title">Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma</span>. In  <i>Resistance to Targeted Therapies in Lymphomas</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, A. C.</span>, <span class="NLM_string-name">Cairo, M. S.</span></span>, Eds.; Resistance to Targeted Anti-Cancer Therapeutics; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Cham, Switzerland</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">110</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1007%2F978-3-030-24424-8_5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=87-110&author=A.+Flower&author=O.+Ablaauthor=A.+C.+Xavier&author=M.+S.+Cairo&title=Resistance+to+Targeted+Therapies+in+Lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-24424-8_5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-030-24424-8_5%26sid%3Dliteratum%253Aachs%26aulast%3DFlower%26aufirst%3DA.%26atitle%3DResistance%2520to%2520Histone%2520Deacetylase%2520Inhibitors%2520in%2520the%2520Treatment%2520of%2520Lymphoma%26btitle%3DResistance%2520to%2520Targeted%2520Therapies%2520in%2520Lymphomas%26aulast%3DXavier%26aufirst%3DA.%2BC.%26pub%3DSpringer%26date%3D2019%26spage%3D87%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yurek-George, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cecil, A. R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, A. H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packham, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5720</span>– <span class="NLM_lpage">5726</span>, <span class="refDoi"> DOI: 10.1021/jm0703800</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0703800" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1WmtL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5720-5726&author=A.+Yurek-Georgeauthor=A.+R.+L.+Cecilauthor=A.+H.+K.+Moauthor=S.+Wenauthor=H.+Rogersauthor=F.+Habensauthor=S.+Maedaauthor=M.+Yoshidaauthor=G.+Packhamauthor=A.+Ganesan&title=The+First+Biologically+Active+Synthetic+Analogues+of+FK228%2C+the+Depsipeptide+Histone+Deacetylase+Inhibitor&doi=10.1021%2Fjm0703800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor</span></div><div class="casAuthors">Yurek-George, Alexander; Cecil, Alexander Richard Liam; Mo, Alex Hon Kit; Wen, Shijun; Rogers, Helen; Habens, Fay; Maeda, Satoko; Yoshida, Minoru; Packham, Graham; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5720-5726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclic peptide lactone analogs of the histone deacetylase (HDAC) inhibitor FK228 such as I (R = Me, Me2CH) are prepd.; their inhibition of human breast cancer cell line and of HDAC 1 and 6 is detd.  The dehydrobutyrine residue in FK228 is not essential and can be replaced by other residues such as D-valine without loss of HDAC inhibition.  Conformational restriction by the macrocyclic scaffold is important for HDAC inhibition; a linear peptide analog inhibits neither HDAC1 or HDAC6 and does not inhibit breast cancer cells.  The bridging disulfide of FK228 can be removed and one of its component cysteines replaced with an alanine residue with little or no loss in HDAC inhibition if the resultant thiol is protected (for example with an acetyl group).  The FK228 analogs are less effective at inhibiting HDAC6 (a class II HDAC) than HDAC1 (a class I HDAC).  The structure of I (R = Me) is detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLSbpJiC7igbVg90H21EOLACvtfcHk0lgs0g96jYE1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1WmtL7M&md5=7c44919259524c0d825e373c8466e536</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm0703800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0703800%26sid%3Dliteratum%253Aachs%26aulast%3DYurek-George%26aufirst%3DA.%26aulast%3DCecil%26aufirst%3DA.%2BR.%2BL.%26aulast%3DMo%26aufirst%3DA.%2BH.%2BK.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DRogers%26aufirst%3DH.%26aulast%3DHabens%26aufirst%3DF.%26aulast%3DMaeda%26aufirst%3DS.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DPackham%26aufirst%3DG.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThe%2520First%2520Biologically%2520Active%2520Synthetic%2520Analogues%2520of%2520FK228%252C%2520the%2520Depsipeptide%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5720%26epage%3D5726%26doi%3D10.1021%2Fjm0703800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, L.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation</span>. <i>ChemistrySelect</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1002/slct.201702295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fslct.201702295" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1KgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=176-187&author=Q.+Zhangauthor=Y.+Daiauthor=Z.+Caiauthor=L.+Mou&title=HDAC+Inhibitors%3A+Novel+Immunosuppressants+for+Allo-+and+Xeno-+Transplantation&doi=10.1002%2Fslct.201702295"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation</span></div><div class="casAuthors">Zhang, Qing; Dai, Yifan; Cai, Zhiming; Mou, Lisha</div><div class="citationInfo"><span class="NLM_cas:title">ChemistrySelect</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176-187</span>CODEN:
                <span class="NLM_cas:coden">CHEMUD</span>;
        ISSN:<span class="NLM_cas:issn">2365-6549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Immune rejection is the major obstacle to graft survival and quality of life of recipients after organ transplantation.  The immunosuppressants applied in clin. face severe safety and efficacy issues.  Histone deacetylases (HDACs) are emerging novel drug targets in the treatment of malignancies and immune disorders.  HDAC inhibitors show potential as valuable immune regulators after allo- or xeno-organ transplantation.  However, studies that evaluate HDAC inhibitors and mechanisms are still limited.  In this review, we focused on the immunomodulatory effects of HDAC inhibitors in transplantation.  Finally, we discussed the implications and challenges of applying HDAC inhibitors in allo- and xeno-transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYyN829xfyirVg90H21EOLACvtfcHk0lgs0g96jYE1Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1KgsQ%253D%253D&md5=c6369c4cc8947c9357dbc266e66b5e9e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fslct.201702295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fslct.201702295%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DMou%26aufirst%3DL.%26atitle%3DHDAC%2520Inhibitors%253A%2520Novel%2520Immunosuppressants%2520for%2520Allo-%2520and%2520Xeno-%2520Transplantation%26jtitle%3DChemistrySelect%26date%3D2018%26volume%3D3%26spage%3D176%26epage%3D187%26doi%3D10.1002%2Fslct.201702295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citraro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’agostino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, E.</span></span> <span> </span><span class="NLM_article-title">Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5546</span>– <span class="NLM_lpage">5562</span>, <span class="refDoi"> DOI: 10.2174/1381612823666171024130001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.2174%2F1381612823666171024130001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=5546-5562&author=R.+Citraroauthor=A.+Leoauthor=M.+Santoroauthor=G.+D%E2%80%99agostinoauthor=A.+Constantiauthor=E.+Russo&title=Role+of+Histone+Deacetylases+%28HDACs%29+in+Epilepsy+and+Epileptogenesis&doi=10.2174%2F1381612823666171024130001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F1381612823666171024130001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666171024130001%26sid%3Dliteratum%253Aachs%26aulast%3DCitraro%26aufirst%3DR.%26aulast%3DLeo%26aufirst%3DA.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599agostino%26aufirst%3DG.%26aulast%3DConstanti%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DE.%26atitle%3DRole%2520of%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520in%2520Epilepsy%2520and%2520Epileptogenesis%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2018%26volume%3D23%26spage%3D5546%26epage%3D5562%26doi%3D10.2174%2F1381612823666171024130001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatain, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walbridge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chittiboina, P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2835</span>, <span class="refDoi"> DOI: 10.1210/jc.2017-00464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1210%2Fjc.2017-00464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28505327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1crntl2isg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=2825-2835&author=J.+Luauthor=G.+P.+Chatainauthor=A.+Bugariniauthor=X.+Wangauthor=D.+Maricauthor=S.+Walbridgeauthor=Z.+Zhuangauthor=P.+Chittiboina&title=Histone+Deacetylase+Inhibitor+SAHA+Is+a+Promising+Treatment+of+Cushing+Disease&doi=10.1210%2Fjc.2017-00464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease</span></div><div class="casAuthors">Lu Jie; Chatain Gregoire P; Chittiboina Prashant; Bugarini Alejandro; Wang Xiang; Walbridge Stuart; Zhuang Zhengping; Chittiboina Prashant; Maric Dragan</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2825-2835</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Context:  Remission failure following transsphenoidal surgery in Cushing disease (CD) from pituitary corticotroph tumors (CtTs) remains clinically challenging.  Histone deacetylase inhibitors (HDACis) are antitumor drugs approved for clinical use, with the potential to affect adrenocorticotropin hormone (ACTH) hypersecretion by inhibiting pro-opiomelanocortin (POMC) transcription.  Objective:  Testing the efficacy of suberoylanilide hydroxamic acid (SAHA) on human and murine ACTH-secreting tumor (AtT-20) cells.  Design:  Cell viability, ACTH secretion (enzyme-linked immunosorbent assay), apoptosis, and gene expression profile were investigated on AtT-20 cells.  In vivo efficacy was examined in an athymic nude mouse AtT-20 xenograft model.  SAHA efficacy against human-derived corticotroph tumor (hCtT) (n = 8) was tested in vitro.  Setting:  National Institutes of Health.  Intervention:  SAHA (0.5 to 8 μM).  Main Outcome Measures:  AtT-20 and hCtT cell survival, in vitro/invivo ACTH measurements.  Results:  SAHA (1 μM) reduced AtT-20 viability to 75% at 24 hours, 43% at 48 hours (analysis of variance; P = 0.002).  Apoptosis was confirmed with elevated BAX/Bcl2 ratio and FACS.  Intriguingly, early (3-hour) significant decline (70%; P < 0.0001) of secreted ACTH and diminished POMC transcription was observed with SAHA (1 μM).  Microarray analysis revealed a direct association between liver X receptor alpha (LXRα) and POMC expression.  Accordingly, SAHA reduced LXRα in AtT-20 cells but not in normal murine corticotrophs.  Xenografted nude-mice tumor involution (126 ± 33/160 ± 35 vs 337 ± 49 mm3; P = 0.0005) was observed with 5-day intraperitoneal SAHA, with reversal of elevated ACTH (P < 0.0001).  SAHA did not affect serum ACTH in nontumor mice.  Lastly, we confirmed that SAHA (1 μM/24 h) decreased hCtT survival (78.92%; P = 0.0007) and ACTH secretion (83.64%; P = 0.03).  Conclusion:  Our findings demonstrate SAHA's efficacy in reducing survival and ACTH secretion in AtT-20 and hCtT cells, providing a potential intervention for recurrent/unremitting CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwKtl5uJA9kK_dlEzl_fBafW6udTcc2ebJxfGGv_Gpzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crntl2isg%253D%253D&md5=5076c79a890e45c6368833c69acf7992</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1210%2Fjc.2017-00464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2017-00464%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChatain%26aufirst%3DG.%2BP.%26aulast%3DBugarini%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMaric%26aufirst%3DD.%26aulast%3DWalbridge%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DChittiboina%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitor%2520SAHA%2520Is%2520a%2520Promising%2520Treatment%2520of%2520Cushing%2520Disease%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2017%26volume%3D102%26spage%3D2825%26epage%3D2835%26doi%3D10.1210%2Fjc.2017-00464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandoná, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consalvi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucciarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccone, V.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors for Muscular Dystrophies: Progress and Prospects</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1517/21678707.2016.1130617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1517%2F21678707.2016.1130617" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=125-127&author=M.+Sandon%C3%A1author=S.+Consalviauthor=L.+Tucciaroneauthor=P.+L.+Puriauthor=V.+Saccone&title=HDAC+Inhibitors+for+Muscular+Dystrophies%3A+Progress+and+Prospects&doi=10.1517%2F21678707.2016.1130617"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1517%2F21678707.2016.1130617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F21678707.2016.1130617%26sid%3Dliteratum%253Aachs%26aulast%3DSandon%25C3%25A1%26aufirst%3DM.%26aulast%3DConsalvi%26aufirst%3DS.%26aulast%3DTucciarone%26aufirst%3DL.%26aulast%3DPuri%26aufirst%3DP.%2BL.%26aulast%3DSaccone%26aufirst%3DV.%26atitle%3DHDAC%2520Inhibitors%2520for%2520Muscular%2520Dystrophies%253A%2520Progress%2520and%2520Prospects%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2016%26volume%3D4%26spage%3D125%26epage%3D127%26doi%3D10.1517%2F21678707.2016.1130617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">The Etiological Changes of Acetylation in Peripheral Nerve Injury-Induced Neuropathic Hypersensitivity</span>. <i>Mol. Pain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1744806918798408</span>, <span class="refDoi"> DOI: 10.1177/1744806918798408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1177%2F1744806918798408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=1744806918798408&author=X.+Wangauthor=X.+Shenauthor=Y.+Xuauthor=S.+Xuauthor=F.+Xiaauthor=B.+Zhuauthor=Y.+Liuauthor=W.+Wangauthor=H.+Wuauthor=F.+Wang&title=The+Etiological+Changes+of+Acetylation+in+Peripheral+Nerve+Injury-Induced+Neuropathic+Hypersensitivity&doi=10.1177%2F1744806918798408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1177%2F1744806918798408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1744806918798408%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DF.%26atitle%3DThe%2520Etiological%2520Changes%2520of%2520Acetylation%2520in%2520Peripheral%2520Nerve%2520Injury-Induced%2520Neuropathic%2520Hypersensitivity%26jtitle%3DMol.%2520Pain%26date%3D2018%26volume%3D14%26spage%3D1744806918798408%26doi%3D10.1177%2F1744806918798408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markelewicz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3307</span>– <span class="NLM_lpage">3315</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-16-2526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28053023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3307-3315&author=D.+T.+Voglauthor=N.+Rajeauthor=S.+Jagannathauthor=P.+Richardsonauthor=P.+Hariauthor=R.+Orlowskiauthor=J.+G.+Supkoauthor=D.+Tamangauthor=M.+Yangauthor=S.+S.+Jonesauthor=C.+Wheelerauthor=R.+J.+Markelewiczauthor=S.+Lonial&title=Ricolinostat%2C+the+First+Selective+Histone+Deacetylase+6+Inhibitor%2C+in+Combination+with+Bortezomib+and+Dexamethasone+for+Relapsed+or+Refractory+Multiple+Myeloma&doi=10.1158%2F1078-0432.CCR-16-2526"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma</span></div><div class="casAuthors">Vogl, Dan T.; Raje, Noopur; Jagannath, Sundar; Richardson, Paul; Hari, Parameswaran; Orlowski, Robert; Supko, Jeffrey G.; Tamang, David; Yang, Min; Jones, Simon S.; Wheeler, Catherine; Markelewicz, Robert J.; Lonial, Sagar</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3307-3315</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity.  Preclin. models suggest that the obsd. synergy is due to the role of HDAC6 in mediating resistance to proteasome inhibition via the aggresome/autophagy pathway of protein degrdn.  Exptl. Design: We conducted a phase I/II trial of the HDAC6-selective inhibitor ricolinostat to define the safety, preliminary efficacy, and recommended phase II dose in combination with std. proteasome inhibitor therapy.  Patients with relapsed or refractory multiple myeloma received oral ricolinostat on days 1-5 and 8-12 of each 21-day cycle.  Results: Single-agent ricolinostat therapy resulted in neither significant toxicity nor clin. responses.  Combination therapy with bortezomib and dexamethasone was well-tolerated during dose escalation but led to dose-limiting diarrhea in an expansion cohort at a ricolinostat dose of 160 mg twice daily.  Combination therapy at a ricolinostat dose of 160 mg daily in a second expansion cohort was well tolerated, with less severe hematol., gastrointestinal, and constitutional toxicities compared with published data on nonselective HDAC inhibitors.  The overall response rate in combination with daily ricolinostat at ≥160 mg was 37%.  The response rate to combination therapy among bortezomib-refractory patients was 14%.  Samples taken during therapy showed dose-dependent increases of acetylated tubulin in peripheral blood lymphocytes.  Conclusions: At the recommended phase II dose of ricolinostat of 160 mg daily, the combination with bortezomib and dexamethasone is safe, well-tolerated, and active, suggesting that selective inhibition of HDAC6 is a promising approach to multiple myeloma therapy.  Clin Cancer Res; 23(13); 3307-15. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFQogphgLWbLVg90H21EOLACvtfcHk0liao5I4W7cD6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSnurbL&md5=2dd174501d2f331aeb0eff42072001d1</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2526%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DRaje%26aufirst%3DN.%26aulast%3DJagannath%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWheeler%26aufirst%3DC.%26aulast%3DMarkelewicz%26aufirst%3DR.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26atitle%3DRicolinostat%252C%2520the%2520First%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Bortezomib%2520and%2520Dexamethasone%2520for%2520Relapsed%2520or%2520Refractory%2520Multiple%2520Myeloma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3307%26epage%3D3315%26doi%3D10.1158%2F1078-0432.CCR-16-2526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suraweera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">92</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffonc.2018.00092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29651407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=92&author=A.+Suraweeraauthor=K.+J.+O%E2%80%99Byrneauthor=D.+J.+Richard&title=Combination+Therapy+With+Histone+Deacetylase+Inhibitors+%28HDACi%29+for+the+Treatment+of+Cancer%3A+Achieving+the+Full+Therapeutic+Potential+of+HDACi&doi=10.3389%2Ffonc.2018.00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span></div><div class="casAuthors">Suraweera Amila; O'Byrne Kenneth J; Richard Derek J; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">92</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression.  Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones.  HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer.  Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents.  While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors.  The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies.  In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies.  We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTprF0Hdrz8rZZoeNcnHOQ9fW6udTcc2eYzgdf10nwCFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D&md5=2f0ace7215bc7519c23cad264f73693d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00092%26sid%3Dliteratum%253Aachs%26aulast%3DSuraweera%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520Therapy%2520With%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACi%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%253A%2520Achieving%2520the%2520Full%2520Therapeutic%2520Potential%2520of%2520HDACi%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D92%26doi%3D10.3389%2Ffonc.2018.00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspeslagh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almouzni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postel-Vinay, S.</span></span> <span> </span><span class="NLM_article-title">Combining Epigenetic Drugs with Other Therapies for Solid Tumours - Past Lessons and Future Promise</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1038/s41571-019-0267-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41571-019-0267-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31570827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOltbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=91-107&author=D.+Morelauthor=D.+Jefferyauthor=S.+Aspeslaghauthor=G.+Almouzniauthor=S.+Postel-Vinay&title=Combining+Epigenetic+Drugs+with+Other+Therapies+for+Solid+Tumours+-+Past+Lessons+and+Future+Promise&doi=10.1038%2Fs41571-019-0267-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise</span></div><div class="casAuthors">Morel, Daphne; Jeffery, Daniel; Aspeslagh, Sandrine; Almouzni, Genevieve; Postel-Vinay, Sophie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-107</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Epigenetic dysregulation has long been recognized as a key factor contributing to tumorigenesis and tumor maintenance that can influence all of the recognized hallmarks of cancer.  Despite regulatory approvals for the treatment of certain haematol. malignancies, the efficacy of the first generation of epigenetic drugs (epi-drugs) in patients with solid tumors has been disappointing; however, successes have now been achieved in selected solid tumor subtypes, thanks to the development of novel compds. and a better understanding of cancer biol. that have enabled precision medicine approaches.  Several lines of evidence support that, beyond their potential as monotherapies, epigenetic drugs could have important roles in synergy with other anticancer therapies or in reversing acquired therapy resistance.  Herein, it review the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other forms of anticancer therapy, including chemotherapy, radiation therapy, hormone therapy, molecularly targeted therapy and immunotherapy.  It provide a crit. appraisal of the preclin. rationale, completed clin. studies and ongoing clin. trials relating to combination therapies incorporating epi-drugs.  Finally, it propose and discuss rational clin. trial designs and drug development strategies, considering key factors including patient selection, tumor biomarker evaluation, drug scheduling and response assessment and study end points, with the aim of optimizing the development of such combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4bPhevWFgGrVg90H21EOLACvtfcHk0lj4S5yaVBDzPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOltbbK&md5=17a9efc27b0eec2b869b9f830a41294e</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Fs41571-019-0267-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41571-019-0267-4%26sid%3Dliteratum%253Aachs%26aulast%3DMorel%26aufirst%3DD.%26aulast%3DJeffery%26aufirst%3DD.%26aulast%3DAspeslagh%26aufirst%3DS.%26aulast%3DAlmouzni%26aufirst%3DG.%26aulast%3DPostel-Vinay%26aufirst%3DS.%26atitle%3DCombining%2520Epigenetic%2520Drugs%2520with%2520Other%2520Therapies%2520for%2520Solid%2520Tumours%2520-%2520Past%2520Lessons%2520and%2520Future%2520Promise%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D17%26spage%3D91%26epage%3D107%26doi%3D10.1038%2Fs41571-019-0267-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, H. N.</span></span> <span> </span><span class="NLM_article-title">The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2018.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.clml.2018.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30001985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=611-627&author=H.+N.+Abramson&title=The+Multiple+Myeloma+Drug+Pipeline%E2%80%942018%3A+A+Review+of+Small+Molecules+and+Their+Therapeutic+Targets&doi=10.1016%2Fj.clml.2018.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets</span></div><div class="casAuthors">Abramson Hanley N</div><div class="citationInfo"><span class="NLM_cas:title">Clinical lymphoma, myeloma & leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">611-627</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation, has changed dramatically in the past 20 years because 3 new classes of small molecule drugs (arbitrarily defined as having a molecular weight of < 900 kDa)-immunomodulators, proteasome inhibitors, and histone deacetylase blockers-have been introduced for the disease.  Therapeutic options for MM expanded further in 2015 when 2 new monoclonal antibodies (daratumumab and elotuzumab) were approved by the Food and Drug Administration for MM.  Although MM remains incurable, the cumulative effect of these advances has resulted in a near-doubling of the 5-year survival rate since the late 1980s.  Despite these advances, therapy for MM continues to pose substantial challenges because resistance to therapy frequently develops, and relapse and recurrence are all too common.  The present review focused on the pipeline for new small molecules in various stages of development and their associated cellular targets.  In addition to newer versions of alkylators, immunomodulators, proteasome inhibitors, and histone deacetylase inhibitors, the present review considered the prospects for adding new classes of small molecules to the MM armamentarium, which offer the potential for oral efficacy, relative simplicity of preparation, and prospects for improvement in the cost-to-benefit ratio.  Included are agents that affect myeloma epigenetics and the ubiquitination-proteasome system and the unfolded protein response, apoptotic mechanisms, chromosomal abnormalities, nuclear protein transport, and various kinases involved in cellular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS29pXs7jYk7MSzjBFCN0BJfW6udTcc2eYF1cly_4f6y7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnsFygsw%253D%253D&md5=3ead649460f6be413b2f7e82b659a8bf</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2018.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2018.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DAbramson%26aufirst%3DH.%2BN.%26atitle%3DThe%2520Multiple%2520Myeloma%2520Drug%2520Pipeline%25E2%2580%25942018%253A%2520A%2520Review%2520of%2520Small%2520Molecules%2520and%2520Their%2520Therapeutic%2520Targets%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2018%26volume%3D18%26spage%3D611%26epage%3D627%26doi%3D10.1016%2Fj.clml.2018.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlowska, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartelink, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripps, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastroserio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, T.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1239</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.70.5350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1200%2FJCO.2016.70.5350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28221861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=1231-1239&author=R.+Aggarwalauthor=S.+Thomasauthor=N.+Pawlowskaauthor=I.+Bartelinkauthor=J.+Grabowskyauthor=T.+Jahanauthor=A.+Crippsauthor=A.+Harbauthor=J.+Lengauthor=A.+Reinertauthor=I.+Mastroserioauthor=T.-G.+Truongauthor=C.+J.+Ryanauthor=P.+N.+Munster&title=Inhibiting+Histone+Deacetylase+as+a+Means+to+Reverse+Resistance+to+Angiogenesis+Inhibitors%3A+Phase+I+Study+of+Abexinostat+Plus+Pazopanib+in+Advanced+Solid+Tumor+Malignancies&doi=10.1200%2FJCO.2016.70.5350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies</span></div><div class="casAuthors">Aggarwal, Rahul; Thomas, Scott; Pawlowska, Nela; Bartelink, Imke; Grabowsky, Jennifer; Jahan, Thierry; Cripps, Amy; Harb, Armand; Leng, Jim; Reinert, Anne; Mastroserio, Ilaria; Truong, Thach-Giao; Ryan, Charles J.; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1231-1239,S1-S2</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance.  Patients and Methods: Pazopanib was administered once a day on days 1 to 28 and abexinostat was administered orally twice a day on days 1 to 5, 8 to 12, and 15 to 19 (schedule A) or on days 1 to 4, 8 to 11, and 15 to 18 (schedule B).  Dose escalation (3 + 3 design) in all solid tumors was followed by dose expansion in renal cell carcinoma (RCC).  Results: Fifty-one patients with RCC (N = 22) were enrolled, including 30 (59%) with one or more lines of prior VEGF-targeting therapy.  Five dose-limiting toxicities, including fatigue (n = 2), thrombocytopenia (n = 2), and elevated AST/ALT (n = 1), were obsd. with schedule A; one dose-limiting toxicity was obsd. (elevated AST/ALT) was obsd. with schedule B.  Grade ≥ 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (10%).  The recommended phase II dose was established as abexinostat 45 mg/m2 twice a day administered per schedule B plus pazopanib 800 mg/d.  Objective response rate was 21% overall and 27% in the RCC subset.  Median duration of response was 9.1 mo (1.2 to > 49 mo).  Eight patients (16%) had durable control of disease for > 12 mo.  Durable tumor regressions were obsd. in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with ongoing response > 3.5 years.  Peripheral blood histone acetylation and HDAC2 gene expression were assocd. with durable response to treatment.  Conclusion: Abexinostat is well tolerated in combination with pazopanib, allowing prolonged exposure and promising durable responses in pazopanib- and other VEGF inhibitor-refractory tumors, which supports epigenetically mediated reversal of treatment resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotzop0Tif1NLVg90H21EOLACvtfcHk0lj4S5yaVBDzPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFGrt7Y%253D&md5=31cf19bad52faca73593d583c71e4a6f</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.70.5350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.70.5350%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DPawlowska%26aufirst%3DN.%26aulast%3DBartelink%26aufirst%3DI.%26aulast%3DGrabowsky%26aufirst%3DJ.%26aulast%3DJahan%26aufirst%3DT.%26aulast%3DCripps%26aufirst%3DA.%26aulast%3DHarb%26aufirst%3DA.%26aulast%3DLeng%26aufirst%3DJ.%26aulast%3DReinert%26aufirst%3DA.%26aulast%3DMastroserio%26aufirst%3DI.%26aulast%3DTruong%26aufirst%3DT.-G.%26aulast%3DRyan%26aufirst%3DC.%2BJ.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DInhibiting%2520Histone%2520Deacetylase%2520as%2520a%2520Means%2520to%2520Reverse%2520Resistance%2520to%2520Angiogenesis%2520Inhibitors%253A%2520Phase%2520I%2520Study%2520of%2520Abexinostat%2520Plus%2520Pazopanib%2520in%2520Advanced%2520Solid%2520Tumor%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26spage%3D1231%26epage%3D1239%26doi%3D10.1200%2FJCO.2016.70.5350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yardley, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail-Khan, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melichar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruickshank, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane with or without Entinostat in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment with a Nonsteroidal Aromatase Inhibitor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2135</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.43.7251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1200%2FJCO.2012.43.7251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23650416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=2128-2135&author=D.+A.+Yardleyauthor=R.+R.+Ismail-Khanauthor=B.+Melicharauthor=M.+Lichinitserauthor=P.+N.+Munsterauthor=P.+M.+Kleinauthor=S.+Cruickshankauthor=K.+D.+Millerauthor=M.+J.+Leeauthor=J.+B.+Trepel&title=Randomized+Phase+II%2C+Double-Blind%2C+Placebo-Controlled+Study+of+Exemestane+with+or+without+Entinostat+in+Postmenopausal+Women+with+Locally+Recurrent+or+Metastatic+Estrogen+Receptor-Positive+Breast+Cancer+Progressing+on+Treatment+with+a+Nonsteroidal+Aromatase+Inhibitor&doi=10.1200%2FJCO.2012.43.7251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor</span></div><div class="casAuthors">Yardley, Denise A.; Ismail-Khan, Roohi R.; Melichar, Bohuslav; Lichinitser, Mikhail; Munster, Pamela N.; Klein, Pamela M.; Cruickshank, Scott; Miller, Kathy D.; Lee, Min J.; Trepel, Jane B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2135</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-pos. (ER+) breast cancer.  This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor exemestane vs. exemestane alone.  Patients and Methods: Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor were randomly assigned to exemestane 25 mg daily plus entinostat 5 mg once per wk (EE) or exemestane plus placebo (EP).  The primary end point was progression-free survival (PFS).  Blood was collected in a subset of patients for evaluation of protein lysine acetylation as a biomarker of entinostat activity.  Results: One hundred thirty patients were randomly assigned (EE group, n = 64; EP group, n = 66).  Based on intent-to-treat anal., treatment with EE improved median PFS to 4.3 mo vs. 2.3 mo with EP (hazard ratio [HR], 0.73; 95% CI, 0.50 to 1.07; one-sided P = .055; two-sided P = .11 [predefined significance level of .10, one-sided]).  Median overall survival was an exploratory end point and improved to 28.1 mo with EE vs. 19.8 mo with EP (HR, 0.59; 95% CI, 0.36 to 0.97; P = .036).  Fatigue and neutropenia were the most frequent grade 3/4 toxicities.  Treatment discontinuation because of adverse events was higher in the EE group vs. the EP group (11% v 2%).  Protein lysine hyperacetylation in the EE biomarker subset was assocd. with prolonged PFS.  Conclusion: Entinostat added to exemestane is generally well tolerated and demonstrated activity in patients with ER+ advanced breast cancer in this signal-finding phase II study.  Acetylation changes may provide an opportunity to maximize clin. benefit with entinostat.  Plans for a confirmatory study are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopc-999rEFo7Vg90H21EOLACvtfcHk0ljsWsgB5e7v5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSntbrF&md5=d11f73761ef87fe34fab169ae22e8390</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.7251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.7251%26sid%3Dliteratum%253Aachs%26aulast%3DYardley%26aufirst%3DD.%2BA.%26aulast%3DIsmail-Khan%26aufirst%3DR.%2BR.%26aulast%3DMelichar%26aufirst%3DB.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DKlein%26aufirst%3DP.%2BM.%26aulast%3DCruickshank%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26atitle%3DRandomized%2520Phase%2520II%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Study%2520of%2520Exemestane%2520with%2520or%2520without%2520Entinostat%2520in%2520Postmenopausal%2520Women%2520with%2520Locally%2520Recurrent%2520or%2520Metastatic%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancer%2520Progressing%2520on%2520Treatment%2520with%2520a%2520Nonsteroidal%2520Aromatase%2520Inhibitor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D2128%26epage%3D2135%26doi%3D10.1200%2FJCO.2012.43.7251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristofanilli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span> <span> </span><span class="NLM_article-title">Tucidinostat plus Exemestane for Postmenopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">806</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30164-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS1470-2045%2819%2930164-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31036468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosFSnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=806-815&author=Z.+Jiangauthor=W.+Liauthor=X.+Huauthor=Q.+Zhangauthor=T.+Sunauthor=S.+Cuiauthor=S.+Wangauthor=Q.+Ouyangauthor=Y.+Yinauthor=C.+Gengauthor=Z.+Tongauthor=Y.+Chengauthor=Y.+Panauthor=Y.+Sunauthor=H.+Wangauthor=T.+Ouyangauthor=K.+Guauthor=J.+Fengauthor=X.+Wangauthor=S.+Wangauthor=T.+Liuauthor=J.+Gaoauthor=M.+Cristofanilliauthor=Z.+Ningauthor=X.+Lu&title=Tucidinostat+plus+Exemestane+for+Postmenopausal+Patients+with+Advanced%2C+Hormone+Receptor-Positive+Breast+Cancer+%28ACE%29%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2819%2930164-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial</span></div><div class="casAuthors">Jiang, Zefei; Li, Wei; Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Cui, Shude; Wang, Shusen; Ouyang, Quchang; Yin, Yongmei; Geng, Cuizhi; Tong, Zhongsheng; Cheng, Ying; Pan, Yueyin; Sun, Yuping; Wang, Hong; Ouyang, Tao; Gu, Kangsheng; Feng, Jifeng; Wang, Xiaojia; Wang, Shubin; Liu, Tianshu; Gao, Jinghua; Cristofanilli, Massimo; Ning, Zhiqiang; Lu, Xianping</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">806-815</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Assess the efficacy and safety of combination in a randomised trial in a larger population of postmenopausal patients with advanced, hormone receptor-pos. breast cancer.  Eligible patients were postmenopausal women with hormone receptor-pos., HER2-neg. breast cancer and who had at least one measurable lesion, adequate organ function.  All patients in both groups also received 25 mg oral exemestane daily.  The primary endpoint was investigator-assessed progression-free survival.  Efficacy analyses were done in the full anal. set population, comprising all patients who received at least one dose of any study treatment, and safety analyses were done in all patients who received at least one dose of any study treatment and for whom at least one safety case report form was available.  The median duration of follow-up was 13·9 mo.  Investigator-assessed median progression-free survival was 7·4 mo in the tucidinostat group and 3·8 mo in the placebo group.  The most common grade 3 or 4 adverse events were neutropenia, thrombocytopenia and leucopenia.  Tucidinostat plus exemestane improved progression-free survival.  Grade 3-4 haematol. adverse events were more common in the tucidinostat plus exemestane group than in the placebo plus exemestane group.  Tucidinostat plus exemestane could represent a new treatment option for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLXAjqoJCxwbVg90H21EOLACvtfcHk0ljsWsgB5e7v5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosFSnsb0%253D&md5=4b411211c8d4765c2f2908e2e09371ad</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930164-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930164-0%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DOuyang%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DOuyang%26aufirst%3DT.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DCristofanilli%26aufirst%3DM.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DX.%26atitle%3DTucidinostat%2520plus%2520Exemestane%2520for%2520Postmenopausal%2520Patients%2520with%2520Advanced%252C%2520Hormone%2520Receptor-Positive%2520Breast%2520Cancer%2520%2528ACE%2529%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2019%26volume%3D20%26spage%3D806%26epage%3D815%26doi%3D10.1016%2FS1470-2045%2819%2930164-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abaza, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadia, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopleva, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrajoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfonso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, L.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkes, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foudray, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span> <span> </span><span class="NLM_article-title">Phase 1 Dose Escalation Multicenter Trial of Pracinostat Alone and in Combination with Azacitidine in Patients with Advanced Hematologic Malignancies</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">4851</span>– <span class="NLM_lpage">4859</span>, <span class="refDoi"> DOI: 10.1002/cncr.30949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcncr.30949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28841236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2017&pages=4851-4859&author=Y.+M.+Abazaauthor=T.+M.+Kadiaauthor=E.+J.+Jabbourauthor=M.+Y.+Konoplevaauthor=G.+Borthakurauthor=A.+Ferrajoliauthor=Z.+Estrovauthor=W.+G.+Wierdaauthor=A.+Alfonsoauthor=T.+H.+Chongauthor=C.+Chuahauthor=L.-P.+Kohauthor=B.-C.+Gohauthor=J.+E.+Changauthor=D.+E.+Durkesauthor=M.+C.+Foudrayauthor=H.+M.+Kantarjianauthor=X.+Q.+Dongauthor=G.+Garcia-Manero&title=Phase+1+Dose+Escalation+Multicenter+Trial+of+Pracinostat+Alone+and+in+Combination+with+Azacitidine+in+Patients+with+Advanced+Hematologic+Malignancies&doi=10.1002%2Fcncr.30949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies</span></div><div class="casAuthors">Abaza, Yasmin M.; Kadia, Tapan M.; Jabbour, Elias J.; Konopleva, Marina Y.; Borthakur, Gautam; Ferrajoli, Alessandra; Estrov, Zeev; Wierda, William G.; Alfonso, Ana; Chong, Toh Han; Chuah, Charles; Koh, Liang-Piu; Goh, Boon-Cher; Chang, Julie E.; Durkes, Daniel E.; Foudray, Maria Cielo; Kantarjian, Hagop M.; Dong, Xiao Qin; Garcia-Manero, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4851-4859</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines.  Pracinostat is reported to have modest clin. activity in patients with advanced solid tumors.  Given the higher preclin. sensitivity of hematol. malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, max. tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematol. malignancies.  METHODS : Pracinostat was administered orally 3 times a week for 3 wk on a 28-day cycle.  Patients were assigned to 7 dose levels using a 3 + 3 dose escalation design.  RESULTS : A total of 44 patients were enrolled, 25 of whom had AML and 14 of whom had myelodysplastic syndrome.  The max. tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg.  Two patients with AML achieved a response: 1 complete remission (CR) and 1 complete cytogenetic response.  Despite a dose-dependent increase in the plasma concn. of pracinostat, a similar increase in histone acetylation was not obsd.  As an extension, 10 addnl. patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine.  Six patients achieved a CR and 3 achieved a CR without platelet recovery with no added toxicity.  CONCLUSIONS : The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematol. malignancies.  Cancer 2017;123:4851-9. © 2017 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xSYY-7MfErVg90H21EOLACvtfcHk0ljsWsgB5e7v5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaqsb%252FI&md5=30a7a705e4982a5ec1bc25ade2fd1ca4</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcncr.30949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.30949%26sid%3Dliteratum%253Aachs%26aulast%3DAbaza%26aufirst%3DY.%2BM.%26aulast%3DKadia%26aufirst%3DT.%2BM.%26aulast%3DJabbour%26aufirst%3DE.%2BJ.%26aulast%3DKonopleva%26aufirst%3DM.%2BY.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAlfonso%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DT.%2BH.%26aulast%3DChuah%26aufirst%3DC.%26aulast%3DKoh%26aufirst%3DL.-P.%26aulast%3DGoh%26aufirst%3DB.-C.%26aulast%3DChang%26aufirst%3DJ.%2BE.%26aulast%3DDurkes%26aufirst%3DD.%2BE.%26aulast%3DFoudray%26aufirst%3DM.%2BC.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDong%26aufirst%3DX.%2BQ.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26atitle%3DPhase%25201%2520Dose%2520Escalation%2520Multicenter%2520Trial%2520of%2520Pracinostat%2520Alone%2520and%2520in%2520Combination%2520with%2520Azacitidine%2520in%2520Patients%2520with%2520Advanced%2520Hematologic%2520Malignancies%26jtitle%3DCancer%26date%3D2017%26volume%3D123%26spage%3D4851%26epage%3D4859%26doi%3D10.1002%2Fcncr.30949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Manero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abaza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medeiros, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaled, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odenike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maness-Harris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamlou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalie, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, E.</span></span> <span> </span><span class="NLM_article-title">Pracinostat plus Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 2 Study</span>. <i>Blood Adv.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1182/bloodadvances.2018027409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1182%2Fbloodadvances.2018027409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30760466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslyht7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=508-518&author=G.+Garcia-Maneroauthor=Y.+Abazaauthor=K.+Takahashiauthor=B.+C.+Medeirosauthor=M.+Arellanoauthor=S.+K.+Khaledauthor=M.+Patnaikauthor=O.+Odenikeauthor=H.+Sayarauthor=M.+Tummalaauthor=P.+Patelauthor=L.+Maness-Harrisauthor=R.+Stuartauthor=E.+Traerauthor=K.+Karamlouauthor=A.+Yacoubauthor=R.+Ghalieauthor=R.+Giorginoauthor=E.+Atallah&title=Pracinostat+plus+Azacitidine+in+Older+Patients+with+Newly+Diagnosed+Acute+Myeloid+Leukemia%3A+Results+of+a+Phase+2+Study&doi=10.1182%2Fbloodadvances.2018027409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study</span></div><div class="casAuthors">Garcia-Manero, Guillermo; Abaza, Yasmin; Takahashi, Koichi; Medeiros, Bruno C.; Arellano, Martha; Khaled, Samer K.; Patnaik, Mrinal; Odenike, Olatoyosi; Sayar, Hamid; Tummala, Mohan; Patel, Prapti; Maness-Harris, Lori; Stuart, Robert; Traer, Elie; Karamlou, Kasra; Yacoub, Abdulraheem; Ghalie, Richard; Giorgino, Ruben; Atallah, Ehab</div><div class="citationInfo"><span class="NLM_cas:title">Blood Advances</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">508-518</span>CODEN:
                <span class="NLM_cas:coden">BALDBA</span>;
        ISSN:<span class="NLM_cas:issn">2473-9537</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine.  This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for std. induction chemotherapy.  Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle.  Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphol. leukemia-free state (MLFS) rates of the combination.  Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen.  Fifty patients (33 de novo, 12 secondary, and 5 therapyrelated AML) were enrolled.  Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%).  Median OS and PFS were 19.1 mo (95% confidence interval [CI], 10-26.5 mo) and 12.6 mo (95% CI, 10-17.7 mo), resp., with a 1-yr OS rate of 62%.  Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities.  The 30- and 60-day all-cause mortality rates were 2% and 10%, resp.  DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment.  Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy.  A larger controlled trial is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHJhiSa1cirVg90H21EOLACvtfcHk0lhDOntBnJpIHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslyht7%252FL&md5=4a1a8b98ee7ef7f39ea5e445feb7aa75</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1182%2Fbloodadvances.2018027409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fbloodadvances.2018027409%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DAbaza%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DMedeiros%26aufirst%3DB.%2BC.%26aulast%3DArellano%26aufirst%3DM.%26aulast%3DKhaled%26aufirst%3DS.%2BK.%26aulast%3DPatnaik%26aufirst%3DM.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DSayar%26aufirst%3DH.%26aulast%3DTummala%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DManess-Harris%26aufirst%3DL.%26aulast%3DStuart%26aufirst%3DR.%26aulast%3DTraer%26aufirst%3DE.%26aulast%3DKaramlou%26aufirst%3DK.%26aulast%3DYacoub%26aufirst%3DA.%26aulast%3DGhalie%26aufirst%3DR.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DAtallah%26aufirst%3DE.%26atitle%3DPracinostat%2520plus%2520Azacitidine%2520in%2520Older%2520Patients%2520with%2520Newly%2520Diagnosed%2520Acute%2520Myeloid%2520Leukemia%253A%2520Results%2520of%2520a%2520Phase%25202%2520Study%26jtitle%3DBlood%2520Adv.%26date%3D2019%26volume%3D3%26spage%3D508%26epage%3D518%26doi%3D10.1182%2Fbloodadvances.2018027409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moufarrij, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2241</span>, <span class="refDoi"> DOI: 10.3390/ijms20092241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20092241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFKisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=2241&author=D.+Banikauthor=S.+Moufarrijauthor=A.+Villagra&title=Immunoepigenetics+Combination+Therapies%3A+An+Overview+of+the+Role+of+HDACs+in+Cancer+Immunotherapy&doi=10.3390%2Fijms20092241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Immunoepigenetics combination therapies: an overview of the role of HDACs in cancer immunotherapy</span></div><div class="casAuthors">Banik, Debarati; Moufarrij, Sara; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2241</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors (HDACis) have positioned these agents as promising drug candidates in combating cancer, autoimmune, neurodegenerative, and infectious diseases.  The same has also encouraged the evaluation of multiple HDACi candidates in preclin. studies in cancer and other diseases as well as the FDA-approval towards clin. use for specific agents.  In this review, we have discussed how the efficacy of immunotherapy can be leveraged by combining it with HDACis.  We have also included a brief overview of the classification of HDACis as well as their various roles in physiol. and pathophysiol. scenarios to target key cellular processes promoting the initiation, establishment, and progression of cancer.  Given the crit. role of the tumor microenvironment (TME) towards the outcome of anticancer therapies, we have also discussed the effect of HDACis on different components of the TME.  We then have gradually progressed into examples of specific pan-HDACis, class I HDACi, and selective HDACis that either have been incorporated into clin. trials or show promising preclin. effects for future consideration.  Finally, we have included examples of ongoing trials for each of the above categories of HDACis as standalone agents or in combination with immunotherapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GmQhr5gjNLVg90H21EOLACvtfcHk0lhDOntBnJpIHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFKisLY%253D&md5=c1f66bb1baecc85c323cd085de31c52e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.3390%2Fijms20092241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20092241%26sid%3Dliteratum%253Aachs%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DMoufarrij%26aufirst%3DS.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DImmunoepigenetics%2520Combination%2520Therapies%253A%2520An%2520Overview%2520of%2520the%2520Role%2520of%2520HDACs%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D2241%26doi%3D10.3390%2Fijms20092241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosás-Umbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Riol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marszalek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzardo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cedeño, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moltó, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group">BCN02 Study Group</span> <span> </span><span class="NLM_article-title"><i>In Vivo</i> Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">418</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffimmu.2020.00418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32265913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=418&author=M.+Ros%C3%A1s-Umbertauthor=M.+Ruiz-Riolauthor=M.+A.+Fern%C3%A1ndezauthor=M.+Marszalekauthor=P.+Collauthor=C.+Manzardoauthor=S.+Cede%C3%B1oauthor=J.+M.+Mir%C3%B3author=B.+Clotetauthor=T.+Hankeauthor=J.+Molt%C3%B3author=B.+Motheauthor=C.+Branderauthor=BCN02+Study+Group&title=In+Vivo+Effects+of+Romidepsin+on+T-Cell+Activation%2C+Apoptosis+and+Function+in+the+BCN02+HIV-1+Kick%26Kill+Clinical+Trial&doi=10.3389%2Ffimmu.2020.00418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial</span></div><div class="casAuthors">Rosas-Umbert, Miriam; Ruiz-Riol, Marta; Fernandez, Marco A.; Marszalek, Marta; Coll, Pep; Manzardo, Christian; Cedeno, Samandhy; Miro, Jose M.; Clotet, Bonaventura; Hanke, Tomas; Molto, Jose; Mothe, Beatriz; Brander, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">418</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy.  However, in vitro expts. suggested that RMD could also impair T-cell functionality, particularly of activated T cells.  Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited.  In order to address whether the in vitro observations are replicated in vivo, we detd. the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clin. trial (NCT02616874).  BCN02 was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent.  Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells.  Although RMD reduced the no. of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8+ T cells was preserved over the RMD treatment.  These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRjmovg4g0LVg90H21EOLACvtfcHk0lgLjdIsQ5sL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGhs7bJ&md5=38312233ee1075cefbb25afb71e0b1d7</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00418%26sid%3Dliteratum%253Aachs%26aulast%3DRos%25C3%25A1s-Umbert%26aufirst%3DM.%26aulast%3DRuiz-Riol%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DM.%2BA.%26aulast%3DMarszalek%26aufirst%3DM.%26aulast%3DColl%26aufirst%3DP.%26aulast%3DManzardo%26aufirst%3DC.%26aulast%3DCede%25C3%25B1o%26aufirst%3DS.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DMolt%25C3%25B3%26aufirst%3DJ.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3D%26atitle%3DIn%2520Vivo%2520Effects%2520of%2520Romidepsin%2520on%2520T-Cell%2520Activation%252C%2520Apoptosis%2520and%2520Function%2520in%2520the%2520BCN02%2520HIV-1%2520Kick%2526Kill%2520Clinical%2520Trial%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D418%26doi%3D10.3389%2Ffimmu.2020.00418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drugs: An Epigenetic Epiphany</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1227</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcmdc.201500394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26891251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1227-1241&author=A.+Ganesan&title=Multitarget+Drugs%3A+An+Epigenetic+Epiphany&doi=10.1002%2Fcmdc.201500394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drugs: an Epigenetic Epiphany</span></div><div class="casAuthors">Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1227-1241</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Epigenetics refers to changes in a biol. phenotype that are not due to an underlying change in genotype.  In eukaryotes, epigenetics involves a set of chem. modifications of the DNA and the histone proteins in nucleosomes.  These dynamic changes are carried out by enzymes and modulate protein-protein and protein-nucleic acid interactions to det. whether specific genes are expressed or silenced.  Both the epigenetic enzymes and recognition domains are currently important drug discovery targets, particularly for the treatment of cancer.  This review summarizes the progress of epigenetic targets that have reached a clin. stage: DNA methyltransferases, histone deacetylases, lysine methyltransferases, lysine demethylases, and bromodomains; this is followed by a comprehensive survey of multitarget drugs that have included an epigenetic target as one of their mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwdZM3u9Wbc7Vg90H21EOLACvtfcHk0lgLjdIsQ5sL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xislehu7w%253D&md5=736284dc3f05db0032c9a304884f980d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500394%26sid%3Dliteratum%253Aachs%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DMultitarget%2520Drugs%253A%2520An%2520Epigenetic%2520Epiphany%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1227%26epage%3D1241%26doi%3D10.1002%2Fcmdc.201500394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lera, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Two-Hit Wonders: The Expanding Universe of Multitargeting Epigenetic Agents</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32784072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKnsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=135-154&author=A.+R.+de+Leraauthor=A.+Ganesan&title=Two-Hit+Wonders%3A+The+Expanding+Universe+of+Multitargeting+Epigenetic+Agents&doi=10.1016%2Fj.cbpa.2020.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Two-hit wonders: The expanding universe of multitargeting epigenetic agents</span></div><div class="casAuthors">de Lera, Angel R.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">135-154</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Multitargeting involves the application of mols. that are deliberately intended to bind to two or more unrelated cellular targets with high affinity.  In epigenetic chem. biol. and drug discovery, the rational design of multitargeting agents has evolved to a sophisticated level, and there are now five examples that have reached clin. trials.  This review covers recent developments in the field and future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwQn-GXR3grVg90H21EOLACvtfcHk0lgLjdIsQ5sL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKnsbvO&md5=b5383c9c221fbcb6dcf7483d98aa7b78</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.05.009%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLera%26aufirst%3DA.%2BR.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DTwo-Hit%2520Wonders%253A%2520The%2520Expanding%2520Universe%2520of%2520Multitargeting%2520Epigenetic%2520Agents%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D135%26epage%3D154%26doi%3D10.1016%2Fj.cbpa.2020.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+Phase+I+Study+of+CUDC-101%2C+a+Multitarget+Inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+Combination+with+Chemoradiation+in+Patients+with+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0lgLjdIsQ5sL1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520CUDC-101%252C%2520a%2520Multitarget%2520Inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520Combination%2520with%2520Chemoradiation%2520in%2520Patients%2520with%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharavi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafeez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuck, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span> <span> </span><span class="NLM_article-title">CUDC-907 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC-Alterations: Results from an Expanded Phase I Trial</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1923</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.3324/haematol.2017.172882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3324%2Fhaematol.2017.172882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28860342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2017&pages=1923-1930&author=Y.+Okiauthor=K.+R.+Kellyauthor=I.+Flinnauthor=M.+R.+Patelauthor=R.+Gharaviauthor=A.+Maauthor=J.+Parkerauthor=A.+Hafeezauthor=D.+Tuckauthor=A.+Younes&title=CUDC-907+in+Relapsed%2FRefractory+Diffuse+Large+B-Cell+Lymphoma%2C+Including+Patients+with+MYC-Alterations%3A+Results+from+an+Expanded+Phase+I+Trial&doi=10.3324%2Fhaematol.2017.172882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial</span></div><div class="casAuthors">Oki, Yasuhiro; Kelly, Kevin R.; Flinn, Ian; Patel, Manish R.; Gharavi, Robert; Ma, Anna; Parker, Jefferson; Hafeez, Amir; Tuck, David; Younes, Anas</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1923-1930</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">CUDC-907 is a first-in-class, oral small mol. inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and γ) enzymes, with demonstrated anti-tumor activity in multiple pre-clin. models, including MYC-driven ones.  In this report, we present the safety and preliminary activity results of CUDC-907, with and without rituximab, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with a particular focus on those with MYC-altered disease.  Thirty-seven DLBCL patients were enrolled, 14 with confirmed MYCaltered disease.  Twenty-five patients received monotherapy treatment, and 12 received the combination of CUDC-907 with rituximab.  CUDC- 907 monotherapy and combination demonstrated similar safety profiles consisting primarily of Grade 1/2 hematol. and gastrointestinal events.  The most frequently reported Grade ≥3 treatment-related events were thrombocytopenia, neutropenia, diarrhea, fatigue, and anemia.  Eleven responses (5 complete responses and 6 partial responses) were reported, for a response rate of 37% (11 out of 30) in evaluable patients [30% (11 out of 37) including all patients].  The objective response rate in evaluable MYC-altered DLBCL patients was 64% (7 out of 11; 4 complete responses and 3 partial responses), while it was 29% (2 out of 7) in MYC unaltered, and 17% (2 out of 12) in those with unknown MYC status.  Median duration of response was 11.2 mo overall; 13.6 mo in MYC-altered patients, 6.0 mo in MYC unaltered, and 7.8 mo in those with MYC status unknown.  The tolerable safety profile and encouraging evidence of durable anti-tumor activity, particularly in MYC-altered patients, support the continued development of CUDC- 907 in these populations of high unmet need.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrypZUdcHYATLVg90H21EOLACvtfcHk0lgr3Cu2rWxiAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2jsrvF&md5=d171b5741d884db0e52b611b5de12e67</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.172882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.172882%26sid%3Dliteratum%253Aachs%26aulast%3DOki%26aufirst%3DY.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DGharavi%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DParker%26aufirst%3DJ.%26aulast%3DHafeez%26aufirst%3DA.%26aulast%3DTuck%26aufirst%3DD.%26aulast%3DYounes%26aufirst%3DA.%26atitle%3DCUDC-907%2520in%2520Relapsed%252FRefractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%252C%2520Including%2520Patients%2520with%2520MYC-Alterations%253A%2520Results%2520from%2520an%2520Expanded%2520Phase%2520I%2520Trial%26jtitle%3DHaematologica%26date%3D2017%26volume%3D102%26spage%3D1923%26epage%3D1930%26doi%3D10.3324%2Fhaematol.2017.172882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gunst, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjær, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olesen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Østergaard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søgaard, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstrup, M.</span></span> <span> </span><span class="NLM_article-title">Fimepinostat, a Novel Dual Inhibitor of HDAC and PI3K, Effectively Reverses HIV-1 Latency Ex Vivo without T Cell Activation</span>. <i>J. Virus Eradication</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S2055-6640(20)30042-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2FS2055-6640%2820%2930042-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31700655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MjmsFCntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=133-137&author=J.+D.+Gunstauthor=K.+Kj%C3%A6rauthor=R.+Olesenauthor=T.+A.+Rasmussenauthor=L.+%C3%98stergaardauthor=P.+W.+Dentonauthor=O.+S.+S%C3%B8gaardauthor=M.+Tolstrup&title=Fimepinostat%2C+a+Novel+Dual+Inhibitor+of+HDAC+and+PI3K%2C+Effectively+Reverses+HIV-1+Latency+Ex+Vivo+without+T+Cell+Activation&doi=10.1016%2FS2055-6640%2820%2930042-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation</span></div><div class="casAuthors">Gunst Jesper D; Kjaer Kathrine; Olesen Rikke; Rasmussen Thomas A; Ostergaard Lars; Denton Paul W; Sogaard Ole S; Tolstrup Martin; Gunst Jesper D; Kjaer Kathrine; Olesen Rikke; Rasmussen Thomas A; Ostergaard Lars; Denton Paul W; Sogaard Ole S; Tolstrup Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virus eradication</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-137</span>
        ISSN:<span class="NLM_cas:issn">2055-6640</span>.
    </div><div class="casAbstract">Objectives:  To test the potential of fimepinostat (CUDC-907), a dual inhibitor of histone deacetylases (HDAC) and phosphatidylinositol-3-kinases (PI3K), to reverse human immunodeficiency virus type 1 (HIV-1) latency in infected cell lines and in CD4+ T cells from HIV-1-infected donors on long-term combination antiretroviral therapy (cART).  Methods:  Latently HIV-1-infected J-lat Tat-GFP and ACH-2 cell lines were stimulated with clinically relevant concentrations of fimepinostat using the HDAC inhibitors (HDACi) panobinostat and romidepsin for comparison.  Next, CD4+ T cells from donors living with HIV-1 on long-term cART were stimulated ex vivo and cell-associated unspliced HIV-1 RNA was measured to quantify changes in HIV-1 transcription.  Finally, the impact of fimepinostat on T cell activation (CD69 expression) and proliferation (Ki67 expression) was determined using peripheral blood mononuclear cells from uninfected donors.  Results:  We found fimepinostat to be a potent latency-reversing agent.  This was true in two latently infected cell lines as well as ex vivo in CD4+ T cells isolated from donors living with HIV-1.  Relative to therapeutic dosing levels, fimepinostat showed latency-reversing potential comparable to romidepsin, which is the most potent HDACi tested in HIV-1 cure-related trials.  Interestingly, in contrast to romidepsin, fimepinostat stimulation resulted in decreased T cell activation and had no negative impact on T cell proliferation.  Conclusions:  At therapeutic concentration, the dual HDAC and PI3K inhibitor fimepinostat was a potent HIV-1 latency-reversing agent and it did not induce T cell activation and proliferation.  The potential of fimepinostat as a latency-reversing agent warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrn5zMD5IQFOb6AVA-44PTfW6udTcc2eaWr41r8AmDabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjmsFCntg%253D%253D&md5=f6975baff3acbff2625d591b285f933d</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS2055-6640%2820%2930042-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2055-6640%252820%252930042-X%26sid%3Dliteratum%253Aachs%26aulast%3DGunst%26aufirst%3DJ.%2BD.%26aulast%3DKj%25C3%25A6r%26aufirst%3DK.%26aulast%3DOlesen%26aufirst%3DR.%26aulast%3DRasmussen%26aufirst%3DT.%2BA.%26aulast%3D%25C3%2598stergaard%26aufirst%3DL.%26aulast%3DDenton%26aufirst%3DP.%2BW.%26aulast%3DS%25C3%25B8gaard%26aufirst%3DO.%2BS.%26aulast%3DTolstrup%26aufirst%3DM.%26atitle%3DFimepinostat%252C%2520a%2520Novel%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520Effectively%2520Reverses%2520HIV-1%2520Latency%2520Ex%2520Vivo%2520without%2520T%2520Cell%2520Activation%26jtitle%3DJ.%2520Virus%2520Eradication%26date%3D2019%26volume%3D5%26spage%3D133%26epage%3D137%26doi%3D10.1016%2FS2055-6640%2820%2930042-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wobser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glunz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tauch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butelmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebeler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhof, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houben, R.</span></span> <span> </span><span class="NLM_article-title">Elucidating the Mechanism of Action of Domatinostat (4SC-202) in Cutaneous T Cell Lymphoma Cells</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.1186/s13045-019-0719-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-019-0719-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30885250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3cblsFWgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=30&author=M.+Wobserauthor=A.+Weberauthor=A.+Glunzauthor=S.+Tauchauthor=K.+Seitzauthor=T.+Butelmannauthor=S.+Hesbacherauthor=M.+Goebelerauthor=R.+Bartzauthor=H.+Kohlhofauthor=D.+Schramaauthor=R.+Houben&title=Elucidating+the+Mechanism+of+Action+of+Domatinostat+%284SC-202%29+in+Cutaneous+T+Cell+Lymphoma+Cells&doi=10.1186%2Fs13045-019-0719-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells</span></div><div class="casAuthors">Wobser Marion; Weber Alexandra; Glunz Amelie; Tauch Saskia; Seitz Kristina; Butelmann Tobias; Hesbacher Sonja; Goebeler Matthias; Schrama David; Houben Roland; Bartz Rene; Kohlhof Hella</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL).  However, there is a need for further improvement of this therapeutic approach.  Here, we compared the mode of action of romidepsin (FK228), an established class I histone deacetylase inhibitor, and domatinostat (4SC-202), a novel inhibitor of class I HDACs, which has been reported to also target the lysine-specific histone demethylase 1A (LSD1).  METHODS:  We performed MTS assays and flow cytometric analyses of propidium iodide or annexin V-stained cells to assess drug impact on cellular proliferation, cell cycle distribution, and survival.  Histone acetylation and methylation as well as caspase activation was analyzed by immunoblot.  Gene expression analysis was performed using NanosString technology.  Knockdown and knockout of LSD1 was achieved with shRNA and CRISPR/Cas9, respectively, while the CRISPR/Cas9 synergistic activation mediator system was used to induce expression of endogenous HDACs and LSD1.  Furthermore, time-lapse fluorescence microscopy and an in vitro tubulin polymerization assay were applied.  RESULTS:  While FK228 as well as 4SC-202 potently induced cell death in six different CTCL cell lines, only in the case of 4SC-202 death was preceded by an accumulation of cells in the G2/M phase of the cell cycle.  Surprisingly, apoptosis and accumulation of cells with double DNA content occurred already at 4SC-202 concentrations hardly affecting histone acetylation and methylation, and provoking significantly less changes in gene expression compared to biologically equivalent doses of FK228.  Indeed, we provide evidence that the 4SC-202-induced G2/M arrest in CTCL cells is independent of de novo transcription.  Furthermore, neither enforced expression of HDAC1 nor knockdown or knockout of LSD1 affected the 4SC-202-induced effects.  Since time-lapse microscopy revealed that 4SC-202 could affect mitotic spindle formation, we performed an in vitro tubulin polymerization assay revealing that 4SC-202 can directly inhibit microtubule formation.  CONCLUSIONS:  We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells.  The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression.  Indeed, the compound is also a potent microtubule-destabilizing agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOPg7NgwlRXz0O18WR3iAofW6udTcc2eaWr41r8AmDabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cblsFWgtA%253D%253D&md5=a62322dcc37b502aabda2a832a0d08a0</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1186%2Fs13045-019-0719-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-019-0719-4%26sid%3Dliteratum%253Aachs%26aulast%3DWobser%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%26aulast%3DGlunz%26aufirst%3DA.%26aulast%3DTauch%26aufirst%3DS.%26aulast%3DSeitz%26aufirst%3DK.%26aulast%3DButelmann%26aufirst%3DT.%26aulast%3DHesbacher%26aufirst%3DS.%26aulast%3DGoebeler%26aufirst%3DM.%26aulast%3DBartz%26aufirst%3DR.%26aulast%3DKohlhof%26aufirst%3DH.%26aulast%3DSchrama%26aufirst%3DD.%26aulast%3DHouben%26aufirst%3DR.%26atitle%3DElucidating%2520the%2520Mechanism%2520of%2520Action%2520of%2520Domatinostat%2520%25284SC-202%2529%2520in%2520Cutaneous%2520T%2520Cell%2520Lymphoma%2520Cells%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2019%26volume%3D12%26spage%3D30%26doi%3D10.1186%2Fs13045-019-0719-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitir, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maolanon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohm, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colaço, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fristrup, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. A.</span></span> <span> </span><span class="NLM_article-title">Chemical Editing of Macrocyclic Natural Products and Kinetic Profiling Reveal Slow, Tight-Binding Histone Deacetylase Inhibitors with Picomolar Affinities</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5134</span>– <span class="NLM_lpage">5146</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.7b00725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWhtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5134-5146&author=B.+Kitirauthor=A.+R.+Maolanonauthor=R.+G.+Ohmauthor=A.+R.+Cola%C3%A7oauthor=P.+Fristrupauthor=A.+S.+Madsenauthor=C.+A.+Olsen&title=Chemical+Editing+of+Macrocyclic+Natural+Products+and+Kinetic+Profiling+Reveal+Slow%2C+Tight-Binding+Histone+Deacetylase+Inhibitors+with+Picomolar+Affinities&doi=10.1021%2Facs.biochem.7b00725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical editing of macrocyclic natural products and kinetic profiling reveal slow, tight-binding histone deacetylase inhibitors with picomolar affinities</span></div><div class="casAuthors">Kitir, Betul; Maolanon, Alex R.; Ohm, Ragnhild G.; Colaco, Ana R.; Fristrup, Peter; Madsen, Andreas S.; Olsen, Christian A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5134-5146</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are validated targets for treatment of certain cancer types and play numerous regulatory roles in biol., ranging from epigenetics to metab.  Small mols. are highly important as tool compds. for probing these mechanisms as well as for the development of new medicines.  Therefore, detailed mechanistic information and precise characterization of the chem. probes used to investigate the effects of HDAC enzymes are vital.  We interrogated Nature's arsenal of macrocyclic nonribosomal peptide HDAC inhibitors by chem. synthesis and evaluation of more than 30 natural products and analogs.  This furnished surprising trends in binding affinities for the various macrocycles, which were then exploited for the design of highly potent class I and IIb HDAC inhibitors.  Furthermore, thorough kinetic investigation revealed unexpected inhibitory mechanisms of important tool compds. as well as the approved drug Istodax (romidepsin).  This work provides novel inhibitors with varying potencies, selectivity profiles, and mechanisms of inhibition and, importantly, affords insight into known tool compds. that will improve the interpretation of their effects in biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0CeWzCSTmbVg90H21EOLACvtfcHk0liluVOMu1t1UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWhtrvO&md5=614f5678846c7ad31987012cc83a7f4b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00725%26sid%3Dliteratum%253Aachs%26aulast%3DKitir%26aufirst%3DB.%26aulast%3DMaolanon%26aufirst%3DA.%2BR.%26aulast%3DOhm%26aufirst%3DR.%2BG.%26aulast%3DCola%25C3%25A7o%26aufirst%3DA.%2BR.%26aulast%3DFristrup%26aufirst%3DP.%26aulast%3DMadsen%26aufirst%3DA.%2BS.%26aulast%3DOlsen%26aufirst%3DC.%2BA.%26atitle%3DChemical%2520Editing%2520of%2520Macrocyclic%2520Natural%2520Products%2520and%2520Kinetic%2520Profiling%2520Reveal%2520Slow%252C%2520Tight-Binding%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Picomolar%2520Affinities%26jtitle%3DBiochemistry%26date%3D2017%26volume%3D56%26spage%3D5134%26epage%3D5146%26doi%3D10.1021%2Facs.biochem.7b00725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitehead, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radetich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atadja, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claiborne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRiner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancost, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tichkule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vash, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stams, T.</span></span> <span> </span><span class="NLM_article-title">Human HDAC Isoform Selectivity Achieved via Exploitation of the Acetate Release Channel with Structurally Unique Small Molecule Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4626</span>– <span class="NLM_lpage">4634</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2011.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=21723733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovF2ju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=4626-4634&author=L.+Whiteheadauthor=M.+R.+Doblerauthor=B.+Radetichauthor=Y.+Zhuauthor=P.+W.+Atadjaauthor=T.+Claiborneauthor=J.+E.+Grobauthor=A.+McRinerauthor=M.+R.+Pancostauthor=A.+Patnaikauthor=W.+Shaoauthor=M.+Shultzauthor=R.+Tichkuleauthor=R.+A.+Tommasiauthor=B.+Vashauthor=P.+Wangauthor=T.+Stams&title=Human+HDAC+Isoform+Selectivity+Achieved+via+Exploitation+of+the+Acetate+Release+Channel+with+Structurally+Unique+Small+Molecule+Inhibitors&doi=10.1016%2Fj.bmc.2011.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors</span></div><div class="casAuthors">Whitehead, Lewis; Dobler, Markus R.; Radetich, Branko; Zhu, Yanyi; Atadja, Peter W.; Claiborne, Tavina; Grob, Jonathan E.; McRiner, Andrew; Pancost, Margaret R.; Patnaik, Anup; Shao, Wenlin; Shultz, Michael; Tichkule, Ritesh; Tommasi, Ruben A.; Vash, Brian; Wang, Ping; Stams, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4626-4634</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein we report the discovery of a family of novel yet simple, amino-acid derived class I HDAC inhibitors that demonstrate isoform selectivity via access to the internal acetate release channel.  Isoform selectivity criteria is discussed on the basis of X-ray crystallog. and mol. modeling of these novel inhibitors bound to HDAC8, potentially revealing insights into the mechanism of enzymic function through novel structural features revealed at the at. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgV7MIGevIxrVg90H21EOLACvtfcHk0liluVOMu1t1UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovF2ju7w%253D&md5=c252ec223e909e92ec165f60a1a33b16</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DWhitehead%26aufirst%3DL.%26aulast%3DDobler%26aufirst%3DM.%2BR.%26aulast%3DRadetich%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DAtadja%26aufirst%3DP.%2BW.%26aulast%3DClaiborne%26aufirst%3DT.%26aulast%3DGrob%26aufirst%3DJ.%2BE.%26aulast%3DMcRiner%26aufirst%3DA.%26aulast%3DPancost%26aufirst%3DM.%2BR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DShultz%26aufirst%3DM.%26aulast%3DTichkule%26aufirst%3DR.%26aulast%3DTommasi%26aufirst%3DR.%2BA.%26aulast%3DVash%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DStams%26aufirst%3DT.%26atitle%3DHuman%2520HDAC%2520Isoform%2520Selectivity%2520Achieved%2520via%2520Exploitation%2520of%2520the%2520Acetate%2520Release%2520Channel%2520with%2520Structurally%2520Unique%2520Small%2520Molecule%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D4626%26epage%3D4634%26doi%3D10.1016%2Fj.bmc.2011.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aidoud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoine, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemercier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1772</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1021/jm301355j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301355j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1772-1776&author=F.+F.+Wagnerauthor=D.+E.+Olsonauthor=J.+P.+Galeauthor=T.+Kayaauthor=M.+We%C3%AFwerauthor=N.+Aidoudauthor=M.+Thomasauthor=E.+L.+Davoineauthor=B.+C.+Lemercierauthor=Y.-L.+Zhangauthor=E.+B.+Holson&title=Potent+and+Selective+Inhibition+of+Histone+Deacetylase+6+%28HDAC6%29+Does+Not+Require+a+Surface-Binding+Motif&doi=10.1021%2Fjm301355j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif</span></div><div class="casAuthors">Wagner, Florence F.; Olson, David E.; Gale, Jennifer P.; Kaya, Taner; Weiwer, Michel; Aidoud, Nadia; Thomas, Meryl; Davoine, Emeline L.; Lemercier, Berenice C.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1772-1776</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).  Several inhibitors, including compd. 14 (BRD9757), exhibited excellent potency and selectivity despite the absence of a surface-binding motif.  The binding of these highly efficient ligands for HDAC6 is rationalized via structure-activity relationships.  These results demonstrate that high selectivity and potent inhibition of HDAC6 can be achieved through careful choice of linker element only.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp84k2hCSqrAbVg90H21EOLACvtfcHk0liluVOMu1t1UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVCjsrk%253D&md5=eee6262f17350f3f7c411ab37840e3fe</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm301355j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301355j%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DOlson%26aufirst%3DD.%2BE.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DAidoud%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDavoine%26aufirst%3DE.%2BL.%26aulast%3DLemercier%26aufirst%3DB.%2BC.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Does%2520Not%2520Require%2520a%2520Surface-Binding%2520Motif%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1772%26epage%3D1776%26doi%3D10.1021%2Fjm301355j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stowe, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madoux, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, D.</span></span> <span> </span><span class="NLM_article-title">Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold That Selectively Inhibit Class I Histone Deacetylases</span>. <i>Chem. Biol. (Oxford, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.chembiol.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25699604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlWjsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=273-284&author=Y.+Wangauthor=R.+L.+Stoweauthor=C.+E.+Pinelloauthor=G.+Tianauthor=F.+Madouxauthor=D.+Liauthor=L.+Y.+Zhaoauthor=J.-L.+Liauthor=Y.+Wangauthor=Y.+Wangauthor=H.+Maauthor=P.+Hodderauthor=W.+R.+Roushauthor=D.+Liao&title=Identification+of+Histone+Deacetylase+Inhibitors+with+Benzoylhydrazide+Scaffold+That+Selectively+Inhibit+Class+I+Histone+Deacetylases&doi=10.1016%2Fj.chembiol.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases</span></div><div class="casAuthors">Wang, Yunfei; Stowe, Ryan L.; Pinello, Christie E.; Tian, Guimei; Madoux, Franck; Li, Dawei; Zhao, Lisa Y.; Li, Jian-Liang; Wang, Yuren; Wang, Yuan; Ma, Haiching; Hodder, Peter; Roush, William R.; Liao, Daiqing</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">273-284</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of histone deacetylases (HDACi) hold considerable therapeutic promise as clin. anticancer therapies.  However, currently known HDACi exhibit limited isoform specificity, off-target activity, and undesirable pharmaceutical properties.  Thus, HDACi with new chemotypes are needed to overcome these limitations.  Here, we identify a class of HDACi with a previously undescribed benzoylhydrazide scaffold that is selective for the class I HDACs.  These compds. are competitive inhibitors with a fast-on/slow-off HDAC-binding mechanism.  We show that the lead compd., UF010, inhibits cancer cell proliferation via class I HDAC inhibition.  This causes global changes in protein acetylation and gene expression, resulting in activation of tumor suppressor pathways and concurrent inhibition of several oncogenic pathways.  The isotype selectivity coupled with interesting biol. activities in suppressing tumor cell proliferation support further preclin. development of the UF010 class of compds. for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3GHZ2LiwvbVg90H21EOLACvtfcHk0lg490dAwtmyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlWjsrg%253D&md5=b4e40e24ebe7e1ee7f6f1dacefaa5a39</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DStowe%26aufirst%3DR.%2BL.%26aulast%3DPinello%26aufirst%3DC.%2BE.%26aulast%3DTian%26aufirst%3DG.%26aulast%3DMadoux%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DL.%2BY.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DLiao%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520Histone%2520Deacetylase%2520Inhibitors%2520with%2520Benzoylhydrazide%2520Scaffold%2520That%2520Selectively%2520Inhibit%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DChem.%2520Biol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D22%26spage%3D273%26epage%3D284%26doi%3D10.1016%2Fj.chembiol.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyners, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinschek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Almes, F.-J.</span></span> <span> </span><span class="NLM_article-title">Perfluorinated Hydroxamic Acids Are Potent and Selective Inhibitors of HDAC-like Enzymes from <i>Pseudomonas aeruginosa</i></span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2017.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28259626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1OrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1508-1512&author=C.+Meynersauthor=B.+Wolffauthor=A.+Kleinschekauthor=A.+Kr%C3%A4merauthor=F.-J.+Meyer-Almes&title=Perfluorinated+Hydroxamic+Acids+Are+Potent+and+Selective+Inhibitors+of+HDAC-like+Enzymes+from+Pseudomonas+aeruginosa&doi=10.1016%2Fj.bmcl.2017.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa</span></div><div class="casAuthors">Meyners, Christian; Wolff, Benjamin; Kleinschek, Alexander; Kraemer, Andreas; Meyer-Almes, Franz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1508-1512</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of perfluorinated suberoylanilide hydroxamic acid (PFSAHA) derivs. was prepd. and profiled against a panel of human and bacterial members of the Histone deacetylase (HDAC) family.  Some of the active substances show nanomolar inhibitory activity and several hundred fold selectivity for the HDAC like enzyme PA3774 from P. aeruginosa.  The extraordinary selectivity against human HDACs results from the distinct oligomeric state of PA3774 which consists of two head-to-head dimers.  The binding pocket is defined by the surface of both opposite monomers confining the access of ligands to the active site.  In addn., the arom. cap group of PFSAHA undergoes an edge-to-face arom. interaction with phenylalanine from the opposite monomer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyU5sZhX7jcLVg90H21EOLACvtfcHk0lg490dAwtmyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1OrsLo%253D&md5=514752697eda40f813ce46a14ac5f4ed</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DMeyners%26aufirst%3DC.%26aulast%3DWolff%26aufirst%3DB.%26aulast%3DKleinschek%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DMeyer-Almes%26aufirst%3DF.-J.%26atitle%3DPerfluorinated%2520Hydroxamic%2520Acids%2520Are%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC-like%2520Enzymes%2520from%2520Pseudomonas%2520aeruginosa%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1508%26epage%3D1512%26doi%3D10.1016%2Fj.bmcl.2017.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänsch, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopranovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wössner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschhöfer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner-Weiß, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Almes, F.-J.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibition of Histone Deacetylase 8 by 3,4-Dihydro-2H-Pyrimido[1,2-c][1,3]Benzothiazin-6-Imine</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1863</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2019.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bbagen.2019.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30611847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1OktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1863&publication_year=2019&pages=577-585&author=M.+Muthauthor=N.+J%C3%A4nschauthor=A.+Kopranovicauthor=A.+Kr%C3%A4merauthor=N.+W%C3%B6ssnerauthor=M.+Jungauthor=F.+Kirschh%C3%B6ferauthor=G.+Brenner-Wei%C3%9Fauthor=F.-J.+Meyer-Almes&title=Covalent+Inhibition+of+Histone+Deacetylase+8+by+3%2C4-Dihydro-2H-Pyrimido%5B1%2C2-c%5D%5B1%2C3%5DBenzothiazin-6-Imine&doi=10.1016%2Fj.bbagen.2019.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine</span></div><div class="casAuthors">Muth, Marius; Jaensch, Niklas; Kopranovic, Aleksandra; Kraemer, Andreas; Woessner, Nathalie; Jung, Manfred; Kirschhoefer, Frank; Brenner-Weiss, Gerald; Meyer-Almes, Franz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1863</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC8 is an established target for T-cell lymphoma and childhood neuroblastoma.  Benzothiazine-imines are promising HDAC8 inhibitors with unknown binding mechanism lacking a usual zinc binding group.  In this study high-resoln. and quant. HPLC-coupled ESI-MS/MS techniques are combined with crystal structure detn. and a variety of biochem. and computational methods to elucidate the reaction mechanism between benzothiazine-imine 1 and HDAC8.  (1) 1 Is a covalent inhibitor of HDAC8; (2) inhibition is reversible in the presence of reducing agents; (3) C153 in the active site and C102 are involved in the inhibition mechanism; (4) 1 modifies various cysteines in HDAC8 forming either thiocyanates or mixed disulfides with 3; (5) 1 and 5 dock in close proximity to C153 within the active site.  This is supposed to accelerate covalent inactivation particularly in HDAC8 and suggested as major determinant for the obsd. nanomolar potency and selectivity of 1.1 and its analogs are interesting model compds. but unsuitable for therapeutic treatment due to their high unselective reactivity towards thiol groups.  However, the postulated preceding non-covalent binding mode of 1 opens a door to optimized next generation compds. that combine potent and selective non-covalent recognition with low reactivity towards C153 at the active site of HDAC8.1 represents a completely new class of inhibitors for HDAC8.  Initial non-covalent interaction at the bottom of the active site is suggested to be the key for its selectivity.  Further optimization of non-covalent interaction and thiol-reactivity provides opportunities to develop therapeutic useful covalent HDAC8 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVvW1gAYv4RrVg90H21EOLACvtfcHk0lg490dAwtmyBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1OktA%253D%253D&md5=5ee3a572b054b4c461828c04c52671d6</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2019.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2019.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nsch%26aufirst%3DN.%26aulast%3DKopranovic%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DW%25C3%25B6ssner%26aufirst%3DN.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DKirschh%25C3%25B6fer%26aufirst%3DF.%26aulast%3DBrenner-Wei%25C3%259F%26aufirst%3DG.%26aulast%3DMeyer-Almes%26aufirst%3DF.-J.%26atitle%3DCovalent%2520Inhibition%2520of%2520Histone%2520Deacetylase%25208%2520by%25203%252C4-Dihydro-2H-Pyrimido%255B1%252C2-c%255D%255B1%252C3%255DBenzothiazin-6-Imine%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2019%26volume%3D1863%26spage%3D577%26epage%3D585%26doi%3D10.1016%2Fj.bbagen.2019.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennen, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissing, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachhap, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leanderson, T.</span></span> <span> </span><span class="NLM_article-title">Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1399</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-2730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F0008-5472.CAN-12-2730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23149916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1386-1399&author=J.+T.+Isaacsauthor=L.+Antonyauthor=S.+L.+Dalrympleauthor=W.+N.+Brennenauthor=S.+Gerberauthor=H.+Hammersauthor=M.+Wissingauthor=S.+Kachhapauthor=J.+Luoauthor=L.+Xingauthor=P.+Bj%C3%B6rkauthor=A.+Olssonauthor=A.+Bj%C3%B6rkauthor=T.+Leanderson&title=Tasquinimod+Is+an+Allosteric+Modulator+of+HDAC4+Survival+Signaling+within+the+Compromised+Cancer+Microenvironment&doi=10.1158%2F0008-5472.CAN-12-2730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment</span></div><div class="casAuthors">Isaacs, John T.; Antony, Lizamma; Dalrymple, Susan L.; Brennen, W. Nathaniel; Gerber, Stephanie; Hammers, Hans; Wissing, Michel; Kachhap, Sushant; Luo, Jun; Xing, Li; Bjoerk, Per; Olsson, Anders; Bjoerk, Anders; Leanderson, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1386-1399</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings define the mechanism of action of an antiangiogenic drug currently in phase III trials and suggest how to leverage its efficacy in combination with other drugs that target the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzLRrQMEPB-bVg90H21EOLACvtfcHk0lioZGeIcQSihA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wks7o%253D&md5=8757c850001639d461b163e4852b802f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-2730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-2730%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DJ.%2BT.%26aulast%3DAntony%26aufirst%3DL.%26aulast%3DDalrymple%26aufirst%3DS.%2BL.%26aulast%3DBrennen%26aufirst%3DW.%2BN.%26aulast%3DGerber%26aufirst%3DS.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DWissing%26aufirst%3DM.%26aulast%3DKachhap%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DP.%26aulast%3DOlsson%26aufirst%3DA.%26aulast%3DBj%25C3%25B6rk%26aufirst%3DA.%26aulast%3DLeanderson%26aufirst%3DT.%26atitle%3DTasquinimod%2520Is%2520an%2520Allosteric%2520Modulator%2520of%2520HDAC4%2520Survival%2520Signaling%2520within%2520the%2520Compromised%2520Cancer%2520Microenvironment%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D1386%26epage%3D1399%26doi%3D10.1158%2F0008-5472.CAN-12-2730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suguro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC4 Regulates Vascular Inflammation via Activation of Autophagy</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1016</span>– <span class="NLM_lpage">1028</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvy051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1093%2Fcvr%2Fcvy051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29529137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlslSjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2018&pages=1016-1028&author=D.+Yangauthor=C.+Xiaoauthor=F.+Longauthor=Z.+Suauthor=W.+Jiaauthor=M.+Qinauthor=M.+Huangauthor=W.+Wuauthor=R.+Suguroauthor=X.+Liuauthor=Y.+Zhu&title=HDAC4+Regulates+Vascular+Inflammation+via+Activation+of+Autophagy&doi=10.1093%2Fcvr%2Fcvy051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC4 regulates vascular inflammation via activation of autophagy</span></div><div class="casAuthors">Yang, Di; Xiao, ChenXi; Long, Fen; Su, ZhengHua; Jia, WanWan; Qin, Ming; Huang, MengWei; Wu, WeiJun; Suguro, Rinkiko; Liu, XinHua; Zhu, YiZhun</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1016-1028</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">1755-3245</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Angiotensin II (Ang II) causes vascular inflammation, leading to vascular endothelial cell dysfunction, and is assocd. with the development of cardiovascular diseases.  Therefore, interventions in inflammation may contribute to the redn. of cardiovascular diseases.  Here, we aim to demonstrate that HDAC4, one of class IIa family histone de-acetylases (HDACs) members, promotes autophagy-dependent vascular inflammation.  Methods and results: By loss-of-function approaches, our study provides the first evidence that HDAC4 mediates Ang II-induced vascular inflammation in vitro and in vivo.  In response to the Ang II, HDAC4 expression is up-regulated rapidly, with increased autophagic flux and inflammatory mediators in vascular endothelial cells (VECs).  In turn, HDAC4 deficiency suppresses activation of autophagy, leading to reduced inflammation in Ang II-induced VECs.  Consistently, using autophagy inhibitor or silencing LC3-II also alleviates vascular inflammation.  Furthermore, HDAC4 regulates autophagy via facilitating transcription factor forkhead box O3a (FoxO3a) de-acetylation, thereby to increase its transcriptional activity.  Loss of HDAC4 in VECs results in inhibition of FoxO3a de-acetylation to block its transcriptional activity, leading to downregulation of the downstream FoxO3a target, and hence reduces autophagy and vascular inflammation.  FoxO3a silencing using siRNA approach significantly inhibits activation of autophagy.  Finally, knockdown of HDAC4 in Ang II-infused mouse models ameliorates vascular inflammation, suggesting that inhibitor of HDAC4 may be potential therapeutics for vascular diseases assocd. with inflammation.  Conclusions: These results suggest that HDAC4-mediated FoxO3a acetylation regulates Ang II-induced autophagy activation, which in turn plays an essential role in causing vascular inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJamMJuSWVDLVg90H21EOLACvtfcHk0lioZGeIcQSihA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlslSjtr8%253D&md5=40497be6174507e76e7dc47669f2c322</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvy051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvy051%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DC.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DJia%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DSuguro%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DHDAC4%2520Regulates%2520Vascular%2520Inflammation%2520via%2520Activation%2520of%2520Autophagy%26jtitle%3DCardiovasc.%2520Res.%26date%3D2018%26volume%3D114%26spage%3D1016%26epage%3D1028%26doi%3D10.1093%2Fcvr%2Fcvy051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1725470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F13543776.2020.1725470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32008402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=263-274&author=C.+Zhaoauthor=H.+Dongauthor=Q.+Xuauthor=Y.+Zhang&title=Histone+Deacetylase+%28HDAC%29+Inhibitors+in+Cancer%3A+A+Patent+Review+%282017-Present%29&doi=10.1080%2F13543776.2020.1725470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)</span></div><div class="casAuthors">Zhao, Chunlong; Dong, Hang; Xu, Qifu; Zhang, Yingjie</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors play a crucial role in restoring the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, which are applied to treat several diseases including cancer.  This review covers recent efforts in the synthesis and applications of inhibitors and hybrid inhibitors targeting HDAC from 2017 to 2019.  HDACs are important epigenetic targets and HDAC inhibitors have become important biol. active compds. for the treatment of cancers.  Among the recent patents available, most of them place emphasis on HDAC selective inhibitors and multitarget HDAC inhibitors.  Although great accomplishments have been achieved in developing HDAC selective inhibitors, there is still an urgent need for discovery of novel HDAC inhibitors with new zinc-binding groups avoiding the unfavorable pharmacokinetics profiles of hydroxamic acid.  Apart from cancer therapy, HDAC inhibitors have recently been considered as a new strategy in treating other human diseases, such as alc. use disorder (AUD), neurol. disorders, age-related diseases, and so forth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdA-S5sLkahbVg90H21EOLACvtfcHk0lioZGeIcQSihA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1CitbY%253D&md5=8c3d1f76892b3d33fb6b41d22d561e96</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%2520in%2520Cancer%253A%2520A%2520Patent%2520Review%2520%25282017-Present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D263%26epage%3D274%26doi%3D10.1080%2F13543776.2020.1725470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tekwani, B. L.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">537</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffphar.2020.00537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32390854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFKkurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=537&author=S.+Shuklaauthor=B.+L.+Tekwani&title=Histone+Deacetylases+Inhibitors+in+Neurodegenerative+Diseases%2C+Neuroprotection+and+Neuronal+Differentiation&doi=10.3389%2Ffphar.2020.00537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases inhibitors in neurodegenerative diseases,neuroprotection and neuronal differentiation</span></div><div class="casAuthors">Shukla, Surabhi; Tekwani, Babu L.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">537</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Histone deacetylases (HADC) are the enzymes that remove acetyl group from lysine residue of histones and non-histone proteins and regulate the process of transcription by binding to transcription factors and regulating fundamental cellular process such as cellular proliferation, differentiation and development.  In neurodegenerative diseases, the histone acetylation homeostasis is greatly impaired, shifting towards a state of hypoacetylation.  The histone hyperacetylation produced by direct inhibition of HDACs leads to neuroprotective actions.  This review attempts to elaborate on role of small mol. inhibitors of HDACs on neuronal differentiation and throws light on the potential of HDAC inhibitors as therapeutic agents for treatment of neurodegenerative diseases.  The role of HDACs in neuronal cellular and disease models and their modulation with HDAC inhibitors are also discussed.  Significance of these HDAC inhibitors has been reviewed on the process of neuronal differentiation, neurite outgrowth and neuroprotection regarding their potential therapeutic application for treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSm-R2zDO-HLVg90H21EOLACvtfcHk0lgTlFqsu8Nlhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFKkurnI&md5=c5b86039e4458e70c2e481b9133d46d2</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00537%26sid%3Dliteratum%253Aachs%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26atitle%3DHistone%2520Deacetylases%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%252C%2520Neuroprotection%2520and%2520Neuronal%2520Differentiation%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D537%26doi%3D10.3389%2Ffphar.2020.00537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zwinderman, M. R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Weerd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span> <span> </span><span class="NLM_article-title">Targeting HDAC Complexes in Asthma and COPD</span>. <i>Epigenomes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.3390/epigenomes3030019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fepigenomes3030019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFyr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=19&author=M.+R.+H.+Zwindermanauthor=S.+de+Weerdauthor=F.+J.+Dekker&title=Targeting+HDAC+Complexes+in+Asthma+and+COPD&doi=10.3390%2Fepigenomes3030019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HDAC complexes in asthma and COPD</span></div><div class="casAuthors">Zwinderman, Martijn R. H.; de Weerd, Sander; Dekker, Frank J.</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">19</span>CODEN:
                <span class="NLM_cas:coden">EPIGD8</span>;
        ISSN:<span class="NLM_cas:issn">2075-4655</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Around three million patients die due to airway inflammatory diseases each year.  The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD).  Therefore, new therapies are urgently needed.  Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation.  Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD.  The diverse set of selective and non-selective HDAC inhibitors used in pre-clin. models of airway inflammation show promising results, but several challenges still need to be overcome.  One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes.  Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWjwu9X9DD_LVg90H21EOLACvtfcHk0lgTlFqsu8Nlhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFyr&md5=797188345106298228cf9cd061721ff3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3390%2Fepigenomes3030019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fepigenomes3030019%26sid%3Dliteratum%253Aachs%26aulast%3DZwinderman%26aufirst%3DM.%2BR.%2BH.%26aulast%3Dde%2BWeerd%26aufirst%3DS.%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26atitle%3DTargeting%2520HDAC%2520Complexes%2520in%2520Asthma%2520and%2520COPD%26jtitle%3DEpigenomes%26date%3D2019%26volume%3D3%26spage%3D19%26doi%3D10.3390%2Fepigenomes3030019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiser, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Function in CD4+ T Cells</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">617</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1038/s41577-018-0037-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41577-018-0037-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30022149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlClsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=617-634&author=W.+Ellmeierauthor=C.+Seiser&title=Histone+Deacetylase+Function+in+CD4%2B+T+Cells&doi=10.1038%2Fs41577-018-0037-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase function in CD4+ T cells</span></div><div class="casAuthors">Ellmeier, Wilfried; Seiser, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">617-634</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The differentiation of T helper cell subsets and their acquisition of effector functions are accompanied by changes in gene expression programs, which in part are regulated and maintained by epigenetic processes.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are key epigenetic regulators that function by mediating dynamic changes in the acetylation of histones at lysine residues.  In addn., many non-histone proteins are also acetylated, and reversible acetylation affects their functional properties, demonstrating that HDACs mediate effects beyond the epigenetic regulation of gene expression.  In this review, we discuss studies revealing that HDACs are key regulators of CD4+ T cell-mediated immunity in mice and humans and that HDACs are promising targets in T cell-mediated immune diseases.  Finally, we discuss unanswered questions and future research directions to promote the concept that isoform-selective HDAC inhibitors might broaden the clin. application of HDAC inhibitors beyond their current use in certain types of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg8hA-jOikkLVg90H21EOLACvtfcHk0lgTlFqsu8Nlhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlClsLvI&md5=bf25f2055c9eebefb78a63b1d8b6f382</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Fs41577-018-0037-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-018-0037-z%26sid%3Dliteratum%253Aachs%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DSeiser%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%2520Function%2520in%2520CD4%252B%2520T%2520Cells%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D617%26epage%3D634%26doi%3D10.1038%2Fs41577-018-0037-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijhawan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khullar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandhwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, A.</span></span> <span> </span><span class="NLM_article-title">HDAC in Obesity: A Critical Insight</span>. <i>Obesity Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">100212</span>, <span class="refDoi"> DOI: 10.1016/j.obmed.2020.100212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.obmed.2020.100212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2020&pages=100212&author=P.+Nijhawanauthor=T.+Behlauthor=G.+Khullarauthor=G.+Palauthor=M.+Kandhwalauthor=A.+Goyal&title=HDAC+in+Obesity%3A+A+Critical+Insight&doi=10.1016%2Fj.obmed.2020.100212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.obmed.2020.100212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.obmed.2020.100212%26sid%3Dliteratum%253Aachs%26aulast%3DNijhawan%26aufirst%3DP.%26aulast%3DBehl%26aufirst%3DT.%26aulast%3DKhullar%26aufirst%3DG.%26aulast%3DPal%26aufirst%3DG.%26aulast%3DKandhwal%26aufirst%3DM.%26aulast%3DGoyal%26aufirst%3DA.%26atitle%3DHDAC%2520in%2520Obesity%253A%2520A%2520Critical%2520Insight%26jtitle%3DObesity%2520Med.%26date%3D2020%26volume%3D18%26spage%3D100212%26doi%3D10.1016%2Fj.obmed.2020.100212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, Y. Y.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors as Antifibrotic Drugs in Cardiac and Pulmonary Fibrosis</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2040622319862697</span>, <span class="refDoi"> DOI: 10.1177/2040622319862697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1177%2F2040622319862697" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2040622319862697&author=X.+Lyuauthor=M.+Huauthor=J.+Pengauthor=X.+Zhangauthor=Y.+Y.+Sanders&title=HDAC+Inhibitors+as+Antifibrotic+Drugs+in+Cardiac+and+Pulmonary+Fibrosis&doi=10.1177%2F2040622319862697"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1177%2F2040622319862697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622319862697%26sid%3Dliteratum%253Aachs%26aulast%3DLyu%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSanders%26aufirst%3DY.%2BY.%26atitle%3DHDAC%2520Inhibitors%2520as%2520Antifibrotic%2520Drugs%2520in%2520Cardiac%2520and%2520Pulmonary%2520Fibrosis%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2019%26volume%3D10%26spage%3D2040622319862697%26doi%3D10.1177%2F2040622319862697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozdarska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeanblanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naassila, M.</span></span> <span> </span><span class="NLM_article-title">Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1766</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00115</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00115" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1OmsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1745-1766&author=E.+Bourguetauthor=K.+Ozdarskaauthor=G.+Moroyauthor=J.+Jeanblancauthor=M.+Naassila&title=Class+I+HDAC+Inhibitors%3A+Potential+New+Epigenetic+Therapeutics+for+Alcohol+Use+Disorder+%28AUD%29&doi=10.1021%2Facs.jmedchem.7b00115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)</span></div><div class="casAuthors">Bourguet, Erika; Ozdarska, Katarzyna; Moroy, Gautier; Jeanblanc, Jerome; Naassila, Mickael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1745-1766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alc. use disorder (AUD) represents a serious public health issue, and discovery of new therapies is a pressing necessity.  Alc. exposure has been widely demonstrated to modulate epigenetic mechanisms, such as histone acetylation/deacetylation balance, in part via histone deacetylase (HDAC) inhibition.  Epigenetic factors have been suggested to play a key role in AUD.  To date, 18 different mammalian HDAC isoforms have been identified, and these have been divided into four classes.  Since recent studies have suggested that both epigenetic mechanisms underlying AUD and the efficacy of HDAC inhibitors (HDACIs) in different animal models of AUD may involve class I HDACs, the authors herein report the development of class I HDACIs, including information regarding their structure, potency, and selectivity.  More effort is required to improve the selectivity, pharmacokinetics, and toxicity profiles of HDACIs to achieve a better understanding of their efficacy in reducing addictive behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SpmCx2VAE7Vg90H21EOLACvtfcHk0liR2SgRxnoRUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1OmsbzE&md5=3d92f98a349cbdfcd4fa148e586a3044</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00115%26sid%3Dliteratum%253Aachs%26aulast%3DBourguet%26aufirst%3DE.%26aulast%3DOzdarska%26aufirst%3DK.%26aulast%3DMoroy%26aufirst%3DG.%26aulast%3DJeanblanc%26aufirst%3DJ.%26aulast%3DNaassila%26aufirst%3DM.%26atitle%3DClass%2520I%2520HDAC%2520Inhibitors%253A%2520Potential%2520New%2520Epigenetic%2520Therapeutics%2520for%2520Alcohol%2520Use%2520Disorder%2520%2528AUD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1745%26epage%3D1766%26doi%3D10.1021%2Facs.jmedchem.7b00115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Close, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamill, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenific, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagarajan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span> <span> </span><span class="NLM_article-title">Exploration of the Internal Cavity of Histone Deacetylase (HDAC) with Selective HDAC1/HDAC2 Inhibitors (SHI-1:2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">978</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2007.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18182289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=973-978&author=J.+L.+Methotauthor=P.+K.+Chakravartyauthor=M.+Chenardauthor=J.+Closeauthor=J.+C.+Cruzauthor=W.+K.+Dahlbergauthor=J.+Flemingauthor=C.+L.+Hamblettauthor=J.+E.+Hamillauthor=P.+Harringtonauthor=A.+Harschauthor=R.+Heidebrechtauthor=B.+Hughesauthor=J.+Jungauthor=C.+M.+Kenificauthor=A.+M.+Kralauthor=P.+T.+Meinkeauthor=R.+E.+Middletonauthor=N.+Ozerovaauthor=D.+L.+Slomanauthor=M.+G.+Stantonauthor=A.+A.+Szewczakauthor=S.+Tyagarajanauthor=D.+J.+Witterauthor=J.+P.+Secristauthor=T.+A.+Miller&title=Exploration+of+the+Internal+Cavity+of+Histone+Deacetylase+%28HDAC%29+with+Selective+HDAC1%2FHDAC2+Inhibitors+%28SHI-1%3A2%29&doi=10.1016%2Fj.bmcl.2007.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2)</span></div><div class="casAuthors">Methot, Joey L.; Chakravarty, Prasun K.; Chenard, Melissa; Close, Joshua; Cruz, Jonathan C.; Dahlberg, William K.; Fleming, Judith; Hamblett, Christopher L.; Hamill, Julie E.; Harrington, Paul; Harsch, Andreas; Heidebrecht, Richard; Hughes, Bethany; Jung, Joon; Kenific, Candia M.; Kral, Astrid M.; Meinke, Peter T.; Middleton, Richard E.; Ozerova, Nicole; Sloman, David L.; Stanton, Matthew G.; Szewczak, Alexander A.; Tyagarajan, Sriram; Witter, David J.; Secrist, J. Paul; Miller, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">973-978</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The authors report herein the initial exploration of novel selective HDAC1/HDAC2 inhibitors (SHI-1:2).  Optimized SHI-1:2 structures exhibit enhanced intrinsic activity against HDAC1 and HDAC2, and are greater than 100-fold selective vs. other HDACs, including HDAC3.  Based on the SAR of these agents and the current understanding of the HDAC active site, the authors postulate that the SHI-1:2 extend the existing HDAC inhibitor pharmacophore to include an internal binding domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpOxv4RIybcrVg90H21EOLACvtfcHk0liR2SgRxnoRUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWktbw%253D&md5=7796d5e1f54e3f5106bedea1f0e47f5a</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DChakravarty%26aufirst%3DP.%2BK.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DClose%26aufirst%3DJ.%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DFleming%26aufirst%3DJ.%26aulast%3DHamblett%26aufirst%3DC.%2BL.%26aulast%3DHamill%26aufirst%3DJ.%2BE.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DHeidebrecht%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKenific%26aufirst%3DC.%2BM.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DOzerova%26aufirst%3DN.%26aulast%3DSloman%26aufirst%3DD.%2BL.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DTyagarajan%26aufirst%3DS.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26atitle%3DExploration%2520of%2520the%2520Internal%2520Cavity%2520of%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520with%2520Selective%2520HDAC1%252FHDAC2%2520Inhibitors%2520%2528SHI-1%253A2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D973%26epage%3D978%26doi%3D10.1016%2Fj.bmcl.2007.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Methot, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidebrecht, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kral, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenific, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. A.</span></span> <span> </span><span class="NLM_article-title">Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/ml4004233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4004233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=340-345&author=J.+L.+Methotauthor=D.+M.+Hoffmanauthor=D.+J.+Witterauthor=M.+G.+Stantonauthor=P.+Harringtonauthor=C.+Hamblettauthor=P.+Siliphaivanhauthor=K.+Wilsonauthor=J.+Hubbsauthor=R.+Heidebrechtauthor=A.+M.+Kralauthor=N.+Ozerovaauthor=J.+C.+Flemingauthor=H.+Wangauthor=A.+A.+Szewczakauthor=R.+E.+Middletonauthor=B.+Hughesauthor=J.+C.+Cruzauthor=B.+B.+Hainesauthor=M.+Chenardauthor=C.+M.+Kenificauthor=A.+Harschauthor=J.+P.+Secristauthor=T.+A.+Miller&title=Delayed+and+Prolonged+Histone+Hyperacetylation+with+a+Selective+HDAC1%2FHDAC2+Inhibitor&doi=10.1021%2Fml4004233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor</span></div><div class="casAuthors">Methot, Joey L.; Hoffman, Dawn Mampreian; Witter, David J.; Stanton, Matthew G.; Harrington, Paul; Hamblett, Christopher; Siliphaivanh, Phieng; Wilson, Kevin; Hubbs, Jed; Heidebrecht, Richard; Kral, Astrid M.; Ozerova, Nicole; Fleming, Judith C.; Wang, Hongmei; Szewczak, Alexander A.; Middleton, Richard E.; Hughes, Bethany; Cruz, Jonathan C.; Haines, Brian B.; Chenard, Melissa; Kenific, Candia M.; Harsch, Andreas; Secrist, J. Paul; Miller, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described.  Kinetic anal. indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 prepns.  Delayed histone hyperacetylation and gene expression changes were also obsd. in cell culture, and histone acetylation was obsd. in vivo beyond disappearance of drug from plasma.  In vivo studies further demonstrated that continuous target inhibition was well tolerated and efficacious in tumor-bearing mice, leading to tumor growth inhibition with either once-daily or intermittent administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9WsDyqz8g8rVg90H21EOLACvtfcHk0ljU_rucfJ6hCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKntw%253D%253D&md5=6cc13071d384ad39cfe3aa7ed4327b0e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fml4004233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4004233%26sid%3Dliteratum%253Aachs%26aulast%3DMethot%26aufirst%3DJ.%2BL.%26aulast%3DHoffman%26aufirst%3DD.%2BM.%26aulast%3DWitter%26aufirst%3DD.%2BJ.%26aulast%3DStanton%26aufirst%3DM.%2BG.%26aulast%3DHarrington%26aufirst%3DP.%26aulast%3DHamblett%26aufirst%3DC.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DK.%26aulast%3DHubbs%26aufirst%3DJ.%26aulast%3DHeidebrecht%26aufirst%3DR.%26aulast%3DKral%26aufirst%3DA.%2BM.%26aulast%3DOzerova%26aufirst%3DN.%26aulast%3DFleming%26aufirst%3DJ.%2BC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DMiddleton%26aufirst%3DR.%2BE.%26aulast%3DHughes%26aufirst%3DB.%26aulast%3DCruz%26aufirst%3DJ.%2BC.%26aulast%3DHaines%26aufirst%3DB.%2BB.%26aulast%3DChenard%26aufirst%3DM.%26aulast%3DKenific%26aufirst%3DC.%2BM.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DSecrist%26aufirst%3DJ.%2BP.%26aulast%3DMiller%26aufirst%3DT.%2BA.%26atitle%3DDelayed%2520and%2520Prolonged%2520Histone%2520Hyperacetylation%2520with%2520a%2520Selective%2520HDAC1%252FHDAC2%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Fml4004233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stubbs, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bariteau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vempati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minehart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivtsov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2348</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F1078-0432.CCR-14-1290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25688158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXoslOkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2348-2358&author=M.+C.+Stubbsauthor=W.+Kimauthor=M.+Bariteauauthor=T.+Davisauthor=S.+Vempatiauthor=J.+Minehartauthor=M.+Witkinauthor=J.+Qiauthor=A.+V.+Krivtsovauthor=J.+E.+Bradnerauthor=A.+L.+Kungauthor=S.+A.+Armstrong&title=Selective+Inhibition+of+HDAC1+and+HDAC2+as+a+Potential+Therapeutic+Option+for+B-ALL&doi=10.1158%2F1078-0432.CCR-14-1290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL</span></div><div class="casAuthors">Stubbs, Matthew C.; Kim, Wonil; Bariteau, Megan; Davis, Tina; Vempati, Sridhar; Minehart, Janna; Witkin, Matthew; Qi, Jun; Krivtsov, Andrei V.; Bradner, James E.; Kung, Andrew L.; Armstrong, Scott A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2348-2358</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematol. malignancies.  One such hematol. malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia development and maintenance, and thus sensitive to small-mol. inhibitors that target epigenetic mechanisms.  Exptl. Design: A panel of B-ALL cell lines was tested for sensitivity to HDACi with varying isoform sensitivity.  Isoform-specific shRNAs were used as further validation of HDACs as relevant therapeutic targets in B-ALL.  Mouse xenografts of B-cell malignancy-derived cell lines and a pediatric B-ALL were used to demonstrate pharmacol. efficacy.  Results: Nonselective HDAC inhibitors were cytotoxic to a panel of B-ALL cell lines as well as to xenografted human leukemia patient samples.  Assessment of isoform-specific HDACi indicated that targeting HDAC1-3 with class I HDAC-specific inhibitors was sufficient to inhibit growth of B-ALL cell lines.  Furthermore, shRNA-mediated knockdown of HDAC1 or HDAC2 resulted in growth inhibition in these cells.  We then assessed a compd. that specifically inhibits only HDAC1 and HDAC2.  This compd. suppressed growth and induced apoptosis in B-ALL cell lines in vitro and in vivo, whereas it was far less effective against other B-cell-derived malignancies.  Conclusions: Here, we show that HDAC inhibitors are a potential therapeutic option for B-ALL, and that a more specific inhibitor of HDAC1 and HDAC2 could be therapeutically useful for patients with B-ALL.  Clin Cancer Res; 21(10); 2348-58. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod1Nglu1KSXbVg90H21EOLACvtfcHk0ljU_rucfJ6hCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXoslOkuro%253D&md5=0f75e4cd1aa5e23856aa4fadbe6342e6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1290%26sid%3Dliteratum%253Aachs%26aulast%3DStubbs%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DBariteau%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DT.%26aulast%3DVempati%26aufirst%3DS.%26aulast%3DMinehart%26aufirst%3DJ.%26aulast%3DWitkin%26aufirst%3DM.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DKrivtsov%26aufirst%3DA.%2BV.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26atitle%3DSelective%2520Inhibition%2520of%2520HDAC1%2520and%2520HDAC2%2520as%2520a%2520Potential%2520Therapeutic%2520Option%2520for%2520B-ALL%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2348%26epage%3D2358%26doi%3D10.1158%2F1078-0432.CCR-14-1290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shearstone, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0169128</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0169128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.pone.0169128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28060870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvVegsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0169128&author=C.+Minauthor=N.+Mooreauthor=J.+R.+Shearstoneauthor=S.+N.+Quayleauthor=P.+Huangauthor=J.+H.+van+Duzerauthor=M.+B.+Jarpeauthor=S.+S.+Jonesauthor=M.+Yang&title=Selective+Inhibitors+of+Histone+Deacetylases+1+and+2+Synergize+with+Azacitidine+in+Acute+Myeloid+Leukemia&doi=10.1371%2Fjournal.pone.0169128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia</span></div><div class="casAuthors">Min, Chengyin; Moore, Nathan; Shearstone, Jeffrey R.; Quayle, Steven N.; Huang, Pengyu; van Duzer, John H.; Jarpe, Matthew B.; Jones, Simon S.; Yang, Min</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0169128/1-e0169128/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells.  Outcomes for patients with AML remain poor, highlighting the need for novel treatment options.  Aberrant epigenetic regulation plays an important role in the pathogenesis of AML, and inhibitors of DNA methyltransferase or histone deacetylase (HDAC) enzymes have exhibited activity in preclin. AML models.  Combination studies with HDAC inhibitors plus DNA methyltransferase inhibitors have potential beneficial clin. activity in AML, however the toxicity profiles of non-selective HDAC inhibitors in the combination setting limit their clin. utility.  In this work, we describe the preclin. development of selective inhibitors of HDAC1 and HDAC2, which are hypothesized to have improved safety profiles, for combination therapy in AML.  We demonstrate that selective inhibition of HDAC1 and HDAC2 is sufficient to achieve efficacy both as a single agent and in combination with azacitidine in preclin. models of AML, including established AML cell lines, primary leukemia cells from AML patient bone marrow samples and in vivo xenograft models of human AML.  Gene expression profiling of AML cells treated with either an HDAC1/2 inhibitor, azacitidine, or the combination of both have identified a list of genes involved in transcription and cell cycle regulation as potential mediators of the combinatorial effects of HDAC1/2 inhibition with azacitidine.  Together, these findings support the clin. evaluation of selective HDAC1/2 inhibitors in combination with azacitidine in AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkinwKH8HeabVg90H21EOLACvtfcHk0ljU_rucfJ6hCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvVegsbw%253D&md5=1f549b8d377869735e758ba914749eab</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0169128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0169128%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DC.%26aulast%3DMoore%26aufirst%3DN.%26aulast%3DShearstone%26aufirst%3DJ.%2BR.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DJarpe%26aufirst%3DM.%2BB.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DM.%26atitle%3DSelective%2520Inhibitors%2520of%2520Histone%2520Deacetylases%25201%2520and%25202%2520Synergize%2520with%2520Azacitidine%2520in%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0169128%26doi%3D10.1371%2Fjournal.pone.0169128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Proteolysis Targeting Chimeras (PROTACs) for Epigenetics Research</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2020.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.cbpa.2020.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32146413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2020&pages=8-16&author=A.+Vogelmannauthor=D.+Robaaauthor=W.+Sipplauthor=M.+Jung&title=Proteolysis+Targeting+Chimeras+%28PROTACs%29+for+Epigenetics+Research&doi=10.1016%2Fj.cbpa.2020.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis targeting chimeras (PROTACs) for epigenetics research</span></div><div class="casAuthors">Vogelmann, Anja; Robaa, Dina; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8-16</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Proteolysis targeting chimeras (PROTACs) are heterobifunctional mols. and allow selective protein degrdn. by addressing the natural ubiquitin proteasome system.  As this new strategy of chem. induced protein degrdn. can serve as a biol. tool and provides new possibilities for drug discovery, it has been applied to a variety of targets including (nuclear) receptors, kinases, and epigenetic proteins.  A lot of PROTACs have already been designed in the field of epigenetics, and their synthesis and characterization highly contributed to structural optimization and improved mechanistic understanding of these mols.  In this review, we will discuss and summarize recent advances in PROTAC discovery with focus on epigenetic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW2o_9L2Y8GbVg90H21EOLACvtfcHk0lgHo722AkFE0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeitrw%253D&md5=6a4f3b70d6c6a446c744b9788b7582cf</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2020.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2020.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmann%26aufirst%3DA.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DProteolysis%2520Targeting%2520Chimeras%2520%2528PROTACs%2529%2520for%2520Epigenetics%2520Research%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2020%26volume%3D57%26spage%3D8%26epage%3D16%26doi%3D10.1016%2Fj.cbpa.2020.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwabe, J. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgkinson, J. T.</span></span> <span> </span><span class="NLM_article-title">PROTAC-Mediated Degradation of Class I Histone Deacetylase Enzymes in Corepressor Complexes</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4479</span>, <span class="refDoi"> DOI: 10.1039/D0CC01485K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1039%2FD0CC01485K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32201871" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXks1Ojtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=4476-4479&author=J.+P.+Smalleyauthor=G.+E.+Adamsauthor=C.+J.+Millardauthor=Y.+Songauthor=J.+K.+S.+Norrisauthor=J.+W.+R.+Schwabeauthor=S.+M.+Cowleyauthor=J.+T.+Hodgkinson&title=PROTAC-Mediated+Degradation+of+Class+I+Histone+Deacetylase+Enzymes+in+Corepressor+Complexes&doi=10.1039%2FD0CC01485K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes</span></div><div class="casAuthors">Smalley, Joshua P.; Adams, Grace E.; Millard, Christopher J.; Song, Yun; Norris, James K. S.; Schwabe, John W. R.; Cowley, Shaun Michael; Hodgkinson, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">4476-4479</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We have identified a proteolysis targeting chimera (PROTAC) of class I HDACs 1, 2 and 3.  The most active degrader consists of a benzamide HDAC inhibitor, an alkyl linker, and the von Hippel-Lindau E3 ligand.  Our PROTAC increased histone acetylation levels and compromised colon cancer HCT116 cell viability, establishing a degrdn. strategy as an alternative to class I HDAC inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGPSST5ixb4LVg90H21EOLACvtfcHk0lgHo722AkFE0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXks1Ojtbs%253D&md5=0da062ae0370678dcf46c882dedbc8d5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1039%2FD0CC01485K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0CC01485K%26sid%3Dliteratum%253Aachs%26aulast%3DSmalley%26aufirst%3DJ.%2BP.%26aulast%3DAdams%26aufirst%3DG.%2BE.%26aulast%3DMillard%26aufirst%3DC.%2BJ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BK.%2BS.%26aulast%3DSchwabe%26aufirst%3DJ.%2BW.%2BR.%26aulast%3DCowley%26aufirst%3DS.%2BM.%26aulast%3DHodgkinson%26aufirst%3DJ.%2BT.%26atitle%3DPROTAC-Mediated%2520Degradation%2520of%2520Class%2520I%2520Histone%2520Deacetylase%2520Enzymes%2520in%2520Corepressor%2520Complexes%26jtitle%3DChem.%2520Commun.%26date%3D2020%26volume%3D56%26spage%3D4476%26epage%3D4479%26doi%3D10.1039%2FD0CC01485K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.-H.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases in Memory and Cognition</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">re12</span>, <span class="refDoi"> DOI: 10.1126/scisignal.aaa0069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1126%2Fscisignal.aaa0069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25492968" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=re12&author=J.+Penneyauthor=L.-H.+Tsai&title=Histone+Deacetylases+in+Memory+and+Cognition&doi=10.1126%2Fscisignal.aaa0069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaa0069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaa0069%26sid%3Dliteratum%253Aachs%26aulast%3DPenney%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DHistone%2520Deacetylases%2520in%2520Memory%2520and%2520Cognition%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dre12%26doi%3D10.1126%2Fscisignal.aaa0069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmc.2016.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27377864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4008-4015&author=F.+F.+Wagnerauthor=M.+We%C3%AFwerauthor=S.+Steinbacherauthor=A.+Schomburgauthor=P.+Reinemerauthor=J.+P.+Galeauthor=A.+J.+Campbellauthor=S.+L.+Fisherauthor=W.-N.+Zhaoauthor=S.+A.+Reisauthor=K.+M.+Hennigauthor=M.+Thomasauthor=P.+M%C3%BCllerauthor=M.+R.+Jefsonauthor=D.+M.+Fassauthor=S.+J.+Haggartyauthor=Y.-L.+Zhangauthor=E.+B.+Holson&title=Kinetic+and+Structural+Insights+into+the+Binding+of+Histone+Deacetylase+1+and+2+%28HDAC1%2C+2%29+Inhibitors&doi=10.1016%2Fj.bmc.2016.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors</span></div><div class="casAuthors">Wagner, Florence F.; Weiwer, Michel; Steinbacher, Stefan; Schomburg, Adrian; Reinemer, Peter; Gale, Jennifer P.; Campbell, Arthur J.; Fisher, Stewart L.; Zhao, Wen-Ning; Reis, Surya A.; Hennig, Krista M.; Thomas, Meryl; Muller, Peter; Jefson, Martin R.; Fass, Daniel M.; Haggarty, Stephen J.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4008-4015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described.  Different kinetic and thermodn. selectivity profiles were obtained by varying the moiety occupying an 11 Å channel leading to the Zn2+ catalytic pocket of HDACs 1 and 2, two paralogs with a high degree of structural similarity.  The design of these novel inhibitors was informed by two ligand-bound crystal structures of truncated hHDAC2.  BRD4884 and BRD7232 possess kinetic selectivity for HDAC1 vs. HDAC2.  We demonstrate that the binding kinetics of HDAC inhibitors can be tuned for individual isoforms in order to modulate target residence time while retaining functional activity and increased histone H4K12 and H3K9 acetylation in primary mouse neuronal cell culture assays.  These chromatin modifiers, with tuned binding kinetic profiles, can be used to define the relation between target engagement requirements and the pharmacodynamic response of HDACs in different disease applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQpWplRRVod7Vg90H21EOLACvtfcHk0lgHo722AkFE0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E&md5=bcbe1addb5d30073f345fd77d529dcd4</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSchomburg%26aufirst%3DA.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DReis%26aufirst%3DS.%2BA.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DJefson%26aufirst%3DM.%2BR.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DKinetic%2520and%2520Structural%2520Insights%2520into%2520the%2520Binding%2520of%2520Histone%2520Deacetylase%25201%2520and%25202%2520%2528HDAC1%252C%25202%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4008%26epage%3D4015%26doi%3D10.1016%2Fj.bmc.2016.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 3 (HDAC3) Inhibitors as Anticancer Agents: A Review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112171</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2020.112171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32163814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvVeisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112171&author=R.+Sarkarauthor=S.+Banerjeeauthor=S.+A.+Aminauthor=N.+Adhikariauthor=T.+Jha&title=Histone+Deacetylase+3+%28HDAC3%29+Inhibitors+as+Anticancer+Agents%3A+A+Review&doi=10.1016%2Fj.ejmech.2020.112171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review</span></div><div class="casAuthors">Sarkar, Rajat; Banerjee, Suvankar; Amin, Sk Abdul; Adhikari, Nilanjan; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112171</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers.  HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory diseases, rheumatoid arthritis (RA), etc.  Inhibition of HDAC3 metalloenzyme is a dynamic approach for drug design and discovery.  This approach has gained considerable interest in recent years.  The development of an effective therapeutic agent against HDAC3 is still challenging.  A lot of work is still in demand.  This current communication is a part of our extended work on HDAC3 inhibitors to achieve deep insight of knowledge about the structural information of HDAC3 inhibitors.  This article is unique in terms of detailed structure-activity relationships (SARs) anal.  This may help to find out some important clues to design better active HDAC3 inhibitors in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo0GLJbEUe9LVg90H21EOLACvtfcHk0ljrsG2WmYrL8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvVeisr0%253D&md5=d9911556755793d92c3e073b89b9b00e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112171%26sid%3Dliteratum%253Aachs%26aulast%3DSarkar%26aufirst%3DR.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DHistone%2520Deacetylase%25203%2520%2528HDAC3%2529%2520Inhibitors%2520as%2520Anticancer%2520Agents%253A%2520A%2520Review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112171%26doi%3D10.1016%2Fj.ejmech.2020.112171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chattopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpita, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrup-Poulsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=363-374&author=F.+F.+Wagnerauthor=M.+Lundhauthor=T.+Kayaauthor=P.+McCarrenauthor=Y.-L.+Zhangauthor=S.+Chattopadhyayauthor=J.+P.+Galeauthor=T.+Galboauthor=S.+L.+Fisherauthor=B.+C.+Meierauthor=A.+Vetereauthor=S.+Richardsonauthor=N.+G.+Morganauthor=D.+P.+Christensenauthor=T.+J.+Gilbertauthor=J.+M.+Hookerauthor=M.+Leroyauthor=D.+Walpitaauthor=T.+Mandrup-Poulsenauthor=B.+K.+Wagnerauthor=E.+B.+Holson&title=An+Isochemogenic+Set+of+Inhibitors+To+Define+the+Therapeutic+Potential+of+Histone+Deacetylases+in+%CE%B2-Cell+Protection&doi=10.1021%2Facschembio.5b00640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection</span></div><div class="casAuthors">Wagner, Florence F.; Lundh, Morten; Kaya, Taner; McCarren, Patrick; Zhang, Yan-Ling; Chattopadhyay, Shrikanta; Gale, Jennifer P.; Galbo, Thomas; Fisher, Stewart L.; Meier, Bennett C.; Vetere, Amedeo; Richardson, Sarah; Morgan, Noel G.; Christensen, Dan Ploug; Gilbert, Tamara J.; Hooker, Jacob M.; Leroy, Melanie; Walpita, Deepika; Mandrup-Poulsen, Thomas; Wagner, Bridget K.; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">363-374</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modulation of histone deacetylase (HDAC) activity has been implicated as a potential therapeutic strategy for multiple diseases.  However, it has been difficult to dissect the role of individual HDACs due to a lack of selective small-mol. inhibitors.  Here, we report the synthesis of a series of highly potent and isoform-selective class I HDAC inhibitors, rationally designed by exploiting minimal structural changes to the clin. experienced HDAC inhibitor CI-994.  We used this toolkit of isochemogenic or chem. matched inhibitors to probe the role of class I HDACs in β-cell pathobiol. and demonstrate for the first time that selective inhibition of an individual HDAC isoform retains beneficial biol. activity and mitigates mechanism-based toxicities.  The highly selective HDAC3 inhibitor BRD3308 suppressed pancreatic β-cell apoptosis induced by inflammatory cytokines, as expected, or now glucolipotoxic stress, and increased functional insulin release.  In addn., BRD3308 had no effect on human megakaryocyte differentiation, while inhibitors of HDAC1 and 2 were toxic.  Our findings demonstrate that the selective inhibition of HDAC3 represents a potential path forward as a therapy to protect pancreatic β-cells from inflammatory cytokines and nutrient overload in diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_12m-jRoObVg90H21EOLACvtfcHk0ljrsG2WmYrL8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCnsL4%253D&md5=0d57ffcfc229ec4efe3857882ff9113e</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00640%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DLundh%26aufirst%3DM.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DMcCarren%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.-L.%26aulast%3DChattopadhyay%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DGalbo%26aufirst%3DT.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DMeier%26aufirst%3DB.%2BC.%26aulast%3DVetere%26aufirst%3DA.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DMorgan%26aufirst%3DN.%2BG.%26aulast%3DChristensen%26aufirst%3DD.%2BP.%26aulast%3DGilbert%26aufirst%3DT.%2BJ.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DLeroy%26aufirst%3DM.%26aulast%3DWalpita%26aufirst%3DD.%26aulast%3DMandrup-Poulsen%26aufirst%3DT.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DAn%2520Isochemogenic%2520Set%2520of%2520Inhibitors%2520To%2520Define%2520the%2520Therapeutic%2520Potential%2520of%2520Histone%2520Deacetylases%2520in%2520%25CE%25B2-Cell%2520Protection%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D363%26epage%3D374%26doi%3D10.1021%2Facschembio.5b00640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresciani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ontoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biancofiore, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cellucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciammaichella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malancona, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossetti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veneziano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span> <span> </span><span class="NLM_article-title">Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00517</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00517" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlals7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=481-486&author=A.+Brescianiauthor=J.+M.+Ontoriaauthor=I.+Biancofioreauthor=A.+Cellucciauthor=A.+Ciammaichellaauthor=A.+Di+Marcoauthor=F.+Ferrignoauthor=A.+Franconeauthor=S.+Malanconaauthor=E.+Monteagudoauthor=E.+Niziauthor=P.+Paceauthor=S.+Ponziauthor=I.+Rossettiauthor=M.+Venezianoauthor=V.+Summaauthor=S.+Harper&title=Improved+Selective+Class+I+HDAC+and+Novel+Selective+HDAC3+Inhibitors%3A+Beyond+Hydroxamic+Acids+and+Benzamides&doi=10.1021%2Facsmedchemlett.8b00517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Improved selective class I HDAC and novel selective HDAC3 inhibitors: Beyond hydroxamic acids and benzamides</span></div><div class="casAuthors">Bresciani, Alberto; Ontoria, Jesus M.; Biancofiore, Ilaria; Cellucci, Antonella; Ciammaichella, Alina; Di Marco, Annalise; Ferrigno, Federica; Francone, Alessandra; Malancona, Savina; Monteagudo, Edith; Nizi, Emanuela; Pace, Paola; Ponzi, Simona; Rossetti, Ilaria; Veneziano, Maria; Summa, Vincenzo; Harper, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">481-486</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The application of class I HDAC inhibitors as cancer therapies is well established, but more recently their development for nononcol. indications has increased.  We report here on the generation of improved class I selective human HDAC inhibitors based on an ethylketone zinc binding group (ZBG) in place of the hydroxamic acid that features the majority of HDAC inhibitors.  We also describe a novel set of HDAC3 isoform selective inhibitors that show stronger potency and selectivity than the most commonly used HDAC3 selective tool compd. RGFP966.  These compds. are again based on an alternative ZBG with respect to the ortho-anilide that is featured in HDAC3 selective compds. reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIzwbKCL5A6bVg90H21EOLACvtfcHk0lhuscFOrJOOXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlals7jO&md5=2882346cee38482adab18732afde3470</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00517%26sid%3Dliteratum%253Aachs%26aulast%3DBresciani%26aufirst%3DA.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DBiancofiore%26aufirst%3DI.%26aulast%3DCellucci%26aufirst%3DA.%26aulast%3DCiammaichella%26aufirst%3DA.%26aulast%3DDi%2BMarco%26aufirst%3DA.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFrancone%26aufirst%3DA.%26aulast%3DMalancona%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DPace%26aufirst%3DP.%26aulast%3DPonzi%26aufirst%3DS.%26aulast%3DRossetti%26aufirst%3DI.%26aulast%3DVeneziano%26aufirst%3DM.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DHarper%26aufirst%3DS.%26atitle%3DImproved%2520Selective%2520Class%2520I%2520HDAC%2520and%2520Novel%2520Selective%2520HDAC3%2520Inhibitors%253A%2520Beyond%2520Hydroxamic%2520Acids%2520and%2520Benzamides%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D481%26epage%3D486%26doi%3D10.1021%2Facsmedchemlett.8b00517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malvaez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McQuown, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogge, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astarabadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">HDAC3-Selective Inhibitor Enhances Extinction of Cocaine-Seeking Behavior in a Persistent Manner</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2647</span>– <span class="NLM_lpage">2652</span>, <span class="refDoi"> DOI: 10.1073/pnas.1213364110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1073%2Fpnas.1213364110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23297220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2647-2652&author=M.+Malvaezauthor=S.+C.+McQuownauthor=G.+A.+Roggeauthor=M.+Astarabadiauthor=V.+Jacquesauthor=S.+Carreiroauthor=J.+R.+Ruscheauthor=M.+A.+Wood&title=HDAC3-Selective+Inhibitor+Enhances+Extinction+of+Cocaine-Seeking+Behavior+in+a+Persistent+Manner&doi=10.1073%2Fpnas.1213364110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner</span></div><div class="casAuthors">Malvaez, Melissa; McQuown, Susan C.; Rogge, George A.; Astarabadi, Mariam; Jacques, Vincent; Carreiro, Samantha; Rusche, James R.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2647-2652, S2647/1-S2647/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonspecific histone deacetylase (HDAC) inhibition has been shown to facilitate the extinction of drug-seeking behavior in a manner resistant to reinstatement.  A key open question is which specific HDAC is involved in the extinction of drug-seeking behavior.  Using the selective HDAC3 inhibitor RGFP966, we investigated the role of HDAC3 in extinction and found that systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement.  We also investigated whether the facilitated extinction is related to the enhancement of extinction consolidation during extinction learning or to neg. effects on performance or reconsolidation.  These are key distinctions with regard to any compd. being used to modulate extinction, because a more rapid decrease in a defined behavior is interpreted as facilitated extinction.  Using an innovative combination of behavioral paradigms, we found that a single treatment of RGFP966 enhances extinction of a previously established cocaine-conditioned place preference, while simultaneously enhancing long-term object-location memory within subjects.  During extinction consolidation, HDAC3 inhibition promotes a distinct pattern of histone acetylation linked to gene expression within the infralimbic cortex, hippocampus, and nucleus accumbens.  Thus, the facilitated extinction of drug-seeking cannot be explained by adverse effects on performance.  These results demonstrate that HDAC3 inhibition enhances the memory processes involved in extinction of drug-seeking behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZzdD0_EQYfrVg90H21EOLACvtfcHk0lhuscFOrJOOXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVCnsb4%253D&md5=37fd432cbf96bd2c30b7d5ac9eefcf45</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1213364110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1213364110%26sid%3Dliteratum%253Aachs%26aulast%3DMalvaez%26aufirst%3DM.%26aulast%3DMcQuown%26aufirst%3DS.%2BC.%26aulast%3DRogge%26aufirst%3DG.%2BA.%26aulast%3DAstarabadi%26aufirst%3DM.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DCarreiro%26aufirst%3DS.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHDAC3-Selective%2520Inhibitor%2520Enhances%2520Extinction%2520of%2520Cocaine-Seeking%2520Behavior%2520in%2520a%2520Persistent%2520Manner%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D2647%26epage%3D2652%26doi%3D10.1073%2Fpnas.1213364110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieszczad, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusche, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudugunti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberger, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaugh, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13124</span>– <span class="NLM_lpage">13132</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0914-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1523%2FJNEUROSCI.0914-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=26400942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=13124-13132&author=K.+M.+Bieszczadauthor=K.+Bechayauthor=J.+R.+Ruscheauthor=V.+Jacquesauthor=S.+Kuduguntiauthor=W.+Miaoauthor=N.+M.+Weinbergerauthor=J.+L.+McGaughauthor=M.+A.+Wood&title=Histone+Deacetylase+Inhibition+via+RGFP966+Releases+the+Brakes+on+Sensory+Cortical+Plasticity+and+the+Specificity+of+Memory+Formation&doi=10.1523%2FJNEUROSCI.0914-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibition via RGFP966 releases the brakes on sensory cortical plasticity and the specificity of memory formation</span></div><div class="casAuthors">Bieszczad, Kasia M.; Bechay, Kiro; Rusche, James R.; Jacques, Vincent; Kudugunti, Shashi; Miao, Wenyan; Weinberger, Norman M.; McGaugh, James L.; Wood, Marcelo A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">13124-13132</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Research over the past decade indicates a novel role for epigenetic mechanisms in memory formation.  Of particular interest is chromatin modification by histone deacetylases (HDACs), which, in general, neg. regulate transcription.  HDAC deletion or inhibition facilitates transcription during memory consolidation and enhances long-lasting forms of synaptic plasticity and long-term memory.  A key open question remains: How does blocking HDAC activity lead to memory enhancements.  To address this question, we tested whether a normal function of HDACs is to gate information processing during memory formation.  We used a class I HDAC inhibitor, RGFP966 (C21H19FN4O), to test the role of HDAC inhibition for information processing in an auditory memory model of learning-induced cortical plasticity.  HDAC inhibition may act beyond memory enhancement per se to instead regulate information in ways that lead to encoding more vivid sensory details into memory.  Indeed, we found that RGFP966 controls memory induction for acoustic details of sound-to-reward learning.  Rats treated with RGFP966 while learning to assoc. sound with reward had stronger memory and addnl. information encoded into memory for highly specific features of sounds assocd. with reward.  Moreover, behavioral effects occurred with unusually specific plasticity in primary auditory cortex (A1).  Class I HDAC inhibition appears to engage A1 plasticity that enables addnl. acoustic features to become encoded in memory.  Thus, epigenetic mechanisms act to regulate sensory cortical plasticity, which offers an information processing mechanism for gating what and how much is encoded to produce exceptionally persistent and vivid memories.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriop2-XG6WvLVg90H21EOLACvtfcHk0lhuscFOrJOOXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSqsbw%253D&md5=0e62a727995215ab22a3dd29003baffe</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0914-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0914-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DBieszczad%26aufirst%3DK.%2BM.%26aulast%3DBechay%26aufirst%3DK.%26aulast%3DRusche%26aufirst%3DJ.%2BR.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DKudugunti%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DW.%26aulast%3DWeinberger%26aufirst%3DN.%2BM.%26aulast%3DMcGaugh%26aufirst%3DJ.%2BL.%26aulast%3DWood%26aufirst%3DM.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibition%2520via%2520RGFP966%2520Releases%2520the%2520Brakes%2520on%2520Sensory%2520Cortical%2520Plasticity%2520and%2520the%2520Specificity%2520of%2520Memory%2520Formation%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D13124%26epage%3D13132%26doi%3D10.1523%2FJNEUROSCI.0914-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suelves, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkham-McCarthy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahue, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginés, S.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of Histone Deacetylase 3 Prevents Cognitive Deficits and Suppresses Striatal CAG Repeat Expansions in Huntington’s Disease Mice</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6082</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-05125-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fs41598-017-05125-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28729730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BC1cjpslCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=6082&author=N.+Suelvesauthor=L.+Kirkham-McCarthyauthor=R.+S.+Lahueauthor=S.+Gin%C3%A9s&title=A+Selective+Inhibitor+of+Histone+Deacetylase+3+Prevents+Cognitive+Deficits+and+Suppresses+Striatal+CAG+Repeat+Expansions+in+Huntington%E2%80%99s+Disease+Mice&doi=10.1038%2Fs41598-017-05125-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice</span></div><div class="casAuthors">Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Suelves Nuria; Gines Silvia; Kirkham-McCarthy Lucy; Lahue Robert S; Lahue Robert S</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6082</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Huntington's disease (HD) is a neurodegenerative disorder whose major symptoms include progressive motor and cognitive dysfunction.  Cognitive decline is a critical quality of life concern for HD patients and families.  The enzyme histone deacetylase 3 (HDAC3) appears to be important in HD pathology by negatively regulating genes involved in cognitive functions.  Furthermore, HDAC3 has been implicated in the aberrant transcriptional patterns that help cause disease symptoms in HD mice.  HDAC3 also helps fuel CAG repeat expansions in human cells, suggesting that HDAC3 may power striatal expansions in the HTT gene thought to drive disease progression.  This multifaceted role suggests that early HDAC3 inhibition offers an attractive mechanism to prevent HD cognitive decline and to suppress striatal expansions.  This hypothesis was investigated by treating Hdh(Q111) knock-in mice with the HDAC3-selective inhibitor RGFP966.  Chronic early treatment prevented long-term memory impairments and normalized specific memory-related gene expression in hippocampus.  Additionally, RGFP966 prevented corticostriatal-dependent motor learning deficits, significantly suppressed striatal CAG repeat expansions, partially rescued striatal protein marker expression and reduced accumulation of mutant huntingtin oligomeric forms.  These novel results highlight RGFP966 as an appealing multiple-benefit therapy in HD that concurrently prevents cognitive decline and suppresses striatal CAG repeat expansions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRtWXDYtrkV4JKJbLTgsvCfW6udTcc2eY-y9JeBGqeb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjpslCmsQ%253D%253D&md5=0c384551190fd157825f8a29f675a79f</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-05125-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-05125-2%26sid%3Dliteratum%253Aachs%26aulast%3DSuelves%26aufirst%3DN.%26aulast%3DKirkham-McCarthy%26aufirst%3DL.%26aulast%3DLahue%26aufirst%3DR.%2BS.%26aulast%3DGin%25C3%25A9s%26aufirst%3DS.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25203%2520Prevents%2520Cognitive%2520Deficits%2520and%2520Suppresses%2520Striatal%2520CAG%2520Repeat%2520Expansions%2520in%2520Huntington%25E2%2580%2599s%2520Disease%2520Mice%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D6082%26doi%3D10.1038%2Fs41598-017-05125-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janczura, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volmar, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartor, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciardi, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahlestedt, C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC3 Reverses Alzheimer’s Disease-Related Pathologies in Vitro and in the 3xTg-AD Mouse Model</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E11148</span>– <span class="NLM_lpage">E11157</span>, <span class="refDoi"> DOI: 10.1073/pnas.1805436115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1073%2Fpnas.1805436115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30397132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1CrtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E11148-E11157&author=K.+J.+Janczuraauthor=C.-H.+Volmarauthor=G.+C.+Sartorauthor=S.+J.+Raoauthor=N.+R.+Ricciardiauthor=G.+Lambertauthor=S.+P.+Brothersauthor=C.+Wahlestedt&title=Inhibition+of+HDAC3+Reverses+Alzheimer%E2%80%99s+Disease-Related+Pathologies+in+Vitro+and+in+the+3xTg-AD+Mouse+Model&doi=10.1073%2Fpnas.1805436115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model</span></div><div class="casAuthors">Janczura, Karolina J.; Volmar, Claude-Henry; Sartor, Gregory C.; Rao, Sunil J.; Ricciardi, Natalie R.; Lambert, Guerline; Brothers, Shaun P.; Wahlestedt, Claes</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">E11148-E11157</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) the leading cause of age-related dementia.  Neuropathol. hallmarks of AD include brain deposition of β-amyloid plaques and accumulation of both hyperphosphorylated and acetylated tau.  RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-assocd. sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ1-42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APPsw).  In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathol. tau phosphorylation at Thr181, Ser202, and Ser396, increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ1-42 protein levels in the brain and periphery, and improves spatial learning and memory.  Finally, we show that RGFP-966 decreases Aβ1-42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEe4-carrying AD patients.  These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins assocd. with AD pathophysiol., supporting the notion that HDAC3 may be a disease-modifying therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx2OY5AvswdLVg90H21EOLACvtfcHk0lhyRHoOH74_1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1CrtrrP&md5=f36c313cbc1bb2c7dc7cc1590351cb18</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1805436115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1805436115%26sid%3Dliteratum%253Aachs%26aulast%3DJanczura%26aufirst%3DK.%2BJ.%26aulast%3DVolmar%26aufirst%3DC.-H.%26aulast%3DSartor%26aufirst%3DG.%2BC.%26aulast%3DRao%26aufirst%3DS.%2BJ.%26aulast%3DRicciardi%26aufirst%3DN.%2BR.%26aulast%3DLambert%26aufirst%3DG.%26aulast%3DBrothers%26aufirst%3DS.%2BP.%26aulast%3DWahlestedt%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520HDAC3%2520Reverses%2520Alzheimer%25E2%2580%2599s%2520Disease-Related%2520Pathologies%2520in%2520Vitro%2520and%2520in%2520the%25203xTg-AD%2520Mouse%2520Model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE11148%26epage%3DE11157%26doi%3D10.1073%2Fpnas.1805436115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">The HDAC3 Inhibitor RGFP966 Ameliorated Ischemic Brain Damage by Downregulating the AIM2 Inflammasome</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1096/fj.201900394RRR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1096%2Ffj.201900394RRR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31914678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=648-662&author=M.-J.+Zhangauthor=Q.-C.+Zhaoauthor=M.-X.+Xiaauthor=J.+Chenauthor=Y.-T.+Chenauthor=X.+Caoauthor=Y.+Liuauthor=Z.-Q.+Yuanauthor=X.-Y.+Wangauthor=Y.+Xu&title=The+HDAC3+Inhibitor+RGFP966+Ameliorated+Ischemic+Brain+Damage+by+Downregulating+the+AIM2+Inflammasome&doi=10.1096%2Ffj.201900394RRR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome</span></div><div class="casAuthors">Zhang, Mei-Juan; Zhao, Qiu-Chen; Xia, Ming-Xu; Chen, Jian; Chen, Yan-Ting; Cao, Xiang; Liu, Yi; Yuan, Zeng-Qiang; Wang, Xiao-Ying; Xu, Yun</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">648-662</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">1530-6860</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Here, we investigated the potential contributions of HDAC3 to inflammasome activation in primary cultured microglia and exptl. stroke models.  In this study, we documented that HDAC3 expression was increased in microglia of mouse exptl. stroke model.  I.p. injection of RGFP966 (a selective inhibitor of HDAC3) decreased infarct size and alleviated neurol. deficits after the onset of middle cerebral artery occlusion (MCAO).  In vitro data indicated that LPS stimulation evoked a time-dependent increase of HDAC3 and absent in melanoma 2 (AIM2) inflammasome in primary cultured microglia.  Interestingly, AIM2 was subjected to spatiotemporal regulation by RGFP966.  The ability of RGFP966 to inhibit the AIM2 inflammasome was confirmed in an exptl. mouse model of stroke.  As expected, AIM2 knockout mice also demonstrated significant resistance to ischemia injury compared with their wild-type littermates.  RGFP966 failed to exhibit extra protective effects in AIM2-/- stroke mice.  Furthermore, we found that RGFP966 enhanced STAT1 acetylation and subsequently attenuated STAT1 phosphorylation, which may at least partially contributed to the neg. regulation of AIM2 by RGFP966.  Together, we initially found that RGFP966 alleviated the inflammatory response and protected against ischemic stroke by regulating the AIM2 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQ01mRJhlBLVg90H21EOLACvtfcHk0lhl9wGQtFassA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFeisrk%253D&md5=f5e57cc9d86792fdbbcc4c0e1f346b70</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1096%2Ffj.201900394RRR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201900394RRR%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.-J.%26aulast%3DZhao%26aufirst%3DQ.-C.%26aulast%3DXia%26aufirst%3DM.-X.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-T.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DZ.-Q.%26aulast%3DWang%26aufirst%3DX.-Y.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DThe%2520HDAC3%2520Inhibitor%2520RGFP966%2520Ameliorated%2520Ischemic%2520Brain%2520Damage%2520by%2520Downregulating%2520the%2520AIM2%2520Inflammasome%26jtitle%3DFASEB%2520J.%26date%3D2020%26volume%3D34%26spage%3D648%26epage%3D662%26doi%3D10.1096%2Ffj.201900394RRR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emont, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">HDAC3-Selective Inhibition Activates Brown and Beige Fat Through PRDM16</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">2520</span>– <span class="NLM_lpage">2527</span>, <span class="refDoi"> DOI: 10.1210/en.2018-00257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1210%2Fen.2018-00257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29757434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2018&pages=2520-2527&author=J.+Liaoauthor=J.+Jiangauthor=H.+Junauthor=X.+Qiaoauthor=M.+P.+Emontauthor=D.-I.+Kimauthor=J.+Wu&title=HDAC3-Selective+Inhibition+Activates+Brown+and+Beige+Fat+Through+PRDM16&doi=10.1210%2Fen.2018-00257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC3-selective inhibition activates brown and beige fat through PRDM16</span></div><div class="casAuthors">Liao, Jiling; Jiang, Juan; Jun, Heejin; Qiao, Xiaona; Emont, Margo P.; Kim, Dong-il; Wu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2520-2527</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">1945-7170</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">It has been reported that class I histone deacetylase (HDAC) inhibition increases thermogenesis in fat, but adipocyte-specific Hdac3 deletions have presented inconsistent results.  In this study, we obsd. that HDAC3 protein levels were lower in brown fat compared with inguinal s.c. adipose tissue, and they decreased in both fat depots upon cold exposure.  PR domain-contg. 16 (PRDM16) phys. interacted with HDAC3, and treatment with HDAC3-selective inhibitor RGFP966 induced thermogenic gene expression in murine and human fat cultures.  This induction was blunted in the absence of PRDM16.  Our results provide evidence that HDAC3 is involved in thermogenesis, suggesting selective inhibition of HDAC3 in brown and beige fat might hold therapeutic potential for counteracting human obesity and metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqb21XRjyTPLVg90H21EOLACvtfcHk0lhl9wGQtFassA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksrzE&md5=d5fdb74f3a6bf631936b87b570763e6e</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1210%2Fen.2018-00257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2018-00257%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DJun%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DX.%26aulast%3DEmont%26aufirst%3DM.%2BP.%26aulast%3DKim%26aufirst%3DD.-I.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DHDAC3-Selective%2520Inhibition%2520Activates%2520Brown%2520and%2520Beige%2520Fat%2520Through%2520PRDM16%26jtitle%3DEndocrinology%26date%3D2018%26volume%3D159%26spage%3D2520%26epage%3D2527%26doi%3D10.1210%2Fen.2018-00257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barton, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keedy, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Margolis, D. M.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e102684</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0102684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1371%2Fjournal.pone.0102684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25136952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1CisrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e102684&author=K.+M.+Bartonauthor=N.+M.+Archinauthor=K.+S.+Keedyauthor=A.+S.+Espesethauthor=Y.+Zhangauthor=J.+Galeauthor=F.+F.+Wagnerauthor=E.+B.+Holsonauthor=D.+M.+Margolis&title=Selective+HDAC+Inhibition+for+the+Disruption+of+Latent+HIV-1+Infection&doi=10.1371%2Fjournal.pone.0102684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition for the disruption of latent HIV-1 infection</span></div><div class="casAuthors">Barton, Kirston M.; Archin, Nancie M.; Keedy, Kara S.; Espeseth, Amy S.; Zhang, Yan-Ling; Gale, Jennifer; Wagner, Florence F.; Holson, Edward B.; Margolis, David M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e102684/1-e102684/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Selective histone deacetylase (HDAC) inhibitors have emerged as a potential anti-latency therapy for persistent human immunodeficiency virus type 1 (HIV-1) infection.  We utilized a combination of small mol. inhibitors and short hairpin (sh)RNA-mediated gene knockdown strategies to delineate the key HDAC(s) to be targeted for selective induction of latent HIV-1 expression.  Individual depletion of HDAC3 significantly induced expression from the HIV-1 promoter in the 2D10 latency cell line model.  However, depletion of HDAC1 or -2 alone or in combination did not significantly induce HIV-1 expression.  Co-depletion of HDAC2 and -3 resulted in a significant increase in expression from the HIV-1 promoter.  Furthermore, concurrent knockdown of HDAC1, -2, and -3 resulted in a significant increase in expression from the HIV-1 promoter.  Using small mol. HDAC inhibitors of differing selectivity to ablate the residual HDAC activity that remained after (sh)RNA depletion, the effect of depletion of HDAC3 was further enhanced.  Enzymic inhibition of HDAC3 with the selective small-mol. inhibitor BRD3308 activated HIV-1 transcription in the 2D10 cell line.  Furthermore, ex vivo exposure to BRD3308 induced outgrowth of HIV-1 from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients.  Taken together these findings suggest that HDAC3 is an essential target to disrupt HIV-1 latency, and inhibition of HDAC2 may also contribute to the effort to purge and eradicate latent HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTcoQnQy8hCrVg90H21EOLACvtfcHk0lhl9wGQtFassA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1CisrbM&md5=d967dbe2a9b6004029ded4b8cad2f657</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0102684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0102684%26sid%3Dliteratum%253Aachs%26aulast%3DBarton%26aufirst%3DK.%2BM.%26aulast%3DArchin%26aufirst%3DN.%2BM.%26aulast%3DKeedy%26aufirst%3DK.%2BS.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGale%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DMargolis%26aufirst%3DD.%2BM.%26atitle%3DSelective%2520HDAC%2520Inhibition%2520for%2520the%2520Disruption%2520of%2520Latent%2520HIV-1%2520Infection%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De102684%26doi%3D10.1371%2Fjournal.pone.0102684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dirice, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, R. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, R. N.</span></span> <span> </span><span class="NLM_article-title">Isoform-Selective Inhibitor of Histone Deacetylase 3 (HDAC3) Limits Pancreatic Islet Infiltration and Protects Female Nonobese Diabetic Mice from Diabetes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">17598</span>– <span class="NLM_lpage">17608</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.804328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1074%2Fjbc.M117.804328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28860191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslehsrfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=17598-17608&author=E.+Diriceauthor=R.+W.+S.+Ngauthor=R.+Martinezauthor=J.+Huauthor=F.+F.+Wagnerauthor=E.+B.+Holsonauthor=B.+K.+Wagnerauthor=R.+N.+Kulkarni&title=Isoform-Selective+Inhibitor+of+Histone+Deacetylase+3+%28HDAC3%29+Limits+Pancreatic+Islet+Infiltration+and+Protects+Female+Nonobese+Diabetic+Mice+from+Diabetes&doi=10.1074%2Fjbc.M117.804328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes</span></div><div class="casAuthors">Dirice, Ercument; Ng, Raymond W. S.; Martinez, Rachael; Hu, Jiang; Wagner, Florence F.; Holson, Edward B.; Wagner, Bridget K.; Kulkarni, Rohit N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">17598-17608</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Preservation of insulin-secreting β-cells is an important goal for therapies aimed at restoring normoglycemia in patients with diabetes.  One approach, the inhibition of histone deacetylases (HDACs), has been reported to suppress pancreatic islet inflammation and β-cell apoptosis in vitro.  In this report, we demonstrate the efficacy of HDAC inhibitors (HDACi) in vivo.  We show that daily administration of BRD3308, an isoform-selective HDAC3 inhibitor, for 2 wk to female nonobese diabetic (NOD) mice, beginning at 3 wk of age, followed by twice-weekly injections until age 25 wk, protects the animals from diabetes.  The preservation of β-cells was because of a significant decrease in islet infiltration of mononuclear cells.  Moreover, the BRD3308 treatment increased basal insulin secretion from islets cultured in vitro.  All metabolic tissues tested in vehicle- or BRD3308-treated groups showed virtually no sign of immune cell infiltration, except minimal infiltration in white adipose tissue in animals treated with the highest BRD3308 dose (10 mg/kg), providing addnl. evidence of protection from immune attack in the treated groups.  Furthermore, pancreata from animals treated with 10 mg/kg BRD3308 exhibited significantly decreased nos. of apoptotic β-cells compared with those treated with vehicle or low-dose BRD3308.  Finally, animals treated with 1 or 10 mg/kg BRD3308 had enhanced β-cell proliferation.  These in vivo results point to the potential use of selective HDAC3 inhibitors as a therapeutic approach to suppress pancreatic islet infiltration and prevent β-cell death with the long-term goal of limiting the progression of type 1 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89zBZOQ7dFrVg90H21EOLACvtfcHk0lhl9wGQtFassA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslehsrfI&md5=b05649e9b132289bd49ad76398f6615c</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.804328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.804328%26sid%3Dliteratum%253Aachs%26aulast%3DDirice%26aufirst%3DE.%26aulast%3DNg%26aufirst%3DR.%2BW.%2BS.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKulkarni%26aufirst%3DR.%2BN.%26atitle%3DIsoform-Selective%2520Inhibitor%2520of%2520Histone%2520Deacetylase%25203%2520%2528HDAC3%2529%2520Limits%2520Pancreatic%2520Islet%2520Infiltration%2520and%2520Protects%2520Female%2520Nonobese%2520Diabetic%2520Mice%2520from%2520Diabetes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D17598%26epage%3D17608%26doi%3D10.1074%2Fjbc.M117.804328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic Abnormalities in Hdac6-Deficient Mice</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.neuropharm.2016.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=27544826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWms7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2016&pages=470-479&author=M.+Fukadaauthor=A.+Nakayamaauthor=T.+Mamiyaauthor=T.-P.+Yaoauthor=Y.+Kawaguchi&title=Dopaminergic+Abnormalities+in+Hdac6-Deficient+Mice&doi=10.1016%2Fj.neuropharm.2016.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic abnormalities in Hdac6-deficient mice</span></div><div class="casAuthors">Fukada, Masahide; Nakayama, Atsuo; Mamiya, Takayoshi; Yao, Tso-Pang; Kawaguchi, Yoshiharu</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">470-479</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (Hdac6), a multifunctional cytoplasmic deacetylase, is abundant in brain.  We previously demonstrated that global Hdac6 depletion causes aberrant emotional behaviors in mice.  Identification of affected brain systems and its mol. basis will lead to new insights into relations between protein acetylation events and psychiatric disorders.  Here we report the dopaminergic abnormalities in Hdac6 KO mice.  The dopamine transmission mediated by D1-like and D2-like G protein-coupled dopamine receptors is known to play roles in controlling movement, cognition, and motivational processes, and its dysfunction causes psychiatric disorders.  We found that Hdac6 KO mice showed significantly increased locomotor response to novel, but not to habituated environment.  In addn., Hdac6 KO mice showed a long-lasting sensitivity to psychostimulants, increased locomotor response to D2-like, but not D1 dopamine receptor agonists, and rapid locomotor response to apomorphine, a direct dopamine agonist, in dopamine-depleted condition.  Hdac6 protein was expressed in dopaminergic neurons and their terminals in adult mice brain, and Hdac6-depletion augmented acetylation levels of dopamine-enriched synaptosomal proteins.  In Hdac6 KO mice, the striatal content of dopamine and its metabolites was normal in basal condition, but mRNA level of D2 dopamine receptor in the striatum was decreased by 30%.  Taken together, our results provide evidence that Hdac6 deficiency leads to aberrant dopamine-dependent behaviors by enhancing postsynaptic dopamine D2 receptor response.  This study points out the possibility that Hdac6 and reversible-acetylation events play a regulatory role in D2 dopamine receptor signaling, and thus participate in the pathol. of the dopamine-related psychiatric disorders such as schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8PJJhzaicLbVg90H21EOLACvtfcHk0lhtpf2Povz-Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWms7nI&md5=f4521641c7a0e965b5ca3679818923d3</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DFukada%26aufirst%3DM.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMamiya%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DT.-P.%26aulast%3DKawaguchi%26aufirst%3DY.%26atitle%3DDopaminergic%2520Abnormalities%2520in%2520Hdac6-Deficient%2520Mice%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D110%26spage%3D470%26epage%3D479%26doi%3D10.1016%2Fj.neuropharm.2016.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lhtpf2Povz-Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Ba%C5%99inkaauthor=M.+B.+Robersauthor=L.+Van+Den%0ABoschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+Penetrable+Histone+Deacetylase+6+Inhibitor+SW-100+Ameliorates+Memory+and+Learning+Impairments+in+a+Mouse+Model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span></div><div class="casAuthors">Kozikowski, Alan P.; Shen, Sida; Pardo, Marta; Tavares, Mauricio T.; Szarics, Dora; Benoy, Veronick; Zimprich, Chad A.; Kutil, Zsofia; Zhang, Guiping; Barinka, Cyril; Robers, Matthew B.; Van Den Bosch, Ludo; Eubanks, James H.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1679-1695</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures.  Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacol. and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-/- mice.  This small mol. demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms.  Moreover, through its inhibition of the α-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates α-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated α-tubulin levels in the hippocampus of Fmr1-/- mice.  Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1-/- mice, thus modeling the intellectual deficiencies assocd. with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphc-8bfGiZh7Vg90H21EOLACvtfcHk0lhtpf2Povz-Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E&md5=b1e70a1a45522720d481985b3a4339f3</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520Penetrable%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SW-100%2520Ameliorates%2520Memory%2520and%2520Learning%2520Impairments%2520in%2520a%2520Mouse%2520Model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">(<i>N</i>-Hydroxycarbonylbenylamino)Quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma <i>in Vitro</i> and <i>in Vivo</i></span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.-Y.+Leeauthor=K.+Nepaliauthor=F.-I.+Huangauthor=C.-Y.+Changauthor=M.-J.+Laiauthor=Y.-H.+Liauthor=H.-L.+Huangauthor=C.-R.+Yangauthor=J.-P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29Quinolines+as+Selective+Histone+Deacetylase+6+Inhibitors+Suppress+Growth+of+Multiple+Myeloma+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0li7qp0KmdFUaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.-I.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DLai%26aufirst%3DM.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26aulast%3DHuang%26aufirst%3DH.-L.%26aulast%3DYang%26aufirst%3DC.-R.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529Quinolines%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520Suppress%2520Growth%2520of%2520Multiple%2520Myeloma%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krukowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golonzhka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laumet, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heijnen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavelaars, A.</span></span> <span> </span><span class="NLM_article-title">HDAC6 Inhibition Effectively Reverses Chemotherapy-Induced Peripheral Neuropathy</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1097/j.pain.0000000000000893</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1097%2Fj.pain.0000000000000893" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=28267067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslyrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2017&pages=1126-1137&author=K.+Krukowskiauthor=J.+Maauthor=O.+Golonzhkaauthor=G.+O.+Laumetauthor=T.+Guttiauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+B.+Jarpeauthor=C.+J.+Heijnenauthor=A.+Kavelaars&title=HDAC6+Inhibition+Effectively+Reverses+Chemotherapy-Induced+Peripheral+Neuropathy&doi=10.1097%2Fj.pain.0000000000000893"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy</span></div><div class="casAuthors">Krukowski, Karen; Ma, Jiacheng; Golonzhka, Olga; Laumet, Geoffroy O.; Gutti, Tanuja; van Duzer, John H.; Mazitschek, Ralph; Jarpe, Matthew B.; Heijnen, Cobi J.; Kavelaars, Annemieke</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1126-1137</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy is one of the most common dose-limiting side effects of cancer treatment.  Currently, there is no Food and Drug Administration-approved treatment available.  Histone deacetylase 6 (HDAC6) is a microtubule-assocd. deacetylase whose function includes regulation of α-tubulin-dependent intracellular mitochondrial transport.  Here, we examd. the effect of HDAC6 inhibition on established cisplatin-induced peripheral neuropathy.  We used a novel HDAC6 inhibitor ACY-1083, which shows 260-fold selectivity towards HDAC6 vs other HDACs.  Our results show that HDAC6 inhibition prevented cisplatin-induced mech. allodynia, and also completely reversed already existing cisplatin-induced mech. allodynia, spontaneous pain, and numbness.  These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clin. trials for cancer treatment.  Mechanistically, treatment with the HDAC6 inhibitor increased α-tubulin acetylation in the peripheral nerve.  In addn., HDAC6 inhibition restored the cisplatin-induced redn. in mitochondrial bioenergetics and mitochondrial content in the tibial nerve, indicating increased mitochondrial transport.  At a later time point, dorsal root ganglion mitochondrial bioenergetics also improved.  HDAC6 inhibition restored the loss of intraepidermal nerve fiber d. in cisplatin-treated mice.  Our results demonstrate that pharmacol. inhibition of HDAC6 completely reverses all the hallmarks of established cisplatin-induced peripheral neuropathy by normalization of mitochondrial function in dorsal root ganglia and nerve, and restoration of intraepidermal innervation.  These results are esp. promising because one of the HDAC6 inhibitors tested here is currently in clin. trials as an add-on cancer therapy, highlighting the potential for a fast clin. translation of our findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PdcGHNGMjrVg90H21EOLACvtfcHk0li7qp0KmdFUaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslyrsLY%253D&md5=a9adb6661143e5735bea8c8481a8c5d5</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1097%2Fj.pain.0000000000000893&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fj.pain.0000000000000893%26sid%3Dliteratum%253Aachs%26aulast%3DKrukowski%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DGolonzhka%26aufirst%3DO.%26aulast%3DLaumet%26aufirst%3DG.%2BO.%26aulast%3DGutti%26aufirst%3DT.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DJarpe%26aufirst%3DM.%2BB.%26aulast%3DHeijnen%26aufirst%3DC.%2BJ.%26aulast%3DKavelaars%26aufirst%3DA.%26atitle%3DHDAC6%2520Inhibition%2520Effectively%2520Reverses%2520Chemotherapy-Induced%2520Peripheral%2520Neuropathy%26jtitle%3DPain%26date%3D2017%26volume%3D158%26spage%3D1126%26epage%3D1137%26doi%3D10.1097%2Fj.pain.0000000000000893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of the First Small Molecule Histone Deacetylase 6 (HDAC6) Degraders</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2493</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29871848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2493-2497&author=K.+Yangauthor=Y.+Songauthor=H.+Xieauthor=H.+Wuauthor=Y.-T.+Wuauthor=E.+D.+Leistenauthor=W.+Tang&title=Development+of+the+First+Small+Molecule+Histone+Deacetylase+6+%28HDAC6%29+Degraders&doi=10.1016%2Fj.bmcl.2018.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span></div><div class="casAuthors">Yang, Ka; Song, Yanling; Xie, Haibo; Wu, Hao; Wu, Yi-Ting; Leisten, Eric D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2493-2497</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins.  Over expression of HDACs have been obsd. in cancers and other diseases.  Targeted protein degrdn. by "hijacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technol. to "knock-out" endogenous disease-causing proteins.  The authors applied this strategy to the development of the first small mol. degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands.  Through cell-based assays, the authors discovered novel bifunctional mols. (dHDAC6) that could selectively degrade HDAC6.  Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9t1stJ7Qkf7Vg90H21EOLACvtfcHk0lhLY15JK6Nw-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF&md5=20be52b05a327184f824ccf9cf88333f</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.-T.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520the%2520First%2520Small%2520Molecule%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Degraders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2493%26epage%3D2497%26doi%3D10.1016%2Fj.bmcl.2018.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novakova, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7042</span>– <span class="NLM_lpage">7057</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7042-7057&author=H.+Wuauthor=K.+Yangauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=Z.+Liauthor=H.+Xieauthor=J.+Liuauthor=K.+A.+Smithauthor=Z.+Novakovaauthor=C.+Barinkaauthor=W.+Tang&title=Development+of+Multifunctional+Histone+Deacetylase+6+Degraders+with+Potent+Antimyeloma+Activity&doi=10.1021%2Facs.jmedchem.9b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity</span></div><div class="casAuthors">Wu, Hao; Yang, Ka; Zhang, Zhongrui; Leisten, Eric D.; Li, Ziyuan; Xie, Haibo; Liu, Jin; Smith, Kerry A.; Novakova, Zora; Barinka, Cyril; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7042-7057</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90.  HDAC6 is involved in multiple disease-relevant pathways.  Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand.  We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degrdn. for the antiproliferation of multiple myeloma (MM).  This new class of degraders exhibited improved potency and selectivity for the degrdn. of HDAC6.  After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb58zf04V2GLVg90H21EOLACvtfcHk0lhLY15JK6Nw-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlams7nO&md5=7aab402404a5fce732b4b68fd76395d4</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00516%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DNovakova%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520Multifunctional%2520Histone%2520Deacetylase%25206%2520Degraders%2520with%2520Potent%2520Antimyeloma%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7042%26epage%3D7057%26doi%3D10.1021%2Facs.jmedchem.9b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Determinants of Affinity and Selectivity in the Binding of Inhibitors to Histone Deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Determinants+of+Affinity+and+Selectivity+in+the+Binding+of+Inhibitors+to+Histone+Deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0lhLY15JK6Nw-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Determinants%2520of%2520Affinity%2520and%2520Selectivity%2520in%2520the%2520Binding%2520of%2520Inhibitors%2520to%2520Histone%2520Deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 6 in Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+Deacetylase+6+in+Cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0lhLY15JK6Nw-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%25206%2520in%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A Patent Review of Histone Deacetylase 6 Inhibitors in Neurodegenerative Diseases (2014–2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+Patent+Review+of+Histone+Deacetylase+6+Inhibitors+in+Neurodegenerative+Diseases+%282014%E2%80%932019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0lgwhK3NAMAQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520Patent%2520Review%2520of%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Neurodegenerative%2520Diseases%2520%25282014%25E2%2580%25932019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=23-39&author=M.+Brindisiauthor=A.+P.+Saraswatiauthor=S.+Brogiauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Old+but+Gold%3A+Tracking+the+New+Guise+of+Histone+Deacetylase+6+%28HDAC6%29+Enzyme+as+a+Biomarker+and+Therapeutic+Target+in+Rare+Diseases&doi=10.1021%2Facs.jmedchem.9b00924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span></div><div class="casAuthors">Brindisi, Margherita; Saraswati, A. Prasanth; Brogi, Simone; Gemma, Sandra; Butini, Stefania; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-39</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation orchestrates many cellular processes and greatly influences key disease mechanisms.  Histone deacetylase (HDAC) enzymes play a crucial role either as biomarkers or therapeutic targets owing to their involvement in specific pathophysiol. pathways.  Beyond their well-characterized role as histone modifiers, HDACs also interact with several non-histone substrates and their increased expression has been highlighted in specific diseases.  HDAC6 isoform, due to its unique cytoplasmic localization, modulates the acetylation status of tubulin, HSP90, TGF-β and peroxiredoxins.  HDAC6 also exerts non-catalytic activities, through its interaction with ubiquitin.  Both catalytic and non-catalytic functions of HDACs are being actively studied in the field of specific rare disorders, beyond the well-established role in carcinogenesis.  This perspective outlines the application of HDAC(6) inhibitors in rare diseases, such as Rett syndrome, inherited retinal disorders, idiopathic pulmonary fibrosis and Charcot-Marie-Tooth disease, highlighting their therapeutic potential as innovative and targeted disease-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kzJmRToypbVg90H21EOLACvtfcHk0lgwhK3NAMAQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK&md5=688368246471313ed025f0c230167052</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00924%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DOld%2520but%2520Gold%253A%2520Tracking%2520the%2520New%2520Guise%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Enzyme%2520as%2520a%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Rare%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D23%26epage%3D39%26doi%3D10.1021%2Facs.jmedchem.9b00924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase 8 (HDAC8) and Its Inhibitors with Selectivity to Other Isoforms: An Overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.ejmech.2018.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30594678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltF2q" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=214-240&author=S.+Banerjeeauthor=N.+Adhikariauthor=S.+A.+Aminauthor=T.+Jha&title=Histone+Deacetylase+8+%28HDAC8%29+and+Its+Inhibitors+with+Selectivity+to+Other+Isoforms%3A+An+Overview&doi=10.1016%2Fj.ejmech.2018.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview</span></div><div class="casAuthors">Banerjee, Suvankar; Adhikari, Nilanjan; Amin, Sk Abdul; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">214-240</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The histone deacetylases (HDACs) enzymes provided crucial role in transcriptional regulation of cells through deacetylation of nuclear histone proteins.  The pan-HDAC inhibitors can confront these conditions but have chances to affect epigenetic functions of other HDAC isoforms.  Designing of selective HDAC8 inhibitors is a key feature to combat the pathophysiol. and diseased conditions involving the HDAC8 activity.  This review is concerned about the structural and positional aspects of HDAC8 in the HDAC family.  It also covers the contributions of HDAC8 in the pathophysiol. conditions, a preliminary discussion about the recent scenario of HDAC8 inhibitors.  This review might help to deliver the structural, functional and computational information in order to identify and design potent and selective HDAC8 inhibitors for target specific treatment of diseases involving HDAC8 enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4KrWyCwpPdrVg90H21EOLACvtfcHk0lgwhK3NAMAQQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltF2q&md5=cf4ca3ae21d10662da0ce32f0c336b72</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DHistone%2520Deacetylase%25208%2520%2528HDAC8%2529%2520and%2520Its%2520Inhibitors%2520with%2520Selectivity%2520to%2520Other%2520Isoforms%253A%2520An%2520Overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D214%26epage%3D240%26doi%3D10.1016%2Fj.ejmech.2018.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1026</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fleu.2008.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=18256683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVSrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1026-1034&author=S.+Balasubramanianauthor=J.+Ramosauthor=W.+Luoauthor=M.+Sirisawadauthor=E.+Vernerauthor=J.+J.+Buggy&title=A+Novel+Histone+Deacetylase+8+%28HDAC8%29-Specific+Inhibitor+PCI-34051+Induces+Apoptosis+in+T-Cell+Lymphomas&doi=10.1038%2Fleu.2008.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas</span></div><div class="casAuthors">Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1026-1034</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have developed a potent, histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 with >200-fold selectivity over the other HDAC isoforms.  PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines.  Unlike broad-spectrum HDAC inhibitors, PCI-34051 does not cause detectable histone or tubulin acetylation.  Cells defective in T-cell receptor signaling were still sensitive to PCI-34051-induced apoptosis, whereas a phospholipase C-γ1 (PLCγ1)-defective line was resistant.  Jurkat cells showed a dose-dependent decrease in PCI-34051-induced apoptosis upon treatment with a PLC inhibitor U73122, but not with an inactive analog.  We found that rapid intracellular calcium mobilization from endoplasmic reticulum (ER) and later cytochrome c release from mitochondria are essential for the apoptotic mechanism.  The rapid Ca2+ flux was dependent on PCI-34051 concn., and was blocked by the PLC inhibitor U73122.  Further, apoptosis was blocked by Ca2+ chelators (BAPTA) and enhanced by Ca2+ effectors (thapsigargin), supporting this model.  These studies show that HDAC8-selective inhibitors have a unique mechanism of action involving PLCγ1 activation and calcium-induced apoptosis, and could offer benefits including a greater therapeutic index for treating T-cell malignancies.  Leukemia (2008) 22, 1026-1034; doi:10.1038/leu.2008.9; published online 7 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-VB4Wb3h1bVg90H21EOLACvtfcHk0lgXJGxSkJxbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVSrtr0%253D&md5=03446a05b396ea9497e4f6f9254cae03</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.9%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DRamos%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520Novel%2520Histone%2520Deacetylase%25208%2520%2528HDAC8%2529-Specific%2520Inhibitor%2520PCI-34051%2520Induces%2520Apoptosis%2520in%2520T-Cell%2520Lymphomas%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1026%26epage%3D1034%26doi%3D10.1038%2Fleu.2008.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Evaluation of <i>ortho</i>-Aryl <i>N</i>-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1815</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201200300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1002%2Fcmdc.201200300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=22907916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1815-1824&author=W.-J.+Huangauthor=Y.-C.+Wangauthor=S.-W.+Chaoauthor=C.-Y.+Yangauthor=L.-C.+Chenauthor=M.-H.+Linauthor=W.-C.+Houauthor=M.-Y.+Chenauthor=T.-L.+Leeauthor=P.+Yangauthor=C.-I.+Chang&title=Synthesis+and+Biological+Evaluation+of+ortho-Aryl+N-Hydroxycinnamides+as+Potent+Histone+Deacetylase+%28HDAC%29+8+Isoform-Selective+Inhibitors&doi=10.1002%2Fcmdc.201200300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Huang, Wei-Jan; Wang, Yi-Ching; Chao, Shi-Wei; Yang, Chen-Yui; Chen, Liang-Chieh; Lin, Mei-Hsiang; Hou, Wen-Chi; Chen, Mei-Yu; Lee, Tai-Lin; Yang, Ping; Chang, Chung-I.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1815-1824, S1815/1-S1815/41</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes that play a crucial role in biol. process and diseases.  In contrast to other isoenzymes, HDAC8 is uniquely incapable of histone acetylation.  To delineate its physiol. function, we developed HDAC8-selective inhibitors using knowledge-based design combined with structural modeling techniques.  Enzyme inhibitory anal. demonstrated that some of the resulting compds. exhibited anti-HDAC8 activity superior to PCI34051, a known HDAC8-specific inhibitor, with IC50 values in the range of 5-50 nM.  Among them, compd. (I) showed antiproliferative effects toward several human lung cancer cell lines (A549, H1299, and CL1-5); it exhibited cytotoxicity against human lung CL1-5 cells similar to that of SAHA yet without significant cytotoxicity for normal IMR-90 cells.  Expression profiling of HDAC isoforms in three cancer cell lines indicated that the HDAC8 level in CL1-5 is higher than that in H1299 and CL1-1 cells, a result consistent with the differential cytotoxicity of compd. I.  These results suggest the effectiveness of our design concept, which may lead to a tool compd. for studying the specific role of HDAC8 in cellular biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop4xm7qu7wc7Vg90H21EOLACvtfcHk0lgXJGxSkJxbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1WrtLzL&md5=05279fdc5e9bc353f12fa3b1b0f3e365</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200300%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DWang%26aufirst%3DY.-C.%26aulast%3DChao%26aufirst%3DS.-W.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DLin%26aufirst%3DM.-H.%26aulast%3DHou%26aufirst%3DW.-C.%26aulast%3DChen%26aufirst%3DM.-Y.%26aulast%3DLee%26aufirst%3DT.-L.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.-I.%26atitle%3DSynthesis%2520and%2520Biological%2520Evaluation%2520of%2520ortho-Aryl%2520N-Hydroxycinnamides%2520as%2520Potent%2520Histone%2520Deacetylase%2520%2528HDAC%2529%25208%2520Isoform-Selective%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1815%26epage%3D1824%26doi%3D10.1002%2Fcmdc.201200300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingham, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">Development of a Potent and Selective HDAC8 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=929-932&author=O.+J.+Inghamauthor=R.+M.+Paranalauthor=W.+B.+Smithauthor=R.+A.+Escobarauthor=H.+Yuehauthor=T.+Snyderauthor=J.+A.+Porcoauthor=J.+E.+Bradnerauthor=A.+B.+Beeler&title=Development+of+a+Potent+and+Selective+HDAC8+Inhibitor&doi=10.1021%2Facsmedchemlett.6b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent and Selective HDAC8 Inhibitor</span></div><div class="casAuthors">Ingham, Oscar J.; Paranal, Ronald M.; Smith, William B.; Escobar, Randolph A.; Yueh, Han; Snyder, Tracy; Porco, John A.; Bradner, James E.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-932</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel, isoform-selective inhibitor of histone deacetylase 8 (HDAC8) has been discovered by the repurposing of a diverse compd. collection.  Medicinal chem. optimization led to the identification of a highly potent (0.8 nM) and selective inhibitor I of HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF0r_7S2dWLVg90H21EOLACvtfcHk0lgXJGxSkJxbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP&md5=69ab76f942dfc6a6b7801b90f48aa619</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00239%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DO.%2BJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DEscobar%26aufirst%3DR.%2BA.%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DT.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520Potent%2520and%2520Selective%2520HDAC8%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Facsmedchemlett.6b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeneke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trippel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burhenne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopp-Schneider, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernekorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deubzer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of HDAC8 Decreases Neuroblastoma Growth in Vitro and in Vivo and Enhances Retinoic Acid-Mediated Differentiation</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1657</span>, <span class="refDoi"> DOI: 10.1038/cddis.2015.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fcddis.2015.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=25695609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=e1657&author=I.+Rettigauthor=E.+Koenekeauthor=F.+Trippelauthor=W.+C.+Muellerauthor=J.+Burhenneauthor=A.+Kopp-Schneiderauthor=J.+Fabianauthor=A.+Schoberauthor=U.+Fernekornauthor=A.+von+Deimlingauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=O.+Wittauthor=I.+Oehme&title=Selective+Inhibition+of+HDAC8+Decreases+Neuroblastoma+Growth+in+Vitro+and+in+Vivo+and+Enhances+Retinoic+Acid-Mediated+Differentiation&doi=10.1038%2Fcddis.2015.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation</span></div><div class="casAuthors">Rettig, I.; Koeneke, E.; Trippel, F.; Mueller, W. C.; Burhenne, J.; Kopp-Schneider, A.; Fabian, J.; Schober, A.; Fernekorn, U.; von Deimling, A.; Deubzer, H. E.; Milde, T.; Witt, O.; Oehme, I.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1657</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">For differentiation-defective malignancies, compds. that modulate transcription, such as retinoic acid and histone deacetylase (HDAC) inhibitors, are of particular interest.  HDAC inhibitors are currently under investigation for the treatment of a broad spectrum of cancer diseases.  However, one clin. drawback is class-specific toxicity of unselective inhibitors, limiting their full anticancer potential.  Selective targeting of individual HDAC isoenzymes in defined tumor entities may therefore be an attractive alternative treatment approach.  We have previously identified HDAC family member 8 (HDAC8) as a novel target in childhood neuroblastoma.  Using small-mol. inhibitors, we now demonstrate that selective inhibition of HDAC8 exhibits antineuroblastoma activity without toxicity in two xenograft mouse models of MYCN oncogene-amplified neuroblastoma.  In contrast, the unselective HDAC inhibitor vorinostat was more toxic in the same models.  HDAC8-selective inhibition induced cell cycle arrest and differentiation in vitro and in vivo.  Upon combination with retinoic acid, differentiation was significantly enhanced, as demonstrated by elongated neurofilament-pos. neurites and upregulation of NTRK1.  Addnl., MYCN oncogene expression was downregulated in vitro and tumor cell growth was markedly reduced in vivo.  Mechanistic studies suggest that cAMP-response element-binding protein (CREB) links HDAC8- and retinoic acid-mediated gene transcription.  In conclusion, HDAC-selective targeting can be effective in tumors exhibiting HDAC isoenzyme-dependent tumor growth in vivo and can be combined with differentiation-inducing agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ55O9b9Q78LVg90H21EOLACvtfcHk0lgYkhlPZummxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSis7s%253D&md5=41a5cfe6aaa685304b3bef0eae03a8ff</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2015.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2015.24%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DI.%26aulast%3DKoeneke%26aufirst%3DE.%26aulast%3DTrippel%26aufirst%3DF.%26aulast%3DMueller%26aufirst%3DW.%2BC.%26aulast%3DBurhenne%26aufirst%3DJ.%26aulast%3DKopp-Schneider%26aufirst%3DA.%26aulast%3DFabian%26aufirst%3DJ.%26aulast%3DSchober%26aufirst%3DA.%26aulast%3DFernekorn%26aufirst%3DU.%26aulast%3Dvon%2BDeimling%26aufirst%3DA.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DSelective%2520Inhibition%2520of%2520HDAC8%2520Decreases%2520Neuroblastoma%2520Growth%2520in%2520Vitro%2520and%2520in%2520Vivo%2520and%2520Enhances%2520Retinoic%2520Acid-Mediated%2520Differentiation%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2015%26volume%3D6%26spage%3De1657%26doi%3D10.1038%2Fcddis.2015.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seok, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, M. H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 8 Improves Vascular Hypertrophy, Relaxation, and Inflammation in Angiotensin II Hypertensive Mice</span>. <i>Clin. Hypertens.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi"> DOI: 10.1186/s40885-019-0118-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs40885-019-0118-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31223486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ptFKqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=13&author=H.+J.+Keeauthor=Y.+Ryuauthor=Y.+M.+Seokauthor=S.+Y.+Choiauthor=S.+Sunauthor=G.+R.+Kimauthor=M.+H.+Jeong&title=Selective+Inhibition+of+Histone+Deacetylase+8+Improves+Vascular+Hypertrophy%2C+Relaxation%2C+and+Inflammation+in+Angiotensin+II+Hypertensive+Mice&doi=10.1186%2Fs40885-019-0118-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice</span></div><div class="casAuthors">Kee Hae Jin; Ryu Yuhee; Choi Sin Young; Sun Simei; Kim Gwi Ran; Jeong Myung Ho; Kee Hae Jin; Ryu Yuhee; Choi Sin Young; Sun Simei; Kim Gwi Ran; Jeong Myung Ho; Seok Young Mi; Choi Sin Young; Sun Simei</div><div class="citationInfo"><span class="NLM_cas:title">Clinical hypertension</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn">2056-5909</span>.
    </div><div class="casAbstract">Background:  The dysregulation of histone deacetylase (HDAC) protein expression or its enzyme activity is implicated in a variety of diseases.  Cardiac HDAC6 and HDAC8 enzyme activity induced by deoxycorticosterone acetate (DOCA) hypertension was attenuated by sodium valproate, a pan-HDAC inhibitor.  However, the HDAC6-selective inhibitor, tubastatin A, did not attenuate angiotensin II-induced hypertension.  The purpose of this study was to investigate whether PCI34051, an HDAC8-selective inhibitor, can modulate angiotensin II-induced hypertension and its regulatory mechanism.  Methods:  An angiotensin II-regulated mouse model was used in this study.  Animals received vehicle or PCI34051 (3 mg·kg - (1)·day- (1)) via intraperitoneal injection.  Systolic blood pressure was measured by the tail-cuff method.  Blood vessel thickness was measured following hematoxylin and eosin staining, VCAM-1 immunohistochemistry was performed in the aortas, and mRNA expression of renin-angiotensin system components, inflammation markers, and NADPH oxidase (Nox) was determined by RT-PCR.  The effect of PCI34051 on vasorelaxation was studied in rat aortic rings, and its effect on nitric oxide (NO) production was determined using DAF-FM DA, a fluorescent dye, in human umbilical vascular endothelial cells (HUVECs).  Results:  PCI34051 administration reduced systolic blood pressure via downregulation of angiotensin II receptor type 1 (AT1) mRNA expression.  PCI34051 treatment attenuated vascular hypertrophy by decreasing E2F3 and GATA6 mRNA expression.  Vascular relaxation after PCI34051 treatment was more dependent on vascular endothelial cells and it was blocked by an NO synthase (NOS) inhibitor.  In addition, NO production increased in HUVECs after PCI34051 treatment; this was decreased by the NOS inhibitor.  The expression of inflammatory molecules and adhesion molecules VCAM-1 and ICAM-1 decreased in the aortas of angiotensin II-infused mice after PCI34051 administration.  However, PCI34051 did not affect Nox or its regulatory subunits.  Conclusions:  PCI34051 lowered high blood pressure through modulation of arterial remodeling, vasoconstriction, and inflammation in an angiotensin II-induced hypertension model.  We suggest that HDAC8 could be a potential therapeutic target for hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTT5hClw2T1CDAEfvC7EH1LfW6udTcc2eZoMC8r32TPabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ptFKqug%253D%253D&md5=0453cd6f56a952926a8a293adb1636d5</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1186%2Fs40885-019-0118-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40885-019-0118-8%26sid%3Dliteratum%253Aachs%26aulast%3DKee%26aufirst%3DH.%2BJ.%26aulast%3DRyu%26aufirst%3DY.%26aulast%3DSeok%26aufirst%3DY.%2BM.%26aulast%3DChoi%26aufirst%3DS.%2BY.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DG.%2BR.%26aulast%3DJeong%26aufirst%3DM.%2BH.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25208%2520Improves%2520Vascular%2520Hypertrophy%252C%2520Relaxation%252C%2520and%2520Inflammation%2520in%2520Angiotensin%2520II%2520Hypertensive%2520Mice%26jtitle%3DClin.%2520Hypertens.%26date%3D2019%26volume%3D25%26spage%3D13%26doi%3D10.1186%2Fs40885-019-0118-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, G.</span></span> <span> </span><span class="NLM_article-title">HADC8 Inhibitor WK2-16 Therapeutically Targets Lipopolysaccharide-Induced Mouse Model of Neuroinflammation and Microglial Activation</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">410</span>, <span class="refDoi"> DOI: 10.3390/ijms20020410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3390%2Fijms20020410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFahs73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=410&author=F.-L.+Linauthor=J.-L.+Yenauthor=Y.-C.+Kuoauthor=J.-J.+Kangauthor=Y.-W.+Chengauthor=W.-J.+Huangauthor=G.+Hsiao&title=HADC8+Inhibitor+WK2-16+Therapeutically+Targets+Lipopolysaccharide-Induced+Mouse+Model+of+Neuroinflammation+and+Microglial+Activation&doi=10.3390%2Fijms20020410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 inhibitor WK2-16 therapeutically targets lipopolysaccharide-induced mouse model of neuroinflammation and microglial activation</span></div><div class="casAuthors">Lin, Fan-Li; Yen, Jing-Lun; Kuo, Yu-Cheng; Kang, Jaw-Jou; Cheng, Yu-Wen; Huang, Wei-Jan; Hsiao, George</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">410/1-410/20</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glial activation and neuroinflammatory processes play important roles in the pathogenesis of brain abscess and neurodegenerative diseases.  Activated glial cells can secrete various proinflammatory cytokines and neurotoxic mediators, which contribute to the exacerbation of neuronal cell death.  The inhibition of glial activation has been shown to alleviate neurodegenerative conditions.  The present study was to investigate the specific HDAC8 inhibitor WK2-16, esp. its effects on the neuroinflammatory responses through glial inactivation.  WK2-16 significantly reduced the gelatinolytic activity of MMP-9, and expression of COX-2/iNOS proteins in striatal lipopolysaccharide (LPS)-induced neuroinflammation in C57BL/6 mice.  The treatment of WK2-16 markedly improved neurobehavioral deficits.  Immunofluorescent staining revealed that WK2-16 reduced LPS-stimulated astrogliosis and microglial activation in situ.  Consistently, cellular studies revealed that WK2-16 significantly suppressed LPS-induced mouse microglia BV-2 cell proliferation.  WK2-16 was proven to concn.-dependently induce the levels of acetylated SMC3 in microglial BV-2 cells.  It also reduced the expression of COX-2/iNOS proteins and TNF-α prodn. in LPS-activated microglial BV-2 cells.  The signaling studies demonstrated that WK2-16 markedly inhibited LPS-activated STAT-1/-3 and Akt activation, but not NF-κB or MAPK signaling.  In summary, the HDAC8 inhibitor WK2-16 exhibited neuroprotective effects through its anti-neuroinflammation and glial inactivation properties, esp. in microglia in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotdGFyq2_YsLVg90H21EOLACvtfcHk0lgYkhlPZummxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFahs73I&md5=517707261c6f79a54a5c3266507d7d70</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.3390%2Fijms20020410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20020410%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DF.-L.%26aulast%3DYen%26aufirst%3DJ.-L.%26aulast%3DKuo%26aufirst%3DY.-C.%26aulast%3DKang%26aufirst%3DJ.-J.%26aulast%3DCheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DHsiao%26aufirst%3DG.%26atitle%3DHADC8%2520Inhibitor%2520WK2-16%2520Therapeutically%2520Targets%2520Lipopolysaccharide-Induced%2520Mouse%2520Model%2520of%2520Neuroinflammation%2520and%2520Microglial%2520Activation%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D410%26doi%3D10.3390%2Fijms20020410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Inhibitor Attenuates Airway Responses to Antigen Stimulus through Synchronously Suppressing Galectin-3 Expression and Reducing Macrophage-2 Polarization</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">62</span>, <span class="refDoi"> DOI: 10.1186/s12931-020-1322-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1186%2Fs12931-020-1322-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32111211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvValtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=62&author=M.-L.+Liauthor=X.-M.+Suauthor=Y.+Renauthor=X.+Zhaoauthor=L.-F.+Kongauthor=J.+Kang&title=HDAC8+Inhibitor+Attenuates+Airway+Responses+to+Antigen+Stimulus+through+Synchronously+Suppressing+Galectin-3+Expression+and+Reducing+Macrophage-2+Polarization&doi=10.1186%2Fs12931-020-1322-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization</span></div><div class="casAuthors">Li, Meng-lu; Su, Xin-ming; Ren, Yuan; Zhao, Xuan; Kong, Ling-fei; Kang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">This study was to investigate of the mechanism by which histone deacetylase (HDAC) 8 inhibitor ameliorated airway hyperresponsiveness (AHR) and allergic airway inflammation.  Repetitive measurements of enhanced pause (Penh) were executed by increasing concns. of acetyl-β-methacholine chloride (0 - 50 mg/mL).  Cells in bronchoalveolar lavage fluid (BALF) and pathol. changes of lungs were examd., resp.  The expression levels of HDAC8, Galecitn (Gal)-3, CD68, CD86, CD163, Arg1 and NOS2 in lungs were measured.  Significant increases in Penh and IL-4 level were detected with a large inflammatory infiltrate, comprised predominantly of macrophages and eosinophils, into the BALF in OVA-exposed lungs.  HDAC8, Gal-3, CD68, CD86, CD163, Arg1 and NOS2 proteins were over-expressed with the significant changes in the Arg1 and NOS2 mRNA levels in the lungs and the IL-4-treated cells.  PCI intervention obviously reduced the counts of CD163+ cells.  Furthermore, Gal-3 knockdown suppressed Arg1 expression in the cells.  Immunofluorescence staining displayed simultaneous changes in HDAC8 and Gal-3 expression in the investigated samples.  Treatment with PCI resulted in synchronous redn. of HDAC8 and Gal-3 expression in the Co-IP complexes.  The HDAC8 inhibitor ameliorates AHR and airway inflammation in animal model of allergic asthma through reducing HDAC8-Gal-3 interaction and M2 macrophage polarization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcIbmDMC1Nm7Vg90H21EOLACvtfcHk0lgY5FA4YiDFTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvValtLs%253D&md5=287694ded95d2e09f47503b8df9db36f</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1186%2Fs12931-020-1322-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-020-1322-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.-L.%26aulast%3DSu%26aufirst%3DX.-M.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DL.-F.%26aulast%3DKang%26aufirst%3DJ.%26atitle%3DHDAC8%2520Inhibitor%2520Attenuates%2520Airway%2520Responses%2520to%2520Antigen%2520Stimulus%2520through%2520Synchronously%2520Suppressing%2520Galectin-3%2520Expression%2520and%2520Reducing%2520Macrophage-2%2520Polarization%26jtitle%3DRespir.%2520Res.%26date%3D2020%26volume%3D21%26spage%3D62%26doi%3D10.1186%2Fs12931-020-1322-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emmons, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faião-Flores, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messina, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondak, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span> <span> </span><span class="NLM_article-title">HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1158%2F0008-5472.CAN-19-0040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30987999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCrsL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=2947-2961&author=M.+F.+Emmonsauthor=F.+Fai%C3%A3o-Floresauthor=R.+Sharmaauthor=R.+Thapaauthor=J.+L.+Messinaauthor=J.+C.+Beckerauthor=D.+Schadendorfauthor=E.+Setoauthor=V.+K.+Sondakauthor=J.+M.+Koomenauthor=Y.+A.+Chenauthor=E.+K.+Lauauthor=L.+Wanauthor=J.+D.+Lichtauthor=K.+S.+M.+Smalley&title=HDAC8+Regulates+a+Stress+Response+Pathway+in+Melanoma+to+Mediate+Escape+from+BRAF+Inhibitor+Therapy&doi=10.1158%2F0008-5472.CAN-19-0040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF Inhibitor therapy</span></div><div class="casAuthors">Emmons, Michael F.; Faiao-Flores, Fernanda; Sharma, Ritin; Thapa, Ram; Messina, Jane L.; Becker, Jurgen C.; Schadendorf, Dirk; Seto, Edward; Sondak, Vernon K.; Koomen, John M.; Chen, Yian A.; Lau, Eric K.; Wan, Lixin; Licht, Jonathan D.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2947-2961</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Melanoma cells have the ability to switch to a dedifferentiated, invasive phenotype in response to multiple stimuli.  Here, we show that exposure of melanomas to multiple stresses including BRAF-MEK inhibitor therapy, hypoxia, and UV irradn. leads to an increase in histone deacetylase 8 (HDAC8) activity and the adoption of a drug-resistant phenotype.  Mass spectrometry-based phosphoproteomics implicated HDAC8 in the regulation of MAPK and AP-1 signaling.  Introduction of HDAC8 into drug-na.ovrddot.ive melanoma cells conveyed resistance both in vitro and in vivo.  HDAC8-mediated BRAF inhibitor resistance was mediated via receptor tyrosine kinase activation, leading to MAPK signaling.  Although HDACs function at the histone level, they also regulate nonhistone substrates, and introduction of HDAC8 decreased the acetylation of c-Jun, increasing its transcriptional activity and enriching for an AP-1 gene signature.  Mutation of the putative c-Jun acetylation site at lysine 273 increased transcriptional activation of c-Jun in melanoma cells and conveyed resistance to BRAF inhibition.  In vivo xenograft studies confirmed the key role of HDAC8 in therapeutic adaptation, with both nonselective and HDAC8-specific inhibitors enhancing the durability of BRAF inhibitor therapy.  Our studies demonstrate that HDAC8-specific inhibitors limit the adaptation of melanoma cells to multiple stresses including BRAF-MEK inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2INUuzvGwQLVg90H21EOLACvtfcHk0lgY5FA4YiDFTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCrsL%252FF&md5=4958b2d9dfeae190f0ddef2e077a1536</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0040%26sid%3Dliteratum%253Aachs%26aulast%3DEmmons%26aufirst%3DM.%2BF.%26aulast%3DFai%25C3%25A3o-Flores%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DThapa%26aufirst%3DR.%26aulast%3DMessina%26aufirst%3DJ.%2BL.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DKoomen%26aufirst%3DJ.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BA.%26aulast%3DLau%26aufirst%3DE.%2BK.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26atitle%3DHDAC8%2520Regulates%2520a%2520Stress%2520Response%2520Pathway%2520in%2520Melanoma%2520to%2520Mediate%2520Escape%2520from%2520BRAF%2520Inhibitor%2520Therapy%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26spage%3D2947%26epage%3D2961%26doi%3D10.1158%2F0008-5472.CAN-19-0040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomason, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynes, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudnitskaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel <i>N</i>-Hydroxy-2-Arylisoindoline-4-Carboxamides as Potent and Selective Inhibitors of HDAC11</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2143</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=29776742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslShtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2143-2147&author=M.+W.+Martinauthor=J.+Y.+Leeauthor=D.+R.+Lanciaauthor=P.+Y.+Ngauthor=B.+Hanauthor=J.+R.+Thomasonauthor=M.+S.+Lynesauthor=C.+G.+Marshallauthor=C.+Contiauthor=A.+Collisauthor=M.+A.+Moralesauthor=K.+Doshiauthor=A.+Rudnitskayaauthor=L.+Yaoauthor=X.+Zheng&title=Discovery+of+Novel+N-Hydroxy-2-Arylisoindoline-4-Carboxamides+as+Potent+and+Selective+Inhibitors+of+HDAC11&doi=10.1016%2Fj.bmcl.2018.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11</span></div><div class="casAuthors">Martin, Matthew W.; Lee, Jennifer Y.; Lancia, David R., Jr.; Ng, Pui Yee; Han, Bingsong; Thomason, Jennifer R.; Lynes, Maureen S.; Marshall, C. Gary; Conti, Chiara; Collis, Alan; Morales, Monica Alvarez; Doshi, Kshama; Rudnitskaya, Aleksandra; Yao, Lili; Zheng, Xiaozhang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2143-2147</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11.  The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported.  An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biol. of HDAC11 and its potential use as a therapeutic target for oncol. and inflammation indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1a4YGLwigwrVg90H21EOLACvtfcHk0lgY5FA4YiDFTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslShtb0%253D&md5=c5eec0204b7c318059e83838181aff4c</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLancia%26aufirst%3DD.%2BR.%26aulast%3DNg%26aufirst%3DP.%2BY.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DThomason%26aufirst%3DJ.%2BR.%26aulast%3DLynes%26aufirst%3DM.%2BS.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DConti%26aufirst%3DC.%26aulast%3DCollis%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DM.%2BA.%26aulast%3DDoshi%26aufirst%3DK.%26aulast%3DRudnitskaya%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Novel%2520N-Hydroxy-2-Arylisoindoline-4-Carboxamides%2520as%2520Potent%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC11%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2143%26epage%3D2147%26doi%3D10.1016%2Fj.bmcl.2018.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span> <span> </span><span class="NLM_article-title">Activity-Guided Design of HDAC11-Specific Inhibitors</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00292</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00292" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1yjs7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1393-1397&author=S.+I.+Sonauthor=J.+Caoauthor=C.-L.+Zhuauthor=S.+P.+Millerauthor=H.+Lin&title=Activity-Guided+Design+of+HDAC11-Specific+Inhibitors&doi=10.1021%2Facschembio.9b00292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Activity-guided design of HDAC11-specific inhibitors</span></div><div class="casAuthors">Son, Se In; Cao, Ji; Zhu, Cheng-Liang; Miller, Seth P.; Lin, Hening</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1393-1397</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mammalian histone deacetylases (HDACs) are a class of enzymes that play important roles in biol. pathways.  Existing HDAC inhibitors target multiple HDACs without much selectivity.  Inhibitors that target one particular HDAC will be useful for investigating the biol. functions of HDACs and for developing better therapeutics.  Here, we report the development of HDAC11-specific inhibitors using an activity-guided rational design approach.  The enzymic activity and biol. function of HDAC11 have been little known, but recent reports suggest that it has efficient defatty-acylation activity and that inhibiting it could be useful for treating a variety of human diseases, including viral infection, multiple sclerosis, and metabolic diseases.  Our best inhibitor, SIS17(I), is active in cells and inhibited the demyristoylation of a known HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs.  The activity-guided design may also be useful for the development of isoform-specific inhibitors for other classes of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYlAO5SOhnvLVg90H21EOLACvtfcHk0lhPZJR08GX7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1yjs7%252FP&md5=c98f2b6413cea1f0fbf337b368818581</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00292%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%2BI.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DC.-L.%26aulast%3DMiller%26aufirst%3DS.%2BP.%26aulast%3DLin%26aufirst%3DH.%26atitle%3DActivity-Guided%2520Design%2520of%2520HDAC11-Specific%2520Inhibitors%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1393%26epage%3D1397%26doi%3D10.1021%2Facschembio.9b00292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Géraldy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue Is Implicated</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4426-4443&author=M.+G%C3%A9raldyauthor=M.+Morgenauthor=P.+Sehrauthor=R.+R.+Steimbachauthor=D.+Moiauthor=J.+Ridingerauthor=I.+Oehmeauthor=O.+Wittauthor=M.+Malzauthor=M.+S.+Nogueiraauthor=O.+Kochauthor=N.+Gunkelauthor=A.+K.+Miller&title=Selective+Inhibition+of+Histone+Deacetylase+10%3A+Hydrogen+Bonding+to+the+Gatekeeper+Residue+Is+Implicated&doi=10.1021%2Facs.jmedchem.8b01936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span></div><div class="casAuthors">Geraldy, Magalie; Morgen, Michael; Sehr, Peter; Steimbach, Raphael R.; Moi, Davide; Ridinger, Johannes; Oehme, Ina; Witt, Olaf; Malz, Mona; Nogueira, Mauro S.; Koch, Oliver; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4426-4443</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of isoenzyme-selective histone deacetylase (HDAC) inhibitors is crit. for understanding the biol. functions of individual HDACs and for validating HDACs as drug targets.  The isoenzyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published.  Using two complementary assays, the authors found tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10.  The authors synthesized tubastatin A derivs. and found that a basic amine in the cap group was required for strong HDAC10 binding.  HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line.  Furthermore, docking into human HDAC10 homol. models indicated that a hydrogen-bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding.  Taken together, the authors' data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the tubastatin A scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl1kc8D1boarVg90H21EOLACvtfcHk0lhPZJR08GX7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D&md5=9c8fbb8ac46ca0db29df3848cb5e9b50</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01936%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25A9raldy%26aufirst%3DM.%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DSehr%26aufirst%3DP.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DMoi%26aufirst%3DD.%26aulast%3DRidinger%26aufirst%3DJ.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DNogueira%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%252010%253A%2520Hydrogen%2520Bonding%2520to%2520the%2520Gatekeeper%2520Residue%2520Is%2520Implicated%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4426%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b01936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst-Gervasoni, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Binding of <i>N</i><sup>8</sup>-Acetylspermidine Analogues to Histone Deacetylase 10 Reveals Molecular Strategies for Blocking Polyamine Deacetylation</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4957</span>– <span class="NLM_lpage">4969</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFynu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4957-4969&author=C.+J.+Herbst-Gervasoniauthor=D.+W.+Christianson&title=Binding+of+N8-Acetylspermidine+Analogues+to+Histone+Deacetylase+10+Reveals+Molecular+Strategies+for+Blocking+Polyamine+Deacetylation&doi=10.1021%2Facs.biochem.9b00906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of N8-Acetylspermidine Analogues to Histone Deacetylase 10 Reveals Molecular Strategies for Blocking Polyamine Deacetylation</span></div><div class="casAuthors">Herbst-Gervasoni, Corey J.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4957-4969</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Eukaryotic histone deacetylase 10 (HDAC10) is a Zn2+-dependent hydrolase that exhibits catalytic specificity for the hydrolysis of the polyamine N8-acetylspermidine.  The recently detd. crystal structure of HDAC10 from Danio rerio (zebrafish) reveals a narrow active site cleft and a neg. charged "gatekeeper" (E274) that favors the binding of the slender cationic substrate.  Since HDAC10 expression is upregulated in advanced-stage neuroblastoma and induces autophagy, the selective inhibition of HDAC10 suppresses the autophagic response and renders cancer cells more susceptible to cytotoxic chemotherapeutic drugs.  Here, we describe X-ray crystal structures of zebrafish HDAC10 complexed with eight different analogs of N8-acetylspermidine.  These analogs contain different Zn2+-binding groups, such as hydroxamate, thiolate, and the tetrahedral gem-diolate resulting from the addn. of a Zn2+-bound water mol. to a ketone carbonyl group.  Notably, the chem. that accompanies the binding of ketonic substrate analogs is identical to the chem. involved in the first step of catalysis, i.e., nucleophilic attack of a Zn2+-bound water mol. at the scissile carbonyl group of N8-acetylspermidine.  The most potent inhibitor studied contains a thiolate Zn2+-binding group.  These structures reveal interesting geometric changes in the metal coordination polyhedron that accommodate inhibitor binding.  Addnl. interactions in the active site highlight features contributing to substrate specificity.  These interactions are likely to contribute to inhibitor binding selectivity and will inform the future design of compds. selective for HDAC10 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2JBdeKMN-dLVg90H21EOLACvtfcHk0lhPZJR08GX7tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFynu77E&md5=e3a349c0f8dda9f061325dfd415c7a93</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00906%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst-Gervasoni%26aufirst%3DC.%2BJ.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBinding%2520of%2520N8-Acetylspermidine%2520Analogues%2520to%2520Histone%2520Deacetylase%252010%2520Reveals%2520Molecular%2520Strategies%2520for%2520Blocking%2520Polyamine%2520Deacetylation%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4957%26epage%3D4969%26doi%3D10.1021%2Facs.biochem.9b00906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective Class IIa Histone Deacetylase Inhibition via a Nonchelating Zinc-Binding Group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+Class+IIa+Histone+Deacetylase+Inhibition+via+a+Nonchelating+Zinc-Binding+Group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0liuif_9e_bDHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibition%2520via%2520a%2520Nonchelating%2520Zinc-Binding%2520Group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papangeli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwangbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, H. J.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1348</span>, <span class="refDoi"> DOI: 10.1164/rccm.201805-0817LE</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1164%2Frccm.201805-0817LE" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30106596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3c7nvFyksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2018&pages=1345-1348&author=A.+Soferauthor=S.+Leeauthor=I.+Papangeliauthor=T.+Adachiauthor=C.+Hwangboauthor=S.+Comhairauthor=P.+DaSilva-Jardineauthor=J.+Kimauthor=J.+J.+Schwarzauthor=S.+C.+Erzurumauthor=H.+J.+Chun&title=Therapeutic+Engagement+of+the+Histone+Deacetylase+IIA-Myocyte+Enhancer+Factor+2+Axis+Improves+Experimental+Pulmonary+Hypertension&doi=10.1164%2Frccm.201805-0817LE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Engagement of the Histone Deacetylase IIA-Myocyte Enhancer Factor 2 Axis Improves Experimental Pulmonary Hypertension</span></div><div class="casAuthors">Sofer Avraham; Lee Seyoung; Papangeli Irinna; Adachi Takaomi; Hwangbo Cheol; Chun Hyung J; Comhair Suzy; Erzurum Serpil C; DaSilva-Jardine Paul; Kim Jongmin; Schwarz John J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1345-1348</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRq_6kKTeex5MERNNga7KD-fW6udTcc2eb5x2vvayM8krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7nvFyksQ%253D%253D&md5=a40b798e2dfe4c3796e430b7f4cf4bb1</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1164%2Frccm.201805-0817LE&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201805-0817LE%26sid%3Dliteratum%253Aachs%26aulast%3DSofer%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPapangeli%26aufirst%3DI.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DHwangbo%26aufirst%3DC.%26aulast%3DComhair%26aufirst%3DS.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSchwarz%26aufirst%3DJ.%2BJ.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DH.%2BJ.%26atitle%3DTherapeutic%2520Engagement%2520of%2520the%2520Histone%2520Deacetylase%2520IIA-Myocyte%2520Enhancer%2520Factor%25202%2520Axis%2520Improves%2520Experimental%2520Pulmonary%2520Hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2018%26volume%3D198%26spage%3D1345%26epage%3D1348%26doi%3D10.1164%2Frccm.201805-0817LE" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Neuroprotective Mechanism of TMP269, a Selective Class IIA Histone Deacetylase Inhibitor, after Cerebral Ischemia/Reperfusion Injury</span>. <i>Neural Regener. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.4103/1673-5374.265562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.4103%2F1673-5374.265562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=31552900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvFehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=277-284&author=L.+Suauthor=D.+Liangauthor=S.-Y.+Kuangauthor=Q.+Dongauthor=X.+Hanauthor=Z.+Wang&title=Neuroprotective+Mechanism+of+TMP269%2C+a+Selective+Class+IIA+Histone+Deacetylase+Inhibitor%2C+after+Cerebral+Ischemia%2FReperfusion+Injury&doi=10.4103%2F1673-5374.265562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotective mechanism of TMP269, a selective class IIA histone deacetylase inhibitor, after cerebral ischemia/reperfusion injury</span></div><div class="casAuthors">Su Lu; Kuang Shen-Yi; Dong Qiang; Han Xiang; Wang Zheng; Liang Dan</div><div class="citationInfo"><span class="NLM_cas:title">Neural regeneration research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-284</span>
        ISSN:<span class="NLM_cas:issn">1673-5374</span>.
    </div><div class="casAbstract">TMP269 is a selective class IIA histone deacetylase inhibitor that has a protective effect on the central nervous system, whose specific mechanism of action is unclear.  We aimed to reveal the optimal concentration of TMP269 for protecting against cerebral ischemia/reperfusion injury and its neuroprotective mechanism.  Male Sprague-Dawley rats were randomly divided into sham, ischemia/reperfusion, and 1, 4, 10 and 16 mg/kg TMP269 groups.  Cerebral ischemia/reperfusion injury was induced by middle cerebral artery occlusion.  TMP269 was intraperitoneally administered at different doses 0.5 hours before ischemia induction.  Western blot assay and immunohistochemistry were used to detect effects of TMP269 on histone 2 acetylation.  The results showed that the level of histone 2 acetylation was increased 24 hours after TMP269 injection. 2,3,5-Triphenyltetrazolium chloride staining was utilized to examine effect of TMP269 on infarct volume.  The results found that different doses of TMP269 could reduce the infarct volume.  Western blot assay, immunohistochemistry and Evans blue staining were employed to measure the effect of TMP269 on blood-brain barrier.  The results showed that TMP269 counteracted the abnormal endothelial cell permeability changes caused by cerebral ischemia/reperfusion.  Western blot assay and immunohistochemistry were used to determine the effect of TMP269 on tissue kallikrein.  The results found that TMP269 up-regulated the expression of tissue kallikrein.  Western blot assay further determined the optimal concentration to be 4 mg/kg.  In conclusion, TMP269 plays a neuroprotective role by up-regulating the level of histone 2 acetylation, alleviating endothelial cell injury after cerebral ischemia/reperfusion, and up-regulating the expression of tissue kallikrein.  The experimental protocol was approved in 2014 by the Department of Laboratory Animal Science, Fudan University, China (approval No. 20140143C001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrdKz2tBsAwwaK-_ZudimnfW6udTcc2eYOZj524HdNuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvFehuw%253D%253D&md5=b8bf2ed761e77bc8d43d52334c69efb1</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.4103%2F1673-5374.265562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F1673-5374.265562%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DD.%26aulast%3DKuang%26aufirst%3DS.-Y.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DNeuroprotective%2520Mechanism%2520of%2520TMP269%252C%2520a%2520Selective%2520Class%2520IIA%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520after%2520Cerebral%2520Ischemia%252FReperfusion%2520Injury%26jtitle%3DNeural%2520Regener.%2520Res.%26date%3D2020%26volume%3D15%26spage%3D277%26epage%3D284%26doi%3D10.4103%2F1673-5374.265562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, B. E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walburg, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vrieling, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mara Pinto Dabés Guimarães, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaink, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottenhoff, T. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haks, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heemskerk, M. T.</span></span> <span> </span><span class="NLM_article-title">Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances <i>in Vitro</i> and <i>in Vivo</i> Anti-Mycobacterial Activity in Human Macrophages and in Zebrafish</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2020.00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.3389%2Ffimmu.2020.00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=32117228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGiurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=36&author=J.+D.+Moreiraauthor=B.+E.+V.+Kochauthor=S.+van+Veenauthor=K.+V.+Walburgauthor=F.+Vrielingauthor=T.+Mara+Pinto+Dab%C3%A9s+Guimar%C3%A3esauthor=A.+H.+Meijerauthor=H.+P.+Spainkauthor=T.+H.+M.+Ottenhoffauthor=M.+C.+Haksauthor=M.+T.+Heemskerk&title=Functional+Inhibition+of+Host+Histone+Deacetylases+%28HDACs%29+Enhances+in+Vitro+and+in+Vivo+Anti-Mycobacterial+Activity+in+Human+Macrophages+and+in+Zebrafish&doi=10.3389%2Ffimmu.2020.00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish</span></div><div class="casAuthors">Moreira, Josimar D.; Koch, Bjorn E. V.; Van Veen, Suzanne; Walburg, Kimberley V.; Vrieling, Frank; Guimaraes, Tania Mara Pinto Dabes; Meijer, Annemarie H.; Spaink, Herman P.; Ottenhoff, Tom H. M.; Haks, Marieelle C.; Heemskerk, Matthias T.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The rapid and persistent increase of drug-resistant Mycobacterium tuberculosis (Mtb) infections poses increasing global problems in combating tuberculosis (TB), prompting for the development of alternative strategies including host-directed therapy (HDT).  Since Mtb is an intracellular pathogen with a remarkable ability to manipulate host intracellular signaling pathways to escape from host defense, pharmacol. reprogramming of the immune system represents a novel, potentially powerful therapeutic strategy that should be effective also against drug-resistant Mtb.  Here, we found that host-pathogen interactions in Mtb-infected primary human macrophages affected host epigenetic features by modifying histone deacetylase (HDAC) transcriptomic levels.  In addn., broad spectrum inhibition of HDACs enhanced the antimicrobial response of both pro-inflammatory macrophages (Mφ1) and anti-inflammatory macrophages (Mφ2), while selective inhibition of class IIa HDACs mainly decreased bacterial outgrowth in Mφ2.  Moreover, chem. inhibition of HDAC activity during differentiation polarized macrophages into a more bactericidal phenotype with a concomitant decrease in the secretion levels of inflammatory cytokines.  Importantly, in vivo chem. inhibition of HDAC activity in Mycobacterium marinum-infected zebrafish embryos, a well-characterized animal model for tuberculosis, significantly reduced mycobacterial burden, validating our in vitro findings in primary human macrophages.  Collectively, these data identify HDACs as druggable host targets for HDT against intracellular Mtb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHZm0Rg24ymrVg90H21EOLACvtfcHk0ljA1qZCjtUpFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGiurnK&md5=8b2b570eda24d14ea00274ca39311809</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2020.00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2020.00036%26sid%3Dliteratum%253Aachs%26aulast%3DMoreira%26aufirst%3DJ.%2BD.%26aulast%3DKoch%26aufirst%3DB.%2BE.%2BV.%26aulast%3Dvan%2BVeen%26aufirst%3DS.%26aulast%3DWalburg%26aufirst%3DK.%2BV.%26aulast%3DVrieling%26aufirst%3DF.%26aulast%3DMara%2BPinto%2BDab%25C3%25A9s%2BGuimar%25C3%25A3es%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DA.%2BH.%26aulast%3DSpaink%26aufirst%3DH.%2BP.%26aulast%3DOttenhoff%26aufirst%3DT.%2BH.%2BM.%26aulast%3DHaks%26aufirst%3DM.%2BC.%26aulast%3DHeemskerk%26aufirst%3DM.%2BT.%26atitle%3DFunctional%2520Inhibition%2520of%2520Host%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520Enhances%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Anti-Mycobacterial%2520Activity%2520in%2520Human%2520Macrophages%2520and%2520in%2520Zebrafish%26jtitle%3DFront.%2520Immunol.%26date%3D2020%26volume%3D11%26spage%3D36%26doi%3D10.3389%2Ffimmu.2020.00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville-Stones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34-39&author=C.+A.+Luckhurstauthor=P.+Brecciaauthor=A.+J.+Stottauthor=O.+Azizauthor=H.+L.+Birchauthor=R.+W.+B%C3%BCrliauthor=S.+J.+Hughesauthor=R.+E.+Jarvisauthor=M.+Lamersauthor=P.+M.+Leonardauthor=K.+L.+Matthewsauthor=G.+McAllisterauthor=S.+Pollackauthor=E.+Saville-Stonesauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Potent%2C+Selective%2C+and+CNS-Penetrant+Tetrasubstituted+Cyclopropane+Class+IIa+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Luckhurst, Christopher A.; Breccia, Perla; Stott, Andrew J.; Aziz, Omar; Birch, Helen L.; Burli, Roland W.; Hughes, Samantha J.; Jarvis, Rebecca E.; Lamers, Marieke; Leonard, Philip M.; Matthews, Kim L.; McAllister, George; Pollack, Scott; Saville-Stones, Elizabeth; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective class IIa HDAC tetrasubstituted cyclopropane hydroxamic acid inhibitors were identified with high oral bioavailability that exhibited good brain and muscle exposure.  Compd. (I) displayed suitable properties for assessment of the impact of class IIa HDAC catalytic site inhibition in preclin. disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01yllqODDNLVg90H21EOLACvtfcHk0lhr5GP4c-cfIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE&md5=dfc4f299bc59bdb7bcf92f7e0bccda0d</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00302%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBirch%26aufirst%3DH.%2BL.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DJarvis%26aufirst%3DR.%2BE.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%2BM.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DSaville-Stones%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DPotent%252C%2520Selective%252C%2520and%2520CNS-Penetrant%2520Tetrasubstituted%2520Cyclopropane%2520Class%2520IIa%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D34%26epage%3D39%26doi%3D10.1021%2Facsmedchemlett.5b00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maillard, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Development and Characterization of a CNS-Penetrant Benzhydryl Hydroxamic Acid Class IIa Histone Deacetylase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=10.1016%2Fj.bmcl.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=30463802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=83-88&author=C.+A.+Luckhurstauthor=O.+Azizauthor=V.+Beaumontauthor=R.+W.+B%C3%BCrliauthor=P.+Brecciaauthor=M.+C.+Maillardauthor=A.+F.+Haughanauthor=M.+Lamersauthor=P.+Leonardauthor=K.+L.+Matthewsauthor=G.+Raphyauthor=A.+J.+Stottauthor=I.+Munoz-Sanjuanauthor=B.+Thomasauthor=M.+Wallauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Development+and+Characterization+of+a+CNS-Penetrant+Benzhydryl+Hydroxamic+Acid+Class+IIa+Histone+Deacetylase+Inhibitor&doi=10.1016%2Fj.bmcl.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor</span></div><div class="casAuthors">Luckhurst, Christopher A.; Aziz, Omar; Beaumont, Vahri; Burli, Roland W.; Breccia, Perla; Maillard, Michel C.; Haughan, Alan F.; Lamers, Marieke; Leonard, Phil; Matthews, Kim L.; Raphy, Gilles; Stott, Andrew J.; Munoz-Sanjuan, Ignacio; Thomas, Beth; Wall, Michael; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor 22(I), with >500-fold selectivity over class I HDACs (1,2,3) and ∼150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.  Dose escalation pharmacokinetic anal. demonstrated that upon oral administration, compd. 22 can reach exposure levels in mouse plasma, muscle and brain in excess of cellular class IIa HDAC IC50 levels for ∼8 h.  Given the interest in aberrant class IIa HDAC function for a no. of neurodegenerative, neuromuscular, cardiac and oncol. indications, compd. 22 (also known as CHDI-390576) provides a selective and potent compd. to query the role of class IIa HDAC biol., and the impact of class IIa catalytic site occupancy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgNfS2AXrN7Vg90H21EOLACvtfcHk0lhr5GP4c-cfIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM&md5=8348010d11e3fe0114ca1a2e596206d4</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DMaillard%26aufirst%3DM.%2BC.%26aulast%3DHaughan%26aufirst%3DA.%2BF.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DRaphy%26aufirst%3DG.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DDevelopment%2520and%2520Characterization%2520of%2520a%2520CNS-Penetrant%2520Benzhydryl%2520Hydroxamic%2520Acid%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D83%26epage%3D88%26doi%3D10.1016%2Fj.bmcl.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00830" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00830" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0e8a3cdd62521","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
